Clustering O 0 0.0014022559626027942
of O 0 3.923404437955469e-05
missense O 0 0.11208989471197128
mutations O 0 0.00039152579847723246
in O 0 4.955913937010337e-06
the O 0 1.5144521967158653e-05
ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9986516833305359
telangiectasia I-Disease 1 0.9999923706054688
gene O 0 3.4045100619550794e-05
in O 0 2.2642161638941616e-06
a O 0 1.6102194422273897e-05
sporadic B-Disease 0 0.022913118824362755
T I-Disease 1 0.998480498790741
- I-Disease 1 0.5648974776268005
cell I-Disease 0 0.2804970145225525
leukaemia I-Disease 1 0.9929996728897095
. O 0 7.355870911851525e-05

Ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.999995231628418
telangiectasia I-Disease 1 0.9999996423721313
( O 0 0.005275880452245474
A B-Disease 1 0.9961608648300171
- I-Disease 1 0.9999804496765137
T I-Disease 1 0.999997615814209
) O 0 1.5481439277209574e-06
is O 0 4.5141854343455634e-07
a O 0 5.500483439391246e-06
recessive B-Disease 0 0.11058755218982697
multi I-Disease 0 0.4491593837738037
- I-Disease 1 0.9981548190116882
system I-Disease 1 0.5176540017127991
disorder I-Disease 1 0.9994650483131409
caused O 0 5.9636204241542146e-05
by O 0 9.634768503019586e-07
mutations O 0 7.475207439711085e-06
in O 0 2.4503964368705056e-07
the O 0 4.004270408586308e-07
ATM O 0 1.9451654225122184e-05
gene O 0 2.9074703888909426e-06
at O 0 1.371488110635255e-06
11q22 O 0 0.00011350864951964468
- O 0 0.00018223396909888834
q23 O 0 0.00025632980396039784
( O 0 3.5716423099074746e-06
ref O 0 0.00015527628420386463
. O 0 1.473555698794371e-06
3 O 0 6.293808837654069e-06
) O 0 5.578674063144717e-06
. O 0 6.74255761623499e-06

The O 0 0.00011294967407593504
risk O 0 0.00040170058491639793
of O 0 1.2141575098212343e-05
cancer B-Disease 0 0.19535981118679047
, O 0 2.0596967260644305e-06
especially O 0 3.006269935212913e-06
lymphoid B-Disease 0 0.0006405580206774175
neoplasias I-Disease 0 0.008430586196482182
, O 0 1.2137347766838502e-06
is O 0 4.861255433752376e-07
substantially O 0 1.2830410014430527e-05
elevated O 0 4.785976852872409e-05
in O 0 4.279637323634233e-06
A B-Disease 1 0.9984707236289978
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 0.0029170061461627483
and O 0 8.135572215905995e-07
has O 0 9.352757501801534e-07
long O 0 4.459443061932689e-06
been O 0 1.1172900258316076e-06
associated O 0 3.094778776357998e-06
with O 0 8.903416528482921e-06
chromosomal O 1 0.9999983310699463
instability O 1 0.9996092915534973
. O 0 0.00013753025268670171

By O 0 0.00016438314924016595
analysing O 0 0.001199195859953761
tumour B-Disease 1 0.9999816417694092
DNA O 0 0.0006024706526659429
from O 0 8.396902558160946e-06
patients O 0 4.82274335809052e-05
with O 0 2.3319455522141652e-06
sporadic B-Disease 0 0.009472309611737728
T I-Disease 1 0.9586489796638489
- I-Disease 0 0.003285750513896346
cell I-Disease 0 0.004268274642527103
prolymphocytic I-Disease 1 0.7410607933998108
leukaemia I-Disease 1 0.999651312828064
( O 0 7.797000580467284e-05
T B-Disease 0 0.14576663076877594
- I-Disease 0 0.0001641003182157874
PLL I-Disease 0 0.0006952152471058071
) O 0 9.546615729050245e-07
, O 0 2.806287113799044e-07
a O 0 1.381485731144494e-06
rare O 0 4.794842880073702e-06
clonal B-Disease 0 0.00048034393694251776
malignancy I-Disease 0 0.03936009481549263
with O 0 7.018856535978557e-07
similarities O 0 2.87333978121751e-06
to O 0 3.534086658874003e-07
a O 0 1.0265813216392417e-05
mature B-Disease 0 9.832135401666164e-05
T I-Disease 0 0.05854931101202965
- I-Disease 0 0.0017732278211042285
cell I-Disease 0 0.0010399885941296816
leukaemia I-Disease 0 0.2643139362335205
seen O 0 3.0369444630196085e-06
in O 0 1.237294782185927e-06
A B-Disease 0 0.39816680550575256
- I-Disease 1 0.9990942478179932
T I-Disease 1 0.9999924898147583
, O 0 4.808599101124855e-07
we O 0 8.222608016694721e-08
demonstrate O 0 3.78061344008529e-07
a O 0 3.486510138372978e-07
high O 0 6.448326530517079e-07
frequency O 0 1.3936784171164618e-06
of O 0 4.561651394396904e-07
ATM O 0 0.00027176804724149406
mutations O 0 4.906948743155226e-05
in O 0 5.58604187972378e-06
T B-Disease 0 0.04572989046573639
- I-Disease 0 0.0006499930168502033
PLL I-Disease 0 0.006593221332877874
. O 0 0.00010082104563480243

In O 0 4.4087959395255893e-05
marked O 0 5.315125599736348e-05
contrast O 0 1.7162446965812705e-05
to O 0 4.4699069690068427e-07
the O 0 5.901441681999131e-07
ATM O 0 7.077472400851548e-05
mutation O 0 1.3955635949969292e-05
pattern O 0 7.407181783491978e-06
in O 0 1.7286475895161857e-06
A B-Disease 1 0.5544348955154419
- I-Disease 1 0.995319664478302
T I-Disease 1 0.9999904632568359
, O 0 3.2095661595121783e-07
the O 0 1.202841701797297e-07
most O 0 1.0654594717607324e-07
frequent O 0 7.436083819811756e-07
nucleotide O 0 4.034120138385333e-06
changes O 0 8.444116588179895e-07
in O 0 4.5991478714313416e-07
this O 0 1.5510552202613326e-06
leukaemia B-Disease 0 0.4521482586860657
were O 0 1.990028249565512e-05
missense O 0 0.003176181809976697
mutations O 0 0.0003589567495509982
. O 0 3.5800952900899574e-05

These O 0 1.7346475942758843e-05
clustered O 0 6.257883796934038e-05
in O 0 2.3267161850526463e-06
the O 0 4.870461793871073e-07
region O 0 1.6505872508787434e-06
corresponding O 0 6.201229894031712e-07
to O 0 9.92365585261723e-08
the O 0 2.0551098600662954e-07
kinase O 0 3.714504600793589e-06
domain O 0 4.790468324245012e-07
, O 0 1.1307304959018438e-07
which O 0 8.127664585799721e-08
is O 0 8.333382339742457e-08
highly O 0 1.5811869502613263e-07
conserved O 0 4.7663755253779527e-07
in O 0 2.1857343313058664e-07
ATM O 0 1.3464753465086687e-05
- O 0 1.9658504243125208e-05
related O 0 1.973753114725696e-06
proteins O 0 4.759344278681965e-07
in O 0 3.859354649193847e-07
mouse O 0 9.019799108500592e-06
, O 0 7.419303074129857e-07
yeast O 0 1.7705795471556485e-05
and O 0 2.8229121653566835e-06
Drosophila O 0 7.355787238338962e-05
. O 0 1.8247666957904585e-05

The O 0 4.9540896725375205e-05
resulting O 0 9.794143261387944e-05
amino O 0 2.967220643768087e-05
- O 0 5.176533159101382e-05
acid O 0 8.437294127361383e-06
substitutions O 0 2.3048455659591127e-06
are O 0 2.3274211002899392e-07
predicted O 0 1.944400992215378e-06
to O 0 1.6493002874540252e-07
interfere O 0 6.592442218789074e-07
with O 0 4.278643075394939e-07
ATP O 0 1.5197446373349521e-05
binding O 0 6.1196078604552895e-06
or O 0 3.3129404073406477e-06
substrate O 0 3.169020055793226e-05
recognition O 0 1.2141990737291053e-05
. O 0 1.8011531210504472e-05

Two O 0 4.225680459057912e-05
of O 0 1.0712363291531801e-05
seventeen O 0 5.051130210631527e-05
mutated O 0 0.0003130912664346397
T B-Disease 0 0.01604929193854332
- I-Disease 0 0.00017079865210689604
PLL I-Disease 0 0.0003790485206991434
samples O 0 1.949908892129315e-06
had O 0 1.007372020467301e-06
a O 0 1.686273435552721e-06
previously O 0 6.9444708969967905e-06
reported O 0 3.291850589448586e-05
A B-Disease 0 0.17155028879642487
- I-Disease 1 0.9895403981208801
T I-Disease 1 0.9999673366546631
allele O 0 0.0001679963170317933
. O 0 1.939460344146937e-05

In O 0 6.851336365798488e-05
contrast O 0 6.878675048938021e-05
, O 0 3.170339141433942e-06
no O 0 2.3816653538233368e-06
mutations O 0 2.556990148150362e-05
were O 0 3.728946182945947e-07
detected O 0 1.4748787862117752e-06
in O 0 1.0756362200936564e-07
the O 0 2.823467752932629e-07
p53 O 0 4.695497409556992e-06
gene O 0 1.048710373652284e-06
, O 0 1.7911008853843668e-07
suggesting O 0 7.052539103824529e-07
that O 0 1.2152041506396927e-07
this O 0 7.059631457195792e-07
tumour B-Disease 1 0.9999727010726929
suppressor O 0 0.005892289336770773
is O 0 7.166285627135949e-07
not O 0 2.7398107249609893e-07
frequently O 0 1.7739331497068633e-06
altered O 0 1.3704519915336277e-05
in O 0 3.3858748338388978e-06
this O 0 9.003591003420297e-06
leukaemia B-Disease 1 0.9027720093727112
. O 0 5.450272510643117e-05

Occasional O 0 0.0034771959763020277
missense O 0 0.2732647657394409
mutations O 0 0.0009769194293767214
in O 0 6.1310111050261185e-06
ATM O 0 7.698273111600429e-05
were O 0 1.6054744946814026e-06
also O 0 6.457649988078629e-07
found O 0 7.838197575438244e-07
in O 0 3.275231165389414e-06
tumour B-Disease 1 0.9999669790267944
DNA O 0 3.991199628217146e-05
from O 0 1.6556399486944429e-06
patients O 0 1.6920042980927974e-05
with O 0 8.599615171078767e-07
B B-Disease 0 5.590427099377848e-05
- I-Disease 0 0.00044354941928759217
cell I-Disease 0 0.000767307763453573
non I-Disease 0 7.470069249393418e-05
- I-Disease 1 0.9637390375137329
Hodgkins I-Disease 1 0.999998927116394
lymphomas I-Disease 1 0.9997995495796204
( O 0 6.232104624359636e-06
B B-Disease 0 7.375496807071613e-06
- I-Disease 0 6.925411071279086e-06
NHL I-Disease 0 3.2201999147218885e-06
) O 0 3.983003011853725e-07
and O 0 2.23635169049885e-07
a O 0 3.186373533026199e-06
B B-Disease 0 2.376869088038802e-05
- I-Disease 0 5.93461882090196e-05
NHL I-Disease 0 4.277568950783461e-05
cell O 0 0.0001306830527028069
line O 0 5.5202388466568664e-05
. O 0 2.353789022890851e-05

The O 0 2.4632392523926683e-05
evidence O 0 5.084910299046896e-06
of O 0 9.398949600836204e-07
a O 0 2.166160811611917e-06
significant O 0 1.5002864302005037e-06
proportion O 0 2.111327376042027e-06
of O 0 1.864216443436817e-07
loss O 0 1.2641799912671559e-05
- O 0 1.7421194570488296e-05
of O 0 3.104277368493058e-07
- O 0 0.0002073782670777291
function O 0 3.3379214983142447e-06
mutations O 0 2.111375579261221e-06
and O 0 6.538576258208195e-08
a O 0 6.431032488762867e-07
complete O 0 3.450512167546549e-06
absence O 0 1.277516730624484e-06
of O 0 8.551579355753347e-08
the O 0 1.7014373554502527e-07
normal O 0 6.139496235846309e-07
copy O 0 4.694207120792271e-07
of O 0 8.582658495015494e-08
ATM O 0 3.4348349799984135e-06
in O 0 1.578580395289464e-07
the O 0 2.4035375645325985e-07
majority O 0 1.3086257695249515e-06
of O 0 8.192134828277631e-07
mutated O 0 0.0005466293659992516
tumours B-Disease 1 0.999916672706604
establishes O 0 6.577156455023214e-05
somatic O 0 8.239589806180447e-05
inactivation O 0 0.00013892739661969244
of O 0 2.1436588326650963e-07
this O 0 1.7230946980362205e-07
gene O 0 8.376838422918809e-07
in O 0 1.8176487515120243e-07
the O 0 4.6181347101992287e-07
pathogenesis O 0 2.4448634576401673e-05
of O 0 7.354225317612872e-07
sporadic B-Disease 0 0.004553990438580513
T I-Disease 1 0.9624292254447937
- I-Disease 0 0.0006054299883544445
PLL I-Disease 0 0.0006601730710826814
and O 0 6.118139026511926e-07
suggests O 0 8.449562187706761e-07
that O 0 1.3092657979996147e-07
ATM O 0 6.40039343124954e-06
acts O 0 1.4466610309682437e-06
as O 0 1.0851312026716187e-06
a O 0 6.266058335313573e-05
tumour B-Disease 1 0.9999914169311523
suppressor O 0 0.0802101120352745
. O 0 5.1113216613885015e-05

As O 0 4.27064805990085e-05
constitutional O 0 8.819343202048913e-05
DNA O 0 4.632086347555742e-05
was O 0 2.312708375029615e-06
not O 0 1.7443888111756678e-07
available O 0 2.3376358626592264e-07
, O 0 2.2700314161738788e-07
a O 0 2.290045358677162e-06
putative O 0 0.000753118481952697
hereditary O 0 0.06021636724472046
predisposition O 0 0.0007188013405539095
to O 0 4.823107246920699e-06
T B-Disease 0 0.24935047328472137
- I-Disease 0 0.00022154266480356455
PLL I-Disease 0 0.0004913180018775165
will O 0 1.0581035212453571e-06
require O 0 1.2032138556605787e-06
further O 0 8.914955174077477e-07
investigation O 0 6.371460131049389e-06
. O 0 3.020644953721785e-06
. O 0 1.4999750419519842e-05

Myotonic B-Disease 1 0.9999988079071045
dystrophy I-Disease 1 0.9999990463256836
protein O 0 0.0018026884645223618
kinase O 0 0.0007705215248279274
is O 0 2.816512278513983e-06
involved O 0 1.646694272494642e-06
in O 0 4.934457251692947e-07
the O 0 3.7560860732810397e-07
modulation O 0 7.544779236923205e-06
of O 0 5.045249054091983e-07
the O 0 1.4387237570190337e-06
Ca2 O 0 0.0001856932940427214
+ O 0 5.237354707787745e-05
homeostasis O 0 0.00011441134847700596
in O 0 8.139544661389664e-06
skeletal O 0 0.19460831582546234
muscle O 0 0.22163406014442444
cells O 0 0.0004163235716987401
. O 0 2.869039417419117e-05

Myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
( O 1 0.8224747776985168
DM B-Disease 1 0.9999998807907104
) O 0 3.581061901059002e-05
, O 0 1.7841433646026417e-06
the O 0 9.328759347226878e-07
most O 0 2.2807953428127803e-06
prevalent O 0 0.00116484344471246
muscular B-Disease 1 0.9999920129776001
disorder I-Disease 1 0.999990701675415
in O 0 4.3252744944766164e-05
adults O 0 0.00041421089554205537
, O 0 4.2946109601871285e-07
is O 0 2.6447034429111227e-07
caused O 0 2.607796659503947e-06
by O 0 3.45680575719598e-07
( O 0 2.3962145405675983e-06
CTG O 0 6.175510497996584e-05
) O 0 5.466812922350073e-07
n O 0 3.0834248718747403e-06
- O 0 4.6920240492909215e-06
repeat O 0 2.304891950188903e-06
expansion O 0 1.3896068367102998e-06
in O 0 3.2433939622933394e-07
a O 0 8.575750030104246e-07
gene O 0 1.9838173557218397e-06
encoding O 0 2.475505652910215e-06
a O 0 2.9060897759336513e-06
protein O 0 6.353809112624731e-06
kinase O 0 5.66814087505918e-05
( O 0 7.615694812557194e-06
DM B-Disease 1 0.9981655478477478
protein O 0 1.4815080248808954e-05
kinase O 0 3.1751398637425154e-05
; O 0 2.8999550067965174e-06
DMPK O 0 0.00012119006714783609
) O 0 6.216032488737255e-07
and O 0 2.433795600609301e-07
involves O 0 1.077403680938005e-06
changes O 0 1.188727651424415e-06
in O 0 9.780876553122653e-07
cytoarchitecture O 0 0.0001873493893072009
and O 0 6.547064458573004e-06
ion O 0 0.0002087144530378282
homeostasis O 0 0.001383755006827414
. O 0 3.539450699463487e-05

To O 0 2.2985432224231772e-05
obtain O 0 1.864145087893121e-05
clues O 0 1.0358520739828236e-05
to O 0 4.4152704958833056e-07
the O 0 4.2661426391532586e-07
normal O 0 1.8838106825569412e-06
biological O 0 9.517626153865422e-07
role O 0 3.9991184053178586e-07
of O 0 2.2202499394552433e-07
DMPK O 0 0.0001314224355155602
in O 0 6.219145234354073e-07
cellular O 0 8.68717506818939e-06
ion O 0 8.765433449298143e-06
homeostasis O 0 4.7143785195657983e-05
, O 0 2.5966787120523804e-07
we O 0 6.127410756562313e-08
have O 0 8.188083455706874e-08
compared O 0 6.102487191128603e-07
the O 0 3.351304087573226e-07
resting O 0 7.726672265562229e-06
[ O 0 6.123139883129625e-06
Ca2 O 0 4.336425263318233e-05
+ O 0 1.778718433342874e-05
] O 0 2.5511021704005543e-06
i O 0 1.8522545985888428e-07
, O 0 7.828651860108948e-08
the O 0 1.1040969383202537e-07
amplitude O 0 1.0785200856844313e-06
and O 0 1.5639552941593138e-07
shape O 0 1.517045006949047e-06
of O 0 4.6300411327138136e-07
depolarization O 0 7.214659126475453e-05
- O 0 0.0003886940539814532
induced O 0 0.014403419569134712
Ca2 O 0 0.000422253564465791
+ O 0 4.139847442274913e-05
transients O 0 3.761218977160752e-05
, O 0 1.453574185461548e-07
and O 0 4.945745146756053e-08
the O 0 4.973452760737018e-08
content O 0 1.022730771182978e-07
of O 0 6.239343264269337e-08
ATP O 0 3.5131090498907724e-06
- O 0 1.1034111594199203e-05
driven O 0 5.952992978563998e-06
ion O 0 6.140987352409866e-06
pumps O 0 6.474770998465829e-06
in O 0 7.122645797608129e-07
cultured O 0 2.849168231477961e-05
skeletal O 0 0.0008103502914309502
muscle O 0 0.000178954767761752
cells O 0 3.541803380358033e-06
of O 0 2.506453995465563e-07
wild O 0 1.5927116692182608e-06
- O 0 1.828675885917619e-05
type O 0 2.288263885930064e-06
and O 0 1.1665975989672006e-06
DMPK O 0 0.0006517861038446426
[ O 0 1.0408150956209283e-05
- O 0 6.512113031931221e-05
/ O 0 0.00013847243099007756
- O 0 0.00022419307788368315
] O 0 0.00010477061005076393
knockout O 0 0.0008060014224611223
mice O 0 0.0010963352397084236
. O 0 3.8893191231181845e-05

In O 0 0.00011550424824235961
vitro O 0 0.0015601060586050153
- O 0 0.0005780011415481567
differentiated O 0 0.0002797003835439682
DMPK O 0 0.0024465315509587526
[ O 0 3.572953210095875e-05
- O 0 0.00011388670100132003
/ O 0 0.00019404434715397656
- O 0 0.00010401654435554519
] O 0 1.397590858687181e-05
myotubes O 0 2.9839740818715654e-05
exhibit O 0 1.7355457657686202e-06
a O 0 1.3416880619843141e-06
higher O 0 2.4222601950896205e-06
resting O 0 1.1602826816670131e-05
[ O 0 5.8550363064568955e-06
Ca2 O 0 5.353296728571877e-05
+ O 0 1.9780552975134924e-05
] O 0 2.807239525282057e-06
i O 0 1.6779848976966605e-07
than O 0 8.692843067592548e-08
do O 0 1.1156700452374935e-07
wild O 0 8.300416425299773e-07
- O 0 7.676377572352067e-05
type O 0 5.71600276089157e-06
myotubes O 0 9.847449109656736e-05
because O 0 1.2711664965081582e-07
of O 0 4.369227468714598e-08
an O 0 1.3586297598067176e-07
altered O 0 3.800922968366649e-06
open O 0 8.080178304226138e-07
probability O 0 5.614277256427158e-07
of O 0 1.7208530778134445e-07
voltage O 0 1.2199655429867562e-05
- O 0 2.5637757062213495e-05
dependent O 0 4.93943343826686e-06
l O 0 0.00010251683852402493
- O 0 1.1101717973360792e-05
type O 0 4.840298970520962e-06
Ca2 O 0 2.9657012419193052e-05
+ O 0 1.055660868587438e-05
and O 0 1.237369133377797e-06
Na O 0 8.35281316540204e-05
+ O 0 6.39494028291665e-05
channels O 0 3.689633740577847e-05
. O 0 2.0681722162407823e-05

The O 0 6.231787847355008e-05
mutant O 0 0.0004304469039198011
myotubes O 0 0.0004963864339515567
exhibit O 0 1.857128881965764e-05
smaller O 0 5.39294751433772e-06
and O 0 1.4432008583753486e-06
slower O 0 4.2428087908774614e-05
Ca2 O 0 0.00012052131933160126
+ O 0 1.7515416402602568e-05
responses O 0 1.907109322019096e-06
upon O 0 6.023814762556867e-07
triggering O 0 9.061114724318031e-06
by O 0 5.199077008910535e-07
acetylcholine O 0 2.7648309696814977e-05
or O 0 1.7555014437675709e-06
high O 0 6.951415343792178e-06
external O 0 3.719986852956936e-05
K O 0 0.00010842771735042334
+ O 0 7.673215441172943e-05
. O 0 1.296498430747306e-05

In O 0 3.1372223020298406e-05
addition O 0 8.855623491399456e-06
, O 0 1.0367516551923472e-06
we O 0 2.647201711170055e-07
observed O 0 7.618642143825127e-07
that O 0 8.41116616356885e-08
these O 0 2.9303083692866494e-07
Ca2 O 0 4.974777766619809e-05
+ O 0 6.612361175939441e-05
transients O 0 0.00027909569325856864
partially O 0 1.9666304069687612e-05
result O 0 2.9873621087972424e-07
from O 0 1.0831507069042345e-07
an O 0 1.3016365585372114e-07
influx O 0 9.538080121274106e-07
of O 0 1.908461513266957e-07
extracellular O 0 5.952374067419441e-06
Ca2 O 0 2.2956362954573706e-05
+ O 0 3.602371634769952e-06
through O 0 3.763335882922547e-07
the O 0 6.20125945260952e-07
l O 0 9.197572944685817e-05
- O 0 4.1517992940498516e-05
type O 0 2.303548899362795e-05
Ca2 O 0 0.00019890886323992163
+ O 0 7.633674249518663e-05
channel O 0 5.831361704622395e-05
. O 0 2.5207045837305486e-05

Neither O 0 0.00016819842858240008
the O 0 8.751051609579008e-06
content O 0 7.096749868651386e-06
nor O 0 3.0209962460503448e-06
the O 0 5.681550874214736e-07
activity O 0 1.3180822406866355e-06
of O 0 5.719387559111055e-07
Na O 0 7.586336869280785e-05
+ O 0 6.0083562857471406e-05
/ O 0 3.6119294236414135e-05
K O 0 2.3616335965925828e-05
+ O 0 2.480542207194958e-05
ATPase O 0 4.515409091254696e-05
and O 0 2.2869637632538797e-06
sarcoplasmic O 0 0.00026517341029830277
reticulum O 0 0.00038287744973786175
Ca2 O 0 0.00021235882013570517
+ O 0 4.191953121335246e-05
- O 0 2.797111483232584e-05
ATPase O 0 5.170864096726291e-05
are O 0 4.460623870272684e-07
affected O 0 2.8428232781152474e-06
by O 0 2.4674329779372783e-06
DMPK O 0 0.0027496637776494026
absence O 0 0.00018117330910172313
. O 0 3.582188583095558e-05

In O 0 3.1481129553867504e-05
conclusion O 0 9.208202754962258e-06
, O 0 1.012270104183699e-06
our O 0 4.752504310090444e-07
data O 0 6.847097324680362e-07
suggest O 0 5.350196943254559e-07
that O 0 1.3312110525021126e-07
DMPK O 0 9.238685015588999e-05
is O 0 1.8425083680995158e-07
involved O 0 2.51329964839897e-07
in O 0 1.5370676464954158e-07
modulating O 0 6.84466340317158e-06
the O 0 1.6484543152728293e-07
initial O 0 9.339673283648153e-07
events O 0 2.6270345188095234e-07
of O 0 2.2578973357667564e-07
excitation O 0 1.4046765500097536e-05
- O 0 6.778013630537316e-05
contraction O 0 0.00013411761028692126
coupling O 0 1.980324122996535e-05
in O 0 2.9785312563035404e-06
skeletal O 0 0.0018827172461897135
muscle O 0 0.0010420826729387045
. O 0 5.26034955328214e-06
. O 0 1.328704001934966e-05

Constitutional O 0 0.0027840237598866224
RB1 O 0 0.31230664253234863
- O 0 0.01660526543855667
gene O 0 0.0004977823118679225
mutations O 0 0.0003225643595214933
in O 0 9.333884008810855e-06
patients O 0 0.00013856329314876348
with O 0 7.0525115916098e-06
isolated O 0 0.0004883284564130008
unilateral B-Disease 0 0.0037911459803581238
retinoblastoma I-Disease 0 0.3326956629753113
. O 0 9.470271470490843e-05

In O 0 0.00016324242460541427
most O 0 3.3494965464342386e-05
patients O 0 0.0002562804438639432
with O 0 4.003050889878068e-06
isolated O 0 0.00011840754450531676
unilateral B-Disease 0 0.0042030164040625095
retinoblastoma I-Disease 1 0.8246640563011169
, O 0 1.499105474067619e-05
tumor B-Disease 0 0.0003566974774003029
development O 0 1.5694553212597384e-06
is O 0 2.734470001541922e-07
initiated O 0 2.297820401508943e-06
by O 0 4.7647620249335887e-07
somatic O 0 4.418506068759598e-05
inactivation O 0 0.00020025046251248568
of O 0 2.742409037637117e-07
both O 0 3.8327880247379653e-07
alleles O 0 5.210719791648444e-06
of O 0 6.848879934295837e-07
the O 0 7.0214932748058345e-06
RB1 O 0 0.012425926513969898
gene O 0 9.606594539945945e-05
. O 0 3.375222149770707e-05

However O 0 4.606875154422596e-05
, O 0 1.955200787051581e-06
some O 0 3.146076892335259e-07
of O 0 2.5490345478829113e-07
these O 0 7.65761285492772e-07
patients O 0 7.797744183335453e-05
can O 0 1.3544554349209648e-06
transmit O 0 4.05026221415028e-05
retinoblastoma B-Disease 0 0.0009707054123282433
predisposition O 0 0.00016235759539995342
to O 0 1.2091632015653886e-06
their O 0 5.397670975071378e-06
offspring O 0 0.0002787832054309547
. O 0 2.0216244593029842e-05

To O 0 2.7109474103781395e-05
determine O 0 4.9962559387495276e-06
the O 0 1.0413633617645246e-06
frequency O 0 4.317676030041184e-06
and O 0 4.183555972758768e-07
nature O 0 7.141240985220065e-07
of O 0 3.787206708238955e-07
constitutional O 0 4.258947228663601e-05
RB1 O 0 0.0876261293888092
- O 0 0.0006259417859837413
gene O 0 3.828379703918472e-05
mutations O 0 4.513962267083116e-05
in O 0 2.326496542082168e-06
patients O 0 2.375794792897068e-05
with O 0 1.0084833093060297e-06
isolated O 0 6.982394552323967e-05
unilateral B-Disease 0 0.000921697064768523
retinoblastoma I-Disease 0 0.008287991397082806
, O 0 8.725374414098042e-07
we O 0 2.2824440293334192e-07
analyzed O 0 1.5947026668072795e-06
DNA O 0 2.4139974357240135e-06
from O 0 6.474206770690216e-07
peripheral O 0 7.45737852412276e-05
blood O 0 2.0935223801643588e-05
and O 0 2.1488137917913264e-06
from O 0 1.1501461813168135e-05
tumor B-Disease 0 0.15897051990032196
tissue O 0 0.0008003291441127658
. O 0 2.6433204766362906e-05

The O 0 2.8479891625465825e-05
analysis O 0 1.784896812750958e-05
of O 0 6.165998456708621e-06
tumors B-Disease 1 0.9995088577270508
from O 0 2.3757991129969014e-06
54 O 0 2.4679937268956564e-05
( O 0 1.6793020449767937e-06
71 O 0 7.150174042180879e-06
% O 0 9.668133316154126e-07
) O 0 1.4538861137225467e-07
of O 0 1.43481841519133e-07
76 O 0 1.897752190416213e-05
informative O 0 1.1343026017129887e-05
patients O 0 0.0001342670584563166
showed O 0 9.404972843185533e-06
loss O 0 1.029801569529809e-05
of O 0 8.383782983401034e-07
constitutional O 0 8.979751873994246e-05
heterozygosity O 0 0.4270198941230774
( O 0 2.8338548872852698e-05
LOH O 1 0.8632166981697083
) O 0 5.993249033053871e-06
at O 0 6.451085027947556e-06
intragenic O 0 0.00045046137529425323
loci O 0 0.00016644236166030169
. O 0 2.9107191949151456e-05

Three O 0 5.305888407747261e-05
of O 0 1.5487461496377364e-05
13 O 0 0.0001431165001122281
uninformative O 0 0.26284101605415344
patients O 0 0.0026004952378571033
had O 0 1.4128193470241968e-05
constitutional O 0 6.974714051466435e-05
deletions O 0 0.0007029367261566222
. O 0 5.2867966587655246e-05

For O 0 6.872077938169241e-05
39 O 0 0.00013542261149268597
randomly O 0 2.9280077797011472e-05
selected O 0 2.0066770957782865e-05
tumors B-Disease 1 0.9965157508850098
, O 0 3.0971971227700124e-06
SSCP O 0 0.0008002768736332655
, O 0 2.5857484615698922e-06
hetero O 0 0.00020520597172435373
- O 0 3.3251115382881835e-05
duplex O 0 0.00025677058147266507
analysis O 0 1.6541123386559775e-06
, O 0 2.1553022122589027e-07
sequencing O 0 8.939422855291923e-07
, O 0 1.095120367722302e-07
and O 0 1.1066037330920153e-07
Southern O 0 7.280832505784929e-07
blot O 0 1.990282726183068e-05
analysis O 0 7.354463491537899e-07
were O 0 2.809334205267078e-07
used O 0 5.388137651607394e-07
to O 0 1.6344172308890847e-06
identify O 0 2.9287732104421593e-05
mutations O 0 0.00012601184425875545
. O 0 1.7332851712126285e-05

Mutations O 0 0.010616838932037354
were O 0 1.4650708180852234e-05
detected O 0 1.602308839210309e-05
in O 0 1.0786558277686709e-06
21 O 0 5.247152330412064e-06
( O 0 1.387014322062896e-06
91 O 0 9.120361028180923e-06
% O 0 1.4630244322688668e-06
) O 0 4.4402344201444066e-07
of O 0 8.066650707405643e-07
23 O 0 0.0005011396133340895
tumors B-Disease 1 0.999879002571106
with O 0 5.473721830639988e-05
LOH O 1 0.9999710321426392
. O 0 8.563338633393869e-05

In O 0 4.6605768147856e-05
6 O 0 4.511182851274498e-05
( O 0 4.68585722046555e-06
38 O 0 1.15396615001373e-05
% O 0 2.2152403289510403e-06
) O 0 2.400330743057566e-07
of O 0 3.026989645604772e-07
16 O 0 9.917694114847109e-05
tumors B-Disease 1 0.9999886751174927
without O 0 4.601034561346751e-06
LOH O 1 0.9689114689826965
, O 0 4.636572157323826e-07
one O 0 2.023707708076472e-07
mutation O 0 3.129897550024907e-06
was O 0 7.571077276224969e-07
detected O 0 1.7009341490847874e-06
, O 0 7.325079565134729e-08
and O 0 6.930471840860264e-08
in O 0 2.1291889140684361e-07
9 O 0 3.1196434520097682e-06
( O 0 5.504710429704573e-07
56 O 0 2.65164089796599e-06
% O 0 6.707616080348089e-07
) O 0 1.251937504775924e-07
of O 0 1.4821075922100135e-07
the O 0 3.91877256333828e-06
tumors B-Disease 1 0.9999933242797852
without O 0 7.125348020053934e-06
LOH O 1 0.9934566617012024
, O 0 1.3308228972164216e-06
both O 0 1.0779257308968226e-06
mutations O 0 1.5319954400183633e-05
were O 0 1.419891532350448e-06
found O 0 5.8200303101330064e-06
. O 0 1.542055542813614e-05

Thus O 0 6.709300942020491e-05
, O 0 3.344074002598063e-06
a O 0 1.3436088011076208e-06
total O 0 5.35395372480707e-07
of O 0 3.3731240023371356e-07
45 O 0 1.3769025827059522e-05
mutations O 0 1.0393341653980315e-05
were O 0 5.388096724345814e-07
identified O 0 4.1810699258348905e-06
in O 0 6.122322702140082e-06
tumors B-Disease 1 0.9997285008430481
of O 0 5.930389761488186e-06
36 O 0 0.0009935806738212705
patients O 0 0.0008619257714599371
. O 0 2.3234670152305625e-05

Thirty O 0 0.0003058360889554024
- O 0 0.00017422024393454194
nine O 0 6.285255039983895e-06
of O 0 5.335893433766614e-07
the O 0 1.1165529940626584e-06
mutations O 0 1.4803752492298372e-05
- O 0 6.623139597650152e-06
including O 0 6.782800596738525e-07
34 O 0 4.23179926656303e-06
small O 0 9.041864927894494e-07
mutations O 0 3.451483280514367e-06
, O 0 1.0493492652585701e-07
2 O 0 5.037234700466797e-07
large O 0 2.7234040089751943e-07
structural O 0 1.1806208021880593e-05
alterations O 0 1.3824339475831948e-05
, O 0 2.968686487747618e-07
and O 0 4.618222817498463e-07
hypermethylation O 0 0.0005319128395058215
in O 0 2.414966729702428e-06
3 O 0 0.00010477231990080327
tumors O 1 0.999943733215332
- O 0 0.0003555403964128345
were O 0 5.60367482194124e-07
not O 0 1.5783155049575726e-07
detected O 0 9.386498618368933e-07
in O 0 1.2256604975391383e-07
the O 0 4.297708358080854e-07
corresponding O 0 9.637024049879983e-06
peripheral O 0 0.00032678889692761004
blood O 0 9.240526560461149e-05
DNA O 0 7.301053847186267e-05
. O 0 2.059072176052723e-05

In O 0 6.055182893760502e-05
6 O 0 9.894173126667738e-05
( O 0 6.810335889895214e-06
17 O 0 1.0784927326312754e-05
% O 0 1.4603313047700794e-06
) O 0 1.1793021315043006e-07
of O 0 6.07722299150737e-08
the O 0 4.196190843686054e-07
36 O 0 4.441593773663044e-05
patients O 0 1.8423115761834197e-05
, O 0 1.8108956112428132e-07
a O 0 1.971764731933945e-06
mutation O 0 9.72267116594594e-06
was O 0 1.1247748261666857e-06
detected O 0 1.0817669817697606e-06
in O 0 1.6053061813181557e-07
constitutional O 0 2.220901023974875e-06
DNA O 0 2.0863476493104827e-06
, O 0 9.928900368549876e-08
and O 0 7.140969415786458e-08
1 O 0 1.8151541780753178e-07
of O 0 7.452761252579876e-08
these O 0 1.259845987533481e-07
mutations O 0 3.078065901718219e-06
is O 0 5.5700770218436446e-08
known O 0 1.6236651845247252e-07
to O 0 1.1039263370093977e-07
be O 0 1.796143465071509e-07
associated O 0 1.4730934481121949e-06
with O 0 2.142055564036127e-06
reduced O 0 0.00026637548580765724
expressivity O 0 0.05098911374807358
. O 0 2.4793265765765682e-05

The O 0 2.0574763766489923e-05
presence O 0 6.485264748334885e-06
of O 0 8.158547188941156e-07
a O 0 3.317236860311823e-06
constitutional O 0 3.336578811286017e-05
mutation O 0 2.438732008158695e-05
was O 0 7.652123485968332e-07
not O 0 7.58226335051404e-08
associated O 0 2.1987131049172604e-07
with O 0 6.19356370634705e-08
an O 0 2.5304669293291226e-07
early O 0 3.670458909255103e-06
age O 0 4.506383902480593e-06
at O 0 3.078124564126483e-06
treatment O 0 0.00015485046606045216
. O 0 2.209475678682793e-05

In O 0 0.00017127291357610375
1 O 0 0.00017502847185824066
patient O 0 0.0005116306128911674
, O 0 8.590151992393658e-06
somatic O 0 0.0006247491692192852
mosaicism O 0 0.22500646114349365
was O 0 1.0523971468501259e-05
demonstrated O 0 5.030263764638221e-06
by O 0 1.6171006222975848e-07
molecular O 0 1.3396296481005265e-06
analysis O 0 5.11335997543938e-07
of O 0 1.6258933044355217e-07
DNA O 0 2.8209478841745295e-06
and O 0 6.523497972921177e-07
RNA O 0 5.10206655235379e-06
from O 0 2.3064244487613905e-06
peripheral O 0 0.0003222318191546947
blood O 0 0.00015493729733861983
. O 0 2.2846290448796935e-05

In O 0 0.00016284009325318038
2 O 0 0.0003666342527139932
patients O 0 0.0003718162188306451
without O 0 2.3673198938922724e-06
a O 0 7.888510481279809e-06
detectable O 0 6.771896005375311e-05
mutation O 0 1.07964933704352e-05
in O 0 7.041477374514216e-07
peripheral O 0 0.00019278330728411674
blood O 0 5.162222441867925e-05
, O 0 2.151017952201073e-06
mosaicism O 0 0.0038166779559105635
was O 0 3.425570639592479e-06
suggested O 0 1.3293450820128783e-06
because O 0 1.7500742899301258e-07
1 O 0 4.7474401299041347e-07
of O 0 1.94369135897432e-07
the O 0 2.7066537313658046e-06
patients O 0 0.00502022122964263
showed O 0 0.004647123161703348
multifocal O 1 0.9999986886978149
tumors B-Disease 1 0.9999998807907104
and O 0 1.0666728940122994e-06
the O 0 3.1837507208365423e-07
other O 0 2.991079384173645e-07
later O 0 2.6732411697594216e-06
developed O 0 1.0235645277134608e-05
bilateral B-Disease 0 3.684809780679643e-05
retinoblastoma I-Disease 0 0.003867299994453788
. O 0 5.2899129514116794e-05

In O 0 3.8134148780955e-05
conclusion O 0 1.2529446394182742e-05
, O 0 1.6973400533970562e-06
our O 0 9.300706551584881e-07
results O 0 1.182955543299613e-06
emphasize O 0 1.969456889128196e-06
that O 0 1.1732311122614192e-07
the O 0 2.1200972355472913e-07
manifestation O 0 3.507320798235014e-06
and O 0 5.916515988246829e-07
transmissibility O 0 7.469520642189309e-05
of O 0 4.749020376948465e-07
retinoblastoma B-Disease 0 0.0001480641949456185
depend O 0 4.931008561470662e-07
on O 0 2.3538501636721776e-07
the O 0 8.794187777994011e-08
nature O 0 1.1948111477977363e-07
of O 0 3.9846742794225065e-08
the O 0 1.0052437460217334e-07
first O 0 8.424876227763889e-07
mutation O 0 1.6028599247874808e-06
, O 0 5.085639287472077e-08
its O 0 5.464957553158456e-08
time O 0 8.514519578284307e-08
in O 0 7.798771406442029e-08
development O 0 2.228159843298272e-07
, O 0 7.067406215810479e-08
and O 0 3.436275264334654e-08
the O 0 4.843004930421557e-08
number O 0 6.306921562782009e-08
and O 0 8.707977627864238e-08
types O 0 1.952767547663825e-07
of O 0 1.437831969042236e-07
cells O 0 2.760777533694636e-06
that O 0 1.0347726231429988e-07
are O 0 2.2734784010935982e-07
affected O 0 2.961005748147727e-06
. O 0 1.8699514612308121e-06
. O 0 1.3152345673006494e-05

Hereditary B-Disease 1 0.9999967813491821
deficiency I-Disease 1 0.9988164901733398
of I-Disease 0 4.223703399475198e-06
the I-Disease 0 1.7066878399418783e-06
fifth I-Disease 0 1.174123099190183e-05
component I-Disease 0 3.6588839975593146e-06
of I-Disease 0 4.901794454781339e-07
complement I-Disease 0 3.3821668239397695e-06
in O 0 2.0320751445979113e-06
man O 0 6.924190529389307e-05
. O 0 2.4955470507848077e-05

I O 0 0.0028965601231902838
. O 0 0.0007725699106231332

Clinical O 0 0.015043744817376137
, O 0 4.306400296627544e-05
immunochemical O 0 0.0008916282677091658
, O 0 3.8708694773959e-06
and O 0 2.3298782707570354e-06
family O 0 1.486747532908339e-05
studies O 0 2.9497146897483617e-05
. O 0 1.7650801964919083e-05

The O 0 1.7037742509273812e-05
first O 0 6.790199677197961e-06
recognized O 0 4.486012130655581e-06
human O 0 3.1545480396744097e-06
kindred O 0 0.00046459195436909795
with O 0 8.22913134470582e-05
hereditary B-Disease 1 0.999977707862854
deficiency I-Disease 1 0.8859495520591736
of I-Disease 0 1.9436430420682882e-07
the I-Disease 0 2.806239081110107e-07
fifth I-Disease 0 6.873187885503285e-06
component I-Disease 0 1.4934970522517688e-06
of I-Disease 0 1.8639391896613233e-07
complement I-Disease 0 3.1366389521281235e-06
( O 0 3.565159431673237e-06
C5 O 0 0.00012005516327917576
) O 0 1.2362886536720907e-06
is O 0 1.170885411738709e-06
described O 0 1.537968091724906e-05
. O 0 1.5197156244539656e-05

The O 0 4.26307124143932e-05
proband O 0 0.0004715109243988991
, O 0 2.1336068130040076e-06
a O 0 2.381538251938764e-06
20 O 0 1.7664038978182361e-06
- O 0 1.1820786312455311e-05
year O 0 1.178511183752562e-06
- O 0 1.4225455743144266e-05
old O 0 1.2988237358513288e-05
black O 0 6.042849781806581e-05
female O 0 8.774524030741304e-05
with O 0 0.005854645743966103
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 0 0.00014611160440836102
age O 0 1.1598026503634173e-05
11 O 0 4.4652388169197366e-06
, O 0 1.612978735465731e-06
lacked O 0 6.791413761675358e-05
serum O 0 0.0005718866595998406
hemolytic O 1 0.7057790756225586
complement O 0 6.1441446632670704e-06
activity O 0 2.1579605800070567e-06
, O 0 6.909030503265967e-07
even O 0 1.107746811612742e-06
during O 0 1.3066793144389521e-05
remission O 0 0.001330584054812789
. O 0 2.551168654463254e-05

C5 O 0 0.03437656909227371
was O 0 0.00022285766317509115
undetectable O 0 0.0002775539760477841
in O 0 4.474266461329535e-06
her O 0 9.02417923498433e-06
serum O 0 5.38908461749088e-05
by O 0 1.3189422816139995e-06
both O 0 2.0742738797707716e-06
immunodiffusion O 0 0.0012886531185358763
and O 0 6.482619937742129e-05
hemolytic O 1 0.9997963309288025
assays O 0 0.001200574915856123
. O 0 5.612514723907225e-05

Other O 0 1.080070433090441e-05
complement O 0 1.346537010249449e-05
components O 0 8.88984232005896e-06
were O 0 7.414577680719958e-07
normal O 0 3.972808826802066e-06
during O 0 3.885052137775347e-06
remission O 0 0.00024886569008231163
of O 0 3.5476855373417493e-06
lupus O 1 0.9988616704940796
, O 0 1.4274104387368425e-06
but O 0 6.103337000240572e-07
C1 O 0 0.00022801352315582335
, O 0 8.747519473217835e-07
C4 O 0 0.00011047498264815658
, O 0 1.6366757336072624e-06
C2 O 0 8.818031346891075e-05
, O 0 6.468331434916763e-07
and O 0 1.0494588877918432e-06
C3 O 0 0.0006033159443177283
levels O 0 7.484858542738948e-06
fell O 0 5.624023106065579e-05
during O 0 3.015878246515058e-05
exacerbations O 1 0.64178866147995
. O 0 6.548706005560234e-05

A O 0 0.00023186321777757257
younger O 0 6.17310797679238e-05
half O 0 7.436981377395568e-06
- O 0 0.00012090600648662075
sister O 0 4.518493733485229e-05
, O 0 7.408386295537639e-07
who O 0 1.1734196050383616e-06
had O 0 5.082917596155312e-06
no O 0 5.394058462115936e-06
underlying O 0 0.328175812959671
disease O 0 0.049899905920028687
, O 0 7.712367278145393e-07
was O 0 1.3088466630506446e-06
also O 0 3.7289177612365165e-07
found O 0 3.9086847891667276e-07
to O 0 5.153405595592631e-07
lack O 0 9.189473530568648e-06
immunochemically O 0 0.018665378913283348
detectable O 0 0.0001704586175037548
C5 O 0 0.0007174111669883132
. O 0 2.1467312762979418e-05

By O 0 0.0002593406825326383
hemolytic O 1 0.9982898831367493
assay O 0 0.0008334092563018203
, O 0 6.935311830602586e-06
she O 0 2.9694638215005398e-06
exhibited O 0 3.96022733184509e-06
1 O 0 2.204976226494182e-06
- O 0 1.2299335139687173e-05
2 O 0 1.9840367713186424e-06
% O 0 4.5124551206754404e-07
of O 0 4.8611902059292333e-08
the O 0 2.034641113368707e-07
normal O 0 2.704035068745725e-06
serum O 0 1.587954830029048e-05
C5 O 0 5.101237184135243e-05
level O 0 4.866107019552146e-07
and O 0 2.0078518048194383e-07
normal O 0 1.213489440488047e-06
concentrations O 0 1.0193999742114102e-06
of O 0 1.1562706703216463e-07
other O 0 2.0664634803324589e-07
complement O 0 6.518368536490016e-06
components O 0 1.749871989886742e-05
. O 0 1.4436468518397305e-05

C5 O 0 0.030971022322773933
levels O 0 3.177114558639005e-05
of O 0 1.042126427819312e-06
other O 0 4.590164905948768e-07
family O 0 1.1388823395463987e-06
members O 0 3.180940382208064e-07
were O 0 1.8727786255112733e-07
either O 0 1.982567994218698e-07
normal O 0 6.415399980141956e-07
or O 0 2.2855675751998206e-07
approximately O 0 2.8153473863312684e-07
half O 0 7.586031074424682e-07
- O 0 9.280785889131948e-06
normal O 0 1.5350386775025981e-06
, O 0 2.847740745437477e-07
consistent O 0 1.051669073603989e-06
with O 0 2.406577323199599e-06
autosomal O 0 0.21391825377941132
codominant O 0 0.014236826449632645
inheritance O 0 3.475120320217684e-05
of O 0 8.946356047090376e-07
the O 0 5.508000413101399e-06
gene O 0 8.740842167753726e-05
determining O 0 0.001571493805386126
C5 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999986886978149
. O 0 8.883678674465045e-05

Normal O 0 0.08997933566570282
hemolytic O 1 0.999862551689148
titers O 0 0.010701862163841724
were O 0 1.2362070265226066e-05
restored O 0 1.8733800970949233e-05
to O 0 1.2985633475182112e-06
both O 0 4.122840891795931e-06
homozygous O 1 0.5217416882514954
C5 B-Disease 1 0.9999986886978149
- I-Disease 1 0.9997673630714417
deficient I-Disease 1 0.9999902248382568
( O 0 4.138039730605669e-05
C5D B-Disease 1 0.9994994401931763
) O 0 4.279257154848892e-06
sera O 0 1.4706297406519298e-05
by O 0 1.9604385670390911e-07
addition O 0 3.879044356835948e-07
of O 0 5.087467798148282e-07
highly O 0 5.910712388867978e-06
purified O 0 4.307796552893706e-05
human O 0 1.6577396309003234e-05
C5 O 0 0.0013104340760037303
. O 0 4.279698623577133e-05

In O 0 6.905147893121466e-05
specific O 0 3.4370244975434616e-05
C5 O 0 0.010058091953396797
titrations O 0 0.02008463628590107
, O 0 2.4828018467815127e-06
however O 0 6.247858550523233e-07
, O 0 1.8767246956485906e-07
it O 0 7.225213494166383e-08
was O 0 3.845489118248224e-07
noted O 0 3.1066258543432923e-07
that O 0 4.460215308199622e-08
when O 0 1.2710974317542423e-07
limited O 0 2.1952833151317463e-07
amounts O 0 1.8269427926043136e-07
of O 0 1.2269224214378482e-07
C5 O 0 3.205588654964231e-05
were O 0 2.3471837096167292e-07
assayed O 0 3.301183369330829e-06
in O 0 1.0085046397989572e-07
the O 0 9.478705464971426e-08
presence O 0 2.348639043248113e-07
of O 0 1.1972315405728295e-07
low O 0 3.7560248529189266e-06
dilutions O 0 8.165727194864303e-05
of O 0 4.888628950538987e-07
either O 0 4.961456397722941e-06
C5D B-Disease 1 0.9996393918991089
serum O 0 5.238498488324694e-05
, O 0 3.396980616798828e-07
curving O 0 4.4561143113242e-06
rather O 0 4.639624080482463e-07
than O 0 3.0454808097601926e-07
linear O 0 4.299181910027983e-06
dose O 0 1.575309033796657e-05
- O 0 8.549965059501119e-06
response O 0 1.1844625760204508e-06
plots O 0 1.552840103613562e-06
were O 0 3.7965617138979724e-07
consistently O 0 1.8486982753529446e-06
obtained O 0 5.705708190362202e-07
, O 0 3.2149637263501063e-07
suggesting O 0 1.8553745348981465e-06
some O 0 7.0969747412164e-07
inhibitory O 0 4.489000275498256e-05
effect O 0 1.238319237018004e-05
. O 0 1.0734974239312578e-05

Further O 0 6.567103264387697e-05
studies O 0 1.8951463061966933e-05
suggested O 0 7.738250133115798e-06
that O 0 6.310525577646331e-07
low O 0 7.600218395964475e-06
dilutions O 0 0.0005331564461812377
of O 0 4.301527951611206e-06
C5D B-Disease 1 0.9999969005584717
serum O 0 0.0002042383566731587
contain O 0 9.502053899268503e-07
a O 0 1.138719312621106e-06
factor O 0 1.0191550927629578e-06
( O 0 5.735714694310445e-07
or O 0 2.0109561660319741e-07
factors O 0 1.9022833441795228e-07
) O 0 1.2216263201025868e-07
interfering O 0 2.2678739242110169e-07
at O 0 1.1454970660906838e-07
some O 0 3.987646834957559e-08
step O 0 4.620443121439166e-07
in O 0 2.1846464903774176e-07
the O 0 9.579512152413372e-07
hemolytic O 0 0.39965584874153137
assay O 0 2.0593903172994033e-05
of O 0 4.7172832751130045e-07
C5 O 0 0.00024840483092702925
, O 0 3.562858239547495e-07
rather O 0 2.1102312075527152e-07
than O 0 1.8308830362911976e-07
a O 0 1.4918485931048053e-06
true O 0 5.214776592765702e-06
C5 O 0 0.0007625147700309753
inhibitor O 0 0.00015930512745399028
or O 0 1.08290169009706e-05
inactivator O 0 0.0005337073816917837
. O 0 2.2309111955109984e-05

Of O 0 6.281895184656605e-05
clinical O 0 0.0014054670464247465
interest O 0 9.59687076829141e-06
are O 0 7.619034363415267e-07
( O 0 8.298358693537011e-07
a O 0 8.577991934544116e-07
) O 0 3.203761593795207e-07
the O 0 2.46929459990497e-07
documentation O 0 1.3492572179529816e-06
of O 0 1.1307600971122156e-06
membranous O 1 0.9977239966392517
glomerulonephritis B-Disease 1 1.0
, O 0 0.0015592076815664768
vasculitis B-Disease 1 0.9999997615814209
, O 0 5.3083786042407155e-05
and O 0 0.0024991135578602552
arthritis B-Disease 1 1.0
in O 0 3.0634819268016145e-06
an O 0 1.2785162653017323e-06
individual O 0 1.6657030528222094e-06
lacking O 0 2.450509782647714e-05
C5 O 0 0.0013481311034411192
( O 0 6.168959316710243e-07
and O 0 9.924849564413307e-08
its O 0 2.1784383363865345e-07
biologic O 0 3.277132782386616e-05
functions O 0 4.665972426209919e-07
) O 0 1.973810697109002e-07
, O 0 8.560783726352383e-08
and O 0 1.102529125773799e-07
( O 0 5.848423256793467e-07
b O 0 8.16245403711946e-07
) O 0 1.9201675627300574e-07
a O 0 5.433474825622397e-07
remarkable O 0 2.471618245181162e-06
propensity O 0 8.554155647289008e-05
to O 0 1.8374863429926336e-05
bacterial B-Disease 1 0.9999834299087524
infections I-Disease 1 0.9994327425956726
in O 0 6.141165727058251e-07
the O 0 5.331687020770914e-07
proband O 0 0.00011096147500211373
, O 0 2.5311959461760125e-07
even O 0 1.2404771609908494e-07
during O 0 3.752763291231531e-07
periods O 0 9.428162002222962e-07
of O 0 1.5575326983707782e-07
low O 0 5.7154793466906995e-06
- O 0 4.192644701106474e-05
dose O 0 1.8607915990287438e-05
or O 0 1.0741657661128556e-06
alternate O 0 7.437534350174246e-06
- O 0 0.00019054462609346956
day O 0 4.4603930291486904e-05
corticosteroid O 0 0.0639168918132782
therapy O 0 0.00430854270234704
. O 0 5.5372947826981544e-05

Other O 0 1.1365786122041754e-05
observations O 0 1.4693483535666019e-05
indicate O 0 2.852801344488398e-06
that O 0 1.843962138536881e-07
the O 0 4.48554914100896e-07
C5D B-Disease 1 0.9962707757949829
state O 0 7.832601909285586e-07
is O 0 1.566319696166829e-07
compatible O 0 9.127697921940126e-07
with O 0 3.363281848578481e-07
normal O 0 6.471844699262874e-06
coagulation O 0 3.8093476177891716e-05
function O 0 4.920453307022399e-07
and O 0 8.72761489745244e-08
the O 0 1.3728134717894136e-07
capacity O 0 4.381712699341733e-07
to O 0 1.9007184448582848e-07
mount O 0 1.2796770533896051e-05
a O 0 3.2132709748111665e-05
neutrophilic O 1 0.8877142071723938
leukocytosis O 1 0.9136006236076355
during O 0 0.0003569053078535944
pyogenic B-Disease 1 0.9920369386672974
infection I-Disease 0 0.016524426639080048
. O 0 9.059317562787328e-06
. O 0 1.9609036826295778e-05

Susceptibility O 1 0.9068428874015808
to O 0 0.001465529901906848
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.009076708927750587
twins O 0 0.15569396317005157
: O 0 1.4751024082215736e-06
the O 0 3.2623358947603265e-07
role O 0 6.656248388026142e-07
of O 0 2.7985791462015186e-07
genes O 0 2.954008095912286e-06
, O 0 9.853415576799307e-07
HLA O 0 0.00015616750170011073
, O 0 3.2839804475770507e-07
and O 0 2.4933748932198796e-07
the O 0 9.82993242359953e-07
environment O 0 3.837389886029996e-05
. O 0 1.603190685273148e-05

OBJECTIVE O 0 0.00015622809587512165
To O 0 3.8845519156893715e-06
determine O 0 2.381059175604605e-06
the O 0 6.4521526610406e-07
relative O 0 7.271275080711348e-06
effects O 0 1.2338185115368105e-05
of O 0 5.58326007649157e-07
genetic O 0 1.4187087799655274e-05
and O 0 9.413320185558405e-07
environmental O 0 7.092508894857019e-06
factors O 0 1.4263980574469315e-06
in O 0 3.2924772312981077e-06
susceptibility O 0 0.030546434223651886
to O 0 0.0009021079749800265
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.0014906602445989847
AS B-Disease 0 0.0002794258180074394
) O 0 1.774861812009476e-05
. O 0 1.6429374227300286e-05

METHODS O 0 0.000579219835344702
Twins O 0 0.0038075787015259266
with O 0 6.1396581259032246e-06
AS B-Disease 0 6.129425310064107e-05
were O 0 1.4622572734879213e-06
identified O 0 1.4504822729577427e-06
from O 0 1.9643255200207932e-07
the O 0 3.811460942415579e-07
Royal O 0 2.0365494492580183e-05
National O 0 1.0175168426940218e-05
Hospital O 0 0.026325462386012077
for O 0 0.0001536368072265759
Rheumatic B-Disease 1 0.9999995231628418
Diseases I-Disease 1 0.8729248642921448
database O 0 0.00017293952987529337
. O 0 5.232252078712918e-05

Clinical O 0 0.0264779943972826
and O 0 6.190233398228884e-05
radiographic O 0 0.018993549048900604
examinations O 0 9.593979484634474e-05
were O 0 1.7866360622065258e-06
performed O 0 2.348908537896932e-06
to O 0 6.099461415942642e-07
establish O 0 2.6592191716190428e-05
diagnoses O 0 0.4530767798423767
, O 0 9.938760740624275e-06
and O 0 9.152967686532065e-05
disease O 1 0.7615348696708679
severity O 1 0.6481885313987732
was O 0 1.6396332284784876e-05
assessed O 0 4.562905814964324e-06
using O 0 6.333496571642172e-07
a O 0 1.3735326547248405e-06
combination O 0 3.456525973888347e-06
of O 0 5.264046194497496e-07
validated O 0 9.565887012286112e-06
scoring O 0 7.15046689947485e-06
systems O 0 4.985178020433523e-05
. O 0 2.5921362976077944e-05

HLA O 0 0.014000479131937027
typing O 0 0.0006118380115367472
for O 0 3.8160087569849566e-05
HLA O 0 0.0027558866422623396
- O 0 0.0002429834275972098
B27 O 0 0.00023163160949479789
, O 0 4.7930184337019455e-06
HLA O 0 0.000286956928903237
- O 0 2.2717977117281407e-05
B60 O 0 2.5616980565246195e-05
, O 0 5.987959639242035e-07
and O 0 1.3988262708153343e-06
HLA O 0 0.002788167679682374
- O 0 0.0003790571936406195
DR1 O 0 0.012448222376406193
was O 0 1.893056946755678e-06
performed O 0 7.977371865308669e-07
by O 0 2.8707904675684404e-07
polymerase O 0 8.46171042212518e-06
chain O 0 2.951971964648692e-06
reaction O 0 4.112573606107617e-07
with O 0 9.902517206228367e-08
sequence O 0 8.618170568297501e-07
- O 0 3.2214686598308617e-06
specific O 0 5.483213385559793e-07
primers O 0 5.769388735643588e-06
, O 0 3.171653020217491e-07
and O 0 4.388537604427256e-07
zygosity O 0 0.00013246142771095037
was O 0 2.9270004233694635e-06
assessed O 0 8.241429895861074e-06
using O 0 6.688766916340683e-06
microsatellite O 0 0.0017355723539367318
markers O 0 0.00018510779773350805
. O 0 3.344038486829959e-05

Genetic O 0 0.002037299331277609
and O 0 1.4270812243921682e-05
environmental O 0 1.7945792933460325e-05
variance O 0 6.183458935993258e-06
components O 0 3.713484375111875e-06
were O 0 3.814297144799639e-07
assessed O 0 1.3090839274809696e-06
with O 0 1.1379568576330712e-07
the O 0 2.037575370650302e-07
program O 0 1.720555815154512e-06
Mx O 0 9.273760952055454e-06
, O 0 8.771672810325981e-08
using O 0 9.348676144327328e-08
data O 0 1.4422843719330558e-07
from O 0 4.9008779257064816e-08
this O 0 3.915123514275365e-08
and O 0 8.199648249274105e-08
previous O 0 4.724973337033589e-07
studies O 0 7.323528734559659e-07
of O 0 3.1007294865048607e-07
twins O 0 0.0005149050266481936
with O 0 2.481845740476274e-06
AS B-Disease 0 0.00020457615028135478
. O 0 1.9590586816775613e-05

RESULTS O 0 0.00023126225278247148
Six O 0 2.0087753000552766e-05
of O 0 4.261086360202171e-06
8 O 0 9.600917837815359e-05
monozygotic O 0 0.15003538131713867
( O 0 3.899788134731352e-05
MZ O 1 0.9381905794143677
) O 0 7.66810990171507e-06
twin O 0 0.00038879428757354617
pairs O 0 3.765597284655087e-05
were O 0 8.624175279692281e-06
disease O 0 0.0001870728883659467
concordant O 0 0.0011545451125130057
, O 0 1.1620128361755633e-06
compared O 0 1.2139987575210398e-06
with O 0 1.6538915303954127e-07
4 O 0 1.2543163165901206e-06
of O 0 2.737220086146408e-07
15 O 0 3.369514615769731e-06
B27 O 0 0.00011828407878056169
- O 0 0.00016570727166254073
positive O 0 7.500400442950195e-06
dizygotic O 0 0.00031755719101056457
( O 0 3.6411140627023997e-06
DZ O 0 0.003639431204646826
) O 0 1.5331821714426042e-06
twin O 0 5.333343506208621e-05
pairs O 0 4.72787633043481e-06
( O 0 1.141229631684837e-06
27 O 0 4.794669166585663e-06
% O 0 5.442695965029998e-07
) O 0 8.673333695696783e-08
and O 0 6.749389314109067e-08
4 O 0 5.192492267269699e-07
of O 0 2.2787465070450708e-07
32 O 0 9.461377885600086e-06
DZ O 0 0.24694278836250305
twin O 0 0.0009257066994905472
pairs O 0 9.115345164900646e-06
overall O 0 1.763513864716515e-05
( O 0 9.638812343837344e-07
12 O 0 1.1124091088277055e-06
. O 0 3.2486383361174376e-07
5 O 0 2.411339892205433e-06
% O 0 3.3464027637819527e-06
) O 0 2.696592673601117e-06
. O 0 6.846575615782058e-06

Nonsignificant O 0 0.10634278506040573
increases O 0 0.00022248610912356526
in O 0 3.015587481058901e-06
similarity O 0 4.3663926589943e-06
with O 0 6.527063192152127e-07
regard O 0 1.3177993878343841e-06
to O 0 8.117173706523317e-07
age O 0 1.4419736544368789e-05
at O 0 2.2085108867031522e-05
disease O 0 0.015596709214150906
onset O 0 0.09721672534942627
and O 0 3.5228072192694526e-07
all O 0 6.487779558028706e-08
of O 0 2.342474090255564e-07
the O 0 8.273094863398e-06
disease O 0 0.011145963333547115
severity O 0 0.004254958126693964
scores O 0 2.301370659552049e-05
assessed O 0 1.0545692020969e-05
were O 0 5.854237770108739e-07
noted O 0 2.6106856694241287e-06
in O 0 6.355324330797885e-06
disease O 0 0.004303382709622383
- O 0 0.008314472623169422
concordant O 1 0.8491919040679932
MZ O 1 0.999951958656311
twins O 0 0.12861353158950806
compared O 0 3.929841113858856e-05
with O 0 1.5270974472514354e-05
concordant O 1 0.7199220657348633
DZ O 1 0.9998615980148315
twins O 0 0.4954788386821747
. O 0 0.00010307261982234195

HLA O 0 0.3325774073600769
- O 0 0.0011719848262146115
B27 O 0 0.0003146280942019075
and O 0 4.29328611062374e-06
B60 O 0 0.00014747705426998436
were O 0 6.785957680222054e-07
associated O 0 8.749397011342808e-07
with O 0 3.0980930887380964e-07
the O 0 5.892736226087436e-06
disease O 0 0.0006119981408119202
in O 0 1.154384790424956e-06
probands O 0 0.0018796040676534176
, O 0 2.458045287312416e-07
and O 0 1.1186916282213133e-07
the O 0 1.637311299873545e-07
rate O 0 3.695731265906943e-06
of O 0 7.612228500875062e-07
disease O 0 7.208420720417053e-05
concordance O 0 0.00019937483011744916
was O 0 4.212640760670183e-06
significantly O 0 1.2243875971762463e-05
increased O 0 2.0443089852051344e-06
among O 0 6.706151225444046e-07
DZ O 0 0.08875101804733276
twin O 0 0.00030523803434334695
pairs O 0 1.8104550463249325e-06
in O 0 1.7427294096705737e-07
which O 0 1.2032019469643274e-07
the O 0 2.2084641670971905e-07
co O 0 1.1792602890636772e-05
- O 0 8.579202403780073e-05
twin O 0 0.000874959456268698
was O 0 4.3555169213505e-06
positive O 0 6.076771796870162e-07
for O 0 2.48345514819448e-07
both O 0 7.959217214192904e-07
B27 O 0 0.0002707885578274727
and O 0 1.356980010314146e-05
DR1 O 0 0.026378918439149857
. O 0 3.4405558835715055e-05

Additive O 0 0.004431724548339844
genetic O 0 0.0009619058691896498
effects O 0 0.00019498913025017828
were O 0 2.1506323264475213e-06
estimated O 0 1.9413216705288505e-06
to O 0 3.371551144937257e-07
contribute O 0 1.016823148347612e-06
97 O 0 4.1006310311786365e-06
% O 0 8.751800351092243e-07
of O 0 8.508268933837826e-08
the O 0 4.330218246195727e-07
population O 0 3.46066235579201e-06
variance O 0 1.0959747669403441e-05
. O 0 1.0530979125178419e-05

CONCLUSION O 0 0.0005986724863760173
Susceptibility O 0 0.0022480215411633253
to O 0 6.2877670643501915e-06
AS B-Disease 0 3.055961860809475e-05
is O 0 1.7205344420290203e-06
largely O 0 4.495275334193138e-06
genetically O 0 6.202967142598936e-06
determined O 0 1.9937026536354097e-06
, O 0 2.0371963671550475e-07
and O 0 1.5086510529727093e-07
the O 0 3.476808103641815e-07
environmental O 0 3.263084636273561e-06
trigger O 0 2.072179631795734e-05
for O 0 6.627339530496101e-07
the O 0 9.193874575430527e-06
disease O 0 0.0005610671360045671
is O 0 1.5188719544312335e-06
probably O 0 6.832786311861128e-06
ubiquitous O 0 9.881349978968501e-05
. O 0 2.124153070326429e-05

HLA O 0 0.48244649171829224
- O 0 0.0013375736307352781
B27 O 0 0.0002663531922735274
accounts O 0 5.686305485141929e-06
for O 0 7.733888764960284e-07
a O 0 2.5574454411980696e-06
minority O 0 6.0002375903422944e-06
of O 0 1.6759312870817666e-07
the O 0 9.978630259865895e-07
overall O 0 0.0005451859324239194
genetic O 0 0.00020489237795118243
susceptibility O 0 0.000218622139072977
to O 0 1.9026041400138638e-06
AS B-Disease 0 0.00011551636998774484
. O 0 2.6673924367059954e-05

Cell O 0 0.010039066895842552
cycle O 0 0.0009252569871023297
- O 0 0.00018353240739088506
dependent O 0 1.903091288113501e-05
colocalization O 0 8.154653914971277e-05
of O 0 1.6051192233135225e-06
BARD1 O 0 0.0005822803359478712
and O 0 4.239562713337364e-06
BRCA1 O 0 0.0001739559811539948
proteins O 0 2.413555421298952e-06
in O 0 9.933966111930204e-07
discrete O 0 1.4579612980014645e-05
nuclear O 0 2.3031558157526888e-05
domains O 0 2.9560418624896556e-05
. O 0 1.5176719898590818e-05

Germ O 0 0.12924794852733612
- O 0 0.008200853131711483
line O 0 0.0003164652443956584
mutations O 0 3.827813998213969e-05
of O 0 9.137896768152132e-07
the O 0 2.565127260822919e-06
BRCA1 O 0 0.00046025827759876847
gene O 0 1.4277249647420831e-05
predispose O 0 2.6007777705672197e-05
women O 0 2.994081341967103e-06
to O 0 8.841985277285858e-07
early O 0 2.176823909394443e-05
- O 0 0.38363566994667053
onset O 1 0.9997913241386414
breast B-Disease 1 0.9999970197677612
and I-Disease 1 0.989294171333313
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
by O 0 2.105090516124619e-06
compromising O 0 2.117805888701696e-05
the O 0 1.309147478423256e-06
genes O 0 9.886814041237812e-06
presumptive O 0 0.0004618648672476411
function O 0 2.4580924673500704e-06
as O 0 1.1199442724318942e-06
a O 0 3.26191948261112e-05
tumor B-Disease 0 0.07259704917669296
suppressor O 0 0.003718629712238908
. O 0 4.2331903387093917e-05

Although O 0 5.2444313041632995e-05
the O 0 8.720110599824693e-06
biochemical O 0 8.487333980156109e-05
properties O 0 6.578232387255412e-06
of O 0 1.1854763215524144e-06
BRCA1 O 0 0.00046390958596020937
polypeptides O 0 3.7590965803246945e-05
are O 0 2.0005008138923586e-07
not O 0 1.2380120040234033e-07
understood O 0 3.7291169974196237e-07
, O 0 7.905161680810124e-08
their O 0 1.0979919551346029e-07
expression O 0 7.625641842423647e-07
pattern O 0 1.8941169628305943e-06
and O 0 2.0592887040038477e-07
subcellular O 0 2.1670246496796608e-05
localization O 0 1.44873029057635e-05
suggest O 0 1.1084960078733275e-06
a O 0 6.713081575071556e-07
role O 0 1.1333099791954737e-06
in O 0 2.6392463041702285e-06
cell O 0 0.0001622693962417543
- O 0 0.00020270766981411725
cycle O 0 0.00024725787807255983
regulation O 0 6.346455484163016e-05
. O 0 2.113359369104728e-05

When O 0 0.0001730588119244203
resting O 0 0.0007857696036808193
cells O 0 0.00014648881915491074
are O 0 7.841427418497915e-07
induced O 0 6.981821934459731e-05
to O 0 7.002869892858143e-07
proliferate O 0 1.2043712558806874e-05
, O 0 1.9490185820814077e-07
the O 0 1.1652515752302861e-07
steady O 0 6.110458343755454e-06
- O 0 8.177037670975551e-06
state O 0 2.1774559400000726e-07
levels O 0 1.722941931348032e-07
of O 0 1.3402168974607775e-07
BRCA1 O 0 2.839861008396838e-05
increase O 0 8.502598234372272e-07
in O 0 3.521336111589335e-07
late O 0 3.7706176954088733e-06
G1 O 0 5.5859985877759755e-05
and O 0 2.0179760440441896e-07
reach O 0 4.2851360149143147e-07
a O 0 7.856338015699293e-07
maximum O 0 5.952073024673155e-06
during O 0 8.965026609075721e-06
S O 0 0.0005365156685002148
phase O 0 0.00010882092465180904
. O 0 3.284704143879935e-05

Moreover O 0 0.000306999048916623
, O 0 8.192414497898426e-06
in O 0 5.843762210133718e-06
S O 0 0.004900273401290178
phase O 0 0.0001400387700414285
cells O 0 2.7947120543103665e-05
, O 0 1.399640268573421e-06
BRCA1 O 0 5.47046511201188e-05
polypeptides O 0 1.4221074707165826e-05
are O 0 3.5512090335032553e-07
hyperphosphorylated O 0 4.07924126193393e-05
and O 0 6.138249659670691e-07
accumulate O 0 4.535383141046623e-06
into O 0 8.370481054953416e-07
discrete O 0 1.1487913070595823e-05
subnuclear O 0 0.00015476203407160938
foci O 0 0.00034646462881937623
termed O 0 8.384799002669752e-05
" O 0 1.259306645806646e-05
BRCA1 O 0 0.00046424890751950443
nuclear O 0 6.753747584298253e-05
dots O 0 0.0005722159403376281
. O 0 3.283135447418317e-05

" O 0 0.0008217945578508079
BRCA1 O 0 0.0793982446193695
associates O 0 0.0022401176393032074
in O 0 9.352470442536287e-06
vivo O 0 0.00014327310782391578
with O 0 2.0580355339916423e-06
a O 0 2.1921732695773244e-05
structurally O 0 0.006688819266855717
related O 0 3.912364263669588e-05
protein O 0 3.75300005543977e-05
termed O 0 0.0002109912602463737
BARD1 O 0 0.01361010130494833
. O 0 6.285982090048492e-05

Here O 0 5.077906098449603e-05
we O 0 3.7581532978947507e-06
show O 0 2.0922411749779712e-06
that O 0 1.3303352375260147e-07
the O 0 1.815514423242348e-07
steady O 0 8.048560630413704e-06
- O 0 1.6845418940647505e-05
state O 0 3.180843179961812e-07
levels O 0 3.225491127523128e-07
of O 0 1.239824314325233e-07
BARD1 O 0 0.00023101034457795322
, O 0 2.832399843555322e-07
unlike O 0 3.4863771247728437e-07
those O 0 6.53629470548367e-08
of O 0 1.7071486979602923e-07
BRCA1 O 0 0.00012115690333303064
, O 0 6.005533919051231e-07
remain O 0 1.048607487064146e-06
relatively O 0 9.98907466964738e-07
constant O 0 2.1534522147703683e-06
during O 0 4.384723524708534e-06
cell O 0 0.00018293870380148292
cycle O 0 0.00018056470435112715
progression O 0 0.00024941793526522815
. O 0 2.1205665689194575e-05

However O 0 9.057408897206187e-05
, O 0 1.2992684787604958e-05
immunostaining O 0 0.0006393488729372621
revealed O 0 3.268636646680534e-05
that O 0 1.1931582548641018e-06
BARD1 O 0 0.0004983928520232439
resides O 0 1.7540121916681528e-05
within O 0 3.138820375170326e-06
BRCA1 O 0 0.0001547288557048887
nuclear O 0 1.1785429705923889e-05
dots O 0 6.315085920505226e-05
during O 0 4.742986675410066e-06
S O 0 7.811662362655625e-05
phase O 0 2.293741545145167e-06
of O 0 9.488744723284981e-08
the O 0 2.8573219879035605e-07
cell O 0 1.286113456444582e-05
cycle O 0 9.194750418828335e-06
, O 0 1.7490364712102746e-07
but O 0 9.181804472291333e-08
not O 0 8.180153088233055e-08
during O 0 6.184664016473107e-07
the O 0 1.9588028408179525e-06
G1 O 0 0.0015223555965349078
phase O 0 0.00010017982276622206
. O 0 2.0974912331439555e-05

Nevertheless O 0 0.000572322285734117
, O 0 1.767003777786158e-05
BARD1 O 0 0.001061296439729631
polypeptides O 0 6.30805006949231e-05
are O 0 3.072066760978487e-07
found O 0 2.6068838110404613e-07
exclusively O 0 3.7738303149126295e-07
in O 0 1.2445238439795503e-07
the O 0 1.422124711325523e-07
nuclear O 0 9.365958817397768e-07
fractions O 0 9.20679156024562e-07
of O 0 1.0048986354149747e-07
both O 0 3.2923878734436585e-07
G1 O 0 0.00015574574354104698
- O 0 2.5084389562834986e-05
and O 0 3.4844169931602664e-06
S O 0 0.001995677361264825
- O 0 0.00041214891825802624
phase O 0 0.00019485995289869606
cells O 0 9.257018973585218e-05
. O 0 1.7686641513137147e-05

Therefore O 0 8.042751142056659e-05
, O 0 5.722744390368462e-06
progression O 0 8.049487951211631e-05
to O 0 1.7766996052159811e-06
S O 0 0.0010658964747563004
phase O 0 1.3773399587080348e-05
is O 0 2.872044717605604e-07
accompanied O 0 9.481252618570579e-07
by O 0 1.2754044576013257e-07
the O 0 1.7900660509440058e-07
aggregation O 0 1.5132809494389221e-06
of O 0 3.873432774526009e-07
nuclear O 0 7.62195122661069e-06
BARD1 O 0 0.0001166954607469961
polypeptides O 0 2.6717356377048418e-05
into O 0 4.322887889429694e-06
BRCA1 O 0 0.00032044213730841875
nuclear O 0 8.590146899223328e-05
dots O 0 0.000358378078090027
. O 0 3.163099245284684e-05

This O 0 4.6031993406359106e-05
cell O 0 0.00027662640786729753
cycle O 0 9.392754145665094e-05
- O 0 5.2038882131455466e-05
dependent O 0 7.253627700265497e-06
colocalization O 0 3.559010292519815e-05
of O 0 9.400850444762909e-07
BARD1 O 0 0.001779542420990765
and O 0 3.874299636663636e-06
BRCA1 O 0 0.00019381708989385515
indicates O 0 1.7012941952998517e-06
a O 0 5.478263460645394e-07
role O 0 1.0216666623819037e-06
for O 0 8.653518648316094e-07
BARD1 O 0 0.0008995585958473384
in O 0 6.061709427740425e-06
BRCA1 O 0 0.0012333926279097795
- O 0 0.002395945368334651
mediated O 0 0.06264486908912659
tumor B-Disease 0 0.11514360457658768
suppression O 0 0.0005308517720550299
. O 0 7.723686576355249e-05

Ethnic O 0 0.0004285410395823419
differences O 0 0.0001100884037441574
in O 0 1.2636099199880846e-05
the O 0 1.4083921996643767e-05
HFE O 0 0.0096123106777668
codon O 0 0.0003142614441458136
282 O 0 0.0003682519309222698
( O 0 7.995636406121776e-05
Cys O 0 0.16631585359573364
/ O 0 0.0016099526546895504
Tyr O 0 0.0037363055162131786
) O 0 4.856179657508619e-05
polymorphism O 0 0.0004392768023535609
. O 0 3.548883614712395e-05

Recent O 0 0.00020408733689691871
studies O 0 5.256593067315407e-05
have O 0 6.693629529763712e-06
shown O 0 2.3332790078711696e-05
that O 0 2.5295714294770733e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 0.03854998201131821
HH B-Disease 1 0.8957335948944092
) O 0 2.3197017071652226e-06
is O 0 3.1106429787541856e-07
likely O 0 7.926176408545871e-07
to O 0 1.5603202996317123e-07
be O 0 1.785268892717795e-07
caused O 0 1.027334519676515e-06
by O 0 2.2770478835809627e-07
homozygosity O 0 5.772966324002482e-05
for O 0 3.6049584650754696e-07
a O 0 4.7189078031806275e-06
Cys282Tyr O 0 0.002650635549798608
mutation O 0 9.92279365163995e-06
in O 0 5.082972620584769e-07
the O 0 1.3891310572944349e-06
HFE O 0 0.0014213421382009983
gene O 0 1.2957370017829817e-05
located O 0 6.8288977672636975e-06
4 O 0 2.2170996089698747e-05
. O 0 1.9971197616541758e-05

5 O 0 0.0007302621961571276
Mb O 0 0.009987336583435535
telomeric O 0 0.009488070383667946
to O 0 5.680738468072377e-05
HLA O 0 0.0059371162205934525
- O 0 0.0002895332872867584
A O 0 7.299063145183027e-05
. O 0 4.0082722989609465e-05

Population O 0 0.00010423588537378237
studies O 0 7.681635906919837e-06
of O 0 6.385051847246359e-07
this O 0 4.6270133680081926e-07
polymorphism O 0 1.0712015864555724e-05
are O 0 1.0822090246165317e-07
facilitated O 0 1.108356514123443e-06
by O 0 1.214033034102613e-07
the O 0 1.2078291433681443e-07
fact O 0 1.6383468448566418e-07
that O 0 1.1421666812339026e-07
the O 0 6.597228434657154e-07
Cys282Tyr O 0 0.0005556358955800533
mutation O 0 2.0264693375793286e-05
creates O 0 6.215638677531388e-06
a O 0 3.889637810061686e-06
Rsal O 0 0.00022164110851008445
restriction O 0 1.763478576322086e-05
site O 0 1.153106950368965e-05
. O 0 1.0870041478483472e-05

We O 0 3.6549641663441435e-05
have O 0 4.209957751299953e-06
studied O 0 3.6916096632921835e-06
the O 0 2.0233924260537606e-06
codon O 0 5.228705776971765e-05
282 O 0 0.00010158109216718003
( O 0 1.806978434615303e-05
Cys O 0 0.027592161670327187
/ O 0 0.0003851020010188222
Tyr O 0 0.00032535579521209
) O 0 2.526406660763314e-06
polymorphism O 0 8.496910595567897e-06
in O 0 4.5884098653914407e-07
different O 0 7.998175988177536e-07
ethnic O 0 7.08585594111355e-06
groups O 0 7.217525308078621e-06
. O 0 1.361535305477446e-05

In O 0 4.361712126410566e-05
agreement O 0 9.914166184898932e-06
with O 0 8.960846571426373e-07
previous O 0 2.8620368084375514e-06
observations O 0 2.37930203184078e-06
the O 0 8.965350843936903e-07
Tyr O 0 0.0002143129677278921
allele O 0 2.126800245605409e-05
appeared O 0 1.9428812265687156e-06
to O 0 1.6485454068515537e-07
be O 0 1.0460898636210914e-07
rare O 0 4.868001042268588e-07
or O 0 4.5023452344139514e-07
absent O 0 4.154082944296533e-06
in O 0 4.185838804460218e-07
Asiatic O 0 2.529347148083616e-05
( O 0 4.2639138086997264e-07
Indian O 0 2.4849998681020224e-07
, O 0 1.6457681795145618e-07
Chinese O 0 4.719618686976901e-07
) O 0 1.985187736863736e-06
populations O 0 1.2221359611430671e-05
. O 0 1.0823863703990355e-05

The O 0 2.433952977298759e-05
highest O 0 1.9370350855751894e-05
allele O 0 3.044747791136615e-05
frequency O 0 1.0200427823292557e-05
( O 0 1.0629054258970427e-06
7 O 0 1.4210415884008398e-06
. O 0 1.5987548351859004e-07
5 O 0 1.0645062502590008e-06
% O 0 1.387412567055435e-06
) O 0 1.9696398112500901e-07
was O 0 2.989265794894891e-07
found O 0 4.78955030303041e-07
in O 0 1.761380872267182e-06
Swedes O 0 0.00031082204077392817
. O 0 2.179644798161462e-05

Saamis O 0 0.016976093873381615
( O 0 7.847836968721822e-05
2 O 0 2.4633380235172808e-05
% O 0 7.567608008685056e-06
) O 0 7.086383675414254e-07
and O 0 3.559173364919843e-07
Mordvinians O 0 7.363015174632892e-05
( O 0 4.921373601973755e-07
1 O 0 2.631209099490661e-07
. O 0 6.639175609279846e-08
8 O 0 8.880876407602045e-07
% O 0 6.620377916988218e-07
) O 0 1.779292517767317e-07
had O 0 4.047231243475835e-07
significantly O 0 1.7085964145735488e-06
lower O 0 1.2520168866103631e-06
frequencies O 0 7.996436579560395e-07
of O 0 2.691043903269019e-07
the O 0 3.191035602867487e-06
Tyr O 0 0.0009992074919864535
allele O 0 0.00015264908142853528
. O 0 1.7563272194820456e-05

Comparisons O 0 0.0001062126102624461
with O 0 1.4447293324337807e-05
allele O 0 8.474086644127965e-05
frequencies O 0 9.686503290140536e-06
based O 0 1.9371382222743705e-06
on O 0 1.463621856601094e-06
prevalence O 0 0.00011154069943586364
estimates O 0 5.192310709389858e-06
of O 0 6.500612244053627e-07
HH B-Disease 0 0.12149979919195175
showed O 0 5.418331966211554e-06
some O 0 1.0066520417240099e-07
disagreements O 0 8.011970180632488e-07
with O 0 1.5208534875910118e-07
the O 0 4.01345005229814e-07
RFLP O 0 8.295612497022375e-05
data O 0 1.1642579238468898e-06
, O 0 3.019142127413943e-07
particularly O 0 9.335132062915363e-07
in O 0 1.8885812096414156e-06
Finns O 0 0.0002021427353611216
. O 0 1.839911419665441e-05

The O 0 6.792035128455609e-05
newly O 0 0.0001413446298101917
described O 0 9.635834430810064e-05
HFE O 0 0.004314511548727751
marker O 0 4.458479816094041e-05
provides O 0 3.0358035019162344e-06
a O 0 1.2972426475243992e-06
new O 0 4.785751457347942e-07
approach O 0 8.506612516612222e-07
to O 0 8.87547670913591e-08
the O 0 1.3812918098210503e-07
screening O 0 9.69484403867682e-07
of O 0 2.0521250121419143e-07
HH B-Disease 0 0.0014861862873658538
as O 0 1.5043107737255923e-07
well O 0 1.1825253665165292e-07
as O 0 6.380231099001321e-08
studies O 0 1.5348147996974149e-07
of O 0 4.4575955371328746e-08
the O 0 1.2311524244523753e-07
relationship O 0 6.217064196789579e-07
between O 0 4.813691703020595e-07
the O 0 1.774161546563846e-06
HFE O 0 0.06431801617145538
Tyr O 0 0.0013097751652821898
allele O 0 3.950183963752352e-05
and O 0 3.0165224416123237e-06
different O 0 1.2830397281504702e-05
disorders O 1 0.9905388355255127
including O 0 0.00042910128831863403
cancer B-Disease 1 0.9750251173973083

Autosomal B-Disease 1 0.9999603033065796
dominant I-Disease 1 0.98759925365448
neurohypophyseal I-Disease 1 0.9999600648880005
diabetes I-Disease 1 0.9999995231628418
insipidus I-Disease 1 0.999881386756897
associated O 0 9.99852127279155e-05
with O 0 5.330076874088263e-06
a O 0 3.660154470708221e-05
missense O 0 0.0008331041317433119
mutation O 0 3.339934119139798e-05
encoding O 0 2.0798970581381582e-05
Gly23 O 0 0.0008006849675439298
- O 0 0.0019754902459681034
- O 0 0.002047373913228512
> O 0 0.0004292391240596771
Val O 0 0.0006375050288625062
in O 0 9.143465831584763e-06
neurophysin O 0 0.0014759625773876905
II O 0 0.0005246213404461741
. O 0 4.0965573134599254e-05

Autosomal B-Disease 1 0.9999408721923828
dominant I-Disease 1 0.9831079244613647
neurohypophyseal I-Disease 1 0.9999666213989258
diabetes I-Disease 1 0.9999998807907104
insipidus I-Disease 1 0.9999843835830688
( O 0 0.00030984001932665706
ADNDI B-Disease 0 0.3161112368106842
) O 0 6.623752142331796e-06
is O 0 1.825763433771499e-06
an O 0 5.8419704146217555e-05
inherited B-Disease 1 1.0
disease I-Disease 1 0.9999990463256836
caused O 0 0.00018391832418274134
by O 0 3.0837866233923705e-06
progressive O 0 0.035924021154642105
degeneration O 0 0.2070913314819336
of O 0 4.427473072610155e-07
the O 0 1.4330204294310533e-06
magnocellular O 0 0.0019035926088690758
neurons O 0 8.904664355213754e-06
of O 0 1.704178487216268e-07
the O 0 3.81519924985696e-07
hypothalamus O 0 1.2446627806639299e-05
leading O 0 9.8385612545826e-07
to O 0 2.3522346737081534e-07
decreased O 0 7.866003215895034e-06
ability O 0 4.5449590402313333e-07
to O 0 1.7060679624592012e-07
produce O 0 5.142055101714504e-07
the O 0 8.101645221358922e-07
hormone O 0 2.4923316232161596e-05
arginine O 0 5.6813885748852044e-05
vasopressin O 0 0.0001194258002215065
( O 0 9.524866982246749e-06
AVP O 0 0.00015486434858758003
) O 0 9.4410706878989e-06
. O 0 9.7696920420276e-06

Affected O 0 0.0008542205905541778
individuals O 0 2.3730188331683166e-05
are O 0 1.0743891607489786e-06
not O 0 7.381607929346501e-07
symptomatic O 0 0.00046904291957616806
at O 0 5.258463716018014e-06
birth O 0 7.901912613306195e-05
, O 0 9.075816365111677e-07
but O 0 6.911390073582879e-07
usually O 0 4.769003680848982e-06
develop O 0 7.830142567399889e-05
diabetes B-Disease 1 0.9839768409729004
insipidus I-Disease 0 0.34100663661956787
at O 0 2.707069370444515e-06
1 O 0 5.042424163548276e-06
- O 0 7.067807746352628e-05
6 O 0 2.492474413884338e-05
yr O 0 0.003302504075691104
of O 0 1.72606814885512e-06
age O 0 1.3694539120479021e-05
. O 0 1.3158542969904374e-05

The O 0 6.648679845966399e-05
genetic O 0 0.0001348792720818892
locus O 0 6.822076829848811e-05
of O 0 1.9684166545630433e-06
the O 0 1.3458617104333825e-05
disease O 0 0.00044935097685083747
is O 0 2.981424813697231e-07
the O 0 9.37939375944552e-07
AVP O 0 0.0005788233829662204
- O 0 0.006891817785799503
neurophysin O 0 0.017315220087766647
II O 0 0.00015517504652962089
( O 0 2.9307825570867863e-06
NPII O 0 7.176425424404442e-05
) O 0 5.658569079969311e-07
gene O 0 1.1649743782982114e-06
, O 0 1.9548078000752867e-07
and O 0 5.454637062030088e-07
mutations O 0 1.4080726032261737e-05
that O 0 1.9210064294838958e-07
cause O 0 6.002063400956104e-06
ADNDI B-Disease 0 0.014694648794829845
have O 0 4.1416046769882087e-07
been O 0 1.8126665679574216e-07
found O 0 1.0702274266805034e-07
in O 0 7.757098785532435e-08
both O 0 8.957960773159357e-08
the O 0 1.66220416986107e-07
signal O 0 1.8361513411946362e-06
peptide O 0 6.77205832744221e-07
of O 0 6.816781450424969e-08
the O 0 2.699412959827896e-07
prepro O 0 6.80349548929371e-05
- O 0 3.574081347323954e-05
AVP O 0 0.00020979966211598366
- O 0 0.00010011095582740381
NPII O 0 0.00019931669521611184
precursor O 0 8.690207323525101e-06
and O 0 7.68987888477568e-07
within O 0 3.131426183244912e-06
NPII O 0 0.0005070060142315924
itself O 0 3.720784661709331e-05
. O 0 2.074085386993829e-05

An O 0 6.402751751011238e-05
affected O 0 6.548455712618306e-05
girl O 0 0.0001401318731950596
who O 0 4.320620973885525e-06
presented O 0 2.678528744581854e-06
at O 0 7.353797286668851e-07
9 O 0 3.151850478388951e-06
months O 0 5.496044650499243e-07
of O 0 8.941914586557687e-08
age O 0 4.863690037382185e-07
and O 0 1.761509054176713e-07
her O 0 2.7788560146291275e-06
similarly O 0 4.787825309904292e-05
affected O 0 3.3352964692312526e-06
younger O 0 2.2497349618788576e-06
brother O 0 2.814608706103172e-06
and O 0 2.3706380147814343e-07
father O 0 1.6312748130076216e-06
were O 0 1.1862572790732884e-07
all O 0 2.2170057789594466e-08
found O 0 1.0384818693864872e-07
to O 0 7.143339786352954e-08
have O 0 1.2381299541175395e-07
a O 0 9.366387416775979e-07
novel O 0 6.773829227313399e-06
missense O 0 0.00019942827930208296
mutation O 0 1.1913166417798493e-05
( O 0 1.5052478374855127e-06
G1758 O 0 5.7243520132033154e-05
- O 0 0.00024695557658560574
- O 0 0.002849574899300933
> O 0 0.00026284283376298845
T O 0 0.00010327698691980913
) O 0 3.461232438439765e-07
encoding O 0 1.03698903330951e-06
the O 0 2.7520715661921713e-07
amino O 0 2.0332847725512693e-06
acid O 0 2.60693377640564e-06
substitution O 0 3.1137494715949288e-06
Gly23 O 0 9.829688497120515e-05
- O 0 9.044143371284008e-05
- O 0 0.0002833801263477653
> O 0 0.00015672855079174042
Val O 0 0.00044260831782594323
within O 0 1.926177901623305e-05
NPII O 0 0.0011185394832864404
. O 0 3.4230408346047625e-05

The O 0 0.00011405471741454676
mutation O 0 0.000415356713347137
was O 0 1.0161669706576504e-05
confirmed O 0 7.122786882973742e-06
by O 0 1.7019011693264474e-06
restriction O 0 1.9091447029495612e-05
endonuclease O 0 0.0003570281551219523
analysis O 0 3.806933091254905e-05
. O 0 2.614417826407589e-05

A O 0 0.0008204025216400623
T1 O 0 0.10952543467283249
- O 0 0.0005054321954958141
weighted O 0 6.246769771678373e-05
magnetic O 0 2.5941688363673165e-05
resonance O 0 2.040933759417385e-05
imaging O 0 3.3111253287643194e-05
of O 0 8.5162389495963e-07
the O 0 2.4492051124980208e-06
fathers O 0 0.0001273491798201576
pituitary O 0 0.0013832346303388476
gland O 0 0.00036262269713915884
demonstrates O 0 7.76958950154949e-06
an O 0 2.6494089979678392e-06
attenuated O 0 0.00044379389146342874
posterior O 0 0.029453933238983154
pituitary O 0 0.00678300904110074
bright O 0 0.00020445817790459841
spot O 0 0.00011231322423554957
. O 0 3.2644904422340915e-05

This O 0 8.098362013697624e-05
mutation O 0 0.0011900560930371284
may O 0 1.1650348824332468e-05
be O 0 3.369253249729809e-07
valuable O 0 3.1487033425037225e-07
for O 0 2.3359532974609465e-07
developing O 0 1.823946490731032e-06
models O 0 2.7693847641785396e-06
of O 0 1.3265185998534434e-06
dominantly B-Disease 1 0.9864387512207031
inherited I-Disease 1 0.9985709190368652
neurodegeneration I-Disease 1 1.0
, O 0 1.1495465059851995e-06
as O 0 1.295389040478767e-07
the O 0 1.5227865901579207e-07
early O 0 8.045983008742041e-07
age O 0 6.936177783245512e-07
of O 0 3.3041047231563425e-07
onset O 0 0.05401182547211647
of O 0 7.3580240496085025e-06
symptoms O 0 0.2858775854110718
suggests O 0 2.110928789988975e-06
that O 0 7.213233743641467e-08
this O 0 2.6497829708205245e-07
mutation O 0 1.6144724213518202e-05
may O 0 8.936677886595135e-07
be O 0 1.0975209363550675e-07
particularly O 0 5.278191679281008e-07
deleterious O 0 1.105057162931189e-05
to O 0 5.160586056263128e-07
the O 0 2.5557874323567376e-06
magnocellular O 0 0.0017174301901832223
neuron O 0 0.00030073331436142325
. O 0 4.371838713268517e-06
. O 0 1.6937463442445733e-05

Frequent O 0 0.0017569587798789144
inactivation O 0 0.0057671815156936646
of O 0 8.006158168427646e-05
PTEN O 0 0.11226893216371536
/ O 0 0.005113549530506134
MMAC1 O 0 0.3624942898750305
in O 0 0.0005053722416050732
primary O 1 0.9945894479751587
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 0.0002705769438762218

Sporadic B-Disease 1 0.9999821186065674
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 1.9402188627282158e-05
the O 0 1.6911532156882458e-06
most O 0 1.0662243994374876e-06
common O 0 1.9301534848636948e-05
male B-Disease 0 0.03204607591032982
cancer I-Disease 0 0.012009805999696255
in O 0 2.1892850554650067e-07
the O 0 1.6803836899725866e-07
Western O 0 5.844598263138323e-07
world O 0 2.0699013703051605e-07
, O 0 1.23720582223541e-07
yet O 0 7.994471928896019e-08
many O 0 1.5091382365994832e-08
of O 0 2.5726352603783198e-08
the O 0 1.3378826224652585e-07
major O 0 4.6755135940657055e-07
genetic O 0 1.4285993756857351e-06
events O 0 1.9631963255051232e-07
involved O 0 1.8568955795217335e-07
in O 0 1.022939599693018e-07
the O 0 2.513414756322163e-07
progression O 0 1.5031526345410384e-05
of O 0 2.670764160939143e-07
this O 0 6.804011718486436e-07
often O 0 3.341985575389117e-05
fatal O 1 0.9823993444442749
cancer B-Disease 1 0.5102556347846985
remain O 0 3.305817244836362e-06
to O 0 7.29993189452216e-07
be O 0 2.1644652861141367e-06
elucidated O 0 0.0003000070864800364
. O 0 2.6705052732722834e-05

Numerous O 0 0.00018745088891591877
cytogenetic O 0 0.005801316350698471
and O 0 3.4845688787754625e-05
allelotype O 0 0.0019625944551080465
studies O 0 2.063050305878278e-05
have O 0 1.9569413325370988e-06
reported O 0 6.866826424811734e-06
frequent O 0 5.435498223960167e-06
loss O 0 2.2886590159032494e-05
of O 0 1.2516086371761048e-06
heterozygosity O 0 0.0008720438345335424
on O 0 9.741511348693166e-06
chromosomal O 0 0.10868178308010101
arm O 0 0.0017781003843992949
10q O 0 0.0007631536573171616
in O 0 3.779405233217403e-05
sporadic B-Disease 1 0.9907256960868835
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 0.00016951463476289064

Deletion O 0 0.004635932389646769
mapping O 0 0.0003511241520754993
studies O 0 2.825734918587841e-05
have O 0 2.130142320311279e-06
unambiguously O 0 2.7201824195799418e-05
identified O 0 2.948851488326909e-06
a O 0 1.2503165862653987e-06
region O 0 1.9295491711091017e-06
of O 0 4.935233164360397e-07
chromosome O 0 6.718622898915783e-05
10q23 O 0 2.9221111617516726e-05
to O 0 1.197274883679711e-07
be O 0 5.894754195878704e-08
the O 0 1.5232470218506933e-07
minimal O 0 2.747062808339251e-06
area O 0 1.358961867481412e-06
of O 0 9.867238759397878e-07
loss O 0 0.0002671188849490136
. O 0 3.37826568284072e-05

A O 0 0.0003134559083264321
new O 0 0.00011996591638308018
tumor B-Disease 0 0.003132153069600463
suppressor O 0 0.0007769598159939051
gene O 0 2.994712849613279e-05
, O 0 4.756031557917595e-06
PTEN O 0 0.0035164591390639544
/ O 0 0.00029134226497262716
MMAC1 O 0 0.001567366998642683
, O 0 9.66961806625477e-07
was O 0 1.178518914457527e-06
isolated O 0 4.334513050707756e-06
recently O 0 1.1898209777427837e-06
at O 0 1.1610651995397347e-07
this O 0 5.8851156836681184e-08
region O 0 4.1394804384253803e-07
of O 0 2.2659953913262143e-07
chromosome O 0 5.93346449022647e-05
10q23 O 0 3.364280200912617e-05
and O 0 2.8376612704050785e-07
found O 0 1.963093296808438e-07
to O 0 8.090528069715219e-08
be O 0 1.081903633348702e-07
inactivated O 0 3.770639068534365e-06
by O 0 2.977635062961781e-07
mutation O 0 4.094800715392921e-06
in O 0 2.682337253645528e-06
three O 0 0.017593886703252792
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 0.08276069909334183
lines O 0 0.00020629102073144168
. O 0 2.591140400909353e-05

We O 0 0.00016009272076189518
screened O 0 0.0010431826813146472
80 O 0 0.0012946834322065115
prostate B-Disease 1 0.9999948740005493
tumors I-Disease 1 0.9999955892562866
by O 0 3.663848929136293e-06
microsatellite O 0 0.00032258714782074094
analysis O 0 2.2108147277322132e-06
and O 0 5.215216560827685e-07
found O 0 1.318396471106098e-06
chromosome O 0 3.934918640879914e-05
10q23 O 0 1.9726903701666743e-05
to O 0 3.10309019369015e-07
be O 0 2.1733586663685855e-07
deleted O 0 3.79449056708836e-06
in O 0 1.312536596742575e-06
23 O 0 2.4562279577367008e-05
cases O 0 8.193680514523294e-06
. O 0 1.1788813026214484e-05

We O 0 1.9307501133880578e-05
then O 0 2.5440322133363225e-06
proceeded O 0 4.97841529067955e-06
with O 0 3.887387833856337e-07
sequence O 0 9.316330533692962e-07
analysis O 0 3.6600528119379305e-07
of O 0 1.0704928854465834e-07
the O 0 3.801999923780386e-07
entire O 0 5.297134066495346e-06
PTEN O 0 0.0008704574429430068
/ O 0 7.287796324817464e-05
MMAC1 O 0 0.0002541251596994698
coding O 0 3.7044908822281286e-05
region O 0 4.021805125375977e-06
and O 0 7.889268545113737e-07
tested O 0 3.2608788842480863e-06
for O 0 4.313369004194101e-07
homozygous O 0 7.267406908795238e-05
deletion O 0 1.341255301667843e-05
with O 0 4.7320082785518025e-07
new O 0 2.561688006608165e-06
intragenic O 0 0.00033673312282189727
markers O 0 4.841184818360489e-06
in O 0 2.9137277124391403e-07
these O 0 1.3300079615419236e-07
23 O 0 2.3934831006044988e-06
cases O 0 4.777397180077969e-07
with O 0 7.913502599876665e-07
10q23 O 0 0.006569521501660347
loss O 0 0.000110172426502686
of O 0 8.770317435846664e-06
heterozygosity O 0 0.12328210473060608
. O 0 7.793640543241054e-05

The O 0 1.075541786121903e-05
identification O 0 4.680029178416589e-06
of O 0 4.0479261542714084e-07
the O 0 4.587259354593698e-07
second O 0 4.588761385093676e-06
mutational O 0 0.0004436920862644911
event O 0 3.063657231905381e-06
in O 0 5.937022251600865e-07
10 O 0 1.4680840649816673e-06
( O 0 1.7317810261374689e-06
43 O 0 1.6456078810733743e-05
% O 0 1.2392430107865948e-05
) O 0 7.2049410846375395e-06
tumors B-Disease 1 0.9950738549232483
establishes O 0 0.00013876230514142662
PTEN O 0 0.007685432210564613
/ O 0 8.765373786445707e-05
MMAC1 O 0 9.9497105111368e-05
as O 0 2.4468235437780095e-07
a O 0 7.663727501494577e-07
main O 0 1.5205617955871276e-06
inactivation O 0 3.4852037060773e-05
target O 0 1.2725253100143163e-06
of O 0 4.011631915545877e-07
10q O 0 0.00011516507947817445
loss O 0 4.265153256710619e-05
in O 0 2.655167190823704e-05
sporadic B-Disease 1 0.9999232292175293
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.6083287593792193e-05
. O 0 3.71596215700265e-05

Risk O 0 0.005044492427259684
reversals O 0 0.0012347184820100665
in O 0 3.902683238266036e-05
predictive O 0 0.0009175044251605868
testing O 0 0.00021211658895481378
for O 0 0.0005859530647285283
Huntington B-Disease 1 1.0
disease I-Disease 1 0.9999725818634033
. O 0 9.960608440451324e-05

The O 0 3.2322459446731955e-05
first O 0 1.3705631317861844e-05
predictive O 0 0.00011530199117260054
testing O 0 4.6748209570068866e-05
for O 0 0.0002157670824090019
Huntington B-Disease 1 1.0
disease I-Disease 1 0.9999594688415527
( O 0 9.259621947421692e-06
HD B-Disease 0 8.199310104828328e-05
) O 0 4.846377805733937e-07
was O 0 2.435313888327073e-07
based O 0 2.55406433780081e-07
on O 0 1.4171666862239363e-07
analysis O 0 4.1605437672842527e-07
of O 0 2.3832507167753647e-07
linked O 0 2.945787309727166e-05
polymorphic O 0 0.00012370676267892122
DNA O 0 5.054311259300448e-06
markers O 0 1.9877641079801833e-06
to O 0 1.6763596022428828e-07
estimate O 0 1.21993161883438e-06
the O 0 2.1954235762677854e-07
likelihood O 0 1.3301897752171499e-06
of O 0 2.732473092237342e-07
inheriting O 0 1.5805757357156835e-05
the O 0 1.6608729538347689e-06
mutation O 0 1.8396885934635065e-05
for O 0 3.0123485430522123e-06
HD B-Disease 0 0.0003147163079120219
. O 0 3.403559094294906e-05

Limits O 0 0.00011287107918178663
to O 0 5.3341450438892934e-06
accuracy O 0 7.230711617012275e-06
included O 0 1.4721582601850969e-06
recombination O 0 9.663555829320103e-06
between O 0 4.6539111053789384e-07
the O 0 3.6760181387762714e-07
DNA O 0 4.3986706259602215e-06
markers O 0 2.508472562112729e-06
and O 0 1.917503027470957e-07
the O 0 5.02728141782427e-07
mutation O 0 5.9179319578106515e-06
, O 0 3.5544482557270385e-07
pedigree O 0 3.143079766232404e-06
structure O 0 5.892533749829454e-07
, O 0 1.0118283455540222e-07
and O 0 9.641039611096858e-08
whether O 0 1.8742635177204647e-07
DNA O 0 1.5362718386313645e-06
samples O 0 3.342963168506685e-07
were O 0 1.4281482663136558e-07
available O 0 1.5060419400469982e-07
from O 0 2.486170842530555e-07
family O 0 1.7217508911926416e-06
members O 0 2.7753389986173715e-06
. O 0 9.688443242339417e-06

With O 0 2.580160253273789e-05
direct O 0 1.6510815839865245e-05
tests O 0 4.2936953832395375e-06
for O 0 8.469618819617608e-07
the O 0 1.2589011930685956e-06
HD B-Disease 0 0.0005007142317481339
mutation O 0 1.1018046279787086e-05
, O 0 2.429208620924328e-07
we O 0 8.095283021702926e-08
have O 0 9.758909413903893e-08
assessed O 0 5.332927344170457e-07
the O 0 1.1392707932600388e-07
accuracy O 0 8.700528724148171e-07
of O 0 1.1760921836412308e-07
results O 0 7.24022243048239e-07
obtained O 0 2.9690485803257616e-07
by O 0 9.861183514203731e-08
linkage O 0 3.839621967927087e-06
approaches O 0 2.3358404632745078e-06
when O 0 2.7530953161658545e-07
requested O 0 6.81414178416162e-07
to O 0 1.0182480991716147e-07
do O 0 7.70886856571451e-08
so O 0 4.37570761846473e-08
by O 0 1.1088961571203981e-07
the O 0 3.461734365828306e-07
test O 0 5.111973223392852e-06
individuals O 0 5.158645308256382e-06
. O 0 8.161160621966701e-06

For O 0 3.344842480146326e-05
six O 0 1.3257079444883857e-05
such O 0 1.0198365316682612e-06
individuals O 0 8.956890269473661e-07
, O 0 2.149308642174219e-07
there O 0 1.267888052325361e-07
was O 0 7.574977303193009e-07
significant O 0 6.452534648815345e-07
disparity O 0 7.919687050161883e-06
between O 0 7.536686439379991e-07
the O 0 3.0148889891279396e-06
tests O 0 2.783808668027632e-05
. O 0 2.5430534151382744e-05

Three O 0 2.7612157282419503e-05
went O 0 1.4581280993297696e-05
from O 0 1.419844124939118e-06
a O 0 6.288013082667021e-06
decreased O 0 0.0002621276071295142
risk O 0 4.139711563766468e-06
to O 0 1.2378018254821654e-07
an O 0 3.308531688617222e-07
increased O 0 1.6211373804253526e-05
risk O 0 9.38069661060581e-06
, O 0 1.481360101251994e-07
while O 0 9.937597411635579e-08
in O 0 7.773316923476159e-08
another O 0 2.8387279371600016e-07
three O 0 5.429579346127866e-07
the O 0 1.7830819842856727e-06
risk O 0 2.7441372367320582e-05
was O 0 1.2173945833637845e-05
decreased O 0 0.0002369032008573413
. O 0 1.8300293959327973e-05

Knowledge O 0 3.005175312864594e-05
of O 0 2.5912659111781977e-06
the O 0 1.1977790563832968e-06
potential O 0 2.2454310055763926e-06
reasons O 0 4.6050200808167574e-07
for O 0 8.778685867127933e-08
these O 0 4.2703188540826886e-08
changes O 0 3.0931039418646833e-07
in O 0 2.565743670857046e-07
results O 0 7.21352250820928e-07
and O 0 1.2496414569795888e-07
impact O 0 2.898990487665287e-07
of O 0 6.919641037939073e-08
these O 0 1.5236436468057946e-07
risk O 0 3.598937610149733e-06
reversals O 0 1.3033278264629189e-05
on O 0 1.2453589306460344e-06
both O 0 8.38071343878255e-07
patients O 0 1.1215069207537454e-05
and O 0 1.3018836853007087e-07
the O 0 3.144918991893064e-07
counseling O 0 2.6968993552145548e-05
team O 0 4.221413689720066e-07
can O 0 9.649833287994625e-08
assist O 0 3.3911769037331396e-07
in O 0 7.652364786281396e-08
the O 0 7.132856438829549e-08
development O 0 1.0987105980575507e-07
of O 0 4.128173003437041e-08
strategies O 0 1.363462615699973e-06
for O 0 1.259310380419265e-07
the O 0 4.371169666228525e-07
prevention O 0 6.0969014157308266e-05
and O 0 5.705147145818046e-07
, O 0 2.519536792533472e-07
where O 0 2.1861137611267623e-07
necessary O 0 4.7474671305280935e-07
, O 0 1.697822682444894e-07
management O 0 4.780059157383221e-07
of O 0 1.0356275481626653e-07
a O 0 4.485212230065372e-06
risk O 0 1.6728872651583515e-05
reversal O 0 1.8962145986733958e-05
in O 0 3.751274846308661e-07
any O 0 4.651195979477052e-07
predictive O 0 2.2188385628396645e-05
testing O 0 5.250966751191299e-06
program O 0 4.714315309684025e-06
. O 0 2.7992036848445423e-06
. O 0 1.0353118341299705e-05

A O 0 0.00037901889299973845
novel O 0 0.0001950796868186444
common O 0 0.00011914643982890993
missense O 0 0.003415590850636363
mutation O 0 0.00016124047397170216
G301C O 0 7.940806972328573e-05
in O 0 1.2038507293254952e-06
the O 0 8.762673928686127e-07
N O 0 2.5516994355712086e-05
- O 0 2.5462128178332932e-05
acetylgalactosamine O 0 0.00024416111409664154
- O 0 7.785084017086774e-05
6 O 0 2.3732856789138168e-05
- O 0 0.00014886516146361828
sulfate O 0 0.0003250413865316659
sulfatase O 0 0.0005266696098260581
gene O 0 2.2523523512063548e-05
in O 0 1.0235001354885753e-05
mucopolysaccharidosis B-Disease 0 0.002988504944369197
IVA I-Disease 1 0.8763296008110046
. O 0 9.150891128228977e-05

Mucopolysaccharidosis B-Disease 1 0.9219390153884888
IVA I-Disease 1 0.999798595905304
( O 0 0.002492699073627591
MPS B-Disease 1 0.9984062314033508
IVA I-Disease 1 0.9999974966049194
) O 0 1.7722468328429386e-05
is O 0 2.1372704850364244e-06
an O 0 1.9286519091110677e-05
autosomal B-Disease 1 0.9999097585678101
recessive I-Disease 1 0.9999915361404419
lysosomal I-Disease 1 0.9999954700469971
storage I-Disease 1 0.9998681545257568
disorder I-Disease 1 0.9999977350234985
caused O 0 8.923446875996888e-05
by O 0 1.6113629044411937e-06
a O 0 0.0001887652324512601
genetic B-Disease 1 0.9990140199661255
defect I-Disease 1 0.9937783479690552
in O 0 3.3043706935131922e-06
N O 0 0.0001203816500492394
- O 0 6.355102959787473e-05
acetylgalactosamine O 0 0.0003473368415143341
- O 0 7.566475687781349e-05
6 O 0 4.107471613679081e-05
- O 0 0.0006635407917201519
sulfate O 0 0.0022408522199839354
sulfatase O 0 0.0035377044696360826
( O 0 1.3321828191692475e-05
GALNS O 0 0.0005904233548790216
) O 0 1.4694268429593649e-05
. O 0 1.7222175301867537e-05

In O 0 3.844891398330219e-05
previous O 0 2.5992134396801703e-05
studies O 0 4.558260570775019e-06
, O 0 4.911489668302238e-07
we O 0 1.4554883875916858e-07
have O 0 1.2222497502989427e-07
found O 0 1.6830364302222733e-07
two O 0 2.685332276541885e-07
common O 0 6.382522315107053e-06
mutations O 0 9.70124892774038e-06
in O 0 3.6950262938262313e-07
Caucasians O 0 1.209260335599538e-05
and O 0 5.90456636473391e-07
Japanese O 0 2.4223570562753594e-06
, O 0 1.3567540690928581e-06
respectively O 0 1.2737875294988044e-05
. O 0 1.0850125363504048e-05

To O 0 3.554791328497231e-05
characterize O 0 7.199312676675618e-05
the O 0 5.274103386909701e-06
mutational O 0 0.0012112119002267718
spectrum O 0 4.148854350205511e-05
in O 0 3.760666800189938e-07
various O 0 3.1465299343835795e-07
ethnic O 0 1.9832043562928447e-06
groups O 0 5.15702424763731e-07
, O 0 3.413344416003383e-07
mutations O 0 1.9162723674526205e-06
in O 0 1.3534749143673253e-07
the O 0 3.778677637455985e-07
GALNS O 0 0.0001453817094443366
gene O 0 2.483789558027638e-06
in O 0 1.2234338555572322e-06
Colombian O 0 0.0002205037308158353
MPS B-Disease 1 0.9950344562530518
IVA I-Disease 1 1.0
patients O 0 0.30226704478263855
were O 0 2.0010722892038757e-06
investigated O 0 7.621107670274796e-06
, O 0 3.3130339716080925e-07
and O 0 5.035793719798676e-07
genetic O 0 4.924842869513668e-06
backgrounds O 0 2.69090514848358e-06
were O 0 2.0006571332942258e-07
extensively O 0 8.056525189203967e-07
analyzed O 0 1.2826538977606106e-06
to O 0 1.307728325627977e-07
identify O 0 6.639783123318921e-07
racial O 0 2.8580489015439525e-06
origin O 0 5.339487074706994e-07
, O 0 1.8368869802998233e-07
based O 0 2.987418952216103e-07
on O 0 6.341020934996777e-07
mitochondrial O 0 1.504350257164333e-05
DNA O 0 1.2163014616817236e-05
( O 0 2.985828814416891e-06
mtDNA O 0 1.498852543591056e-05
) O 0 4.673196144722169e-06
lineages O 0 3.083531919401139e-05
. O 0 1.7382510122843087e-05

Three O 0 0.00012696626072283834
novel O 0 0.00023118086392059922
missense O 0 0.11254750192165375
mutations O 0 0.0013498782645910978
never O 0 1.181579409603728e-05
identified O 0 4.494409495237051e-06
previously O 0 1.531132170384808e-06
in O 0 2.8487619374573114e-07
other O 0 1.4005239279413217e-07
populations O 0 1.130486339206982e-06
and O 0 1.9027261544124485e-07
found O 0 1.3787412456167658e-07
in O 0 1.1504543095952613e-07
16 O 0 4.390010701627034e-07
out O 0 1.0734554933833351e-07
of O 0 2.313576601409295e-07
19 O 0 7.043934601824731e-06
Colombian O 0 3.2668544008629397e-05
MPS B-Disease 0 0.19690759479999542
IVA I-Disease 1 0.9999221563339233
unrelated O 0 0.0003766276640817523
alleles O 0 1.636484194023069e-05
account O 0 2.640686489030486e-06
for O 0 2.3035820504446747e-06
84 O 0 7.592199108330533e-05
. O 0 2.422915531496983e-05

2 O 0 0.00027817944646812975
% O 0 2.6412166334921494e-05
of O 0 9.879762501441292e-07
the O 0 1.2919891787532833e-06
alleles O 0 8.119024641928263e-06
in O 0 9.175377044812194e-07
this O 0 1.4017456351211877e-06
study O 0 1.5423143850057386e-05
. O 0 1.7431264495826326e-05

The O 0 6.01167485001497e-05
G301C O 0 0.0006414998206309974
and O 0 1.6669057004037313e-05
S162F O 0 0.000823475478682667
mutations O 0 5.470966061693616e-05
account O 0 7.393546184175648e-06
for O 0 6.336611022561556e-06
68 O 0 0.0002207723882747814
. O 0 3.767882299143821e-05

4 O 0 0.0008947508176788688
% O 0 0.00013343249156605452
and O 0 1.1749518307624385e-05
10 O 0 3.5597266105469316e-05
. O 0 3.348199970787391e-05

5 O 0 0.0002460608375258744
% O 0 2.9296783395693637e-05
of O 0 1.7603111928110593e-06
mutations O 0 3.784129876294173e-05
, O 0 6.814518656028667e-07
respectively O 0 1.8134566062144586e-06
, O 0 1.5998134017536358e-07
whereas O 0 2.68997155217221e-07
the O 0 1.0989766963120928e-07
remaining O 0 1.8292422510057804e-06
F69V O 0 0.00023648054047953337
is O 0 1.6338111663571908e-07
limited O 0 2.7884129849553574e-07
to O 0 1.400654952021796e-07
a O 0 1.805656324904703e-06
single O 0 9.936278729583137e-06
allele O 0 8.430537855019793e-05
. O 0 2.121852958225645e-05

The O 0 6.667117850156501e-05
skewed O 0 0.00039399080560542643
prevalence O 0 0.0007509448332712054
of O 0 3.2105992886499735e-06
G301C O 0 0.00015781470574438572
in O 0 1.232608610735042e-06
only O 0 4.227041188187286e-07
Colombian O 0 3.550566179910675e-05
patients O 0 2.8000606107525527e-05
and O 0 5.577246611210285e-07
haplotype O 0 3.7729878386016935e-05
analysis O 0 7.169547302510182e-07
by O 0 1.940231868502451e-07
restriction O 0 1.6848829318405478e-06
fragment O 0 3.959453351853881e-06
length O 0 3.540006900948356e-06
polymorphisms O 0 1.172592328657629e-05
in O 0 2.290201877030995e-07
the O 0 4.3899942170355644e-07
GALNS O 0 0.0003495983546599746
gene O 0 3.3933422400878044e-06
suggest O 0 8.953534234024119e-07
that O 0 1.6589608264894196e-07
G301C O 0 1.1798733794421423e-05
originated O 0 7.142909907997819e-07
from O 0 2.7718951400856895e-07
a O 0 1.505349814578949e-06
common O 0 7.227801688713953e-06
ancestor O 0 3.630311039160006e-05
. O 0 2.3065626010065898e-05

Investigation O 0 0.0001656548265600577
of O 0 4.474172783375252e-06
the O 0 3.3093785987148294e-06
genetic O 0 1.6988386050798e-05
background O 0 3.6961296245863196e-06
by O 0 2.49987010647601e-07
means O 0 2.9054530159555725e-07
of O 0 1.5341153414283326e-07
mtDNA O 0 6.191436568769859e-06
lineages O 0 2.275591896250262e-06
indicate O 0 5.127805025040288e-07
that O 0 4.202197700919896e-08
all O 0 6.522844131495731e-08
our O 0 5.788086809843662e-07
patients O 0 1.2456722288334277e-05
are O 0 7.463871298796221e-08
probably O 0 3.41424623684361e-07
of O 0 2.475885310104786e-07
native O 0 3.446920800342923e-06
American O 0 1.9449167666607536e-05
descent O 0 0.001191486488096416

Low O 0 0.0005087220924906433
frequency O 0 0.00012955644342582673
of O 0 1.453166623832658e-05
BRCA1 O 0 0.02004915103316307
germline O 0 0.07806132733821869
mutations O 0 0.00012297100329305977
in O 0 4.140216788073303e-06
45 O 0 0.00010430449765408412
German O 1 0.8475591540336609
breast B-Disease 1 0.9999998807907104
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 0.0005927670281380415
. O 0 7.622312114108354e-05

In O 0 2.1742098397226073e-05
this O 0 2.535044359319727e-06
study O 0 2.346790324736503e-06
we O 0 6.129018856881885e-07
investigated O 0 1.0762436431832612e-05
45 O 0 3.3020849514286965e-05
German O 1 0.6585435271263123
breast B-Disease 1 0.9999997615814209
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 4.443788202479482e-05
for O 0 6.24448512098752e-06
germline O 0 0.20468251407146454
mutations O 0 2.5672450647107325e-05
in O 0 1.0175167517445516e-06
the O 0 6.625376045121811e-06
BRCA1 O 0 0.0013155111810192466
gene O 0 8.093853830359876e-05
. O 0 2.467438389430754e-05

We O 0 5.318487455951981e-05
identified O 0 4.723234451375902e-05
four O 0 1.415474707755493e-05
germline O 0 0.01107525173574686
mutations O 0 7.053554145386443e-05
in O 0 3.1002437026472762e-06
three O 0 9.871988004306331e-05
breast B-Disease 1 0.9999977350234985
cancer I-Disease 1 0.9866567254066467
families O 0 1.0617995940265246e-05
and O 0 9.169760915028746e-07
in O 0 4.48274886366562e-06
one O 0 9.150437108473852e-05
breast B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 2.69786651188042e-05
. O 0 2.3057263831560704e-07
among O 0 1.4130802128420328e-07
these O 0 9.057540495405192e-08
were O 0 2.344452099123373e-07
one O 0 6.551503020091332e-07
frameshift O 0 0.005856475327163935
mutation O 0 6.067851700208848e-06
, O 0 2.36944018183749e-07
one O 0 2.7948584602199844e-07
nonsense O 0 1.6229687389568426e-05
mutation O 0 6.210057563293958e-06
, O 0 1.6332394636719982e-07
one O 0 1.4870884967876918e-07
novel O 0 1.5829507447051583e-06
splice O 0 4.865951632382348e-05
site O 0 4.856834038946545e-06
mutation O 0 4.971820089849643e-06
, O 0 4.36799439285096e-07
and O 0 8.98709458851954e-07
one O 0 5.867797881364822e-06
missense O 0 0.001583837321959436
mutation O 0 0.0002962286816909909
. O 0 2.873140874726232e-05

The O 0 0.0001704991009319201
missense O 0 0.02078785002231598
mutation O 0 0.000410456646932289
was O 0 8.177022209565621e-06
also O 0 1.785276936061564e-06
found O 0 1.3828881719746278e-06
in O 0 2.1163671135582263e-06
2 O 0 1.980628258024808e-05
. O 0 1.4727292182215024e-05

8 O 0 0.0005247023655101657
% O 0 2.0187848349451087e-05
of O 0 4.129232991090248e-07
the O 0 2.890650137032935e-07
general O 0 6.233343015082937e-07
population O 0 6.228493703019922e-07
, O 0 1.9973249720806052e-07
suggesting O 0 7.31448267288215e-07
that O 0 7.920466060795661e-08
it O 0 1.705131040807828e-07
is O 0 7.851679129089462e-07
not O 0 4.061904292029794e-06
disease O 0 0.0004106206470169127
associated O 0 1.9072995200986043e-05
. O 0 2.0705736460513435e-05

The O 0 3.939601083402522e-05
average O 0 6.726476567564532e-05
age O 0 1.5264131434378214e-05
of O 0 7.717621883784886e-06
disease O 0 0.11193453520536423
onset O 1 0.8835452198982239
in O 0 5.250986760074738e-06
those O 0 1.4556233054463519e-06
families O 0 2.1789546735817567e-05
harbouring O 0 0.002966665429994464
causative O 0 0.0011924811406061053
mutations O 0 9.48790620896034e-05
was O 0 3.97564781451365e-06
between O 0 4.176000857114559e-06
32 O 0 4.556981002679095e-05
. O 0 2.168715582229197e-05

3 O 0 0.0006937696598470211
and O 0 9.193627920467407e-05
37 O 0 0.00038828354445286095
. O 0 9.492848039371893e-05

4 O 0 0.0005167606868781149
years O 0 2.2065067241783254e-05
, O 0 2.5388017093064263e-06
whereas O 0 2.5998726869147504e-06
the O 0 7.856787647142482e-07
family O 0 3.2337782158720074e-06
harbouring O 0 5.684065763489343e-05
the O 0 2.0991205929021817e-06
missense O 0 0.00041155098006129265
mutation O 0 1.089422312361421e-05
had O 0 6.073637450754177e-07
an O 0 2.534775944695866e-07
average O 0 2.243095650555915e-06
age O 0 7.869588785069936e-07
of O 0 3.760483764381206e-07
onset O 0 0.0006335916696116328
of O 0 2.3326886093855137e-06
51 O 0 0.0001335989945800975
. O 0 1.7349502741126344e-05

2 O 0 0.0018002678407356143
years O 0 0.00040597066981717944
. O 0 0.0001755504636093974

These O 0 2.7466296160127968e-05
findings O 0 2.377617420279421e-05
show O 0 5.801803126814775e-06
that O 0 1.1824829471152043e-06
BRCA1 O 0 0.00021484203170984983
is O 0 1.220676494995132e-06
implicated O 0 7.412516879412578e-06
in O 0 3.158956474180741e-07
a O 0 1.139178721132339e-06
small O 0 9.527642532702885e-07
fraction O 0 4.428116426424822e-06
of O 0 1.024312587105669e-05
breast B-Disease 1 0.9999998807907104
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.029079562111292e-05
suggesting O 0 2.5559386358509073e-06
the O 0 2.7318529305375705e-07
involvement O 0 2.199498567279079e-06
of O 0 5.754117751166632e-07
another O 0 8.41010933072539e-06
susceptibility O 0 0.000995510257780552
gene O 0 3.82253565476276e-05
( O 0 2.3384673113469034e-05
s O 0 0.0005655505228787661
) O 0 8.119147241814062e-05

Paternal O 0 0.3168436884880066
transmission O 1 0.812252402305603
of O 0 0.013537987135350704
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.003751419484615326

We O 0 5.40259679837618e-05
report O 0 1.504096326243598e-05
a O 0 8.030428944039159e-06
rare O 0 1.1710490980476607e-05
case O 0 1.2219144991831854e-05
of O 0 3.153677607770078e-05
paternally O 1 0.999792754650116
transmitted O 1 0.999657392501831
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.84095698595047
DM B-Disease 1 0.9999998807907104
) O 0 0.0001550605520606041
. O 0 6.739877426298335e-05

The O 0 4.599601015797816e-05
proband O 0 0.000514703628141433
is O 0 2.4936796307883924e-06
a O 0 3.162795565003762e-06
23 O 0 1.1959701623709407e-05
year O 0 2.4507753551006317e-06
old O 0 8.699954196345061e-05
, O 0 9.169584518531337e-05
mentally B-Disease 1 0.9999998807907104
retarded I-Disease 1 0.9999998807907104
male O 0 0.3367637097835541
who O 0 0.06333018094301224
suffers O 1 0.9999972581863403
severe O 1 0.9999945163726807
muscular B-Disease 1 0.9999990463256836
weakness I-Disease 1 0.9935996532440186
. O 0 9.39435776672326e-05

He O 0 8.150471694534644e-05
presented O 0 4.101866579730995e-05
with O 0 2.959567791549489e-05
respiratory O 1 0.9564477205276489
and O 0 1.655510459386278e-05
feeding O 0 0.00018513764371164143
difficulties O 0 0.00014176008698996156
at O 0 1.461048213968752e-05
birth O 0 0.0005272431881166995
. O 0 3.419011409278028e-05

His O 0 0.00026649259962141514
two O 0 0.0002532626094762236
sibs O 1 0.9924790859222412
suffer O 0 0.18974897265434265
from O 0 7.09232990629971e-05
childhood O 0 0.08538290113210678
onset O 1 0.9999905824661255
DM B-Disease 1 0.9999997615814209
. O 0 0.00042918717372231185

Their O 0 3.885370460920967e-05
late O 0 4.743827594211325e-05
father O 0 1.3430178114504088e-05
had O 0 2.2336669189826353e-06
the O 0 6.2829684566168e-07
adult O 0 4.448178970051231e-06
type O 0 2.3119387151382398e-06
of O 0 1.1473298400233034e-06
DM B-Disease 1 0.9999994039535522
, O 0 1.5272440805347287e-06
with O 0 9.91574552244856e-07
onset O 0 0.006554778199642897
around O 0 2.0823345039389096e-06
30 O 0 4.460761829250259e-06
years O 0 6.541110906255199e-06
. O 0 1.0673713404685259e-05

Only O 0 2.0917525034747086e-05
six O 0 8.610615623183548e-06
other O 0 7.145226277316397e-07
cases O 0 1.1007363127646386e-06
of O 0 7.212030368464184e-07
paternal O 0 0.004608154762536287
transmission O 0 0.10309631377458572
of O 0 9.763111302163452e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 2.7615080398391e-05
been O 0 9.387767022417393e-06
reported O 0 3.125450530205853e-05
recently O 0 2.8291649869061075e-05
. O 0 1.7596179532120004e-05

We O 0 1.9941453501814976e-05
review O 0 8.91082345333416e-06
the O 0 1.532011424387747e-06
sex O 0 7.741808076389134e-06
related O 0 7.72223029343877e-06
effects O 0 3.195726822013967e-05
on O 0 1.8084023395203985e-05
transmission O 0 0.013558130711317062
of O 0 0.00025074457516893744
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.00040072412230074406

Decreased O 0 0.009438998997211456
fertility O 0 0.001308729057200253
of O 0 5.467148639581865e-06
males O 0 3.68063738278579e-05
with O 0 3.426420107643935e-06
adult O 0 0.0009371538762934506
onset O 1 0.9998835325241089
DM B-Disease 1 1.0
and O 0 1.073962266673334e-05
contraction O 0 0.00011221473687328398
of O 0 1.596332452891147e-07
the O 0 2.665141209945432e-07
repeat O 0 8.191375854949001e-06
upon O 0 5.154968789611303e-07
male O 0 5.958740985079203e-06
transmission O 0 1.1353329682606272e-05
contribute O 0 2.3719769615127007e-07
to O 0 4.733894698460972e-08
the O 0 1.2821533346141223e-07
almost O 0 3.591568713545712e-07
absent O 0 2.9623784030263778e-06
occurrence O 0 1.6000420828277129e-06
of O 0 7.306778115889756e-07
paternal O 0 0.0006109858513809741
transmission O 0 0.016455359756946564
of O 0 0.00016866963414940983
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.0003996967279817909

Also O 0 2.4234494048869237e-05
the O 0 2.6269617592333816e-06
fathers O 0 8.890876415534876e-06
of O 0 4.1447341914135905e-07
the O 0 1.3701926491194172e-06
reported O 0 7.263319275807589e-05
congenitally O 0 0.057436615228652954
affected O 0 5.767617039964534e-06
children O 0 6.023795776854968e-06
showed O 0 3.871744411299005e-06
, O 0 1.5889294502358098e-07
on O 0 2.1321962151432672e-07
average O 0 1.3138416079527815e-06
, O 0 3.691993413212913e-07
shorter O 0 1.5377348972833715e-05
CTG O 0 0.00012074171536369249
repeat O 0 9.034727554535493e-06
lengths O 0 4.0681152313482016e-05
and O 0 9.260294291379978e-07
hence O 0 3.963280050811591e-06
less O 0 6.633981229242636e-06
severe O 1 0.957547664642334
clinical O 1 0.9833971858024597
symptoms O 0 0.4703750014305115
than O 0 3.5095686712338647e-07
the O 0 3.4562847872621205e-07
mothers O 0 8.655583769723307e-06
of O 0 4.83938492834568e-07
children O 0 4.281821384211071e-05
with O 0 0.0050867167301476
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.00036953005474060774

We O 0 2.9115686629666016e-05
conclude O 0 5.6499546190025285e-05
that O 0 2.571542154328199e-06
paternal O 0 0.0004323993343859911
transmission O 0 0.06699644029140472
of O 0 0.0008354050223715603
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 1.5497567801503465e-05
rare O 0 4.398016244522296e-06
and O 0 9.511682605989336e-07
preferentially O 0 1.100795270758681e-05
occurs O 0 1.0597506161502679e-06
with O 0 4.81831250453979e-07
onset O 0 0.005223172251135111
of O 0 2.2667657049169065e-06
DM B-Disease 1 0.9999966621398926
past O 0 4.419417109602364e-06
30 O 0 1.666557977841876e-06
years O 0 2.1962527796404174e-07
in O 0 1.1976952407621866e-07
the O 0 4.256730505858286e-07
father O 0 8.174089998647105e-06
. O 0 3.023071485586115e-06
. O 0 1.048505146172829e-05

The O 0 0.0002604711044114083
RB1 O 0 0.02183782309293747
gene O 0 0.0002191392850363627
mutation O 0 8.67942871991545e-05
in O 0 3.841805209958693e-06
a O 0 1.656238418945577e-05
child O 0 0.0003242373059038073
with O 0 0.00018922076560556889
ectopic B-Disease 1 0.9999994039535522
intracranial I-Disease 1 0.9999983310699463
retinoblastoma I-Disease 1 0.9984468817710876
. O 0 0.00032123984419740736

The O 0 0.00022186883143149316
RB1 O 0 0.06337849795818329
gene O 0 0.00029442383674904704
mutation O 0 0.00012698346108663827
was O 0 4.687864475272363e-06
investigated O 0 4.708124379249057e-06
in O 0 6.845099278507405e-07
a O 0 7.1981280598265585e-06
child O 0 0.00010813511471496895
with O 0 2.265268449264113e-05
ectopic B-Disease 1 0.9999991655349731
intracranial I-Disease 1 0.9998685121536255
retinoblastoma I-Disease 0 0.05898388475179672
using O 0 4.175419690000126e-06
DNA O 0 6.512912932521431e-06
obtained O 0 4.571929537178221e-07
from O 0 1.3815447630349809e-07
both O 0 1.655206034456569e-07
the O 0 6.203246698532894e-07
pineal B-Disease 0 0.00039643479976803064
and I-Disease 0 1.7063173800124787e-05
retinal I-Disease 1 0.9980762004852295
tumours I-Disease 1 0.9999867677688599
of O 0 3.1479903555009514e-06
the O 0 1.331476687482791e-05
patient O 0 0.001804474857635796
. O 0 5.6676497479202226e-05

A O 0 0.0005092934006825089
nonsense O 0 0.0012917212443426251
mutation O 0 0.0003469881776254624
in O 0 5.733309080824256e-06
exon O 0 0.00011193985847057775
17 O 0 2.1145810023881495e-05
( O 0 1.885786105049192e-06
codon O 0 8.321806490130257e-06
556 O 0 4.661214461521013e-06
) O 0 2.373103598074522e-07
of O 0 9.552210400443073e-08
the O 0 5.639422511194425e-07
RB1 O 0 0.0010314249666407704
gene O 0 2.218735289716278e-06
was O 0 5.303804755385499e-07
found O 0 1.442588342115414e-07
to O 0 6.008587405403887e-08
be O 0 7.45236334864785e-08
present O 0 2.475278506608447e-07
homozygously O 0 2.628632319101598e-05
in O 0 2.688942970507924e-07
both O 0 2.3183805808457691e-07
the O 0 1.0686705991247436e-06
retinal B-Disease 0 0.0012363602872937918
and I-Disease 0 7.538823410868645e-06
the I-Disease 0 3.4759588743327186e-05
pineal I-Disease 1 0.7049055099487305
tumours I-Disease 1 0.999990701675415
. O 0 8.647317736176774e-05

The O 0 2.0235725969541818e-05
same O 0 9.293496077589225e-06
mutation O 0 2.781081093417015e-05
was O 0 1.23508664273686e-06
present O 0 5.473479518514068e-07
heterozygously O 0 7.715148240095004e-05
in O 0 2.4683481569809373e-07
the O 0 2.3530601822585595e-07
DNA O 0 1.3162808727429365e-06
from O 0 9.602024420019006e-08
the O 0 1.7171220179079683e-07
constitutional O 0 2.9419386464724084e-06
cells O 0 9.253205348613847e-07
of O 0 9.330666017604017e-08
the O 0 5.660425586029305e-07
patient O 0 3.37850688083563e-05
, O 0 8.549831136406283e-07
proving O 0 2.808091039696592e-06
it O 0 5.9430728782672304e-08
to O 0 1.2153965656125365e-07
be O 0 1.8224201880912005e-07
of O 0 1.236765115208982e-06
germline O 0 0.0005000803503207862
origin O 0 1.6521398720215075e-05
. O 0 1.7896436474984512e-05

The O 0 4.928295675199479e-05
initial O 0 0.000279824947938323
mutation O 0 0.0001448369730496779
was O 0 3.7536942727456335e-06
shown O 0 1.211376911669504e-06
to O 0 2.6170096134592313e-07
have O 0 3.546728066794458e-07
occurred O 0 1.907116711663548e-06
in O 0 5.817632882099133e-07
the O 0 2.7467040126794018e-06
paternally O 0 0.0006282296380959451
derived O 0 6.403002043953165e-05
RB1 O 0 0.005634722765535116
allele O 0 0.00033527982304804027
. O 0 4.2918702092720196e-05

The O 0 6.751880573574454e-05
mutation O 0 0.00014660495799034834
is O 0 7.288537062777323e-07
in O 0 2.2272207900186913e-07
an O 0 1.719504609809519e-07
area O 0 3.802783226092288e-07
of O 0 6.886764225555453e-08
the O 0 1.172928989490174e-07
gene O 0 4.2199241079288186e-07
that O 0 3.192391062611932e-08
encodes O 0 4.794669052898826e-07
the O 0 2.057270762634289e-07
protein O 0 7.784813647049305e-07
- O 0 4.6420991566265e-06
binding O 0 5.812132144455973e-07
region O 0 7.802846084814519e-07
known O 0 1.7091393544887978e-07
as O 0 6.042006361894892e-08
the O 0 1.2682774297445576e-07
pocket O 0 0.0002152180386474356
region O 0 1.8280945823789807e-06
and O 0 2.1411089790035476e-07
has O 0 3.728768547262007e-07
been O 0 2.8715214739349904e-07
detected O 0 1.0144452744498267e-06
in O 0 1.660936419511927e-07
other O 0 1.278295229667492e-07
cases O 0 8.130112405524414e-07
of O 0 1.0869748621189501e-06
retinoblastoma B-Disease 0 0.003093299688771367
. O 0 3.89539582101861e-06
. O 0 1.2392642929626163e-05

Low O 0 0.0005679893656633794
levels O 0 3.154158912366256e-05
of O 0 3.0924893508199602e-06
beta O 0 1.3761557056568563e-05
hexosaminidase O 0 4.337228165240958e-05
A O 0 3.5653090435516788e-06
in O 0 1.3572432635555742e-06
healthy O 0 1.2812412933271844e-05
individuals O 0 1.432714270777069e-06
with O 0 4.970492682332406e-06
apparent O 1 0.85427325963974
deficiency O 1 0.6411265134811401
of O 0 1.5702815971962991e-06
this O 0 3.332721007609507e-06
enzyme O 0 7.254126103362069e-05
. O 0 2.3611382857779972e-05

Appreciable O 0 0.002893232274800539
beta O 0 0.0005236404249444604
hexosaminidase O 0 0.0013169973390176892
A O 0 2.6099110982613638e-05
( O 0 3.8112789297883864e-06
hex O 0 2.7790105377789587e-05
A O 0 4.020343567390228e-06
) O 0 6.895700721543108e-07
activity O 0 8.08949266684067e-07
has O 0 4.0217753394244937e-07
been O 0 4.858455895373481e-07
detected O 0 2.46580771090521e-06
in O 0 9.75328703134437e-07
cultured O 0 7.331165397772565e-05
skin O 0 0.0033801509998738766
fibroblasts O 0 0.00012780207907781005
and O 0 5.962033901596442e-05
melanoma B-Disease 1 0.9999289512634277
tissue O 0 0.0006483926554210484
from O 0 2.4023008791118627e-06
healthy O 0 1.6525355022167787e-05
individuals O 0 1.0075776799567393e-06
previously O 0 4.179766165179899e-06
reported O 0 9.465692528465297e-06
as O 0 1.5067386129885563e-06
having O 0 2.621520616230555e-05
deficiency B-Disease 0 0.0017239688895642757
of I-Disease 0 1.6524805346307403e-07
hex I-Disease 0 5.196891288505867e-05
A I-Disease 0 2.490970246071811e-06
activity O 0 8.876769470589352e-07
indistinguishable O 0 8.982664780887717e-07
from O 0 8.583100452597137e-08
that O 0 8.743192836391245e-08
of O 0 6.853486524960317e-07
patients O 0 0.0007857815944589674
with O 0 0.0007366977515630424
Tay B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9838210344314575
( O 0 4.564744085655548e-05
TSD B-Disease 0 0.17341692745685577
) O 0 1.7704242054605857e-05
. O 0 1.8461754734744318e-05

Identification O 0 0.0001806234213290736
and O 0 1.1292027011222672e-05
quantitation O 0 0.0005624578916467726
of O 0 2.874211304515484e-06
hex O 0 0.00013514989404939115
A O 0 5.883694939257111e-06
, O 0 8.075725759226771e-07
amounting O 0 4.244627689331537e-06
to O 0 9.505407660981291e-07
3 O 0 1.1249486306041945e-05
. O 0 1.4380761967913713e-05

5 O 0 0.000856497383210808
% O 0 0.00021574647689703852
- O 0 0.0004750532389152795
6 O 0 0.00013049710833001882
. O 0 3.096926229773089e-05

9 O 0 0.0005464004352688789
% O 0 2.3144441001932137e-05
of O 0 7.845332561373652e-07
total O 0 1.3981327811052324e-06
beta O 0 5.185803274798673e-06
hexosaminidase O 0 3.269983426434919e-05
activity O 0 1.1211795936105773e-06
, O 0 1.1820517187288715e-07
has O 0 1.2760858680849196e-07
been O 0 1.4987047336489923e-07
obtained O 0 2.718979317251069e-07
by O 0 2.869780360015284e-07
cellulose O 0 2.082131504721474e-05
acetate O 0 5.5015090765664354e-05
gel O 0 0.0006612148135900497
electrophoresis O 0 0.0003022227610927075
, O 0 1.6645120695102378e-06
DEAE O 0 7.487349648727104e-05
- O 0 2.7125402993988246e-05
cellulose O 0 1.990180135180708e-05
ion O 0 8.672828698763624e-06
- O 0 1.031304054777138e-05
exchange O 0 3.7009122024755925e-06
chromatography O 0 2.1161986296647228e-05
, O 0 1.2114554692743695e-06
radial O 0 3.1606479751644656e-05
immunodiffusion O 0 0.00012302803224883974
, O 0 1.1668145134535735e-06
and O 0 3.634280119513278e-06
radioimmunoassay O 0 0.0008867675787769258
. O 0 2.585080983408261e-05

Previous O 0 0.0001933823514264077
family O 0 4.0422979509457946e-05
studies O 0 8.327014256792609e-06
suggested O 0 2.9821324005752103e-06
that O 0 1.5572743450320559e-07
these O 0 1.4941808501589549e-07
individuals O 0 5.513936685019871e-07
may O 0 5.891977252758807e-07
be O 0 1.0609432621322412e-07
compound O 0 1.1952882232435513e-05
heterozygotes O 0 4.029820047435351e-05
for O 0 1.372585671788329e-07
the O 0 3.926431304535072e-07
common O 0 2.099188577631139e-06
mutant O 0 8.895037899492308e-05
TSD B-Disease 0 0.002881834516301751
gene O 0 2.7000821773981443e-06
and O 0 3.3371659924341657e-07
a O 0 2.083401113850414e-06
rare O 0 5.9566955314949155e-06
( O 0 3.974404535256326e-06
allelic O 0 5.55184087716043e-05
) O 0 4.843568149226485e-06
mutant O 0 7.690019265282899e-05
gene O 0 4.406853986438364e-05
. O 0 1.9269127733423375e-05

Thus O 0 5.5115760915214196e-05
, O 0 3.0446317396126688e-06
the O 0 1.1362319582985947e-06
postulated O 0 2.2510746930493042e-05
rate O 0 9.776916158443782e-06
mutant O 0 3.4995573514606804e-05
gene O 0 2.493865167707554e-06
appears O 0 5.528922883968335e-07
to O 0 6.465038637770704e-08
code O 0 2.28092957854642e-07
for O 0 5.070432607112707e-08
the O 0 1.610618056702151e-07
expression O 0 6.092636226640025e-07
of O 0 1.8154278791371325e-07
low O 0 2.2997780888545094e-06
amounts O 0 9.016015383167542e-07
of O 0 6.905941063450882e-07
hex O 0 9.246449189959094e-05
A O 0 2.93605808110442e-05
. O 0 1.777492434484884e-05

Heterozygotes O 0 0.007934482768177986
for O 0 1.6344267351087183e-05
the O 0 8.310797966259997e-06
rare O 0 1.2529519153758883e-05
mutant O 0 0.0003250469744671136
may O 0 4.326133421272971e-06
be O 0 3.3302922020084225e-07
indistinguishable O 0 2.867355760827195e-06
from O 0 6.045505642759963e-07
heterozygotes O 0 2.4228809706983157e-05
for O 0 5.223503762863402e-07
the O 0 2.207176521551446e-06
common O 0 3.681659291032702e-05
TSD B-Disease 0 0.12324106693267822
mutant O 0 0.0009910441003739834
. O 0 3.243612445658073e-05

However O 0 4.5658674935111776e-05
, O 0 4.472875843930524e-06
direct O 0 3.163220753776841e-06
visualization O 0 1.7535605365992524e-05
and O 0 1.2600470427059918e-06
quantitation O 0 0.000282242544926703
of O 0 6.41376061594201e-07
hex O 0 6.814963126089424e-05
A O 0 1.3882212215321488e-06
by O 0 1.496718056159807e-07
the O 0 1.6804077063170553e-07
methods O 0 1.477460614296433e-06
described O 0 6.770781055820407e-06
may O 0 2.2247252218221547e-06
prevent O 0 2.4211931304307655e-06
false O 0 9.11030474526342e-06
- O 0 0.0006827373872511089
positive O 0 1.9667804735945538e-05
prenatal O 1 0.5190845131874084
diagnosis O 1 0.5139128565788269
of O 0 6.322811714198906e-06
TSD B-Disease 1 0.9961405396461487
in O 0 1.6420555766671896e-05
fetuses O 0 0.01132636982947588
having O 0 6.126973630671273e-07
the O 0 3.2955512097032624e-07
incomplete O 0 7.923501470941119e-06
hex B-Disease 0 0.017810318619012833
A I-Disease 0 0.0033260376658290625
deficiency I-Disease 0 0.0029669657815247774
of O 0 1.4441891948990815e-07
the O 0 3.61890243993912e-07
type O 0 2.3832262741052546e-06
described O 0 1.984793698284193e-06
in O 0 4.117463561215118e-07
the O 0 1.3174287687434116e-06
four O 0 1.45262902151444e-05
healthy O 0 0.0002535032108426094
individuals O 0 5.397236600401811e-05

The O 0 0.00025053718127310276
tumor B-Disease 0 0.009037873707711697
suppressor O 0 0.0033252472057938576
gene O 0 0.0001915052271215245
Smad4 O 0 0.002475583925843239
/ O 0 0.0004295717226341367
Dpc4 O 0 0.00034616811899468303
is O 0 9.049369964486687e-07
required O 0 6.727116783622478e-07
for O 0 3.269985882070614e-07
gastrulation O 0 8.612645615357906e-05
and O 0 6.954936679903767e-07
later O 0 6.686564688607177e-07
for O 0 3.7304471334209666e-07
anterior O 0 0.00017458561342209578
development O 0 1.2162283837824361e-06
of O 0 4.850234063269454e-07
the O 0 3.5539703731046757e-06
mouse O 0 0.00024343539553228766
embryo O 0 0.000312608084641397
. O 0 3.8148406019899994e-05

Mutations O 0 0.0030742064118385315
in O 0 2.36998366744956e-05
the O 0 1.9737437469302677e-05
SMAD4 O 0 0.1262778490781784
/ O 0 0.0389515720307827
DPC4 O 1 0.6838276982307434
tumor B-Disease 0 0.021999677643179893
suppressor O 0 0.0008073736098594964
gene O 0 8.939678082242608e-06
, O 0 6.479692160610284e-07
a O 0 7.021226906545053e-07
key O 0 1.8211377437182819e-06
signal O 0 2.3621623768121935e-06
transducer O 0 1.4456418284680694e-05
in O 0 2.990560403759446e-07
most O 0 3.8630074072898424e-07
TGFbeta O 0 0.0006230238941498101
- O 0 0.000346546497894451
related O 0 7.352013199124485e-06
pathways O 0 7.080492650857195e-06
, O 0 1.985271467219718e-07
are O 0 7.577348526410788e-08
involved O 0 3.048805297112267e-07
in O 0 4.1026942199096084e-07
50 O 0 3.6776241358893458e-06
% O 0 7.419985195156187e-06
of O 0 1.0728864253906067e-05
pancreatic B-Disease 1 0.9999966621398926
cancers I-Disease 1 0.9972745776176453
. O 0 4.384348358144052e-05

Homozygous O 0 0.07286162674427032
Smad4 O 0 0.03679369390010834
mutant O 0 0.1714305728673935
mice O 0 0.4862273037433624
die O 0 0.0008300042827613652
before O 0 9.037200470629614e-06
day O 0 1.2374042853480205e-05
7 O 0 4.076425830135122e-05
. O 0 1.8110535165760666e-05

5 O 0 0.0007693314109928906
of O 0 0.00011554842785699293
embryogenesis O 0 0.003915898967534304
. O 0 0.0002833666221704334

Mutant O 0 0.002801247639581561
embryos O 0 0.0003619814815465361
have O 0 5.215104920353042e-06
reduced O 0 7.265563453984214e-06
size O 0 2.178564045607345e-06
, O 0 7.388657650153618e-07
fail O 0 4.4978223741054535e-06
to O 0 3.334124585308018e-07
gastrulate O 0 8.949301991378888e-05
or O 0 5.490245484907064e-07
express O 0 1.3759331523033325e-06
a O 0 1.0024997436630656e-06
mesodermal O 0 5.8150908444076777e-05
marker O 0 9.909270374919288e-06
, O 0 5.698915970242524e-07
and O 0 6.368547360580123e-07
show O 0 7.806993380654603e-06
abnormal O 0 0.00010389521048637107
visceral O 0 0.00018111233657691628
endoderm O 0 0.0013076128670945764
development O 0 5.3116797062102705e-05
. O 0 3.915096021955833e-05

Growth B-Disease 1 0.9999743700027466
retardation I-Disease 1 0.9999979734420776
of O 0 1.5896259355940856e-05
the O 0 1.2354858881735709e-05
Smad4 O 0 0.300061970949173
- O 0 0.2251937985420227
deficient O 0 0.0022322458680719137
embryos O 0 2.7908821721212007e-05
results O 0 2.086373569909483e-06
from O 0 5.75936610403005e-07
reduced O 0 7.757203093206044e-06
cell O 0 2.950068846985232e-05
proliferation O 0 5.18070282851113e-06
rather O 0 8.266275131063594e-07
than O 0 7.180385068750184e-07
increased O 0 1.689874079602305e-05
apoptosis O 0 0.00022651533072348684
. O 0 1.834210524975788e-05

Aggregation O 0 0.0005663958145305514
of O 0 2.5316419851151295e-05
mutant O 0 0.0006060257437638938
Smad4 O 0 0.0056796991266310215
ES O 0 0.0007307883934117854
cells O 0 2.155219226551708e-05
with O 0 1.0076180387841305e-06
wild O 0 9.73501937551191e-06
- O 0 9.81467601377517e-05
type O 0 2.496870729373768e-05
tetraploid O 0 0.00037377685657702386
morulae O 0 0.0009275957709178329
rescues O 0 0.0004737251438200474
the O 0 2.3395512471324764e-05
gastrulation B-Disease 0 0.010832807049155235
defect I-Disease 0 0.004371216055005789
. O 0 8.575685933465138e-05

These O 0 2.584725916676689e-05
results O 0 2.4247739929705858e-05
indicate O 0 4.652713869290892e-06
that O 0 3.919412847608328e-07
Smad4 O 0 0.00014375372848007828
is O 0 5.156610995982192e-07
initially O 0 1.7490509662820841e-06
required O 0 1.9649232285701146e-07
for O 0 5.046832285415803e-08
the O 0 1.1341236927364662e-07
differentiation O 0 9.61039518188045e-07
of O 0 1.060866381408232e-07
the O 0 2.542605841426848e-07
visceral O 0 7.774458936182782e-06
endoderm O 0 4.2993993702111766e-05
and O 0 2.08998685025108e-07
that O 0 9.597171413133765e-08
the O 0 3.640502654889133e-07
gastrulation B-Disease 0 0.0002107879554387182
defect I-Disease 0 3.138113606837578e-05
in O 0 2.8076738090021536e-07
the O 0 8.86843508851598e-07
epiblast O 0 0.0009217599290423095
is O 0 4.783113922712801e-07
secondary O 0 1.7539819054945838e-06
and O 0 1.0160670171899255e-06
non O 0 1.2105940186302178e-05
- O 0 0.00029399554478004575
cell O 0 0.00018410517077427357
autonomous O 0 0.00011059050302719697
. O 0 2.8616643248824403e-05

Rescued O 0 0.007258674129843712
embryos O 0 0.0016764650354161859
show O 0 0.0002907085872720927
severe O 0 0.3043748736381531
anterior O 1 0.6271171569824219
truncations O 0 0.39707762002944946
, O 0 8.228394108300563e-06
indicating O 0 5.386820703279227e-06
a O 0 1.4381421351572499e-06
second O 0 1.5872785752435448e-06
important O 0 1.978005172986741e-07
role O 0 8.199880880965793e-07
for O 0 9.010488497551705e-07
Smad4 O 0 0.00038703461177647114
in O 0 5.407202479545958e-06
anterior O 0 0.0032164030708372593
patterning O 0 0.028864869847893715
during O 0 6.235188629943877e-05
embryogenesis O 0 0.0009723007096908987
. O 0 4.6096916776150465e-05

Prevalence O 0 0.005381350871175528
of O 0 2.951416354335379e-05
p16 O 0 0.00037702530971728265
and O 0 1.4095088772592135e-05
CDK4 O 0 0.3954419195652008
germline O 0 0.2788028419017792
mutations O 0 0.00016805062477942556
in O 0 9.935084563039709e-06
48 O 0 0.0011519963154569268
melanoma B-Disease 1 0.9998332262039185
- O 0 0.14257743954658508
prone O 0 0.0008824250544421375
families O 0 1.75823261088226e-05
in O 0 4.411694135342259e-06
France O 0 5.513157884706743e-05
. O 0 2.1993326299707405e-05

The O 0 0.0001460277708247304
French O 0 0.005131780635565519
Familial B-Disease 1 0.9993347525596619
Melanoma I-Disease 1 0.9999947547912598
Study O 0 0.00023647175112273544
Group O 0 0.00012093447730876505
. O 0 4.365453060017899e-05

Germline O 1 0.9897326827049255
mutations O 0 0.002233085222542286
in O 0 9.935094567481428e-06
the O 0 4.254021405358799e-06
p16 O 0 8.293064456665888e-05
and O 0 3.4422230328345904e-06
CDK4 O 0 0.012141574174165726
genes O 0 7.880780685809441e-06
have O 0 4.846710339734273e-07
been O 0 6.078811338738888e-07
reported O 0 1.599427378096152e-06
in O 0 2.032327586221072e-07
a O 0 7.141050559766882e-07
subset O 0 6.676893463009037e-06
of O 0 1.8543380519986385e-06
melanoma B-Disease 1 0.9978644251823425
pedigrees O 0 8.18263360997662e-05
, O 0 3.307884810510586e-07
but O 0 1.589681346558791e-07
their O 0 3.4564362749733846e-07
prevalence O 0 7.176528015406802e-05
is O 0 2.3181395647497993e-07
not O 0 1.5783335527430609e-07
well O 0 8.749229891691357e-07
known O 0 6.818433121225098e-06
. O 0 1.0940616448351648e-05

We O 0 1.610930121387355e-05
searched O 0 2.4020575438044034e-05
for O 0 1.7723367591315764e-06
such O 0 1.8074241552312742e-06
germline O 0 0.003241433762013912
mutations O 0 2.5681511033326387e-05
in O 0 9.231936815012887e-07
48 O 0 3.22091618727427e-05
French O 0 0.0047398838214576244
melanoma B-Disease 1 0.9998385906219482
- O 0 0.18709632754325867
prone O 0 0.0003931147512048483
families O 0 2.9921116038167384e-06
selected O 0 2.7646299827210896e-07
according O 0 1.2998229692584573e-07
to O 0 6.053033274611153e-08
two O 0 1.5510032369547844e-07
major O 0 4.2265537558705546e-07
criteria O 0 9.321431662101531e-07
families O 0 3.9185908917716006e-07
with O 0 1.1761706986135323e-07
at O 0 2.625544084366993e-07
least O 0 1.9040366794342845e-07
three O 0 2.0283485469008156e-07
affected O 0 6.11850111909007e-07
members O 0 2.058157804185612e-07
( O 0 6.254583126974467e-07
n O 0 7.3822166086756624e-06
= O 0 1.1305141015327536e-05
20 O 0 3.769183649637853e-07
) O 0 1.3938577581029676e-07
or O 0 9.63407273957273e-08
families O 0 1.270429805799722e-07
with O 0 6.967982812966511e-08
two O 0 4.1949584783651517e-07
affected O 0 8.291887638733897e-07
members O 0 1.0919041670831575e-07
, O 0 3.460109709862991e-08
one O 0 1.669154769956549e-08
of O 0 2.2033052715642043e-08
them O 0 4.616223492348581e-08
affected O 0 2.44536551008423e-07
before O 0 9.595323291478053e-08
the O 0 8.851149857491691e-08
age O 0 1.8205075491550815e-07
of O 0 7.051880857034121e-08
50 O 0 6.214995096343046e-07
( O 0 5.783534788861289e-07
n O 0 6.6317920754954685e-06
= O 0 1.9559824067982845e-05
28 O 0 1.051105527949403e-06
) O 0 9.555071756039979e-08
, O 0 4.511224105385736e-08
and O 0 7.255070499923022e-08
one O 0 2.2479368055883242e-07
additional O 0 2.1623548036586726e-06
minor O 0 2.138172567356378e-05
criterion O 0 9.144053183263168e-05
. O 0 1.9918872567359358e-05

Sixteen O 0 0.0005110562196932733
different O 0 6.817354733357206e-05
p16 O 0 0.0026108191814273596
germline O 0 0.16499324142932892
mutations O 0 0.000307295355014503
were O 0 1.6887936453713337e-06
found O 0 6.741399261045444e-07
in O 0 4.1430112673879194e-07
21 O 0 4.888013336312724e-06
families O 0 1.1714952279362478e-06
, O 0 2.431266921121278e-07
while O 0 2.2676513822261768e-07
one O 0 5.678235197592585e-07
germline O 0 0.0002506305754650384
mutation O 0 8.145182619045954e-06
, O 0 4.2729627125481784e-07
Arg24His O 0 6.894179387018085e-05
, O 0 4.962091679772129e-07
was O 0 1.031963506648026e-06
detected O 0 1.547931333334418e-06
in O 0 4.856213422499422e-07
the O 0 3.0341393539856654e-06
CDK4 O 0 0.0025448868982493877
gene O 0 7.23597695468925e-05
. O 0 2.22034959733719e-05

The O 0 2.3462227545678616e-05
frequency O 0 2.2745853129890747e-05
of O 0 2.090119323838735e-06
p16 O 0 6.692138413200155e-05
gene O 0 1.1235998499614652e-05
mutation O 0 4.599227395374328e-06
in O 0 1.727148486452279e-07
our O 0 2.6369315264673787e-07
sample O 0 7.836493978174985e-07
( O 0 6.174256554913882e-07
44 O 0 2.2697768145008013e-06
% O 0 8.70543374276167e-07
) O 0 1.1643140851447242e-07
is O 0 3.816538196588226e-08
among O 0 3.801238435130472e-08
the O 0 7.073582963812441e-08
highest O 0 9.098556574826944e-07
rates O 0 1.6098606465675402e-06
yet O 0 2.570173762705963e-07
reported O 0 7.128190304683812e-07
and O 0 1.5400257780129323e-07
the O 0 3.432954542859079e-07
CDK4 O 0 0.004577180836349726
mutation O 0 3.3966350656555733e-06
is O 0 7.852894867710347e-08
the O 0 1.502684767729079e-07
second O 0 6.57498958389624e-06
mutation O 0 2.6884456019615754e-05
detected O 0 2.4111652692226926e-06
in O 0 3.2755355050539947e-07
this O 0 7.529660024374607e-07
gene O 0 1.0492373803572264e-05
worldwide O 0 1.372154747514287e-05
. O 0 1.32075983856339e-05

In O 0 4.651554627344012e-05
summary O 0 5.041592157795094e-05
, O 0 2.105191015289165e-06
our O 0 1.1593583622016013e-06
results O 0 1.4410128414965584e-06
show O 0 6.432002237488632e-07
frequent O 0 1.2440768841770478e-06
involvement O 0 1.9191420506103896e-06
of O 0 2.746806444520189e-07
the O 0 7.528446985816117e-07
p16 O 0 3.590024061850272e-05
gene O 0 7.379493126791203e-06
in O 0 5.061657702754019e-06
familial B-Disease 1 0.9520976543426514
melanoma I-Disease 1 0.9999724626541138
and O 0 2.7058304112870246e-06
confirm O 0 1.438125764252618e-06
the O 0 1.5956413790263468e-07
role O 0 3.267516888172395e-07
of O 0 1.3181534086470492e-07
the O 0 6.245224994927412e-07
CDK4 O 0 0.0003622666699811816
gene O 0 4.372951934783487e-06
as O 0 9.55454879658646e-07
a O 0 3.91911125916522e-05
melanoma B-Disease 1 0.9964424967765808
- O 0 0.0016660619294270873
predisposing O 0 0.001168975606560707
gene O 0 4.30714717367664e-05
. O 0 5.107357992528705e-06
. O 0 2.183576907555107e-05

Progression O 0 0.002782493829727173
of O 0 3.599358387873508e-05
somatic O 0 0.0012140832841396332
CTG O 0 0.00445214007049799
repeat O 0 0.00014407523849513382
length O 0 2.9935566999483854e-05
heterogeneity O 0 8.317300671478733e-05
in O 0 2.081728780467529e-06
the O 0 3.5316948014951777e-06
blood O 0 0.00012813655484933406
cells O 0 0.00022965730750001967
of O 0 8.239440649049357e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9987724423408508
. O 0 0.00010039115295512602

The O 0 4.111163434572518e-05
genetic O 0 0.00011135028034914285
basis O 0 1.764790795277804e-05
of O 0 9.10182498046197e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.5349823236465454
DM B-Disease 1 1.0
) O 0 4.182290012977319e-06
is O 0 1.3703883894322644e-07
the O 0 1.0641291936508424e-07
expansion O 0 6.974756843192154e-07
of O 0 1.0492891533431248e-07
an O 0 5.460242391563952e-07
unstable O 0 0.0006834773230366409
CTG O 0 0.0014963648281991482
repeat O 0 5.088888428872451e-06
in O 0 1.5956169363562367e-07
the O 0 2.597451498331793e-07
34 O 0 2.2048836854082765e-06
UTR O 0 1.3547211892728228e-05
of O 0 3.9715519051242154e-07
the O 0 1.2522233419076656e-06
DM B-Disease 1 0.9993529915809631
protein O 0 1.4373687008628622e-05
kinase O 0 2.6019984943559393e-05
gene O 0 6.027634753991151e-06
on O 0 5.651683295582188e-06
chromosome O 0 0.00035532884066924453
19 O 0 6.778627721359953e-05
. O 0 2.2905018340679817e-05

One O 0 1.3615898751595523e-05
of O 0 1.3235325013738475e-06
the O 0 6.896306103953975e-07
principal O 0 1.382943651151436e-06
features O 0 6.123941602709237e-07
of O 0 3.764305063214124e-07
the O 0 8.02302747615613e-06
DM B-Disease 1 1.0
mutation O 0 9.65742437983863e-05
is O 0 1.386042214335248e-07
an O 0 1.9967193054526433e-07
extraordinarily O 0 1.1133864973089658e-05
high O 0 2.205871851401753e-06
level O 0 4.184039141819085e-07
of O 0 2.71440910637466e-07
somatic O 0 0.0001367876393487677
mosaicism O 0 0.059330690652132034
, O 0 5.28608495642402e-07
due O 0 3.7182928736001486e-07
to O 0 7.36923624344854e-08
an O 0 1.638061064568319e-07
extremely O 0 1.3832443528372096e-06
high O 0 1.3887084833186236e-06
degree O 0 1.8371583792031743e-06
of O 0 1.4705204876008793e-07
somatic O 0 3.713336991495453e-05
instability O 0 1.7653363101999275e-05
both O 0 2.1383989690093586e-07
within O 0 2.488889379037573e-07
and O 0 1.602085148988408e-07
between O 0 7.49359060137067e-07
different O 0 2.3690881789661944e-06
tissues O 0 6.763674173271284e-05
. O 0 1.8650804122444242e-05

This O 0 3.464571636868641e-05
instability O 0 0.00036764718242920935
appears O 0 2.0027804566780105e-05
to O 0 4.495805967508204e-07
be O 0 2.2644313446562592e-07
biased O 0 8.054328759499185e-07
towards O 0 3.279564566582849e-07
further O 0 2.341147649076447e-07
expansion O 0 9.944970997821656e-07
and O 0 1.9681978358221386e-07
continuous O 0 1.8260629985888954e-06
throughout O 0 1.8348035268900276e-07
the O 0 7.712971950013525e-08
life O 0 1.6528461799225624e-07
of O 0 3.152208805090595e-08
an O 0 8.790581773610029e-08
individual O 0 9.324759986384379e-08
, O 0 6.844688726914683e-08
features O 0 2.2740552196864883e-07
that O 0 6.434554222778388e-08
could O 0 1.7499507976026507e-07
be O 0 6.243939054684233e-08
associated O 0 1.4096022482590342e-07
with O 0 7.610357499743259e-08
the O 0 5.49686262729665e-07
progressive O 0 2.964341183542274e-05
nature O 0 7.569994409095671e-07
of O 0 6.390412750079122e-07
the O 0 1.9616592908278108e-05
disease O 0 0.005570614244788885
. O 0 2.528835648263339e-05

Although O 0 5.922678246861324e-05
increasing O 0 3.908940198016353e-05
measured O 0 3.9486094465246424e-05
allele O 0 2.8682814445346594e-05
size O 0 4.066183464601636e-06
between O 0 4.703914783021901e-06
patients O 0 5.403725663200021e-05
clearly O 0 1.2338564374658745e-06
correlates O 0 2.928480171249248e-06
with O 0 2.1106336589582497e-07
an O 0 7.8845749840184e-07
increased O 0 3.7011512176832184e-05
severity O 0 0.02014508843421936
of O 0 7.48376669434947e-06
symptoms O 0 0.1087525337934494
and O 0 3.205149141649599e-07
an O 0 2.1423549867449765e-07
earlier O 0 2.5430304049223196e-06
age O 0 5.42779332590726e-07
of O 0 1.6414325898495008e-07
onset O 0 0.03144828602671623
, O 0 1.5794175567407365e-07
this O 0 3.9352027414452095e-08
correlation O 0 4.760542537951551e-07
is O 0 6.359964999091972e-08
not O 0 3.729849495925919e-08
precise O 0 6.651070521002111e-07
and O 0 3.863044355512102e-07
measured O 0 6.485740414063912e-06
allele O 0 5.047774720878806e-06
length O 0 3.2825760172272567e-06
cannot O 0 2.8498490678430244e-07
be O 0 3.5294849709543996e-08
used O 0 6.755532666602448e-08
as O 0 5.25313303967323e-08
an O 0 1.684214936403805e-07
accurate O 0 2.5457359242864186e-06
predictor O 0 3.37407982442528e-05
of O 0 3.676993003409734e-07
age O 0 2.986637809954118e-06
of O 0 4.227701083436841e-06
onset O 1 0.8175160884857178
. O 0 3.5713965189643204e-05

In O 0 3.0010654882062227e-05
order O 0 4.148192601860501e-06
to O 0 5.98157896547491e-07
further O 0 9.090491062124784e-07
characterize O 0 4.7720382099214476e-06
the O 0 8.182257715816377e-07
dynamics O 0 2.2995802282821387e-05
of O 0 3.2336731692339526e-06
DM B-Disease 1 0.9999997615814209
CTG O 0 0.08615685999393463
repeat O 0 5.8656951296143234e-05
somatic O 0 6.258874054765329e-05
instability O 0 3.88570006180089e-05
, O 0 4.4874360582980444e-07
we O 0 9.761943431385589e-08
have O 0 1.1661787624461795e-07
studied O 0 5.965501941318507e-07
repeat O 0 3.1717422643851023e-06
length O 0 2.1653286239597946e-06
changes O 0 2.7741057806451863e-07
over O 0 1.8253196287787432e-07
time O 0 3.620780262281187e-07
in O 0 2.580356294856756e-06
111 O 0 0.10579201579093933
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.27131038904190063
with O 0 5.6627700359968e-06
varying O 0 0.00024273798044305295
clinical O 0 0.279005765914917
severity O 0 0.25588467717170715
and O 0 7.352448392339284e-06
CTG O 0 0.0011557660764083266
repeat O 0 8.10656729299808e-06
size O 0 6.601646873605205e-07
over O 0 1.8364910658874578e-07
time O 0 2.1056396803942334e-07
intervals O 0 8.019286497074063e-07
of O 0 1.495799040185375e-07
1 O 0 2.266491037516971e-06
- O 0 4.5875283831264824e-05
7 O 0 1.2540037459984887e-05
years O 0 6.299536835285835e-06
. O 0 9.99411531665828e-06

We O 0 3.465791087364778e-05
have O 0 2.3891727778391214e-06
found O 0 7.049284249660559e-07
a O 0 8.558282615922508e-07
direct O 0 8.61816261021886e-07
progression O 0 9.544654858473223e-06
of O 0 1.0510498071880647e-07
the O 0 1.5437724698585953e-07
size O 0 5.278045591694536e-07
heterogeneity O 0 5.3459402806765866e-06
over O 0 4.3425251305961865e-07
time O 0 2.8602610768757586e-07
related O 0 5.016630097998132e-07
to O 0 1.8227800069325895e-07
initial O 0 4.031316620967118e-06
CTG O 0 0.00013165611017029732
repeat O 0 4.396485564939212e-06
size O 0 5.297657139635703e-07
and O 0 8.42833358660755e-08
the O 0 1.0656240334583345e-07
time O 0 2.0802552569421096e-07
interval O 0 1.1577430996112525e-06
and O 0 1.603295629593049e-07
always O 0 3.172287961206166e-07
biased O 0 2.1562182155321352e-06
towards O 0 1.296336108680407e-06
further O 0 2.6773768695420586e-06
expansion O 0 2.7511936423252337e-05
. O 0 1.4391313015948981e-05

Attempts O 0 0.00019186346617061645
to O 0 6.9290308601921424e-06
mathematically O 0 1.998110383283347e-05
model O 0 4.710445864475332e-06
the O 0 1.287917370973446e-06
dynamics O 0 3.3436022931709886e-05
have O 0 9.054290330823278e-07
proved O 0 2.0055028926435625e-06
only O 0 2.970433570226305e-07
partially O 0 1.4666911738459021e-05
successful O 0 1.2975345953236683e-06
suggesting O 0 1.3444187061395496e-06
that O 0 8.413653063144011e-08
individual O 0 1.0783950443737922e-07
specific O 0 2.584025651231059e-07
genetic O 0 2.6176437586400425e-06
and O 0 6.76991419368278e-07
/ O 0 9.381413110531867e-05
or O 0 8.002768936421489e-07
environmental O 0 1.8703776731854305e-06
factors O 0 2.5823848659456416e-07
also O 0 1.472042896466519e-07
play O 0 1.3836518064636039e-07
a O 0 5.073238753539044e-07
role O 0 1.712864332148456e-06
in O 0 2.8182696496514836e-06
somatic O 0 0.0004907567636109889
mosaicism O 0 0.008928364142775536
. O 0 9.054877409653272e-06
. O 0 1.9486189557937905e-05

Aspartylglucosaminuria B-Disease 1 0.9968662858009338
among O 0 0.0005147117190063
Palestinian O 0 0.003332010470330715
Arabs O 0 0.0018119014566764235
. O 0 0.00021579914027824998

Aspartylglucosaminuria B-Disease 1 0.9999903440475464
( O 0 0.008311917074024677
AGU B-Disease 1 0.9999867677688599
) O 0 2.1807132725371048e-05
is O 0 2.792891791614238e-06
a O 0 2.425708225928247e-05
rare O 0 0.00017072669288609177
disorder B-Disease 0 0.41476142406463623
of I-Disease 0 1.5959716392899281e-06
glycoprotein I-Disease 0 0.00034146918915212154
metabolism I-Disease 0 0.000615348108112812
caused O 0 1.4108293726167176e-05
by O 0 9.153963560493139e-07
the O 0 8.258779416792095e-06
deficiency B-Disease 0 0.014800271950662136
of I-Disease 0 6.479308467532974e-07
the I-Disease 0 5.180698281037621e-06
lysosomal I-Disease 1 0.515658438205719
enzyme I-Disease 0 0.00016525693354196846
aspartylglucosaminidase I-Disease 0 0.0038058895152062178
( O 0 1.3877812307327986e-05
AGA O 0 0.00027115229750052094
) O 0 1.297353082918562e-05
. O 0 1.2579623216879554e-05

AGU B-Disease 1 0.9999929666519165
is O 0 0.0003495950368233025
inherited O 0 0.006193412933498621
as O 0 1.2148813766543753e-05
an O 0 7.111949526006356e-05
autosomal O 1 0.9999730587005615
recessive O 1 0.999961256980896
trait O 0 0.0014296486042439938
and O 0 3.1492334073845996e-06
occurs O 0 1.428125301572436e-06
with O 0 1.4423558525322733e-07
a O 0 1.3726435099670198e-06
high O 0 3.7733373119408498e-06
frequency O 0 3.0252344913606066e-06
in O 0 3.063868518893287e-07
Finland O 0 1.0401036888652015e-05
because O 0 2.2054250337077974e-07
of O 0 1.8754113284558116e-07
a O 0 2.876018243114231e-06
founder O 0 4.9031506932806224e-05
effect O 0 1.7787862816476263e-05
. O 0 1.4054229723114986e-05

While O 0 9.549483365844935e-05
very O 0 1.0745657164079603e-05
few O 0 1.240441997651942e-05
patients O 0 0.0001504699612269178
with O 0 6.118808869359782e-06
AGU B-Disease 1 0.9999983310699463
have O 0 4.360154889582191e-06
been O 0 1.1808218687292538e-06
reported O 0 2.500466280253022e-06
from O 0 1.833131619832784e-07
non O 0 1.1311537946312455e-06
- O 0 9.217965271091089e-06
Finnish O 0 5.783711458207108e-05
origin O 0 1.6980249029074912e-06
, O 0 1.1957862398048746e-06
we O 0 1.5358031077994383e-06
diagnosed O 1 0.8898930549621582
the O 0 1.112699737859657e-05
disorder O 1 0.9468268156051636
in O 0 3.6262858884583693e-06
8 O 0 0.00010297065455233678
patients O 0 4.237366374582052e-05
originating O 0 9.60172883424093e-07
from O 0 3.6076551168662263e-07
3 O 0 1.7418334437024896e-06
unrelated O 0 8.311036253871862e-06
families O 0 1.3351234429137548e-06
, O 0 1.1214390127634033e-07
all O 0 5.689315685231122e-08
Palestinian O 0 1.1007617104041856e-05
Arabs O 0 3.872254183079349e-06
from O 0 2.0990634652662266e-07
the O 0 2.9294756132003386e-07
region O 0 2.7387341106077656e-06
of O 0 1.0947252349069458e-06
Jerusalem O 0 0.00021837319945916533
. O 0 2.6863110178965144e-05

The O 0 0.0002604910114314407
clinical O 0 0.2870931625366211
diagnosis O 1 0.9886411428451538
of O 0 8.03959192126058e-05
AGU B-Disease 1 0.9999998807907104
is O 0 6.091177056077868e-06
often O 0 1.3470792055159109e-06
difficult O 0 9.608249911252642e-07
, O 0 1.3869981785319396e-07
in O 0 1.1603357563672034e-07
particular O 0 1.7613058389542857e-07
early O 0 3.022011298980942e-07
in O 0 7.181235162079247e-08
the O 0 8.985168875597083e-08
course O 0 7.610356647091976e-07
of O 0 1.9078282775808475e-07
the O 0 6.4637529249012005e-06
disease O 0 0.0006122814957052469
, O 0 2.8766470450136694e-07
and O 0 1.5053814195198356e-07
most O 0 3.719405938795717e-08
of O 0 9.875884643406607e-08
the O 0 3.7234242427075515e-06
patients O 0 0.00928791705518961
are O 0 2.56390922004357e-06
diagnosed O 1 0.9174885749816895
after O 0 2.145723783542053e-06
the O 0 3.5296403666507103e-07
age O 0 7.866399869271845e-07
of O 0 2.628385118441656e-07
5 O 0 4.169339263171423e-06
years O 0 4.879583684669342e-06
. O 0 7.035086127871182e-06

However O 0 0.00011529517360031605
, O 0 1.1244402230659034e-05
since O 0 8.011489626369439e-06
these O 0 1.1412819276301889e-06
patients O 0 3.339892646181397e-05
excrete O 0 7.229676612041658e-06
early O 0 9.748563343237038e-07
large O 0 3.108243902261165e-07
amounts O 0 2.405145096417982e-07
of O 0 1.3067409554423648e-07
aspartylglucosamine O 0 4.481421274249442e-05
in O 0 4.609071311278967e-07
urine O 0 3.311907448733109e-06
, O 0 3.306847133899282e-07
biochemical O 0 5.072090061730705e-06
screening O 0 1.7019856386468746e-06
is O 0 2.5854478735709563e-07
easy O 0 7.065801241878944e-07
by O 0 8.052116413637123e-07
urine O 0 2.4519335056538694e-05
chromatography O 0 0.00019280680862721056
. O 0 5.199332463234896e-06
. O 0 1.3750288417213596e-05

Detection O 0 0.0008524952572770417
of O 0 3.092408223892562e-05
heterozygous O 0 0.00035875968751497567
carriers O 0 2.8975033274036832e-05
of O 0 1.927002358570462e-06
the O 0 3.3259359042858705e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999828338623047
telangiectasia I-Disease 1 0.9999992847442627
( O 0 1.840211552917026e-05
ATM O 0 3.8293623219942674e-05
) O 0 1.4737651099494542e-06
gene O 0 2.69354973170266e-06
by O 0 8.891274205780064e-07
G2 O 0 0.0007904751691967249
phase O 0 4.088533387403004e-05
chromosomal O 0 0.0014204056933522224
radiosensitivity O 0 0.0008214957197196782
of O 0 6.4625874074408785e-06
peripheral O 0 0.06372150778770447
blood O 0 0.003189466195181012
lymphocytes O 0 0.005286762956529856
. O 0 4.6240096708061174e-05

In O 0 0.004287570249289274
ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.999988317489624
telangiectasia I-Disease 1 0.9999996423721313
( O 0 0.0037385213654488325
A B-Disease 1 0.9984596967697144
- I-Disease 1 0.9999972581863403
T I-Disease 1 1.0
) O 0 3.665666008600965e-05
patients O 0 7.080706564011052e-05
, O 0 7.050528552099422e-07
mutations O 0 3.4100457924068905e-06
in O 0 1.3219049321833154e-07
a O 0 6.454700383073941e-07
single O 0 9.653750794313964e-07
gene O 0 9.448639843867568e-07
, O 0 2.7636625077320787e-07
ATM O 0 6.72008354740683e-06
, O 0 3.4017784855677746e-07
result O 0 8.815446221888124e-07
in O 0 2.636871386130224e-06
an O 0 0.0549100898206234
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 1.4306717730505625e-06
embraces O 0 8.018621883820742e-06
a O 0 2.225395746791037e-06
variety O 0 6.445338840421755e-07
of O 0 2.715105438255705e-07
clinical O 0 2.2088563127908856e-05
features O 0 1.9074950614594854e-06
and O 0 1.2263204780538217e-06
manifests O 0 3.2416362955700606e-05
extreme O 0 2.5750616259756498e-05
radiosensitivity O 0 8.083393913693726e-05
and O 0 4.02876224825377e-07
a O 0 1.324086838394578e-06
strong O 0 1.9586459529818967e-06
pre O 0 4.4123546103946865e-05
- O 0 0.00016454873548354954
disposition O 0 0.00014011516759637743
to O 0 1.3071080502413679e-05
malignancy B-Disease 0 0.35841313004493713
. O 0 3.903434844687581e-05

Heterozygotes O 0 0.0028132989536970854
for O 0 7.083626314852154e-06
the O 0 2.1929115519014886e-06
ATM O 0 6.402671715477481e-05
gene O 0 8.410333975916728e-06
have O 0 4.5295416839508107e-07
no O 0 5.37185314897215e-07
clinical O 0 1.8520371668273583e-05
expression O 0 1.5220765590129304e-06
of O 0 3.861121626869135e-07
A B-Disease 1 0.9118223786354065
- I-Disease 1 0.9998668432235718
T I-Disease 1 0.9999991655349731
but O 0 2.9220414035080466e-06
may O 0 9.85348378890194e-06
be O 0 1.544161136735056e-06
cancer B-Disease 0 0.0012686415575444698
prone O 0 1.1544229892024305e-05
with O 0 4.993441962142242e-07
a O 0 1.0218460374744609e-05
moderate O 0 0.004423965699970722
increase O 0 5.652729214489227e-06
in O 0 5.83759572236886e-07
in O 0 2.7454393602965865e-06
vitro O 0 0.00047982746036723256
radiosensitivity O 0 0.0015563583001494408
. O 0 2.9783563149976544e-05

We O 0 3.781608393182978e-05
performed O 0 1.8338047084398568e-05
a O 0 8.658440492581576e-06
blind O 0 5.6331264204345644e-05
chromosomal O 0 0.00031521383789367974
analysis O 0 5.374136435420951e-06
on O 0 3.831698904832592e-06
G2 O 0 0.1332373023033142
- O 0 0.00047831665142439306
phase O 0 5.27960219187662e-05
lymphocytes O 0 3.0472920116153546e-05
from O 0 5.528427209355868e-07
7 O 0 8.546948265575338e-06
unrelated O 0 6.021612716722302e-05
A B-Disease 1 0.9869517087936401
- I-Disease 1 0.9999978542327881
T I-Disease 1 1.0
patients O 0 0.002320951083675027
, O 0 7.694691248616436e-07
13 O 0 2.557757625254453e-06
obligate O 0 5.73417310079094e-06
A B-Disease 0 0.1989654004573822
- I-Disease 1 0.9993042945861816
T I-Disease 1 0.9999995231628418
heterozygotes O 0 0.0010351829696446657
( O 0 1.3204803508415353e-06
parents O 0 3.6275616821512813e-07
of O 0 1.4405276260731625e-07
the O 0 1.0281617051077774e-06
patients O 0 5.4882417316548526e-05
) O 0 3.6901451494486537e-07
, O 0 1.2088860046333139e-07
and O 0 1.544061092317861e-07
14 O 0 1.1874495839947485e-06
normal O 0 9.049784353010182e-07
controls O 0 2.3740278720651986e-06
following O 0 9.012112514028559e-07
X O 0 3.023367935384158e-05
- O 0 7.91217553341994e-06
irradiation O 0 2.997987166963867e-06
with O 0 2.344789606922859e-07
1 O 0 1.160466808869387e-06
Gy O 0 0.0001011837666737847
in O 0 1.892986887241932e-07
order O 0 1.8885170049998123e-07
to O 0 1.0418784057719677e-07
evaluate O 0 8.96374331205152e-07
this O 0 1.7176296296383953e-07
cytogenetic O 0 3.77240139641799e-05
method O 0 5.889618250876083e-07
as O 0 7.029252913071105e-08
a O 0 3.3801890708673454e-07
tool O 0 2.063142801489448e-06
for O 0 3.5398886666371254e-07
detection O 0 5.908469574933406e-06
of O 0 1.6683931107763783e-06
ATM O 0 0.0002871090837288648
carriers O 0 9.469295764574781e-05
. O 0 1.8036920664599165e-05

Both O 0 0.00019109192362520844
A B-Disease 1 0.6845670938491821
- I-Disease 1 0.9992714524269104
T I-Disease 1 0.9999929666519165
homozygotes O 0 0.0024138358421623707
and O 0 7.699316483922303e-06
heterozygotes O 0 0.0006851314683444798
showed O 0 1.5598661775584333e-05
significantly O 0 8.03078910394106e-06
increased O 0 1.9013851897398126e-06
levels O 0 8.065481438279676e-07
of O 0 4.0727468331169803e-07
radiation O 0 0.00040410092333331704
- O 0 0.00134432059712708
induced O 0 0.21479424834251404
chromatid O 1 0.9785335659980774
damage O 0 5.141386645846069e-05
relative O 0 1.7955233033717377e-06
to O 0 1.4585120311494393e-07
that O 0 1.311870505560364e-07
of O 0 6.785854793633916e-07
normal O 0 1.4148309674055781e-05
controls O 0 7.376396388281137e-05
. O 0 2.7013700673705898e-05

These O 0 2.1088775611133315e-05
results O 0 9.004612365970388e-06
show O 0 2.0824020339205163e-06
that O 0 2.444234610265994e-07
the O 0 5.710863320018689e-07
G2 O 0 0.012895496562123299
- O 0 0.00018412202189210802
phase O 0 3.603638106142171e-05
chromosomal O 0 0.0006587784155271947
radiosensitivity O 0 0.00030272165895439684
assay O 0 3.13960736093577e-05
can O 0 1.7127013052231632e-07
be O 0 4.481337256834195e-08
used O 0 8.890912539527562e-08
for O 0 7.581294170222463e-08
the O 0 2.3884749111857673e-07
detection O 0 5.322447577782441e-06
of O 0 1.6487449556734646e-06
A B-Disease 1 0.8987079858779907
- I-Disease 1 0.9998168349266052
T I-Disease 1 0.9999935626983643
heterozygotes O 0 0.0034329937770962715
. O 0 4.0217346395365894e-05

In O 0 5.802322266390547e-05
combination O 0 6.321442197076976e-05
with O 0 3.847866082651308e-06
molecular O 0 5.7282722991658375e-05
genetic O 0 2.9102418920956552e-05
analyses O 0 3.582244517019717e-06
, O 0 3.889297488512966e-07
this O 0 1.5344490122970456e-07
test O 0 1.0864225714612985e-06
may O 0 3.353263764438452e-07
be O 0 2.1116600024129184e-08
of O 0 3.0034787101840266e-08
value O 0 7.168877402818907e-08
in O 0 8.56996464904114e-08
studies O 0 2.021454719169924e-07
of O 0 1.4176858087466826e-07
familial B-Disease 0 7.795439887559041e-05
and I-Disease 0 3.335732117193402e-06
sporadic I-Disease 0 0.005382869858294725
cancers I-Disease 0 0.3651396334171295
aimed O 0 5.458338819153141e-06
at O 0 3.414461104966904e-07
determination O 0 7.756357831567584e-07
of O 0 5.753635434757598e-08
the O 0 1.1680664613322733e-07
potential O 0 3.466994087375497e-07
involvement O 0 9.65820845522103e-07
of O 0 3.275679034686618e-07
ATM O 0 0.00043517089216038585
mutations O 0 7.667233148822561e-05
in O 0 6.9587781581503805e-06
tumor B-Disease 0 0.4274260401725769
risk O 0 1.7835627659223974e-05
or O 0 1.518414364909404e-06
development O 0 3.459451136222924e-06
. O 0 3.181666897944524e-06
. O 0 1.213849554915214e-05

Ataxia B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999295473098755
telangiectasia I-Disease 1 0.9999750852584839
: O 0 2.6805557354236953e-05
identification O 0 9.08782021724619e-06
and O 0 1.2628320291696582e-06
detection O 0 1.1494827049318701e-05
of O 0 8.557694286537298e-07
founder O 0 8.552116923965514e-05
- O 0 0.0011777180479839444
effect O 0 1.2724981388601009e-05
mutations O 0 3.808782594205695e-06
in O 0 1.2542093941192434e-07
the O 0 2.896649675676599e-07
ATM O 0 1.3768343706033193e-05
gene O 0 2.8701354040094884e-06
in O 0 1.0486904784556828e-06
ethnic O 0 1.3917279829911422e-05
populations O 0 6.297141953837126e-05
. O 0 2.1069157810416073e-05

To O 0 1.7040292732417583e-05
facilitate O 0 1.113995040213922e-05
the O 0 1.2832351785618812e-06
evaluation O 0 3.4733589018287603e-06
of O 0 6.164666501717875e-07
ATM O 0 0.00013055113959126174
heterozygotes O 0 0.0001667966425884515
for O 0 7.663275027880445e-07
susceptibility O 0 6.0376423789421096e-05
to O 0 4.92808965191216e-07
other O 0 7.858661206228135e-07
diseases O 0 0.0001321914023719728
, O 0 3.3740633398338105e-07
such O 0 2.6754779014481755e-07
as O 0 1.4971610653446987e-05
breast B-Disease 1 0.99997878074646
cancer I-Disease 1 0.8609009981155396
, O 0 4.6653138952024165e-07
we O 0 6.654807549466568e-08
have O 0 6.569666766154114e-08
attempted O 0 2.364975443924777e-06
to O 0 9.101336928551973e-08
define O 0 8.666006010571436e-07
the O 0 1.584625834993858e-07
most O 0 1.5434839895078767e-07
common O 0 1.2895445706817554e-06
mutations O 0 2.7743544706027023e-06
and O 0 8.36598204045913e-08
their O 0 1.734892407512234e-07
frequencies O 0 4.186448222753825e-06
in O 0 5.394243999035098e-06
ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9994670748710632
telangiectasia I-Disease 1 0.9999996423721313
( O 0 7.354441186180338e-05
A B-Disease 1 0.5959992408752441
- I-Disease 1 0.9964893460273743
T I-Disease 1 0.9999767541885376
) O 0 3.438476369410637e-06
homozygotes O 0 3.845581159112044e-05
from O 0 8.013055321498541e-07
10 O 0 1.892055138341675e-06
ethnic O 0 9.592076821718365e-06
populations O 0 3.3401061955373734e-05
. O 0 1.5647756299586035e-05

Both O 0 0.00011113334767287597
genomic O 0 0.0015264119720086455
mutations O 0 0.0002826941490639001
and O 0 1.1449153589637717e-06
their O 0 1.0200535598414717e-06
effects O 0 6.792550721002044e-06
on O 0 2.129530912498012e-06
cDNA O 0 4.669402915169485e-05
were O 0 5.0253538574907e-06
characterized O 0 0.00012574141146615148
. O 0 2.8358150302665308e-05

Protein O 0 0.0005356993060559034
- O 0 0.0002943070721812546
truncation O 0 0.00016689432959537953
testing O 0 1.0713487426983193e-05
of O 0 5.345148110791342e-07
the O 0 4.725045528175542e-07
entire O 0 2.4347339149244362e-06
ATM O 0 1.3294794371176977e-05
cDNA O 0 1.6636071450193413e-05
detected O 0 5.425114977697376e-06
92 O 0 4.230621016176883e-06
( O 0 1.3966189271741314e-06
66 O 0 9.452377526031341e-06
% O 0 2.4546441181882983e-06
) O 0 1.043377324094763e-06
truncating O 0 2.927670175267849e-05
mutations O 0 6.998149274295429e-06
in O 0 7.656152547497186e-07
140 O 0 9.914356269291602e-06
mutant O 0 0.00014280801406130195
alleles O 0 7.345294579863548e-05
screened O 0 6.0451904573710635e-05
. O 0 2.7189633328816853e-05

The O 0 4.8918675020104274e-05
haplotyping O 0 0.0014482339611276984
of O 0 1.0790532542159781e-05
patients O 0 0.0002842874964699149
with O 0 2.9772986636089627e-06
identical O 0 0.04673250764608383
mutations O 0 0.00041089399019256234
indicates O 0 1.8380065966994152e-06
that O 0 4.154420807367387e-08
almost O 0 6.550585140985277e-08
all O 0 1.3433694157072296e-08
of O 0 2.7672616198515243e-08
these O 0 3.451850361102515e-08
represent O 0 1.7438466670682828e-07
common O 0 7.561126835753385e-07
ancestry O 0 5.102212526253425e-06
and O 0 2.3627588063845906e-07
that O 0 1.7320490997008164e-07
very O 0 4.906358412881673e-07
few O 0 1.5089417502167635e-06
spontaneously O 0 2.1529700461542234e-05
recurring O 0 9.096974827116355e-05
ATM O 0 0.0014974764781072736
mutations O 0 0.00028040341567248106
exist O 0 7.678969268454239e-06
. O 0 9.76398223428987e-06

Assays O 0 0.0012644557282328606
requiring O 0 9.032154048327357e-05
minimal O 0 3.8803413190180436e-05
amounts O 0 4.447118044481613e-06
of O 0 8.152285886353638e-07
genomic O 0 2.4898086849134415e-05
DNA O 0 4.3413347157184035e-06
were O 0 2.563887164797052e-07
designed O 0 9.6422775186511e-07
to O 0 9.7049493774648e-08
allow O 0 4.396450776766869e-07
rapid O 0 4.024828740512021e-06
screening O 0 1.7529450815345626e-06
for O 0 4.582807946462708e-07
common O 0 4.3527097659534775e-06
ethnic O 0 5.172673991182819e-05
mutations O 0 0.0003112834529019892
. O 0 1.4645525880041532e-05

These O 0 4.662266292143613e-05
rapid O 0 0.00021819314861204475
assays O 0 0.000244357215706259
detected O 0 5.975204840069637e-05
mutations O 0 2.1992069378029555e-05
in O 0 9.346480851490924e-07
76 O 0 2.0979974578949623e-05
% O 0 1.9887158941855887e-06
of O 0 3.856624459785962e-07
Costa O 0 1.6406844224547967e-05
Rican O 0 0.0012223718222230673
patients O 0 0.00017193380335811526
( O 0 7.963089387885702e-07
3 O 0 4.405394520290429e-07
) O 0 1.3595850134606735e-07
, O 0 6.637985450197448e-08
50 O 0 3.218497965917777e-07
% O 0 2.494521424978302e-07
of O 0 9.777261311683105e-08
Norwegian O 0 0.04411592707037926
patients O 0 0.0002653099945746362
( O 0 7.301184723473853e-07
1 O 0 4.7060675001375785e-07
) O 0 1.255386905540945e-07
, O 0 7.691611614291105e-08
25 O 0 3.9757998138156836e-07
% O 0 4.5277232629814534e-07
of O 0 1.792628552266251e-07
Polish O 0 0.004945847205817699
patients O 0 6.262629176490009e-05
( O 0 6.331461008812767e-07
4 O 0 5.835297542944318e-07
) O 0 1.1038842728794407e-07
, O 0 5.0555033936916516e-08
and O 0 8.005351048723242e-08
14 O 0 1.3809456049784785e-06
% O 0 5.704505383619107e-07
of O 0 1.155506694772157e-07
Italian O 0 0.014640276320278645
patients O 0 0.0005480305990204215
( O 0 8.13367933005793e-07
1 O 0 5.996519689688284e-07
) O 0 1.7475291258506331e-07
, O 0 4.177256585080613e-08
as O 0 3.4179659991195877e-08
well O 0 5.73807312775898e-08
as O 0 1.432838416803861e-07
in O 0 6.727809136464202e-07
patients O 0 5.500514816958457e-06
of O 0 3.585141996609309e-07
Amish O 0 8.134973177220672e-05
/ O 0 8.151947258738801e-05
Mennonite O 0 7.387836376437917e-05
and O 0 1.4066025642023305e-06
Irish O 0 1.6414091078331694e-05
English O 0 1.0701508472266141e-05
backgrounds O 0 5.010008317185566e-05
. O 0 2.0553210561047308e-05

Additional O 0 0.0003100586764048785
mutations O 0 0.0005093617946840823
were O 0 2.24332893594692e-06
observed O 0 1.914612084874534e-06
in O 0 2.99080568311183e-07
Japanese O 0 8.571270200263825e-07
, O 0 2.189055265944262e-07
Utah O 0 1.984447408176493e-06
Mormon O 0 2.6877760319621302e-06
, O 0 2.4600714709777094e-07
and O 0 4.1921109072973195e-07
African O 0 5.180288098927122e-06
American O 0 1.538019387226086e-05
patients O 0 0.0001970955345313996
. O 0 2.0154107915004715e-05

These O 0 2.6333196728955954e-05
assays O 0 6.695163756376132e-05
should O 0 2.825131559802685e-06
facilitate O 0 2.3734346541459672e-06
screening O 0 4.766207439388381e-06
for O 0 1.3881576705898624e-06
A B-Disease 1 0.8258339166641235
- I-Disease 1 0.9999048709869385
T I-Disease 1 0.9999986886978149
heterozygotes O 0 0.000248450058279559
in O 0 6.150021363282576e-07
the O 0 1.1687545793392928e-06
populations O 0 6.316164217423648e-06
studied O 0 5.905821581109194e-06
. O 0 3.215511014786898e-06
. O 0 1.3880670849175658e-05

The O 0 0.00041647758916951716
von B-Disease 1 0.9104060530662537
Hippel I-Disease 1 0.9987321496009827
- I-Disease 1 0.9655677080154419
Lindau I-Disease 1 0.9915485978126526
tumor I-Disease 0 0.0675986036658287
suppressor O 0 0.0010609052842482924
gene O 0 1.9386263375054114e-05
is O 0 9.381969903188292e-07
required O 0 7.171680636020028e-07
for O 0 4.6182449864318187e-07
cell O 0 3.7471992982318625e-05
cycle O 0 3.125742659904063e-05
exit O 0 1.7249361917492934e-05
upon O 0 4.510601684160065e-06
serum O 0 9.155395673587918e-05
withdrawal O 0 0.00029963263659738004
. O 0 3.7353256630012766e-05

The O 0 7.108702993718907e-05
inactivation O 0 0.0007830435060895979
of O 0 6.31668854111922e-06
the O 0 1.2436709766916465e-05
von B-Disease 1 0.9735158681869507
Hippel I-Disease 1 0.9995629191398621
- I-Disease 1 0.6589986085891724
Lindau I-Disease 1 0.9432066082954407
( I-Disease 0 5.51051962247584e-05
VHL I-Disease 0 0.0045403363183140755
) I-Disease 0 2.1210540580796078e-05
tumor I-Disease 0 0.0005709021934308112
suppressor O 0 0.0007075886824168265
gene O 0 4.0990275010699406e-05
predisposes O 0 0.00020803358347620815
affected O 0 6.2903582147555426e-06
individuals O 0 6.275818122958299e-07
to O 0 2.980169142574596e-07
the O 0 3.2292630294250557e-06
human O 0 0.0011818428756669164
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 0.9999996423721313
and O 0 2.230567361038993e-06
is O 0 6.780672947570565e-07
associated O 0 2.8889410259580472e-06
with O 0 8.421956408710685e-06
sporadic B-Disease 1 0.918899416923523
renal I-Disease 1 1.0
cell I-Disease 1 0.999998927116394
carcinomas I-Disease 1 1.0
( O 0 0.00039972589001990855
RCC B-Disease 0 0.34598401188850403
) O 0 9.834351658355445e-06
and O 0 1.5179311048996169e-05
brain B-Disease 0 0.002482205629348755
hemangioblastomas I-Disease 0 0.009453406557440758
. O 0 6.0127182223368436e-05

VHL O 0 0.42975685000419617
- O 0 0.008241076953709126
negative O 0 0.00028921739431098104
786 O 0 0.0010890254052355886
- O 0 0.00668764766305685
0 O 0 0.00019141177472192794
RCC B-Disease 0 0.057869814336299896
cells O 0 1.547340798424557e-05
are O 0 3.2949793649095227e-07
tumorigenic O 0 7.272551010828465e-05
in O 0 1.5314125221266295e-06
nude O 0 0.0009831649949774146
mice O 0 0.00012647687981370836
which O 0 3.6284959037402587e-07
is O 0 2.2477480854377063e-07
suppressed O 0 1.1099156154159573e-06
by O 0 1.4215321186838992e-07
the O 0 4.174939078893658e-07
reintroduction O 0 8.583424641983584e-05
of O 0 8.968507245299406e-06
VHL B-Disease 0 0.07811719924211502
. O 0 5.7870107411872596e-05

Remarkably O 0 0.0032334665302187204
, O 0 1.7354732335661538e-05
this O 0 1.5714772416686174e-06
occurs O 0 2.105042312905425e-06
without O 0 6.028814709679864e-07
affecting O 0 1.2309311614444596e-06
the O 0 3.436636575315788e-07
growth O 0 6.99289194017183e-06
rate O 0 5.101901024318067e-06
and O 0 4.616743183305516e-07
cell O 0 3.1782055884832516e-05
cycle O 0 8.169850843842141e-06
profile O 0 1.281888444282231e-06
of O 0 1.8212161023711815e-07
these O 0 2.6623925464264175e-07
cells O 0 5.360198429116281e-06
in O 0 1.2299993841224932e-06
culture O 0 8.214743502321653e-06
. O 0 1.1379484931239858e-05

The O 0 9.74264185060747e-05
786 O 0 0.0009300400270149112
- O 0 0.0007061143987812102
0 O 0 3.297443254268728e-05
cell O 0 4.4686188630294055e-05
line O 0 5.050981599197257e-06
, O 0 2.919268240475503e-07
like O 0 4.3517206904652994e-07
many O 0 1.114852693717694e-06
cancer B-Disease 0 0.035679928958415985
cells O 0 1.8547731087892316e-05
, O 0 4.5869091991335154e-07
fails O 0 2.528865479689557e-06
to O 0 1.8067572682411992e-07
exit O 0 2.823437171173282e-06
the O 0 7.597390094815637e-07
cell O 0 2.345629945921246e-05
cycle O 0 2.8557018595165573e-05
upon O 0 5.336302365321899e-06
serum O 0 0.00011215888662263751
withdrawal O 0 0.0001638104731682688
. O 0 3.745577487279661e-05

Here O 0 4.869734766543843e-05
, O 0 4.172577519057086e-06
it O 0 5.09361882450321e-07
is O 0 3.239134400701005e-07
shown O 0 7.043747132229328e-07
that O 0 1.2224980139308173e-07
reintroduction O 0 8.440835699730087e-06
of O 0 2.0935257794008066e-07
the O 0 5.033431307310821e-07
wild O 0 3.519855681588524e-06
- O 0 0.0001655766536714509
type O 0 1.2571157640195452e-05
VHL B-Disease 0 0.00042753139859996736
gene O 0 4.947485194861656e-06
restores O 0 2.0943431081832387e-05
the O 0 6.175263820296095e-07
ability O 0 1.2388734376145294e-06
of O 0 1.0256185305479448e-06
VHL O 0 0.16693001985549927
- O 0 0.3487461805343628
negative O 0 0.0005726715316995978
RCC B-Disease 1 0.9949970245361328
cancer I-Disease 0 0.18430955708026886
cells O 0 5.670460268447641e-06
to O 0 2.483592425051029e-07
exit O 0 3.7039840208308306e-06
the O 0 7.163402528931329e-07
cell O 0 2.2720878405380063e-05
cycle O 0 1.1315063602523878e-05
and O 0 7.870586955505132e-07
enter O 0 7.364630619122181e-06
G0 O 0 0.0010678177932277322
/ O 0 0.00011586066102609038
quiescence O 0 0.0003699342196341604
in O 0 5.317232080415124e-06
low O 0 8.673545380588621e-05
serum O 0 0.0004226835153531283
. O 0 2.6791958589456044e-05

Both O 0 0.0002124449092661962
VHL O 0 0.032013531774282455
- O 0 0.0012930779485031962
positive O 0 2.4354993001907133e-05
and O 0 7.203216227935627e-06
VHL O 0 0.13310693204402924
- O 0 0.07904238253831863
negative O 0 9.25821004784666e-05
RCC B-Disease 0 0.004633956588804722
cells O 0 7.717187145317439e-06
exit O 0 4.0255154090118594e-06
the O 0 7.924150509097672e-07
cell O 0 3.0204691938706674e-05
cycle O 0 1.609066384844482e-05
by O 0 1.2168317198302248e-06
contact O 0 1.1464831004559528e-05
inhibition O 0 8.77714337548241e-05
. O 0 1.6610565580776893e-05

The O 0 0.0001682252186583355
cyclin O 0 0.0035149322357028723
- O 0 0.00041633291402831674
dependent O 0 8.741842611925676e-05
kinase O 0 0.00026837122277356684
inhibitor O 0 9.943640179699287e-05
, O 0 2.1160867618164048e-06
p27 O 0 8.972954674391076e-05
, O 0 9.041114594765531e-07
accumulates O 0 3.204010681656655e-06
upon O 0 6.299155188571604e-07
serum O 0 9.180136657960247e-06
withdrawal O 0 2.1543582988670096e-05
, O 0 1.3468462611854193e-07
only O 0 4.044220958121514e-08
in O 0 5.574796091423195e-08
the O 0 7.795484435746403e-08
presence O 0 2.8558289955071814e-07
of O 0 2.531727147925267e-07
VHL B-Disease 0 0.004384411498904228
, O 0 3.5827494571094576e-07
as O 0 7.436432269969373e-08
a O 0 5.142810550751165e-07
result O 0 2.3703894669324654e-07
of O 0 6.741360891737713e-08
the O 0 1.7051017664471146e-07
stabilization O 0 9.195680831908248e-06
of O 0 2.5912981982401107e-07
the O 0 1.5468451692868257e-06
protein O 0 1.5663927115383558e-05
. O 0 9.330448847322259e-06

We O 0 4.7842975618550554e-05
propose O 0 4.455584712559357e-05
that O 0 8.257331955974223e-07
the O 0 8.958393777902529e-07
loss O 0 7.729354365437757e-06
of O 0 5.250468575468403e-07
wild O 0 1.1087317943747621e-05
- O 0 0.002653564093634486
type O 0 3.698487125802785e-05
VHL B-Disease 0 0.002879444509744644
gene O 0 6.734114322171081e-06
results O 0 1.0094994422615855e-06
in O 0 2.1266643557282805e-07
a O 0 9.165284495793458e-07
specific O 0 1.6165038232429652e-06
cellular O 0 0.00011902675032615662
defect O 0 0.00012091430835425854
in O 0 1.4036772881809156e-06
serum O 0 7.42869742680341e-05
- O 0 5.2581475756596774e-05
dependent O 0 3.3399560379621107e-06
growth O 0 2.383280843787361e-06
control O 0 1.6017384041333571e-06
, O 0 4.935529887006851e-07
which O 0 8.275968639281928e-07
may O 0 6.662137366220122e-06
initiate O 0 0.00010935372847598046
tumor B-Disease 0 0.01015476044267416
formation O 0 8.668081136420369e-05
. O 0 2.6497313228901476e-05

This O 0 1.681392859609332e-05
is O 0 2.716415565373609e-06
corrected O 0 1.895162495202385e-05
by O 0 4.231231969242799e-07
the O 0 4.5259275793796405e-07
reintroduction O 0 2.1528818251681514e-05
of O 0 5.695861773347133e-07
wild O 0 6.159045824460918e-06
- O 0 0.0005742255016230047
type O 0 2.564832175266929e-05
VHL B-Disease 0 0.0016382524045184255
, O 0 2.302014081578818e-06
implicating O 0 4.7954064939403906e-05
VHL B-Disease 0 0.0007939995266497135
as O 0 3.1228859143084264e-07
the O 0 4.644467423986498e-07
first O 0 4.603075467457529e-06
tumor B-Disease 0 0.001245575025677681
suppressor O 0 9.401544230058789e-05
involved O 0 3.8998751961116795e-07
in O 0 8.990997457658523e-08
the O 0 1.181638040748112e-07
regulation O 0 1.1267954960203497e-06
of O 0 1.553226667283525e-07
cell O 0 4.119647928746417e-05
cycle O 0 2.0620354916900396e-05
exit O 0 5.8499740589468274e-06
, O 0 3.0474623713416804e-07
which O 0 1.1843129499311544e-07
is O 0 7.630866605268238e-08
consistent O 0 3.1378874609799823e-07
with O 0 1.2059037146627816e-07
its O 0 5.281162316350674e-07
gatekeeper O 0 7.037416798993945e-05
function O 0 1.0784439155031578e-06
in O 0 4.4632875528805016e-07
the O 0 2.986677827720996e-06
kidney O 0 0.02611549384891987
. O 0 5.563043941947399e-06
. O 0 1.7233182006748393e-05

Piebaldism B-Disease 1 0.9999591112136841
with O 0 0.009821886196732521
deafness B-Disease 1 0.9999998807907104
: O 0 3.302021650597453e-05
molecular O 0 3.43338142556604e-05
evidence O 0 2.0280867829569615e-06
for O 0 9.208652613779122e-07
an O 0 1.0749511602625716e-05
expanded O 0 0.02734486572444439
syndrome O 1 0.999994158744812
. O 0 4.391441325424239e-05

In O 0 3.335703877382912e-05
a O 0 1.56930345838191e-05
South O 0 7.721361725998577e-06
African O 0 6.300865152297774e-06
girl O 0 1.7021338862832636e-05
of O 0 1.2224006695760181e-06
Xhosa O 0 0.18610720336437225
stock O 0 1.1714142601704225e-05
with O 0 3.040407364096609e-06
severe O 0 0.2730698883533478
piebaldism B-Disease 0 0.3519255220890045
and O 0 9.991021215682849e-05
profound O 1 0.7927122712135315
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 1.3505803508451208e-05
identified O 0 5.808984496979974e-06
a O 0 2.1629612092510797e-06
novel O 0 5.558292286877986e-06
missense O 0 4.339561201049946e-05
substitution O 0 2.0682334707089467e-06
at O 0 3.693898804613127e-07
a O 0 6.036247555130103e-07
highly O 0 7.351014232881425e-07
conserved O 0 9.70974156189186e-07
residue O 0 9.059282888301823e-07
in O 0 1.0971755415312145e-07
the O 0 2.2418096534693177e-07
intracellular O 0 3.454025090832147e-06
kinase O 0 4.924518634652486e-06
domain O 0 4.094892176453868e-07
of O 0 1.5434545730386162e-07
the O 0 6.131778604867577e-07
KIT O 0 0.0001925850665429607
proto O 0 0.0019466078374534845
- O 0 0.0006452908273786306
oncogene O 0 0.0008148941560648382
, O 0 1.0082590961246751e-05
R796G O 0 0.00040974473813548684
. O 0 2.9866359909647144e-05

Though O 0 0.00026941465330310166
auditory B-Disease 0 0.009318966418504715
anomalies I-Disease 0 0.018625766038894653
have O 0 5.636859896185342e-06
been O 0 1.9776819044636795e-06
observed O 0 4.199139311822364e-06
in O 0 1.0742385256889975e-06
mice O 0 2.4377533918595873e-05
with O 0 1.1197007552254945e-06
dominant O 0 5.1990824431413785e-05
white O 0 6.0276328440522775e-05
spotting O 0 0.00020084076095372438
( O 0 1.4319808542495593e-05
W O 0 0.021588101983070374
) O 0 8.982004828794743e-07
due O 0 6.627965376537759e-07
to O 0 7.041617777758802e-07
KIT O 0 0.382340669631958
mutations O 0 0.001218289602547884
, O 0 1.9652392438729294e-05
deafness B-Disease 1 0.9999997615814209
is O 0 1.248344801751955e-06
not O 0 3.5734817060983914e-07
typical O 0 4.849216111324495e-06
in O 0 1.7289789866481442e-06
human O 0 8.7181651906576e-06
piebaldism B-Disease 0 0.0023668985813856125
. O 0 2.2447957235272042e-05

Thus O 0 9.00580344023183e-05
, O 0 4.886987881036475e-06
the O 0 1.2431198683771072e-06
occurrence O 0 1.2776053154084366e-05
of O 0 8.339673513546586e-06
sensorineural B-Disease 1 0.9999998807907104
deafness I-Disease 1 1.0
in O 0 4.70263184979558e-05
this O 0 2.576031192802475e-06
patient O 0 0.00010007068340200931
extends O 0 1.0527474842092488e-05
considerably O 0 7.079237093421398e-06
the O 0 2.8235268700882443e-07
phenotypic O 0 4.16324837715365e-06
range O 0 6.504718044197944e-07
of O 0 2.4074330440271297e-07
piebaldism B-Disease 0 0.00012044915638398379
due O 0 1.2350914175840444e-06
to O 0 5.149652224645251e-07
KIT O 0 0.0006545418873429298
gene O 0 1.2918074389745016e-05
mutation O 0 7.961623850860633e-06
in O 0 4.2975977976311697e-07
humans O 0 5.961043711977254e-07
and O 0 3.7305824207578553e-07
tightens O 0 0.01294206827878952
the O 0 8.866016401043453e-07
clinical O 0 2.1658945115632378e-05
similarity O 0 1.3367007341003045e-06
between O 0 4.926801580040774e-07
piebaldism B-Disease 0 7.740993169136345e-05
and O 0 1.8387237332717632e-07
the O 0 1.9918921623229835e-07
various O 0 3.728455340024084e-07
forms O 0 5.289996352075832e-06
of O 0 7.149955490604043e-05
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 0.9999997615814209
. O 0 1.4129917872196529e-05
. O 0 2.5369128707097843e-05

Cycloheximide O 0 0.0036511800717562437
facilitates O 0 0.0001461623323848471
the O 0 5.179576874070335e-06
identification O 0 5.829351266584126e-06
of O 0 1.2854115993832238e-06
aberrant O 0 5.139141285326332e-05
transcripts O 0 1.6335323380189948e-05
resulting O 0 5.018715455662459e-06
from O 0 4.261568165020435e-07
a O 0 8.743232342567353e-07
novel O 0 2.442268623781274e-06
splice O 0 7.93790677562356e-05
- O 0 5.714763392461464e-05
site O 0 3.114138507953612e-06
mutation O 0 4.211969553580275e-06
in O 0 4.900382464256836e-07
COL17A1 O 0 0.00014339174958877265
in O 0 1.002302724373294e-06
a O 0 8.70569419930689e-06
patient O 0 0.0002475933579262346
with O 0 3.219435893697664e-05
generalized O 1 0.7729077339172363
atrophic B-Disease 1 0.9999967813491821
benign I-Disease 1 0.999985933303833
epidermolysis I-Disease 1 0.9999867677688599
bullosa I-Disease 1 0.9999004602432251
. O 0 0.0005186242051422596

Patients O 1 0.8306946754455566
with O 0 0.0004946161643601954
generalized O 0 0.21091890335083008
atrophic B-Disease 1 0.9999741315841675
benign I-Disease 1 0.9999773502349854
epidermolysis I-Disease 1 0.9999879598617554
bullosa I-Disease 1 0.9998681545257568
often O 0 0.00016841429169289768
show O 0 3.614021261455491e-05
decreased O 0 0.00010599892266327515
expression O 0 5.622052867693128e-06
of O 0 1.087922782971873e-06
type O 0 1.983389665838331e-05
XVII O 0 0.07870589196681976
collagen O 0 7.084719254635274e-05
, O 0 1.5448446220034384e-06
a O 0 5.376135504775448e-06
transmembrane O 0 2.968131775560323e-05
hemidesmosomal O 0 6.960761675145477e-05
protein O 0 5.515427346836077e-06
encoded O 0 5.3602852858603e-06
by O 0 3.5419113828538684e-06
COL17A1 O 0 0.0007160867098718882
. O 0 2.775175562419463e-05

This O 0 2.742298056546133e-05
report O 0 1.1957956303376704e-05
documents O 0 3.3144890494440915e-06
a O 0 2.6789937237481354e-06
novel O 0 5.512366897164611e-06
splice O 0 0.00019192422041669488
- O 0 0.00020100054098293185
site O 0 4.521114533417858e-06
mutation O 0 5.653882908518426e-06
in O 0 5.53612437670381e-07
COL17A1 O 0 0.00023054365010466427
in O 0 1.0418282272439683e-06
a O 0 7.982142960827332e-06
patient O 0 0.00010429952089907601
with O 0 1.1021304089808837e-05
generalized O 0 0.08088476210832596
atrophic B-Disease 1 0.9999942779541016
benign I-Disease 1 0.9998829364776611
epidermolysis I-Disease 1 0.9999940395355225
bullosa I-Disease 1 0.999861478805542
, O 0 4.6516624934156425e-06
and O 0 6.54118366583134e-07
applies O 0 8.770933845880791e-07
a O 0 4.364196968253964e-07
new O 0 5.817122428197763e-07
methodology O 0 1.4514785107166972e-06
to O 0 1.706829664271936e-07
define O 0 1.3356634553929325e-06
and O 0 3.8803688084954047e-07
characterize O 0 4.308141342335148e-06
the O 0 9.316365776612656e-07
resulting O 0 8.577896551287267e-06
mRNA O 0 1.4343193470267579e-05
splice O 0 0.00018802979320753366
variants O 0 8.419226651312783e-05
. O 0 2.7956446501775645e-05

Mutational O 0 0.011097228154540062
analysis O 0 0.00012441966100595891
of O 0 1.519911256764317e-05
COL17A1 O 0 0.0034392394591122866
identified O 0 3.86123574571684e-05
a O 0 1.911660910991486e-05
maternally O 0 0.003370270598679781
inherited O 0 0.015676680952310562
G O 0 0.01136850193142891
- O 0 4.874674414168112e-05
to O 0 1.0681856110750232e-06
- O 0 0.0012657978804782033
T O 0 0.004852445796132088
transversion O 0 2.400562516413629e-05
at O 0 2.3273634042197955e-07
the O 0 1.7851513689493004e-07
- O 0 4.419631750351982e-06
1 O 0 1.4085717339185067e-06
position O 0 1.0907516525549e-06
of O 0 8.985585964182974e-07
exon O 0 0.00010492078581592068
32 O 0 5.865616913069971e-05
. O 0 2.5714714865898713e-05

This O 0 3.3257270843023434e-05
acceptor O 0 0.000143321231007576
splice O 0 0.0006358923274092376
- O 0 0.00046088191447779536
site O 0 1.3606823813461233e-05
mutation O 0 7.992342943907715e-06
led O 0 8.370337809537887e-07
to O 0 1.0496754754285575e-07
the O 0 1.5251148965944594e-07
formation O 0 1.1064460068155313e-06
of O 0 1.8824822234364547e-07
aberrant O 0 1.2883108865935355e-05
transcripts O 0 3.6029214243171737e-06
present O 0 1.2099476407456677e-06
at O 0 1.4090257991483668e-06
extremely O 0 7.799433660693467e-06
low O 0 3.432595622143708e-05
levels O 0 1.6041587514337152e-05
. O 0 1.4705356988997664e-05

Based O 0 7.941889634821564e-05
on O 0 7.496788839489454e-06
our O 0 2.2208714653970674e-06
recent O 0 1.9223712115490343e-06
finding O 0 1.789422412912245e-06
that O 0 5.325659913069103e-07
cycloheximide O 0 0.00020383861556183547
stabilized O 0 0.00027797187794931233
mutant O 0 8.34730381029658e-05
COL17A1 O 0 0.00014268673839978874
transcripts O 0 6.469166692113504e-06
in O 0 9.279000323658693e-07
keratinocytes O 0 7.498532067984343e-05
homozygous O 0 3.37320780090522e-05
for O 0 4.1452008758824377e-07
a O 0 9.322141522716265e-06
frameshift O 0 0.3204125761985779
mutation O 0 1.25167025544215e-05
, O 0 1.660112900481181e-07
the O 0 1.34484281488767e-07
effects O 0 1.1922176099687931e-06
of O 0 9.887419594178937e-08
the O 0 3.410262934266939e-07
splice O 0 7.512739830417559e-05
- O 0 5.6130716984625906e-05
site O 0 2.0349684746179264e-06
mutation O 0 2.06274353331537e-06
on O 0 2.770737523860589e-07
splicing O 0 2.911277078965213e-06
of O 0 3.912541046702245e-07
COL17A1 O 0 0.00019542317022569478
transcripts O 0 4.45418072558823e-06
were O 0 4.433608182807802e-07
determined O 0 6.265173624342424e-07
using O 0 5.120181754136865e-07
reverse O 0 1.2407330359565094e-05
transcriptase O 0 5.4602554882876575e-05
polymerase O 0 1.4739262041985057e-05
chain O 0 3.386194521226571e-06
reaction O 0 5.235074240772519e-07
of O 0 1.1152211953913138e-07
total O 0 3.091876976668573e-07
RNA O 0 1.347235979665129e-06
from O 0 3.7541593655987526e-07
keratinocytes O 0 1.85407461685827e-05
incubated O 0 1.4386770089913625e-05
for O 0 1.3888595731259556e-06
2 O 0 1.667590913712047e-05
. O 0 1.8774866475723684e-05

5 O 0 0.0005849592853337526
h O 0 0.0002873547491617501
in O 0 1.4150992910799687e-06
the O 0 6.443808615586022e-07
presence O 0 9.385191788169323e-07
or O 0 4.4937141296941263e-07
absence O 0 1.3217124887887621e-06
of O 0 4.032798699427076e-07
10 O 0 3.3284454730164725e-06
microg O 0 0.00030050257919356227
cycloheximide O 0 0.0005767098045907915
per O 0 2.4863347789505497e-05
ml O 0 0.0006983231287449598
. O 0 2.197821049776394e-05

Using O 0 4.429491673363373e-05
this O 0 2.9822858778061345e-06
approach O 0 4.548785000224598e-06
, O 0 6.933804002073884e-07
an O 0 7.989683012965543e-07
abnormally O 0 0.00018782337429001927
spliced O 0 0.0008442275575362146
transcript O 0 0.00018346346041653305
was O 0 3.71367923435173e-06
identified O 0 1.1079654314016807e-06
that O 0 4.541657361301077e-08
contains O 0 9.256041977323548e-08
an O 0 8.660306605179358e-08
extra O 0 9.848380386756617e-07
264 O 0 2.6866846383200027e-06
bases O 0 8.632187018520199e-07
upstream O 0 9.516763839201303e-07
from O 0 2.239734584463804e-07
exon O 0 4.066043402417563e-06
32 O 0 1.859874259935168e-06
, O 0 2.5406131953786826e-07
resulting O 0 1.4467203754975344e-06
in O 0 3.34804553858703e-07
a O 0 5.027961378800683e-06
premature O 0 0.00014747479872312397
termination O 0 8.909265307011083e-05
codon O 0 3.836819087155163e-05
27 O 0 1.632605562917888e-05
bp O 0 1.427147799404338e-05
downstream O 0 2.7890084766113432e-06
from O 0 4.23352474854255e-07
the O 0 1.2510524811659707e-06
cryptic O 0 8.038556552492082e-05
splice O 0 0.0003368171164765954
site O 0 5.255199721432291e-05
. O 0 3.45458829542622e-05

Three O 0 3.8392419810406864e-05
other O 0 5.293008598528104e-06
splice O 0 0.00010457448661327362
variants O 0 1.9026123482035473e-05
, O 0 7.9081917192525e-07
including O 0 2.704515225104842e-07
one O 0 1.745850113366032e-07
derived O 0 3.829554486856068e-07
from O 0 1.4022894845311384e-07
the O 0 1.2349106270903576e-07
skipping O 0 1.255091660823382e-06
of O 0 2.129150402652158e-07
exon O 0 2.0301253243815154e-05
32 O 0 4.354781594884116e-06
, O 0 3.816633409314818e-07
were O 0 6.792905082875222e-07
also O 0 1.7643363889874308e-06
identified O 0 1.772093128238339e-05
. O 0 1.5763098417664878e-05

These O 0 2.988359483424574e-05
results O 0 2.0163142835372128e-05
indicate O 0 5.814643373014405e-06
the O 0 7.416925882353098e-07
usefulness O 0 5.182511813472956e-06
of O 0 9.109497227655083e-07
cycloheximide O 0 0.027737651020288467
treatment O 0 0.00011582607112359256
in O 0 6.511222068183997e-07
evaluating O 0 2.541466528782621e-06
the O 0 7.167181479417195e-07
abnormal O 0 7.896391252870671e-06
processing O 0 6.267695766837278e-07
of O 0 1.3210328120294434e-07
mRNA O 0 1.1634964494078304e-06
due O 0 3.035314932731126e-07
to O 0 1.7004754226945806e-07
splice O 0 2.8625760023714975e-05
- O 0 0.00013085560931358486
site O 0 8.50194464874221e-06
mutations O 0 7.799887498549651e-06
, O 0 2.663321936324792e-07
because O 0 2.2107990105268982e-07
( O 0 5.006822334507888e-07
i O 0 2.394637590441562e-07
) O 0 4.676691105487407e-07
aberrant O 0 4.783921667694813e-06
splicing O 0 8.48570289235795e-06
often O 0 1.1999238722637529e-06
generates O 0 2.563319867476821e-06
a O 0 3.2216867111856118e-06
premature O 0 0.00011550468479981646
termination O 0 5.838038487127051e-05
codon O 0 2.5311253921245225e-05
, O 0 4.511758220360207e-07
( O 0 1.0973823236781755e-06
ii O 0 3.6401140732778003e-06
) O 0 3.977222036155581e-07
transcripts O 0 1.1138483841932612e-06
with O 0 5.48327591332054e-07
premature O 0 0.00027659081388264894
termination O 0 0.0001652928622206673
codons O 0 2.387323183938861e-05
can O 0 3.2206071409746073e-07
occur O 0 4.86083308715024e-07
at O 0 2.192644927845322e-07
low O 0 4.028149760415545e-06
or O 0 1.236720208908082e-06
undetectable O 0 1.9450095351203345e-05
levels O 0 5.819014745611639e-07
due O 0 2.9445334348565666e-07
to O 0 1.3212041949373088e-07
nonsense O 0 2.2997298856353154e-06
- O 0 4.117347543797223e-06
mediated O 0 1.5894456737441942e-05
mRNA O 0 2.300964979440323e-06
decay O 0 1.057021336237085e-06
, O 0 9.885495444450498e-08
and O 0 1.175038377709825e-07
( O 0 7.852241310501995e-07
iii O 0 1.001739929051837e-05
) O 0 1.7247798211883492e-07
the O 0 6.605539226711699e-08
levels O 0 1.1214903850031988e-07
of O 0 2.9824029468272784e-08
these O 0 4.387198515587443e-08
transcripts O 0 5.281282824398659e-07
can O 0 9.511141030316139e-08
be O 0 1.1704751301522265e-07
increased O 0 1.66183792771335e-06
by O 0 1.7251728650080622e-06
cycloheximide O 0 0.0009540760656818748
. O 0 2.6792111384565942e-05

A O 0 0.0004902611253783107
deletion O 0 0.02480148710310459
mutation O 0 0.0002597073616925627
in O 0 4.602171429723967e-06
COL17A1 O 0 0.0005666410434059799
in O 0 1.4225412314772257e-06
five O 0 1.8727783981375978e-06
Austrian O 0 0.00014535855734720826
families O 0 7.491464202757925e-06
with O 0 8.323211659444496e-06
generalized O 0 0.15298858284950256
atrophic B-Disease 1 0.999990701675415
benign I-Disease 1 0.9998993873596191
epidermolysis I-Disease 1 0.9999738931655884
bullosa I-Disease 1 0.9964970946311951
represents O 0 3.0351633540703915e-05
propagation O 0 2.043379754468333e-05
of O 0 1.280676315218443e-06
an O 0 3.006172391906148e-06
ancestral O 0 0.00018894748063758016
allele O 0 0.000323920336086303
. O 0 3.905296034645289e-05

Patients O 1 0.875766932964325
with O 0 0.00036785140400752425
generalized O 1 0.7213134169578552
atrophic B-Disease 1 0.9999904632568359
benign I-Disease 1 0.9999887943267822
epidermolysis I-Disease 1 0.9999945163726807
bullosa I-Disease 1 0.9999585151672363
, O 0 3.600127456593327e-05
a O 0 1.0182827281823847e-05
usually O 0 3.842303613055265e-06
nonlethal O 0 4.962132516084239e-05
form O 0 7.39646611691569e-06
of O 0 6.936793397471774e-06
junctional B-Disease 1 0.9993972778320312
epidermolysis I-Disease 1 0.9999867677688599
bullosa I-Disease 1 0.9994168281555176
, O 0 7.103609277692158e-06
have O 0 2.159628365916433e-06
generalized O 0 9.432220394955948e-05
blistering B-Disease 0 0.29771703481674194
, O 0 3.4980697819264606e-05
nail B-Disease 1 0.9990147352218628
dystrophy I-Disease 1 0.9999673366546631
, O 0 7.793313852744177e-05
patchy B-Disease 1 0.9955623149871826
alopecia I-Disease 1 0.9999997615814209
, O 0 6.767363811377436e-05
and O 0 0.00015939540753606707
dental B-Disease 1 0.9998190999031067
abnormalities I-Disease 1 0.9999947547912598
. O 0 7.596189243486151e-05

Skin B-Disease 1 0.9996187686920166
fragility I-Disease 1 0.9882673621177673
in O 0 5.530671842279844e-05
most O 0 4.199279828753788e-06
cases O 0 3.356723709657672e-06
is O 0 5.113906240694632e-07
due O 0 1.34854974476184e-06
to O 0 9.217580441145401e-07
mutations O 0 4.849456672673114e-06
in O 0 1.9594367017816694e-07
the O 0 5.10445318013808e-07
gene O 0 4.65029143015272e-06
encoding O 0 1.4485230167338159e-05
type O 0 6.794535147491843e-05
XVII O 1 0.536281406879425
collagen O 0 0.0004331904638092965
( O 0 1.1124907359771896e-05
COL17A1 O 0 0.0004791396495420486
) O 0 8.423176950600464e-06
. O 0 1.2071793207724113e-05

Recently O 0 0.00042842014227062464
, O 0 1.2894047358713578e-05
we O 0 2.057393658105866e-06
reported O 0 5.28616328665521e-06
five O 0 1.2108029068258475e-06
Austrian O 0 0.0001054923195624724
families O 0 8.638398867333308e-06
with O 0 5.487122962222202e-06
generalized O 0 0.048804137855768204
atrophic B-Disease 1 0.9999843835830688
benign I-Disease 1 0.9997349381446838
epidermolysis I-Disease 1 0.9999899864196777
bullosa I-Disease 1 0.9998144507408142
who O 0 2.964530540339183e-05
share O 0 6.076856607251102e-06
the O 0 1.4464651485468494e-06
same O 0 9.99011353997048e-06
COL17A1 O 0 0.018831679597496986
mutation O 0 0.00027273697196505964
. O 0 2.137210321961902e-05

Affected O 0 0.0010105592664331198
individuals O 0 1.984596747206524e-05
in O 0 2.301311724295374e-06
three O 0 2.166181502616382e-06
families O 0 6.0027446124877315e-06
are O 0 3.366131124948879e-07
homozygous O 0 2.3507785954279825e-05
for O 0 2.5960844141081907e-07
4003delTC O 0 6.719199882354587e-05
, O 0 2.7430891691437864e-07
whereas O 0 4.684547150191065e-07
those O 0 6.599229607218149e-08
in O 0 1.0872449252019578e-07
two O 0 2.9004976909163815e-07
others O 0 1.5254798881869647e-06
are O 0 8.688994626027124e-07
compound O 0 0.00010063585068564862
heterozygotes O 0 0.0009365924634039402
. O 0 2.2061281924834475e-05

To O 0 2.7249983759247698e-05
determine O 0 1.0390755960543174e-05
if O 0 5.839751224812062e-07
the O 0 4.684011116751208e-07
occurrence O 0 2.314230869160383e-06
of O 0 2.3448210129117797e-07
4003delTC O 0 5.979496199870482e-05
in O 0 3.1777869935467606e-07
these O 0 1.201571393494305e-07
unrelated O 0 1.1897293916263152e-05
families O 0 2.801035407173913e-06
signifies O 0 2.5248916699638357e-06
propagation O 0 1.0607101330606383e-06
of O 0 7.109440502972575e-08
an O 0 2.043984324018311e-07
ancestral O 0 8.775102287472691e-06
allele O 0 6.9631396399927326e-06
or O 0 3.5390513630773057e-07
a O 0 1.4785149460294633e-06
mutational O 0 0.00016175296332221478
hot O 0 9.274185686081182e-06
spot O 0 3.816738626483129e-06
, O 0 7.579724297102075e-07
haplotypes O 0 2.0968413082300685e-05
were O 0 4.525504664343316e-07
determined O 0 9.071542308447533e-07
for O 0 4.658085401842982e-07
polymorphisms O 0 3.068141813855618e-05
both O 0 4.189109574781469e-07
within O 0 9.103869160753675e-07
and O 0 2.0036027308378834e-06
flanking O 0 0.0007510701543651521
COL17A1 O 0 0.03299049660563469
. O 0 4.084737884113565e-05

Five O 0 0.0002543808950576931
intragenic O 0 0.007357761729508638
polymorphisms O 0 0.0009433617233298719
were O 0 3.267833790232544e-06
chosen O 0 1.8075309071718948e-06
based O 0 1.1160088888573227e-06
on O 0 1.662142153691093e-06
their O 0 5.174407306185458e-06
informativeness O 0 0.0017170535866171122
. O 0 3.260802986915223e-05

One O 0 1.5240419998008292e-05
of O 0 1.3728687235925463e-06
these O 0 2.285543700963899e-07
, O 0 2.792575060084346e-07
not O 0 1.1016673084895956e-07
previously O 0 1.8515354440751253e-06
reported O 0 2.664465228008339e-06
, O 0 1.6562117366447637e-07
was O 0 5.401230964707793e-07
2988 O 0 1.827316009439528e-05
A O 0 2.30261775868712e-06
or O 0 7.827769650248229e-07
C O 0 3.0107630664133467e-06
that O 0 6.730633117513207e-08
introduces O 0 8.095883003989002e-07
a O 0 4.451164556940057e-07
new O 0 3.7339853520279576e-07
restriction O 0 1.1227161849092226e-06
site O 0 8.583155022279243e-07
for O 0 8.06876698788983e-07
Eco0109 O 0 0.00016567518468946218
I O 0 1.2017208973702509e-05
. O 0 1.2421868632372934e-05

All O 0 1.837605486798566e-05
the O 0 1.0863036550290417e-05
4003delTC O 0 0.00029145783628337085
alleles O 0 4.619972241926007e-05
showed O 0 4.8060956032713875e-06
the O 0 3.904084167061228e-07
same O 0 8.603668106843543e-07
haplotype O 0 2.6072517357533798e-05
for O 0 3.1275234846361855e-07
these O 0 4.079915640886611e-07
five O 0 3.978997028752929e-06
polymorphic O 0 0.0004706835316028446
markers O 0 0.00016387655341532081
. O 0 1.9873805285897106e-05

Fourteen O 0 0.0005735679878853261
microsatellite O 0 0.009501342661678791
polymorphisms O 0 0.0011531217023730278
were O 0 1.7359495814162074e-06
selected O 0 6.63790899579908e-07
based O 0 5.146205808159721e-07
on O 0 2.9100289111738675e-07
their O 0 2.395925946530042e-07
high O 0 7.230428309412673e-06
heterozygosity O 0 0.00016896404849831015
and O 0 2.2502703700411075e-07
their O 0 1.983721631404478e-07
location O 0 1.4404605508389068e-06
within O 0 1.2314195600993116e-06
10q23 O 0 5.4867869039298967e-05
- O 0 7.243094296427444e-05
q25 O 0 0.00019686433370225132
near O 0 4.337877544458024e-05
COL17A1 O 0 0.0010966062545776367
. O 0 2.735796442721039e-05

Three O 0 0.00010604653652990237
families O 0 5.5867280025267974e-05
shared O 0 4.0106464439304546e-05
microsatellite O 0 0.023783547803759575
polymorphisms O 0 0.0010049446718767285
covering O 0 1.3194669008953497e-05
at O 0 1.3085870023132884e-06
most O 0 5.951397952230764e-07
19 O 0 9.45893316384172e-06
cM O 0 7.495564932469279e-05
, O 0 2.931803635419783e-07
whereas O 0 4.518923617524706e-07
the O 0 1.6449584450128896e-07
others O 0 4.172996739271184e-07
shared O 0 3.498277294511354e-07
smaller O 0 5.934491582593182e-07
regions O 0 5.266767288958363e-07
consistent O 0 3.8195025808818173e-07
with O 0 9.315409243981776e-08
cross O 0 1.258243514712376e-06
- O 0 5.839957339048851e-06
over O 0 3.181073964242387e-07
events O 0 2.810861872148962e-07
during O 0 4.09352537644736e-07
passage O 0 6.954319360374939e-07
of O 0 1.1073004202444281e-07
this O 0 2.5399785386071017e-07
mutation O 0 2.1858857053302927e-06
through O 0 5.429346856544726e-07
several O 0 1.6191452232305892e-06
generations O 0 1.319448074355023e-05
. O 0 1.3607758774014656e-05

These O 0 2.8000020392937586e-05
results O 0 2.369671710766852e-05
indicate O 0 4.4515691115520895e-06
that O 0 6.514787287414947e-07
4003delTC O 0 9.4612616521772e-05
occurs O 0 1.2413901231411728e-06
on O 0 2.9680126090170234e-07
a O 0 9.874129318632185e-07
single O 0 3.1725498956802767e-06
ancestral O 0 2.3528193196398206e-05
allele O 0 4.063195228809491e-05
. O 0 2.8849019599874737e-06
. O 0 1.1897066542587709e-05

The O 0 0.0001426263333996758
haptoglobin O 0 0.0018266105325892568
- O 0 0.00042720159399323165
gene O 0 0.00015890994109213352
deletion O 0 0.0003052778774872422
responsible O 0 3.391108475625515e-05
for O 0 9.139655958279036e-06
anhaptoglobinemia B-Disease 0 0.009783589281141758
. O 0 5.066708035883494e-05

We O 0 2.849871998478193e-05
have O 0 3.0292530937003903e-06
found O 0 1.7890623666971806e-06
an O 0 6.821579745519557e-07
allelic O 0 6.783957360312343e-05
deletion O 0 3.9771261072019115e-05
of O 0 4.3339363742234127e-07
the O 0 1.500818825661554e-06
haptoglobin O 0 0.0006055915728211403
( O 0 2.948727797047468e-06
Hp O 0 1.0825227036548313e-05
) O 0 3.752355439701205e-07
gene O 0 5.372631903810543e-07
from O 0 1.0718515142116303e-07
an O 0 2.2395144583242654e-07
individual O 0 7.845332561373652e-07
with O 0 2.458181597830844e-06
anhaptoglobinemia B-Disease 0 0.010433412156999111
. O 0 3.318038579891436e-05

The O 0 8.664758206577972e-05
Hp O 0 0.0003189754206687212
gene O 0 3.6880515835946426e-05
cluster O 0 1.1038247976102866e-05
consists O 0 1.4042838074601605e-06
of O 0 3.8257070400504745e-07
coding O 0 2.6997015083907172e-05
regions O 0 8.702944001015567e-07
of O 0 9.921726018546906e-08
the O 0 2.1779128189791663e-07
alpha O 0 1.88031788184162e-06
chain O 0 1.453883555768698e-06
and O 0 1.6093022736640705e-07
beta O 0 1.0680969353416003e-06
chain O 0 1.0122585081262514e-06
of O 0 1.1311727377005809e-07
the O 0 3.5064238090853905e-07
haptoglobin O 0 5.295081791700795e-05
gene O 0 3.201677145625581e-06
( O 0 7.957661409818684e-07
Hp O 0 3.8210796446946915e-06
) O 0 1.379527674316705e-07
and O 0 4.483166904378777e-08
of O 0 4.016684584939867e-08
the O 0 1.3910796781146928e-07
alpha O 0 1.7684991462374455e-06
chain O 0 1.7251202280021971e-06
and O 0 1.4483090637895657e-07
beta O 0 1.0072567420138512e-06
chain O 0 7.137877560126071e-07
of O 0 7.584042549524384e-08
the O 0 3.7074369174661115e-07
haptoglobin O 0 5.437874642666429e-05
- O 0 3.3451709896326065e-05
related O 0 5.334084107744275e-06
gene O 0 6.0229112932574935e-06
( O 0 3.348861127960845e-06
Hpr O 0 8.605011680629104e-05
) O 0 3.652437499113148e-07
, O 0 9.382366528143393e-08
in O 0 1.1333830229887099e-07
tandem O 0 4.969961992173921e-06
from O 0 3.328380842049228e-07
the O 0 6.561839427376981e-07
5 O 0 4.702550995716592e-06
side O 0 1.45598396557034e-05
. O 0 1.8558843294158578e-05

Southern O 0 0.00027866734308190644
blot O 0 0.0005045549478381872
and O 0 1.4305695003713481e-05
PCR O 0 0.00020596575632225722
analyses O 0 8.755107955948915e-06
have O 0 6.217728127921873e-07
indicated O 0 1.4094761127125821e-06
that O 0 4.982890544624752e-08
the O 0 8.797508854740954e-08
individual O 0 1.5774367057019845e-07
with O 0 2.843729589585564e-07
anhaptoglobinemia B-Disease 0 0.0005536851240321994
was O 0 2.8210392883920576e-06
homozygous O 0 9.018457603815477e-06
for O 0 1.0531066862995431e-07
the O 0 2.3086617773060425e-07
gene O 0 2.181198169637355e-06
deletion O 0 1.1963763427047525e-05
and O 0 1.2096656121229898e-07
that O 0 3.83386584701384e-08
the O 0 1.1673448341298354e-07
gene O 0 1.530090003143414e-06
deletion O 0 1.8490987713448703e-05
was O 0 5.729498298023827e-07
included O 0 1.658173118812556e-07
at O 0 1.6300604954722075e-07
least O 0 8.704705578566063e-08
from O 0 6.073677383255927e-08
the O 0 1.2790562209374912e-07
promoter O 0 2.7088308343081735e-06
region O 0 1.0543423059061752e-06
of O 0 2.227624236184056e-07
Hp O 0 1.106845957110636e-05
to O 0 3.8073702057772607e-07
Hpr O 0 5.313371730153449e-05
alpha O 0 1.9155561403749743e-06
but O 0 1.2518218284185423e-07
not O 0 1.3619015248877986e-07
to O 0 5.754303629146307e-07
Hpr O 0 0.00024768448201939464
beta O 0 1.7746537196217105e-05
( O 0 5.029736257711193e-06
Hpdel O 0 8.577991684433073e-05
) O 0 8.606018127466086e-06
. O 0 9.977659829019103e-06

In O 0 4.0890718082664534e-05
addition O 0 1.1271715266047977e-05
, O 0 1.2618304481293308e-06
we O 0 1.9412017593367636e-07
found O 0 1.9624549452146312e-07
seven O 0 4.790326784132048e-07
individuals O 0 1.5075249848450767e-07
with O 0 2.0142229573139048e-07
hypohaptoglobinemia B-Disease 0 0.0001636157976463437
in O 0 3.414252773836779e-07
three O 0 3.84132533781667e-07
families O 0 9.68587983152247e-07
, O 0 7.403598090149899e-08
and O 0 6.21896774077868e-08
the O 0 1.4430686690047878e-07
genotypes O 0 7.3753071774262935e-06
of O 0 5.324268315121117e-08
six O 0 2.1047060272394447e-07
of O 0 4.403823083976022e-08
the O 0 1.5221709759316582e-07
seven O 0 8.384758416468685e-07
individuals O 0 1.5769522576647432e-07
were O 0 9.00276901916186e-08
found O 0 1.5288544830127648e-07
to O 0 1.9502309100971615e-07
be O 0 8.643381761430646e-07
Hp2 O 0 0.000907165405806154
/ O 0 0.000345634383847937
Hpdel O 0 0.0007851177360862494
. O 0 2.839598346326966e-05

The O 0 7.025333616184071e-05
phenotypes O 0 0.002167645376175642
and O 0 6.515248514915584e-06
genotypes O 0 0.0002459674724377692
in O 0 5.8246502021575e-07
one O 0 1.0409011963474768e-07
of O 0 8.100519011122742e-08
these O 0 4.7800678970588706e-08
three O 0 3.339534373481001e-07
families O 0 2.9493266993085854e-06
showed O 0 1.1579219290069886e-06
the O 0 1.1917363451630081e-07
father O 0 6.930881113476062e-07
to O 0 1.6534957580915943e-07
be O 0 1.7987284195442044e-07
hypohaptoglobinemic B-Disease 0 7.385560456896201e-05
( O 0 1.110034190787701e-06
Hp2 O 0 1.644875192141626e-05
) O 0 2.576412043708842e-07
and O 0 1.9144809471072222e-07
Hp2 O 0 9.25972854020074e-05
/ O 0 4.278197229723446e-05
Hpdel O 0 4.59003567812033e-05
, O 0 1.20317437790618e-07
the O 0 9.958240809737617e-08
mother O 0 1.1453149681983632e-06
to O 0 1.0503323721877678e-07
be O 0 1.1585168380179311e-07
Hp2 O 0 1.1912347872566897e-05
- O 0 5.776782472821651e-06
1 O 0 7.691822361266532e-07
and O 0 4.616215107944299e-07
Hp1 O 0 0.00019902345957234502
/ O 0 5.953614163445309e-05
Hp2 O 0 3.648250276455656e-05
, O 0 1.159956255492034e-07
one O 0 4.1129808892037545e-08
of O 0 2.9229054732127224e-08
the O 0 7.005655788816512e-08
two O 0 2.031418802062035e-07
children O 0 5.842213113282924e-07
to O 0 9.043108661899169e-08
be O 0 1.6355306797777303e-07
hypohaptoglobinemic B-Disease 0 5.4957934480626136e-05
( O 0 6.784870834053436e-07
Hp2 O 0 1.3086134458717424e-05
) O 0 2.909285115038074e-07
and O 0 2.510477656869625e-07
Hp2 O 0 0.00017430100706405938
/ O 0 5.00977439514827e-05
Hpdel O 0 4.7622477723052725e-05
, O 0 1.251048473704941e-07
and O 0 5.580658068993216e-08
the O 0 7.383559363915992e-08
other O 0 6.088361459433145e-08
child O 0 1.7472705167165259e-06
to O 0 1.3951915889265365e-07
be O 0 1.329500776137138e-07
Hp1 O 0 2.0599558411049657e-05
and O 0 6.822933187322633e-07
Hp1 O 0 0.00025021634064614773
/ O 0 4.508534038905054e-05
Hpdel O 0 6.421511352527887e-05
, O 0 2.9900471076871327e-07
showing O 0 7.159025017244858e-07
an O 0 2.3335019250225741e-07
anomalous O 0 2.0260113160475157e-05
inheritance O 0 1.4017057765158825e-05
of O 0 7.734346354482113e-07
Hp O 0 0.0002718076575547457
phenotypes O 0 7.397571607725695e-05
in O 0 4.625530891644303e-07
the O 0 7.269218826877477e-07
child O 0 1.557587347633671e-05
with O 0 6.308621777861845e-06
Hp1 O 0 0.02378256246447563
. O 0 3.762991036637686e-05

The O 0 7.196037768153474e-05
Hp2 O 0 0.004588781856000423
/ O 0 0.0015526814386248589
Hpdel O 0 0.0019972678273916245
individuals O 0 2.130823077095556e-06
had O 0 7.687972356507089e-07
an O 0 2.7503293154040875e-07
extremely O 0 1.8606319827085827e-06
low O 0 2.180946239604964e-06
level O 0 2.9512526111830084e-07
of O 0 2.320740861705417e-07
Hp O 0 2.533810584282037e-05
( O 0 1.025830783873971e-06
mean O 0 1.2197828027638025e-06
+ O 0 9.357841918244958e-06
/ O 0 8.780225471127778e-06
- O 0 7.760531843814533e-06
SD O 0 0.00010364397166995332
= O 0 2.9560418624896556e-05
0 O 0 2.3797538233338855e-06
. O 0 5.576433181886387e-07
049 O 0 6.703226245008409e-05
+ O 0 9.624183803680353e-06
/ O 0 9.784760550246574e-06
- O 0 6.5414601522206794e-06
0 O 0 2.3210118342831265e-06
. O 0 4.596587075411662e-07
043 O 0 5.344768214854412e-05
mg O 0 8.535952656529844e-05
/ O 0 2.5103076040977612e-05
ml O 0 4.453562723938376e-05
; O 0 2.1894302335567772e-06
n O 0 7.401956281682942e-06
= O 0 1.6687157767591998e-05
6 O 0 9.906236755341524e-07
) O 0 1.1066796901104681e-07
, O 0 6.69456667878876e-08
compared O 0 1.4997571895492e-07
with O 0 3.77185109812217e-08
the O 0 9.209533402554371e-08
level O 0 1.889262648546719e-07
( O 0 1.3793567177344812e-07
1 O 0 1.4542619908297638e-07
. O 0 5.995193674834809e-08
64 O 0 1.6443513004560373e-06
+ O 0 4.526058546616696e-06
/ O 0 5.258609235170297e-06
- O 0 2.4947692054411164e-06
1 O 0 6.080302341615607e-07
. O 0 3.3465101978435996e-07
07 O 0 1.0670608389773406e-05
mg O 0 5.379360300139524e-05
/ O 0 1.9437302398728207e-05
ml O 0 2.899164246628061e-05
) O 0 3.756680655442324e-07
obtained O 0 3.271704827056965e-07
from O 0 2.459747747707297e-07
52 O 0 5.153423444426153e-06
healthy O 0 4.0096342672768515e-06
volunteers O 0 6.116871645645006e-06
having O 0 2.048809847110533e-06
phenotype O 0 0.00042127963388338685
Hp2 O 0 0.00012118139420635998
, O 0 4.086816431936313e-07
whereas O 0 4.899359282717342e-07
the O 0 2.137909547172967e-07
serum O 0 1.3546539776143618e-05
Hp O 0 4.257942237018142e-06
level O 0 1.3130721754350816e-07
of O 0 4.480012805174738e-08
an O 0 1.4946995463560597e-07
individual O 0 3.2341094424737094e-07
with O 0 9.10438984647044e-07
Hp1 O 0 0.003057272871956229
/ O 0 0.0003394433297216892
Hpdel O 0 0.0004579137603286654
was O 0 1.085365511244163e-05
0 O 0 3.5579865652834997e-05
. O 0 1.7779975678422488e-05

50 O 0 0.0006188693805597723
mg O 0 0.00321777630597353
/ O 0 0.0005124722956679761
ml O 0 0.0004020599590148777
, O 0 1.0280588185196393e-06
which O 0 2.3820146566322364e-07
was O 0 2.2621952666668221e-07
approximately O 0 1.9432020792464755e-07
half O 0 1.5696693367317494e-07
the O 0 6.328177448722272e-08
level O 0 1.081561080695792e-07
of O 0 6.978556399417357e-08
Hp O 0 5.633979526464827e-06
in O 0 2.6081769988195447e-07
control O 0 2.8088998078601435e-06
sera O 0 7.160593668231741e-06
from O 0 1.803008444767329e-07
the O 0 5.353279561859381e-07
Hp1 O 0 0.007017255760729313
phenotype O 0 0.000690070737618953
( O 0 3.5440197621028346e-07
1 O 0 3.121915312931378e-07
. O 0 1.3534827303374186e-07
26 O 0 1.5717934047643212e-06
+ O 0 4.9645423132460564e-06
/ O 0 4.905899459117791e-06
- O 0 2.216599114035489e-06
0 O 0 1.379483364871703e-06
. O 0 1.65380484418165e-07
33 O 0 2.108984972437611e-06
mg O 0 2.3019983927952126e-05
/ O 0 1.4741483028046787e-05
ml O 0 2.7649442927213386e-05
; O 0 1.1403080861782655e-06
n O 0 1.1554219781828579e-05
= O 0 1.1183230526512489e-05
9 O 0 1.486426640440186e-06
) O 0 1.916227034826079e-07
, O 0 1.3314064517544466e-07
showing O 0 9.527461770630907e-07
a O 0 1.7212796592502855e-06
gene O 0 7.48365937397466e-06
- O 0 8.835944026941434e-05
dosage O 0 0.00028312765061855316
effect O 0 2.467050035193097e-05
. O 0 1.7445699995732866e-05

The O 0 3.220817961846478e-05
other O 0 6.380666036420735e-06
allele O 0 7.96452077338472e-05
( O 0 4.654688837035792e-06
Hp2 O 0 6.943636981304735e-05
) O 0 4.2412028733451734e-07
of O 0 1.336729695822214e-07
individuals O 0 2.6643127171155356e-07
with O 0 3.867519353661919e-07
Hp2 O 0 0.011999071575701237
/ O 0 0.0005047814920544624
Hpdel O 0 0.0003426902985665947
was O 0 8.498901138409565e-07
found O 0 1.449858331170617e-07
to O 0 6.818861919555275e-08
have O 0 7.279604830046082e-08
, O 0 5.609225439684451e-08
in O 0 5.8315592355029366e-08
all O 0 6.395314500196037e-08
exons O 0 1.0314643986930605e-05
, O 0 3.98329916606599e-07
no O 0 4.1413323970118654e-07
mutation O 0 3.0903313472663285e-06
, O 0 2.179485676379045e-07
by O 0 8.045684012358834e-07
DNA O 0 1.930783037096262e-05
sequencing O 0 6.702676910208538e-05
. O 0 1.830497058108449e-05

On O 0 2.1310617739800364e-05
the O 0 2.207416628152714e-06
basis O 0 7.073177243910322e-07
of O 0 1.563504952173389e-07
the O 0 3.255833860293933e-07
present O 0 4.965036168869119e-07
study O 0 4.816888008463138e-07
, O 0 1.193369456586879e-07
the O 0 9.29017858197767e-08
mechanism O 0 6.173985411805916e-07
of O 0 1.5179017509581172e-07
anhaptoglobinemia B-Disease 0 5.015610804548487e-05
and O 0 1.54366645688242e-07
the O 0 1.2347504707577173e-07
mechanism O 0 5.717598696719506e-07
of O 0 1.302595364904846e-07
anomalous O 0 1.874309418781195e-05
inheritance O 0 1.013331439025933e-05
of O 0 9.276691343984567e-07
Hp O 0 0.0004295563558116555
phenotypes O 0 0.00015984225319698453
were O 0 1.144261432273197e-06
well O 0 2.272050778628909e-06
explained O 0 2.1274048776831478e-05
. O 0 1.4884883057675324e-05

However O 0 3.782138446695171e-05
, O 0 4.313091267249547e-06
the O 0 1.6772597746239626e-06
mechanism O 0 9.763293746800628e-06
of O 0 4.434391939867055e-06
hypohaptoglobinemia B-Disease 0 0.007806243374943733
remains O 0 0.00012096320278942585
unknown O 0 0.0002721426426433027

ATM O 0 0.03189906105399132
mutations O 0 0.0038875623140484095
and O 0 4.9840087740449235e-05
phenotypes O 0 0.08883265405893326
in O 0 0.00018198133329860866
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999940395355225
telangiectasia I-Disease 1 0.9999998807907104
families O 0 8.352446457138285e-05
in O 0 6.486467896138493e-07
the O 0 4.315953106015513e-07
British O 0 3.1788856631465023e-06
Isles O 0 8.833600077196024e-06
: O 0 3.206188523563469e-07
expression O 0 3.721379187027196e-07
of O 0 1.063875529894176e-07
mutant O 0 5.219020295044174e-06
ATM O 0 5.58029114472447e-06
and O 0 2.3681975847011927e-07
the O 0 5.752926881541498e-07
risk O 0 1.2579107533383649e-05
of O 0 9.48893739405321e-06
leukemia B-Disease 1 0.9999990463256836
, O 0 0.019770776852965355
lymphoma B-Disease 1 1.0
, O 0 7.884773367550224e-05
and O 0 0.000485242810100317
breast B-Disease 1 0.9999969005584717
cancer I-Disease 1 0.9984851479530334
. O 0 7.272051152540371e-05

We O 0 3.959091191063635e-05
report O 0 8.73524186317809e-06
the O 0 1.269711674467544e-06
spectrum O 0 6.030595613992773e-06
of O 0 5.30359216099896e-07
59 O 0 2.0432629753486253e-05
ATM O 0 0.00020501844119280577
mutations O 0 3.274439586675726e-05
observed O 0 6.891874818393262e-06
in O 0 1.2465657164284494e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999617338180542
telangiectasia I-Disease 1 0.9999998807907104
( O 0 0.0002804723917506635
A B-Disease 1 0.9986489415168762
- I-Disease 1 0.9999963045120239
T I-Disease 1 0.9999998807907104
) O 0 1.034232263918966e-05
patients O 0 1.4558840121026151e-05
in O 0 4.191603011349798e-07
the O 0 1.054369363373553e-06
British O 0 1.5966314094839618e-05
Isles O 0 0.00010343368194298819
. O 0 2.552456317062024e-05

Of O 0 4.7376164729939774e-05
51 O 0 0.00032212556106969714
ATM O 0 0.0010132837342098355
mutations O 0 0.00025485208607278764
identified O 0 6.102875886426773e-06
in O 0 5.9529878626563e-07
families O 0 1.494397452006524e-06
native O 0 6.936753038644383e-07
to O 0 1.190561746966523e-07
the O 0 1.6096367971840664e-07
British O 0 1.3797186966257868e-06
Isles O 0 3.055114348171628e-06
, O 0 2.20870020939401e-07
11 O 0 7.694030728089274e-07
were O 0 1.945054322050055e-07
founder O 0 1.4733318494108971e-05
mutations O 0 3.5019365896005183e-06
, O 0 8.074665203139375e-08
and O 0 6.251935502632477e-08
2 O 0 2.823774423177383e-07
of O 0 4.623290550398451e-08
these O 0 6.962734744320187e-08
11 O 0 1.0492676665307954e-06
conferred O 0 2.501038807167788e-06
a O 0 4.259140041540377e-06
milder O 0 0.2392800748348236
clinical O 0 0.019311463460326195
phenotype O 0 0.0010670110350474715
with O 0 4.957815917805419e-07
respect O 0 3.6795395885746984e-07
to O 0 6.769371907466848e-07
both O 0 3.542344074958237e-06
cerebellar B-Disease 1 0.9934031367301941
degeneration I-Disease 1 0.9837580323219299
and O 0 1.2286978744668886e-05
cellular O 0 0.00024363021657336503
features O 0 5.693619095836766e-05
. O 0 4.574465856421739e-05

We O 0 3.4430340747348964e-05
report O 0 7.120389454939868e-06
, O 0 5.604155717264803e-07
in O 0 3.1968332336873573e-07
two O 0 1.120799083764723e-06
A B-Disease 1 0.9099250435829163
- I-Disease 1 0.9999216794967651
T I-Disease 1 0.9999991655349731
families O 0 2.7171827241545543e-06
, O 0 1.686770616515787e-07
an O 0 2.680071986560506e-07
ATM O 0 4.697719487012364e-05
mutation O 0 6.635341378569137e-06
( O 0 6.572673783011851e-07
7271T O 0 1.4660030501545407e-05
- O 0 4.984113547834568e-05
- O 0 0.0002993722155224532
> O 0 0.00018547334184404463
G O 0 0.0002365951077081263
) O 0 3.391018310594518e-07
that O 0 7.544510793877635e-08
may O 0 3.2521720072509197e-07
be O 0 6.4592207138503e-08
associated O 0 1.5544951281754038e-07
with O 0 7.36181888782994e-08
an O 0 4.042093451062101e-07
increased O 0 3.0438417525147088e-05
risk O 0 3.340701732668094e-05
of O 0 1.1917211850231979e-05
breast B-Disease 1 0.9999898672103882
cancer I-Disease 1 0.7717971801757812
in O 0 8.82298252236069e-07
both O 0 6.628849860135233e-07
homozygotes O 0 0.0003589170519262552
and O 0 2.977914846269414e-06
heterozygotes O 0 0.00027460645651444793
( O 0 1.9209712718293304e-06
relative O 0 4.066617293574382e-06
risk O 0 3.3820119824667927e-06
12 O 0 9.010583426061203e-07
. O 0 1.2762195922277897e-07
7 O 0 1.5277001921276678e-06
; O 0 1.766147875059687e-06
P O 0 0.0002793080930132419
= O 0 2.8658345399890095e-05
. O 0 2.846323354788183e-07
0025 O 0 3.385724994586781e-05
) O 0 2.3280648520085379e-07
, O 0 5.6750419474838054e-08
although O 0 7.279215452626886e-08
there O 0 2.2998227322545972e-08
is O 0 9.563093072983975e-08
a O 0 1.2322689144639298e-06
less O 0 8.740008524910081e-06
severe O 1 0.689604640007019
A B-Disease 1 0.9998782873153687
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
phenotype O 0 0.13633771240711212
in O 0 3.0995647648524027e-07
terms O 0 4.001773561412847e-07
of O 0 1.2716685660052462e-07
the O 0 5.053874474469922e-07
degree O 0 1.865189005911816e-05
of O 0 1.573981535329949e-05
cerebellar B-Disease 1 0.9997952580451965
degeneration I-Disease 1 0.9998064637184143
. O 0 0.0001383796479785815

This O 0 8.186575723811984e-05
mutation O 0 0.00033235890441574156
( O 0 1.6952039004536346e-05
7271T O 0 0.00017777443281374872
- O 0 0.000377504009520635
- O 0 0.0027909069322049618
> O 0 0.0005124767194502056
G O 0 0.0003890161751769483
) O 0 4.109789983886003e-07
also O 0 1.4672173165308777e-07
allows O 0 1.7911419547544938e-07
expression O 0 1.3186210878757265e-07
of O 0 5.82891246381223e-08
full O 0 7.243489221764321e-07
- O 0 1.1765944691433106e-05
length O 0 2.09913264370698e-06
ATM O 0 2.6832788080355385e-06
protein O 0 3.3499586038487905e-07
at O 0 8.584721200577405e-08
a O 0 2.0525008892491314e-07
level O 0 2.578998419267009e-07
comparable O 0 7.850586030144768e-07
with O 0 1.8256538680816448e-07
that O 0 1.9976373266672454e-07
in O 0 1.1561133987925132e-06
unaffected O 0 0.0001386835938319564
individuals O 0 5.626633992505958e-06
. O 0 9.834361662797164e-06

In O 0 3.161322820233181e-05
addition O 0 7.363527856796281e-06
, O 0 1.0386725080024917e-06
we O 0 1.677893664009389e-07
have O 0 1.9615119128957303e-07
studied O 0 1.4967537254051422e-06
18 O 0 2.008836599998176e-05
A B-Disease 1 0.9662958979606628
- I-Disease 1 0.9999970197677612
T I-Disease 1 1.0
patients O 0 0.00014293879212345928
, O 0 2.599602453301486e-07
in O 0 2.473433369232225e-07
15 O 0 1.1051004094042582e-06
families O 0 1.088942099158885e-06
, O 0 4.308098766614421e-07
who O 0 1.0812577784236055e-05
developed O 0 0.00881526991724968
leukemia B-Disease 1 0.9999984502792358
, O 0 0.001812777016311884
lymphoma B-Disease 1 1.0
, O 0 1.910572791530285e-05
preleukemic O 1 0.6571760177612305
T O 0 0.20013466477394104
- O 0 0.00012924883048981428
cell O 0 0.00021327762806322426
proliferation O 0 3.14684039040003e-05
, O 0 6.405968633771408e-06
or O 0 0.0012047005584463477
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 7.494865258195205e-06
mostly O 0 2.8153147013654234e-06
in O 0 5.031924047216307e-06
childhood O 0 0.00022948656987864524
. O 0 4.288114359951578e-05

A O 0 0.00010239794210065156
wide O 0 3.030495463463012e-05
variety O 0 4.126247404201422e-06
of O 0 1.2899282637590659e-06
ATM O 0 0.0003641978546511382
mutation O 0 4.8825921112438664e-05
types O 0 8.776221989137412e-07
, O 0 3.864341238113411e-07
including O 0 1.4664930176877533e-06
missense O 0 0.003710700897499919
mutations O 0 9.373998182127252e-06
and O 0 1.425706841473584e-07
in O 0 2.6380635631539917e-07
- O 0 4.21885124524124e-05
frame O 0 9.686854900792241e-05
deletions O 0 3.491207826300524e-05
, O 0 4.6306683998409426e-07
were O 0 2.627978972213896e-07
seen O 0 7.244062771860627e-07
in O 0 9.457663736611721e-07
these O 0 2.162587861676002e-06
patients O 0 0.00022391685342881829
. O 0 2.3200438590720296e-05

We O 0 2.1262407244648784e-05
also O 0 3.323871396787581e-06
show O 0 1.5304664202631102e-06
that O 0 2.123753972682607e-07
25 O 0 1.3760145520791411e-06
% O 0 4.4446662172958895e-07
of O 0 8.190050948542194e-08
all O 0 1.694665030527176e-07
A B-Disease 1 0.9036474227905273
- I-Disease 1 0.9999971389770508
T I-Disease 1 1.0
patients O 0 0.00017829118587542325
carried O 0 1.5942952131808852e-06
in O 0 4.376567517283547e-07
- O 0 9.493824109085836e-06
frame O 0 3.297364673926495e-05
deletions O 0 4.547677235677838e-05
or O 0 6.72803480483708e-06
missense O 0 0.004026246722787619
mutations O 0 2.2380858354154043e-05
, O 0 1.2639546298487403e-07
many O 0 3.728483832787788e-08
of O 0 6.633315052795297e-08
which O 0 1.869841241841641e-07
were O 0 1.4794443359278375e-07
also O 0 2.411044590644451e-07
associated O 0 3.443946070547099e-07
with O 0 1.978420272052972e-07
expression O 0 1.0318788099539233e-06
of O 0 5.850810680385621e-07
mutant O 0 5.3231804486131296e-05
ATM O 0 0.00012501786113716662
protein O 0 3.375086816959083e-05
. O 0 1.362422335660085e-05

The O 0 8.899975364329293e-05
DMPK O 0 0.0025851966347545385
gene O 0 0.0001301022566622123
of O 0 2.123986996593885e-05
severely O 1 0.9987347722053528
affected O 1 0.8783206939697266
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9985242486000061
is O 0 7.75706212152727e-06
hypermethylated O 0 0.0032005945686250925
proximal O 0 0.0005104561569169164
to O 0 1.0710509741329588e-06
the O 0 1.103244017031102e-06
largely O 0 6.096238394093234e-06
expanded O 0 2.0072013285243884e-05
CTG O 0 0.0006821851711720228
repeat O 0 0.00013544998364523053
. O 0 3.111992555204779e-05

Using O 0 8.751243149163201e-05
methylation O 0 0.00016879948088899255
- O 0 0.00019178391085006297
sensitive O 0 1.724335743347183e-05
restriction O 0 1.1585611900954973e-05
enzymes O 0 8.191243068722542e-06
, O 0 2.7535233471098763e-07
we O 0 1.0186774801468346e-07
characterized O 0 8.215896514229826e-07
the O 0 1.6584404249897489e-07
methylation O 0 2.999951902893372e-06
pattern O 0 6.119240424595773e-06
on O 0 3.1017941637401236e-07
the O 0 2.3151879702254519e-07
5 O 0 6.7547591697803e-07
side O 0 2.031946024771969e-07
of O 0 4.9643446686786774e-08
the O 0 3.7399155417006114e-07
CTG O 0 0.00013464875519275665
repeat O 0 2.887156142605818e-06
in O 0 1.4059961017665046e-07
the O 0 2.6190269863946014e-07
DMPK O 0 9.894777031149715e-05
gene O 0 7.984206149558304e-07
of O 0 1.3024487088841852e-07
normal O 0 2.4365017452510074e-06
individuals O 0 2.7780666300714074e-07
and O 0 2.0237617093243898e-07
of O 0 1.5851894659135723e-06
patients O 0 0.0013707346515730023
affected O 0 1.2407176654960494e-05
with O 0 7.49009195715189e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 8.086275556706823e-06
showing O 0 4.058291779074352e-06
expansions O 0 6.86664998283959e-06
of O 0 6.182682454891619e-07
the O 0 2.7882613267138368e-06
repetitive O 0 0.0002778057532850653
sequence O 0 3.273365291533992e-05
. O 0 1.9964250896009617e-05

The O 0 5.723691720049828e-05
gene O 0 6.708187720505521e-05
segment O 0 4.8467973101651296e-05
analyzed O 0 1.6835396309033968e-05
corresponds O 0 1.0777740499179345e-05
to O 0 8.913297051549307e-07
the O 0 1.1838877753689303e-06
genomic O 0 4.1852748836390674e-05
SacI O 0 0.00013565058179665357
- O 0 2.5368381102452986e-05
HindIII O 0 4.754606561618857e-05
fragment O 0 7.118440407793969e-06
carrying O 0 4.194384928268846e-06
exons O 0 3.107037264271639e-05
11 O 0 1.1322145837766584e-05
- O 0 5.516602686839178e-05
15 O 0 2.2058715330786072e-05
. O 0 1.4245872080209665e-05

There O 0 3.5033372114412487e-05
is O 0 5.3497137741942424e-06
constitutive O 0 6.709998706355691e-05
methylation O 0 3.0324090403155424e-05
in O 0 3.3771323160181055e-06
intron O 0 0.00025511026615276933
12 O 0 3.931672836188227e-06
at O 0 4.3010871308979404e-07
restriction O 0 8.022981319300015e-07
sites O 0 2.982903879455989e-07
of O 0 1.9788485872140882e-07
SacII O 0 4.250421989127062e-05
and O 0 7.211747856672446e-07
HhaI O 0 5.627419159281999e-05
, O 0 2.7563689286580484e-07
localized O 0 2.388421080468106e-06
1 O 0 5.326066343513958e-07
, O 0 1.7765763971056003e-07
159 O 0 5.633463388221571e-06
- O 0 1.4474157069344074e-05
1 O 0 1.078645595953276e-06
, O 0 2.49969843935105e-07
232 O 0 2.93118205263454e-06
bp O 0 4.001390607299982e-06
upstream O 0 4.460011382434459e-07
of O 0 8.510266269468048e-08
the O 0 3.0812154250270396e-07
CTG O 0 0.0001241599820787087
repeat O 0 1.041968153003836e-05
, O 0 2.3485719680138573e-07
whereas O 0 4.3745478706114227e-07
most O 0 4.342036419302531e-08
, O 0 7.883584629553297e-08
if O 0 3.4484283872870947e-08
not O 0 1.4857327812478616e-08
all O 0 1.137843508303149e-08
, O 0 1.9283955765558858e-08
of O 0 1.53150381265732e-08
the O 0 5.018601001438583e-08
other O 0 2.821109035267e-08
sites O 0 9.485940211106936e-08
of O 0 9.698861447304807e-08
SacII O 0 6.488768849521875e-05
, O 0 3.582947840641282e-07
HhaI O 0 2.5476994778728113e-05
, O 0 1.4277641469107039e-07
and O 0 1.349595208921528e-07
HpaII O 0 3.23500316881109e-05
in O 0 1.2795820225619536e-07
this O 0 6.817990794161233e-08
region O 0 5.263262892185594e-07
are O 0 5.717686946127287e-08
unmethylated O 0 2.1801355615025386e-05
, O 0 1.6929527646425413e-07
in O 0 1.906573317000948e-07
normal O 0 1.778175942490634e-06
individuals O 0 1.9626197911293275e-07
and O 0 7.688618808288084e-08
most O 0 8.023602759976711e-08
of O 0 2.0682635692992335e-07
the O 0 6.585884420928778e-06
patients O 0 0.0005029336898587644
. O 0 1.7252652469323948e-05

In O 0 2.2220294340513647e-05
a O 0 7.276901669683866e-06
number O 0 8.15440898804809e-07
of O 0 5.299820031723357e-07
young O 0 5.91865955357207e-06
and O 0 1.2267565580259543e-05
severely O 1 0.9470487236976624
affected O 0 0.00019824091577902436
patients O 0 0.00016144016990438104
, O 0 4.325587212861137e-07
however O 0 2.1648193637702207e-07
, O 0 8.419866048825497e-08
complete O 0 4.1058410715777427e-07
methylation O 0 7.725382147327764e-07
of O 0 5.2558892349452435e-08
these O 0 4.553818655494979e-08
restriction O 0 4.046166282023478e-07
sites O 0 2.052156418130835e-07
was O 0 2.0831417657518614e-07
found O 0 2.516813708552945e-07
in O 0 2.714826052852004e-07
the O 0 2.145901817129925e-06
mutated O 0 0.0001215508091263473
allele O 0 0.00016173350741155446
. O 0 2.5400164304301143e-05

In O 0 1.8439039195072837e-05
most O 0 1.954988420038717e-06
of O 0 7.071902246025275e-07
these O 0 8.045039407988952e-07
patients O 0 2.7751038942369632e-05
, O 0 2.6952304210681177e-07
the O 0 5.08444657043583e-07
onset O 0 0.014525235630571842
of O 0 2.256656443933025e-06
the O 0 7.732065569143742e-05
disease O 1 0.8566479086875916
was O 0 0.02336690202355385
congenital O 1 0.9999994039535522
. O 0 0.00013661141565535218

Preliminary O 0 0.00025221004034392536
in O 0 5.252969640423544e-05
vivo O 0 0.001859160140156746
footprinting O 0 0.0025327648036181927
data O 0 3.951361577492207e-06
gave O 0 1.3810615655529546e-06
evidence O 0 4.4074116090087045e-07
for O 0 2.4361827399843605e-07
protein O 0 1.6728603213778115e-06
- O 0 8.684754902787972e-06
DNA O 0 2.5228048343706178e-06
contact O 0 8.282482895083376e-07
in O 0 2.6304664402232447e-07
normal O 0 1.2084403806511546e-06
genes O 0 6.354732704494381e-07
at O 0 1.702635188394197e-07
an O 0 2.3377296543003467e-07
Sp1 O 0 4.380599784781225e-05
consensus O 0 8.765616144046362e-07
binding O 0 5.499567805600236e-07
site O 0 3.427543617817719e-07
upstream O 0 3.9476378788094735e-07
of O 0 6.840721056278198e-08
the O 0 2.4179942670343735e-07
CTG O 0 8.804772369330749e-05
repeat O 0 6.903886969666928e-06
and O 0 1.38587296305559e-07
for O 0 9.478940654616963e-08
a O 0 5.685865289706271e-07
significant O 0 3.249747635436506e-07
reduction O 0 1.6074891391326673e-06
of O 0 3.397563119733604e-08
this O 0 3.864355235805306e-08
interaction O 0 2.3844600605116284e-07
in O 0 1.7915689909386856e-07
cells O 0 8.393607231482747e-07
with O 0 1.9742775236863963e-07
a O 0 4.9472869250166696e-06
hypermethylated O 0 0.0021365422289818525
DMPK O 0 0.002843499183654785
gene O 0 2.2406549760489725e-05
. O 0 3.4918216442747507e-06
. O 0 1.677152067713905e-05

The O 0 0.00039789071888662875
hemochromatosis B-Disease 1 0.9999797344207764
gene O 0 8.914924546843395e-05
product O 0 1.1462130714789964e-05
complexes O 0 6.731237590429373e-06
with O 0 6.694668286399974e-07
the O 0 1.0578371529845754e-06
transferrin O 0 5.7226705393986776e-05
receptor O 0 8.539256668882445e-06
and O 0 8.300472131850256e-07
lowers O 0 5.0374783313600346e-05
its O 0 6.966041610212415e-07
affinity O 0 2.3813020106899785e-06
for O 0 9.12535597308306e-07
ligand O 0 2.642630170157645e-05
binding O 0 2.679640419955831e-05
. O 0 2.10968228202546e-05

We O 0 7.322320016101003e-05
recently O 0 6.250302976695821e-05
reported O 0 1.180521667265566e-05
the O 0 7.658087497475208e-07
positional O 0 1.322807111137081e-05
cloning O 0 5.921838237554766e-06
of O 0 4.1514434201417316e-07
a O 0 3.0270061870396603e-06
candidate O 0 1.4831521184532903e-05
gene O 0 2.5388515496160835e-05
for O 0 3.915876004612073e-05
hereditary B-Disease 1 0.9999997615814209
hemochromatosis I-Disease 1 1.0
called O 0 0.010314290411770344
HFE O 1 0.9706786870956421
. O 0 9.018057608045638e-05

The O 0 2.7220143238082528e-05
gene O 0 2.166797457903158e-05
product O 0 3.5378131997276796e-06
, O 0 5.366297841646883e-07
a O 0 5.29056876530376e-07
member O 0 3.460902462393278e-07
of O 0 9.167909809093544e-08
the O 0 3.889549873292708e-07
major O 0 1.9567976323742187e-06
histocompatibility O 0 0.00023292546393349767
complex O 0 2.88959404315392e-06
class O 0 2.1860087144887075e-06
I O 0 4.556912074349384e-07
- O 0 5.526120276044821e-06
like O 0 3.0762123515160056e-07
family O 0 8.846151331454166e-07
, O 0 2.2264985943820648e-07
was O 0 3.135090480554936e-07
found O 0 1.1666704580193255e-07
to O 0 7.603436813496955e-08
have O 0 1.7251878148272226e-07
a O 0 2.6409811653138604e-06
mutation O 0 1.1313596587569918e-05
, O 0 8.828133104543667e-07
Cys O 0 0.0005221429746598005
- O 0 9.597255120752379e-05
282 O 0 9.104324999498203e-05
- O 0 0.0004517511697486043
- O 0 0.0005721145425923169
> O 0 0.00018244677630718797
Tyr O 0 0.00017952780763152987
( O 0 1.5004209217295283e-06
C282Y O 0 1.3324610335985199e-05
) O 0 3.255082390296593e-07
, O 0 1.3984646329845418e-07
in O 0 3.2890142165342695e-07
85 O 0 3.6031274248671252e-06
% O 0 2.12938880395086e-06
of O 0 1.1046336112485733e-06
patient O 0 0.0002528697659727186
chromosomes O 0 0.0002514088700991124
. O 0 1.8974518752656877e-05

This O 0 4.317975617595948e-05
mutation O 0 0.00011625641491264105
eliminates O 0 3.102980917901732e-05
the O 0 1.134096009991481e-06
ability O 0 1.814283450585208e-06
of O 0 4.477697643778811e-07
HFE O 0 0.00044961151434108615
to O 0 5.133451281835733e-07
associate O 0 1.4322019978862954e-06
with O 0 7.547734526269778e-07
beta2 O 0 0.004071386530995369
- O 0 0.0005476820515468717
microglobulin O 0 0.0015345338033512235
( O 0 2.7645057798508788e-06
beta2m O 0 4.878915206063539e-05
) O 0 7.292263717317837e-07
and O 0 5.070519932814932e-07
prevents O 0 7.177535735536367e-06
cell O 0 3.9933202060637996e-05
- O 0 3.446697519393638e-05
surface O 0 1.2317800610617269e-05
expression O 0 1.713413803372532e-05
. O 0 1.350088496110402e-05

A O 0 0.0003029783256351948
second O 0 0.00018619468028191477
mutation O 0 9.774392674444243e-05
that O 0 3.6220754395799304e-07
has O 0 3.450705605700932e-07
no O 0 1.9739310630484397e-07
effect O 0 5.488831789079995e-07
on O 0 7.183220986917149e-07
beta2m O 0 0.00025898980675265193
association O 0 8.736547556509322e-07
, O 0 2.408324064617773e-07
H63D O 0 0.00013047845277469605
, O 0 2.7276510650153796e-07
was O 0 2.3444275143447157e-07
found O 0 9.53788230617647e-08
in O 0 6.795050211394482e-08
eight O 0 2.2989834747022542e-07
out O 0 1.3357930583879352e-07
of O 0 1.6775304345628683e-07
nine O 0 1.633196006878279e-05
patients O 0 8.33826488815248e-05
heterozygous O 0 9.488810974289663e-06
for O 0 4.512644409260247e-07
the O 0 1.6002542224669014e-06
C282Y O 0 0.00033948535565286875
mutant O 0 0.00023920924286358058
. O 0 2.1288535208441317e-05

In O 0 1.8030401406576857e-05
this O 0 2.065213720925385e-06
report O 0 2.886735046558897e-06
, O 0 6.78468950354727e-07
we O 0 2.3726374820398632e-07
demonstrate O 0 1.2447095514289686e-06
in O 0 6.863270982648828e-07
cultured O 0 3.5855176975019276e-05
293 O 0 0.0001139492669608444
cells O 0 1.69653012562776e-05
overexpressing O 0 7.410958642140031e-05
wild O 0 2.613099468362634e-06
- O 0 1.1739037290681154e-05
type O 0 1.7378745269525098e-06
or O 0 7.974625759743503e-07
mutant O 0 5.5675078328931704e-05
HFE O 0 0.0004914430319331586
proteins O 0 6.189962391545123e-07
that O 0 4.5216307142936785e-08
both O 0 7.637768817403412e-08
the O 0 1.4495707034711813e-07
wild O 0 1.8655410940482398e-06
- O 0 5.507519745151512e-05
type O 0 3.1282891086448217e-06
and O 0 1.0906735496973852e-06
H63D O 0 0.004607002250850201
HFE O 0 0.0016724371816962957
proteins O 0 2.0248148757673334e-06
form O 0 1.0445262432767777e-06
stable O 0 4.041209194838302e-06
complexes O 0 1.7028411321007297e-06
with O 0 3.085226296661858e-07
the O 0 1.6223725651798304e-06
transferrin O 0 0.0003392086655367166
receptor O 0 3.754768113140017e-05
( O 0 1.048901231115451e-05
TfR O 0 0.0010948422132059932
) O 0 1.4330301382869948e-05
. O 0 1.4589571037504356e-05

The O 0 5.441733810584992e-05
C282Y O 0 0.0011279414175078273
mutation O 0 0.00011503303539939225
nearly O 0 7.4909207796736155e-06
completely O 0 4.426026407600148e-06
prevents O 0 2.0776867586391745e-06
the O 0 2.9522490763156384e-07
association O 0 4.772534225594427e-07
of O 0 1.6789611834155949e-07
the O 0 6.479178864537971e-07
mutant O 0 9.391088678967208e-05
HFE O 0 0.0007211454794742167
protein O 0 3.337074758746894e-06
with O 0 1.277836076951644e-06
the O 0 8.87885380507214e-06
TfR O 0 0.01067335158586502
. O 0 4.0969949623104185e-05

Studies O 0 9.336967923445627e-05
on O 0 1.2558839443954639e-05
cell O 0 0.00013301199942361563
- O 0 8.736408926779404e-05
associated O 0 4.069395345140947e-06
transferrin O 0 1.4243171790440101e-05
at O 0 8.220238214562414e-07
37 O 0 3.0729856916877907e-06
degrees O 0 4.968942903360585e-06
C O 0 1.1476119652797934e-05
suggest O 0 4.6807426201667113e-07
that O 0 6.947161068637797e-08
the O 0 3.2119510251504835e-07
overexpressed O 0 3.359041875228286e-05
wild O 0 4.007351890322752e-06
- O 0 0.00011683174670906737
type O 0 9.389539627591148e-06
HFE O 0 0.0005116091342642903
protein O 0 3.0748267363378545e-06
decreases O 0 1.2884185025541228e-06
the O 0 1.1358967100250084e-07
affinity O 0 5.259047952677065e-07
of O 0 1.6886602338672674e-07
the O 0 9.898832331600715e-07
TfR O 0 0.0012329543242231011
for O 0 5.335544301487971e-06
transferrin O 0 0.0005731600103899837
. O 0 2.6860498110181652e-05

The O 0 0.00011361812357790768
overexpressed O 0 0.0013538514031097293
H63D O 0 0.0031898391898721457
protein O 0 1.988531403185334e-05
does O 0 1.2569051932587172e-06
not O 0 1.7468528312747367e-07
have O 0 8.123448935748456e-08
this O 0 6.488770054602355e-08
effect O 0 4.3758331003118656e-07
, O 0 6.422341414236143e-08
providing O 0 1.252569319376562e-07
the O 0 6.748192049599311e-08
first O 0 1.5218776638903364e-07
direct O 0 2.106929315459638e-07
evidence O 0 1.7647626293637586e-07
for O 0 1.3047286984146922e-07
a O 0 1.382117034154362e-06
functional O 0 6.2682252064405475e-06
consequence O 0 3.0237806640798226e-06
of O 0 5.740885740124213e-07
the O 0 4.529629677563207e-06
H63D O 0 0.1232256069779396
mutation O 0 0.0001937084598466754
. O 0 2.0749283066834323e-05

Addition O 0 0.0001367221848340705
of O 0 1.599341157998424e-05
soluble O 0 0.00012751223403029144
wild O 0 2.046505869657267e-05
- O 0 0.0003439609135966748
type O 0 5.265583240543492e-05
HFE O 0 0.024599183350801468
/ O 0 0.0003116644511464983
beta2m O 0 0.0003472264506854117
heterodimers O 0 0.00029596954118460417
to O 0 2.03968215828354e-06
cultured O 0 6.60267032799311e-05
cells O 0 1.0753551578090992e-05
also O 0 4.987388138033566e-07
decreased O 0 3.891949290846242e-06
the O 0 2.6284902787665487e-07
apparent O 0 2.9312129754544003e-06
affinity O 0 8.768274710746482e-07
of O 0 9.351083463116083e-08
the O 0 2.023167269271653e-07
TfR O 0 9.85131919151172e-05
for O 0 1.0501841529730882e-07
its O 0 1.8168289273035043e-07
ligand O 0 9.735454113979358e-07
under O 0 3.55606886159876e-07
steady O 0 8.019715096452273e-06
- O 0 3.9268259570235386e-05
state O 0 5.629406700791151e-07
conditions O 0 3.0918758966436144e-06
, O 0 1.513968044264402e-07
both O 0 1.1697732560378427e-07
in O 0 5.957411985946237e-07
293 O 0 3.5438479244476184e-05
cells O 0 6.246278189792065e-06
and O 0 6.638757099608483e-07
in O 0 6.347062480926979e-06
HeLa O 0 0.3447043001651764
cells O 0 0.00018077985441777855
. O 0 2.1508236386580393e-05

Furthermore O 0 0.00015958443691488355
, O 0 6.913717243151041e-06
at O 0 1.838081857385987e-06
4 O 0 4.124468887312105e-06
degrees O 0 1.342293035122566e-05
C O 0 1.9482249626889825e-05
, O 0 2.2338278427014302e-07
the O 0 2.601971118565416e-07
added O 0 9.472106512475875e-07
soluble O 0 2.678099463082617e-06
complex O 0 1.3194630810176022e-06
of O 0 1.0726772643465665e-06
HFE O 0 0.1370946317911148
/ O 0 0.0003232958843000233
beta2m O 0 0.00011761352652683854
inhibited O 0 7.696505235799123e-06
binding O 0 9.210787652591534e-07
of O 0 3.0315251819956757e-07
transferrin O 0 1.558855001349002e-05
to O 0 1.017412841974874e-06
HeLa O 0 0.001377910957671702
cell O 0 0.00011224544141441584
TfR O 0 0.00032829149859026074
in O 0 7.777563837407797e-07
a O 0 2.9687080314033665e-06
concentration O 0 4.298608109820634e-05
- O 0 4.550640005618334e-05
dependent O 0 1.4639744222222362e-05
manner O 0 2.3349462935584597e-05
. O 0 1.563476507726591e-05

Scatchard O 0 0.0016283626900985837
plots O 0 8.142795559251681e-05
of O 0 3.4516708637966076e-06
these O 0 6.01515182552248e-07
data O 0 1.061618945641385e-06
indicate O 0 6.026595542607538e-07
that O 0 5.705093997221411e-08
the O 0 1.7478642178048176e-07
added O 0 1.1015976042472175e-06
heterodimer O 0 6.024817412253469e-05
substantially O 0 1.197514393425081e-05
reduced O 0 1.2369868045425392e-06
the O 0 2.1454565057865693e-07
affinity O 0 1.1531403742992552e-06
of O 0 6.08217533226707e-07
TfR O 0 0.0008672613184899092
for O 0 4.182705197308678e-06
transferrin O 0 0.00046564804506488144
. O 0 1.9776516637648456e-05

These O 0 2.720239535847213e-05
results O 0 2.1362931875046343e-05
establish O 0 6.605598173337057e-06
a O 0 2.300578671565745e-06
molecular O 0 5.6371391110587865e-06
link O 0 6.233864041860215e-06
between O 0 1.5369752190963482e-06
HFE O 0 0.003314337460324168
and O 0 5.619612011287245e-07
a O 0 9.090404091693927e-07
key O 0 1.8228893168270588e-06
protein O 0 7.572102731501218e-07
involved O 0 2.3053176789744612e-07
in O 0 2.2337383143167244e-07
iron O 0 1.1020568308595102e-05
transport O 0 1.4571303381671896e-06
, O 0 1.2564576934437355e-07
the O 0 2.0001803591185308e-07
TfR O 0 0.00046252793981693685
, O 0 1.636900748280823e-07
and O 0 1.2186765729893523e-07
raise O 0 4.5702296347371885e-07
the O 0 8.138461282669596e-08
possibility O 0 3.671274555472337e-07
that O 0 7.240679167352937e-08
alterations O 0 4.242960585543187e-06
in O 0 2.632007181091467e-07
this O 0 1.4214154475666874e-07
regulatory O 0 3.997595285909483e-06
mechanism O 0 2.5045474103535526e-06
may O 0 5.738795039178513e-07
play O 0 1.1547731304517583e-07
a O 0 4.011548071503057e-07
role O 0 6.077501666368335e-07
in O 0 5.209430469221843e-07
the O 0 1.677304567238025e-06
pathogenesis O 0 0.0008256696164608002
of O 0 9.447432239539921e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 8.310600969707593e-05
. O 0 4.088868809049018e-05

Genomic O 0 0.0013128739083185792
organization O 0 6.168089748825878e-05
of O 0 5.76636330151814e-06
the O 0 8.352998520422261e-06
UBE3A O 0 0.0021507006604224443
/ O 0 0.0003813264484051615
E6 O 0 0.000346839806297794
- O 0 0.00026004386018030345
AP O 0 0.0001061664370354265
gene O 0 1.1490508768474683e-05
and O 0 2.7101536943519022e-06
related O 0 4.8907990276347846e-05
pseudogenes O 0 0.0009817384416237473
. O 0 6.407820910681039e-05

The O 0 0.00013194970961194485
UBE3A O 0 0.002285919850692153
gene O 0 0.00011837953934445977
encodes O 0 4.7376026486745104e-05
the O 0 3.5043619845964713e-06
E6 O 0 0.00014151536743156612
- O 0 0.00010931411088677123
AP O 0 4.355639612185769e-05
ubiquitin O 0 2.2661177354166284e-05
- O 0 1.2131527910241857e-05
protein O 0 1.4479819583357312e-06
ligase O 0 2.412154117337195e-06
and O 0 3.0139236173454265e-07
has O 0 4.960653541274951e-07
recently O 0 3.016545633727219e-06
been O 0 4.387914032122353e-07
shown O 0 4.4529309661811567e-07
to O 0 2.2661292575776315e-07
be O 0 8.869111525200424e-07
mutated O 0 0.0005524499574676156
in O 0 0.373436838388443
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9660288095474243
who O 0 2.6948040613206103e-05
lack O 0 1.3744572243012954e-05
15q11 O 0 0.000720251293387264
- O 0 0.00018549439846538007
q13 O 0 0.00021863881556782871
deletions O 0 4.2495634261285886e-05
or O 0 6.420213139790576e-06
chromosome O 0 0.00016212122864089906
15 O 0 1.9469322069198824e-05
paternal O 0 0.00031936794403009117
uniparental B-Disease 0 0.45381224155426025
disomy I-Disease 0 0.03306791931390762
. O 0 6.0247482906561345e-05

Previous O 0 0.00038149606552906334
UBE3A O 0 0.0017511682817712426
cDNA O 0 0.0003982016642112285
analysis O 0 2.767489968391601e-05
has O 0 3.708391886902973e-06
shown O 0 3.0047738164284965e-06
a O 0 1.9041871155422996e-06
coding O 0 3.0167238946887664e-05
region O 0 3.5651016787596745e-06
of O 0 9.187057230519713e-07
approximately O 0 4.5068222789268475e-06
2 O 0 1.3547095477406401e-05
. O 0 1.5553150660707615e-05

6 O 0 0.00056453887373209
kb O 0 0.004772752523422241
and O 0 7.286560503416695e-06
a O 0 9.810876690607984e-06
3 O 0 1.771397000993602e-05
- O 0 0.0002480283146724105
untranslated O 0 0.0006256158812902868
region O 0 1.6559919458813965e-05
( O 0 2.9048787837382406e-06
UTR O 0 6.617862527491525e-05
) O 0 5.432728471532755e-07
of O 0 2.572581934146001e-07
< O 0 1.7794700397644192e-05
50 O 0 9.948395245373831e-07
bp O 0 3.1805141134100268e-06
, O 0 1.6080396392226248e-07
whereas O 0 3.3044636893464485e-07
Northern O 0 2.8060463819201686e-07
analysis O 0 3.4608297028171364e-07
has O 0 2.6206285497210047e-07
indicated O 0 6.498516995634418e-07
mRNA O 0 4.879667017121392e-07
sizes O 0 7.693913062212232e-07
of O 0 2.747781309153652e-07
5 O 0 4.056566012877738e-06
- O 0 4.212447311147116e-05
8 O 0 2.1676838514395058e-05
kb O 0 0.0018042162992060184
. O 0 3.002482480951585e-05

We O 0 3.234675750718452e-05
have O 0 4.272109435987659e-06
analyzed O 0 6.952840976737207e-06
additional O 0 2.073567657134845e-06
cDNA O 0 1.6923368093557656e-05
clones O 0 1.715204052743502e-05
and O 0 5.418530122369702e-07
provide O 0 5.549043180508306e-07
evidence O 0 3.2650532943989674e-07
for O 0 1.5924064200589783e-07
an O 0 5.973028009975678e-07
additional O 0 5.599445557891158e-06
0 O 0 3.9333433960564435e-05
. O 0 1.547249121358618e-05

5 O 0 0.0003225284453947097
kb O 0 0.0008845734409987926
of O 0 6.3791326283535454e-06
5 O 0 1.5215326129691675e-05
- O 0 9.551332186674699e-05
UTR O 0 0.0002598510473035276
and O 0 2.18915465666214e-06
> O 0 1.7593392840353772e-05
2 O 0 2.9784118851239327e-06
kb O 0 7.401064794976264e-05
of O 0 8.261671951004246e-07
3 O 0 1.3582384781329893e-05
- O 0 0.0002699973410926759
UTR O 0 0.0015929525252431631
. O 0 3.973157436121255e-05

We O 0 2.719611620705109e-05
have O 0 2.285415803271462e-06
established O 0 1.4475608622888103e-06
the O 0 6.20857349531434e-07
genomic O 0 8.867252290656324e-06
organization O 0 1.2549958228191826e-06
of O 0 3.3809820365604537e-07
UBE3A O 0 7.499096682295203e-05
and O 0 3.9805652818358794e-07
the O 0 2.6809155428964004e-07
sequence O 0 1.2125939292673138e-06
of O 0 7.870053195802029e-07
intron O 0 0.00040666823042556643
- O 0 0.00017580876010470092
exon O 0 0.0002525512536522001
borders O 0 8.139100100379437e-05
. O 0 2.8987080440856516e-05

We O 0 2.8926080631208606e-05
have O 0 3.6276489936426515e-06
also O 0 1.2510548685895628e-06
mapped O 0 6.599716925848043e-06
two O 0 5.348890681489138e-07
highly O 0 1.5333050669141812e-06
homologous O 0 4.151948360231472e-06
processed O 0 1.6693319366822834e-06
pseudogenes O 0 7.4838235377683304e-06
, O 0 3.610263945574843e-07
UBE3AP1 O 0 6.95391499903053e-05
and O 0 5.654658252751688e-07
UBE3AP2 O 0 0.00012328791490290314
, O 0 1.4068800169297901e-07
to O 0 6.68169448658773e-08
chromosomes O 0 1.201790496452304e-06
2 O 0 5.390008368522103e-07
and O 0 1.553262194420313e-07
21 O 0 1.0394137461844366e-06
, O 0 1.1200836524949409e-07
respectively O 0 7.508240855713666e-07
, O 0 1.3295463929807738e-07
and O 0 2.1044431264272134e-07
determined O 0 1.277710680369637e-06
their O 0 1.0193241450906498e-06
genomic O 0 5.096729000797495e-05
organization O 0 1.3756453881796915e-05
. O 0 1.5080991033755708e-05

These O 0 1.9826917196041904e-05
results O 0 8.88664635567693e-06
will O 0 5.231994464338641e-07
form O 0 2.5211448928530444e-07
the O 0 1.334276618081276e-07
basis O 0 3.1611503459316737e-07
for O 0 2.0246999099526874e-07
studies O 0 5.444460953185626e-07
of O 0 4.1754248059078236e-07
mutation O 0 8.109026566671673e-06
and O 0 9.731193131301552e-07
imprinting O 0 0.00011138893023598939
of O 0 4.8652623263478745e-06
UBE3A O 0 0.002636426594108343
. O 0 2.805735493893735e-05

Mutation O 0 0.00594477029517293
spectrum O 0 0.0007704998715780675
and O 0 2.6079605959239416e-05
genotype O 0 0.010828771628439426
- O 0 0.07894083857536316
phenotype O 0 0.2514505982398987
analyses O 0 3.714505510288291e-05
in O 0 2.0336672605481e-05
Cowden B-Disease 1 0.99916672706604
disease I-Disease 0 0.07875384390354156
and O 0 2.4834203941281885e-05
Bannayan B-Disease 1 0.9995405673980713
- I-Disease 1 0.9999861717224121
Zonana I-Disease 1 0.9999995231628418
syndrome I-Disease 1 0.9999953508377075
, O 0 1.0216784176009241e-05
two O 0 9.527953079668805e-05
hamartoma B-Disease 1 0.9999732971191406
syndromes I-Disease 1 0.9998478889465332
with O 0 0.0002610185765661299
germline O 1 0.9920822381973267
PTEN O 1 0.9429634213447571
mutation O 0 0.0008610293734818697
. O 0 5.5805521697038785e-05

The O 0 0.0004179959651082754
tumour B-Disease 1 0.9999560117721558
suppressor O 0 0.40104231238365173
gene O 0 0.000491479819174856
PTEN O 0 0.003934877924621105
, O 0 3.0944895570428343e-06
which O 0 1.0513642791920574e-06
maps O 0 5.655468612530967e-06
to O 0 3.5097834825137397e-06
10q23 O 0 0.0006351222400553524
. O 0 3.901894160662778e-05

3 O 0 0.00011330933921271935
and O 0 5.850152774655726e-06
encodes O 0 1.9508834157022648e-05
a O 0 6.266862328629941e-06
403 O 0 2.431280336168129e-05
amino O 0 1.6223993952735327e-05
acid O 0 1.5236975741572678e-05
dual O 0 2.1110750822117552e-05
specificity O 0 3.1506748200627044e-05
phosphatase O 0 0.0013993397587910295
( O 0 3.80753340323281e-06
protein O 0 4.034485755255446e-06
tyrosine O 0 1.7599972125026397e-05
phosphatase O 0 0.00030423770658671856
; O 0 2.324899469385855e-06
PTPase O 0 6.69719374855049e-05
) O 0 4.631286572021054e-07
, O 0 1.9618862268089288e-07
was O 0 3.876581331496709e-07
shown O 0 2.72769796083594e-07
recently O 0 4.7654845047873096e-07
to O 0 8.861471201271343e-08
play O 0 1.57140675582923e-07
a O 0 8.866709322319366e-07
broad O 0 5.291610705171479e-06
role O 0 2.517056373108062e-06
in O 0 3.292696874268586e-06
human O 0 2.8422507966752164e-05
malignancy B-Disease 0 0.42935147881507874
. O 0 3.2703326724004e-05

Somatic O 0 0.02539926953613758
PTEN O 0 0.33160656690597534
deletions O 0 0.0022543149534612894
and O 0 5.984956078464165e-05
mutations O 0 0.00018357021326664835
were O 0 1.0822529930010205e-06
observed O 0 1.7471388673584443e-06
in O 0 1.1382611546650878e-06
sporadic B-Disease 0 0.0012991322437301278
breast I-Disease 1 0.9942541718482971
, I-Disease 0 5.2822710131295025e-05
brain I-Disease 0 0.06310464441776276
, I-Disease 0 2.316148857062217e-05
prostate I-Disease 1 0.9999271631240845
and I-Disease 0 0.022291598841547966
kidney I-Disease 1 0.9999984502792358
cancer I-Disease 1 0.9986114501953125
cell O 0 0.002011996926739812
lines O 0 1.4913172890373971e-05
and O 0 5.693657385563711e-07
in O 0 6.447336886594712e-07
several O 0 1.7536206087243045e-06
primary O 0 0.00024879162083379924
tumours B-Disease 1 0.9998152852058411
such O 0 4.198002443445148e-06
as O 0 9.016802505357191e-05
endometrial B-Disease 1 0.9999920129776001
carcinomas I-Disease 1 1.0
, O 1 0.997394323348999
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9761337041854858
thyroid B-Disease 1 1.0
tumours I-Disease 1 0.9999998807907104
. O 0 0.00022385967895388603

In O 0 4.807274672202766e-05
addition O 0 2.4325652702827938e-05
, O 0 5.418445653049275e-06
PTEN O 0 0.002928124973550439
was O 0 3.2226791972789215e-06
identified O 0 1.8788964553095866e-06
as O 0 2.0035058412304352e-07
the O 0 5.974714554213278e-07
susceptibility O 0 2.96931521006627e-05
gene O 0 5.388844783738023e-06
for O 0 2.457778236930608e-06
two O 0 0.0002364897809457034
hamartoma B-Disease 1 0.9999997615814209
syndromes I-Disease 1 1.0
Cowden B-Disease 1 0.9999997615814209
disease I-Disease 1 0.9444295167922974
( O 0 8.918101229937747e-06
CD B-Disease 0 2.558890264481306e-05
; O 0 7.447996722476091e-06
MIM O 0 0.00047629792243242264
158350 O 0 5.77091850573197e-05
) O 0 1.2804466678062454e-06
and O 0 8.267898579106259e-07
Bannayan B-Disease 0 0.0003633929300121963
- I-Disease 0 0.0005344001110643148
Zonana I-Disease 0 0.03898755460977554
( I-Disease 0 3.491179086267948e-06
BZS I-Disease 0 7.426579395541921e-05
) I-Disease 0 1.7644979379838333e-06
or I-Disease 0 2.4271346319437725e-06
Ruvalcaba I-Disease 0 0.0008617682033218443
- I-Disease 0 0.0005116484244354069
Riley I-Disease 0 0.0009111744584515691
- I-Disease 1 0.9779517650604248
Smith I-Disease 1 0.9775359034538269
syndrome I-Disease 1 0.9999921321868896
( O 0 4.287631600163877e-05
MIM O 0 0.0023269695229828358
153480 O 0 0.0006035162950865924
) O 0 1.6067278920672834e-05
. O 0 2.281972592754755e-05

Constitutive O 0 0.0012202964862808585
DNA O 0 0.0001410981931257993
from O 0 7.064567853376502e-06
37 O 0 1.8591632397146896e-05
CD B-Disease 0 1.5482470189454034e-05
families O 0 3.207991539966315e-06
and O 0 5.283852146931167e-07
seven O 0 2.996989451276022e-06
BZS B-Disease 0 0.00033624854404479265
families O 0 4.830098987440579e-06
was O 0 4.474748948268825e-06
screened O 0 2.131002656824421e-05
for O 0 1.3823640983900987e-05
germline O 0 0.08627598732709885
PTEN O 0 0.2554459273815155
mutations O 0 0.0006505411001853645
. O 0 4.939216159982607e-05

PTEN O 1 0.9986875653266907
mutations O 0 0.03164992481470108
were O 0 1.67593370861141e-05
identified O 0 1.0768144420580938e-05
in O 0 6.321934051811695e-07
30 O 0 6.985840173001634e-07
of O 0 1.408022285431798e-07
37 O 0 8.82745189301204e-06
( O 0 1.1576370297916583e-06
81 O 0 8.351301403308753e-06
% O 0 7.788133302710776e-07
) O 0 1.2509171654073725e-07
CD B-Disease 0 1.2338740589257213e-06
families O 0 4.1136678419206874e-07
, O 0 1.3760300987541996e-07
including O 0 3.3997937975982495e-07
missense O 0 1.566822720633354e-05
and O 0 3.933995174065785e-07
nonsense O 0 6.037984803697327e-06
point O 0 4.914253167953575e-06
mutations O 0 9.043443242262583e-06
, O 0 1.8639283894117398e-07
deletions O 0 4.977712251275079e-06
, O 0 3.8573639926653414e-07
insertions O 0 4.856778559769737e-06
, O 0 3.831417529909231e-07
a O 0 2.0686852622020524e-06
deletion O 0 0.00022005406208336353
/ O 0 3.8303191104205325e-05
insertion O 0 1.7970420230994932e-05
and O 0 2.1337637008400634e-06
splice O 0 0.00035285900230519474
site O 0 6.327449955279008e-05
mutations O 0 0.00015021979925222695
. O 0 2.268217212986201e-05

These O 0 3.8378584577003494e-05
mutations O 0 0.00013485562521964312
were O 0 1.0670137271517888e-06
scattered O 0 9.279089567826304e-07
over O 0 2.9557594416473876e-07
the O 0 2.2793857112901605e-07
entire O 0 9.702040415504598e-07
length O 0 2.3198633698484628e-06
of O 0 3.8180894534889376e-07
PTEN O 0 0.0012362799607217312
, O 0 1.4346542798193695e-07
with O 0 7.351000874677993e-08
the O 0 1.1426548240933698e-07
exception O 0 1.8732592366177414e-07
of O 0 3.797375569547512e-08
the O 0 7.138940105733127e-08
first O 0 3.362537768225593e-07
, O 0 2.3486457223498292e-07
fourth O 0 3.0855721888656262e-06
and O 0 9.53722519625444e-07
last O 0 1.017478007270256e-05
exons O 0 0.00031603986280970275
. O 0 1.5414996596518904e-05

A O 0 0.00016624377167318016
hot O 0 0.00012627466639969498
spot O 0 5.818952195113525e-05
for O 0 6.4065247897815425e-06
PTEN O 0 0.02334994450211525
mutation O 0 2.8077107344870456e-05
in O 0 6.168606319079117e-07
CD B-Disease 0 6.4753762671898585e-06
was O 0 1.2718653579213424e-06
identified O 0 9.509623168924008e-07
in O 0 2.400912251232512e-07
exon O 0 1.1194467333552893e-05
5 O 0 9.278602419726667e-07
that O 0 4.5360128098081987e-08
contains O 0 7.949464020384767e-08
the O 0 1.7578692279585084e-07
PTPase O 0 2.8767519324901514e-05
core O 0 3.4877480175055098e-06
motif O 0 2.072112920359359e-06
, O 0 1.2779710800714383e-07
with O 0 8.832380160583853e-08
13 O 0 4.823700692213606e-07
of O 0 6.926137530172127e-08
30 O 0 6.966546948206087e-07
( O 0 3.9132575579969853e-07
43 O 0 1.9497135781421093e-06
% O 0 7.38010157874669e-07
) O 0 4.3383613501646323e-07
CD B-Disease 0 7.734073733445257e-06
mutations O 0 8.020693712751381e-06
identified O 0 1.7985620388571988e-06
in O 0 6.597045967282611e-07
this O 0 1.8109748225469957e-06
exon O 0 0.00019359655561856925
. O 0 3.3412270568078384e-05

Seven O 0 5.560498539125547e-05
of O 0 5.597577001026366e-06
30 O 0 8.31171746540349e-06
( O 0 2.6506070298637496e-06
23 O 0 3.89106617149082e-06
% O 0 1.0314951168766129e-06
) O 0 1.481727593954929e-07
were O 0 3.841735107812383e-08
within O 0 4.611893444916859e-08
the O 0 5.017318827071904e-08
core O 0 1.6680749013175955e-06
motif O 0 1.9463786884443834e-06
, O 0 1.170066639133438e-07
the O 0 1.1868094418332475e-07
majority O 0 6.849062970104569e-07
( O 0 1.6651647172238881e-07
five O 0 7.296327453332196e-08
of O 0 5.7991929480749604e-08
seven O 0 3.8347440067809657e-07
) O 0 1.2585407205278898e-07
of O 0 4.010369281104431e-08
which O 0 2.139847481430479e-07
were O 0 7.229982657008804e-07
missense O 0 0.00030044731101952493
mutations O 0 1.696355320746079e-05
, O 0 3.032681945569493e-07
possibly O 0 5.988244993204717e-07
pointing O 0 9.885606004900183e-07
to O 0 8.422259156759537e-08
the O 0 1.7486595993432275e-07
functional O 0 1.3840559631717042e-06
significance O 0 7.072529797369498e-07
of O 0 3.490136464279203e-07
this O 0 7.526458034590178e-07
region O 0 2.06269232876366e-05
. O 0 1.7322059647995047e-05

Germline O 1 0.9989331364631653
PTEN O 1 0.9966705441474915
mutations O 0 0.010441705584526062
were O 0 9.624440281186253e-06
identified O 0 5.280877758195857e-06
in O 0 3.6623887922360154e-07
four O 0 2.905137534980895e-07
of O 0 2.5192798602802213e-07
seven O 0 2.427329263809952e-06
( O 0 2.2559697754331864e-06
57 O 0 2.1136616851435974e-05
% O 0 3.457900902503752e-06
) O 0 1.8035395896731643e-06
BZS B-Disease 0 0.00012247261474840343
families O 0 6.7116420723323245e-06
studied O 0 1.2994121789233759e-05
. O 0 1.3503910849976819e-05

Interestingly O 0 0.001074153813533485
, O 0 1.8661121430341154e-05
none O 0 3.7141467146284413e-06
of O 0 8.191768188225979e-07
these O 0 8.189236950784107e-07
mutations O 0 2.5830750018940307e-05
was O 0 1.214162011820008e-06
observed O 0 1.523488094790082e-06
in O 0 3.9419944641849725e-07
the O 0 1.4990336012488115e-06
PTPase O 0 0.00035919022047892213
core O 0 4.89113008370623e-05
motif O 0 8.398369391215965e-05
. O 0 2.4254493837361224e-05

It O 0 2.0692648831754923e-05
is O 0 3.056145942537114e-06
also O 0 8.802676916275232e-07
worthy O 0 9.79121750788181e-07
of O 0 2.3088597345122253e-07
note O 0 2.083572098854347e-06
that O 0 1.235075473005054e-07
a O 0 8.086638558779669e-07
single O 0 2.0701436369563453e-06
nonsense O 0 8.241358955274336e-06
point O 0 2.9801819891872583e-06
mutation O 0 6.249018952075858e-06
, O 0 3.833873734038207e-07
R233X O 0 1.6913978470256552e-05
, O 0 2.6594639734867087e-07
was O 0 4.669133204515674e-07
observed O 0 4.77530193165876e-07
in O 0 1.1984812431364844e-07
the O 0 3.811315423263295e-07
germline O 0 5.909003448323347e-05
DNA O 0 1.6531913615835947e-06
from O 0 1.3915533259023505e-07
two O 0 2.64539465888447e-07
unrelated O 0 1.075765430869069e-05
CD B-Disease 0 1.6620517271803692e-05
families O 0 4.9810842028819025e-06
and O 0 9.435159995518916e-07
one O 0 4.390669801068725e-06
BZS B-Disease 0 0.0010406812652945518
family O 0 4.067312693223357e-05
. O 0 2.3808524929336272e-05

Genotype O 1 0.9763743281364441
- O 1 0.9381498694419861
phenotype O 1 0.5942897796630859
studies O 0 1.7541560737299733e-05
were O 0 9.816499186854344e-07
not O 0 1.4647791601873905e-07
performed O 0 5.077236551187525e-07
on O 0 2.0991053872876364e-07
this O 0 1.0047376264310515e-07
small O 0 3.892711220032652e-07
group O 0 1.348318164673401e-06
of O 0 1.1531667496456066e-06
BZS B-Disease 0 0.0007443243521265686
families O 0 3.437411578488536e-05
. O 0 1.5644220184185542e-05

However O 0 0.00010980387014569715
, O 0 1.9337316189194098e-05
genotype O 0 0.0014636582927778363
- O 0 0.003010653890669346
phenotype O 0 0.001955294981598854
analysis O 0 6.29515352557064e-06
inthe O 0 0.0001234472874784842
group O 0 1.7942139720616979e-06
of O 0 1.8370096199760155e-07
CD B-Disease 0 1.8820255718310364e-05
families O 0 4.292991434340365e-06
revealed O 0 1.684447511252074e-06
two O 0 1.9863301758960006e-07
possible O 0 3.792663960666687e-07
associations O 0 2.882100318402081e-07
worthy O 0 3.0713317755726166e-07
of O 0 9.080408602812895e-08
follow O 0 4.4867556425742805e-07
- O 0 5.486312147695571e-06
up O 0 8.592909352955758e-07
in O 0 9.72259385889629e-07
independent O 0 5.824199888593284e-06
analyses O 0 1.418619376636343e-05
. O 0 8.669678209116682e-06

The O 0 2.403806138318032e-05
first O 0 5.031501586927334e-06
was O 0 1.6691504924892797e-06
an O 0 3.8811015201645205e-07
association O 0 1.158065515483031e-06
noted O 0 3.775803349981288e-07
in O 0 1.0348140477844936e-07
the O 0 1.4781963386667485e-07
group O 0 6.519498469970131e-07
of O 0 1.613308313608286e-07
CD B-Disease 0 1.4545031262969133e-05
families O 0 1.399077518726699e-05
with O 0 4.9884220061358064e-05
breast B-Disease 1 0.9999940395355225
disease I-Disease 1 0.7420453429222107
. O 0 3.841223588096909e-05

A O 0 0.0002092827926389873
correlation O 0 0.00011662582983262837
was O 0 7.622452358191367e-06
observed O 0 2.6066902591992402e-06
between O 0 3.2168588859349256e-07
the O 0 3.493546216759569e-07
presence O 0 1.2904573623018223e-06
/ O 0 3.3210264518857e-05
absence O 0 1.8540833934821421e-06
of O 0 3.2782043035695096e-07
a O 0 1.2512299690570217e-05
PTEN O 0 0.09076490253210068
mutation O 0 1.012652319332119e-05
and O 0 1.9745561985473614e-07
the O 0 3.4098533774340467e-07
type O 0 3.2748532703408273e-06
of O 0 2.6629561489244225e-06
breast O 1 0.5251234173774719
involvement O 0 0.00013173111074138433
( O 0 3.1393767130794004e-05
unaffected O 0 0.0004781224124599248
versus O 0 0.002760009840130806
benign O 1 0.7820218205451965
versus O 1 0.8046826124191284
malignant O 1 0.9999440908432007
) O 0 4.696268661064096e-05
. O 0 3.1747069442644715e-05

Specifically O 0 5.1904975407524034e-05
and O 0 2.4026971914281603e-06
more O 0 3.9750190694576304e-07
directly O 0 4.95173878789501e-07
, O 0 1.5012267340352992e-07
an O 0 1.8465190976257873e-07
association O 0 5.841471875100979e-07
was O 0 9.412315193912946e-07
also O 0 2.771762979136838e-07
observed O 0 4.350500546479452e-07
between O 0 9.052739358139661e-08
the O 0 9.140897816450888e-08
presence O 0 2.991644123540027e-07
of O 0 2.096068811852092e-07
a O 0 1.0022912647400517e-05
PTEN O 0 0.10370904952287674
mutation O 0 0.00046386022586375475
and O 0 0.000454931752756238
malignant B-Disease 1 0.9999998807907104
breast I-Disease 1 0.9999996423721313
disease I-Disease 1 0.948776364326477
. O 0 4.800713577424176e-05

Secondly O 0 0.000980424345470965
, O 0 7.01315502737998e-06
there O 0 8.178880079867668e-07
appeared O 0 1.394865876136464e-06
to O 0 1.2948468963713822e-07
be O 0 7.438091387257373e-08
an O 0 2.236790948018097e-07
interdependent O 0 2.7342213797965087e-05
association O 0 1.2358194680928136e-06
between O 0 6.340628146972449e-07
mutations O 0 4.743389581562951e-06
upstream O 0 5.893640491194674e-07
and O 0 8.287873498602494e-08
within O 0 1.1264425126000788e-07
the O 0 1.9579161403271428e-07
PTPase O 0 3.8402711652452126e-05
core O 0 2.4918231247283984e-06
motif O 0 1.8235343759442912e-06
, O 0 1.3635623474783642e-07
the O 0 1.1233915131469985e-07
core O 0 1.272986537514953e-06
motif O 0 1.5132851558519178e-06
containing O 0 3.065897260512429e-07
the O 0 2.027259995429631e-07
majority O 0 7.884334536356619e-07
of O 0 3.796398573285842e-07
missense O 0 0.0030366554856300354
mutations O 0 1.6829168089316227e-05
, O 0 1.498509050179564e-07
and O 0 6.888156889317543e-08
the O 0 1.2133837401506753e-07
involvement O 0 9.900569466481102e-07
of O 0 9.204458706335572e-08
all O 0 8.990997457658523e-08
major O 0 8.608690791334084e-07
organ O 0 4.608487506629899e-05
systems O 0 2.1169900719542056e-05
( O 0 1.4244010344555136e-06
central O 0 1.7327772638964234e-06
nervous O 0 1.2354693353699986e-05
system O 0 4.76684817840578e-06
, O 0 3.998678494099295e-06
thyroid O 1 0.9247978329658508
, O 0 9.4779034043313e-06
breast O 1 0.774678647518158
, O 0 2.9949900635983795e-05
skin O 1 0.8017416596412659
and O 0 0.0010489339474588633
gastrointestinal O 1 0.9999967813491821
tract O 1 0.9554622769355774
) O 0 3.2418527553090826e-05
. O 0 2.8179498258396052e-05

However O 0 4.406080915941857e-05
, O 0 2.04002844839124e-06
these O 0 1.592933500660365e-07
observations O 0 7.516429718634754e-07
would O 0 1.9953982643983181e-07
need O 0 1.4537336312514526e-07
to O 0 9.171372283844903e-08
be O 0 8.111867089155567e-08
confirmed O 0 2.510583101411612e-07
by O 0 4.634706485262541e-08
studying O 0 1.541533265481121e-07
a O 0 2.8350697789392143e-07
larger O 0 3.416070057937759e-07
number O 0 1.5073409542765148e-07
of O 0 2.6862235813496227e-07
CD B-Disease 0 2.6886893465416506e-05
families O 0 1.8493245079298504e-05
. O 0 1.1509701835166197e-05

Molecular O 0 0.0962439477443695
defects O 1 0.9814251661300659
leading O 0 4.85975579067599e-05
to O 0 2.7170037810719805e-06
human O 0 5.84852887186571e-06
complement B-Disease 0 9.139223402598873e-05
component I-Disease 0 0.15258407592773438
C6 I-Disease 1 1.0
deficiency I-Disease 1 0.9999915361404419
in O 0 8.184326247828722e-07
an O 0 6.991212444518169e-07
African O 0 4.623741006071214e-06
- O 0 4.162515324424021e-05
American O 0 9.407592187926639e-06
family O 0 1.6698970284778625e-05
. O 0 2.1840311092091724e-05

Complement B-Disease 0 0.03288871794939041
component I-Disease 1 0.9894906878471375
C6 I-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
( O 0 0.00020787357061635703
C6D B-Disease 0 0.3852522075176239
) O 0 2.7881365895154886e-05
was O 0 4.5962508011143655e-05
diagnosed O 0 0.40644654631614685
in O 0 6.096036599956278e-07
a O 0 2.923150759670534e-06
16 O 0 6.606272108911071e-06
- O 0 3.11320363834966e-05
year O 0 1.9963661088695517e-06
- O 0 9.194233825837728e-06
old O 0 4.661712409870233e-06
African O 0 3.5202417620894266e-06
- O 0 1.552982212160714e-05
American O 0 5.006104856875027e-06
male O 0 5.044410499976948e-05
with O 0 0.0001696774852462113
meningococcal B-Disease 1 0.9999996423721313
meningitis I-Disease 1 0.9999936819076538
. O 0 0.00011728034587576985

The O 0 0.000255492894211784
patients O 0 0.010652802884578705
father O 0 1.7407393897883594e-05
and O 0 1.0126891538675409e-06
two O 0 1.2884615898656193e-06
brothers O 0 3.561543417163193e-05
also O 0 9.723345328893629e-07
had O 0 2.1886223748879274e-06
C6D B-Disease 0 0.0005058409296907485
, O 0 2.2248558195769874e-07
but O 0 1.09397007008738e-07
gave O 0 4.337451287028671e-07
no O 0 1.3747406057973421e-07
history O 0 3.3879152283589065e-07
of O 0 1.036042021951289e-06
meningitis B-Disease 1 0.9971729516983032
or O 0 1.1182675734744407e-05
other O 0 6.770916115783621e-06
neisserial B-Disease 1 0.9588015079498291
infection I-Disease 0 0.03438356891274452
. O 0 3.3522159355925396e-05

By O 0 3.324962381157093e-05
using O 0 1.6633102859486826e-05
exon O 0 0.00010976744670188054
- O 0 5.385544500313699e-05
specific O 0 3.922257747035474e-06
polymerase O 0 2.5026112780324183e-05
chain O 0 1.6115032849484123e-05
reaction O 0 4.876764251093846e-06
( O 0 1.2510023452705354e-06
PCR O 0 1.1506562259455677e-05
) O 0 7.008061402302701e-07
/ O 0 5.446317118185107e-06
single O 0 1.1665520105452742e-06
- O 0 1.3492440302798059e-05
strand O 0 1.542587961012032e-05
conformation O 0 4.08366304327501e-06
polymorphism O 0 3.2356999781768536e-06
as O 0 1.277873593608092e-07
a O 0 3.938439760986512e-07
screening O 0 1.6534719406990916e-06
step O 0 8.024504154491297e-07
and O 0 1.8199173723587592e-07
nucleotide O 0 2.556406798248645e-06
sequencing O 0 1.149305376202392e-06
of O 0 1.1518451970005117e-07
target O 0 1.0934272722806782e-06
exons O 0 4.898568931821501e-06
, O 0 1.9915123061764461e-07
we O 0 6.144450992451311e-08
determined O 0 2.1716638798352506e-07
that O 0 4.206030723707954e-08
the O 0 2.3623914557902026e-07
proband O 0 0.00010531511361477897
was O 0 9.54975803324487e-07
a O 0 1.255757297258242e-06
compound O 0 1.3970550753583666e-05
heterozygote O 0 4.333915785537101e-05
for O 0 8.400397746299859e-07
two O 0 6.511372703243978e-06
C6 O 0 0.21322579681873322
gene O 0 0.0001473807351430878
mutations O 0 0.00016429759853053838
. O 0 2.014726669585798e-05

The O 0 1.8999906387762167e-05
first O 0 9.105015124077909e-06
, O 0 2.0193306227156427e-06
1195delC O 0 1.4771514543099329e-05
located O 0 9.076526907847438e-07
in O 0 4.863109666075616e-07
exon O 0 1.3380882592173293e-05
7 O 0 5.6615717767272145e-06
, O 0 1.6111373213334446e-07
is O 0 8.529929118594737e-08
a O 0 6.375790917445556e-07
novel O 0 5.5751529544068035e-06
mutation O 0 5.6870212574722245e-06
, O 0 1.4151450500321516e-07
while O 0 8.936015660765406e-08
the O 0 8.695795372659632e-08
second O 0 7.351532644861436e-07
, O 0 2.0104613440707908e-07
1936delG O 0 6.4449354795215186e-06
in O 0 2.901549009948212e-07
exon O 0 7.799969353072811e-06
12 O 0 9.14579572963703e-07
, O 0 1.1920204912030385e-07
has O 0 1.2559807771594933e-07
been O 0 1.0532954775044345e-07
described O 0 4.6167519940354396e-07
before O 0 2.079743381955268e-07
to O 0 2.3217192790525587e-07
cause O 0 3.568248075680458e-06
C6D B-Disease 0 0.00011714320135070011
in O 0 2.66074778210168e-07
an O 0 4.475371042644838e-07
unrelated O 0 1.5307587091228925e-05
African O 0 4.339923179941252e-06
- O 0 6.243065581656992e-05
American O 0 6.595632839889731e-06
individual O 0 6.941405899851816e-06
. O 0 1.1268479283899069e-05

Both O 0 0.0003050730738323182
mutations O 0 0.0022715169470757246
result O 0 3.098444358329289e-05
in O 0 1.3814903468301054e-05
premature O 0 0.0011074022622779012
termination O 0 0.0007472827564924955
codons O 0 0.00023543104180134833
and O 0 1.9759208953473717e-05
C6 O 0 0.16058868169784546
null O 0 0.0015059198485687375
alleles O 0 0.0005486593581736088
. O 0 6.975845462875441e-05

Allele O 0 0.0021037135738879442
- O 0 0.0003154492296744138
specific O 0 1.341343522653915e-05
PCR O 0 0.0001039987982949242
indicated O 0 4.345767138147494e-06
that O 0 1.2704673224561702e-07
the O 0 2.3015435601791978e-07
probands O 0 5.262482227408327e-05
two O 0 9.67343680713384e-07
brothers O 0 3.69973604392726e-05
also O 0 9.818802482186584e-07
inherited O 0 9.375366062158719e-06
the O 0 5.358878070182982e-07
1195delC O 0 9.66260049608536e-05
mutation O 0 2.2937524590815883e-06
from O 0 1.4708740536661935e-07
their O 0 3.3229127893719124e-07
heterozygous O 0 1.1258608537900727e-05
mother O 0 2.684656010387698e-06
and O 0 2.0042817538978852e-07
the O 0 4.484963085360505e-07
1936delG O 0 0.0001387551601510495
mutation O 0 5.296634299156722e-06
from O 0 3.974924140948133e-07
their O 0 7.14494717612979e-07
homozygous O 0 0.00014311636914499104
father O 0 1.2166285159764811e-05
. O 0 3.7335369142965646e-06
. O 0 1.6695879821782e-05

PAX6 O 1 0.9702391624450684
mutations O 0 0.08162262290716171
reviewed O 0 0.0015223576920107007
. O 0 0.0003165090165566653

Mutations O 0 0.0231015682220459
in O 0 3.980620749644004e-05
PAX6 O 0 0.003160561667755246
are O 0 1.7238949112652335e-06
responsible O 0 2.2249544144870015e-06
for O 0 6.575081101800606e-07
human O 0 4.246749540470773e-06
aniridia B-Disease 1 0.9989718198776245
and O 0 2.529420044083963e-06
have O 0 5.053565814705507e-07
also O 0 5.681160359927162e-07
been O 0 3.3999882020907535e-07
found O 0 3.854727310681483e-07
in O 0 2.1565492716035806e-06
patients O 0 0.00014468499284703285
with O 0 8.421715392614715e-06
Peters B-Disease 1 0.9999254941940308
anomaly I-Disease 1 0.9995896220207214
, O 0 2.7078362109023146e-05
with O 0 0.036497924476861954
congenital B-Disease 1 1.0
cataracts I-Disease 1 0.9999994039535522
, O 0 1.7470290913479403e-05
with O 0 5.548099579755217e-05
autosomal B-Disease 1 0.9996625185012817
dominant I-Disease 0 0.08071016520261765
keratitis I-Disease 1 0.7441990971565247
, O 0 1.6930348465393763e-06
and O 0 1.926148115671822e-06
with O 0 2.1473066226462834e-05
isolated B-Disease 0 0.08488542586565018
foveal I-Disease 1 0.999994158744812
hypoplasia I-Disease 1 0.9999992847442627
. O 0 0.00014419770741369575

No O 0 5.8684818213805556e-05
locus O 0 0.00012449253699742258
other O 0 2.2242033992370125e-06
than O 0 1.3512827763406676e-06
chromosome O 0 0.00016324070747941732
11p13 O 0 0.00010667760216165334
has O 0 1.439562424820906e-06
been O 0 7.202276606221858e-07
implicated O 0 7.807708243490197e-06
in O 0 1.692324417490454e-06
aniridia B-Disease 1 0.9979516863822937
, O 0 1.035409809446719e-06
and O 0 1.1191265230081626e-06
PAX6 O 0 0.0016453178832307458
is O 0 5.979525781185657e-07
clearly O 0 4.1940944583984674e-07
the O 0 1.1030928703803511e-07
major O 0 2.1034841779510316e-07
, O 0 1.2067251020653202e-07
if O 0 6.473466385159554e-08
not O 0 5.694472449135901e-08
only O 0 1.2084686318303284e-07
, O 0 5.927274742134614e-07
gene O 0 8.190922926587518e-06
responsible O 0 1.1347678992024157e-05
. O 0 1.606773912499193e-05

Twenty O 0 0.0004421219346113503
- O 0 0.0003962824703194201
eight O 0 1.909315869852435e-05
percent O 0 1.3142052011971828e-05
of O 0 8.680124778948084e-07
identified O 0 1.8610151528264396e-05
PAX6 O 0 0.01853123866021633
mutations O 0 3.476572237559594e-05
are O 0 5.215853207118926e-07
C O 0 3.418470441829413e-05
- O 0 0.00012240828073117882
T O 0 0.00026395911118015647
changes O 0 8.925230758904945e-07
at O 0 3.9865827261564846e-07
CpG O 0 1.156083271780517e-05
dinucleotides O 0 2.9133518182788976e-05
, O 0 2.7288999149277515e-07
20 O 0 5.979941875011718e-07
% O 0 5.464165155899536e-07
are O 0 5.061050600829731e-08
splicing O 0 2.9336681564018363e-06
errors O 0 3.366976898178109e-06
, O 0 1.6851498685355182e-07
and O 0 1.1152233270195211e-07
more O 0 8.71606999908181e-08
than O 0 1.2044669972510746e-07
30 O 0 8.832503795019875e-07
% O 0 6.676312409581442e-07
are O 0 1.315002009505406e-07
deletion O 0 2.1817471861140803e-05
or O 0 2.79738901554083e-06
insertion O 0 7.749457290628925e-05
events O 0 1.6879814211279154e-05
. O 0 1.850732405728195e-05

There O 0 1.771075949363876e-05
is O 0 3.5906070934288437e-06
a O 0 6.640025731030619e-06
noticeably O 0 0.0004909659037366509
elevated O 0 0.0001427467359462753
level O 0 1.2215383549118997e-06
of O 0 3.345760148931731e-07
mutation O 0 5.162302386452211e-06
in O 0 1.5279624676622916e-07
the O 0 2.535888086185878e-07
paired O 0 3.050124405490351e-06
domain O 0 5.912951337450068e-07
compared O 0 4.969735414306342e-07
with O 0 6.204098923490164e-08
the O 0 1.7919363415330736e-07
rest O 0 3.783437705351389e-07
of O 0 2.120475386391263e-07
the O 0 1.768583501871035e-06
gene O 0 3.469858711468987e-05
. O 0 1.580952448421158e-05

Increased O 0 0.001350743928924203
mutation O 0 0.00018139508028980345
in O 0 2.316677409908152e-06
the O 0 2.1382431896199705e-06
homeodomain O 0 7.692029612371698e-05
is O 0 6.214900167833548e-07
accounted O 0 1.134657509282988e-06
for O 0 1.3145731259101012e-07
by O 0 2.2243975195124222e-07
the O 0 1.0459397117301705e-06
hypermutable O 0 0.0003140787302982062
CpG O 0 8.600000001024455e-05
dinucleotide O 0 7.444489892804995e-05
in O 0 2.830333414749475e-06
codon O 0 4.750554580823518e-05
240 O 0 4.9725491408025846e-05
. O 0 1.8503529645386152e-05

Very O 0 5.2340939873829484e-05
nearly O 0 1.949196848727297e-05
all O 0 1.908947069750866e-06
mutations O 0 4.284174428903498e-05
appear O 0 2.2333535980578745e-06
to O 0 7.736500720056938e-07
cause O 0 1.065467677108245e-05
loss O 0 8.353658813575748e-06
of O 0 1.0675037742657878e-07
function O 0 2.432101666727249e-07
of O 0 6.508266636728877e-08
the O 0 1.6294264071348152e-07
mutant O 0 3.7005582271376625e-05
allele O 0 5.4913898566155694e-06
, O 0 8.313077870525376e-08
and O 0 4.439421275037603e-08
more O 0 2.8489839820622365e-08
than O 0 6.823572107350628e-08
80 O 0 4.2998897242796374e-07
% O 0 3.6447545426199213e-07
of O 0 1.4726116148722213e-07
exonic O 0 4.6680001105414703e-05
substitutions O 0 4.1513740143273026e-06
result O 0 2.619316774143954e-06
in O 0 2.67721611635352e-06
nonsense O 0 8.93993565114215e-05
codons O 0 0.0002921611594501883
. O 0 3.880582153215073e-05

In O 0 2.9128685127943754e-05
a O 0 1.1163846465933602e-05
gene O 0 7.982790521054994e-06
with O 0 6.470330617958098e-07
such O 0 4.890620175501681e-07
extraordinarily O 0 3.369317710166797e-05
high O 0 4.173894467385253e-06
sequence O 0 1.1088638984801946e-06
conservation O 0 7.908070642770326e-07
throughout O 0 2.1753616863406933e-07
evolution O 0 3.68339811984697e-07
, O 0 9.3985406124375e-08
there O 0 1.010306718285392e-07
are O 0 2.0253139609849313e-07
presumed O 0 7.068893319228664e-05
undiscovered O 0 0.0002811690210364759
missense O 0 0.001505007385276258
mutations O 0 1.35984964799718e-05
, O 0 1.4278322169047897e-07
these O 0 4.7481009346483916e-08
are O 0 5.468346486736664e-08
hypothesized O 0 1.2363923360680928e-06
to O 0 1.3853815516995382e-07
exist O 0 1.621019549702396e-07
in O 0 9.369705367134884e-08
as O 0 2.8207975333316426e-07
- O 0 5.033209890825674e-05
yet O 0 3.8905800465727225e-06
unidentified O 0 5.464350033435039e-05
phenotypes O 0 0.0003065877826884389
. O 0 4.371313480078243e-06
. O 0 2.0465917259571142e-05

Genetic O 0 0.00394792202860117
heterogeneity O 0 0.0021029566414654255
and O 0 3.1200899684336036e-05
penetrance O 0 0.0010789339430630207
analysis O 0 6.95042126608314e-06
of O 0 1.012441998682334e-06
the O 0 2.415863036731025e-06
BRCA1 O 0 0.0005804224638268352
and O 0 1.6489824702148326e-05
BRCA2 O 0 0.02142805978655815
genes O 0 7.236908277263865e-05
in O 0 0.00013512761506717652
breast B-Disease 1 0.999993085861206
cancer I-Disease 1 0.9960635304450989
families O 0 0.0001952268648892641
. O 0 4.29800566053018e-05

The O 0 0.18992650508880615
Breast B-Disease 1 0.9999998807907104
Cancer I-Disease 1 0.9999991655349731
Linkage O 0 0.019741248339414597
Consortium O 0 0.001668608165346086
. O 0 0.0001523517130408436

The O 0 4.550535959424451e-05
contribution O 0 2.3114133000490256e-05
of O 0 6.698297511320561e-06
BRCA1 O 0 0.0007916733738966286
and O 0 2.6061654352815822e-05
BRCA2 O 1 0.6440044641494751
to O 0 0.00022964461822994053
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 3.4117903851438314e-05
assessed O 0 8.218660696002189e-06
by O 0 2.8109556637900823e-07
linkage O 0 9.158547072729561e-06
and O 0 9.598029464541469e-07
mutation O 0 4.435081336850999e-06
analysis O 0 4.6124657160362403e-07
in O 0 2.923742954408226e-07
237 O 0 1.0811937499966007e-05
families O 0 1.1162059081470943e-06
, O 0 7.060992857077508e-08
each O 0 3.9491055758844595e-08
with O 0 5.626563037708365e-08
at O 0 1.5924490526231239e-07
least O 0 1.2918668801376043e-07
four O 0 3.790335654230148e-07
cases O 0 1.2414150205586338e-06
of O 0 4.88029581902083e-06
breast B-Disease 1 0.9999732971191406
cancer I-Disease 1 0.686610996723175
, O 0 5.564002663049905e-07
collected O 0 6.044704150554026e-07
by O 0 9.945966894520097e-07
the O 0 6.474168912973255e-05
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999995231628418
Linkage O 0 0.0022805973421782255
Consortium O 0 0.0001416043087374419
. O 0 2.5414386982447468e-05

Families O 0 0.00038790874532423913
were O 0 5.29570479557151e-06
included O 0 2.156222308258293e-06
without O 0 9.605960258340929e-07
regard O 0 6.998209869379934e-07
to O 0 2.521491069273907e-07
the O 0 5.045976081419212e-07
occurrence O 0 8.548717232770287e-06
of O 0 8.552672625228297e-06
ovarian B-Disease 1 0.9999406337738037
or I-Disease 0 2.6616904506227e-05
other I-Disease 0 1.2714161130134016e-05
cancers I-Disease 1 0.7538087964057922
. O 0 4.914863166050054e-05

Overall O 1 0.597503662109375
, O 0 0.0005805286346003413
disease O 0 0.02103583514690399
was O 0 6.138821845524944e-06
linked O 0 2.0383584342198446e-05
to O 0 8.544695901946397e-07
BRCA1 O 0 0.00010143696999875829
in O 0 3.1915209319777205e-07
an O 0 2.6365040639575454e-07
estimated O 0 2.110445620928658e-06
52 O 0 8.534925655112602e-06
% O 0 6.440503170779266e-07
of O 0 5.947790171489942e-08
families O 0 6.707475108669314e-07
, O 0 1.3884448435419472e-07
to O 0 2.1098448144130089e-07
BRCA2 O 0 6.125351501395926e-05
in O 0 4.338377834756102e-07
32 O 0 3.6047840694664046e-06
% O 0 5.940975711382634e-07
of O 0 6.885503012199479e-08
families O 0 6.575545512532699e-07
, O 0 8.099066661770848e-08
and O 0 6.286756359941137e-08
to O 0 7.15281558427705e-08
neither O 0 3.347691404087527e-07
gene O 0 4.211047723856609e-07
in O 0 1.53686684711829e-07
16 O 0 2.5505112262180774e-06
% O 0 8.139762712744414e-07
( O 0 2.793294129332935e-07
95 O 0 7.398903676403279e-07
% O 0 1.1508309398777783e-06
confidence O 0 1.0752726211649133e-06
interval O 0 4.5673027671000455e-06
[ O 0 3.6324192933534505e-06
CI O 0 0.00013477643369697034
] O 0 6.938685601198813e-06
6 O 0 2.632695213833358e-06
% O 0 1.4770380403206218e-06
- O 0 1.3911746464145835e-05
28 O 0 6.4676000874897e-06
% O 0 1.0760378472696175e-06
) O 0 2.510530521249166e-07
, O 0 3.1982057180357515e-07
suggesting O 0 2.7896576284547336e-06
other O 0 1.4884324173181085e-06
predisposition O 0 0.0008035746868699789
genes O 0 5.3839015890844166e-05
. O 0 2.5258010282414034e-05

The O 0 5.425029303296469e-05
majority O 0 6.660318467766047e-05
( O 0 7.243535037559923e-06
81 O 0 1.4722292689839378e-05
% O 0 1.4313677638710942e-06
) O 0 1.9465814204977505e-07
of O 0 2.605792701615428e-07
the O 0 1.1393785825930536e-05
breast B-Disease 1 0.9999992847442627
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.894227691285778e-05
were O 0 6.901523761371209e-07
due O 0 1.3721161167268292e-06
to O 0 5.160930527381424e-07
BRCA1 O 0 9.087428770726547e-05
, O 0 2.597154207251151e-07
with O 0 1.464633783143654e-07
most O 0 1.5702322286870185e-07
others O 0 8.338579959854542e-07
( O 0 1.0913686310232151e-06
14 O 0 2.450616420901497e-06
% O 0 1.8556523855295382e-06
) O 0 5.433454361991608e-07
due O 0 1.3060573564871447e-06
to O 0 3.669594434541068e-06
BRCA2 O 0 0.0017385216196998954
. O 0 2.3737429728498682e-05

Conversely O 0 0.0008106877794489264
, O 0 6.643382221227512e-06
the O 0 9.638517894927645e-07
majority O 0 1.059458554664161e-06
of O 0 1.584429440981694e-07
families O 0 7.887418291829817e-07
with O 0 3.87349160746453e-07
male B-Disease 0 2.084128027490806e-05
and I-Disease 0 9.662303455115762e-06
female I-Disease 0 0.3792039752006531
breast I-Disease 1 0.9999971389770508
cancer I-Disease 1 0.9050300717353821
were O 0 1.1608608474489301e-06
due O 0 3.834659764834214e-06
to O 0 3.7133497698960127e-06
BRCA2 O 0 0.011758534237742424
( O 0 1.2662082554015797e-05
76 O 0 0.00010437752644065768
% O 0 1.0266812751069665e-05
) O 0 4.762045591633068e-06
. O 0 8.27548501547426e-06

The O 0 5.9695434174500406e-05
largest O 0 4.675806121667847e-05
proportion O 0 1.8341370378038846e-05
( O 0 4.039976374770049e-06
67 O 0 1.7439528164686635e-05
% O 0 2.079014620903763e-06
) O 0 2.0305938619458175e-07
of O 0 7.599681595138463e-08
families O 0 1.047163436851406e-06
due O 0 3.597300235469447e-07
to O 0 6.857546708260998e-08
other O 0 7.815419422740888e-08
genes O 0 5.949082719780563e-07
was O 0 3.483685020455596e-07
found O 0 1.2368435875487194e-07
in O 0 1.1803282973232854e-07
families O 0 2.690220242129726e-07
with O 0 9.588956118022907e-08
four O 0 5.15195608841168e-07
or O 0 4.4134642962490034e-07
five O 0 7.668012358408305e-07
cases O 0 8.99037786439294e-07
of O 0 1.6930348465393763e-06
female O 0 0.4107035994529724
breast B-Disease 1 0.9999951124191284
cancer I-Disease 1 0.9349595904350281
only O 0 6.824770025559701e-06
. O 0 1.9651681213872507e-05

These O 0 2.7210096959606744e-05
estimates O 0 3.6822562833549455e-05
were O 0 1.5620250906067668e-06
not O 0 4.3856383058482606e-07
substantially O 0 1.3405943718680646e-05
affected O 0 7.628566436324036e-07
either O 0 2.1007515726978454e-07
by O 0 1.3895005679387396e-07
changing O 0 7.007452609286702e-07
the O 0 4.4878382254864846e-07
assumed O 0 6.303894224402029e-06
penetrance O 0 3.2870666473172605e-05
model O 0 2.097735659845057e-06
for O 0 5.764547381659213e-07
BRCA1 O 0 7.638771057827398e-05
or O 0 3.7388099372037686e-07
by O 0 1.8936061962904205e-07
including O 0 6.563822694261034e-07
or O 0 4.5065257836540695e-06
excluding O 0 0.00017750801634974778
BRCA1 O 0 0.021944446489214897
mutation O 0 0.00013011592091061175
data O 0 1.6888252503122203e-05
. O 0 1.9047745809075423e-05

Among O 0 8.248693484347314e-05
those O 0 7.767085662635509e-06
families O 0 2.8858934456366114e-05
with O 0 4.976443960913457e-05
disease O 0 0.08432651311159134
due O 0 7.949605787871405e-06
to O 0 1.5807813724677544e-06
BRCA1 O 0 0.0004587368748616427
that O 0 3.0307043630273256e-07
were O 0 7.90338901879295e-07
tested O 0 1.5666230410715798e-06
by O 0 5.4947140171179853e-08
one O 0 4.0708282966761544e-08
of O 0 4.5573202100968047e-08
the O 0 1.2554659178931615e-07
standard O 0 1.8606691583045176e-06
screening O 0 2.0391764792293543e-06
methods O 0 1.0126852885150583e-06
, O 0 8.205317385545641e-07
mutations O 0 3.6374383398651844e-06
were O 0 1.2497366697061807e-07
detected O 0 5.373298108679592e-07
in O 0 8.07847015948937e-08
the O 0 1.709449009013042e-07
coding O 0 6.598841991944937e-06
sequence O 0 7.808890813976177e-07
or O 0 1.913024334498914e-07
splice O 0 5.993351805955172e-06
sites O 0 3.2357846180275374e-07
in O 0 1.1046614645238151e-07
an O 0 1.6745637765325228e-07
estimated O 0 1.982071808015462e-06
63 O 0 8.116066965158097e-06
% O 0 1.202530143018521e-06
( O 0 3.071938010634767e-07
95 O 0 1.4694846868223976e-06
% O 0 1.9817960037471494e-06
CI O 0 0.000140082323923707
51 O 0 1.4897294022375718e-05
% O 0 3.002762696269201e-06
- O 0 2.7842255803989246e-05
77 O 0 2.047788439085707e-05
% O 0 5.852021786267869e-06
) O 0 4.298017756809713e-06
. O 0 6.34507750874036e-06

The O 0 4.922513835481368e-05
estimated O 0 5.605689875665121e-05
sensitivity O 0 4.156545037403703e-05
was O 0 3.2239549909718335e-06
identical O 0 4.095292297279229e-06
for O 0 2.0536560896289302e-07
direct O 0 6.947863084860728e-07
sequencing O 0 2.2623858058068436e-06
and O 0 3.9732299228489865e-07
other O 0 7.79069637246721e-07
techniques O 0 1.9619921658886597e-05
. O 0 1.8391710909781978e-05

The O 0 8.507574239047244e-05
penetrance O 0 0.0022385292686522007
of O 0 2.1730325897806324e-05
BRCA2 O 0 0.02940412610769272
was O 0 7.124750027287519e-06
estimated O 0 2.1081202703499002e-06
by O 0 3.080278077050025e-07
maximizing O 0 3.293513600510778e-06
the O 0 8.243948173003446e-07
LOD O 0 0.00029666785849258304
score O 0 1.781273567758035e-06
in O 0 1.6685060018062359e-06
BRCA2 O 0 0.0028254997450858355
- O 0 0.005514480639249086
mutation O 0 3.404980816412717e-05
families O 0 8.579530117458489e-07
, O 0 1.828560414196545e-07
over O 0 2.0535229339202488e-07
all O 0 1.9000061968199589e-07
possible O 0 2.5923409339156933e-06
penetrance O 0 0.0002021851687459275
functions O 0 1.1368540071998723e-05
. O 0 1.4469811503659002e-05

The O 0 3.0065855753491633e-05
estimated O 0 3.2985662983264774e-05
cumulative O 0 7.23075499990955e-05
risk O 0 4.232487845001742e-05
of O 0 6.344266694213729e-06
breast B-Disease 1 0.9998565912246704
cancer I-Disease 1 0.7971562743186951
reached O 0 1.1231894859520253e-05
28 O 0 2.5073006327147596e-05
% O 0 1.5790260476933327e-06
( O 0 3.671988793030323e-07
95 O 0 1.5211478512355825e-06
% O 0 2.1680561985704117e-06
CI O 0 8.319442713400349e-05
9 O 0 3.7471916130016325e-06
% O 0 1.0001896271205624e-06
- O 0 6.676396878901869e-06
44 O 0 3.4982713259523734e-06
% O 0 6.962089855733211e-07
) O 0 6.994547874228374e-08
by O 0 5.30667811915464e-08
age O 0 3.08122139358602e-07
50 O 0 2.2953578593387647e-07
years O 0 1.7567060695000691e-07
and O 0 1.686085511209967e-07
84 O 0 5.94610446569277e-06
% O 0 1.095909851756005e-06
( O 0 3.0042156140552834e-07
95 O 0 1.1512865967233665e-06
% O 0 2.0866061731794616e-06
CI O 0 9.248398419003934e-05
43 O 0 9.709745427244343e-06
% O 0 1.4692914191982709e-06
- O 0 6.024290087225381e-06
95 O 0 3.7133497698960127e-06
% O 0 1.1106313877462526e-06
) O 0 2.5501435629848856e-07
by O 0 2.2544526245837915e-07
age O 0 1.5036039258120582e-06
70 O 0 3.347003030285123e-06
years O 0 6.017165560479043e-06
. O 0 1.2511368367995601e-05

The O 0 0.0006757060182280838
corresponding O 1 0.9957348704338074
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.05938791111111641
were O 0 1.7468706573708914e-05
0 O 0 8.599023567512631e-05
. O 0 2.8155885956948623e-05

4 O 0 0.00046636504703201354
% O 0 5.972788858343847e-05
( O 0 5.0510971050243825e-06
95 O 0 7.6045475907449145e-06
% O 0 5.4347106015484314e-06
CI O 0 0.00016646568838041276
0 O 0 5.078905360278441e-06
% O 0 1.815235350477451e-06
- O 0 1.0008156095864251e-05
1 O 0 1.0245744306303095e-06
% O 0 7.039408842501871e-07
) O 0 9.429424352447313e-08
by O 0 4.547707632696074e-08
age O 0 2.641477010456583e-07
50 O 0 1.9915387383662164e-07
years O 0 1.593339220562484e-07
and O 0 1.9530972394932178e-07
27 O 0 5.790864634036552e-06
% O 0 7.384128366538789e-07
( O 0 3.0873130185682385e-07
95 O 0 1.1401417623346788e-06
% O 0 1.3702514252145193e-06
CI O 0 4.6178050979506224e-05
0 O 0 2.7642922759696376e-06
% O 0 1.1597122693274287e-06
- O 0 5.009562755731167e-06
47 O 0 7.758408173685893e-06
% O 0 7.237584895847249e-07
) O 0 1.5510181583522353e-07
by O 0 1.4350291621667566e-07
age O 0 1.5710501202192972e-06
70 O 0 3.6436811114981538e-06
years O 0 5.269895154924598e-06
. O 0 1.1380895557522308e-05

The O 0 6.258361099753529e-05
lifetime O 0 0.00043211213778704405
risk O 0 0.00026096502551808953
of O 0 4.9354348448105156e-05
breast B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9991081357002258
appears O 0 1.4015373380971141e-05
similar O 0 9.441929478271049e-07
to O 0 3.2118623494170606e-07
the O 0 8.402977869081951e-07
risk O 0 7.718924280197825e-06
in O 0 1.2452259170459001e-06
BRCA1 O 0 0.0007089234422892332
carriers O 0 7.183466095739277e-06
, O 0 2.0158987013019214e-07
but O 0 9.29675465499713e-08
there O 0 4.977220058322018e-08
was O 0 1.5722942237061943e-07
some O 0 3.7466765689941894e-08
suggestion O 0 2.2326392468130507e-07
of O 0 7.693372339190319e-08
a O 0 4.440143129613716e-06
lower O 0 0.0001661358546698466
risk O 0 1.108401920646429e-05
in O 0 1.3201755564296036e-06
BRCA2 O 0 0.00043746992014348507
carriers O 0 8.04937462817179e-06
< O 0 1.3399859199125785e-05
50 O 0 8.384126886085141e-07
years O 0 3.4788445191225037e-07
of O 0 7.099581580405356e-07
age O 0 7.805698260199279e-06
. O 0 8.967797839432023e-06

Eye B-Disease 1 0.8560858368873596
movement I-Disease 0 0.0936044454574585
abnormalities I-Disease 1 0.9960619807243347
correlate O 0 0.0003645606921054423
with O 0 3.336826921440661e-05
genotype O 0 0.06416311115026474
in O 0 9.062420576810837e-05
autosomal O 1 0.997143566608429
dominant O 1 0.766676127910614
cerebellar B-Disease 1 0.9999902248382568
ataxia I-Disease 1 0.9999983310699463
type I-Disease 0 0.005688527598977089
I I-Disease 0 9.726017015054822e-05
. O 0 4.984664701623842e-05

We O 0 5.871806206414476e-05
compared O 0 5.8384841395309195e-05
horizontal O 0 0.0001683516602497548
eye O 0 0.00035567671875469387
movements O 0 2.0032390239066444e-05
( O 0 3.348794052726589e-06
visually O 0 6.970867161726346e-06
guided O 0 7.776008715154603e-06
saccades O 0 0.0006684496765956283
, O 0 1.066845811692474e-06
antisaccades O 0 7.08001825842075e-05
, O 0 2.2558700152330857e-07
and O 0 1.7377703898091568e-07
smooth O 0 6.668162768619368e-06
pursuit O 0 3.628971899161115e-05
) O 0 4.282790939669212e-07
in O 0 2.0247057364031207e-07
control O 0 1.9983262973255478e-06
subjects O 0 1.4571844531019451e-06
( O 0 1.2110084526284481e-06
n O 0 1.3353654139791615e-05
= O 0 3.1966166716301814e-05
14 O 0 1.3848493836121634e-06
) O 0 2.5263292968702444e-07
and O 0 3.5768911743616627e-07
patients O 0 3.947632649214938e-06
with O 0 1.4327291353311011e-07
three O 0 3.5843694945469906e-07
forms O 0 1.1333964948789799e-06
of O 0 2.8949286843271693e-06
autosomal O 0 0.12124648690223694
dominant O 0 0.00035604971344582736
cerebellar B-Disease 1 0.5992792844772339
ataxias I-Disease 0 0.04901183396577835
type I-Disease 0 1.8803695638780482e-05
I I-Disease 0 4.439838448888622e-06
spinocerebellar B-Disease 0 0.01056269183754921
ataxias I-Disease 0 0.00038647878682240844
1 I-Disease 0 2.5159956749121193e-06
and I-Disease 0 4.442157433004468e-07
2 I-Disease 0 1.7521160771138966e-06
( O 0 1.3114167813910171e-06
SCA1 B-Disease 0 3.9192418626043946e-05
, O 0 5.740754431826645e-07
n O 0 6.4150840444199275e-06
= O 0 9.767232768354006e-06
11 O 0 1.119121066039952e-06
; O 0 8.57953807553713e-07
SCA2 B-Disease 0 2.4594462956883945e-05
, O 0 5.812619860989798e-07
n O 0 5.995175797579577e-06
= O 0 7.0020078055677e-06
10 O 0 4.0570003534412535e-07
) O 0 2.7584198392105463e-07
and O 0 5.572716759161267e-07
SCA3 B-Disease 1 0.9931723475456238
/ O 0 0.0009044238831847906
Machado B-Disease 0 0.00014377881598193198
- I-Disease 0 0.0010868820827454329
Joseph I-Disease 0 0.0034716553054749966
disease I-Disease 0 0.0007019978365860879
( O 0 8.269450518127996e-06
MJD B-Disease 1 0.988195538520813
) O 0 3.2396767437603557e-06
( O 0 3.3860330859170062e-06
n O 0 2.38887187151704e-05
= O 0 5.6937111367005855e-05
16 O 0 7.72148632677272e-06
) O 0 5.2356058404257055e-06
. O 0 8.440311830781866e-06

In O 0 0.00010384509369032457
SCA1 B-Disease 0 0.0018408815376460552
, O 0 1.0113715688930824e-05
saccade O 0 0.0003012541274074465
amplitude O 0 3.916940477211028e-05
was O 0 3.427907358855009e-06
significantly O 0 1.072329996532062e-05
increased O 0 2.8827350888604997e-06
, O 0 9.998882433137624e-07
resulting O 0 5.961332590231905e-06
in O 0 3.6016983813169645e-06
hypermetria B-Disease 0 0.0008494107751175761
. O 0 3.524989733705297e-05

The O 0 7.978241774253547e-05
smooth O 0 0.0002993487869389355
pursuit O 0 0.0005052722408436239
gain O 0 0.0004559628141578287
was O 0 5.6092827435350046e-05
decreased O 0 0.0006266541313380003
. O 0 4.975105548510328e-05

In O 0 0.0001651885686442256
SCA2 B-Disease 0 0.001889083650894463
, O 0 2.536131432862021e-05
saccade O 0 0.0006445561302825809
velocity O 0 0.00014217513671610504
was O 0 2.8463246053433977e-05
markedly O 0 0.0010062744840979576
decreased O 0 0.0003303123521618545
. O 0 3.3708343835314736e-05

The O 0 2.3981299818842672e-05
percentage O 0 6.661436782451347e-05
of O 0 1.5143780274229357e-06
errors O 0 1.3865403161616996e-05
in O 0 1.6435486713817227e-06
antisaccades O 0 0.0005693212151527405
was O 0 1.9182580217602663e-06
greatly O 0 1.2910334135085577e-06
increased O 0 1.073885073310521e-06
and O 0 2.611101308502839e-07
was O 0 1.3965176322017214e-06
significantly O 0 5.165409675100818e-06
correlated O 0 4.94875939693884e-06
with O 0 1.005854414870555e-06
age O 0 4.488097329158336e-05
at O 0 8.88940630829893e-05
disease O 0 0.19830717146396637
onset O 1 0.9603023529052734
. O 0 8.162471931427717e-05

In O 0 2.609259172459133e-05
addition O 0 5.365850483940449e-06
, O 0 8.310436214742367e-07
a O 0 8.860310458658205e-07
correlation O 0 1.8116486444341717e-06
between O 0 5.2154553031869e-07
smooth O 0 6.065439265512396e-06
pursuit O 0 4.881107815890573e-05
gain O 0 9.689385478850454e-06
and O 0 1.3226943451627449e-07
the O 0 1.4121722813342785e-07
number O 0 1.810987129147179e-07
of O 0 5.217574425842031e-07
trinucleotide O 0 0.0017007241258397698
repeats O 0 6.679036596324295e-05
was O 0 4.639236067305319e-06
found O 0 5.6581552598800045e-06
. O 0 1.1804327186837327e-05

In O 0 0.0001539255172247067
SCA3 B-Disease 1 0.9759460687637329
, O 0 9.737090294947848e-06
gaze B-Disease 0 0.00016346998745575547
- I-Disease 0 0.000339525198796764
evoked I-Disease 0 0.0004666580935008824
nystagmus I-Disease 1 0.5554448962211609
was O 0 8.148429515131284e-06
often O 0 8.098191983663128e-07
present O 0 3.327047863876942e-07
as O 0 1.7490198445102578e-07
was O 0 1.186910708383948e-06
saccade O 0 6.164743535919115e-05
hypometria O 0 3.904934783349745e-05
and O 0 5.518681973626371e-07
smooth O 0 1.4429668226512149e-05
pursuit O 0 6.964619387872517e-05
gain O 0 6.342056440189481e-05
was O 0 1.1607497071963735e-05
markedly O 0 0.0007739069405943155
decreased O 0 0.0003110010293312371
. O 0 3.0152628823998384e-05

Three O 0 6.932018732186407e-05
major O 0 2.4566355932620354e-05
criteria O 0 1.047327805281384e-05
, O 0 2.5202798497048207e-06
saccade O 0 0.00010748066415544599
amplitude O 0 9.912153473123908e-06
, O 0 7.569560693809763e-07
saccade O 0 3.4728680475382134e-05
velocity O 0 4.46023386757588e-06
, O 0 2.0567411240790534e-07
and O 0 7.8199221320574e-08
presence O 0 3.4791034408954147e-07
of O 0 1.8954148117700242e-07
gaze B-Disease 0 2.629472510307096e-05
- I-Disease 0 9.80522672762163e-05
evoked I-Disease 0 7.093871681718156e-05
nystagmus I-Disease 0 0.0013431496918201447
, O 0 4.248919083238434e-07
permitted O 0 3.9393563611156424e-07
the O 0 1.5879115267125599e-07
correct O 0 2.6723182600107975e-06
assignment O 0 1.5713183074694825e-06
of O 0 1.1599872351553131e-07
90 O 0 4.895688334727311e-07
% O 0 2.5288747451668314e-07
of O 0 4.636660833057249e-08
the O 0 1.816712824620481e-07
SCA1 B-Disease 0 0.00011072176857851446
, O 0 1.6955864623469097e-07
90 O 0 4.5136945914237003e-07
% O 0 1.7689380626961793e-07
of O 0 3.049049013270633e-08
the O 0 1.1486311279895745e-07
SCA2 B-Disease 0 0.00011338543117744848
, O 0 1.431996992096174e-07
and O 0 1.7348395431326935e-07
93 O 0 4.161803644819884e-06
% O 0 5.980746209388599e-07
of O 0 7.162740445210147e-08
the O 0 4.889188289780577e-07
patients O 0 1.8100519810104743e-05
with O 0 8.029977038859215e-07
SCA3 B-Disease 1 0.9996333122253418
to O 0 3.6684079418591864e-07
their O 0 3.0283524665719597e-07
genetically O 0 8.676195648149587e-06
confirmed O 0 5.054364464740502e-06
patient O 0 1.9633624106063507e-05
group O 0 1.3799924545310205e-06
and O 0 1.844333183953495e-07
, O 0 3.0409069040615577e-07
therefore O 0 3.3244469932469656e-07
, O 0 2.1132882466190495e-07
may O 0 4.4809101495957293e-07
help O 0 5.21108972861839e-07
orient O 0 1.8746579371509142e-05
diagnoses O 0 0.00011202367750229314
of O 0 5.07667493820918e-07
SCA1 B-Disease 0 0.0032510031014680862
, O 0 8.9956091642307e-07
SCA2 B-Disease 0 0.00013796369603369385
, O 0 2.6469896852177044e-07
and O 0 4.619768958491477e-07
SCA3 B-Disease 1 0.9826149940490723
at O 0 1.3243821967989788e-06
early O 0 2.2789711238146992e-06
clinical O 0 2.9306227588676848e-05
stages O 0 5.814754331368022e-06
of O 0 7.009524551904178e-07
the O 0 1.9191225874237716e-05
diseases O 0 0.06628843396902084
. O 0 4.280012490198715e-06
. O 0 1.579346280777827e-05

Genetic O 0 0.0008609005599282682
basis O 0 3.854995884466916e-05
and O 0 7.505559096898651e-06
molecular O 0 7.057334732962772e-05
mechanism O 0 0.0001421984488843009
for O 0 0.0002545041497796774
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 0 0.0012582384515553713

Ventricular B-Disease 1 0.9999915361404419
fibrillation I-Disease 1 0.999997615814209
causes O 0 0.001952934660948813
more O 0 5.3955504881741945e-06
than O 0 1.1335143881296972e-06
300 O 0 1.918973566716886e-06
, O 0 6.280380375756067e-07
000 O 0 3.583871148293838e-06
sudden O 0 2.8682758056675084e-05
deaths O 0 7.869950422900729e-06
each O 0 2.149181455024518e-07
year O 0 6.966347427805886e-07
in O 0 3.133195605187211e-07
the O 0 1.1714148513419786e-06
USA O 0 2.659117672010325e-05
alone O 0 1.4748542525921948e-05
. O 0 1.2761099242197815e-05

In O 0 2.7118370780954137e-05
approximately O 0 8.991904905997217e-06
5 O 0 7.134187399060465e-06
- O 0 3.9457860111724585e-05
12 O 0 5.913311269978294e-06
% O 0 1.0960384315694682e-06
of O 0 8.276484209090995e-08
these O 0 9.324546113020915e-08
cases O 0 3.179948464548943e-07
, O 0 8.557828579114357e-08
there O 0 5.300588412637808e-08
are O 0 5.906132116706431e-08
no O 0 6.600249093935417e-07
demonstrable O 0 0.017606575042009354
cardiac O 1 0.9998273253440857
or O 0 2.927929745055735e-05
non O 0 0.00010007602395489812
- O 1 0.8348006010055542
cardiac O 1 0.9999657869338989
causes O 0 1.8721746528171934e-05
to O 0 1.484121696648799e-07
account O 0 1.8707419258134905e-07
for O 0 5.97733560425695e-08
the O 0 1.1417484557796342e-07
episode O 0 1.364698391626007e-06
, O 0 1.5876450731866498e-07
which O 0 1.1722445947270899e-07
is O 0 1.3551061783800833e-07
therefore O 0 4.771878820974962e-07
classified O 0 9.325075552624185e-06
as O 0 3.703449328895658e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 0 0.2004086971282959
IVF B-Disease 1 0.9999997615814209
) O 0 7.288213237188756e-05
. O 0 2.96326707029948e-05

A O 0 0.0002454087953083217
distinct O 0 9.642149234423414e-05
group O 0 2.1040525098214857e-05
of O 0 7.476861355826259e-06
IVF B-Disease 1 1.0
patients O 1 0.6469889283180237
has O 0 2.082425908156438e-06
been O 0 3.9533568951810594e-07
found O 0 2.3511445590429503e-07
to O 0 8.587161914874741e-08
present O 0 1.9875051293638535e-07
with O 0 2.841333355263487e-07
a O 0 6.873227448522812e-06
characteristic O 0 8.483238343615085e-05
electrocardiographic O 0 0.014631067402660847
pattern O 0 0.00036701367935165763
. O 0 2.5910194381140172e-05

Because O 0 1.813663220673334e-05
of O 0 1.2679704468609998e-06
the O 0 4.891063554168795e-07
small O 0 3.749150323528738e-07
size O 0 3.7640970163010934e-07
of O 0 1.1787376763550128e-07
most O 0 1.4275926218942914e-07
pedigrees O 0 2.879709654735052e-06
and O 0 1.722439009199661e-07
the O 0 2.0187343352517928e-07
high O 0 6.620026397285983e-06
incidence O 0 0.00044426240492612123
of O 0 7.805689392625936e-07
sudden B-Disease 0 0.0015057579148560762
death I-Disease 0 2.3279382730834186e-05
, O 0 3.6229394595466147e-07
however O 0 2.1401086769401445e-07
, O 0 2.417463917936402e-07
molecular O 0 4.035474830743624e-06
genetic O 0 3.2383238703914685e-06
studies O 0 6.030861641193042e-07
of O 0 4.489113791805721e-07
IVF B-Disease 1 0.9999942779541016
have O 0 1.7342485989502165e-06
not O 0 2.83542675560966e-07
yet O 0 1.0963843806166551e-06
been O 0 1.2786894103555824e-06
done O 0 6.019053671479924e-06
. O 0 1.6115018297568895e-05

Because O 0 0.0012711719609797
IVF B-Disease 1 0.9999964237213135
causes O 0 0.4714214503765106
cardiac O 1 0.9999877214431763
rhythm O 1 0.8872629404067993
disturbance O 0 0.006819671485573053
, O 0 3.435624648773228e-06
we O 0 7.041691674203321e-07
investigated O 0 4.343339242041111e-06
whether O 0 6.525102662635618e-07
malfunction O 0 5.927763777435757e-05
of O 0 3.986415606505034e-07
ion O 0 8.730744411877822e-06
channels O 0 2.0856873561569955e-06
could O 0 9.451388223169488e-07
cause O 0 4.350286872067954e-06
the O 0 1.760527766236919e-06
disorder O 0 0.17928335070610046
by O 0 3.7228844007586304e-07
studying O 0 2.5298663786088582e-06
mutations O 0 5.434073045762489e-06
in O 0 3.621968573952472e-07
the O 0 2.181905529141659e-06
cardiac O 1 0.6465582251548767
sodium O 0 0.00021640390332322568
channel O 0 6.61258163745515e-05
gene O 0 4.550492303678766e-05
SCN5A O 0 0.000774806016124785
. O 0 6.396562093868852e-05

We O 0 3.03364413412055e-05
have O 0 3.113072352789459e-06
now O 0 1.744074097587145e-06
identified O 0 3.2429659313493175e-06
a O 0 5.616030193777988e-06
missense O 0 0.000494912383146584
mutation O 0 8.700340913492255e-06
, O 0 2.5548024495947175e-07
a O 0 1.1254282981099095e-06
splice O 0 0.00022065304801799357
- O 0 0.00033323271782137454
donor O 0 3.276738789281808e-05
mutation O 0 9.882261110760737e-06
, O 0 2.126562890225614e-07
and O 0 4.2586063386806927e-07
a O 0 1.4035745152796153e-05
frameshift O 0 0.1179494708776474
mutation O 0 7.4700051300169434e-06
in O 0 1.7535292329284857e-07
the O 0 2.96348702022442e-07
coding O 0 1.655609958106652e-05
region O 0 2.097995775329764e-06
of O 0 4.3902204538426304e-07
SCN5A O 0 0.0003119328757748008
in O 0 2.014114670600975e-06
three O 0 1.3929256056144368e-05
IVF B-Disease 1 0.9999986886978149
families O 0 0.0001942698290804401
. O 0 2.7237101676291786e-05

We O 0 2.827023490681313e-05
show O 0 7.259814992721658e-06
that O 0 9.325486303168873e-07
sodium O 0 5.127118583914125e-06
channels O 0 8.96647122772265e-07
with O 0 2.195796184878418e-07
the O 0 8.282221983790805e-07
missense O 0 0.00017000120715238154
mutation O 0 2.1939591533737257e-05
recover O 0 1.2558048183564097e-05
from O 0 4.877610990661196e-07
inactivation O 0 0.00010073455632664263
more O 0 2.037950395106236e-07
rapidly O 0 1.0429932899569394e-06
than O 0 1.0470380118476896e-07
normal O 0 3.986255876498035e-07
and O 0 1.1891523854501429e-07
that O 0 9.666984368550402e-08
the O 0 7.568954742964706e-07
frameshift O 0 0.01555602066218853
mutation O 0 1.7294347344432026e-05
causes O 0 1.0128262601938331e-06
the O 0 2.7967834625997057e-07
sodium O 0 3.574037691578269e-06
channel O 0 1.1961888048972469e-06
to O 0 1.500458068903754e-07
be O 0 2.540225807479146e-07
non O 0 3.6635065043810755e-06
- O 0 4.255564999766648e-05
functional O 0 5.0625203584786505e-05
. O 0 1.5617850294802338e-05

Our O 0 0.00013345677871257067
results O 0 4.029597039334476e-05
indicate O 0 1.0375595593359321e-05
that O 0 1.0799898291224963e-06
mutations O 0 1.0668932191038039e-05
in O 0 1.1658112271106802e-06
cardiac O 0 0.15888282656669617
ion O 0 4.368539521237835e-05
- O 0 2.5187537175952457e-05
channel O 0 4.101601007278077e-06
genes O 0 8.286243655675207e-07
contribute O 0 2.439307138502045e-07
to O 0 9.83633086093505e-08
the O 0 3.206549479273235e-07
risk O 0 2.9616328447445994e-06
of O 0 8.325389444507891e-07
developing O 0 3.6519682907965034e-05
IVF B-Disease 1 0.9999922513961792
. O 0 1.136253649747232e-05
. O 0 1.8841410565073602e-05

Molecular O 0 0.0009713516919873655
heterogeneity O 0 0.0013723999727517366
in O 0 4.06543149438221e-05
mucopolysaccharidosis B-Disease 0 0.01051766611635685
IVA I-Disease 1 0.6153975129127502
in O 0 6.748694431735203e-06
Australia O 0 1.3038347788096871e-06
and O 0 3.8817381664557615e-07
Northern O 0 1.563014507155458e-06
Ireland O 0 1.595016101418878e-06
: O 0 4.864918992097955e-07
nine O 0 1.0877744216486462e-06
novel O 0 2.6823349799087737e-06
mutations O 0 5.564513685385464e-06
including O 0 4.1397564132239495e-07
T312S O 0 6.816574750700966e-05
, O 0 2.5086541199925705e-07
a O 0 8.26951520593866e-07
common O 0 2.034483486568206e-06
allele O 0 9.200891327054705e-06
that O 0 5.613987354990968e-07
confers O 0 3.434452446526848e-05
a O 0 8.207483915612102e-05
mild O 1 0.9791258573532104
phenotype O 1 0.9513670802116394
. O 0 4.3092015403090045e-05

Mucopolysaccharidosis B-Disease 1 0.9405936002731323
IVA I-Disease 1 0.9996514320373535
( O 0 0.0037392997182905674
MPS B-Disease 1 0.9985172152519226
IVA I-Disease 1 0.9999967813491821
) O 0 2.997441879415419e-05
is O 0 2.946925633295905e-06
an O 0 2.4909177227527834e-05
autosomal B-Disease 1 0.9998737573623657
recessive I-Disease 1 0.9999912977218628
lysosomal I-Disease 1 0.9999992847442627
storage I-Disease 1 0.9998733997344971
disorder I-Disease 1 0.9999970197677612
caused O 0 0.0001268798514502123
by O 0 1.701886617411219e-06
a O 0 0.00021280007786117494
genetic B-Disease 1 0.9966013431549072
defect I-Disease 1 0.9879485368728638
in O 0 5.482243068399839e-06
N O 0 0.0001403553324053064
- O 0 6.099564416217618e-05
acetylgalactosamine O 0 0.0002721977070905268
- O 0 0.0001403036731062457
6 O 0 4.4348133087623864e-05
- O 0 0.0005782262305729091
sulfate O 0 0.0017211663071066141
sulfatase O 0 0.003492602612823248
( O 0 1.502095165051287e-05
GALNS O 0 0.0005460604443214834
) O 0 1.294277171837166e-05
. O 0 1.6064184819697402e-05

Previous O 0 0.00017360040510538965
studies O 0 3.14071548928041e-05
of O 0 3.926827503164532e-06
patients O 0 9.097123256651685e-05
from O 0 5.114198415867577e-07
a O 0 1.9976193925685948e-06
British O 0 8.31622128316667e-06
- O 0 8.131877984851599e-05
Irish O 0 1.4370329154189676e-05
population O 0 1.0625751656334614e-06
showed O 0 7.072738981150906e-07
that O 0 5.916651701909359e-08
the O 0 2.655064861301071e-07
I113F O 0 0.00035673737875185907
mutation O 0 4.1270618567068595e-06
is O 0 7.22504793770895e-08
the O 0 7.556017322940534e-08
most O 0 1.2212780120535172e-07
common O 0 1.170160999208747e-06
single O 0 1.010582855087705e-05
mutation O 0 3.883155295625329e-05
among O 0 4.899723080598051e-06
MPS B-Disease 1 0.9973055124282837
IVA I-Disease 1 1.0
patients O 0 0.17521658539772034
and O 0 4.1012958718056325e-06
produces O 0 1.2705094377452042e-05
a O 0 8.920707477955148e-05
severe O 1 0.9958308339118958
clinical O 1 0.9870016574859619
phenotype O 1 0.9794889688491821
. O 0 4.715556133305654e-05

We O 0 4.823332710657269e-05
studied O 0 4.7494046157225966e-05
mutations O 0 4.050648203701712e-05
in O 0 6.073642566661874e-07
the O 0 6.534169756378105e-07
GALNS O 0 0.00016968946147244424
gene O 0 2.3633160708413925e-06
from O 0 4.5448982177731523e-07
23 O 0 5.981076355965342e-06
additional O 0 8.951554264058359e-06
MPS B-Disease 1 0.9993380904197693
IVA I-Disease 1 1.0
patients O 0 0.3552102744579315
( O 0 2.140434389730217e-06
15 O 0 5.545800263462297e-07
from O 0 1.3435032997222152e-07
Australia O 0 9.952354673714581e-08
, O 0 6.041245370624893e-08
8 O 0 2.19673665924347e-07
from O 0 6.286073528372071e-08
Northern O 0 3.159890411552624e-07
Ireland O 0 2.971320327560534e-07
) O 0 9.87418999898182e-08
, O 0 4.547551668565575e-08
with O 0 9.056797267703587e-08
various O 0 6.12180485859426e-07
clinical O 0 0.025882985442876816
phenotypes O 1 0.6654853224754333
( O 0 2.09378977160668e-05
severe O 0 0.026621609926223755
, O 0 1.1955547734032734e-06
16 O 0 5.445818260341184e-06
cases O 0 7.064501232889597e-07
; O 0 8.734040193303372e-07
intermediate O 0 1.1132228792121168e-06
, O 0 2.2762878870707937e-07
4 O 0 3.140649823762942e-06
cases O 0 1.175641841655306e-06
; O 0 6.355457571771694e-06
mild O 0 0.010536987334489822
, O 0 1.4209779237717157e-06
3 O 0 7.318889856833266e-06
cases O 0 3.879957148456015e-06
) O 0 4.269441433280008e-06
. O 0 1.0655854566721246e-05

We O 0 2.0970412151655182e-05
found O 0 4.24964628109592e-06
two O 0 1.6492655277033919e-06
common O 0 7.828883099136874e-06
mutations O 0 7.165888291638112e-06
that O 0 1.252951733476948e-07
together O 0 3.9438970134142437e-07
accounted O 0 1.5985002619345323e-06
for O 0 2.0257003541246377e-07
32 O 0 2.3788848011463415e-06
% O 0 3.8222901821427513e-07
of O 0 5.215425247229177e-08
the O 0 2.5304669293291226e-07
44 O 0 4.8287538447766565e-06
unrelated O 0 1.742534732329659e-05
alleles O 0 9.416584362043068e-06
in O 0 1.2597058685059892e-06
these O 0 3.824995474133175e-06
patients O 0 0.00023064017295837402
. O 0 2.1733578250859864e-05

One O 0 2.5963865482481197e-05
is O 0 4.933609943691408e-06
the O 0 3.232381232010084e-06
T312S O 0 0.0006766336155124009
mutation O 0 3.154953083139844e-05
, O 0 4.919393177260645e-07
a O 0 1.3961328022560338e-06
novel O 0 6.551924343511928e-06
mutation O 0 1.285871894651791e-05
found O 0 9.58823989094526e-07
exclusively O 0 3.0866024189890595e-06
in O 0 6.396671324182535e-06
milder O 1 0.6259447932243347
patients O 0 0.015901047736406326
. O 0 4.400697798701003e-05

The O 0 1.6186748325708322e-05
other O 0 1.3387253829932888e-06
is O 0 5.455188443193038e-07
the O 0 6.957981213417952e-07
previously O 0 4.368192094261758e-06
described O 0 5.938618414802477e-06
I113F O 0 8.88272188603878e-05
that O 0 6.668167884527065e-07
produces O 0 8.034419806790538e-06
a O 0 4.139393422519788e-05
severe O 1 0.9898549318313599
phenotype O 1 0.9908012747764587
. O 0 7.683033618377522e-05

The O 0 5.399933797889389e-05
I113F O 0 0.0006032793899066746
and O 0 1.4183597158989869e-05
T312S O 0 0.0012060949811711907
mutations O 0 6.582885544048622e-05
accounted O 0 4.9210161705559585e-06
for O 0 4.27447503170697e-07
8 O 0 4.1001540012075566e-06
( O 0 7.655210652046662e-07
18 O 0 1.4635827483289177e-06
% O 0 4.23390446258054e-07
) O 0 1.0453738497062659e-07
and O 0 9.946851520226119e-08
6 O 0 2.357103539907257e-06
( O 0 3.670185719784058e-07
14 O 0 5.957911639598024e-07
% O 0 3.4614438959579275e-07
) O 0 9.830367275753815e-08
of O 0 1.1543150435500138e-07
44 O 0 3.690381390697439e-06
unrelated O 0 1.962388887477573e-05
alleles O 0 2.3928161681396887e-05
, O 0 2.458786411807523e-06
respectively O 0 1.6115587641252205e-05
. O 0 9.801637133932672e-06

The O 0 3.755323268705979e-05
relatively O 0 2.4523824322386645e-05
high O 0 8.718381650396623e-06
residual O 0 5.115700696478598e-05
GALNS O 0 0.000748910941183567
activity O 0 5.6170047173509374e-06
seen O 0 1.1806744169007288e-06
when O 0 3.0744175205654756e-07
the O 0 3.797644012593082e-07
T312S O 0 1.6285719539155252e-05
mutant O 0 1.4948044736229349e-05
cDNA O 0 8.549181984562892e-06
is O 0 6.202229201335285e-07
overexpressed O 0 1.4440350241784472e-05
in O 0 6.457779022639443e-07
mutant O 0 9.630662680137902e-05
cells O 0 3.1395118185173487e-06
provides O 0 3.5474653259370825e-07
an O 0 8.925454864083804e-08
explanation O 0 4.1317031218568445e-07
for O 0 1.9468433265501517e-07
the O 0 3.4500942547310842e-06
mild O 1 0.9855170845985413
phenotype O 1 0.9963047504425049
in O 0 1.7766298697097227e-05
patients O 0 0.0001584641431691125
with O 0 1.5750059674246586e-06
this O 0 6.131724603619659e-06
mutation O 0 0.00021256363834254444
. O 0 2.3581205823575146e-05

The O 0 1.7557562387082726e-05
distribution O 0 9.294285518990364e-06
and O 0 8.349521749551059e-07
relative O 0 1.9598119251895696e-06
frequencies O 0 1.0490585964362253e-06
of O 0 9.720232441168264e-08
the O 0 2.8809407126573205e-07
I113F O 0 2.6244822947774082e-05
and O 0 9.95615891952184e-07
T312S O 0 0.00015307572903111577
mutations O 0 4.130089564569062e-06
in O 0 1.484154381614644e-07
Australia O 0 2.460296570916398e-07
corresponded O 0 7.254446927618119e-07
to O 0 8.865055178830517e-08
those O 0 1.1848845815620734e-07
observed O 0 4.069299279763072e-07
in O 0 6.768726734662778e-08
Northern O 0 4.385274223750457e-07
Ireland O 0 4.999407678951684e-07
and O 0 8.917474048075746e-08
are O 0 2.3797797510383134e-08
unique O 0 8.730412304203128e-08
to O 0 4.082000870653246e-08
these O 0 2.172176927217606e-08
two O 0 1.1563930968350178e-07
populations O 0 1.589841872373654e-06
, O 0 1.7066700763734843e-07
suggesting O 0 5.596165806309727e-07
that O 0 4.6836809985961736e-08
both O 0 1.9893634828349605e-07
mutations O 0 5.22594336871407e-06
were O 0 1.636078224009907e-07
probably O 0 2.2565305357602483e-07
introduced O 0 2.994932799538219e-07
to O 0 5.992438190105531e-08
Australia O 0 9.175501958225141e-08
by O 0 7.496115017602278e-08
Irish O 0 1.6194431964322575e-06
migrants O 0 1.1898619050043635e-06
during O 0 4.6074012516328366e-07
the O 0 3.986483818607667e-07
19th O 0 8.119705853459891e-06
century O 0 1.4398849998542573e-05
. O 0 1.369773963233456e-05

Haplotype O 0 0.005960345268249512
analysis O 0 8.421362872468308e-05
using O 0 1.3559192666434683e-05
6 O 0 3.2379037293139845e-05
RFLPs O 0 0.00011995103704975918
provides O 0 2.7586720534600317e-06
additional O 0 9.72087832451507e-07
data O 0 6.215540224729921e-07
that O 0 1.054708818060135e-07
the O 0 4.4608449911720527e-07
I113F O 0 0.00015238441119436175
mutation O 0 6.4896512412815355e-06
originated O 0 9.416759212399484e-07
from O 0 2.5895761268657225e-07
a O 0 1.180442382064939e-06
common O 0 5.127211807121057e-06
ancestor O 0 3.149248368572444e-05
. O 0 1.2376036465866491e-05

The O 0 2.9499029551516287e-05
other O 0 4.349444679974113e-06
9 O 0 2.0300982214394026e-05
novel O 0 2.206351018685382e-05
mutations O 0 3.5371293051866814e-05
identified O 0 1.2751700069202343e-06
in O 0 3.1385428655994474e-07
these O 0 2.513017136607232e-07
23 O 0 5.198833969188854e-05
patients O 0 1.551245804876089e-05
were O 0 8.653025673766024e-08
each O 0 6.93705857202076e-08
limited O 0 2.189527350537901e-07
to O 0 1.6719467055281712e-07
a O 0 1.34410981900146e-06
single O 0 6.412924903997919e-06
family O 0 1.5738283764221705e-05
. O 0 1.3831949218001682e-05

These O 0 1.5694577086833306e-05
data O 0 8.60907221067464e-06
provide O 0 2.0314048470027046e-06
further O 0 1.1158706456626533e-06
evidence O 0 7.349765951403242e-07
for O 0 4.0862940409169823e-07
extensive O 0 5.747087925556116e-06
allelic O 0 0.00024100496375467628
heterogeneity O 0 0.00025185346021316946
in O 0 6.693744126096135e-06
MPS B-Disease 1 0.5894190073013306
IVA I-Disease 1 0.9998968839645386
in O 0 7.594748694828013e-06
British O 0 4.16714210587088e-05
- O 0 0.06114700064063072
Irish O 0 0.0067835161462426186
patients O 0 7.676098903175443e-05
and O 0 2.915940342518297e-07
provide O 0 3.30178011154203e-07
evidence O 0 1.542118468478293e-07
for O 0 5.5101416762681765e-08
their O 0 2.069577504926201e-07
transmission O 0 9.718647561385296e-06
to O 0 1.0229200597677846e-07
Australia O 0 1.7653786699156626e-07
by O 0 1.3229087869603973e-07
British O 0 2.23156098400068e-06
- O 0 4.1286075429525226e-05
Irish O 0 1.243780025106389e-05
migrants O 0 9.356289410789032e-06
. O 0 2.6208185772702564e-06
. O 0 1.0862974704650696e-05

Identification O 0 0.0001999837113544345
of O 0 3.186065441695973e-05
constitutional O 0 0.0004449615371413529
WT1 O 1 0.9080770611763
mutations O 0 0.000591974298004061
, O 0 2.6145226001972333e-06
in O 0 3.99309965359862e-06
patients O 0 0.00010218695388175547
with O 0 6.760134965588804e-06
isolated O 0 0.04282183572649956
diffuse B-Disease 1 0.9999452829360962
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 2.5953415843105176e-06
and O 0 4.310794849970989e-07
analysis O 0 1.1870805565195042e-06
of O 0 1.4332158571050968e-06
genotype O 0 0.062026247382164
/ O 0 0.07683932036161423
phenotype O 0 0.008613495156168938
correlations O 0 6.104069143475499e-06
by O 0 1.6631301491543127e-07
use O 0 2.631831534927187e-07
of O 0 3.3378978514519986e-07
a O 0 5.097723715152824e-06
computerized O 0 0.0008244016207754612
mutation O 0 9.973809937946498e-05
database O 0 2.1960504454909824e-05
. O 0 1.3712548025068827e-05

Constitutional O 0 0.0009278612560592592
mutations O 0 0.00020804149971809238
of O 0 3.38797144650016e-06
the O 0 4.053762040712172e-06
WT1 O 0 0.0010464435908943415
gene O 0 1.1360088137735147e-05
, O 0 8.078568498604e-07
encoding O 0 3.7034226352261612e-06
a O 0 4.459443061932689e-06
zinc O 0 0.00017014473269227892
- O 0 2.7745905754272826e-05
finger O 0 2.0624169337679632e-05
transcription O 0 5.707319814973744e-06
factor O 0 1.2361070957922493e-06
involved O 0 9.105058325076243e-07
in O 0 2.9661355256394017e-06
renal O 1 0.9981613755226135
and O 0 9.377056812809315e-06
gonadal O 1 0.9021769165992737
development O 0 2.9281311526574427e-06
, O 0 2.0660201016653446e-07
are O 0 4.2276983691635905e-08
found O 0 1.8796120571096253e-07
in O 0 3.876876917274785e-07
most O 0 8.805648690213275e-07
patients O 0 3.757433296414092e-05
with O 0 9.766459697857499e-06
Denys B-Disease 1 0.9999758005142212
- I-Disease 1 0.9999990463256836
Drash I-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
( O 0 9.55128634814173e-05
DDS B-Disease 1 0.9999995231628418
) O 0 1.1570009519346058e-05
, O 0 3.260123094150913e-06
or O 0 4.0044746128842235e-05
diffuse B-Disease 1 0.9994957447052002
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 0.0013281393330544233
DMS B-Disease 0 0.09118494391441345
) O 0 1.7711270174913807e-06
associated O 0 1.6357458889615373e-06
with O 0 1.2508783129305812e-06
pseudohermaphroditism B-Disease 1 0.9923987984657288
and O 0 2.462539305270184e-05
/ O 0 0.08223091065883636
or O 0 0.00017467101861257106
Wilms B-Disease 1 0.9999889135360718
tumor I-Disease 1 0.9814000129699707
( O 0 7.574121264042333e-05
WT B-Disease 1 0.9939970970153809
) O 0 2.517399116186425e-05
. O 0 2.8252068659639917e-05

Most O 0 0.00026684196200221777
mutations O 0 0.004353636410087347
in O 0 0.0002916535595431924
DDS B-Disease 1 1.0
patients O 1 0.9884776473045349
lie O 0 5.070401311968453e-05
in O 0 1.9172741758666234e-06
exon O 0 3.070371531066485e-05
8 O 0 4.225637439958518e-06
or O 0 9.214899137077737e-07
exon O 0 1.3385757483774796e-05
9 O 0 3.6444873785512755e-06
, O 0 3.8108285593807523e-07
encoding O 0 5.675378361047478e-06
zinc O 0 6.1901388107799e-05
finger O 0 1.5100160453584976e-05
2 O 0 3.045020775971352e-06
or O 0 1.049284605869616e-06
zinc O 0 3.639882561401464e-05
finger O 0 7.476191512978403e-06
3 O 0 1.3065543953416636e-06
, O 0 1.811816332519811e-07
respectively O 0 4.652136453842104e-07
, O 0 6.677147013078866e-08
with O 0 7.551766856295217e-08
a O 0 1.0207317018284812e-06
hot O 0 8.453289410681464e-06
spot O 0 1.502765644545434e-05
( O 0 2.677440761544858e-06
R394W O 0 4.686310057877563e-05
) O 0 1.5634066130587598e-06
in O 0 1.8878555465562386e-06
exon O 0 8.262761548394337e-05
9 O 0 5.035951471654698e-05
. O 0 2.1524279873119667e-05

We O 0 2.2513817384606227e-05
analyzed O 0 1.9152135791955516e-05
a O 0 3.7709667140006786e-06
series O 0 3.3318533496640157e-06
of O 0 1.2414812999850255e-06
24 O 0 8.071940101217479e-05
patients O 0 4.417237869347446e-05
, O 0 5.369650466491294e-07
10 O 0 7.891721907071769e-07
with O 0 1.1158780353071052e-06
isolated B-Disease 0 0.0005618821014650166
DMS I-Disease 1 0.7704025506973267
( O 0 7.6101187005406246e-06
IDMS B-Disease 0 0.0013215728104114532
) O 0 6.820317821620847e-07
, O 0 1.861083092080662e-07
10 O 0 2.595569412733312e-07
with O 0 4.788901719621208e-07
DDS B-Disease 1 0.9999940395355225
, O 0 1.0420955049994518e-06
and O 0 3.0405067263927776e-07
4 O 0 3.1090432912606047e-06
with O 0 2.9859486403438495e-06
urogenital B-Disease 1 0.9834310412406921
abnormalities I-Disease 1 0.9986207485198975
and O 0 3.8722504541510716e-05
/ O 0 0.020885813981294632
or O 0 9.750113531481475e-05
WT B-Disease 1 0.9999444484710693
. O 0 8.466195140499622e-05

We O 0 0.00010260799172101542
report O 0 7.367588113993406e-05
WT1 O 0 0.005727378651499748
heterozygous O 0 0.0015710105653852224
mutations O 0 8.029109449125826e-05
in O 0 2.361288579777465e-06
16 O 0 5.9937970945611596e-05
patients O 0 5.939771290286444e-05
, O 0 4.031990954445064e-07
4 O 0 1.7938956489160773e-06
of O 0 4.1770979919419915e-07
whom O 0 5.139224867889425e-06
presented O 0 6.404056875908282e-06
with O 0 1.1046315194107592e-05
IDMS B-Disease 1 0.8631168007850647
. O 0 5.359170609153807e-05

One O 0 4.674932642956264e-05
male O 0 8.74132601893507e-05
and O 0 4.468391580303432e-06
two O 0 7.305612143682083e-06
female O 0 0.001082489499822259
IDMS B-Disease 1 0.9971711039543152
patients O 0 0.00265880418010056
with O 0 3.0989172955742106e-05
WT1 O 1 0.9774022102355957
mutations O 0 0.011313076131045818
underwent O 1 0.6896539926528931
normal O 0 0.00048438645899295807
puberty O 0 0.003448422998189926
. O 0 8.281290502054617e-05

Two O 0 0.00023981578124221414
mutations O 0 0.0016141260275617242
associated O 0 1.5986473954399116e-05
with O 0 3.521655344229657e-06
IDMS B-Disease 0 0.3746858239173889
are O 0 3.071932326292881e-07
different O 0 1.9655830385545414e-07
from O 0 2.9229900633254147e-07
those O 0 4.658400598600565e-07
described O 0 2.3785740268067457e-05
in O 0 7.419967732857913e-05
DDS B-Disease 1 1.0
patients O 1 0.973721981048584
. O 0 5.339143899618648e-05

No O 0 0.0005562410224229097
WT1 O 0 0.4492190480232239
mutations O 0 0.0019589897710829973
were O 0 7.785269190208055e-06
detected O 0 6.938738351891516e-06
in O 0 4.5146501292947505e-07
the O 0 3.0972628906056343e-07
six O 0 3.4250706448801793e-06
other O 0 2.9110383366059978e-06
IDMS B-Disease 1 0.9991176724433899
patients O 0 0.0034376285038888454
, O 0 1.3839146504324162e-06
suggesting O 0 6.477458100562217e-06
genetic O 0 1.8663649825612083e-05
heterogeneity O 0 6.75260234856978e-05
of O 0 2.9014042866037926e-06
this O 0 1.9548988348105922e-05
disease O 0 0.016147779300808907
. O 0 3.359730544616468e-05

We O 0 9.223007509717718e-05
analyzed O 0 0.00030699698254466057
genotype O 0 0.01651599630713463
/ O 0 0.015706628561019897
phenotype O 0 0.01901291310787201
correlations O 0 2.6906949642580003e-05
, O 0 4.5446901708601217e-07
on O 0 2.2315325054478308e-07
the O 0 1.1813643396862972e-07
basis O 0 1.4881071308536775e-07
of O 0 4.502937400729934e-08
the O 0 1.1084119222459776e-07
constitution O 0 4.5297105089048273e-07
of O 0 8.715753807564397e-08
a O 0 2.7283037979941582e-06
WT1 O 0 0.000736089248675853
mutation O 0 4.811686267203186e-06
database O 0 5.516629357771308e-07
of O 0 1.937159055387383e-07
84 O 0 9.004132152767852e-06
germ O 0 0.00017606459732633084
- O 0 0.0002626351488288492
line O 0 7.138564251363277e-05
mutations O 0 3.938176178053254e-06
, O 0 9.463712302704153e-08
to O 0 5.781841849739067e-08
compare O 0 4.2643205233616754e-07
the O 0 1.1821351364460497e-07
distribution O 0 5.703282113245223e-07
and O 0 1.4818137117345032e-07
type O 0 5.060824150859844e-07
of O 0 2.1287301876782294e-07
mutations O 0 7.470995114999823e-06
, O 0 1.1464532434501962e-07
according O 0 1.3579250435213908e-07
to O 0 1.1887804163279725e-07
the O 0 8.139887199831719e-07
different O 0 7.156292667787056e-06
symptoms O 0 0.007482624147087336
. O 0 2.3350621631834656e-05

This O 0 3.642211959231645e-05
demonstrated O 0 0.00012349191820248961
( O 0 4.110434929316398e-06
1 O 0 2.0337733985797968e-06
) O 0 5.418178830041143e-07
the O 0 2.705015447190817e-07
association O 0 5.55911242372531e-07
between O 0 7.056171966723923e-07
mutations O 0 3.6179540074954275e-06
in O 0 2.1476776623785554e-07
exons O 0 1.1269876267760992e-05
8 O 0 2.459175675539882e-06
and O 0 3.7008663866799907e-07
9 O 0 4.7712055675219744e-06
and O 0 1.0873895917029586e-06
DMS B-Disease 0 0.09918271750211716
; O 0 2.6159068511333317e-06
( O 0 6.879712941554317e-07
2 O 0 9.109053848987969e-07
) O 0 5.9468254676176e-07
among O 0 5.486807026500173e-07
patients O 0 1.236564276041463e-05
with O 0 1.3325945928954752e-06
DMS B-Disease 0 0.13902504742145538
, O 0 2.30589805028103e-07
a O 0 3.686592435769853e-07
higher O 0 4.0533188894187333e-07
frequency O 0 6.63241621623456e-07
of O 0 1.9505732495872508e-07
exon O 0 1.3722097719437443e-05
8 O 0 1.2183075341454241e-05
mutations O 0 4.4605490074900445e-06
among O 0 2.7233414812144474e-07
46 O 0 5.2087625590502284e-06
, O 0 2.0591210159182083e-06
XY O 1 0.6094709038734436
patients O 0 4.195524888928048e-05
with O 0 7.585018124700582e-07
female O 0 0.00014101264241617173
phenotype O 0 0.0009275139309465885
than O 0 2.7421842219155224e-07
among O 0 4.0627614339427964e-07
46 O 0 1.4353196092997678e-05
, O 0 3.244651907152729e-06
XY O 1 0.8868575096130371
patients O 0 3.974821083829738e-05
with O 0 5.658245640915993e-07
sexual O 0 7.473852747352794e-06
ambiguity O 0 6.812895662733354e-06
or O 0 4.54513383374433e-06
male O 0 0.0002287758979946375
phenotype O 0 0.08908426016569138
; O 0 2.8201193345012143e-06
and O 0 4.2431324231984036e-07
( O 0 1.0346182079956634e-06
3 O 0 1.2349688631729805e-06
) O 0 3.6115449120188714e-07
statistically O 0 8.228678325394867e-07
significant O 0 1.8050936034796905e-07
evidence O 0 1.8141021485007514e-07
that O 0 1.1186490667114413e-07
mutations O 0 2.2258116132434225e-06
in O 0 2.635696887409722e-07
exons O 0 2.209130434494e-05
8 O 0 2.6063075893034693e-06
and O 0 2.9926832212368026e-07
9 O 0 3.5530724744603503e-06
preferentially O 0 4.021087988803629e-06
affect O 0 7.432929010064981e-07
amino O 0 1.4759820032850257e-06
acids O 0 6.142483357507444e-07
with O 0 1.1351105655421634e-07
different O 0 2.1421485030259646e-07
functions O 0 1.3035003121331101e-06
. O 0 1.7130506648754817e-06
. O 0 8.038697160372976e-06

The O 0 0.00010522537195356563
185delAG O 0 0.00956589262932539
BRCA1 O 0 0.03255697712302208
mutation O 0 0.00012109638191759586
originated O 0 3.693324742926052e-06
before O 0 4.721342747870949e-07
the O 0 2.1033777386492147e-07
dispersion O 0 3.936399934900692e-06
of O 0 1.4469823383933544e-07
Jews O 0 9.091054380405694e-07
in O 0 1.3454651082156488e-07
the O 0 1.962937972166401e-07
diaspora O 0 2.610464207464247e-06
and O 0 1.839081562593492e-07
is O 0 1.1957003209772665e-07
not O 0 1.6470823993586237e-07
limited O 0 1.2265811619727174e-06
to O 0 1.636771003177273e-06
Ashkenazim O 0 0.00020023442630190402
. O 0 1.7698605006444268e-05

The O 0 0.00010751429363153875
185delAG O 0 0.002348660957068205
mutation O 0 0.00031338477856479585
in O 0 9.271064300264698e-06
BRCA1 O 0 0.000600877043325454
is O 0 2.0468216916924575e-06
detected O 0 5.911947027925635e-06
in O 0 7.374417236860609e-07
Ashkenazi O 0 0.0001543854596093297
Jews O 0 2.383396804361837e-06
both O 0 2.938149066267215e-07
in O 0 1.6325307115039323e-06
familial B-Disease 1 0.786300778388977
breast I-Disease 1 0.999998927116394
and I-Disease 1 0.9990837574005127
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
and O 0 2.126069148289389e-06
in O 0 4.78276717785775e-07
the O 0 8.644964282211731e-07
general O 0 5.530865564651322e-06
population O 0 1.4252232176659163e-05
. O 0 1.283032452192856e-05

All O 0 8.124381565721706e-05
tested O 0 0.00023327839153353125
Ashkenazi O 0 0.011572398245334625
mutation O 0 0.0001802655606297776
carriers O 0 1.2081605746061541e-05
share O 0 1.7901001001519035e-06
the O 0 3.802921071383025e-07
same O 0 7.900329137555673e-07
allelic O 0 3.3520434953970835e-05
pattern O 0 1.6376285202568397e-05
at O 0 1.8755093833533465e-06
the O 0 5.902938482904574e-06
BRCA1 O 0 0.0012858869740739465
locus O 0 0.00031475527794100344
. O 0 2.928789945144672e-05

Our O 0 5.1691284170374274e-05
previous O 0 2.1863734218641184e-05
study O 0 9.055464943230618e-06
showed O 0 4.668710516853025e-06
that O 0 1.9980926424523204e-07
this O 0 3.976107052494626e-07
Ashkenazi O 0 0.017458369955420494
mutation O 0 2.297066203027498e-05
also O 0 6.068119660085358e-07
occurs O 0 3.2494685342498997e-07
in O 0 1.353995315866996e-07
Iraqi O 0 1.7598092654225184e-06
Jews O 0 9.576506272424012e-07
with O 0 3.709431268816843e-07
a O 0 3.3593946682231035e-06
similar O 0 1.1742204151232727e-05
allelic O 0 0.001154570491053164
pattern O 0 0.0006060173036530614
. O 0 3.394253144506365e-05

We O 0 1.49160605360521e-05
extended O 0 1.2271181731193792e-05
our O 0 1.3485831686921301e-06
analysis O 0 1.2865068583778339e-06
to O 0 1.8648655952802073e-07
other O 0 2.0044424786647141e-07
non O 0 2.0303414203226566e-06
- O 0 1.885431629489176e-05
Ashkenazi O 0 3.9542159356642514e-05
subsets O 0 3.082972170886933e-06
354 O 0 2.985629862450878e-06
of O 0 1.8598517215195898e-07
Moroccan O 0 1.2311152204347309e-05
origin O 0 9.651633945395588e-07
, O 0 3.8966595639067236e-07
200 O 0 1.0007182709159679e-06
Yemenites O 0 2.025348658207804e-05
and O 0 6.149024329715758e-07
150 O 0 3.0404942208406283e-06
Iranian O 0 1.1836206795123871e-05
Jews O 0 1.6707937902538106e-05
. O 0 1.0059924534289166e-05

Heteroduplex O 0 0.004098787903785706
analysis O 0 8.475621871184558e-05
complemented O 0 5.2067127398913726e-05
by O 0 2.576628503447864e-06
direct O 0 3.3151370644191047e-06
DNA O 0 5.561107627727324e-06
sequencing O 0 4.183837972959736e-06
of O 0 8.072176456153102e-07
abnormally O 0 0.00010247284808428958
migrating O 0 5.12037013322697e-06
bands O 0 4.005204573331866e-06
were O 0 1.4794134131079772e-06
employed O 0 2.6433081075083464e-05
. O 0 1.0521041076572146e-05

Four O 0 2.3143558792071417e-05
of O 0 3.334046596137341e-06
Moroccan O 0 0.00014948904572520405
origin O 0 3.2605680644337554e-06
( O 0 1.0768304719022126e-06
1 O 0 6.539649461956287e-07
. O 0 1.0964182450834414e-07
1 O 0 7.328237643378088e-07
% O 0 7.748121788608842e-07
) O 0 1.1442119074445145e-07
and O 0 9.78952101604591e-08
none O 0 1.3890222305690259e-07
of O 0 5.15298275161058e-08
the O 0 2.5839469230959367e-07
Yemenites O 0 7.232742063933983e-05
or O 0 3.4463775477888703e-07
Iranians O 0 7.659928655812109e-07
was O 0 2.028886427751786e-07
a O 0 4.148400023495924e-07
carrier O 0 2.8630931865336606e-06
of O 0 2.6218381776743627e-07
the O 0 2.6781149244925473e-06
185delAG O 0 0.0007565935957245529
mutation O 0 0.00012390485790092498
. O 0 1.6574376786593348e-05

BRCA1 O 0 0.06093369424343109
allelic O 0 0.0038068245630711317
patterns O 0 0.0002652202092576772
were O 0 2.917552819781122e-06
determined O 0 1.2116772722947644e-06
for O 0 1.3321304948021861e-07
four O 0 1.7741180613484175e-07
of O 0 8.554939512350757e-08
these O 0 6.638301641714861e-08
individuals O 0 7.429130732816702e-08
and O 0 6.506554228735695e-08
for O 0 1.1683651734983869e-07
12 O 0 6.000490202495712e-07
additional O 0 1.058028828992974e-06
non O 0 3.2221200854110066e-06
- O 0 3.717684739967808e-05
Ashkenazi O 0 0.0003123852366115898
185delAG O 0 0.00014014323824085295
mutation O 0 1.71678821061505e-05
carriers O 0 7.056447429931723e-06
who O 0 6.115535597928101e-06
had O 0 0.00023166078608483076
breast B-Disease 1 0.999997615814209
/ I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 0.00011465315037639812

Six O 0 0.0002894664939958602
non O 0 0.00029811926651746035
- O 0 0.008668230846524239
Ashkenazi O 0 0.01791507750749588
individuals O 0 3.5500172543834196e-06
shared O 0 9.303385013481602e-07
the O 0 4.853037580687669e-07
common O 0 3.0993096515885554e-06
Ashkenazi O 0 0.000713710964191705
haplotype O 0 0.00029617699328809977
, O 0 3.1962969160304056e-07
four O 0 2.435035355574655e-07
had O 0 5.147383603798517e-07
a O 0 6.89722696733952e-07
closely O 0 1.2914729268231895e-06
related O 0 1.1202839687030064e-06
pattern O 0 1.850372427725233e-05
, O 0 1.654344288226639e-07
and O 0 1.033257959193179e-07
the O 0 2.0181992965717654e-07
rest O 0 1.340181597697665e-06
( O 0 1.4230338365450734e-06
n O 0 1.1478100532258395e-05
= O 0 1.3892535207560286e-05
6 O 0 1.5442451513081323e-06
) O 0 4.851158905694319e-07
displayed O 0 1.0075411864818307e-06
a O 0 3.0388189315999625e-06
distinct O 0 2.891554504458327e-05
BRCA1 O 0 0.0007308434578590095
allelic O 0 0.0014865939738228917
pattern O 0 0.000718402792699635
. O 0 6.308242154773325e-05

We O 0 3.8525737181771547e-05
conclude O 0 2.75325910479296e-05
that O 0 1.2945891967319767e-06
the O 0 2.7730002329917625e-06
185delAG O 0 0.036790668964385986
BRCA1 O 0 0.09272745251655579
mutation O 0 8.217423601308838e-05
occurs O 0 1.2544669516501017e-06
in O 0 1.6198202956729801e-07
some O 0 1.0437560860054873e-07
non O 0 2.506690861991956e-06
- O 0 0.00010029633995145559
Ashkenazi O 0 0.0027286445256322622
populations O 0 4.071242983627599e-06
at O 0 5.367838298298011e-07
rates O 0 1.771383722370956e-06
comparable O 0 1.1171388223374379e-06
with O 0 1.5936248587422597e-07
that O 0 3.188600317116652e-07
of O 0 1.848765123213525e-06
Ashkenazim O 0 0.00078103895066306
. O 0 2.1257539629004896e-05

The O 0 3.853562520816922e-05
majority O 0 2.1556079445872456e-05
of O 0 1.94968561118003e-06
Jewish O 0 3.088184894295409e-05
185delAG O 0 0.0016776003176346421
mutation O 0 3.8265839975792915e-05
carriers O 0 2.550756789787556e-06
have O 0 1.581117459181769e-07
a O 0 7.16390843535919e-07
common O 0 2.0200973267492373e-06
allelic O 0 0.00012435323151294142
pattern O 0 3.5009830753551796e-05
, O 0 3.3336826277263754e-07
supporting O 0 5.264839160190604e-07
the O 0 1.5874906011958956e-07
founder O 0 2.4425576157227624e-06
effect O 0 4.83210783386312e-07
notion O 0 3.7417993326016585e-07
, O 0 1.0113092940855495e-07
but O 0 5.7583338985978116e-08
dating O 0 4.590410469518247e-07
the O 0 2.5660006031102967e-07
mutations O 0 1.6364307384719723e-06
origin O 0 1.3194991765885788e-07
to O 0 4.8178431910628206e-08
an O 0 9.023192149015813e-08
earlier O 0 8.583637622905371e-07
date O 0 7.304499831661815e-07
than O 0 3.9353909642159124e-07
currently O 0 1.817915517676738e-06
estimated O 0 7.766981070744805e-06
. O 0 1.0408021807961632e-05

However O 0 4.792393519892357e-05
, O 0 2.57220426647109e-06
the O 0 7.044593530736165e-07
different O 0 6.235560476852697e-07
allelic O 0 2.8547954570967704e-05
pattern O 0 1.4586231372959446e-05
at O 0 8.642030024930136e-07
the O 0 1.0579764193607843e-06
BRCA1 O 0 0.00012466621410567313
locus O 0 1.3835444406140596e-05
even O 0 3.0583746024603897e-07
in O 0 1.7270265573188226e-07
some O 0 1.2395477710924752e-07
Jewish O 0 5.736448201787425e-06
mutation O 0 1.0907798241532873e-05
carriers O 0 2.4294481590914074e-06
, O 0 1.9826588015803281e-07
might O 0 3.282521561231988e-07
suggest O 0 4.450850212833757e-07
that O 0 1.1317381165554252e-07
the O 0 1.0204563523075194e-06
mutation O 0 1.867287210188806e-05
arose O 0 4.9587506509851664e-06
independently O 0 3.565336328392732e-06
. O 0 1.6439876162621658e-06
. O 0 7.958253263495862e-06

Crystal O 0 0.0010510203428566456
structure O 0 4.2774423491209745e-05
of O 0 6.223355740075931e-06
the O 0 1.584877463756129e-05
hemochromatosis B-Disease 1 0.9999953508377075
protein O 0 6.55254116281867e-05
HFE O 0 0.00320760952308774
and O 0 1.0116457360709319e-06
characterization O 0 4.338809958426282e-06
of O 0 3.792779921241163e-07
its O 0 9.366218023387773e-07
interaction O 0 2.1712012312491424e-06
with O 0 2.6291172616765834e-06
transferrin O 0 0.00045561959268525243
receptor O 0 0.00013593726907856762
. O 0 2.2626818463322707e-05

HFE O 0 0.16842062771320343
is O 0 3.572275454644114e-05
an O 0 1.3484413102560211e-05
MHC O 0 0.002950150053948164
- O 0 0.0003433042438700795
related O 0 7.032094799797051e-06
protein O 0 2.237310127384262e-06
that O 0 1.4191792274687032e-07
is O 0 2.2085737327870447e-07
mutated O 0 2.8262418254598742e-06
in O 0 6.315920018096222e-07
the O 0 3.006786073456169e-06
iron B-Disease 0 0.07428532093763351
- I-Disease 1 0.9994205236434937
overload I-Disease 1 0.9999549388885498
disease I-Disease 1 0.9999362230300903
hereditary B-Disease 1 0.9999998807907104
hemochromatosis I-Disease 1 1.0
. O 0 0.00040514080319553614

HFE O 0 0.023803921416401863
binds O 0 0.00044147169683128595
to O 0 2.7131532988278195e-05
transferrin O 0 0.0005846861167810857
receptor O 0 0.00012566805526148528
( O 0 9.464356480748393e-06
TfR O 0 0.0007868497632443905
) O 0 1.5527156165262568e-06
and O 0 4.213128477204009e-07
reduces O 0 2.854943431884749e-06
its O 0 3.9906453253024665e-07
affinity O 0 1.2723785403068177e-06
for O 0 2.843431445853639e-07
iron O 0 1.0553971151239239e-05
- O 0 1.1517629900481552e-05
loaded O 0 1.1754314982681535e-05
transferrin O 0 3.4725038858596236e-05
, O 0 1.8172030422647367e-06
implicating O 0 3.3067270123865455e-05
HFE O 0 0.0020804982632398605
in O 0 9.429381861991715e-06
iron O 0 0.00037106938543729484
metabolism O 0 0.0002830407174769789
. O 0 2.407481224508956e-05

The O 0 0.00036503208684735
2 O 0 0.0006215071189217269
. O 0 0.0002336737234145403

6 O 0 0.00034486237564124167
A O 0 8.175808761734515e-05
crystal O 0 0.00010073532030219212
structure O 0 7.1023087002686225e-06
of O 0 1.3478373830366763e-06
HFE O 0 0.015012363903224468
reveals O 0 1.3328169188753236e-05
the O 0 4.2756084894790547e-07
locations O 0 2.047540192506858e-06
of O 0 2.878586656152038e-06
hemochromatosis B-Disease 1 0.9999998807907104
mutations O 0 0.00017955040675587952
and O 0 4.2096422703252756e-07
a O 0 2.4837113414832857e-06
patch O 0 0.028260914608836174
of O 0 7.076382075865695e-07
histidines O 0 0.0021413653157651424
that O 0 1.7477859159953368e-07
could O 0 2.7616627562565554e-07
be O 0 7.656043976567162e-08
involved O 0 3.5290750588501396e-07
in O 0 9.326134886578075e-07
pH O 0 0.00027606787625700235
- O 0 7.285920582944527e-05
dependent O 0 1.7574548110133037e-05
interactions O 0 1.2426561625034083e-05
. O 0 1.0169968845730182e-05

We O 0 3.386836397112347e-05
also O 0 6.427724201785168e-06
demonstrate O 0 9.917665920511354e-06
that O 0 9.334633546131954e-07
soluble O 0 2.6065234123962e-05
TfR O 0 0.003511379938572645
and O 0 2.9881107366236392e-06
HFE O 0 0.004349277354776859
bind O 0 7.702012226218358e-06
tightly O 0 4.786240424436983e-06
at O 0 4.0468222550771316e-07
the O 0 1.7728899592839298e-07
basic O 0 8.736772656448011e-07
pH O 0 1.0608694537950214e-05
of O 0 9.274491930000295e-08
the O 0 2.698985781535157e-07
cell O 0 1.392272133671213e-05
surface O 0 1.4101873375693685e-06
, O 0 1.4910875734130968e-07
but O 0 5.788451673538475e-08
not O 0 4.542384957062495e-08
at O 0 1.531390694253787e-07
the O 0 7.069494927236519e-07
acidic O 0 5.27878146385774e-05
pH O 0 5.559851706493646e-05
of O 0 1.8619863340063603e-06
intracellular O 0 5.5408287153113633e-05
vesicles O 0 0.00020183211017865688
. O 0 2.9513545086956583e-05

TfR O 1 0.9852733016014099
HFE O 1 0.7851147651672363
stoichiometry O 0 0.004057928454130888
( O 0 8.69006325956434e-05
2 O 0 2.2038337192498147e-05
1 O 0 6.470375865319511e-06
) O 0 1.387310817335674e-06
differs O 0 2.758982645900687e-06
from O 0 1.0551569857852883e-06
TfR O 0 0.00037203708779998124
transferrin O 0 4.314155739848502e-05
stoichiometry O 0 1.4388225281436462e-05
( O 0 1.1309521141811274e-06
2 O 0 1.137878030021966e-06
2 O 0 1.0131103636012995e-06
) O 0 2.3175451246970624e-07
, O 0 9.910812792668366e-08
implying O 0 5.936699380981736e-07
a O 0 1.8707883953084092e-07
different O 0 8.309146437568415e-08
mode O 0 5.995370884193107e-07
of O 0 9.435738945740013e-08
binding O 0 5.308363597578136e-07
for O 0 2.395752289885422e-07
HFE O 0 0.0003313995839562267
and O 0 6.118698934187705e-07
transferrin O 0 1.9787459677900188e-05
to O 0 5.463341494760243e-07
TfR O 0 0.0008404839900322258
, O 0 3.2293971230501484e-07
consistent O 0 4.1659035332486383e-07
with O 0 1.6241762068602839e-07
our O 0 4.2447231862752233e-07
demonstration O 0 4.237590019329218e-06
that O 0 1.9807667683835462e-07
HFE O 0 0.00021995273709762841
, O 0 7.034677764750086e-07
transferrin O 0 1.4012981409905478e-05
, O 0 4.046204651331209e-07
and O 0 7.021735655143857e-07
TfR O 0 0.003076990135014057
form O 0 2.1697976535506314e-06
a O 0 7.655030458408874e-06
ternary O 0 0.0001417627790942788
complex O 0 6.402641884051263e-05
. O 0 2.811338345054537e-05

Identification O 0 7.046454993542284e-05
of O 0 3.407877557037864e-06
three O 0 2.887470145651605e-06
novel O 0 2.0921073883073404e-05
mutations O 0 1.8706363334786147e-05
and O 0 2.886914387545403e-07
a O 0 8.895031555766764e-07
high O 0 8.35175910651742e-07
frequency O 0 1.1432317705839523e-06
of O 0 1.0340031764144442e-07
the O 0 5.417899728854536e-07
Arg778Leu O 0 0.0007513822056353092
mutation O 0 1.6180050806724466e-05
in O 0 1.2833195341954706e-06
Korean O 0 4.751814412884414e-05
patients O 0 0.00014165819447953254
with O 0 1.7154150555143133e-05
Wilson B-Disease 0 0.4193098843097687
disease I-Disease 0 0.06840363889932632
. O 0 5.002822581445798e-05

Four O 0 0.00027618766762316227
mutations O 0 0.0004850862314924598
- O 0 0.00012141771003371105
- O 0 9.726758435135707e-05
R778L O 0 8.894732309272513e-05
, O 0 1.130109012592584e-06
A874V O 0 2.1288740754243918e-05
, O 0 5.365381525734847e-07
L1083F O 0 1.1251278010604437e-05
, O 0 2.469857633968786e-07
and O 0 1.9560089015158155e-07
2304delC O 0 4.213391730445437e-05
- O 0 3.659634239738807e-05
- O 0 9.455343388253823e-06
in O 0 1.8516082889163954e-07
the O 0 1.6287955872940074e-07
copper O 0 4.583661393553484e-06
- O 0 8.198847353924066e-06
transporting O 0 4.036394784634467e-06
enzyme O 0 2.5830497634160565e-06
, O 0 5.064914034846879e-07
P O 0 6.705577834509313e-05
- O 0 1.6007845260901377e-05
type O 0 4.382412043923978e-06
ATPase O 0 5.549988054553978e-05
( O 0 1.7258903426409233e-06
ATP7B O 0 5.041135227656923e-05
) O 0 4.998921667720424e-07
, O 0 1.8112496036337689e-07
were O 0 1.6374535505292442e-07
identified O 0 1.2764719485858222e-06
in O 0 1.2159511015852331e-06
Korean O 0 8.348378469236195e-05
Patients O 0 0.0001965406263479963
with O 0 1.7572201613802463e-05
Wilson B-Disease 0 0.09234798699617386
disease I-Disease 0 0.015568561851978302
. O 0 2.4342640244867653e-05

Arg778Leu O 0 0.006246401462703943
, O 0 1.657791835896205e-05
the O 0 1.9862764020217583e-06
most O 0 6.436420108002494e-07
frequently O 0 2.999056732733152e-06
reported O 0 6.263683644647244e-06
mutation O 0 1.4521236835207674e-06
of O 0 6.588702916587863e-08
this O 0 8.080381519448565e-08
enzyme O 0 1.2815877425964572e-06
, O 0 1.3779984442408022e-07
was O 0 1.7495803206202254e-07
found O 0 8.141039131714933e-08
in O 0 6.974723731900667e-08
six O 0 2.526006426251115e-07
of O 0 1.630589139267613e-07
eight O 0 1.27072271425277e-05
unrelated O 0 0.000736367073841393
patients O 0 0.00016371066158171743
studied O 0 1.6380843135266332e-06
, O 0 2.4136812726283097e-07
an O 0 3.999942350674246e-07
allele O 0 6.443927304644603e-06
frequency O 0 3.641346665972378e-06
of O 0 9.575575177223072e-07
37 O 0 2.5595249098842032e-05
. O 0 1.2063230315106921e-05

5 O 0 0.0003331907500978559
% O 0 3.633605228969827e-05
, O 0 9.566593917043065e-07
which O 0 2.3597344522841013e-07
is O 0 1.6254871582077612e-07
considerably O 0 3.903286597051192e-06
higher O 0 8.168123031282448e-07
than O 0 9.170952353088069e-08
those O 0 8.716801147556907e-08
in O 0 1.78587839627653e-07
other O 0 3.608240035646304e-07
Asian O 0 5.860734745510854e-06
populations O 0 2.38370612350991e-05
. O 0 1.2846143363276497e-05

The O 0 3.8205456803552806e-05
novel O 0 4.248578625265509e-05
single O 0 1.571609936945606e-05
nucleotide O 0 4.345834895502776e-05
deletion O 0 6.754675268894061e-05
, O 0 2.1878668121644296e-06
2304delC O 0 6.86840430716984e-05
, O 0 5.94397931763524e-07
was O 0 6.348802230604633e-07
found O 0 3.1753575058246497e-07
in O 0 5.410139465311659e-07
one O 0 2.745585788943572e-06
patient O 0 0.0003124299109913409
. O 0 3.5090153687633574e-05

Since O 0 0.00013167269935365766
a O 0 4.203887147014029e-05
mutation O 0 8.674297714605927e-05
at O 0 4.328444447310176e-06
cDNA O 0 5.207944559515454e-05
nucleotide O 0 8.317919127875939e-05
2302 O 0 0.0006407207692973316
( O 0 2.746832478806027e-06
2302insC O 0 2.2430069293477573e-05
) O 0 4.652934819660004e-07
had O 0 4.743366730508569e-07
been O 0 1.9471087853162317e-07
previously O 0 8.151104680109711e-07
described O 0 1.2889075833300012e-06
, O 0 1.2074066546574613e-07
this O 0 5.339950703842078e-08
region O 0 2.5612234821892343e-07
of O 0 7.811409830082994e-08
the O 0 3.5399222042542533e-07
ATP7B O 0 0.012359756976366043
gene O 0 6.16208353676484e-06
may O 0 1.258913243873394e-06
be O 0 2.4068637571872387e-07
susceptible O 0 4.923851520288736e-06
to O 0 1.2193407883387408e-06
gene O 0 3.236373231629841e-05
rearrangements O 0 0.026935609057545662
causing O 0 0.01854858733713627
Wilson B-Disease 0 0.12360551208257675
disease I-Disease 0 0.043215468525886536
. O 0 4.011277633253485e-05

Disruption O 0 0.0011692405678331852
of O 0 1.067303128365893e-05
splicing O 0 9.368656174046919e-05
regulated O 0 1.519191027909983e-05
by O 0 1.4656108078270336e-06
a O 0 6.163970283523668e-06
CUG O 0 0.000877954182215035
- O 0 0.0001319080765824765
binding O 0 2.3005983166513033e-05
protein O 0 3.7396312109194696e-05
in O 0 4.06951985496562e-05
myotonic B-Disease 1 0.9999995231628418
dystrophy I-Disease 1 0.9999998807907104
. O 0 0.0002838738728314638

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9199614524841309
DM B-Disease 1 1.0
) O 0 6.425554602174088e-05
is O 0 1.9445642465143465e-06
caused O 0 5.077089554106351e-06
by O 0 3.4385149660920433e-07
a O 0 1.6152062016772106e-06
CTG O 0 0.00013021261838730425
expansion O 0 3.1435715754923876e-06
in O 0 2.6635098038241267e-07
the O 0 4.1706340425662347e-07
3 O 0 3.270733259341796e-06
untranslated O 0 7.170234312070534e-05
region O 0 3.0257854177762056e-06
of O 0 8.406865390497842e-07
the O 0 8.136215001286473e-06
DM B-Disease 1 0.9999978542327881
gene O 0 0.00020093537750653923
. O 0 3.123528586002067e-05

One O 0 3.331894549774006e-05
model O 0 4.7517689381493255e-05
of O 0 1.1265685316175222e-05
DM B-Disease 1 0.9999997615814209
pathogenesis O 0 0.02206013724207878
suggests O 0 1.4942641428206116e-05
that O 0 4.5811211180080136e-07
RNAs O 0 3.7571496704913443e-06
from O 0 1.180591624461158e-07
the O 0 1.0582028409089617e-07
expanded O 0 1.0910356422755285e-06
allele O 0 2.7002752176485956e-06
create O 0 4.066048688855517e-07
a O 0 5.087540557724424e-07
gain O 0 3.6956996609660564e-06
- O 0 5.76035608901293e-06
of O 0 2.694253851132089e-07
- O 0 3.694345286930911e-05
function O 0 1.799219035092392e-06
mutation O 0 1.4791114608669886e-06
by O 0 7.993922679361276e-08
the O 0 1.3909205165418825e-07
inappropriate O 0 6.361517534969607e-07
binding O 0 2.786599964110792e-07
of O 0 9.15354689823289e-08
proteins O 0 3.4132239079553983e-07
to O 0 1.8284208636032417e-07
the O 0 1.2894621477244073e-06
CUG O 0 0.0014074569335207343
repeats O 0 0.00010107681737281382
. O 0 1.3503447007678915e-05

Data O 0 0.00011792156146839261
presented O 0 2.9084299967507832e-05
here O 0 2.3264567516889656e-06
indicate O 0 2.1017967810621485e-06
that O 0 1.5213785786727385e-07
the O 0 4.2085707718797494e-07
conserved O 0 4.3387271944084205e-06
heterogeneous O 0 3.843766535283066e-05
nuclear O 0 1.2803178833564743e-05
ribonucleoprotein O 0 7.109272701200098e-05
, O 0 8.558698709748569e-07
CUG O 0 5.767782568000257e-05
- O 0 8.155730029102415e-06
binding O 0 2.2278632059169468e-06
protein O 0 1.5496299283768167e-06
( O 0 9.052321843228128e-07
CUG O 0 0.00015168881509453058
- O 0 9.941213647834957e-05
BP O 0 4.5305358071345836e-05
) O 0 4.3254715365037555e-07
, O 0 2.0905012831917702e-07
may O 0 3.770060743590875e-07
mediate O 0 4.270565568731399e-06
the O 0 6.647728127973096e-07
trans O 0 4.967022323398851e-05
- O 0 9.152671555057168e-05
dominant O 0 5.859572411281988e-06
effect O 0 7.940657269500662e-07
of O 0 2.3651595881801768e-07
the O 0 1.4442900919675594e-06
RNA O 0 3.790229675360024e-05
. O 0 9.458797649131157e-06

CUG O 1 0.6506879329681396
- O 0 0.23585978150367737
BP O 0 0.0013517745537683368
was O 0 5.202139618631918e-06
found O 0 4.1220249613616033e-07
to O 0 1.752476066485542e-07
bind O 0 1.2285432831049548e-06
to O 0 2.238186596059677e-07
the O 0 7.973956144269323e-07
human O 0 1.1708424608514179e-05
cardiac O 1 0.9998888969421387
troponin O 1 0.996566653251648
T O 0 0.12019003927707672
( O 0 1.8971793451783014e-06
cTNT O 0 1.7901968021760695e-05
) O 0 6.63859907490405e-07
pre O 0 4.118211563763907e-06
- O 0 6.617924555030186e-06
messenger O 0 5.7408487919019535e-06
RNA O 0 2.481762749084737e-06
and O 0 3.3749577710295853e-07
regulate O 0 2.0505399334069807e-06
its O 0 1.0616270174068632e-06
alternative O 0 8.676030120113865e-06
splicing O 0 7.516271580243483e-05
. O 0 2.1720959921367466e-05

Splicing O 0 0.0009541061008349061
of O 0 4.7442710638279095e-05
cTNT O 0 0.0013696476817131042
was O 0 2.9043805625406094e-05
disrupted O 0 0.00044508007704280317
in O 0 4.531681042863056e-05
DM B-Disease 1 0.9999997615814209
striated O 1 0.9897947907447815
muscle O 0 0.004619884304702282
and O 0 2.0099219000258017e-06
in O 0 2.5973299671022687e-06
normal O 0 1.687168696662411e-05
cells O 0 1.1013917173841037e-05
expressing O 0 2.4842017865012167e-06
transcripts O 0 3.2421496598544763e-06
that O 0 5.911051061957551e-07
contain O 0 5.2629184210672975e-06
CUG O 0 0.0014809437561780214
repeats O 0 0.0001733000681269914
. O 0 3.176938844262622e-05

Altered O 0 0.0009637749753892422
expression O 0 9.249783033737913e-05
of O 0 6.6788425101549365e-06
genes O 0 2.757705624389928e-05
regulated O 0 1.1617730706348084e-05
posttranscriptionally O 0 0.00010669398034224287
by O 0 1.776071144377056e-06
CUG O 0 0.02157912589609623
- O 0 0.011745396070182323
BP O 0 0.0003820962447207421
therefore O 0 1.692941054898256e-06
may O 0 1.8745348597803968e-06
contribute O 0 2.4547564407839673e-06
to O 0 4.852194706472801e-06
DM B-Disease 1 0.9999983310699463
pathogenesis O 0 0.01024562306702137
. O 0 1.3641735677083489e-05
. O 0 2.4107184799504466e-05

Identification O 0 8.802405500318855e-05
of O 0 4.984496172255604e-06
a O 0 9.967426194634754e-06
novel O 0 2.5001252652145922e-05
nonsense O 0 0.0001301347801927477
mutation O 0 2.1197092792135663e-05
and O 0 5.609422260022257e-07
a O 0 2.4311307242896874e-06
missense O 0 3.1717900128569454e-05
substitution O 0 1.975892928385292e-06
in O 0 4.500911074956093e-07
the O 0 9.279672781303816e-07
vasopressin O 0 4.7605502913938835e-05
- O 0 8.137237455230206e-05
neurophysin O 0 0.000302701722830534
II O 0 1.4244706108001992e-05
gene O 0 1.5594932847307064e-06
in O 0 3.204739584816707e-07
two O 0 9.214495548803825e-07
Spanish O 0 9.898446478473488e-06
kindreds O 0 0.00012372765922918916
with O 0 1.788512417988386e-05
familial B-Disease 1 0.9603099226951599
neurohypophyseal I-Disease 1 0.9999827146530151
diabetes I-Disease 1 0.9999994039535522
insipidus I-Disease 1 0.9997386336326599
. O 0 0.00018058450950775295

Familial B-Disease 1 0.9998642206192017
neurohypophyseal I-Disease 1 0.9999858140945435
diabetes I-Disease 1 0.9999998807907104
insipidus I-Disease 1 0.9999935626983643
( O 0 0.007595119532197714
FNDI B-Disease 1 0.9999847412109375
) O 0 1.8403799913357943e-05
is O 0 3.3390294902346795e-06
an O 0 2.3659687940380536e-05
autosomal B-Disease 1 0.9998705387115479
dominant I-Disease 1 0.9995761513710022
disease I-Disease 1 0.9961155652999878
caused O 0 0.005199680104851723
by O 0 6.949453381821513e-05
deficiency O 1 0.7386954426765442
in O 0 1.0545353461566265e-06
the O 0 4.391394668346038e-06
antidiuretic O 0 0.0041822283528745174
hormone O 0 6.858710548840463e-05
arginine O 0 3.607399412430823e-05
vasopressin O 0 5.842895188834518e-05
( O 0 1.6298923810609267e-06
AVP O 0 1.3764221876044758e-05
) O 0 3.868829026032472e-07
encoded O 0 4.5482283894671127e-07
by O 0 1.7499775140095153e-07
the O 0 5.254686357147875e-07
AVP O 0 0.00015733452164568007
- O 0 0.00016089323617052287
neurophysin O 0 0.0006173918955028057
II O 0 6.808986654505134e-05
( O 0 3.449511950748274e-06
AVP O 0 6.477689748862758e-05
- O 0 8.441020327154547e-05
NPII O 0 0.00020626545301638544
) O 0 1.7622764971747529e-06
gene O 0 4.567668383970158e-06
on O 0 5.1261845328554045e-06
chromosome O 0 0.0003147426759824157
20p13 O 0 0.0005251146503724158
. O 0 2.5431212634430267e-05

In O 0 1.8936196283902973e-05
this O 0 2.1934804408374475e-06
study O 0 1.7682579027678003e-06
, O 0 3.2494187962583965e-07
we O 0 1.3229315243279416e-07
analyzed O 0 7.11390214291896e-07
two O 0 1.7960304887765233e-07
families O 0 1.020444642563234e-06
with O 0 4.858238185079244e-07
FNDI B-Disease 1 0.9446741342544556
using O 0 9.737784694152651e-07
direct O 0 8.955241810326697e-07
automated O 0 5.368788151827175e-06
fluorescent O 0 9.356985174235888e-06
, O 0 3.8649753264508035e-07
solid O 0 1.4026682038092986e-06
phase O 0 3.2636851301504066e-06
, O 0 2.802991900807683e-07
single O 0 1.1230931704631075e-06
- O 0 1.0540533367020544e-05
stranded O 0 7.047657163639087e-06
DNA O 0 2.4055839276115876e-06
sequencing O 0 2.7330722787155537e-06
of O 0 7.637862040610344e-07
PCR O 0 4.254095983924344e-05
- O 0 3.805241431109607e-05
amplified O 0 8.180246368283406e-05
AVP O 0 0.0004933904856443405
- O 0 0.0006429250352084637
NPII O 0 0.005016240756958723
DNA O 0 0.00020011876767966896
. O 0 3.8805377698736265e-05

In O 0 1.8645894670044072e-05
one O 0 1.456091240470414e-06
of O 0 3.102545917954558e-07
the O 0 6.650239470218366e-07
families O 0 6.088296231610002e-06
, O 0 1.2581425608004793e-06
affected O 0 1.8445967953084619e-06
individuals O 0 2.983233855502476e-07
presented O 0 5.76278864627966e-07
a O 0 8.998981115837523e-07
novel O 0 4.393857579998439e-06
nonsense O 0 2.4862541977199726e-05
mutation O 0 5.079491529613733e-06
in O 0 2.738595981099934e-07
exon O 0 4.355766577646136e-06
3 O 0 5.583872280112701e-07
of O 0 6.728207324613322e-08
the O 0 1.291613216380938e-07
gene O 0 4.505781419084087e-07
, O 0 6.697005972000625e-08
consisting O 0 2.141247819054115e-07
in O 0 1.471214829962264e-07
a O 0 2.3658124064240837e-06
G O 0 0.003028900595381856
to O 0 7.250711746564775e-07
T O 0 0.00012026507465634495
transition O 0 2.3404249986924697e-06
at O 0 4.29817561098389e-07
nucleotide O 0 4.0891113712859806e-06
2101 O 0 1.3856136320100632e-05
, O 0 1.7916953254371037e-07
which O 0 9.743658324623539e-08
produces O 0 2.0427604852102377e-07
a O 0 3.3381303410351393e-07
stop O 0 9.427334930478537e-07
signal O 0 1.5833009001653409e-06
in O 0 7.686784329052898e-07
codon O 0 2.3551314370706677e-05
82 O 0 1.8583619748824276e-05
( O 0 6.44040119368583e-06
Glu O 0 0.0016747914487496018
) O 0 2.6279542453266913e-06
of O 0 2.7125688575324602e-06
NPII O 0 0.0015080306911841035
. O 0 2.6650988729670644e-05

The O 0 0.00011661626922432333
premature O 0 0.0034034871496260166
termination O 0 0.0007637771777808666
eliminates O 0 6.182456854730844e-05
part O 0 1.7143449895229423e-06
of O 0 4.815808551938972e-07
the O 0 1.09980464912951e-06
C O 0 5.8378936955705285e-05
- O 0 2.7861327907885425e-05
terminal O 0 7.672827450733166e-06
domain O 0 3.514585955599614e-07
of O 0 1.5273359110778983e-07
NPII O 0 0.00013843084161635488
, O 0 1.589754106134933e-07
including O 0 1.057845651075695e-07
a O 0 4.61615769609125e-07
cysteine O 0 1.3342528291104827e-06
residue O 0 9.569513395035756e-07
in O 0 1.3607005655558169e-07
position O 0 6.726083370267588e-07
85 O 0 1.8298301256436389e-06
, O 0 1.3288618561091425e-07
which O 0 1.0922103399479965e-07
could O 0 1.1904867847079004e-07
be O 0 5.5878899729577824e-08
involved O 0 1.548845318666281e-07
in O 0 1.3824792688410525e-07
the O 0 3.458177388893091e-07
correct O 0 8.345712558366358e-06
folding O 0 1.7664156985119916e-05
of O 0 7.621068789376295e-07
the O 0 4.44977376901079e-06
prohormone O 0 0.007779167499393225
. O 0 3.82634716515895e-05

In O 0 2.6985740987583995e-05
the O 0 4.366838311398169e-06
second O 0 8.987644832814112e-06
family O 0 4.780314611707581e-06
, O 0 5.084979761704744e-07
a O 0 8.20551349534071e-07
G279A O 0 1.0152912182093132e-05
substitution O 0 1.389347062286106e-06
at O 0 3.8050833950364904e-07
position O 0 5.454423330775171e-07
- O 0 2.7999162739433814e-06
1 O 0 3.57461345856791e-07
of O 0 7.564121062841878e-08
the O 0 2.1246432879706845e-07
signal O 0 2.7233309083385393e-06
peptide O 0 1.5195413425317383e-06
was O 0 3.0393874794754083e-07
observed O 0 5.865548473593662e-07
in O 0 1.456529901133763e-07
all O 0 2.417118025732634e-07
affected O 0 3.600592208385933e-06
individuals O 0 4.257552518538432e-06
. O 0 1.2578291716636159e-05

This O 0 9.321594552602619e-05
missense O 0 0.008274887688457966
mutation O 0 0.00033778598299250007
, O 0 3.2490270314156078e-06
which O 0 1.4576514786313055e-06
replaces O 0 0.00016277148097287863
Ala O 0 0.009158836677670479
with O 0 4.311339125706581e-06
Thr O 0 0.03673170506954193
, O 0 6.917238692949468e-07
is O 0 2.3552513539470965e-07
frequent O 0 3.9126935007516295e-06
among O 0 8.743651051190682e-06
FNDI B-Disease 1 0.9999998807907104
patients O 0 0.006316477432847023
and O 0 5.857672249476309e-07
is O 0 1.7307412747413764e-07
thought O 0 1.4358313649154297e-07
to O 0 8.781415772318724e-08
reduce O 0 1.0100849294758518e-06
the O 0 1.269831386707665e-07
efficiency O 0 1.137976823883946e-06
of O 0 1.7922046424700966e-07
cleavage O 0 1.1295570402580779e-05
by O 0 8.740431667320081e-07
signal O 0 1.9893204807885922e-05
peptidases O 0 0.00011718778841895983
. O 0 3.031027290489874e-06
. O 0 1.1905318388016894e-05

Genetic O 0 0.0017794599989429116
heterogeneity O 0 0.0010205731960013509
of O 0 3.420739813009277e-05
Saethre B-Disease 1 0.9936489462852478
- I-Disease 1 0.999972939491272
Chotzen I-Disease 1 0.9999990463256836
syndrome I-Disease 1 0.9999996423721313
, O 0 1.8370006955592544e-06
due O 0 2.2318504306895193e-06
to O 0 8.686765795573592e-07
TWIST O 0 0.00033727256231941283
and O 0 4.2527823097771034e-05
FGFR O 1 0.8283495306968689
mutations O 0 0.0006803075084462762
. O 0 2.736845453910064e-05

Thirty O 0 0.0005727779935114086
- O 0 0.0007605100981891155
two O 0 1.3226179362391122e-05
unrelated O 0 0.00192990992218256
patients O 0 0.0001192053168779239
with O 0 5.718831630474597e-07
features O 0 2.744588528003078e-06
of O 0 1.7886359273688868e-06
Saethre B-Disease 1 0.9720947742462158
- I-Disease 1 0.9991047978401184
Chotzen I-Disease 1 0.9999936819076538
syndrome I-Disease 1 0.9999955892562866
, O 0 1.928726987898699e-06
a O 0 1.0126783308805898e-05
common O 0 0.00013715229579247534
autosomal B-Disease 1 0.966806173324585
dominant I-Disease 0 0.006197232753038406
condition I-Disease 0 0.000331840303260833
of O 0 4.57253236163524e-06
craniosynostosis B-Disease 1 0.9997974038124084
and O 0 0.0001439668849343434
limb B-Disease 1 0.8684588074684143
anomalies I-Disease 0 0.0016311558429151773
, O 0 1.1616582469287096e-06
were O 0 4.6934195552239544e-07
screened O 0 2.887729124267935e-06
for O 0 5.096641189084039e-07
mutations O 0 9.041209523275029e-06
in O 0 5.30970567069744e-07
TWIST O 0 7.765110058244318e-05
, O 0 1.73447347151523e-06
FGFR2 O 0 0.0002640693564899266
, O 0 1.3005785604036646e-06
and O 0 3.9573128560732584e-06
FGFR3 O 0 0.0017990993801504374
. O 0 3.214159733033739e-05

Nine O 0 0.0001732275413814932
novel O 0 4.4500393414637074e-05
and O 0 4.433102276379941e-06
three O 0 6.6112006606999785e-06
recurrent O 0 0.12709297239780426
TWIST O 1 0.5161110162734985
mutations O 0 0.00017575813399162143
were O 0 7.70815404393943e-07
found O 0 7.60734508276073e-07
in O 0 1.4198955113897682e-06
12 O 0 1.7282327462453395e-05
families O 0 2.141880577255506e-05
. O 0 2.1788468075101264e-05

Seven O 0 0.0001187128946185112
families O 0 3.469028160907328e-05
were O 0 1.2378814062685706e-06
found O 0 2.769284606074507e-07
to O 0 1.0531548610970276e-07
have O 0 9.344343965267399e-08
the O 0 2.6759602178572095e-07
FGFR3 O 0 0.012704232707619667
P250R O 0 0.002946888329461217
mutation O 0 8.938595783547498e-06
, O 0 1.0915939441247247e-07
and O 0 7.365933640812727e-08
one O 0 9.035419168412773e-08
individual O 0 1.2742117405650788e-07
was O 0 2.615607286315935e-07
found O 0 1.0618462908951187e-07
to O 0 9.58162544861807e-08
have O 0 1.5363730199169368e-07
an O 0 5.371146016841521e-07
FGFR2 O 0 0.0011459143133834004
VV269 O 0 0.0003529131936375052
- O 0 0.00014294097491074353
270 O 0 7.322237070184201e-05
deletion O 0 0.00039210866088978946
. O 0 3.0133855034364387e-05

To O 0 2.7899213819182478e-05
date O 0 1.652287937758956e-05
, O 0 1.4982304037403082e-06
our O 0 1.0544729320827173e-06
detection O 0 5.244856311037438e-06
rate O 0 2.1803350591653725e-06
for O 0 2.787700452699937e-07
TWIST O 0 0.00012470876390580088
or O 0 4.695774805441033e-06
FGFR O 0 0.063789501786232
mutations O 0 1.3593854419013951e-05
is O 0 2.8288985731705907e-07
68 O 0 7.1860836214909796e-06
% O 0 1.0196566790909856e-06
in O 0 2.0510725562417065e-07
our O 0 1.0795233720273245e-06
Saethre B-Disease 1 0.611094057559967
- I-Disease 1 0.9998922348022461
Chotzen I-Disease 1 0.9999997615814209
syndrome I-Disease 1 1.0
patients O 0 0.0008671427494846284
, O 0 3.299142292689794e-07
including O 0 3.816494995589892e-07
our O 0 6.907864644745132e-07
five O 0 6.570746336365119e-06
patients O 0 6.276062777033076e-05
elsewhere O 0 4.895972324447939e-06
reported O 0 5.565485025726957e-06
with O 0 2.702364326978568e-06
TWIST O 0 0.022550789639353752
mutations O 0 0.0005286156083457172
. O 0 2.0901970856357366e-05

More O 0 2.03884846996516e-05
than O 0 3.4907795907201944e-06
35 O 0 5.9435537878016476e-06
different O 0 1.189398972201161e-06
TWIST O 0 0.00024076129193417728
mutations O 0 2.8117863621446304e-05
are O 0 1.3323413838861597e-07
now O 0 2.1933225013981428e-07
known O 0 3.7129140650904446e-07
in O 0 4.5871018983234535e-07
the O 0 1.2691887150140246e-06
literature O 0 8.440940291620791e-06
. O 0 1.2667554983636364e-05

The O 0 1.6623243936919607e-05
most O 0 2.191082558056223e-06
common O 0 2.5335775717394426e-06
phenotypic O 0 1.346560111414874e-05
features O 0 1.6405168707933626e-06
, O 0 3.44311871458558e-07
present O 0 1.2952791905718186e-07
in O 0 6.312517797368855e-08
more O 0 3.732881026508039e-08
than O 0 4.526350494415965e-08
a O 0 3.746619654521055e-07
third O 0 1.791604745449149e-06
of O 0 2.1171291564314743e-07
our O 0 1.042511144078162e-06
patients O 0 1.5432529835379682e-05
with O 0 5.911355742682645e-07
TWIST O 0 0.018496306613087654
mutations O 0 3.9140169974416494e-05
, O 0 2.4146066834873636e-07
are O 0 1.4631233113959752e-07
coronal B-Disease 0 0.00013495981693267822
synostosis I-Disease 0 0.00023409364803228527
, O 0 1.5126430525924661e-06
brachycephaly B-Disease 0 9.324759594164789e-05
, O 0 1.6556841728743166e-06
low B-Disease 0 5.3214906074572355e-05
frontal I-Disease 1 0.9631875157356262
hairline I-Disease 1 0.9999799728393555
, O 0 2.1649981135851704e-05
facial B-Disease 1 0.900931179523468
asymmetry I-Disease 0 0.01401186641305685
, O 0 1.746337875374593e-05
ptosis B-Disease 1 0.9124475717544556
, O 0 7.462642315658741e-06
hypertelorism B-Disease 0 0.00225582136772573
, O 0 1.6334074643964414e-06
broad B-Disease 0 1.4242613360693213e-05
great I-Disease 0 3.099528385064332e-06
toes I-Disease 0 4.234894004184753e-05
, O 0 2.0651939394156216e-06
and O 0 4.343206455814652e-06
clinodactyly B-Disease 0 0.0012166891247034073
. O 0 2.925976150436327e-05

Significant O 0 0.00017623959865886718
intra O 0 0.00039369077421724796
- O 0 0.00029955405625514686
and O 0 7.935183930385392e-06
interfamilial O 0 0.000657623924780637
phenotypic O 0 0.00015512475511059165
variability O 0 0.00010567474237177521
is O 0 5.300295242705033e-07
present O 0 5.803231601930747e-07
for O 0 5.543927841245022e-07
either O 0 4.658103534893598e-06
TWIST O 0 0.023063920438289642
mutations O 0 0.0006586456438526511
or O 0 2.35718962358078e-05
FGFR O 0 0.191579207777977
mutations O 0 0.00036031511262990534
. O 0 2.6468473151908256e-05

The O 0 3.9053742511896417e-05
overlap O 0 3.80297024094034e-05
in O 0 7.192651992227184e-06
clinical O 0 6.565137300640345e-05
features O 0 2.177712303819135e-06
and O 0 5.465316235131468e-07
the O 0 2.636494116359245e-07
presence O 0 4.63614782120203e-07
, O 0 1.2917745095819555e-07
in O 0 7.11013186105447e-08
the O 0 1.0874045841546831e-07
same O 0 3.0942780426812533e-07
genes O 0 4.6726341906833113e-07
, O 0 7.873982355022235e-08
of O 0 8.524139616383763e-08
mutations O 0 1.2249435030753375e-06
for O 0 4.6468329628623906e-08
more O 0 5.322887375314167e-08
than O 0 8.249328686815716e-08
one O 0 2.8809958507736155e-07
craniosynostotic B-Disease 0 0.0054464382119476795
condition I-Disease 0 2.6550862457952462e-05
- O 0 7.1989929892879445e-06
such O 0 1.0627214663827544e-07
as O 0 3.315044239116105e-07
Saethre B-Disease 0 0.0001162850167020224
- I-Disease 0 3.7813737435499206e-05
Chotzen I-Disease 0 9.549155947752297e-05
, I-Disease 0 6.9328052632045e-07
Crouzon I-Disease 0 2.978807970066555e-05
, I-Disease 0 5.124989002069924e-07
and I-Disease 0 1.6195807575059007e-06
Pfeiffer I-Disease 1 0.6294050216674805
syndromes I-Disease 1 0.981097936630249
- O 0 5.756660539191216e-05
support O 0 9.843375892160111e-07
the O 0 2.8181574407426524e-07
hypothesis O 0 1.3277007155920728e-06
that O 0 6.844206268397102e-08
TWIST O 0 1.294811772822868e-05
and O 0 6.444576570174831e-07
FGFRs O 0 0.00011574835662031546
are O 0 4.264897413008839e-08
components O 0 1.3300764578616509e-07
of O 0 3.368076306742296e-08
the O 0 8.982632948573155e-08
same O 0 2.387021993399685e-07
molecular O 0 2.1796738565171836e-06
pathway O 0 1.6277440408885013e-06
involved O 0 1.8401938461920508e-07
in O 0 8.869317014159606e-08
the O 0 1.5027134736556036e-07
modulation O 0 8.135625648719724e-06
of O 0 8.862483014127065e-07
craniofacial O 1 0.9634382724761963
and O 0 4.599249950842932e-05
limb O 0 0.34913477301597595
development O 0 5.5618552323721815e-06
in O 0 2.3638481252419297e-06
humans O 0 4.173217803327134e-06
. O 0 1.9474298369459575e-06
. O 0 1.2540946045191959e-05

Mutation O 0 0.002670043148100376
analysis O 0 0.0001873608271125704
of O 0 6.033366662450135e-05
UBE3A O 1 0.9925268888473511
in O 1 0.9611173272132874
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.999841570854187
. O 0 0.00026377648464404047

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.003763932967558503
AS B-Disease 0 0.00040000907029025257
) O 0 4.64693130197702e-06
is O 0 9.90778630693967e-07
caused O 0 3.0811083888693247e-06
by O 0 8.582590567129955e-07
chromosome O 0 0.00011894574709003791
15q11 O 0 0.00010655743244569749
- O 0 8.198754949262366e-05
q13 O 0 8.241672912845388e-05
deletions O 0 9.127800694841426e-06
of O 0 5.235897901911812e-07
maternal O 0 3.8666967157041654e-05
origin O 0 1.3064734503132058e-06
, O 0 3.69492056506715e-07
by O 0 6.839637762823259e-07
paternal O 0 0.00011923385318368673
uniparental B-Disease 1 0.860661506652832
disomy I-Disease 0 0.4863714277744293
( O 0 2.5788489438127726e-05
UPD B-Disease 1 0.9989583492279053
) O 0 1.593538172528497e-06
15 O 0 8.934019319895015e-07
, O 0 1.2850644282025314e-07
by O 0 2.8406395813362906e-07
imprinting O 0 0.032375991344451904
defects O 1 0.5380131602287292
, O 0 3.157251740049105e-07
and O 0 2.8218741476848663e-07
by O 0 5.696166454072227e-07
mutations O 0 9.076085916603915e-06
in O 0 5.930112934038334e-07
the O 0 3.0714768399775494e-06
UBE3A O 0 0.0012536841677501798
gene O 0 5.3074367315275595e-05
. O 0 1.623327989364043e-05

UBE3A O 0 0.012571771629154682
encodes O 0 0.0004315504338592291
a O 0 5.891544060432352e-05
ubiquitin O 0 0.00018609139078762382
- O 0 7.034926966298372e-05
protein O 0 1.2987927220819984e-05
ligase O 0 1.381989750370849e-05
and O 0 1.5966946875778376e-06
shows O 0 1.0444592589919921e-05
brain O 0 0.00020780459453817457
- O 0 0.00014363355876412243
specific O 0 1.9955017705797218e-05
imprinting O 0 0.0012023081071674824
. O 0 6.550366379087791e-05

Here O 0 6.433617090806365e-05
we O 0 1.463695298298262e-05
describe O 0 4.967259519617073e-05
UBE3A O 0 0.001453709788620472
coding O 0 0.001024831086397171
- O 0 0.002327311784029007
region O 0 0.00010007220407715067
mutations O 0 6.983805360505357e-05
detected O 0 4.1565795072529e-06
by O 0 3.4346442134847166e-07
SSCP O 0 7.895119051681831e-05
analysis O 0 8.004470828382182e-07
in O 0 5.237206437413988e-07
13 O 0 8.544861884729471e-06
AS B-Disease 0 2.145517646567896e-05
individuals O 0 1.6160537370524253e-06
or O 0 3.4424856494297273e-06
families O 0 2.2149522919789888e-05
. O 0 1.9849941963911988e-05

Two O 0 5.689445970347151e-05
identical O 0 0.0001224136503878981
de O 0 0.00012675480684265494
novo O 0 6.21686558588408e-05
5 O 0 1.0918382940872107e-05
- O 0 4.85784221382346e-05
bp O 0 2.0329227481852286e-05
duplications O 0 1.1827180969703477e-05
in O 0 1.1107871387139312e-06
exon O 0 4.017901301267557e-05
16 O 0 1.3012376257393043e-05
were O 0 2.4063594992185244e-06
found O 0 7.480876320187235e-06
. O 0 1.4532386558130383e-05

Among O 0 1.8707843992160633e-05
the O 0 2.1643106720148353e-06
other O 0 6.815591291342571e-07
11 O 0 3.3920869100256823e-06
unique O 0 2.4502751330146566e-06
mutations O 0 1.2917063031636644e-05
, O 0 1.977993946411516e-07
8 O 0 9.30621581574087e-07
were O 0 9.863948946531309e-08
small O 0 1.785221144245952e-07
deletions O 0 3.3998755952779902e-06
or O 0 5.769448421233392e-07
insertions O 0 1.547709689475596e-05
predicted O 0 1.7142865544883534e-05
to O 0 4.78474760257086e-07
cause O 0 5.3140183808864094e-06
frameshifts O 0 0.0002706274972297251
, O 0 4.487739602154761e-07
1 O 0 7.03031844295765e-07
was O 0 3.77135535245543e-07
a O 0 8.630046295365901e-07
mutation O 0 1.2590091955644311e-06
to O 0 4.9620251019177886e-08
a O 0 4.1237356640522194e-07
stop O 0 8.453963005194964e-07
codon O 0 2.0992886220483342e-06
, O 0 1.5800202390892082e-07
1 O 0 4.63395082306306e-07
was O 0 3.629769480539835e-07
a O 0 2.5454664864810184e-06
missense O 0 0.00014462678518611938
mutation O 0 4.213223292026669e-06
, O 0 1.5260256702731567e-07
and O 0 1.1910250918845122e-07
1 O 0 9.646885246183956e-07
was O 0 1.1953746934523224e-06
predicted O 0 3.792609504671418e-06
to O 0 9.831304481622283e-08
cause O 0 5.306445132191584e-07
insertion O 0 1.4611017604693188e-06
of O 0 8.758782854556557e-08
an O 0 2.964759175938525e-07
isoleucine O 0 0.002533055143430829
in O 0 1.915277181296915e-07
the O 0 2.7066411689702363e-07
hect O 0 2.2542801161762327e-05
domain O 0 3.803719152983831e-07
of O 0 7.764958809275413e-08
the O 0 2.6289919219379954e-07
UBE3A O 0 6.993029091972858e-05
protein O 0 1.041035716298211e-06
, O 0 8.535072026916168e-08
which O 0 5.758455046134259e-08
functions O 0 1.364720247920559e-07
in O 0 2.3338269272699108e-07
E2 O 0 1.0268849109706935e-05
binding O 0 1.749543116602581e-06
and O 0 7.341149625972321e-07
ubiquitin O 0 3.259093500673771e-05
transfer O 0 1.8235210518469103e-05
. O 0 2.5556104446877725e-05

Eight O 0 5.175091791898012e-05
of O 0 3.532263917804812e-06
the O 0 2.9107857244525803e-06
cases O 0 5.613186658592895e-06
were O 0 1.4910775689713773e-06
familial O 0 0.0005523596773855388
, O 0 1.3108065104461275e-06
and O 0 9.515829333395232e-07
five O 0 1.7349251493214979e-06
were O 0 2.3127217900764663e-06
sporadic O 0 0.00017183332238346338
. O 0 2.1302550521795638e-05

In O 0 3.220925646019168e-05
two O 0 1.1968886610702612e-05
familial O 0 0.03375023975968361
cases O 0 1.0955243851640262e-05
and O 0 1.2059857681379071e-06
one O 0 9.367683446726005e-07
sporadic O 0 5.6099783250829205e-05
case O 0 8.73792487254832e-06
, O 0 2.044326720351819e-06
mosaicism O 0 0.000461063435068354
for O 0 1.9752258140215417e-06
UBE3A O 0 0.048633553087711334
mutations O 0 6.107085209805518e-05
was O 0 1.511472305537609e-06
detected O 0 1.380172761855647e-06
in O 0 1.3331471393485117e-07
the O 0 1.9766586945024756e-07
mother O 0 3.2058690067060525e-06
of O 0 9.805722811506712e-08
three O 0 7.915389232948655e-07
AS B-Disease 0 0.0002681656333152205
sons O 0 0.00022537507175002247
, O 0 1.1699081881033635e-07
in O 0 7.630823262161357e-08
the O 0 1.764614410149079e-07
maternal O 0 1.303748013015138e-05
grandfather O 0 2.032111979133333e-06
of O 0 6.92753800990431e-08
two O 0 1.0022112206797829e-07
AS B-Disease 0 3.673733317555161e-06
first O 0 4.4806793653151544e-07
cousins O 0 4.407761934999144e-06
, O 0 1.0541637607275334e-07
and O 0 6.199840640874754e-08
in O 0 1.102482869441701e-07
the O 0 1.4588236751933437e-07
mother O 0 2.5587628442735877e-06
of O 0 1.5854965340622584e-07
an O 0 1.2532998425740516e-06
AS B-Disease 0 0.000382306519895792
daughter O 0 0.02635704167187214
. O 0 4.490408900892362e-05

The O 0 2.011643118748907e-05
frequencies O 0 1.4434926015383098e-05
with O 0 1.224646780428884e-06
which O 0 8.420698804911808e-07
we O 0 6.530088967338088e-07
detected O 0 6.682588718831539e-06
mutations O 0 3.66480662705726e-06
were O 0 2.3766051526763476e-07
5 O 0 1.3501195326171e-06
( O 0 5.50029710666422e-07
14 O 0 1.2578655059769517e-06
% O 0 4.567135931665689e-07
) O 0 6.245154082762383e-08
of O 0 4.645317730478382e-08
35 O 0 3.9648119809498894e-07
in O 0 1.219757876924632e-07
sporadic O 0 1.0520398973312695e-05
cases O 0 7.126395757950377e-07
and O 0 2.6108523343282286e-07
8 O 0 3.236397333239438e-06
( O 0 4.3419456119409006e-07
80 O 0 4.72151384656172e-07
% O 0 3.6748824072674324e-07
) O 0 7.378913124966857e-08
of O 0 5.950854031766539e-08
10 O 0 5.292617970553692e-07
in O 0 8.235044788307277e-07
familial O 0 0.0010935986647382379
cases O 0 9.847001820162404e-06
. O 0 3.5982511690235697e-06
. O 0 1.61417992785573e-05

The O 0 0.000427365506766364
hemochromatosis B-Disease 1 0.9999866485595703
845 O 1 0.8825572729110718
G O 1 0.7110085487365723
- O 0 0.0019277611281722784
- O 0 0.0002415082708466798
> O 0 1.9627595975180157e-05
A O 0 3.3032049486791948e-06
and O 0 8.534866537956987e-07
187 O 0 1.4681535503768828e-05
C O 0 3.278229996794835e-05
- O 0 0.00010213580389972776
- O 0 0.0008723471546545625
> O 0 0.0006970751564949751
G O 0 0.01654238812625408
mutations O 0 2.1181047486606985e-05
: O 0 1.1254969649598934e-06
prevalence O 0 2.383512764936313e-05
in O 0 1.7977303059524274e-06
non O 0 1.9675366274896078e-05
- O 0 0.0005778380436822772
Caucasian O 0 0.0032721005845814943
populations O 0 0.00010576246859272942
. O 0 2.2346735931932926e-05

Hemochromatosis B-Disease 1 0.9995379447937012
, O 0 0.0003614401211962104
the O 0 0.0003726794384419918
inherited B-Disease 1 0.9999997615814209
disorder I-Disease 1 0.9999998807907104
of I-Disease 0 7.800154889991973e-06
iron I-Disease 0 0.009450563229620457
metabolism I-Disease 0 0.00014956646191421896
, O 0 7.993706958586699e-07
leads O 0 5.327759481588146e-06
, O 0 5.574019041887368e-07
if O 0 3.5145322385687905e-07
untreated O 0 2.64997888734797e-05
, O 0 2.058829124962358e-07
to O 0 4.4826666112385283e-07
progressive O 0 0.0001267214393010363
iron B-Disease 0 0.00022095305030234158
overload I-Disease 0 0.0005103112198412418
and O 0 8.300073204736691e-06
premature B-Disease 0 0.0006679450161755085
death I-Disease 0 0.00016504213272128254
. O 0 2.6843366867979057e-05

The O 0 0.0002955524832941592
hemochromatosis B-Disease 1 0.9999737739562988
gene O 0 0.0003470702504273504
, O 0 1.48108974826755e-05
HFE O 0 0.010751895606517792
, O 0 2.9039231321803527e-06
recently O 0 1.0722379556682426e-05
has O 0 8.38695768834441e-07
been O 0 3.2394126492363284e-07
identified O 0 1.1641858463917742e-06
, O 0 1.0767426772417821e-07
and O 0 7.236688759348908e-08
characterization O 0 1.028843485073594e-06
of O 0 8.167555876070764e-08
this O 0 1.6271157221581234e-07
gene O 0 1.4889121757732937e-06
has O 0 4.022178359264217e-07
shown O 0 1.9850538990340283e-07
that O 0 3.0404020634478e-08
it O 0 3.0867088440800217e-08
contains O 0 1.0700437513833094e-07
two O 0 3.465922873147065e-07
mutations O 0 3.765177325476543e-06
that O 0 7.784578315295221e-08
result O 0 3.9202427615236957e-07
in O 0 4.256673662439425e-07
amino O 0 4.020535925519653e-06
acid O 0 3.8290140764729585e-06
substitutions O 0 1.9542444533726666e-06
- O 0 7.0549335760006215e-06
cDNA O 0 2.443241282890085e-05
nucleotides O 0 1.8223474398837425e-05
845 O 0 6.758695963071659e-05
G O 0 0.00023946186411194503
- O 0 4.2834555642912164e-05
- O 0 6.768486491637304e-05
> O 0 1.78109658008907e-05
A O 0 2.37792733059905e-06
( O 0 1.04875448414532e-06
C282Y O 0 8.799111128610093e-06
) O 0 4.6605379111497314e-07
and O 0 2.4398516984547314e-07
187 O 0 7.133574854378821e-06
C O 0 2.6526917281444184e-05
- O 0 8.799938223091885e-05
- O 0 0.0004285248869564384
> O 0 0.00027335344930179417
G O 0 0.0007761790766380727
( O 0 9.585254701960366e-06
H63D O 0 0.00034467061050236225
) O 0 1.2152556337241549e-05
. O 0 1.2983420674572699e-05

Although O 0 0.0082838274538517
hemochromatosis B-Disease 1 0.9999961853027344
is O 0 1.246833289769711e-05
common O 0 7.1316435423796065e-06
in O 0 3.23112999467412e-06
Caucasians O 0 9.430295176571235e-05
, O 0 1.9961187263106694e-06
affecting O 0 7.718349479546305e-06
> O 0 5.864358536200598e-05
= O 0 4.880190681433305e-05
1 O 0 1.606162072675943e-06
/ O 0 1.578028968651779e-05
300 O 0 3.8555728565370373e-07
individuals O 0 6.308160749313174e-08
of O 0 3.002287485287525e-08
northern O 0 1.7547638719861425e-07
European O 0 2.2361426488259895e-07
origin O 0 2.2790899834035372e-07
, O 0 8.660373396196519e-08
it O 0 3.9182463495990305e-08
has O 0 1.1287911405588602e-07
not O 0 4.8847983435962306e-08
been O 0 1.0024177043987947e-07
recognized O 0 2.6849275513995963e-07
in O 0 3.402145409836521e-07
other O 0 7.112532216524414e-07
populations O 0 2.0039840819663368e-05
. O 0 9.929864972946234e-06

The O 0 2.828493234119378e-05
present O 0 5.303018042468466e-06
study O 0 1.9240258097852347e-06
used O 0 7.167741955527163e-07
PCR O 0 1.3403476259554736e-05
and O 0 3.028664252724411e-07
restriction O 0 2.440226808175794e-06
- O 0 1.5073070244397968e-05
enzyme O 0 3.333124595883419e-06
digestion O 0 2.7400769795349333e-06
to O 0 1.0810393291649234e-07
analyze O 0 4.874978571933752e-07
the O 0 1.0512603410006705e-07
frequency O 0 5.909997184971871e-07
of O 0 6.243724470778034e-08
the O 0 2.7484045972414606e-07
845 O 0 9.88007741398178e-05
G O 0 0.0009219913044944406
- O 0 2.1234885934973136e-05
- O 0 2.0710793251055293e-05
> O 0 4.45894102085731e-06
A O 0 5.122550419400795e-07
and O 0 3.0993578548077494e-07
187 O 0 5.469584266393213e-06
C O 0 1.9187602447345853e-05
- O 0 3.639608257799409e-05
- O 0 0.00027065043104812503
> O 0 0.0002624116314109415
G O 0 0.0014868318103253841
mutations O 0 7.313712558243424e-06
in O 0 5.482684741764388e-07
HLA O 0 6.23945306870155e-05
- O 0 5.599515134235844e-06
typed O 0 3.1552460768580204e-06
samples O 0 6.20774471826735e-07
from O 0 4.547842422653048e-07
non O 0 2.3818950012355344e-06
- O 0 4.562719914247282e-05
Caucasian O 0 0.00012116428843000904
populations O 0 2.0196387140458683e-06
, O 0 1.6957902460035257e-07
comprising O 0 3.823314500550623e-07
Australian O 0 6.934371867828304e-07
Aboriginal O 0 1.4452215282290126e-06
, O 0 2.2910735708592256e-07
Chinese O 0 1.8812941959822638e-07
, O 0 2.136768273430789e-07
and O 0 5.678230081684887e-07
Pacific O 0 1.5660551071050577e-05
Islanders O 0 0.0001367221848340705
. O 0 2.0759021936100908e-05

Results O 0 0.0006084999768063426
showed O 0 4.429014370543882e-05
that O 0 8.661411357024917e-07
the O 0 1.2858212130595348e-06
845 O 0 0.0005065985023975372
G O 0 0.01589389145374298
- O 0 0.0002341228973818943
- O 0 0.00028074151487089694
> O 0 4.7576180804753676e-05
A O 0 6.682422736048466e-06
mutation O 0 7.780652595101856e-06
was O 0 4.949180265612085e-07
present O 0 1.6296500859880325e-07
in O 0 1.4347774879297504e-07
these O 0 1.1079574591121855e-07
populations O 0 1.324215531894879e-06
( O 0 4.663685899686243e-07
allele O 0 1.6445238770756987e-06
frequency O 0 9.140581482824928e-07
0 O 0 4.83275300666719e-07
. O 0 7.044688743462757e-08
32 O 0 1.1667010539895273e-06
% O 0 5.784797849628376e-07
) O 0 8.920672200929403e-08
, O 0 4.2205840600217925e-08
and O 0 6.222337134431655e-08
, O 0 2.228300104434311e-07
furthermore O 0 3.899949660990387e-07
, O 0 7.350005404305193e-08
it O 0 4.1726380572981725e-08
was O 0 2.8034568799739645e-07
always O 0 1.5662718055864389e-07
seen O 0 2.7403044100537954e-07
in O 0 1.3039922919233504e-07
conjunction O 0 1.8024409200734226e-06
with O 0 1.404798126714013e-06
HLA O 0 0.019383858889341354
haplotypes O 0 0.00017717269656714052
common O 0 1.8465805169398664e-06
in O 0 5.966930416434479e-07
Caucasians O 0 1.2714027434412856e-05
, O 0 4.2622386331458983e-07
suggesting O 0 1.5114621874090517e-06
that O 0 2.3075523358784267e-07
845 O 0 0.0002126281033270061
G O 0 0.048229798674583435
- O 0 0.00015502212045248598
- O 0 0.00031143188243731856
> O 0 3.084770287387073e-05
A O 0 2.816791948134778e-06
may O 0 7.486048048122029e-07
have O 0 6.833339938339122e-08
been O 0 5.5766996354122966e-08
introduced O 0 2.9104560894666065e-07
into O 0 2.0351885154923366e-07
these O 0 1.835444152220589e-07
populations O 0 2.780462409646134e-06
by O 0 1.7899292288348079e-06
Caucasian O 0 0.00016955423052422702
admixture O 0 0.00035696785198524594
. O 0 4.230744525557384e-05

187 O 0 0.0015288398135453463
C O 0 0.0011008117580786347
- O 0 0.0004847079108003527
- O 0 0.0006569116958416998
> O 0 0.00029461426311172545
G O 0 0.0003075741115026176
was O 0 1.0215089787379839e-06
present O 0 3.59134276095574e-07
at O 0 2.4933748932198796e-07
an O 0 3.554173702013941e-07
allele O 0 7.85655720392242e-06
frequency O 0 4.024725058116019e-06
of O 0 1.1342312973283697e-06
2 O 0 1.9705805243575014e-05
. O 0 1.4791956346016377e-05

68 O 0 0.004764370620250702
% O 0 6.635017780354246e-05
in O 0 1.0087140935866046e-06
the O 0 4.3986440800836135e-07
two O 0 8.05700153705402e-07
populations O 0 6.89350508764619e-06
analyzed O 0 2.943774006780586e-06
( O 0 6.465259616561525e-07
Australian O 0 9.921515129462932e-07
Aboriginal O 0 2.5057515813387e-06
and O 0 5.494745209944085e-07
Chinese O 0 1.5915092035356793e-06
) O 0 6.813057552790269e-06
. O 0 1.1942058335989714e-05

In O 0 3.6550965887727216e-05
the O 0 6.413634764612652e-06
Australian O 0 9.659529496275354e-06
Aboriginal O 0 1.255473125638673e-05
samples O 0 1.9882002106896834e-06
, O 0 6.194184720698104e-07
187 O 0 7.012372861936456e-06
C O 0 1.5170945516729262e-05
- O 0 2.8821583327953704e-05
- O 0 0.0001491538860136643
> O 0 9.148256503976882e-05
G O 0 9.865663741948083e-05
was O 0 4.0097123132909473e-07
found O 0 9.348337925985106e-08
to O 0 5.209360764979465e-08
be O 0 6.346768799403435e-08
associated O 0 5.074438718111196e-07
with O 0 1.208931507790112e-06
HLA O 0 0.19333873689174652
haplotypes O 0 0.00018614906002767384
common O 0 2.1460143670992693e-06
in O 0 1.1833110420411685e-06
Caucasians O 0 4.3959578761132434e-05
, O 0 5.430397322925273e-07
suggesting O 0 1.1792587883974193e-06
that O 0 5.6881329868474495e-08
it O 0 7.003905722058335e-08
was O 0 3.146310803003871e-07
introduced O 0 1.3859632872481598e-06
by O 0 7.835178053028358e-07
recent O 0 7.92972969065886e-06
admixture O 0 0.0003664095711428672
. O 0 3.636891779024154e-05

In O 0 1.4700884094054345e-05
the O 0 2.760409188340418e-06
Chinese O 0 1.6787161030151765e-06
samples O 0 9.066162647286546e-07
analyzed O 0 9.872189821180655e-07
, O 0 2.67865118530608e-07
187 O 0 4.315358182793716e-06
C O 0 6.97258246873389e-06
- O 0 2.3316086299018934e-05
- O 0 0.0001676234824117273
> O 0 0.0001342608011327684
G O 0 0.00016280857380479574
was O 0 3.711349449986301e-07
present O 0 1.2815274885724648e-07
in O 0 1.4324996300274506e-07
association O 0 3.553160468072747e-07
with O 0 9.989744853555749e-08
a O 0 7.023791681604052e-07
wide O 0 1.966368245120975e-06
variety O 0 3.6202351338943117e-07
of O 0 4.6959445398897515e-07
HLA O 0 0.0027222158387303352
haplotypes O 0 0.0001133047990151681
, O 0 4.6906004058655526e-07
showing O 0 8.121355676848907e-07
this O 0 1.0405815942249319e-07
mutation O 0 7.463970064236491e-07
to O 0 6.572587096798088e-08
be O 0 7.449606442833101e-08
widespread O 0 4.901294232695363e-07
and O 0 3.298211197488854e-07
likely O 0 1.3891417438571807e-06
to O 0 1.7163164045541635e-07
predate O 0 7.897369869169779e-06
the O 0 2.597069794774143e-07
more O 0 2.596391368570039e-07
genetically O 0 3.086396418439108e-06
restricted O 0 2.707954990910366e-06
845 O 0 0.00022809156507719308
G O 0 0.0047904024831950665
- O 0 0.0002651693648658693
- O 0 0.0002564821043051779
> O 0 8.540723501937464e-05
A O 0 3.669227226055227e-05
mutation O 0 0.00026016312767751515
. O 0 3.72687864000909e-05

Genotype O 1 0.8409151434898376
- O 0 0.2928929030895233
phenotype O 0 0.2151719629764557
correlations O 0 0.0023263609036803246
in O 0 0.0004676666867453605
attenuated B-Disease 1 0.9975646734237671
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999996423721313
coli I-Disease 1 0.9999690055847168
. O 0 0.0005830427980981767

Germ O 0 0.06306383013725281
- O 0 0.003583169775083661
line O 0 0.00043846771586686373
mutations O 0 6.115389260230586e-05
of O 0 1.831144686548214e-06
the O 0 7.001200174272526e-06
tumor B-Disease 0 0.010872487910091877
suppressor O 0 0.0013643489219248295
APC O 0 0.00011420532973716035
are O 0 1.027682401399943e-06
implicated O 0 6.074638804420829e-05
in O 0 9.08602523850277e-05
attenuated B-Disease 1 0.9996633529663086
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 0.9999978542327881
( O 0 0.00037261846591718495
AAPC B-Disease 1 0.9999394416809082
) O 0 3.7179281662247377e-06
, O 0 8.329884622071404e-07
a O 0 4.082946361450013e-06
variant O 0 0.000195094762602821
of O 0 6.11995201325044e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.0011135870590806007
FAP B-Disease 0 0.005571557208895683
) O 0 3.38841273332946e-05
. O 0 2.392250462435186e-05

AAPC B-Disease 1 0.9999457597732544
is O 0 4.834315041080117e-05
recognized O 0 1.051802155416226e-05
by O 0 1.1222152807022212e-06
the O 0 7.594898079332779e-07
occurrence O 0 4.088245532329893e-06
of O 0 9.268264307138452e-07
< O 0 0.00012427392357494682
100 O 0 3.572606374291354e-06
colonic B-Disease 0 0.0006142000202089548
adenomas I-Disease 0 0.0009832531213760376
and O 0 4.333762717578793e-07
a O 0 2.985128503496526e-06
later O 0 2.8379088689689524e-05
onset O 1 0.9926553964614868
of O 0 0.3136691451072693
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 4.8581619921606034e-05
age O 0 9.051164852280635e-06
> O 0 2.6919371521216817e-05
40 O 0 2.694916702239425e-06
years O 0 1.9624847027444048e-06
) O 0 5.860566943738377e-06
. O 0 8.909328244044445e-06

The O 0 2.29121396841947e-05
aim O 0 1.554031223349739e-05
of O 0 6.586271297237545e-07
this O 0 4.09988587080079e-07
study O 0 1.2047569271089742e-06
was O 0 1.151669835053326e-06
to O 0 1.1457902928668773e-06
assess O 0 7.435720908688381e-05
genotype O 0 0.0019600947853177786
- O 0 0.003270374843850732
phenotype O 0 0.012365084141492844
correlations O 0 0.0001597726222826168
in O 0 4.375948628876358e-05
AAPC B-Disease 1 0.9999595880508423
families O 0 0.00021908435155637562
. O 0 4.534201434580609e-05

By O 0 3.80297024094034e-05
protein O 0 3.7489153328351676e-05
- O 0 4.71996572741773e-05
truncation O 0 0.00010461168130859733
test O 0 7.201320840977132e-06
( O 0 2.0270426830393262e-06
PTT O 0 3.2511441077076597e-06
) O 0 3.2162088814402523e-07
assay O 0 1.4474186400548206e-06
, O 0 7.006230617889742e-08
the O 0 1.0966503793952143e-07
entire O 0 5.806917897643871e-07
coding O 0 4.9454524742031936e-06
region O 0 7.266563670782489e-07
of O 0 1.1318654458136734e-07
the O 0 3.258014089624339e-07
APC B-Disease 0 9.577014679962303e-06
gene O 0 1.5847859913264983e-06
was O 0 6.931720690772636e-07
screened O 0 1.9269380118203117e-06
in O 0 5.41596250513976e-07
affected O 0 1.4740307960892096e-06
individuals O 0 4.477586514894938e-07
from O 0 6.882016236886557e-07
11 O 0 1.5480314687010832e-05
AAPC B-Disease 1 0.998708963394165
kindreds O 0 0.0002270485565531999
, O 0 3.7726036339336133e-07
and O 0 2.1449942266826838e-07
their O 0 3.300174569176306e-07
phenotypic O 0 2.089304143737536e-05
differences O 0 1.094499839382479e-05
were O 0 6.230642611626536e-06
examined O 0 0.00011239913146710023
. O 0 2.549291093600914e-05

Five O 0 0.00020600603602360934
novel O 0 0.0002157213748432696
germ O 0 0.0023381283972412348
- O 0 0.0011403021635487676
line O 0 0.0002644581254571676
APC B-Disease 0 0.0005172822857275605
mutations O 0 2.551112811488565e-05
were O 0 9.36757544423017e-07
identified O 0 3.075545237152255e-06
in O 0 1.6021385818021372e-06
seven O 0 1.9997498384327628e-05
kindreds O 0 0.001476390054449439
. O 0 3.39597936545033e-05

Mutations O 0 0.010058140382170677
were O 0 8.044587048061658e-06
located O 0 2.7968071663053706e-06
in O 0 3.7495365745598974e-07
three O 0 3.134235839752364e-07
different O 0 1.7003958419081755e-07
regions O 0 3.7501013139262795e-07
of O 0 1.0732937738566761e-07
the O 0 4.810561904378119e-07
APC B-Disease 0 2.5473154892097227e-05
gene O 0 1.6414761603300576e-06
( O 0 3.442914930928964e-07
1 O 0 3.892243682912522e-07
) O 0 1.0215921975031961e-07
at O 0 5.6331881381765925e-08
the O 0 5.629128096984459e-08
5 O 0 3.378371218332177e-07
end O 0 3.400571984002454e-07
spanning O 0 1.0345629561925307e-06
exons O 0 5.112343387736473e-06
4 O 0 1.098280563383014e-06
and O 0 2.2634792173903406e-07
5 O 0 7.904210406195489e-07
, O 0 1.3733516368574783e-07
( O 0 2.664307601207838e-07
2 O 0 3.044400500584743e-07
) O 0 9.759244079532436e-08
within O 0 1.2290549022964115e-07
exon O 0 3.956897671741899e-06
9 O 0 1.3373255569604225e-06
, O 0 1.0619191215255341e-07
and O 0 1.022412874362999e-07
( O 0 3.746055199371767e-07
3 O 0 4.1951264506678854e-07
) O 0 1.2823208805912145e-07
at O 0 6.824378573355716e-08
the O 0 8.482894031658361e-08
3 O 0 8.711048735676741e-07
distal O 0 3.248218126827851e-05
end O 0 1.0451331036165357e-06
of O 0 3.083781905388605e-07
the O 0 1.6490595271534403e-06
gene O 0 2.9644994356203824e-05
. O 0 1.9512166545609944e-05

Variability O 0 0.0017681075260043144
in O 0 1.0303349881723989e-05
the O 0 2.3079824131855275e-06
number O 0 2.5104109226958826e-06
of O 0 0.00011123959120595828
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 4.998564691049978e-05
most O 0 4.6688745669598575e-07
apparent O 0 1.9834160411846824e-05
in O 0 6.125086429165094e-07
individuals O 0 3.9867882151156664e-07
with O 0 4.787066245626193e-07
mutations O 0 1.1287052984698676e-05
in O 0 2.0987111781778367e-07
region O 0 1.5871560208324809e-06
1 O 0 9.981075663745287e-07
, O 0 1.498606252425816e-07
and O 0 3.7827521737199277e-07
upper O 0 0.0002558102714829147
- O 1 0.7534518837928772
gastrointestinal O 1 0.9785584211349487
manifestations O 0 4.8928657633950934e-05
were O 0 1.355225549559691e-06
more O 0 7.590032282678294e-07
severe O 0 0.014938551001250744
in O 0 2.905543851738912e-06
them O 0 2.38817938225111e-06
. O 0 1.941312621056568e-05

In O 0 4.529226862359792e-05
individuals O 0 6.499269147752784e-06
with O 0 2.48037395067513e-06
mutations O 0 1.9231347323511727e-05
in O 0 3.059302002839104e-07
either O 0 4.045838295496651e-07
region O 0 1.3685562407772522e-06
2 O 0 2.0457093796721892e-06
or O 0 3.741906198229117e-07
region O 0 1.034225533658173e-06
3 O 0 7.070627816574415e-07
, O 0 6.79564706729252e-08
the O 0 4.5711971097261994e-08
average O 0 2.030959791454734e-07
number O 0 3.228137401833919e-08
of O 0 9.13131330548822e-08
adenomas B-Disease 0 0.0008893695194274187
tended O 0 4.258547050994821e-06
to O 0 1.0425642926747969e-07
be O 0 4.688668298058474e-08
lower O 0 4.680885297148052e-07
than O 0 3.494045586194261e-08
those O 0 3.124643299656782e-08
in O 0 9.636075759544838e-08
individuals O 0 1.0541035067035409e-07
with O 0 1.7291476694936136e-07
mutations O 0 3.7340246308303904e-06
in O 0 1.4669178938220284e-07
region O 0 9.47765443015669e-07
1 O 0 9.501999898020586e-07
, O 0 2.539356103170576e-07
although O 0 3.6826114069299365e-07
age O 0 1.4961871102059376e-06
at O 0 2.7079265692009358e-06
diagnosis O 0 0.011268410831689835
was O 0 1.5275387340807356e-05
similar O 0 2.0516981749096885e-05
. O 0 2.2909125618753023e-05

In O 0 0.00010463373473612592
all O 0 1.753680953697767e-05
AAPC B-Disease 1 0.9980013966560364
kindreds O 0 0.0008726256783120334
, O 0 2.1179641862545395e-06
a O 0 2.5387535060872324e-06
predominance O 0 4.6072047553025186e-05
of O 0 3.0843366403132677e-06
right O 0 0.0002450669417157769
- O 1 0.9568591117858887
sided O 1 0.9999898672103882
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 0.0017560198903083801
rectal B-Disease 1 0.9999761581420898
polyp I-Disease 1 0.99748295545578
sparing O 0 0.0010833600535988808
was O 0 5.667714503942989e-05
observed O 0 5.0187212764285505e-05
. O 0 2.8015967473038472e-05

No O 0 0.0021058046258985996
desmoid B-Disease 1 0.9988413453102112
tumors I-Disease 1 0.9999994039535522
were O 0 1.3172465514799114e-05
found O 0 3.7875418001931394e-06
in O 0 2.348688894926454e-06
these O 0 4.173015440755989e-06
kindreds O 0 0.000726322818081826
. O 0 3.298928277217783e-05

Our O 0 5.610341759165749e-05
data O 0 1.5719742805231363e-05
suggest O 0 7.899124284449499e-06
that O 0 4.787833063346625e-07
, O 0 6.073469194234349e-07
in O 0 2.8552265121106757e-06
AAPC B-Disease 1 0.9999927282333374
families O 0 1.1762635040213354e-05
, O 0 1.322184886021205e-07
the O 0 8.384864713661955e-08
location O 0 2.1612547129734594e-07
of O 0 9.757290087009096e-08
the O 0 1.0824273886100855e-06
APC B-Disease 0 0.0005576948169618845
mutation O 0 4.2816867789952084e-05
may O 0 3.329001174279256e-06
partially O 0 2.142953235306777e-05
predict O 0 7.517070571338991e-06
specific O 0 3.0739531666768016e-06
phenotypic O 0 7.072285370668396e-05
expression O 0 2.8827247660956345e-05
. O 0 2.0139004845987074e-05

This O 0 1.7502776245237328e-05
should O 0 3.4788188258971786e-06
help O 0 1.2303900120969047e-06
in O 0 2.5507856094009185e-07
the O 0 2.3696661344274617e-07
design O 0 2.0949228201061487e-06
of O 0 4.760633487421728e-07
tailored O 0 0.02175196073949337
clinical O 0 0.004996956791728735
- O 0 0.008409391157329082
management O 0 1.2583377611008473e-05
protocols O 0 4.86761973661487e-06
in O 0 2.2921530273833923e-07
this O 0 3.1664151833865617e-07
subset O 0 7.135623036447214e-06
of O 0 3.3217195323231863e-06
FAP B-Disease 0 0.2782013416290283
patients O 0 0.0007471138960681856
. O 0 5.194480763748288e-06
. O 0 1.2661587788898032e-05

Wilms B-Disease 1 0.9991217255592346
' I-Disease 0 0.017360739409923553
tumor I-Disease 0 0.011115768924355507
1 O 0 1.5359819371951744e-05
and O 0 2.9309107958397362e-06
Dax O 0 0.001815160852856934
- O 0 4.8442379920743406e-05
1 O 0 2.8999550067965174e-06
modulate O 0 9.233855053025763e-06
the O 0 7.654626301700773e-07
orphan O 0 9.389252227265388e-05
nuclear O 0 1.2443257219274528e-05
receptor O 0 8.977818652056158e-06
SF O 0 0.00017914219642989337
- O 0 7.931885193102062e-06
1 O 0 1.189915224131255e-06
in O 0 3.1364544383905013e-07
sex O 0 2.0434436009963974e-06
- O 0 1.2314580999372993e-05
specific O 0 2.486033736204263e-06
gene O 0 1.2828158105548937e-05
expression O 0 1.6953412341536023e-05
. O 0 1.275289923796663e-05

Products O 0 0.00016866432270035148
of O 0 1.7175954781123437e-05
steroidogenic O 0 0.0025766605976969004
factor O 0 1.9386761778150685e-05
1 O 0 7.871503839851357e-06
( O 0 4.527042619884014e-06
SF O 0 0.0014725974760949612
- O 0 1.6538675481569953e-05
1 O 0 2.904975872297655e-06
) O 0 1.417828002558963e-06
and O 0 2.9058569452899974e-06
Wilms B-Disease 1 0.9688655138015747
tumor I-Disease 0 0.0026740028988569975
1 O 0 4.340598025009967e-06
( O 0 2.3501229406974744e-06
WT1 O 0 9.081036114366725e-05
) O 0 9.66359834819741e-07
genes O 0 6.818536348873749e-07
are O 0 4.9924132383694086e-08
essential O 0 2.09827490493808e-07
for O 0 4.133358117996977e-07
mammalian O 0 1.7125397789641283e-05
gonadogenesis O 0 0.0001132063043769449
prior O 0 3.6421072309167357e-06
to O 0 1.4217071111488622e-06
sexual O 0 1.9906263332813978e-05
differentiation O 0 0.0001296322006965056
. O 0 2.9662811357411556e-05

In O 0 5.697464803233743e-05
males O 0 8.081906707957387e-05
, O 0 5.121170943311881e-06
SF O 0 0.004466759506613016
- O 0 7.105232361936942e-05
1 O 0 2.0671211586886784e-06
participates O 0 1.0581801461739815e-06
in O 0 2.25241535645182e-07
sexual O 0 7.064494411679334e-07
development O 0 3.0057199751354347e-07
by O 0 1.1768775465270664e-07
regulating O 0 1.2928963997183018e-06
expression O 0 5.651337460221839e-07
of O 0 1.8880919583352807e-07
the O 0 1.3970238796900958e-06
polypeptide O 0 0.00016290547500830144
hormone O 0 8.090727351373062e-05
Mullerian O 0 0.0014799103373661637
inhibiting O 0 0.0001939677749760449
substance O 0 4.3950360122835264e-05
( O 0 2.3388085537590086e-05
MIS O 0 0.0011833800235763192
) O 0 1.8945662304759026e-05
. O 0 2.1309011572157033e-05

Here O 0 5.058448005001992e-05
, O 0 5.416533895186149e-06
we O 0 1.401353870278399e-06
show O 0 2.498888306945446e-06
that O 0 1.1598615401453571e-06
WT1 O 0 0.0006188983097672462
- O 0 0.0002836758503690362
KTS O 0 0.0018173444550484419
isoforms O 0 1.8092339814756997e-05
associate O 0 5.0607936827873345e-06
and O 0 1.084531163542124e-06
synergize O 0 0.0001011095882859081
with O 0 2.9977154554217122e-06
SF O 0 0.0465162992477417
- O 0 4.639929466065951e-05
1 O 0 2.3635977868252667e-06
to O 0 8.647364211356035e-07
promote O 0 5.8493210417509545e-06
MIS O 0 0.000964019272942096
expression O 0 4.1414943552808836e-05
. O 0 1.8077678760164417e-05

In O 0 0.00011887330038007349
contrast O 0 0.00023985601728782058
, O 0 3.389414632692933e-05
WT1 O 0 0.024660123512148857
missense O 0 0.05976700037717819
mutations O 0 0.0002860287786461413
, O 0 1.7002578260871815e-06
associated O 0 1.6604279835519264e-06
with O 0 1.1479559134386363e-06
male B-Disease 0 0.00012300736852921546
pseudohermaphroditism I-Disease 1 0.9995859265327454
in O 0 3.6565328628057614e-05
Denys B-Disease 1 0.9987610578536987
- I-Disease 1 0.9998136162757874
Drash I-Disease 1 0.9999955892562866
syndrome I-Disease 1 0.9999972581863403
, O 0 2.9314448966033524e-06
fail O 0 8.737707503314596e-06
to O 0 6.088622512834263e-07
synergize O 0 0.0001647272438276559
with O 0 5.32300100530847e-06
SF O 1 0.7138378024101257
- O 0 0.0006470558582805097
1 O 0 3.372988794581033e-05
. O 0 1.8668491975404322e-05

Additionally O 0 0.00020826977561227977
, O 0 5.914687335462077e-06
the O 0 1.631522081879666e-06
X O 0 0.00032560681574977934
- O 0 0.0003679843503050506
linked O 0 4.098363206139766e-05
, O 0 1.2253044587851036e-06
candidate O 0 4.642475687433034e-06
dosage O 0 2.7538422727957368e-05
- O 0 1.783139305189252e-05
sensitive O 0 3.2433772503281944e-06
sex O 0 2.973899199787411e-06
- O 0 2.6533318305155262e-05
reversal O 0 2.3959468308021314e-05
gene O 0 3.171869366269675e-06
, O 0 5.45132422757888e-07
Dax O 0 0.00032362493220716715
- O 0 2.4506429326720536e-05
1 O 0 2.380548266955884e-06
, O 0 5.136791401127994e-07
antagonizes O 0 1.6604040865786374e-05
synergy O 0 7.80043046688661e-06
between O 0 1.4865796629237593e-06
SF O 0 0.0015753215411677957
- O 0 4.683745282818563e-05
1 O 0 2.8849378850281937e-06
and O 0 8.696638360561337e-07
WT1 O 0 0.0003484028857201338
, O 0 4.3205079691688297e-07
most O 0 9.857441796157218e-08
likely O 0 2.3760793510518852e-07
through O 0 9.44322877671766e-08
a O 0 2.72158644065712e-07
direct O 0 4.248246341376216e-07
interaction O 0 8.421678785452968e-07
with O 0 1.0689498139981879e-06
SF O 0 0.11744994670152664
- O 0 0.0003009811043739319
1 O 0 3.8392641727114096e-05
. O 0 1.8654362065717578e-05

We O 0 3.342785930726677e-05
propose O 0 5.794796743430197e-05
that O 0 2.957619017252e-06
WT1 O 0 0.0002528264303691685
and O 0 4.181237272860017e-06
Dax O 0 0.12426631152629852
- O 0 0.00016177348152268678
1 O 0 4.602579792845063e-06
functionally O 0 1.509834601165494e-05
oppose O 0 1.6202110373342293e-06
each O 0 1.3409956522991706e-07
other O 0 1.0227093127923581e-07
in O 0 5.349012894839689e-07
testis O 0 4.7884692321531475e-05
development O 0 1.159252292382007e-06
by O 0 5.321730327523255e-07
modulating O 0 7.483444642275572e-05
SF O 0 0.010659311898052692
- O 0 7.780497253406793e-05
1 O 0 5.812808012706228e-06
- O 0 5.752643846790306e-05
mediated O 0 0.00024767854483798146
transactivation O 0 0.0008172098314389586
. O 0 8.636027814645786e-06
. O 0 1.5985497157089412e-05

A O 0 0.00038153259083628654
mouse O 0 0.0006682652165181935
model O 0 0.00013697834219783545
for O 0 8.243377669714391e-05
Prader B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999997615814209
imprinting O 0 0.48076748847961426
- O 0 0.18594743311405182
centre O 0 0.001497504417784512
mutations O 0 0.0006130697438493371
. O 0 5.207591675571166e-05

Imprinting O 0 0.0029482091777026653
in O 0 3.102649498032406e-05
the O 0 7.005975930951536e-06
15q11 O 0 0.00024824903812259436
- O 0 0.0001422228669980541
q13 O 0 6.674566975561902e-05
region O 0 3.867880423058523e-06
involves O 0 1.7928541637957096e-06
an O 0 5.510288474397385e-07
imprinting O 0 0.00013650217442773283
centre O 0 3.304967685835436e-05
( O 0 2.048059741355246e-06
IC O 0 2.1093563191243447e-05
) O 0 2.6730933200269646e-07
, O 0 5.970339600480656e-08
mapping O 0 7.255125069605128e-07
in O 0 4.942661391282854e-08
part O 0 1.1566787350147933e-07
to O 0 4.7400657621210485e-08
the O 0 1.0722215648684141e-07
promoter O 0 1.7979600670514628e-06
and O 0 1.5123980290354666e-07
first O 0 6.999804895713169e-07
exon O 0 2.4285365725518204e-05
of O 0 3.384025148989167e-06
SNRPN O 0 0.003608396975323558
. O 0 3.09214556182269e-05

Deletion O 0 0.0022778150159865618
of O 0 1.62599917530315e-05
this O 0 4.273009835742414e-06
IC O 0 0.00015341458492912352
abolishes O 0 0.00034894474083557725
local O 0 5.350101673684549e-06
paternally O 0 7.482645742129534e-05
derived O 0 4.069891929248115e-06
gene O 0 3.597160230128793e-06
expression O 0 1.9273606994829606e-06
and O 0 6.631973974435823e-07
results O 0 1.1315463780192658e-05
in O 0 0.00011941760749323294
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0025443898048251867
PWS B-Disease 1 0.9999866485595703
) O 0 7.22200347809121e-05
. O 0 5.121840877109207e-05

We O 0 2.035712532233447e-05
have O 0 2.5856695629045134e-06
created O 0 3.118388121947646e-06
two O 0 2.0463728560571326e-06
deletion O 0 0.013281415216624737
mutations O 0 0.00014719957835040987
in O 0 2.247200427518692e-06
mice O 0 6.303311965893954e-05
to O 0 1.0550352271820884e-06
understand O 0 7.521029147028457e-06
PWS B-Disease 1 0.9989305138587952
and O 0 5.069485382591665e-07
the O 0 2.41944746903755e-07
mechanism O 0 1.5278764067261363e-06
of O 0 3.272076014582126e-07
this O 0 1.3831071328240796e-06
IC O 0 0.0004202603886369616
. O 0 2.095547824865207e-05

Mice O 0 0.06267870962619781
harbouring O 0 0.0020528328604996204
an O 0 2.6867593987844884e-05
intragenic O 0 0.004055995959788561
deletion O 0 0.0009139812318608165
in O 0 6.1564564930449706e-06
Snrpn O 0 0.0005478329258039594
are O 0 9.127375619755185e-07
phenotypically O 0 0.00022401743626687676
normal O 0 3.8128821415739367e-06
, O 0 3.9192113376884663e-07
suggesting O 0 1.2736763892462477e-06
that O 0 1.7478424751971033e-07
mutations O 0 2.1297382772900164e-06
of O 0 1.6333500241216825e-07
SNRPN O 0 0.004186251666396856
are O 0 1.8306856475192035e-07
not O 0 1.8886105124238384e-07
sufficient O 0 1.714910695227445e-06
to O 0 3.703115226016962e-06
induce O 0 0.0003932987747248262
PWS B-Disease 1 0.9999116659164429
. O 0 4.0465096390107647e-05

Mice O 0 0.007136430125683546
with O 0 1.28056699395529e-05
a O 0 1.003975012281444e-05
larger O 0 1.11190101961256e-05
deletion O 0 9.540045721223578e-05
involving O 0 5.6505086831748486e-06
both O 0 1.0177622016271926e-06
Snrpn O 0 0.00012614685692824423
and O 0 9.184429359265778e-07
the O 0 2.7039293399866438e-06
putative O 0 0.012393095530569553
PWS O 1 0.9999890327453613
- O 0 0.02901500090956688
IC O 0 0.0004237190878484398
lack O 0 3.826655756711261e-06
expression O 0 1.3615590432891622e-06
of O 0 2.404647432285856e-07
the O 0 8.387734169446048e-07
imprinted O 0 0.00010944302630377933
genes O 0 9.075825801119208e-06
Zfp127 O 0 9.479269647272304e-05
( O 0 2.300052301507094e-06
mouse O 0 8.321092536789365e-06
homologue O 0 2.2590209482586943e-05
of O 0 8.569643341616029e-07
ZNF127 O 0 0.00036019404069520533
) O 0 1.2922528185299598e-06
, O 0 6.510054504360596e-07
Ndn O 0 9.885610052151605e-05
and O 0 3.043373055788834e-07
Ipw O 0 1.0891023521253373e-05
, O 0 2.454372349802725e-07
and O 0 3.021829684257682e-07
manifest O 0 5.428448275779374e-06
several O 0 8.531179673809675e-07
phenotypes O 0 0.0003186471585649997
common O 0 1.774628253770061e-05
to O 0 5.912599590374157e-05
PWS B-Disease 1 0.9999995231628418
infants O 1 0.9151097536087036
. O 0 5.245676584308967e-05

These O 0 1.1888186236319598e-05
data O 0 7.052753971947823e-06
demonstrate O 0 2.995080649270676e-06
that O 0 1.1418290313258694e-07
both O 0 7.987841854628641e-08
the O 0 8.837418619123127e-08
position O 0 2.1907345626459573e-07
of O 0 6.293090848430438e-08
the O 0 1.4880504295433639e-07
IC O 0 1.54032986756647e-05
and O 0 1.3049550773303054e-07
its O 0 8.58670290426744e-08
role O 0 2.248921049385899e-07
in O 0 8.288078845453128e-08
the O 0 7.942991686604728e-08
coordinate O 0 1.1861411621794105e-06
expression O 0 5.240653990767896e-07
of O 0 1.1306237013286591e-07
genes O 0 5.183279654374928e-07
is O 0 7.71088295437039e-08
conserved O 0 3.236136478790286e-07
between O 0 1.5705137457189267e-07
mouse O 0 3.0039484499866376e-06
and O 0 1.6219782139614836e-07
human O 0 2.404259760169225e-07
, O 0 1.0329899424732503e-07
and O 0 8.56377226909899e-08
indicate O 0 2.765283682037989e-07
that O 0 2.8236984306317936e-08
the O 0 1.0743362821585833e-07
mouse O 0 7.286449545063078e-06
is O 0 8.986934574295447e-08
a O 0 2.402625511876977e-07
suitable O 0 5.228732220530219e-07
model O 0 2.209940021202783e-06
system O 0 1.0604998124108533e-06
in O 0 1.5974380573879898e-07
which O 0 7.720935002453189e-08
to O 0 7.798652035262421e-08
investigate O 0 5.173940280656097e-07
the O 0 1.4445501506088476e-07
molecular O 0 1.4715054703628994e-06
mechanisms O 0 7.832145456632134e-07
of O 0 1.3725541236908612e-07
imprinting O 0 1.9518138287821785e-05
in O 0 2.747864868979377e-07
this O 0 9.083144902888307e-08
region O 0 6.967955528125458e-07
of O 0 1.9047649857384386e-07
the O 0 1.121414925364661e-06
genome O 0 1.6434969438705593e-05
. O 0 4.019937478005886e-06
. O 0 1.4186627595336176e-05

Mutations O 0 0.0011543658329173923
of O 0 4.722455287264893e-06
the O 0 2.368803734498215e-06
ATM O 0 5.293445792631246e-05
gene O 0 1.5481140508200042e-05
detected O 0 1.2868520570918918e-05
in O 0 3.418609367145109e-06
Japanese O 0 0.00021004964946769178
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
telangiectasia I-Disease 1 1.0
patients O 1 0.529123067855835
: O 0 1.4984932477091206e-06
possible O 0 1.1393635759304743e-06
preponderance O 0 7.02240413374966e-06
of O 0 1.4419983074276388e-07
the O 0 2.879139060496527e-07
two O 0 1.5535169950453565e-06
founder O 0 0.00013221662084106356
mutations O 0 3.074731648666784e-05
4612del165 O 0 6.850552745163441e-05
and O 0 5.834568128193496e-06
7883del5 O 0 0.0006132789421826601
. O 0 3.61707279807888e-05

The O 0 8.492045162711293e-05
ATM O 0 0.0007540901424363256
( O 0 6.30277136224322e-05
A O 0 0.1679881513118744
- O 1 0.9872531294822693
T O 1 0.9998416900634766
, O 0 2.5445756364206318e-06
mutated O 0 1.102925216400763e-05
) O 0 1.1966372994720587e-06
gene O 0 2.3624686491530156e-06
on O 0 1.2403854725562269e-06
human O 0 8.481981240038294e-06
chromosome O 0 0.0005187804345041513
11q22 O 0 0.0006192547152750194
. O 0 3.503144034766592e-05

3 O 0 0.00029355776496231556
has O 0 1.3419116839941125e-05
recently O 0 1.572742075950373e-05
been O 0 6.988859126977331e-07
identified O 0 1.0744832934506121e-06
as O 0 1.2994821929623868e-07
the O 0 2.3519832836882415e-07
gene O 0 1.5962197039698367e-06
responsible O 0 5.289983846523683e-07
for O 0 2.7542350267140137e-07
the O 0 4.163562152825762e-06
human O 0 0.00026132032508030534
recessive B-Disease 1 0.9999978542327881
disease I-Disease 1 0.9997170567512512
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999990463256836
telangiectasia I-Disease 1 1.0
( O 0 0.0008319205371662974
A B-Disease 1 0.9841048121452332
- I-Disease 1 0.9999032020568848
T I-Disease 1 0.9999921321868896
) O 0 3.41937666235026e-05
. O 0 2.3479531591874547e-05

In O 0 2.9173219445510767e-05
order O 0 4.75269462185679e-06
to O 0 5.991466878185747e-07
define O 0 3.0742814942641417e-06
the O 0 4.929269152853522e-07
types O 0 8.83472750956571e-07
of O 0 1.0845767519640503e-06
disease O 0 0.00031593680614605546
- O 0 0.001502596540376544
causing O 0 5.3156225476413965e-05
ATM O 0 0.00023756550217512995
mutations O 0 9.638365554565098e-06
in O 0 4.990975526197872e-07
Japanese O 0 1.0838449270522688e-05
A B-Disease 1 0.9829556941986084
- I-Disease 1 0.9999988079071045
T I-Disease 1 1.0
patients O 0 0.00012649170821532607
as O 0 1.0776383874144813e-07
well O 0 8.08554574405207e-08
as O 0 5.4978173125164176e-08
to O 0 7.132176449431427e-08
look O 0 3.0053703881094407e-07
for O 0 1.7736545032676077e-07
possible O 0 1.0908318017754937e-06
mutational O 0 0.0002070633345283568
hotspots O 0 3.3918422559509054e-05
, O 0 6.112126698099019e-07
reverse O 0 1.0576239219517447e-05
- O 0 1.0917591680481564e-05
transcribed O 0 4.501435796555597e-06
RNA O 0 1.6407452676503453e-06
derived O 0 4.790765615325654e-07
from O 0 2.4442931589874206e-07
ten O 0 8.482180078317469e-07
patients O 0 6.17654495727038e-06
belonging O 0 8.465710834570928e-07
to O 0 2.067407791628284e-07
eight O 0 1.2998222018723027e-06
unrelated O 0 1.643114592297934e-05
Japanese O 0 1.162255102826748e-05
A B-Disease 1 0.6624910831451416
- I-Disease 1 0.9982553124427795
T I-Disease 1 0.9999713897705078
families O 0 3.607088046919671e-06
was O 0 7.310611636057729e-07
analyzed O 0 1.125037670135498e-06
for O 0 4.19650689309492e-07
mutations O 0 4.368396275822306e-06
by O 0 2.8201307600284053e-07
the O 0 7.060116331558675e-07
restriction O 0 1.0700274287955835e-05
endonuclease O 0 0.0001177965896204114
fingerprinting O 0 9.632738510845229e-05
method O 0 4.960547448717989e-05
. O 0 2.9653536330442876e-05

As O 0 2.9254291803226806e-05
has O 0 7.3569226515246555e-06
been O 0 1.873807491392654e-06
reported O 0 3.5921348171541467e-06
by O 0 2.672415178039955e-07
others O 0 1.685178517618624e-06
, O 0 7.233893484226428e-07
mutations O 0 4.299309239286231e-06
that O 0 7.613493835378904e-08
lead O 0 1.0823066531884251e-06
to O 0 3.553512897269684e-07
exon O 0 2.054016113106627e-05
skipping O 0 1.737893035169691e-05
or O 0 4.129290118726203e-06
premature O 0 4.314081888878718e-05
protein O 0 1.9066910681431182e-06
truncation O 0 1.6505809981026687e-05
were O 0 5.490946932695806e-07
also O 0 4.61181457467319e-07
predominant O 0 5.121146841702284e-06
in O 0 1.1404027873140876e-06
our O 0 4.304047706682468e-06
mutants O 0 0.00018670457939151675
. O 0 1.8735623598331586e-05

Six O 0 0.00015505818009842187
different O 0 1.6988014976959676e-05
mutations O 0 7.850403198972344e-05
were O 0 9.934865374816582e-07
identified O 0 1.386603116770857e-06
on O 0 2.900782476444874e-07
12 O 0 9.645469845054322e-07
of O 0 2.119272437539621e-07
the O 0 1.1179903367519728e-06
16 O 0 1.5946989151416346e-05
alleles O 0 6.054033656255342e-05
examined O 0 5.3844098147237673e-05
. O 0 2.583791865617968e-05

Four O 0 5.975643580313772e-05
were O 0 6.7248793129692785e-06
deletions O 0 4.8187808715738356e-05
involving O 0 7.669338629057165e-06
a O 0 1.354943378828466e-05
loss O 0 5.9520472859730944e-05
of O 0 3.9518789662906784e-07
a O 0 1.978296722882078e-06
single O 0 3.670084424811648e-06
exon O 0 6.61120138829574e-05
exon O 0 4.7287598135881126e-05
7 O 0 6.032131295796717e-06
, O 0 6.767551781194925e-07
exon O 0 1.1559840459085535e-05
16 O 0 3.350014367242693e-06
, O 0 6.045499958418077e-07
exon O 0 2.4213102733483538e-05
33 O 0 7.587168965983437e-06
or O 0 2.091172063956037e-06
exon O 0 7.103247480699793e-05
35 O 0 3.559163087629713e-05
. O 0 1.745668487274088e-05

The O 0 3.376703170943074e-05
others O 0 9.81669745669933e-06
were O 0 1.5321181763283676e-06
minute O 0 3.631802883319324e-06
deletions O 0 1.0700376151362434e-05
, O 0 7.04271315044025e-07
4649delA O 0 1.917055487865582e-05
in O 0 7.413008233925211e-07
exon O 0 2.238252454844769e-05
33 O 0 6.210839728737483e-06
and O 0 9.066551456271554e-07
7883del5 O 0 5.586967745330185e-05
in O 0 3.1963108995114453e-06
exon O 0 0.00016723985027056187
55 O 0 6.219409260665998e-05
. O 0 1.8628976249601692e-05

The O 0 7.264773739734665e-05
mutations O 0 0.0002492068742867559
4612del165 O 0 0.00014637934509664774
and O 0 2.1936918983556097e-06
7883del5 O 0 0.00010037373431259766
were O 0 5.535264335776446e-07
found O 0 1.797870936570689e-07
in O 0 7.902613674559689e-08
more O 0 5.4879372157756734e-08
than O 0 6.990386225425027e-08
two O 0 2.0192446470446157e-07
unrelated O 0 1.484912536398042e-05
families O 0 4.205214736430207e-06
; O 0 2.7043961381423287e-06
44 O 0 7.516066943935584e-06
% O 0 1.1245227824474568e-06
( O 0 1.6179151884898602e-07
7 O 0 2.1237863734313578e-07
of O 0 3.0815733964573155e-08
16 O 0 2.7113483724861e-07
) O 0 5.5349268279769603e-08
of O 0 3.460848674308181e-08
the O 0 1.5910295303456223e-07
mutant O 0 4.8193738621193916e-05
alleles O 0 3.6320072922535473e-06
had O 0 2.39618401565167e-07
one O 0 4.6789036645122906e-08
of O 0 8.389807959474638e-08
the O 0 5.661192403749737e-07
two O 0 4.396511030790862e-06
mutations O 0 0.0001076347180060111
. O 0 1.448039802198764e-05

The O 0 7.497337355744094e-05
4612del165 O 0 0.006618439219892025
mutations O 0 0.00012480300210881978
in O 0 7.977851055329666e-07
three O 0 4.424653354817565e-07
different O 0 2.099576050795804e-07
families O 0 9.7173290214414e-07
were O 0 1.193289875800474e-07
all O 0 3.621726207825304e-08
ascribed O 0 1.1091113947259146e-06
to O 0 8.629094594425624e-08
the O 0 1.4076731247314456e-07
same O 0 1.657482130212884e-06
T O 0 0.005502185318619013
- O 0 2.7915370083064772e-05
- O 0 2.4871033019735478e-05
> O 0 3.0859960133966524e-06
A O 0 7.079304964463518e-07
substitution O 0 9.948973911377834e-07
at O 0 2.866082695618388e-07
the O 0 3.3389613918188843e-07
splice O 0 3.092021870543249e-05
donor O 0 1.0050067430711351e-05
site O 0 3.7677277759939898e-06
in O 0 2.908845999627374e-06
intron O 0 0.0008925938745960593
33 O 0 0.000115915150672663
. O 0 2.0811308786505833e-05

Microsatellite O 0 0.014272250235080719
genotyping O 0 0.0018590788822621107
around O 0 1.8108394215232693e-05
the O 0 6.259682322706794e-06
ATM O 0 5.5094158597057685e-05
locus O 0 5.8972491387976333e-05
also O 0 2.456051561239292e-06
indicated O 0 3.0426058401644696e-06
that O 0 9.589852822955436e-08
a O 0 9.207784046338929e-07
common O 0 3.254593593737809e-06
haplotype O 0 0.00019512265862431377
was O 0 1.3115443380229408e-06
shared O 0 4.5410814664137433e-07
by O 0 2.2112249098427128e-07
the O 0 5.201110298003186e-07
mutant O 0 4.7991117753554136e-05
alleles O 0 9.3656608441961e-06
in O 0 1.1311333310004557e-06
both O 0 5.56135182705475e-06
mutations O 0 0.00013685654266737401
. O 0 1.9289278498035856e-05

This O 0 2.599557956273202e-05
suggests O 0 1.2569598766276613e-05
that O 0 4.855982069784659e-07
these O 0 2.3258502324097208e-07
two O 0 1.2774851256835973e-06
founder O 0 0.00023340208281297237
mutations O 0 9.205479000229388e-05
may O 0 1.8332991658098763e-06
be O 0 1.9378815352411038e-07
predominant O 0 3.9608735278306995e-06
among O 0 1.0108896049132454e-06
Japanese O 0 5.7399233810428996e-06
ATM O 0 8.780357165960595e-05
mutant O 0 0.0002996149123646319
alleles O 0 0.00010399116581538692
. O 0 1.9964876628364436e-05

W474C O 0 0.007553647737950087
amino O 0 0.0003726460272446275
acid O 0 0.00014357782492879778
substitution O 0 2.303430301253684e-05
affects O 0 1.131494627770735e-05
early O 0 1.4895939557391102e-06
processing O 0 6.07083450177015e-07
of O 0 9.20498521850277e-08
the O 0 1.5325272784139088e-07
alpha O 0 9.72310431279766e-07
- O 0 7.047610779409297e-07
subunit O 0 5.490041417033353e-07
of O 0 1.0311690346043179e-07
beta O 0 1.2468765362427803e-06
- O 0 4.257519776729168e-06
hexosaminidase O 0 1.9185223209206015e-05
A O 0 9.666639471106464e-07
and O 0 2.984702121011651e-07
is O 0 4.465109952889179e-07
associated O 0 2.1602668311970774e-06
with O 0 1.0584855772322044e-05
subacute O 1 0.9999980926513672
G B-Disease 1 0.9945666790008545
( I-Disease 0 2.1489435312105343e-05
M2 I-Disease 0 0.00048710411647334695
) I-Disease 0 1.4783832739340141e-05
gangliosidosis I-Disease 0 0.00039274615119211376
. O 0 2.0978954125894234e-05

Mutations O 0 0.0021179174073040485
in O 0 9.580787263985258e-06
the O 0 5.648509613820352e-06
HEXA O 0 0.0042532943189144135
gene O 0 1.2764238817908335e-05
, O 0 5.713368977922073e-07
encoding O 0 1.924950765896938e-06
the O 0 4.558111470487347e-07
alpha O 0 1.9903418433386832e-06
- O 0 1.7117702100222232e-06
subunit O 0 1.1973038454016205e-06
of O 0 3.0160111919030896e-07
beta O 0 3.3391822853445774e-06
- O 0 1.6846543076098897e-05
hexosaminidase O 0 5.394179606810212e-05
A O 0 2.581158696557395e-06
( O 0 1.0569517598923994e-06
Hex O 0 1.10991568362806e-05
A O 0 1.1234144494665088e-06
) O 0 3.0919065352463804e-07
, O 0 9.063381867235876e-08
that O 0 5.4879166100363364e-08
abolish O 0 2.644658025019453e-06
Hex O 0 1.5164089745667297e-05
A O 0 4.395257292344468e-06
enzyme O 0 1.662448084971402e-05
activity O 0 2.3803781004971825e-05
cause O 0 0.001144932466559112
Tay B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999949932098389
Sachs I-Disease 1 0.9999998807907104
disease I-Disease 0 0.4610807001590729
( O 0 2.445623613311909e-05
TSD B-Disease 0 0.14374637603759766
) O 0 1.62019853178208e-06
, O 0 4.584609314406407e-07
the O 0 1.2822124517697375e-06
fatal O 0 0.008501553907990456
infantile B-Disease 0 0.07822944223880768
form I-Disease 0 3.3466549211880192e-06
of I-Disease 0 2.2092149265517946e-06
G I-Disease 0 0.07215385138988495
( I-Disease 0 5.944460099271964e-06
M2 I-Disease 0 0.0001392542035318911
) I-Disease 0 2.3154007067205384e-06
gangliosidosis I-Disease 0 4.490713035920635e-05
, I-Disease 0 1.470604729547631e-06
Type I-Disease 0 6.056295205780771e-06
1 I-Disease 0 1.2043150491081178e-05
. O 0 1.404517206538003e-05

Less O 0 0.003046486061066389
severe O 1 0.9915168285369873
, O 0 0.00017306391964666545
subacute O 1 0.9999890327453613
( O 0 0.0005332779255695641
juvenile O 1 0.9923572540283203
- O 1 0.9719508290290833
onset O 1 0.9966621398925781
) O 0 1.078629520634422e-05
and O 0 1.4726309018442407e-05
chronic O 1 0.999321699142456
( O 0 1.3844763088854961e-05
adult O 0 5.1244260248495266e-05
- O 0 0.06276300549507141
onset O 1 0.6108953356742859
) O 0 8.292394113595947e-07
variants O 0 1.6195637044802424e-06
are O 0 1.0998176236398649e-07
characterized O 0 1.698431333352346e-06
by O 0 9.64344906151382e-08
a O 0 1.0001333521358902e-06
broad O 0 1.494376738264691e-05
spectrum O 0 1.5249594980559777e-05
of O 0 4.1916950976883527e-07
clinical O 0 7.954744796734303e-05
manifestations O 0 1.117064221034525e-05
and O 0 3.5097292538921465e-07
are O 0 1.1278022071792293e-07
associated O 0 4.932782076139119e-07
with O 0 2.547586177570338e-07
residual O 0 2.0589739506249316e-05
levels O 0 4.7617413656553254e-07
of O 0 2.510731746951933e-07
Hex O 0 4.6006451157154515e-05
A O 0 7.177001862146426e-06
enzyme O 0 2.7549716833163984e-05
activity O 0 2.1882524379179813e-05
. O 0 1.9632874682429247e-05

We O 0 6.003722228342667e-05
identified O 0 3.188047048752196e-05
a O 0 1.7311193005298264e-05
1422 O 0 0.0036739716306328773
G O 0 0.0690961480140686
- O 0 0.0014648393262177706
- O 0 0.0024773625191301107
> O 0 0.00019460836483631283
C O 0 2.9950813768664375e-05
( O 0 1.1382155662431614e-06
amino O 0 1.604329668225546e-06
acid O 0 1.7548653659105184e-06
W474C O 0 5.819402758788783e-06
) O 0 1.7447548827931314e-07
substitution O 0 2.6355712634540396e-07
in O 0 6.495505999737361e-08
the O 0 7.824845482673481e-08
first O 0 1.6301163441312383e-07
position O 0 2.990243785916391e-07
of O 0 1.1583223624711536e-07
exon O 0 7.09940377419116e-06
13 O 0 1.1009127547367825e-06
of O 0 2.1844256536951434e-07
HEXA O 0 0.0003613061271607876
of O 0 1.7478325275988027e-07
a O 0 9.15970076675876e-07
non O 0 2.040686013060622e-06
- O 0 1.4593147170671728e-05
Jewish O 0 1.1299675861664582e-05
proband O 0 0.00015954866830725223
who O 0 3.8548487282241695e-06
manifested O 0 3.1270665203919634e-05
a O 0 1.6579007933614776e-05
subacute O 1 0.9526761770248413
variant O 0 0.00011658346193144098
of O 0 4.461203843675321e-06
G B-Disease 0 0.052732501178979874
( I-Disease 0 9.586023224983364e-06
M2 I-Disease 0 0.0004289068456273526
) I-Disease 0 1.059460100805154e-05
gangliosidosis I-Disease 0 0.0002671547990757972
. O 0 1.8022665244643576e-05

On O 0 3.439171632635407e-05
the O 0 5.22965729032876e-06
second O 0 3.9813043258618563e-05
maternally O 0 0.0015166742959991097
inherited O 0 0.0008608493371866643
allele O 0 2.8133848900324665e-05
, O 0 5.139192467140674e-07
we O 0 1.1937838451103744e-07
identified O 0 8.496826353621145e-07
the O 0 6.857599146314897e-07
common O 0 9.804403816815466e-05
infantile O 1 0.9999443292617798
disease O 0 0.3101963400840759
- O 0 0.003036295995116234
causing O 0 3.7022731703473255e-05
4 O 0 1.7142474462161772e-05
- O 0 0.00017610019131097943
bp O 0 6.013176971464418e-05
insertion O 0 2.6571809939923696e-05
, O 0 4.092325980309397e-06
+ O 0 3.906033452949487e-05
TATC O 0 0.0002963365404866636
1278 O 0 0.0002045248547801748
, O 0 1.5443658867297927e-06
in O 0 2.3498450900660828e-06
exon O 0 0.00015468029596377164
11 O 0 4.381476901471615e-05
. O 0 2.0397137632244267e-05

Pulse O 0 0.008166152983903885
- O 0 0.0012517941650003195
chase O 0 0.0001392783597111702
analysis O 0 6.90351862431271e-06
using O 0 3.4319273254368454e-06
proband O 0 0.00024229890550486743
fibroblasts O 0 2.7011201382265426e-05
revealed O 0 4.348851689428557e-06
that O 0 1.2668412807670393e-07
the O 0 1.8832417936209822e-07
W474C O 0 1.650861304369755e-05
- O 0 4.047029051434947e-06
containing O 0 9.492289905210782e-07
alpha O 0 2.3473519377148477e-06
- O 0 1.8689316902964492e-06
subunit O 0 1.969062395801302e-06
precursor O 0 2.307007434865227e-06
was O 0 5.896125685467268e-07
normally O 0 5.488638521455869e-07
synthesized O 0 1.5153460708461353e-06
, O 0 1.620894352072355e-07
but O 0 8.998597422760213e-08
not O 0 7.354773146062143e-08
phosphorylated O 0 9.818090802582446e-07
or O 0 2.5050204044418933e-07
secreted O 0 8.922371534936246e-07
, O 0 9.281924207016345e-08
and O 0 1.2468629506656725e-07
the O 0 3.306153359972086e-07
mature O 0 4.7721064220240805e-06
lysosomal O 0 7.388532685581595e-05
alpha O 0 6.795751232857583e-06
- O 0 6.302493602561299e-06
subunit O 0 5.321503522282001e-06
was O 0 1.6475614756927826e-06
not O 0 1.2894596466139774e-06
detected O 0 2.5529578124405816e-05
. O 0 1.321256331721088e-05

When O 0 4.039661871502176e-05
the O 0 9.009637324197683e-06
W474C O 0 9.765002323547378e-05
- O 0 1.3394082998274826e-05
containing O 0 1.646136865929293e-06
alpha O 0 4.664781044994015e-06
- O 0 4.625549081538338e-06
subunit O 0 3.4043464438582305e-06
was O 0 1.924475327541586e-06
transiently O 0 2.3331967895501293e-05
co O 0 9.16411227080971e-06
- O 0 8.1687521742424e-06
expressed O 0 3.824496275228739e-07
with O 0 1.3349689709230006e-07
the O 0 2.6935961727758695e-07
beta O 0 1.956349933607271e-06
- O 0 1.3675282843905734e-06
subunit O 0 9.1067869334438e-07
to O 0 1.711412949134683e-07
produce O 0 3.608770100527181e-07
Hex O 0 8.308563337777741e-06
A O 0 1.5156250583459041e-06
( O 0 9.582628308635321e-07
alphabeta O 0 1.977904321392998e-05
) O 0 4.0883134033720125e-07
in O 0 4.5312830820876115e-07
COS O 0 0.0011931321350857615
- O 0 8.771987631917e-05
7 O 0 1.1574888048926368e-05
cells O 0 1.380923322358285e-06
, O 0 6.142798980590669e-08
the O 0 1.022684017470965e-07
mature O 0 6.493672231044911e-07
alpha O 0 7.995186024345458e-07
- O 0 7.999777267286845e-07
subunit O 0 7.223035822789825e-07
was O 0 2.2917487285667448e-07
present O 0 1.2257038406460197e-07
, O 0 7.52654472080394e-08
but O 0 3.799100056767202e-08
its O 0 7.687768288633379e-08
level O 0 1.611942650470155e-07
was O 0 1.9734021350359399e-07
much O 0 6.78721434610452e-08
lower O 0 4.4156575995657477e-07
than O 0 4.160391853247347e-08
that O 0 2.454718028843672e-08
from O 0 6.000478691703393e-08
normal O 0 4.1487521684757667e-07
alpha O 0 1.0041119367087958e-06
- O 0 1.3294845757627627e-06
subunit O 0 1.4095501228439389e-06
transfections O 0 1.059492387867067e-05
, O 0 1.8293732750862546e-07
although O 0 1.468068262511224e-07
higher O 0 2.556650144924788e-07
than O 0 4.530202701857888e-08
in O 0 1.636318529563141e-07
those O 0 4.2503211261646356e-07
cells O 0 3.6708511288452428e-06
transfected O 0 2.4887118343031034e-05
with O 0 2.013984783388878e-07
an O 0 2.7623266873888497e-07
alpha O 0 3.981866939284373e-06
- O 0 7.044028734526364e-06
subunit O 0 1.0088035196531564e-05
associated O 0 5.128096745465882e-06
with O 0 1.1385866855562199e-05
infantile O 1 0.6759551763534546
TSD B-Disease 1 0.8802605867385864
. O 0 0.00010155600466532633

Furthermore O 0 0.0002961264399345964
, O 0 7.313294190680608e-06
the O 0 8.924295116230496e-07
precursor O 0 4.2709648369054776e-06
level O 0 4.4351557448862877e-07
of O 0 1.2396020565574872e-07
the O 0 2.4817504140628444e-07
W474C O 0 1.4806435501668602e-05
alpha O 0 1.7074106608561124e-06
- O 0 1.1481988622108474e-06
subunit O 0 6.688516691610857e-07
was O 0 2.3192032472252322e-07
found O 0 1.324047218531632e-07
to O 0 9.350191731982704e-08
accumulate O 0 1.642257643652556e-06
in O 0 1.3172537194350298e-07
comparison O 0 2.0763467034612404e-07
to O 0 7.365835585915192e-08
the O 0 1.8192424988683342e-07
normal O 0 2.2089536741987104e-06
alpha O 0 4.000623448519036e-06
- O 0 5.436410901893396e-06
subunit O 0 1.3987961210659705e-05
precursor O 0 2.7672576834447682e-05
levels O 0 8.236967914854176e-06
. O 0 1.0795843081723433e-05

We O 0 3.942874536733143e-05
conclude O 0 4.2042320274049416e-05
that O 0 1.4057013686397113e-06
the O 0 1.909791990328813e-06
1422 O 0 0.0007500001229345798
G O 0 0.018754562363028526
- O 0 0.00030008889734745026
- O 0 0.0038126499857753515
> O 0 0.0006784599972888827
C O 0 7.772214303258806e-05
mutation O 0 2.4173539259209065e-06
is O 0 9.367328601683766e-08
the O 0 1.7639752059039893e-07
cause O 0 1.2094665180484299e-06
of O 0 3.7420917919916974e-07
Hex B-Disease 0 0.01802724413573742
A I-Disease 0 0.04019413888454437
enzyme I-Disease 1 0.9999227523803711
deficiency I-Disease 1 0.9998276233673096
in O 0 1.9159947441949043e-06
the O 0 5.725615665141959e-06
proband O 0 0.0016751463990658522
. O 0 2.923962165368721e-05

The O 0 6.797322566853836e-05
resulting O 0 9.207419498125091e-05
W474C O 0 0.00016324754687957466
substitution O 0 1.634486034163274e-05
clearly O 0 4.125362011109246e-06
interferes O 0 7.07556546331034e-06
with O 0 5.067677761871892e-07
alpha O 0 2.996549255840364e-06
- O 0 2.352609726585797e-06
subunit O 0 1.1595850537560182e-06
processing O 0 5.760925887443591e-07
, O 0 1.037697785477576e-07
but O 0 6.097832994100827e-08
because O 0 5.2463938970959134e-08
the O 0 8.570749088221419e-08
base O 0 5.658407644659746e-07
substitution O 0 9.517825674265623e-07
falls O 0 5.692013019142905e-06
at O 0 7.787682676507757e-08
the O 0 4.962082300608017e-08
first O 0 1.1596731042118336e-07
position O 0 2.1564207486335363e-07
of O 0 1.1804599608922217e-07
exon O 0 6.5145404732902534e-06
13 O 0 1.5855705441936152e-06
, O 0 3.420738607928797e-07
aberrant O 0 5.923510798311327e-06
splicing O 0 1.0575865417195018e-05
may O 0 8.646374567433668e-07
also O 0 2.7691683612829365e-07
contribute O 0 4.041345675886987e-07
to O 0 3.253468889852229e-07
Hex B-Disease 0 0.00043551597627811134
A I-Disease 0 0.0007470896816812456
deficiency I-Disease 0 0.0351017564535141
in O 0 5.938613298894779e-07
this O 0 6.538027719216188e-07
proband O 0 0.0002562858280725777
. O 0 4.413019723870093e-06
. O 0 1.3128836144460365e-05

Two O 0 0.000271115597570315
frequent O 0 0.001572179258801043
missense O 0 0.409254789352417
mutations O 0 0.18606635928153992
in O 0 0.0014253909466788173
Pendred B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
. O 0 0.00032364713842980564

Pendred B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
is O 0 0.008291142992675304
an O 1 0.8432027697563171
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9594138264656067
by O 0 3.4420856536598876e-05
early O 0 0.0008403874817304313
childhood O 1 0.9913910627365112
deafness B-Disease 1 1.0
and O 1 0.6953974366188049
goiter B-Disease 1 1.0
. O 0 0.00044694246025756

A O 0 0.00014117626415099949
century O 0 2.3375443561235443e-05
after O 0 4.7591170186933596e-06
its O 0 8.517895366821904e-07
recognition O 0 1.1914243032151717e-06
as O 0 8.650572453916539e-07
a O 0 0.0001841032353695482
syndrome O 1 0.9999181032180786
by O 0 1.5362162457677186e-06
Vaughan O 0 0.00010187453881371766
Pendred O 0 0.0006686634151265025
, O 0 9.577456694387365e-07
the O 0 3.469009016043856e-06
disease O 0 0.000537281041033566
gene O 0 1.087852524506161e-05
( O 0 3.938776899303775e-06
PDS O 0 0.00020088040037080646
) O 0 7.309224656637525e-07
was O 0 6.822575642217998e-07
mapped O 0 9.681147275841795e-06
to O 0 1.6181741102627711e-06
chromosome O 0 0.00018616059969644994
7q22 O 0 0.0003094099520239979
- O 0 0.00036175447166897357
q31 O 0 0.000819047330878675
. O 0 2.8085703888791613e-05

1 O 0 0.0001207685490953736
and O 0 9.91563229035819e-06
, O 0 2.8924557682330487e-06
recently O 0 4.616030764736934e-06
, O 0 3.1594984761795786e-07
found O 0 3.505862196107046e-07
to O 0 2.6739934355646255e-07
encode O 0 6.315598056971794e-06
a O 0 8.660380444780458e-06
putative O 0 0.00034866173518821597
sulfate O 0 0.0010705593740567565
transporter O 0 0.000852363184094429
. O 0 3.7701469409512356e-05

We O 0 3.6909434129484e-05
performed O 0 2.4081724404823035e-05
mutation O 0 1.4350623132486362e-05
analysis O 0 1.2178161341580562e-06
of O 0 2.527461901991046e-07
the O 0 8.250121936725918e-07
PDS B-Disease 0 0.0007775445701554418
gene O 0 5.950381819275208e-06
in O 0 1.8171076590078883e-06
patients O 0 1.9230852558393963e-05
from O 0 6.585894993804686e-07
14 O 0 3.491538564048824e-06
Pendred B-Disease 0 0.00010740853758761659
families O 0 8.659578156766656e-07
originating O 0 5.293788944982225e-07
from O 0 1.7226462034614087e-07
seven O 0 3.35187621658406e-07
countries O 0 7.525396483742952e-08
and O 0 2.231487741255478e-07
identified O 0 2.8980111892451532e-06
all O 0 7.258605592141976e-07
mutations O 0 3.9452555938623846e-05
. O 0 1.0019041837949771e-05

The O 0 7.909330452093855e-05
mutations O 0 0.0001544823608128354
include O 0 2.7747726107918425e-06
three O 0 1.589105181665218e-06
single O 0 1.7640672922425438e-06
base O 0 3.7819045246578753e-06
deletions O 0 9.314961062045768e-06
, O 0 4.2708484215836506e-07
one O 0 3.4318742336836294e-07
splice O 0 3.398888657102361e-05
site O 0 6.229573045857251e-06
mutation O 0 1.0461848432896659e-05
and O 0 1.9096628420811612e-06
10 O 0 1.809402965591289e-05
missense O 0 0.0012061139568686485
mutations O 0 0.00020515550568234175
. O 0 2.3324113499256782e-05

One O 0 0.00020589250198099762
missense O 0 0.01359335333108902
mutation O 0 0.0008792710723355412
( O 0 2.1452822693390772e-05
L236P O 0 0.00022636011999566108
) O 0 2.0252302874723682e-06
was O 0 8.807858193904394e-07
found O 0 3.2474548561367556e-07
in O 0 1.9039877940940642e-07
a O 0 2.743164941421128e-06
homozygous O 0 4.407156666275114e-05
state O 0 2.7388179546505853e-07
in O 0 1.5913953177459916e-07
two O 0 4.861857973992301e-07
consanguineous O 0 0.0008624947513453662
families O 0 2.1765890778624453e-06
and O 0 1.809219440929155e-07
in O 0 2.0709951797925896e-07
a O 0 1.4298395853984402e-06
heterozygous O 0 1.1100161827926058e-05
state O 0 1.7102938443258608e-07
in O 0 1.367057222978474e-07
five O 0 3.5613973636827723e-07
additional O 0 1.0046933311969042e-06
non O 0 6.095733169786399e-06
- O 0 0.00022485155204776675
consanguineous O 0 0.0022968712728470564
families O 0 3.3619868190726265e-05
. O 0 1.7048794688889757e-05

Another O 0 0.0005860282108187675
missense O 0 0.04523870348930359
mutation O 0 0.0005895735812373459
( O 0 1.0508435480005573e-05
T416P O 0 0.00023998958931770176
) O 0 1.5600659253323101e-06
was O 0 6.327410915218934e-07
found O 0 2.11393739846244e-07
in O 0 1.3380842744936672e-07
a O 0 2.4762048269622028e-06
homozygous O 0 8.564456220483407e-05
state O 0 2.5917356083482446e-07
in O 0 1.619744551817348e-07
one O 0 1.0065790689850473e-07
family O 0 3.429034620694438e-07
and O 0 1.1655139076083287e-07
in O 0 1.7049457312623417e-07
a O 0 1.841786229306308e-06
heterozygous O 0 1.2155141121183988e-05
state O 0 4.83012684071582e-07
in O 0 5.547196337829519e-07
four O 0 3.244283561798511e-06
families O 0 2.3567221433040686e-05
. O 0 1.6050724298111163e-05

Pendred B-Disease 1 0.9973107576370239
patients O 0 0.12282363325357437
in O 0 8.062058441282716e-06
three O 0 3.474667437330936e-06
non O 0 9.157175554719288e-06
- O 0 0.00020405287796165794
consanguineous O 0 0.0026159235276281834
families O 0 6.720711553498404e-06
were O 0 5.63210221571353e-07
shown O 0 4.870610155194299e-07
to O 0 1.6024458204810799e-07
be O 0 3.32360997390424e-07
compound O 0 1.7184638636535965e-05
heterozygotes O 0 7.936846668599173e-05
for O 0 1.981364903258509e-06
L236P O 0 0.0003291966568212956
and O 0 1.092931142920861e-05
T416P O 0 0.0010052213910967112
. O 0 4.500861177803017e-05

In O 0 2.887594746425748e-05
total O 0 6.841295544290915e-06
, O 0 1.0157338010685635e-06
one O 0 2.2840421820546908e-07
or O 0 1.904207351799414e-07
both O 0 5.8023797322448445e-08
of O 0 9.69780700188494e-08
these O 0 1.894209589181628e-07
mutations O 0 2.835569375747582e-06
were O 0 9.206284801166476e-08
found O 0 9.136591927472182e-08
in O 0 9.246689813835474e-08
nine O 0 2.0554823265683808e-07
of O 0 7.419728120794389e-08
the O 0 2.951156830022228e-07
14 O 0 5.276241154206218e-06
families O 0 5.926878202444641e-06
analyzed O 0 1.929825884872116e-05
. O 0 1.3392831533565186e-05

The O 0 2.3624310415470973e-05
identification O 0 1.2594591680681333e-05
of O 0 1.8063883544527926e-06
two O 0 2.4438015771011123e-06
frequent O 0 5.5584787332918495e-05
PDS B-Disease 0 0.36170729994773865
mutations O 0 3.591565109672956e-05
will O 0 4.615057491719199e-07
facilitate O 0 2.1273328911775025e-06
the O 0 2.0225049865985056e-06
molecular O 0 0.0004074486205354333
diagnosis O 1 0.932868242263794
of O 0 0.0008979688282124698
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.00015239804633893073

Insertional O 0 0.21419480443000793
mutation O 0 0.0014344340888783336
by O 0 1.3990389561513439e-05
transposable O 0 0.0006953974952921271
element O 0 2.5527386242174543e-05
, O 0 3.2520867989660474e-06
L1 O 0 0.0017447983846068382
, O 0 7.170579010562506e-07
in O 0 6.122341460468306e-07
the O 0 2.0843212951149326e-06
DMD B-Disease 1 0.9999914169311523
gene O 0 1.3784580914943945e-05
results O 0 3.5893131098418962e-06
in O 0 2.9945895221317187e-06
X B-Disease 1 0.7659257054328918
- I-Disease 1 0.9858365058898926
linked I-Disease 1 0.8099050521850586
dilated I-Disease 1 0.9993194341659546
cardiomyopathy I-Disease 1 0.9999996423721313
. O 0 0.00027952948585152626

X B-Disease 1 0.970556378364563
- I-Disease 1 0.9981099367141724
linked I-Disease 1 0.9326674938201904
dilated I-Disease 1 0.999937891960144
cardiomyopathy I-Disease 1 1.0
( O 0 0.0005074542132206261
XLDCM B-Disease 0 0.31876546144485474
) O 0 2.165847035939805e-06
is O 0 3.308335863039247e-07
a O 0 4.320649622968631e-06
clinical O 0 0.003105346579104662
phenotype O 0 0.01124750915914774
of O 0 6.747123393324728e-07
dystrophinopathy B-Disease 0 0.0014326402451843023
which O 0 7.144033702388697e-07
is O 0 3.217675441646861e-07
characterized O 0 5.205882189329714e-06
by O 0 9.831713896346628e-07
preferential O 0 0.00010852083505596966
myocardial B-Disease 1 0.9997666478157043
involvement I-Disease 0 4.2916737584164366e-05
without O 0 1.7553105635670363e-06
any O 0 9.58302052822546e-07
overt O 0 5.533785224542953e-05
clinical O 0 0.003739207284525037
signs O 0 0.00030653548310510814
of O 0 0.00010573361942078918
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.0004075410543009639

To O 0 2.2063364667701535e-05
date O 0 9.212111763190478e-06
, O 0 9.93879893940175e-07
several O 0 9.948006436388823e-07
mutations O 0 9.02322426554747e-06
in O 0 8.871683121469687e-07
the O 0 1.3914625014876947e-05
Duchenne B-Disease 1 0.9999933242797852
muscular I-Disease 1 0.9999957084655762
dystrophy I-Disease 1 0.9999809265136719
gene O 0 0.00021295899932738394
, O 0 2.5068200557143427e-05
DMD O 1 0.9999995231628418
, O 0 2.1768298665847396e-06
have O 0 4.1060445710172644e-07
been O 0 7.320260237975162e-07
identified O 0 4.5335495997278485e-06
in O 0 3.024576471943874e-06
patients O 0 3.581772398320027e-05
with O 0 1.3669819054484833e-06
XLDCM B-Disease 0 0.4133320450782776
, O 0 7.261375571943063e-07
but O 0 1.327433096776076e-07
a O 0 1.105097226172802e-06
pathogenic O 0 1.8543875057730475e-06
correlation O 0 6.696775471937144e-07
of O 0 1.5429688460244506e-07
these O 0 3.3098885410254297e-07
cardiospecific O 0 0.014163501560688019
mutations O 0 5.4511976486537606e-05
in O 0 1.8705935644902638e-06
DMD O 1 0.9999312162399292
with O 0 1.396518996443774e-06
the O 0 3.400883997528581e-06
XLDCM B-Disease 1 0.8483036756515503
phenotype O 0 0.051744382828474045
has O 0 1.306052354266285e-06
remained O 0 3.861714048980502e-06
to O 0 7.802697155057103e-07
be O 0 2.188524149460136e-06
elucidated O 0 0.0002733596775215119
. O 0 2.744673656707164e-05

We O 0 3.950733662350103e-05
report O 0 5.352587322704494e-06
here O 0 5.075571039014903e-07
the O 0 2.706334214508388e-07
identification O 0 5.42963107363903e-07
of O 0 1.590263565276473e-07
a O 0 1.6980296777546755e-06
unique O 0 1.7398346017216682e-06
de O 0 7.366309091594303e-06
novo O 0 1.6141735613928176e-05
L1 O 0 5.597687413683161e-05
insertion O 0 7.694068699493073e-06
in O 0 5.217265766077617e-07
the O 0 5.765240871369315e-07
muscle O 0 1.8012491636909544e-05
exon O 0 1.7166325051221065e-05
1 O 0 2.9266038836794905e-06
in O 0 3.04698187392205e-06
DMD O 1 0.9999608993530273
in O 0 3.1750835205457406e-06
three O 0 1.1456742868176661e-05
XLDCM B-Disease 1 0.9699982404708862
patients O 0 9.850172500591725e-05
from O 0 4.0104043819155777e-07
two O 0 1.095925426852773e-06
unrelated O 0 4.881479253526777e-05
Japanese O 0 2.352191040699836e-05
families O 0 3.2814012229209766e-05
. O 0 1.6857053196872585e-05

The O 0 2.2655061911791563e-05
insertion O 0 0.00012152125418651849
was O 0 6.469321306212805e-06
a O 0 3.1414344903168967e-06
5 O 0 3.771919637074461e-06
- O 0 1.2007621080556419e-05
truncated O 0 9.538821359456051e-06
form O 0 6.475485179180396e-07
of O 0 2.205454450177058e-07
human O 0 8.498593047079339e-07
L1 O 0 0.0005408994620665908
inversely O 0 4.05094979214482e-05
integrated O 0 4.255275143805193e-06
in O 0 2.0129594702211762e-07
the O 0 2.7530086299520917e-07
5 O 0 2.3656475605093874e-06
- O 0 2.4284370738314465e-05
untranslated O 0 7.858448225306347e-05
region O 0 2.0521772512438474e-06
in O 0 3.507473991248844e-07
the O 0 3.869459987981827e-07
muscle O 0 1.666352545726113e-05
exon O 0 1.3377476534515154e-05
1 O 0 1.3942660643806448e-06
, O 0 1.6662799851019372e-07
which O 0 1.4199616771293222e-07
affected O 0 2.0933060795869096e-07
the O 0 7.480646502244781e-08
transcription O 0 1.038776531459007e-06
or O 0 1.5738002900889114e-07
the O 0 1.0208831469071811e-07
stability O 0 9.046763693731918e-07
of O 0 9.008025614321014e-08
the O 0 4.398660564675083e-07
muscle O 0 2.3412098016706295e-05
form O 0 3.295658075330721e-07
of O 0 1.9873306200679508e-07
dystrophin O 0 5.581249206443317e-05
transcripts O 0 2.568179525042069e-06
but O 0 1.299551541933397e-07
not O 0 4.373588069483958e-08
that O 0 2.3936369331067908e-08
of O 0 6.369506877490494e-08
the O 0 9.71575332187058e-07
brain O 0 0.00042221881449222565
or O 0 4.414008799358271e-06
Purkinje O 0 0.3777702748775482
cell O 0 0.00010881179332500324
form O 0 6.155783580652496e-07
, O 0 2.54867984494922e-07
probably O 0 5.172875034986646e-07
due O 0 2.1824807561188209e-07
to O 0 7.837004289967808e-08
its O 0 2.4194611114580766e-07
unique O 0 5.863194019184448e-07
site O 0 7.667529189347988e-07
of O 0 6.637383762608806e-07
integration O 0 3.087148070335388e-05
. O 0 1.987989162444137e-05

We O 0 2.602963832032401e-05
speculate O 0 1.1299622201477177e-05
that O 0 3.808241899605491e-07
this O 0 1.8240598365082406e-07
insertion O 0 2.8336473860690603e-06
of O 0 1.81775973828735e-07
an O 0 4.720010338132852e-07
L1 O 0 0.020661845803260803
sequence O 0 4.194921075395541e-06
in O 0 2.5296660624007927e-06
DMD O 1 0.9999953508377075
is O 0 1.288816633859824e-06
responsible O 0 5.910262075303763e-07
for O 0 7.484842257099444e-08
some O 0 3.381181556960655e-08
of O 0 5.13229601040166e-08
the O 0 8.628781955621889e-08
population O 0 2.3167739016116684e-07
of O 0 2.4307291823788546e-07
Japanese O 0 1.4173374438541941e-05
patients O 0 1.989846168726217e-05
with O 0 1.8586615624371916e-06
XLDCM B-Disease 0 0.016421599313616753
. O 0 4.752558652398875e-06
. O 0 1.3679633411811665e-05

Severe O 1 0.9982341527938843
early O 0 0.0020006485283374786
- O 1 0.9921488761901855
onset O 1 0.9999912977218628
obesity B-Disease 1 0.9999995231628418
, O 0 0.009995785541832447
adrenal B-Disease 1 0.9999996423721313
insufficiency I-Disease 1 0.9999998807907104
and O 0 9.096827852772549e-05
red O 0 0.013864189386367798
hair O 1 0.9297605156898499
pigmentation O 1 0.992082953453064
caused O 0 0.0002883143606595695
by O 0 1.8708486095420085e-05
POMC O 1 0.9944393634796143
mutations O 0 0.0004144792619626969
in O 0 6.981651040405268e-06
humans O 0 1.6518155462108552e-05
. O 0 1.5094444279384334e-05

Sequential O 0 0.0010025377850979567
cleavage O 0 0.000511536025442183
of O 0 7.063651992211817e-06
the O 0 3.2799350719869835e-06
precursor O 0 1.7487909644842148e-05
protein O 0 6.861066140118055e-06
pre O 0 2.5140690922853537e-05
- O 0 7.95064916019328e-05
pro O 0 5.0482602091506124e-05
- O 0 0.00042630554526112974
opiomelanocortin O 0 0.0010642375564202666
( O 0 9.893377864500508e-06
POMC O 0 0.0003559876640792936
) O 0 1.7321543737125467e-06
generates O 0 2.84730549537926e-06
the O 0 1.4791961575610912e-06
melanocortin O 0 0.00045903128921054304
peptides O 0 4.540349618764594e-05
adrenocorticotrophin O 0 0.0003052208630833775
( O 0 5.890398369956529e-06
ACTH O 0 0.0001148023729911074
) O 0 1.5569817151117604e-06
, O 0 1.0267957577525522e-06
melanocyte O 0 0.0002545689349062741
- O 0 9.498841973254457e-05
stimulating O 0 4.2903928260784596e-05
hormones O 0 2.7335641789250076e-05
( O 0 2.402259497102932e-06
MSH O 0 0.00010896130697801709
) O 0 5.465467438625637e-07
alpha O 0 1.2679137171289767e-06
, O 0 1.3569852796990745e-07
beta O 0 7.76592798956699e-07
and O 0 1.0949428030926356e-07
gamma O 0 1.2870357295469148e-06
as O 0 7.457581574499272e-08
well O 0 6.119971374118904e-08
as O 0 1.0011585516167543e-07
the O 0 4.2143460632360075e-07
opioid O 0 7.073175220284611e-05
- O 0 2.9874507163185626e-05
receptor O 0 1.5745039490866475e-05
ligand O 0 2.3276654246728867e-05
beta O 0 4.857351814280264e-05
- O 0 0.00014811304572504014
endorphin O 0 0.0018457516562193632
. O 0 4.402389458846301e-05

While O 0 6.97685027262196e-05
a O 0 2.2270634872256778e-05
few O 0 6.811959792685229e-06
cases O 0 3.445711172389565e-06
of O 0 2.6755110411613714e-06
isolated O 0 0.1852571666240692
ACTH B-Disease 1 0.9999561309814453
deficiency I-Disease 1 0.9547079205513
have O 0 1.0654700872692047e-06
been O 0 1.3545600268116686e-06
reported O 0 1.829380744311493e-05
( O 0 5.201038675295422e-06
OMIM O 0 0.014892623759806156
201400 O 0 7.516995538026094e-05
) O 0 6.606823603760859e-07
, O 0 3.0081343993515475e-07
an O 0 1.103404883906478e-06
inherited O 0 0.01896139420568943
POMC O 1 0.9929932951927185
defect O 0 0.0014311462873592973
has O 0 6.899338700350199e-07
not O 0 1.6358568188934441e-07
been O 0 3.485579327389132e-07
described O 0 2.3542190774605842e-06
so O 0 1.2196013585707988e-06
far O 0 6.012197900417959e-06
. O 0 1.1549063856364228e-05

Recent O 0 0.00014934857608750463
studies O 0 2.827438584063202e-05
in O 0 3.0378453175217146e-06
animal O 0 4.92277649755124e-06
models O 0 7.4637523539422546e-06
elucidated O 0 2.673486596904695e-05
a O 0 1.5884248796282918e-06
central O 0 9.083021268452285e-07
role O 0 7.118788403204235e-07
of O 0 4.4601304693969723e-07
alpha O 0 9.79178093984956e-06
- O 0 6.731218309141695e-05
MSH O 0 0.0002463920973241329
in O 0 2.36126538766257e-07
the O 0 1.5114116536096844e-07
regulation O 0 7.263113843691826e-07
of O 0 1.0518319726315895e-07
food O 0 6.958061362638546e-07
intake O 0 3.1347069580078823e-06
by O 0 1.7422009079837153e-07
activation O 0 1.9834956219710875e-06
of O 0 1.9295055153634166e-07
the O 0 9.00236386769393e-07
brain O 0 6.96424103807658e-05
melanocortin O 0 0.0004618481616489589
- O 0 5.246857472229749e-05
4 O 0 9.10565722733736e-06
- O 0 3.1548388506053016e-05
receptor O 0 8.590545803599525e-06
( O 0 2.391488806097186e-06
MC4 O 0 0.00027818899252451956
- O 0 4.207464735372923e-05
R O 0 0.0001603791897650808
; O 0 1.034860929394199e-06
refs O 0 6.105081865825923e-06
3 O 0 1.68904182373808e-06
- O 0 9.915897862811107e-06
5 O 0 1.3837601500199526e-06
) O 0 1.6885088882645505e-07
and O 0 5.807904557286747e-08
the O 0 8.719428734593748e-08
linkage O 0 1.9996969058411196e-06
of O 0 2.5556943228366436e-07
human O 0 2.3606355625815922e-06
obesity B-Disease 0 0.3913624882698059
to O 0 7.515068887187226e-07
chromosome O 0 3.769039540202357e-05
2 O 0 6.794984983571339e-07
in O 0 1.0149421569849437e-07
close O 0 3.070942113936326e-07
proximity O 0 5.131385591994331e-07
to O 0 1.93928286762457e-07
the O 0 6.875895337543625e-07
POMC O 0 0.0018154294230043888
locus O 0 7.635956535523292e-06
, O 0 1.5255861285368155e-07
led O 0 2.4434237388959446e-07
to O 0 5.0263800233096845e-08
the O 0 8.747513646767402e-08
proposal O 0 4.833084403799148e-07
of O 0 7.967345538872905e-08
an O 0 2.9390571398835164e-07
association O 0 1.1140556352984277e-06
of O 0 5.88779812460416e-07
POMC O 0 0.00723678432404995
with O 0 7.82935330789769e-06
human O 0 6.669534195680171e-05
obesity B-Disease 1 0.9969117045402527
. O 0 5.9308506024535745e-05

The O 0 3.0920986318960786e-05
dual O 0 4.312460805522278e-05
role O 0 1.1467280273791403e-05
of O 0 2.7153021164849633e-06
alpha O 0 2.6499461455387063e-05
- O 0 6.828813639003783e-05
MSH O 0 0.00035890779690817
in O 0 7.549281804131169e-07
regulating O 0 4.232860646879999e-06
food O 0 1.4679202422485105e-06
intake O 0 4.908117716695415e-06
and O 0 7.69059795402427e-07
influencing O 0 1.2825858902942855e-05
hair O 0 0.002101150108501315
pigmentation O 0 0.4530121684074402
predicts O 0 0.00047473047743551433
that O 0 2.4174175905500306e-07
the O 0 1.0157124279430718e-06
phenotype O 0 0.007625119760632515
associated O 0 1.3419913784673554e-06
with O 0 3.5643498108584026e-07
a O 0 1.585600148246158e-05
defect O 0 0.006258809939026833
in O 0 3.6512085443973774e-06
POMC O 0 0.01545433048158884
function O 0 2.2418573735194514e-06
would O 0 4.4205708604749816e-07
include O 0 2.3796810637577437e-06
obesity B-Disease 1 0.9316068291664124
, O 0 2.301728727616137e-06
alteration O 0 8.211117528844625e-05
in O 0 1.610591061762534e-05
pigmentation O 1 0.9485074281692505
and O 0 0.0056865401566028595
ACTH B-Disease 1 0.9999864101409912
deficiency I-Disease 1 0.991201639175415
. O 0 3.831740468740463e-05

The O 0 2.8522319553303532e-05
observation O 0 4.056056059198454e-05
of O 0 2.3293139292945853e-06
these O 0 2.4136338652169798e-06
symptoms O 0 0.00047666081809438765
in O 0 5.617120564238576e-07
two O 0 7.747339054731128e-07
probands O 0 0.00015404065197799355
prompted O 0 2.300523874509963e-06
us O 0 3.250627855777566e-07
to O 0 1.050210158837217e-07
search O 0 1.2074382311766385e-06
for O 0 7.03987893757585e-07
mutations O 0 7.68446443544235e-06
within O 0 1.6744501181165106e-06
their O 0 3.3221822377527133e-06
POMC O 0 0.03245420381426811
genes O 0 5.554064773605205e-05
. O 0 2.1851978090126067e-05

Patient O 0 0.021474694833159447
1 O 0 4.167205770500004e-05
was O 0 4.181396889180178e-06
found O 0 7.566760586996679e-07
to O 0 1.2735496568438975e-07
be O 0 1.0681759476938169e-07
a O 0 7.613811590090336e-07
compound O 0 1.8213449948234484e-05
heterozygote O 0 5.620136653305963e-05
for O 0 2.5589332608433324e-07
two O 0 6.999071047175676e-07
mutations O 0 5.937967216596007e-06
in O 0 4.703240961134725e-07
exon O 0 1.913480991788674e-05
3 O 0 5.251387392490869e-06
( O 0 1.1640624961728463e-06
G7013T O 0 1.5228217307594605e-05
, O 0 4.046683557135111e-07
C7133delta O 0 3.686961281346157e-05
) O 0 2.590801386759267e-07
which O 0 8.346282953652917e-08
interfere O 0 3.1273029321710055e-07
with O 0 1.2879083044481376e-07
appropriate O 0 4.916917077935068e-07
synthesis O 0 1.4821503100392874e-06
of O 0 5.123991968503105e-07
ACTH O 0 0.00010767280764412135
and O 0 2.4503406166331843e-06
alpha O 0 5.389676152844913e-05
- O 0 0.00019693963986355811
MSH O 0 0.003453813958913088
. O 0 4.6014083636691794e-05

Patient O 0 0.048790305852890015
2 O 0 0.00010447402019053698
was O 0 1.268695905309869e-05
homozygous O 0 5.8644927776185796e-05
for O 0 7.496757348235406e-07
a O 0 4.892033302894561e-06
mutation O 0 1.672847429290414e-05
in O 0 1.1520334055603598e-06
exon O 0 5.1109851483488455e-05
2 O 0 1.2613656508619897e-05
( O 0 3.885218575305771e-06
C3804A O 0 5.956770837656222e-05
) O 0 2.345837174289045e-06
which O 0 2.6878199150814908e-06
abolishes O 0 0.0003769146278500557
POMC O 0 0.004880284890532494
translation O 0 8.214570698328316e-05
. O 0 4.090639413334429e-05

These O 0 1.7331396520603448e-05
findings O 0 1.1225180969631765e-05
represent O 0 9.596492418495473e-07
the O 0 2.2177802350142883e-07
first O 0 2.9999009143466537e-07
examples O 0 3.804277923791233e-07
of O 0 3.100770982200629e-07
a O 0 0.00011340943456161767
genetic B-Disease 1 0.9985914826393127
defect I-Disease 1 0.9589465260505676
within O 0 8.615162983005575e-07
the O 0 7.205031238299853e-07
POMC O 0 0.0012243923265486956
gene O 0 2.1022337932663504e-06
and O 0 2.292260319336492e-07
define O 0 3.45818443747703e-06
a O 0 3.3769938454497606e-06
new O 0 5.777917613158934e-05
monogenic B-Disease 1 0.9998196959495544
endocrine I-Disease 1 0.9999814033508301
disorder I-Disease 1 0.996547281742096
resulting O 0 2.3897857317933813e-05
in O 0 1.9930125745304395e-06
early O 0 2.6114597858395427e-05
- O 1 0.8739633560180664
onset O 1 0.9999737739562988
obesity B-Disease 1 0.9999995231628418
, O 0 0.0005329226842150092
adrenal B-Disease 1 0.9999992847442627
insufficiency I-Disease 1 0.9999998807907104
and O 0 5.182034510653466e-05
red O 0 0.002312827855348587
hair O 0 0.303192138671875
pigmentation O 1 0.8004636168479919
. O 0 1.3632372429128736e-05
. O 0 2.4966420824057423e-05

A O 0 0.0003209756687283516
European O 0 0.00014348968397825956
multicenter O 0 0.23912036418914795
study O 0 5.463364868774079e-05
of O 0 6.3134721131064e-05
phenylalanine B-Disease 1 0.9999998807907104
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 0.9999996423721313
: O 0 2.1537539396376815e-06
classification O 0 4.748897936224239e-06
of O 0 3.7528420193666534e-07
105 O 0 5.369115388020873e-05
mutations O 0 1.1245119821978733e-05
and O 0 1.3912573137986328e-07
a O 0 7.464745976903941e-07
general O 0 6.236565468498156e-07
system O 0 1.0328387816116447e-06
for O 0 3.969200577103038e-07
genotype O 0 5.6738306739134714e-05
- O 0 3.204497625119984e-05
based O 0 3.1970180316420738e-06
prediction O 0 2.3465070626116358e-05
of O 0 6.84713086229749e-06
metabolic O 1 0.9775725603103638
phenotype O 1 0.723057746887207
. O 0 4.1649414924904704e-05

Phenylketonuria B-Disease 1 0.9998672008514404
( O 0 0.003507667686790228
PKU B-Disease 1 0.8890849351882935
) O 0 5.319019692251459e-05
and O 0 4.0986873500514776e-05
mild B-Disease 1 0.9982308745384216
hyperphenylalaninemia I-Disease 1 1.0
( O 0 0.020608440041542053
MHP B-Disease 1 0.9999997615814209
) O 0 1.2109208000765648e-05
are O 0 2.5912115688697668e-06
allelic B-Disease 1 0.8847245573997498
disorders I-Disease 1 0.9999449253082275
caused O 0 5.698834138456732e-05
by O 0 1.6706427459212136e-06
mutations O 0 1.6669755495968275e-05
in O 0 6.339624292195367e-07
the O 0 1.2204018275951967e-06
gene O 0 1.5150806575547904e-05
encoding O 0 0.00010311902588000521
phenylalanine O 0 0.12323281913995743
hydroxylase O 1 0.9676387310028076
( O 0 0.00012075092672603205
PAH O 0 0.03377451375126839
) O 0 2.083434628730174e-05
. O 0 2.017884071392473e-05

Previous O 0 0.00020058640802744776
studies O 0 3.4277283702977e-05
have O 0 1.4004052673044498e-06
suggested O 0 1.7483789633843116e-06
that O 0 1.390535828704742e-07
the O 0 5.230348278928432e-07
highly O 0 5.313420388119994e-06
variable O 0 0.0001573657209519297
metabolic O 0 0.41847068071365356
phenotypes O 0 0.10447970777750015
of O 0 0.00014495289360638708
PAH B-Disease 1 0.9999974966049194
deficiency I-Disease 1 0.9775843024253845
correlate O 0 0.0003306793805677444
with O 0 0.00011648978397715837
PAH O 1 0.9985973238945007
genotypes O 0 0.017643200233578682
. O 0 7.998046203283593e-05

We O 0 8.46983675728552e-05
identified O 0 5.423937545856461e-05
both O 0 7.295815976249287e-06
causative O 0 0.0005927549209445715
mutations O 0 0.00031975822639651597
in O 0 6.77716388963745e-06
686 O 0 0.31678879261016846
patients O 0 0.0004949713475070894
from O 0 1.693172180239344e-06
seven O 0 5.842787231813418e-06
European O 0 1.037242964230245e-05
centers O 0 4.172025001025759e-05
. O 0 2.1443658624775708e-05

On O 0 1.7421774828108028e-05
the O 0 1.6649375993438298e-06
basis O 0 8.677401410750463e-07
of O 0 1.8436965376622538e-07
the O 0 3.53018577925468e-07
phenotypic O 0 8.892598089005332e-06
characteristics O 0 1.2715767070403672e-06
of O 0 5.516556029760977e-07
297 O 0 0.0002897307276725769
functionally O 0 0.021566931158304214
hemizygous O 1 0.7348929047584534
patients O 0 6.840473361080512e-05
, O 0 2.4222177330557315e-07
105 O 0 8.206421284739918e-07
of O 0 6.113134531915421e-08
the O 0 3.6156356486571894e-07
mutations O 0 4.234439529682277e-06
were O 0 8.588635580508708e-08
assigned O 0 4.204105721328233e-07
to O 0 4.615748139258358e-08
one O 0 7.328839046749636e-08
of O 0 1.177899378035363e-07
four O 0 1.0605230045257485e-06
arbitrary O 0 8.458424417767674e-05
phenotype O 0 0.04365689679980278
categories O 0 3.6783498217118904e-05
. O 0 1.7618629499338567e-05

We O 0 3.327960803289898e-05
proposed O 0 2.4089764337986708e-05
and O 0 3.209111355317873e-06
tested O 0 5.412908649304882e-06
a O 0 8.28871748126403e-07
simple O 0 8.729635396775848e-07
model O 0 9.885397957987152e-07
for O 0 2.042300764060201e-07
correlation O 0 2.5384676973772002e-06
between O 0 1.337018261438061e-06
genotype O 0 6.143358041299507e-05
and O 0 2.5271681352023734e-06
phenotypic O 0 0.0001015884627122432
outcome O 0 3.479760198388249e-05
. O 0 2.3408323613693938e-05

The O 0 0.0001679640990914777
observed O 0 0.0004617180966306478
phenotype O 0 0.016806473955512047
matched O 0 0.00011457205982878804
the O 0 4.551961865217891e-06
predicted O 0 0.00036699548945762217
phenotype O 0 0.0008280909387394786
in O 0 1.140106974162336e-06
79 O 0 3.453672252362594e-05
% O 0 8.824580959299055e-07
of O 0 4.364812866697321e-08
the O 0 1.7806100061079633e-07
cases O 0 3.811518922702817e-07
, O 0 1.1414370959528242e-07
and O 0 1.0064197653036899e-07
in O 0 1.1834210766892284e-07
only O 0 7.047927397252352e-08
5 O 0 3.3162646673190466e-07
of O 0 1.5783847118200356e-07
184 O 0 3.212211231584661e-05
patients O 0 2.8682841730187647e-05
was O 0 6.097676532590413e-07
the O 0 4.764703191995068e-07
observed O 0 4.91498940391466e-06
phenotype O 0 2.5026971343322657e-05
more O 0 5.6654599234207126e-08
than O 0 6.402784435977082e-08
one O 0 6.106212424583646e-08
category O 0 4.06784835149665e-07
away O 0 2.995126919813629e-07
from O 0 1.6840800753925578e-07
that O 0 2.7343889996700455e-07
expected O 0 5.037027676735306e-06
. O 0 8.248782251030207e-06

Among O 0 3.6631576222134754e-05
the O 0 4.863527010456892e-06
seven O 0 4.161033757554833e-06
contributing O 0 3.4794657040038146e-06
centers O 0 2.055499180642073e-06
, O 0 2.778347720777674e-07
the O 0 2.4345058591279667e-07
proportion O 0 1.5909308785921894e-06
of O 0 3.811232147654664e-07
patients O 0 2.657992263266351e-05
for O 0 1.7014988884511695e-07
whom O 0 1.649861701480404e-06
the O 0 5.754084781983693e-07
observed O 0 8.993774827104062e-06
phenotype O 0 0.00012800660624634475
did O 0 1.7612755698337423e-07
not O 0 5.287612481197357e-08
match O 0 2.2281172107341263e-07
the O 0 5.522051083062252e-07
predicted O 0 9.884629253065214e-05
phenotype O 0 0.0002198803995270282
was O 0 1.291103558287432e-06
4 O 0 3.0824401164863957e-06
% O 0 1.7956997453438817e-06
- O 0 9.066681741387583e-06
23 O 0 6.78577180224238e-06
% O 0 2.035116040133289e-06
( O 0 9.815375960897654e-07
P O 0 4.1678096749819815e-05
< O 0 1.0863947863981593e-05
. O 0 3.193280520008557e-07
0001 O 0 1.6454258002340794e-05
) O 0 2.4920484520407626e-07
, O 0 1.0152054841228164e-07
suggesting O 0 3.520678149016021e-07
that O 0 4.0669632994649874e-08
differences O 0 2.3493247169881215e-07
in O 0 1.2280509054107824e-07
methods O 0 3.841376496893645e-07
used O 0 2.769120897028188e-07
for O 0 5.01953024922841e-07
mutation O 0 1.1016008102160413e-05
detection O 0 2.4430362827843055e-05
or O 0 1.203080864797812e-05
phenotype O 1 0.535588264465332
classification O 0 6.29543064860627e-05
may O 0 2.2809258553024847e-06
account O 0 2.296146135449817e-07
for O 0 9.269946588119637e-08
a O 0 7.625409352840506e-07
considerable O 0 1.1371251957825734e-06
proportion O 0 1.4524728157994105e-06
of O 0 9.398268616678251e-07
genotype O 0 0.0049269553273916245
- O 0 0.03797775134444237
phenotype O 0 0.07876058667898178
inconsistencies O 0 0.0002995846443809569
. O 0 3.898397699231282e-05

Our O 0 4.679191260947846e-05
data O 0 1.7526428564451635e-05
indicate O 0 5.488159331434872e-06
that O 0 5.766813160335005e-07
the O 0 2.9955579066154314e-06
PAH O 1 0.8558724522590637
- O 0 0.02681758627295494
mutation O 0 0.00010447729437146336
genotype O 0 2.230821701232344e-05
is O 0 1.7036487065524852e-07
the O 0 1.6564123939133424e-07
main O 0 8.627743000033661e-07
determinant O 0 5.687606972060166e-06
of O 0 1.2093707937310683e-06
metabolic O 1 0.9675455093383789
phenotype O 0 0.2854006886482239
in O 0 2.787194944176008e-06
most O 0 7.800966159265954e-06
patients O 0 0.0189038198441267
with O 0 0.010628841817378998
PAH B-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9997500777244568
. O 0 5.5436194088542834e-05

In O 0 2.656998549355194e-05
the O 0 4.371825980342692e-06
present O 0 2.41099974118697e-06
study O 0 1.090685032067995e-06
, O 0 2.1730726018631685e-07
the O 0 1.960546995860568e-07
classification O 0 3.734295205504168e-06
of O 0 7.868320039960963e-07
105 O 0 0.017890680581331253
PAH O 1 0.9979637861251831
mutations O 0 6.497653521364555e-05
may O 0 4.961032118444564e-07
allow O 0 1.344697864169575e-07
the O 0 1.0948738804472669e-07
prediction O 0 2.035512125075911e-06
of O 0 1.0646427739402498e-07
the O 0 5.740951678490092e-07
biochemical O 0 0.0002597756974864751
phenotype O 0 0.0011803387897089124
in O 0 1.0629379403326311e-06
> O 0 2.1378973542596214e-05
10 O 0 7.459145763277775e-07
, O 0 3.3044636893464485e-07
000 O 0 2.6751026780402754e-06
genotypes O 0 2.1667623514076695e-05
, O 0 2.34179069025231e-07
which O 0 1.7877904667784605e-07
may O 0 3.75358666815373e-07
be O 0 3.366997347598044e-08
useful O 0 9.264361722216563e-08
for O 0 9.708781334438754e-08
the O 0 3.5371957096685946e-07
management O 0 5.014935595681891e-06
of O 0 1.7352891745758825e-06
hyperphenylalaninemia B-Disease 1 0.9997667670249939
in O 0 0.00012667274859268218
newborns O 1 0.6233711242675781
. O 0 4.140009332331829e-05

Somatic O 0 0.003634012769907713
instability O 0 0.00042337997001595795
of O 0 8.209949555748608e-06
the O 0 4.390950380184222e-06
CTG O 0 0.0011941621778532863
repeat O 0 7.844177889637649e-05
in O 0 2.8315241706877714e-06
mice O 0 3.33405623678118e-05
transgenic O 0 8.597274245403241e-06
for O 0 9.165223104901088e-07
the O 0 2.3028063878882676e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 0.0001901444629766047
is O 0 1.2489497294154717e-06
age O 0 1.1583526884351159e-06
dependent O 0 1.0626014272929751e-06
but O 0 9.863497041351366e-08
not O 0 9.418944557637587e-08
correlated O 0 8.733649110581609e-07
to O 0 1.0138180073226977e-07
the O 0 2.4174775603569287e-07
relative O 0 3.152971885356237e-06
intertissue O 0 6.238060450414196e-05
transcription O 0 1.1738678040273953e-05
levels O 0 2.697214995350805e-06
and O 0 2.6251011604472296e-06
proliferative O 1 0.8251798152923584
capacities O 0 0.00021053649834357202
. O 0 2.7028723707189783e-05

A O 0 0.00030483989394269884
( O 0 5.479842366185039e-05
CTG O 0 0.0003932472609449178
) O 0 3.059038590436103e-06
nexpansion O 0 2.440453681629151e-05
in O 0 5.852842264175706e-07
the O 0 6.014710152157932e-07
3 O 0 4.092341441719327e-06
- O 0 6.820268754381686e-05
untranslated O 0 0.0003758993116207421
region O 0 1.159488510893425e-05
( O 0 2.8364972877170658e-06
UTR O 0 4.558858199743554e-05
) O 0 5.586605311691528e-07
of O 0 1.9943841778058413e-07
the O 0 1.3306439541338477e-06
DM O 1 0.9999934434890747
protein O 0 1.4957269740989432e-05
kinase O 0 2.9739345336565748e-05
gene O 0 4.086132776137674e-06
( O 0 1.3381994676819886e-06
DMPK O 0 7.96067834016867e-05
) O 0 5.695492859558726e-07
is O 0 2.902838787122164e-07
responsible O 0 2.5642882519605337e-06
for O 0 9.867250810202677e-06
causing O 0 0.21582135558128357
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.16291069984436035
DM B-Disease 1 0.9999998807907104
) O 0 5.8956804423360154e-05
. O 0 3.439007923589088e-05

Major O 0 0.0002011412288993597
instability O 0 0.00029320368776097894
, O 0 2.440559910610318e-06
with O 0 4.2227424046359374e-07
very O 0 2.8558889653140795e-07
large O 0 2.7417607384450093e-07
expansions O 0 3.6884214296151185e-06
between O 0 4.5144696514398674e-07
generations O 0 6.440914717131818e-07
and O 0 1.9495614367315284e-07
high O 0 1.5521709428867325e-06
levels O 0 4.5998584141671017e-07
of O 0 2.7369952704248135e-07
somatic O 0 0.00010474903683643788
mosaicism O 0 0.019902149215340614
, O 0 1.0364847184973769e-06
is O 0 8.560764399589971e-07
observed O 0 7.207318503787974e-06
in O 0 7.198567800514866e-06
patients O 0 0.00039070702041499317
. O 0 3.7593043089145795e-05

There O 0 2.3447129933629185e-05
is O 0 2.7954072265856666e-06
a O 0 1.9499459540384123e-06
good O 0 9.984008784158505e-07
correlation O 0 1.8883921484302846e-06
between O 0 8.554757755518949e-07
repeat O 0 1.3069996384729166e-05
size O 0 1.4490802868749597e-06
( O 0 4.3563005647229147e-07
at O 0 1.4620465549342043e-07
least O 0 1.671315459361722e-07
in O 0 2.577872066922282e-07
leucocytes O 0 0.00016215755022130907
) O 0 1.4180957350617973e-06
, O 0 9.869215773505857e-07
clinical O 0 9.734868217492476e-05
severity O 0 0.0023037809878587723
and O 0 2.549854343669722e-06
age O 0 1.0097429367306177e-05
of O 0 5.807992693007691e-06
onset O 1 0.5197025537490845
. O 0 4.2411662434460595e-05

The O 0 0.00021697660849895328
trinucleotide O 0 0.1160208135843277
repeat O 0 0.0011433755280449986
instability O 0 0.0003263489343225956
mechanisms O 0 4.2926396417897195e-05
involved O 0 1.0026641575677786e-05
in O 0 7.881817509769462e-06
DM B-Disease 1 0.9999996423721313
and O 0 1.0723402738221921e-05
other O 0 2.824177954607876e-06
human O 0 0.00024305644910782576
genetic B-Disease 1 0.9999924898147583
diseases I-Disease 1 0.9999669790267944
are O 0 2.4252535695268307e-06
unknown O 0 2.5337769329780713e-05
. O 0 1.6139027138706297e-05

We O 0 4.157183502684347e-05
studied O 0 3.5759632737608626e-05
somatic O 0 0.0001495301112299785
instability O 0 9.194653830491006e-05
by O 0 1.2863780511906953e-06
measuring O 0 9.267838322557509e-06
the O 0 1.1994387705271947e-06
CTG O 0 0.00037705260911025107
repeat O 0 1.598792186996434e-05
length O 0 3.071702394663589e-06
at O 0 2.8146922659288975e-07
several O 0 1.620769012333767e-07
ages O 0 1.0588152008494944e-06
in O 0 9.509435727750315e-08
various O 0 1.3419155209248856e-07
tissues O 0 1.0968800552291214e-06
of O 0 1.873027031251695e-07
transgenic O 0 1.9469824110274203e-05
mice O 0 1.863652687461581e-05
carrying O 0 1.55504369558912e-06
a O 0 2.248855480502243e-06
( O 0 2.138952822861029e-06
CTG O 0 6.271809252211824e-05
) O 0 5.644475322696962e-07
55expansion O 0 8.83360826264834e-06
surrounded O 0 9.599110626368201e-07
by O 0 1.4453686958404433e-07
45 O 0 1.0798611356221954e-06
kb O 0 2.749276245594956e-05
of O 0 1.633035395798288e-07
the O 0 6.202134841259976e-07
human O 0 3.317284608783666e-06
DM B-Disease 1 0.999993085861206
region O 0 4.676562639360782e-06
, O 0 2.5618732024668134e-07
using O 0 5.104243996356672e-07
small O 0 1.2210584827698767e-06
- O 0 3.5620836570160463e-05
pool O 0 4.011063720099628e-05
PCR O 0 0.0002495378430467099
. O 0 2.2105823518359102e-05

These O 0 4.618483580998145e-05
mice O 0 0.0007375807035714388
have O 0 2.0186548681522254e-06
been O 0 6.893774866512103e-07
shown O 0 9.392695119458949e-07
to O 0 2.63070717210212e-07
reproduce O 0 2.786897312034853e-06
the O 0 2.932401912403293e-07
intergenerational O 0 4.12322478950955e-05
and O 0 6.692408192066068e-07
somatic O 0 1.4680512322229333e-05
instability O 0 4.24002746512997e-06
of O 0 1.1732422677823706e-07
the O 0 3.7566198329841427e-07
55 O 0 6.9365687522804365e-06
CTG O 0 0.00015007446927484125
repeat O 0 1.0664373803592753e-05
suggesting O 0 1.020883701130515e-06
that O 0 6.398889951242381e-08
surrounding O 0 4.7440997263947793e-07
sequences O 0 6.926136961737939e-07
and O 0 1.2026512763441133e-07
the O 0 2.648550321282528e-07
chromatin O 0 6.902162112965016e-06
environment O 0 2.321020701856469e-06
are O 0 1.4871565667817777e-07
involved O 0 8.862998583936132e-07
in O 0 3.055842853427748e-06
instability O 0 0.0003404768940526992
mechanisms O 0 0.0001430316478945315
. O 0 2.792607483570464e-05

As O 0 3.048030339414254e-05
observed O 0 1.728344795992598e-05
in O 0 5.844615316163981e-07
some O 0 9.261728450837836e-08
of O 0 1.0020009000299979e-07
the O 0 3.516295521421853e-07
tissues O 0 2.2112966689746827e-05
of O 0 1.4757899407413788e-05
DM B-Disease 1 1.0
patients O 0 0.4597184956073761
, O 0 6.756234256499738e-07
there O 0 8.686710373240203e-08
is O 0 7.728522177785635e-08
a O 0 4.92277251851192e-07
tendency O 0 2.4555081381549826e-06
for O 0 3.378326312031277e-07
repeat O 0 1.2311705177125987e-05
length O 0 7.206782356661279e-06
and O 0 7.11257882812788e-07
somatic O 0 4.649426045943983e-05
mosaicism O 0 0.0002133016096195206
to O 0 2.698862147099135e-07
increase O 0 6.525576168314728e-07
with O 0 1.2186882258902187e-07
the O 0 3.014668266132503e-07
age O 0 8.58709313433792e-07
of O 0 2.207091398531702e-07
the O 0 1.654576067267044e-06
mouse O 0 0.00016643125854898244
. O 0 1.793452065612655e-05

Furthermore O 0 0.0003559761098586023
, O 0 6.617734925384866e-06
we O 0 7.745713901385898e-07
observed O 0 1.5376701867353404e-06
no O 0 2.57863661090596e-07
correlation O 0 8.364241352865065e-07
between O 0 3.1687082469034067e-07
the O 0 8.898917371880088e-07
somatic O 0 0.00010295710671925917
mutation O 0 2.80424010270508e-05
rate O 0 1.2779976714227814e-05
and O 0 2.7769247026299126e-06
tissue O 0 0.00037346972385421395
proliferation O 0 7.612882473040372e-05
capacity O 0 1.5416524547617882e-05
. O 0 1.366096330457367e-05

The O 0 7.189981988631189e-05
somatic O 0 0.0017542135901749134
mutation O 0 0.00048593292012810707
rates O 0 1.1865510714414995e-05
in O 0 6.019105853738438e-07
different O 0 3.9863013512331236e-07
tissues O 0 4.581327630148735e-06
were O 0 1.8949320690353488e-07
also O 0 1.609549400427568e-07
not O 0 5.799768132419558e-08
correlated O 0 8.430068305642635e-07
to O 0 7.49597219851239e-08
the O 0 1.4810846948876133e-07
relative O 0 2.707188059503096e-06
inter O 0 2.0438556020963006e-05
- O 0 0.00020652108651120216
tissue O 0 2.2259975594352e-05
difference O 0 5.55696033188724e-07
in O 0 1.7213028513651807e-07
transcriptional O 0 2.1487646790774306e-06
levels O 0 1.274256788974526e-07
of O 0 3.972168727273129e-08
the O 0 1.2511988245478278e-07
three O 0 4.256137913216662e-07
genes O 0 1.78170841991232e-06
( O 0 5.990318641124759e-07
DMAHP O 0 5.502872954821214e-05
, O 0 3.3682891853459296e-07
DMPK O 0 6.394141382770613e-05
and O 0 5.522604169527767e-07
59 O 0 4.9120326366391964e-06
) O 0 3.5711380519387603e-07
surrounding O 0 7.07172034708492e-07
the O 0 9.652076187194325e-07
repeat O 0 3.824435407295823e-05
. O 0 3.4309161947021494e-06
. O 0 1.2125444300181698e-05

A O 0 0.00045334509923122823
novel O 0 0.00044980202801525593
missense O 0 0.12860853970050812
mutation O 0 0.0010089504066854715
in O 0 1.9269127733423375e-05
patients O 0 0.0001227829634444788
from O 0 1.0445222642374574e-06
a O 0 7.63573007134255e-06
retinoblastoma B-Disease 0 0.008086073212325573
pedigree O 0 6.459639553213492e-05
showing O 0 7.8983039202285e-06
only O 0 6.174250870571996e-07
mild O 0 0.00016068029799498618
expression O 0 2.519602276152e-06
of O 0 9.502452940068906e-07
the O 0 1.8021186406258494e-05
tumor B-Disease 1 0.8565365672111511
phenotype O 0 0.17356128990650177
. O 0 5.103733201394789e-05

We O 0 1.4653656762675382e-05
have O 0 2.0805498479603557e-06
used O 0 1.064161097019678e-06
single O 0 2.3090037757356185e-06
strand O 0 2.2556219846592285e-05
conformation O 0 6.935722012713086e-06
polymorphism O 0 5.917401267652167e-06
analysis O 0 4.3920712755607383e-07
to O 0 1.0034354147592239e-07
study O 0 2.1421546136934921e-07
the O 0 1.6582079354066082e-07
27 O 0 2.0352674710011343e-06
exons O 0 2.954174306069035e-06
of O 0 1.8277478375239298e-07
the O 0 7.538267823292699e-07
RB1 O 0 0.0006947306683287024
gene O 0 1.935081400006311e-06
in O 0 2.463827968313126e-07
individuals O 0 2.396424179096357e-07
from O 0 2.4323128400283167e-07
a O 0 1.6467618024762487e-06
family O 0 5.517263161891606e-06
showing O 0 2.0098252207390033e-05
mild O 0 0.0005488066235557199
expression O 0 3.576278004402411e-06
of O 0 8.899630756786792e-07
the O 0 1.0942514563794248e-05
retinoblastoma B-Disease 1 0.7210158705711365
phenotype O 1 0.5602542757987976
. O 0 7.61780611355789e-05

In O 0 3.827182808890939e-05
this O 0 3.8280609260255005e-06
family O 0 1.5153435015236028e-05
affected O 0 6.1965461100044195e-06
individuals O 0 2.296619868502603e-06
developed O 0 2.3205593606689945e-05
unilateral B-Disease 1 0.8958501219749451
tumors I-Disease 1 0.9999998807907104
and O 0 1.8834246020560386e-06
, O 0 2.3256860970377602e-07
as O 0 8.983334964796086e-08
a O 0 3.061053064357111e-07
result O 0 2.3121297942907404e-07
of O 0 1.4632936995440105e-07
linkage O 0 1.1785811693698633e-05
analysis O 0 1.9834485556202708e-06
, O 0 1.0180796152781113e-06
unaffected O 0 5.046585283707827e-05
mutation O 0 1.4485368410532828e-05
carriers O 0 1.8269478232468828e-06
were O 0 2.150175930637488e-07
also O 0 2.9633881126756023e-07
identified O 0 1.522310299151286e-06
within O 0 6.179387241900258e-07
the O 0 2.0939680780429626e-06
pedigree O 0 0.00011460309906397015
. O 0 2.0966634110664017e-05

A O 0 0.00011979808914475143
single O 0 3.411933721508831e-05
band O 0 2.3942109692143276e-05
shift O 0 1.6107274859678e-05
using O 0 3.455438445598702e-06
SSCP O 0 0.0003412790538277477
was O 0 2.3749880710965954e-06
identified O 0 1.5933497934383922e-06
in O 0 3.459351489709661e-07
exon O 0 3.122143607470207e-05
21 O 0 4.3009863475163e-06
which O 0 1.816279819877309e-07
resulted O 0 1.4142951840767637e-06
in O 0 3.174249059156864e-07
a O 0 3.875230959238252e-06
missense O 0 0.0002174092223867774
mutation O 0 6.460671102104243e-06
converting O 0 2.0313505046942737e-06
a O 0 2.3954651169333374e-06
cys O 0 0.0068330285139381886
- O 0 0.0004180866526439786
- O 0 0.00027270213468000293
> O 0 4.402813647175208e-05
arg O 0 2.218396184616722e-05
at O 0 9.433504715161689e-07
nucleotide O 0 4.058946160512278e-06
position O 0 1.4890073316564667e-06
28 O 0 2.6594182145345258e-06
in O 0 8.229784498325898e-07
the O 0 3.5918710636906326e-06
exon O 0 0.0002276789746247232
. O 0 2.89511117443908e-05

The O 0 0.00010144635598408058
mutation O 0 0.00038146390579640865
destroyed O 0 4.4185188016854227e-05
an O 0 8.625063856015913e-06
NdeI O 0 0.0009974304120987654
restriction O 0 8.566906763007864e-05
enzyme O 0 8.173492824425921e-05
site O 0 2.954579031211324e-05
. O 0 2.466118530719541e-05

Analysis O 0 3.3686428650980815e-05
of O 0 2.1428872969408985e-06
all O 0 3.598240425617405e-07
family O 0 1.4362054798766621e-06
members O 0 6.606502438444295e-07
demonstrated O 0 1.5344386383731035e-06
that O 0 1.0388007609662964e-07
the O 0 6.796793172725302e-07
missense O 0 0.0001745251938700676
mutation O 0 2.3315062207984738e-05
co O 0 1.7387732441420667e-05
- O 0 6.333124474622309e-05
segregated O 0 4.343134423834272e-05
with O 0 8.500890544382855e-06
patients O 0 0.011527018621563911
with O 0 9.973248961614445e-05
tumors B-Disease 1 1.0
or O 0 7.233773430925794e-06
who O 0 1.8144236264561187e-06
, O 0 1.004095864232113e-07
as O 0 5.446362294492246e-08
a O 0 3.127135812519555e-07
result O 0 2.5531318215143983e-07
of O 0 1.115091450287764e-07
linkage O 0 9.892236448649783e-06
analysis O 0 1.4757918052055174e-06
had O 0 1.0031825468104216e-06
been O 0 3.765978533465386e-07
predicted O 0 2.2356871340889484e-06
to O 0 2.062665487301274e-07
carry O 0 1.5218848830045317e-06
the O 0 3.50028039974859e-06
predisposing O 0 0.0010856474982574582
mutation O 0 0.00022731196077074856
. O 0 2.2858928787172772e-05

These O 0 9.320186109107453e-06
observations O 0 5.593691639660392e-06
point O 0 1.5020960972833564e-06
to O 0 2.75659488124802e-07
another O 0 5.642866085509013e-07
region O 0 1.2196373972983565e-06
of O 0 2.6091498739333474e-07
the O 0 1.2114946912333835e-06
RB1 O 0 0.0018203590298071504
gene O 0 2.609951252452447e-06
where O 0 5.397910172177944e-07
mutations O 0 1.953106220753398e-06
only O 0 5.7965831246065136e-08
modify O 0 1.283587721445656e-06
the O 0 9.569698988798336e-08
function O 0 1.49977566366033e-07
of O 0 3.5238816309401955e-08
the O 0 1.2907955238006252e-07
gene O 0 5.476017008732015e-07
and O 0 1.1126036270070472e-07
raise O 0 4.823438075618469e-07
important O 0 8.999438705359353e-08
questions O 0 3.5179124324713484e-07
for O 0 3.8052647255426564e-07
genetic O 0 1.9668143067974597e-05
counseling O 0 5.015639544581063e-05
in O 0 7.695953740949335e-07
families O 0 1.3257875934868935e-06
with O 0 3.3598129789425e-07
these O 0 5.36977836418373e-07
distinctive O 0 8.788231207290664e-05
phenotypes O 0 0.0031439983285963535
. O 0 5.845535270054825e-06
. O 0 1.689292366791051e-05

Maternal B-Disease 0 0.08722549676895142
disomy I-Disease 1 0.6797422766685486
and O 0 0.005156573839485645
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
consistent O 0 5.3623811254510656e-05
with O 0 7.344774076045724e-06
gamete O 0 0.0004815000866074115
complementation O 0 0.02487560734152794
in O 0 2.2856729628983885e-06
a O 0 3.570222133930656e-06
case O 0 2.8125050448579714e-06
of O 0 1.1279705631750403e-06
familial O 0 0.005232501775026321
translocation O 0 0.058329254388809204
( O 0 5.309246262186207e-06
3 O 0 2.813387709466042e-06
; O 0 1.189546424029686e-06
15 O 0 7.440048648277298e-07
) O 0 3.966271719946235e-07
( O 0 5.952908281869895e-07
p25 O 0 2.0337156456662342e-05
; O 0 1.2689853292613407e-06
q11 O 0 1.533938484499231e-05
. O 0 5.775062845714274e-07
2 O 0 3.817408014583634e-06
) O 0 4.486333182285307e-06
. O 0 8.017978871066589e-06

Maternal B-Disease 1 0.627652645111084
uniparental I-Disease 1 0.9969502091407776
disomy I-Disease 1 0.9684591293334961
( I-Disease 0 0.0003917130525223911
UPD I-Disease 1 0.9997214674949646
) I-Disease 0 4.487651494855527e-06
for I-Disease 0 7.604334655297862e-07
chromosome I-Disease 0 9.990573744289577e-05
15 I-Disease 0 1.22810990887956e-06
is O 0 9.36545276886136e-08
responsible O 0 2.2653644293768593e-07
for O 0 6.32323065019591e-08
an O 0 1.6081101250620122e-07
estimated O 0 1.4460872534982627e-06
30 O 0 9.95820073512732e-07
% O 0 5.146725925442297e-07
of O 0 1.5262118324699259e-07
cases O 0 2.4064672743406845e-06
of O 0 4.333647302701138e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0034715731162577868
PWS B-Disease 1 0.9999834299087524
) O 0 3.653072417364456e-05
. O 0 3.198397462256253e-05

We O 0 3.297358489362523e-05
report O 0 5.06602373206988e-06
on O 0 1.0695331411625375e-06
an O 0 5.167554490981274e-07
unusual O 0 1.363404180665384e-06
case O 0 9.949314971891e-07
of O 0 3.040773322027235e-07
maternal B-Disease 0 0.00010920336353592575
disomy I-Disease 0 0.002269874792546034
15 I-Disease 0 6.1809291764802765e-06
in O 0 1.7113669628088246e-06
PWS B-Disease 1 0.9996271133422852
that O 0 1.546601851032392e-07
is O 0 1.1255254861453068e-07
most O 0 7.553654057801396e-08
consistent O 0 3.3867812021526333e-07
with O 0 1.298923422154985e-07
adjacent O 0 1.5313103176595178e-06
- O 0 1.2461687219911255e-05
1 O 0 1.3750056950811995e-06
segregation O 0 1.339395907962171e-06
of O 0 9.032421388610601e-08
a O 0 1.9842675555992173e-06
paternal O 0 0.0019926291424781084
t O 0 0.048479411751031876
( O 0 1.0073210887640016e-06
3 O 0 8.030850722207106e-07
; O 0 8.347666380359442e-07
15 O 0 8.143956051753776e-07
) O 0 2.906872396124527e-07
( O 0 4.2050280057992495e-07
p25 O 0 9.953635526471771e-06
; O 0 5.901447366341017e-07
q11 O 0 7.47633384889923e-06
. O 0 1.0720641796524433e-07
2 O 0 2.4342506321772817e-07
) O 0 1.303644125982828e-07
with O 0 1.7172071409277123e-07
simultaneous O 0 5.123398750583874e-06
maternal O 0 0.00011559481208678335
meiotic O 0 0.0018070739461109042
nondisjunction O 0 0.0005031772889196873
for O 0 5.035293725086376e-06
chromosome O 0 0.0005700113833881915
15 O 0 2.8411315724952146e-05
. O 0 1.636894558032509e-05

The O 0 0.00010809789091581479
patient O 0 0.006880358327180147
( O 0 2.77710296359146e-05
J O 0 0.00034169660648331046
. O 0 8.003318612281873e-07
B O 0 2.701679022720782e-06
. O 0 1.0812558315365095e-07
) O 0 1.2327608089890418e-07
, O 0 5.98576690435948e-08
a O 0 4.7321523766186147e-07
17 O 0 2.641913170009502e-06
- O 0 1.4860856026643887e-05
year O 0 1.3578750213127933e-06
- O 0 1.5356317817349918e-05
old O 0 1.2198886906844564e-05
white O 0 2.4967184799606912e-05
male O 0 1.4563270269718487e-05
with O 0 3.350960241732537e-06
PWS B-Disease 1 0.9999973773956299
, O 0 8.70565827426617e-07
was O 0 4.4106619156991655e-07
found O 0 1.1504794628081072e-07
to O 0 9.729284045079112e-08
have O 0 1.3474912918809423e-07
47 O 0 1.919198666655575e-06
chromosomes O 0 1.965835735973087e-06
with O 0 1.4520722402266983e-07
a O 0 1.1873850098709227e-06
supernumerary O 0 0.0017085593426600099
, O 0 8.108817723950779e-07
paternal O 0 8.172994421329349e-05
der O 0 0.0002473531349096447
( O 0 5.716705118175014e-07
15 O 0 2.771229219433735e-07
) O 0 7.673894941717663e-08
consisting O 0 8.739275614289e-08
of O 0 3.054992703255266e-08
the O 0 1.0594186505841208e-07
short O 0 1.920511522257584e-06
arm O 0 2.4089122234727256e-05
and O 0 1.8707491733493953e-07
the O 0 3.0246812343648344e-07
proximal O 0 0.00015171428094618022
long O 0 1.843568134063389e-05
arm O 0 4.510933285928331e-05
of O 0 5.066846711088147e-07
chromosome O 0 5.935847002547234e-05
15 O 0 1.7783913790481165e-06
, O 0 5.311154041010013e-07
and O 0 2.2080164399085334e-06
distal O 0 0.0499456524848938
chromosome O 0 0.0158051960170269
arm O 0 0.002613913733512163
3p O 0 0.008161057718098164
. O 0 6.890163786010817e-05

The O 0 0.00012069162767147645
t O 0 0.008478978648781776
( O 0 6.736592695233412e-06
3 O 0 3.069169679292827e-06
; O 0 1.1482011359476019e-06
15 O 0 8.244230684795184e-07
) O 0 2.1187491938690073e-07
was O 0 1.6201431662921095e-07
present O 0 6.786515172052532e-08
in O 0 4.302465228533947e-08
the O 0 8.092904835166337e-08
balanced O 0 2.481613819327322e-06
state O 0 2.256799547240007e-07
in O 0 2.4200519987971347e-07
the O 0 2.223838464487926e-06
patients O 0 9.198572661262006e-05
father O 0 4.986678504792508e-06
and O 0 9.715317901282106e-07
a O 0 8.911732948035933e-06
sister O 0 0.00034983071964234114
. O 0 2.866345676011406e-05

Fluorescent O 0 0.0009884611936286092
in O 0 1.946000338648446e-05
situ O 0 7.816900324542075e-05
hybridization O 0 1.983643051062245e-05
analysis O 0 4.8853848966246005e-06
demonstrated O 0 4.356273166195024e-06
that O 0 2.5909054102157825e-07
the O 0 1.5161598412305466e-06
PWS B-Disease 1 0.9994887113571167
critical O 0 6.414711151592201e-06
region O 0 3.948043286072789e-06
resided O 0 2.3427830910804914e-06
on O 0 2.735972373102413e-07
the O 0 2.138233838877568e-07
derivative O 0 8.711482223588973e-06
chromosome O 0 3.2093081244966015e-05
3 O 0 9.056103635884938e-07
and O 0 1.089397514419943e-07
that O 0 5.4163610485602476e-08
there O 0 5.0798028894405434e-08
was O 0 4.81915776617825e-07
no O 0 2.2605345861848036e-07
deletion O 0 7.360326435446041e-06
of O 0 1.7468310886670224e-07
the O 0 1.649978116802231e-06
PWS B-Disease 1 0.9998685121536255
region O 0 3.5894122447643895e-06
on O 0 3.911705448444991e-07
the O 0 2.5258424329877016e-07
normal O 0 1.0429147323520738e-06
pair O 0 1.4736020830241614e-06
of O 0 4.7586269147359417e-07
15s O 0 3.835015377262607e-05
present O 0 2.1093690065754345e-06
in O 0 3.1919639695843216e-06
J O 0 0.0007271465728990734
. O 0 1.989971315197181e-05

B O 0 0.0136198615655303
. O 0 0.0008169809589162469

Methylation O 0 0.00045665225479751825
analysis O 0 2.9699582228204235e-05
at O 0 4.171391992713325e-06
exon O 0 2.8349119020276703e-05
alpha O 0 4.9239361032960005e-06
of O 0 2.0914983167585888e-07
the O 0 3.7888392512286373e-07
small O 0 2.040658955593244e-06
nuclear O 0 8.983831321529578e-06
ribonucleoprotein O 0 9.168763062916696e-05
- O 0 2.896652222261764e-05
associated O 0 3.1071522244019434e-06
polypeptide O 0 2.054384458460845e-05
N O 0 1.4767726497666445e-05
( O 0 1.0530560530241928e-06
SNRPN O 0 2.0875597328995354e-05
) O 0 5.970368306407181e-07
gene O 0 9.554030384606449e-07
showed O 0 7.315696279874828e-07
a O 0 4.6079546223154466e-07
pattern O 0 6.586832569155376e-06
characteristic O 0 8.494330927533156e-07
of O 0 9.176324766713151e-08
only O 0 9.21471681181174e-08
the O 0 4.0663744016455894e-07
maternal O 0 4.327122587710619e-05
chromosome O 0 7.76324377511628e-05
15 O 0 3.4247148050781107e-06
in O 0 2.836583689713734e-06
J O 0 0.0005106432945467532
. O 0 1.4278488379204646e-05

B O 0 0.01605846732854843
. O 0 0.0012070424854755402

Maternal B-Disease 0 0.05773000419139862
disomy I-Disease 0 0.09758944809436798
was O 0 4.0796887333272025e-05
confirmed O 0 7.95192681835033e-06
by O 0 8.264067901109229e-07
polymerase O 0 1.3418874004855752e-05
chain O 0 7.866513442422729e-06
reaction O 0 1.1497000969029614e-06
analysis O 0 5.925093091718736e-07
of O 0 3.2071181976789376e-07
microsatellite O 0 0.00013476703315973282
repeats O 0 8.568494195060339e-06
at O 0 5.974007990516839e-07
the O 0 5.923381536376837e-07
gamma O 0 1.4357740838022437e-05
- O 0 2.591478914837353e-05
aminobutyric O 0 0.00014744821237400174
acid O 0 2.346482506254688e-05
receptor O 0 1.407636227668263e-05
beta3 O 0 3.898739305441268e-05
subunit O 0 1.5788567907293327e-05
( O 0 5.9907288232352585e-06
GABRB3 O 0 0.0001800597383407876
) O 0 7.923033081169706e-06
locus O 0 9.50872854446061e-05
. O 0 2.0178647901047952e-05

A O 0 0.0003260563244111836
niece O 0 0.042265910655260086
( O 0 5.588023122982122e-05
B O 0 2.4314287657034583e-05
. O 0 6.348905117192771e-07
B O 0 2.7199646410736023e-06
. O 0 9.427446201470957e-08
) O 0 9.835449077399971e-08
with O 0 7.668612767020022e-08
45 O 0 7.514223057114577e-07
chromosomes O 0 1.1453860224719392e-06
and O 0 7.754213982025249e-08
the O 0 1.0463651989311984e-07
derivative O 0 1.9325011635373812e-06
3 O 0 9.044633202393015e-07
but O 0 8.395538486638543e-08
without O 0 1.4383202540102502e-07
the O 0 2.35993709907234e-07
der O 0 3.0226847229641862e-05
( O 0 7.186982884377358e-07
15 O 0 5.298617224980262e-07
) O 0 3.434703330640332e-07
demonstrated O 0 1.6422684439021396e-06
a O 0 2.8414817734301323e-06
phenotype O 0 0.0016622449038550258
consistent O 0 1.1772035577450879e-06
with O 0 1.5404943098928925e-07
that O 0 2.1935024108188372e-07
reported O 0 1.8034191953120171e-06
for O 0 4.2527457821961434e-07
haploinsufficiency O 0 0.00012564864300657064
of O 0 1.607585659257893e-06
distal O 0 0.02917756326496601
3 O 0 0.00015250912110786885
p O 0 0.0006617876351810992
. O 0 2.4254351956187747e-05

Uniparental B-Disease 1 0.9999523162841797
disomy I-Disease 1 0.9994875192642212
associated O 0 0.00026502631953917444
with O 0 1.0359301086282358e-05
unbalanced O 0 0.00047628837637603283
segregation O 0 8.251407416537404e-05
of O 0 1.706424200165202e-06
non O 0 1.0625532922858838e-05
- O 0 0.00012376601807773113
Robertsonian O 0 0.0004508834390435368
translocations O 0 0.00046055015991441905
has O 0 1.705909994598187e-06
been O 0 9.874034958556877e-07
reported O 0 4.600683951139217e-06
previously O 0 1.3130525076121558e-06
but O 0 1.1170796199166944e-07
has O 0 1.449211310955434e-07
not O 0 4.8283489206824015e-08
, O 0 4.097500649891117e-08
to O 0 3.86534324547938e-08
our O 0 8.342033197550336e-08
knowledge O 0 1.3305395896168193e-07
, O 0 9.535790468362393e-08
been O 0 1.6513588718680694e-07
observed O 0 5.20748358212586e-07
in O 0 2.119032131986387e-07
a O 0 2.249831595690921e-06
case O 0 1.0575169653748162e-05
of O 0 1.3204085007600952e-05
PWS B-Disease 1 0.9999902248382568
. O 0 8.003188850125298e-05

Furthermore O 0 0.00037607780541293323
, O 0 1.0221559932688251e-05
our O 0 2.4874377686501248e-06
findings O 0 2.1673447463399498e-06
are O 0 1.3393481879120372e-07
best O 0 3.964449035720463e-07
interpreted O 0 1.1748416000045836e-06
as O 0 5.875396595911297e-07
true O 0 4.784346401720541e-06
gamete O 0 9.293848415836692e-05
complementation O 0 0.0015185956144705415
resulting O 0 3.4661345125641674e-05
in O 0 9.149109246209264e-06
maternal B-Disease 0 0.05365275591611862
UPD I-Disease 1 0.999997615814209
15 I-Disease 0 0.00026065445854328573
and O 0 0.00011904786515515298
PWS B-Disease 1 0.9998918771743774

Schwartz B-Disease 1 0.8945692777633667
- I-Disease 1 0.9993488192558289
Jampel I-Disease 1 0.9999556541442871
syndrome I-Disease 1 0.9999985694885254
type I-Disease 0 6.438441050704569e-05
2 I-Disease 0 2.4054388632066548e-05
and O 0 1.0723075320129283e-05
Stuve B-Disease 1 0.9605013728141785
- I-Disease 1 0.9998370409011841
Wiedemann I-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999961853027344
: O 0 2.187722884627874e-06
a O 0 1.979614125957596e-06
case O 0 2.0368595414765878e-06
for O 0 9.57512725108245e-07
" O 0 4.0490022001904435e-06
lumping O 0 4.188009916106239e-05
" O 0 9.796758604352362e-06
. O 0 1.708810668787919e-05

Recent O 0 0.00024293086607940495
studies O 0 6.34825264569372e-05
demonstrated O 0 1.2005513781332411e-05
the O 0 6.167718424876512e-07
existence O 0 1.0529906830925029e-06
of O 0 2.129670093609093e-07
a O 0 2.0743846107507125e-06
genetically O 0 1.610569415788632e-05
distinct O 0 3.079525413340889e-06
, O 0 5.418876298790565e-07
usually O 0 6.445350777539716e-07
lethal O 0 3.098006345680915e-06
form O 0 2.4619887994958845e-07
of O 0 1.9022506592136779e-07
the O 0 2.1558955722866813e-06
Schwartz B-Disease 0 0.11175420880317688
- I-Disease 1 0.9859543442726135
Jampel I-Disease 1 0.999991774559021
syndrome I-Disease 1 0.9999984502792358
( O 0 1.6497564502060413e-05
SJS B-Disease 0 0.001266700099222362
) O 0 9.222494554705918e-07
of O 0 8.243932256846165e-07
myotonia B-Disease 1 0.7221906781196594
and O 0 3.5923429095419124e-05
skeletal B-Disease 1 0.996783971786499
dysplasia I-Disease 1 0.9999678134918213
, O 0 3.3510114008095115e-06
which O 0 5.579901198871084e-07
we O 0 4.95237202358112e-07
called O 0 1.1121003808511887e-05
SJS B-Disease 0 0.018302354961633682
type I-Disease 0 1.2226885701238643e-05
2 I-Disease 0 2.008250703511294e-05
. O 0 1.3133970242051873e-05

This O 0 0.00044894698658026755
disorder O 1 0.9983079433441162
is O 0 4.737557446787832e-06
reminiscent O 0 7.793640543241054e-05
of O 0 1.631629515941313e-06
another O 0 2.1335406927391887e-05
rare O 0 5.4270527471089736e-05
condition O 0 9.987295925384387e-05
, O 0 9.399415716870863e-07
the O 0 4.099778379895724e-06
Stuve B-Disease 1 0.9935500025749207
- I-Disease 1 0.9999936819076538
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 9.053065878106281e-05
SWS B-Disease 1 0.8123582601547241
) O 0 9.579421202943195e-07
, O 0 1.9436875220435468e-07
which O 0 1.325229703752484e-07
comprises O 0 5.728455221287732e-07
campomelia B-Disease 0 3.568652391550131e-05
at O 0 5.685914175046491e-07
birth O 0 1.2922177120344713e-05
with O 0 5.978447006782517e-06
skeletal B-Disease 1 0.9738543629646301
dysplasia I-Disease 1 0.9999905824661255
, O 0 3.327404920128174e-05
contractures B-Disease 0 0.3669280409812927
, O 0 1.425130676580011e-06
and O 0 1.5835576050449163e-06
early B-Disease 0 1.3629473869514186e-05
death I-Disease 0 9.441551810596138e-05
. O 0 1.8104110495187342e-05

To O 0 2.4597347874077968e-05
test O 0 8.331876415468287e-06
for O 0 1.007597802527016e-06
possible O 0 3.2655968880135333e-06
nosologic O 0 0.00044875041930936277
identity O 0 1.1440954040153883e-05
between O 0 1.935112777573522e-06
these O 0 1.8569925259726006e-06
disorders O 1 0.6372364163398743
, O 0 5.324725407263031e-07
we O 0 1.2036632313083828e-07
reviewed O 0 5.16472198341944e-07
the O 0 1.3216376260061224e-07
literature O 0 1.8164737980441714e-07
and O 0 7.343195562725668e-08
obtained O 0 1.6756852971866465e-07
a O 0 2.453365937071794e-07
follow O 0 2.9805065082655346e-07
- O 0 1.7877372329166974e-06
up O 0 7.36912397769629e-08
of O 0 2.457135117595044e-08
the O 0 5.2685656726225716e-08
only O 0 5.874472464029168e-08
two O 0 4.3084685330541106e-07
surviving O 0 0.00015868387708906084
patients O 0 2.740347736107651e-05
, O 0 1.4536989567659475e-07
one O 0 1.1444345915379017e-07
with O 0 1.1923835927518667e-06
SJS B-Disease 0 0.015836456790566444
type I-Disease 0 1.2335187875578413e-06
2 I-Disease 0 8.599762963967805e-07
at O 0 2.213263030625967e-07
age O 0 3.942949433621834e-07
10 O 0 1.9217318936171068e-07
years O 0 1.0717553777794819e-07
and O 0 6.59439791661498e-08
another O 0 2.634126587963692e-07
with O 0 9.488018690717581e-07
SWS B-Disease 0 0.35098978877067566
at O 0 2.286364178871736e-06
age O 0 3.0901662739779567e-06
7 O 0 8.849865480442531e-06
years O 0 4.884741883870447e-06
. O 0 1.430337579222396e-05

Patients O 1 0.982720673084259
reported O 0 0.0002589982177596539
as O 0 5.5402624639100395e-06
having O 0 1.328123744315235e-05
either O 0 3.5300126910442486e-05
neonatal O 1 0.9999998807907104
SJS B-Disease 1 0.9999661445617676
or O 0 9.024716564454138e-05
SWS B-Disease 1 0.8548106551170349
presented O 0 3.8265789044089615e-06
a O 0 2.107111185978283e-06
combination O 0 5.642463747790316e-06
of O 0 5.174996431378531e-07
a O 0 5.440437234938145e-05
severe O 1 0.9380372166633606
, O 0 8.426238491665572e-05
prenatal O 1 0.9999377727508545
- O 1 0.9999949932098389
onset O 1 0.9999998807907104
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 0.9999994039535522
( O 0 6.58108401694335e-05
with O 0 0.00012843625154346228
congenital B-Disease 1 1.0
joint I-Disease 1 0.9490397572517395
contractures I-Disease 1 0.9999971389770508
, O 0 0.0002200624585384503
respiratory O 1 0.9728067517280579
and O 0 7.2314282988372725e-06
feeding O 0 8.238049485953525e-05
difficulties O 0 6.388796464307234e-05
, O 0 7.801677952556929e-07
tendency O 0 3.127626996501931e-06
to O 0 4.233605181980238e-07
hyperthermia B-Disease 0 0.19696064293384552
, O 0 2.416371103208803e-07
and O 0 2.440615105570032e-07
frequent O 0 3.1591416700393893e-06
death O 0 1.893372245831415e-05
in O 0 1.4677634680992924e-06
infancy O 0 8.549858466722071e-05
) O 0 3.192598398982227e-07
with O 0 2.4898582751120557e-07
a O 0 3.4323561521887314e-06
distinct O 0 3.395982275833376e-05
campomelic B-Disease 0 0.011576598510146141
- I-Disease 0 0.08151054382324219
metaphyseal I-Disease 1 0.7100710272789001
skeletal I-Disease 1 0.9803479313850403
dysplasia I-Disease 1 0.9999762773513794
. O 0 0.0002536301326472312

The O 0 2.8358286726870574e-05
similarity O 0 2.2222648112801835e-05
of O 0 1.261944703401241e-06
the O 0 2.129464064637432e-06
clinical O 0 0.00018680428911466151
and O 0 5.186124781175749e-06
radiographic O 1 0.617713451385498
findings O 0 1.5130691281228792e-05
is O 0 2.652078592291218e-07
so O 0 1.501985735785638e-07
extensive O 0 7.617225037392927e-07
that O 0 2.1511952752462093e-07
these O 0 1.1425232742112712e-06
disorders O 1 0.9112142324447632
appear O 0 3.5636637676361715e-06
to O 0 2.2884597683514585e-07
be O 0 2.919841790571809e-07
a O 0 3.221351789761684e-06
single O 0 1.4620043657487258e-05
entity O 0 5.520933700609021e-05
. O 0 2.1848100004717708e-05

The O 0 3.243683386244811e-05
follow O 0 1.527640597487334e-05
- O 0 3.185974128427915e-05
up O 0 1.2956193131685723e-06
observation O 0 1.91518711289973e-06
of O 0 1.345083973092187e-07
an O 0 1.895581078770192e-07
identical O 0 5.1226120376668405e-06
and O 0 3.204305585313705e-07
unique O 0 9.035383072841796e-07
pattern O 0 1.7389274944434874e-05
of O 0 2.131619794454309e-06
progressive O 1 0.5069235563278198
bone B-Disease 1 0.9789626002311707
dysplasia I-Disease 1 0.9999229907989502
in O 0 3.240378191549098e-06
the O 0 1.4388184581548558e-06
two O 0 1.3957140254206024e-05
patients O 0 0.0004761594464071095
( O 0 1.1292288490949431e-06
one O 0 1.7834004495398403e-07
with O 0 1.0826958032339462e-06
SJS B-Disease 0 0.2538924217224121
type I-Disease 0 1.8400708086119266e-06
2 I-Disease 0 8.533352229278535e-07
, O 0 9.406592482719134e-08
one O 0 1.2087937761862122e-07
with O 0 6.086904704716289e-07
SWS B-Disease 0 0.34808996319770813
) O 0 8.98105440683139e-07
surviving O 0 2.134783244400751e-06
beyond O 0 1.1099230050604092e-06
infancy O 0 9.748797310749069e-06
adds O 0 9.673916565589025e-07
to O 0 6.508080474532107e-08
the O 0 1.0027887498154087e-07
evidence O 0 2.343555536299391e-07
in O 0 3.047026382319018e-07
favor O 0 1.3731606713918154e-06
of O 0 1.3299691090651322e-06
identity O 0 5.7362431107321754e-05
. O 0 1.846161285357084e-05

The O 0 8.823011012282223e-05
hypothesis O 0 0.00012232171138748527
that O 0 5.890656666451832e-06
SWS B-Disease 0 0.48583343625068665
and O 0 1.7275915524805896e-05
SJS B-Disease 0 0.0935407280921936
type I-Disease 0 2.431805569358403e-06
2 I-Disease 0 1.1414418850108632e-06
are O 0 7.63960414928988e-08
the O 0 2.855905165688455e-07
same O 0 6.906363068992505e-06
disorder O 1 0.6836593151092529
should O 0 5.505550007001148e-07
be O 0 2.1544926198657777e-07
testable O 0 2.010696562138037e-06
by O 0 2.868653155019274e-07
molecular O 0 3.9594797272002324e-06
methods O 0 4.48591390522779e-06
. O 0 2.6064092253363924e-06
. O 0 1.0770814697025344e-05

A O 0 0.0002598317223601043
mouse O 0 0.00035884385579265654
model O 0 0.00011360208736732602
of O 0 6.0244154155952856e-05
severe O 1 0.9999957084655762
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.0005085563170723617
defects O 1 0.9937546253204346
in O 0 4.792311301571317e-05
hemostasis O 1 0.9893903136253357
and O 0 0.000829061318654567
thrombosis B-Disease 1 0.9999101161956787
. O 0 0.0002490952319931239

von B-Disease 1 0.999099612236023
Willebrand I-Disease 1 0.999382495880127
factor I-Disease 0 0.0028057177551090717
( I-Disease 0 0.0005635633715428412
vWf I-Disease 0 0.28066587448120117
) I-Disease 0 0.0025790168438106775
deficiency I-Disease 1 0.9997391104698181
causes O 1 0.5487117767333984
severe O 1 0.9999995231628418
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 0.9999995231628418
in O 0 4.847079253522679e-05
humans O 0 5.572389636654407e-05
. O 0 3.405802635825239e-05

We O 0 2.4460645363433287e-05
generated O 0 9.839435733738355e-06
a O 0 4.113112936465768e-06
mouse O 0 2.279623549839016e-05
model O 0 3.7742297536169644e-06
for O 0 8.079654207904241e-07
this O 0 1.5430968005603063e-06
disease O 0 2.797783599817194e-05
by O 0 4.6124921482260106e-07
using O 0 3.989008291682694e-06
gene O 0 1.9595763660618104e-05
targeting O 0 3.99027849198319e-05
. O 0 1.8918795831268653e-05

vWf B-Disease 0 0.4651001989841461
- I-Disease 1 0.9673916697502136
deficient I-Disease 1 0.685422956943512
mice O 0 0.001044575939886272
appeared O 0 1.87879559234716e-05
normal O 0 7.024936166999396e-06
at O 0 1.0209176934949937e-06
birth O 0 1.9365956177352928e-05
; O 0 1.5236217905112426e-06
they O 0 2.52307415848918e-07
were O 0 5.96260122165404e-07
viable O 0 1.2759979654219933e-05
and O 0 3.049525275855558e-06
fertile O 0 9.657571354182437e-05
. O 0 1.8265025573782623e-05

Neither O 0 0.0028582075610756874
vWf O 0 0.010188193060457706
nor O 0 0.0004825416544917971
vWf O 0 0.005234214011579752
propolypeptide O 0 0.050042156130075455
( O 0 0.0001402818743372336
von B-Disease 1 0.902320921421051
Willebrand I-Disease 1 0.996566653251648
antigen O 0 0.0017024201806634665
II O 0 6.582069909200072e-05
) O 0 1.4061935189602082e-06
were O 0 3.7468268487828027e-07
detectable O 0 1.5437033198395511e-06
in O 0 3.1162872460299695e-07
plasma O 0 6.434127044485649e-06
, O 0 6.432087502616923e-07
platelets O 0 1.7822891095420346e-05
, O 0 3.818875882188877e-07
or O 0 1.1375536814739462e-06
endothelial O 0 0.0002787901321426034
cells O 0 4.76788954983931e-06
of O 0 4.0471542206432787e-07
the O 0 2.979872078867629e-06
homozygous O 0 0.0007544020772911608
mutant O 0 0.001078760833479464
mice O 0 0.0006589001859538257
. O 0 2.9353497666306794e-05

The O 0 0.0001247681211680174
mutant O 0 0.04626014083623886
mice O 0 0.38473016023635864
exhibited O 0 0.0006031431257724762
defects O 1 0.7674958109855652
in O 0 6.927115009602858e-06
hemostasis O 0 0.012353064492344856
with O 0 2.2458464172814274e-06
a O 0 1.8833163267117925e-05
highly O 0 2.031804615398869e-05
prolonged O 1 0.5584897994995117
bleeding O 1 0.541752815246582
time O 0 1.4970092934163404e-06
and O 0 8.590287734477897e-07
spontaneous O 0 1.5177342902461533e-05
bleeding O 0 0.0003045580815523863
events O 0 6.140433583823324e-07
in O 0 3.7839211586288e-07
approximately O 0 8.294513236251078e-07
10 O 0 1.0053470305138035e-06
% O 0 2.2725687358615687e-06
of O 0 1.7844258763943799e-06
neonates O 0 0.00819248054176569
. O 0 3.0120208975858986e-05

As O 0 2.73702808044618e-05
in O 0 6.195193236635532e-06
the O 0 4.0303939385921694e-06
human O 0 2.1978270524414256e-05
disease O 0 0.00017926812870427966
, O 0 2.719230849379528e-07
the O 0 2.9719865324295824e-07
factor O 0 2.2512888335768366e-06
VIII O 0 0.00011949279723921791
level O 0 5.393402489062282e-07
in O 0 1.8249158983962843e-07
these O 0 1.2129277138228645e-07
mice O 0 1.1675297173496801e-05
was O 0 7.692196959396824e-07
reduced O 0 2.519023155400646e-06
strongly O 0 5.697535243598395e-07
as O 0 6.520580342339599e-08
a O 0 3.392072756014386e-07
result O 0 1.889684284606119e-07
of O 0 5.623998688975007e-08
the O 0 1.7858017997696152e-07
lack O 0 7.968558861648489e-07
of O 0 2.261000418002368e-07
protection O 0 7.049398845992982e-06
provided O 0 3.4741935905913124e-06
by O 0 4.360945240478031e-06
vWf O 0 0.0005304248770698905
. O 0 1.9754461391130462e-05

Defective O 1 0.986079752445221
thrombosis B-Disease 1 0.9998700618743896
in O 0 0.00010466187814017758
mutant O 0 0.022724172100424767
mice O 0 0.014315489679574966
was O 0 7.648579412489198e-06
also O 0 8.465548830827174e-07
evident O 0 1.6358690118067898e-06
in O 0 2.571102868387243e-07
an O 0 3.47934218325463e-07
in O 0 1.5499964547416312e-06
vivo O 0 9.63765342021361e-05
model O 0 1.162873741122894e-05
of O 0 1.2703859283647034e-05
vascular B-Disease 1 0.999985933303833
injury I-Disease 1 0.9670740365982056
. O 0 0.00010422863124404103

In O 0 2.753524313447997e-05
this O 0 3.101734364463482e-06
model O 0 7.898070180090144e-06
, O 0 1.3303470041137189e-06
the O 0 1.3160724847693928e-06
exteriorized O 0 0.0004059518687427044
mesentery O 0 0.0010070897405967116
was O 0 7.162765541579574e-06
superfused O 0 0.00014536867092829198
with O 0 2.35576862905873e-06
ferric O 0 0.003369000507518649
chloride O 0 2.5741042918525636e-05
and O 0 4.0709298332330945e-07
the O 0 5.757119652116671e-07
accumulation O 0 5.058004717284348e-06
of O 0 1.0235664831270697e-06
fluorescently O 0 0.0011192753445357084
labeled O 0 0.00010344857582822442
platelets O 0 0.0001606000296305865
was O 0 2.455423782521393e-06
observed O 0 3.313101615276537e-06
by O 0 1.4413303688343149e-06
intravital O 0 0.0003541389596648514
microscopy O 0 0.00010179287346545607
. O 0 2.0515377400442958e-05

We O 0 2.9602791983052157e-05
conclude O 0 2.3437629351974465e-05
that O 0 9.418195645594096e-07
these O 0 5.86710939387558e-07
mice O 0 4.136737697990611e-05
very O 0 2.016542111960007e-06
closely O 0 3.6743917007697746e-05
mimic O 0 0.1402023285627365
severe O 1 0.9950377345085144
human O 0 0.022080490365624428
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 0.9999758005142212
and O 0 2.9245170480862726e-06
will O 0 4.570325415897969e-07
be O 0 7.613014219032266e-08
very O 0 6.728284063228784e-08
useful O 0 1.1381413145272745e-07
for O 0 5.6395737857428685e-08
investigating O 0 3.8109232036731555e-07
the O 0 7.135958668413878e-08
role O 0 3.340343539548485e-07
of O 0 2.2932091781058261e-07
vWf O 0 2.2887898012413643e-05
in O 0 4.394987627165392e-07
normal O 0 2.0920997485518456e-06
physiology O 0 5.1741803872573655e-06
and O 0 1.128738858824363e-06
in O 0 1.5273479220923036e-05
disease O 0 0.0003031063242815435
models O 0 1.4316531633085106e-05
. O 0 3.906526217178907e-06
. O 0 1.4754943549633026e-05

Oral O 0 0.002375558251515031
contraceptives O 0 0.07049820572137833
and O 0 1.941275695571676e-05
the O 0 1.2969634553883225e-05
risk O 0 0.0003056439745705575
of O 0 0.000223145994823426
hereditary B-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00015625984815414995

Hereditary B-Disease 1 0.9999980926513672
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 0.9999978542327881
Clinical O 0 0.48603343963623047
Study O 0 0.00021001181448809803
Group O 0 0.00010110659786732867
. O 0 4.842436101171188e-05

BACKGROUND O 0 0.0009288595174439251
Women O 0 8.314793376484886e-05
with O 0 7.270817604876356e-06
mutations O 0 4.852217170991935e-05
in O 0 5.562718570217839e-07
either O 0 6.453469723055605e-07
the O 0 9.812979442358483e-07
BRCA1 O 0 0.00015372587949968874
or O 0 9.941443295247154e-07
the O 0 1.1723345778591465e-06
BRCA2 O 0 0.0003613519365899265
gene O 0 1.8875063005907577e-06
have O 0 1.7089601556108391e-07
a O 0 1.4439732467508293e-06
high O 0 3.300447860965505e-05
lifetime O 0 0.00014000991359353065
risk O 0 0.0003070936072617769
of O 0 0.00044840536429546773
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 0.00015190652629826218

Oral O 0 0.005041600205004215
contraceptives O 1 0.9580621123313904
protect O 0 0.19070567190647125
against O 1 0.99363774061203
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 6.281557944021188e-06
general O 0 2.1470480078278342e-06
, O 0 2.907476641667017e-07
but O 0 9.066804551594032e-08
it O 0 6.168241384330031e-08
is O 0 7.36120071564983e-08
not O 0 4.881240300846912e-08
known O 0 2.1860010690488707e-07
whether O 0 1.3058789249953406e-07
they O 0 8.019839725648126e-08
also O 0 2.1954403450763493e-07
protect O 0 1.963325075848843e-06
against O 0 3.5638745430333074e-06
hereditary B-Disease 0 0.003772044787183404
forms I-Disease 0 2.9032422389718704e-05
of I-Disease 0 0.000754764536395669
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 0.00012364864232949913

METHODS O 0 0.0002561331493780017
We O 0 1.4010736776981503e-05
enrolled O 0 4.863298454438336e-05
207 O 0 0.0001643798459554091
women O 0 6.147131352918223e-05
with O 0 0.00032467133132740855
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
and O 0 2.780281874947832e-06
161 O 0 8.237391739385203e-06
of O 0 1.7105645611081854e-07
their O 0 2.698774608234089e-07
sisters O 0 1.3205898540036287e-05
as O 0 1.989132130120197e-07
controls O 0 1.0808305432874477e-06
in O 0 2.1828887497576943e-07
a O 0 1.5065418210724602e-06
case O 0 3.817055130639346e-06
- O 0 0.00010240526898996904
control O 0 3.3159474696731195e-05
study O 0 1.8039705537375994e-05
. O 0 1.528249958937522e-05

All O 0 2.090711313940119e-05
the O 0 1.8748993170447648e-05
patients O 0 0.00019077767501585186
carried O 0 6.304712314886274e-06
a O 0 5.3788844525115564e-06
pathogenic O 0 1.8435241145198233e-05
mutation O 0 1.2044309187331237e-05
in O 0 5.096028985462908e-07
either O 0 2.3172078726929612e-06
BRCA1 O 0 0.0003926001372747123
( O 0 3.4628544653969584e-06
179 O 0 9.483183930569794e-06
women O 0 2.428753305139253e-06
) O 0 9.533696356811561e-07
or O 0 2.8399779239407508e-06
BRCA2 O 0 0.0007504276582039893
( O 0 4.37571361544542e-06
28 O 0 1.9289775082143024e-05
women O 0 8.20249169919407e-06
) O 0 5.881742254132405e-06
. O 0 1.0216033842880279e-05

The O 0 2.0831823348999023e-05
control O 0 4.555650957627222e-05
women O 0 1.554458140162751e-05
were O 0 1.278501713386504e-06
enrolled O 0 7.984085641510319e-06
regardless O 0 9.165721621684497e-07
of O 0 1.2538374960513465e-07
whether O 0 2.0943724621247384e-07
or O 0 4.865392497777066e-07
not O 0 1.371397644334138e-07
they O 0 2.1433399410852871e-07
had O 0 3.2508155527466442e-06
either O 0 1.0005302101490088e-05
mutation O 0 9.004154708236456e-05
. O 0 1.4465989806922153e-05

Lifetime O 0 0.000676667143125087
histories O 0 0.00011552384967217222
of O 0 6.5901444941118825e-06
oral O 0 6.897723505971953e-05
- O 0 0.0011020372621715069
contraceptive O 0 0.02087213844060898
use O 0 1.0582285767668509e-06
were O 0 2.8063246304554923e-07
obtained O 0 3.099718526300421e-07
by O 0 1.0147079620992372e-07
interview O 0 1.097925633075647e-06
or O 0 1.927888746422468e-07
by O 0 9.921176769012163e-08
written O 0 2.6558498689155385e-07
questionnaire O 0 2.0217335077177268e-06
and O 0 2.1079181067307218e-07
were O 0 3.146851099700143e-07
compared O 0 3.5925902466260595e-06
between O 0 1.5999779634512379e-06
patients O 0 3.085288335569203e-05
and O 0 3.897993963164481e-07
control O 0 6.388447673089104e-06
women O 0 2.722676754274289e-06
, O 0 1.6892883536456793e-07
after O 0 5.271712097965064e-07
adjustment O 0 2.7848727768287063e-06
for O 0 1.7220119730154693e-07
year O 0 4.905404580313188e-07
of O 0 2.4684612753844704e-07
birth O 0 6.303233385551721e-05
and O 0 2.711443812586367e-06
parity O 0 6.200205098139122e-05
. O 0 1.2348638847470284e-05

RESULTS O 0 0.00023255019914358854
The O 0 2.0412491721799597e-05
adjusted O 0 0.0004493908490985632
odds O 0 0.0004216357774566859
ratio O 0 0.005008782260119915
for O 0 0.28418537974357605
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 5.957081611995818e-06
with O 0 2.9069721563246276e-07
any O 0 1.6184860385237698e-07
past O 0 3.8493490706059674e-07
use O 0 3.981593863500166e-07
of O 0 6.792704994040832e-07
oral O 0 3.370651029399596e-05
contraceptives O 0 0.11723408102989197
was O 0 2.6216579499305226e-05
0 O 0 3.527226363075897e-05
. O 0 1.3550467883760575e-05

5 O 0 0.00022409501252695918
( O 0 2.7314717954141088e-05
95 O 0 1.8088732758769765e-05
percent O 0 1.5750205420772545e-05
confidence O 0 3.305334985270747e-06
interval O 0 4.892872766504297e-06
, O 0 2.7473302566249913e-07
0 O 0 9.740199402585858e-07
. O 0 9.231288800037873e-08
3 O 0 4.665278652282723e-07
to O 0 1.5157463906234625e-07
0 O 0 1.2138725651311688e-06
. O 0 2.549793123307609e-07
8 O 0 3.0687276648677653e-06
) O 0 3.259374125264003e-06
. O 0 8.631589480501134e-06

The O 0 5.469786992762238e-05
risk O 0 0.00017177763220388442
decreased O 0 4.954968608217314e-05
with O 0 8.652090741634311e-07
increasing O 0 3.224892907383037e-06
duration O 0 7.9648898463347e-06
of O 0 1.8748767161014257e-07
use O 0 4.708419965027133e-07
( O 0 1.2386087746563135e-06
P O 0 1.0437842320243362e-05
for O 0 1.4050310426227952e-07
trend O 0 1.498691972301458e-06
, O 0 2.1050776410902472e-07
< O 0 4.43075214207056e-06
0 O 0 5.353922460926697e-07
. O 0 8.32388309390808e-08
001 O 0 2.128946107404772e-06
) O 0 1.0163660135731334e-07
; O 0 7.435581039771932e-08
use O 0 4.152052213157731e-08
for O 0 3.952601801415767e-08
six O 0 2.0795371824533504e-07
or O 0 1.0825125684732484e-07
more O 0 4.776230966285766e-08
years O 0 1.8320410788419395e-07
was O 0 2.84805594219506e-07
associated O 0 1.9895607294984075e-07
with O 0 8.805550777424287e-08
a O 0 2.308728426214657e-06
60 O 0 6.5278495640086476e-06
percent O 0 1.1845466360682622e-05
reduction O 0 1.7883299733512104e-05
in O 0 5.24887400388252e-06
risk O 0 0.00010629640746628866
. O 0 1.4492582522507291e-05

Oral O 0 0.0019242072012275457
- O 0 0.001933572581037879
contraceptive O 0 0.024304870516061783
use O 0 4.389452806208283e-05
protected O 0 0.0006241289665922523
against O 1 0.6763496398925781
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
both O 0 1.1792227496698615e-06
for O 0 3.9895570580483763e-07
carriers O 0 1.3723778238272644e-06
of O 0 1.7073539027023799e-07
the O 0 2.522694103390677e-06
BRCA1 O 0 0.010947002097964287
mutation O 0 6.149054388515651e-05
( O 0 2.2653262021776754e-06
odds O 0 9.640773896535393e-06
ratio O 0 3.2195521271205507e-06
, O 0 2.4419654209850705e-07
0 O 0 7.428633921335859e-07
. O 0 8.859426259277825e-08
5 O 0 4.7102702183110523e-07
; O 0 2.6199114699920756e-07
95 O 0 9.54544134401658e-07
percent O 0 1.6164220824066433e-06
confidence O 0 5.371166480472311e-07
interval O 0 1.1227247114220518e-06
, O 0 1.0176249531923531e-07
0 O 0 3.231957350635639e-07
. O 0 4.463364078333143e-08
3 O 0 1.7685940179035242e-07
to O 0 7.333313334356717e-08
0 O 0 6.039328468432359e-07
. O 0 9.017772129027435e-08
9 O 0 6.857807761662116e-07
) O 0 7.58560503300032e-08
and O 0 3.690039207526752e-08
for O 0 7.249121836139238e-08
carriers O 0 6.566471597579948e-07
of O 0 1.0483069701194836e-07
the O 0 1.9984424852736993e-06
BRCA2 O 0 0.033087108284235
mutation O 0 2.744519224506803e-05
( O 0 1.2754254612445948e-06
odds O 0 6.40766756987432e-06
ratio O 0 3.7095057905389694e-06
, O 0 3.6232262345947674e-07
0 O 0 6.486814072559355e-07
. O 0 7.0104540839111e-08
4 O 0 6.218137400537671e-07
; O 0 4.2439944536454277e-07
95 O 0 1.5787263691890985e-06
percent O 0 2.115205006703036e-06
confidence O 0 5.643985332426382e-07
interval O 0 1.0316781526853447e-06
, O 0 9.704985615144324e-08
0 O 0 4.082889404344314e-07
. O 0 4.297708144918033e-08
2 O 0 2.090020672085302e-07
to O 0 7.177757055387701e-08
1 O 0 4.1141819906442834e-07
. O 0 1.3900373119213327e-07
1 O 0 1.4174603393257712e-06
) O 0 2.568255467849667e-06
. O 0 4.398007604322629e-06

CONCLUSIONS O 0 0.000791586993727833
Oral O 0 0.0004946888075210154
- O 0 0.0015731391031295061
contraceptive O 0 0.040328070521354675
use O 0 1.1349075066391379e-05
may O 0 6.183181540109217e-06
reduce O 0 5.4267557061393745e-06
the O 0 1.3545354704547208e-06
risk O 0 8.245593926403672e-05
of O 0 0.00037285691360011697
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
in O 0 4.956627890351228e-06
women O 0 7.770388947392348e-06
with O 0 4.163582161709201e-06
pathogenic O 0 4.578516382025555e-05
mutations O 0 1.1968715625698678e-05
in O 0 7.903373671069858e-07
the O 0 5.166207301954273e-06
BRCA1 O 0 0.003207189030945301
or O 0 9.422421135241166e-05
BRCA2 O 0 0.012320389039814472
gene O 0 0.0007025020895525813

A O 0 0.00020789439440704882
Japanese O 0 7.948480924824253e-05
family O 0 3.0178232918842696e-05
with O 0 1.0710401511460077e-05
adrenoleukodystrophy B-Disease 1 0.9999951124191284
with O 0 2.722185854509007e-06
a O 0 7.954065040394198e-06
codon O 0 5.890027750865556e-05
291 O 0 3.403601294849068e-05
deletion O 0 0.00010866765660466626
: O 0 1.108022502194217e-06
a O 0 3.886104423145298e-06
clinical O 0 0.00011075619113398716
, O 0 1.2044065442751162e-06
biochemical O 0 4.099911166122183e-05
, O 0 1.2435147027645144e-06
pathological O 0 4.3376498069847e-05
, O 0 1.187847146866261e-06
and O 0 3.05432786262827e-06
genetic O 0 0.00011138797708554193
report O 0 1.6472080460516736e-05
. O 0 1.7710659449221566e-05

We O 0 3.1050793040776625e-05
report O 0 1.11621011456009e-05
a O 0 4.426090072229272e-06
Japanese O 0 8.607159543316811e-06
family O 0 8.665833775012288e-06
with O 0 4.4022297515766695e-05
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.044251132756471634
ALD B-Disease 1 0.9999998807907104
) O 0 9.515248393654474e-07
with O 0 1.6502757205216767e-07
a O 0 7.668640478186717e-07
three O 0 5.661149202751403e-07
base O 0 2.973448317789007e-06
pair O 0 1.3607784239866305e-05
deletion O 0 0.00020456795755308121
( O 0 2.9592724786198232e-06
delGAG O 0 3.171357457176782e-05
291 O 0 8.529857041139621e-06
) O 0 1.1350427939760266e-06
in O 0 1.03570016563026e-06
the O 0 9.891708941722754e-06
ALD B-Disease 1 0.9999978542327881
gene O 0 0.00010527084668865427
. O 0 2.545897223171778e-05

A O 0 0.00012822833377867937
variety O 0 1.6593545296927914e-05
of O 0 2.770932724160957e-06
phenotypes O 0 0.0005323297809809446
were O 0 2.1790544906252762e-06
observed O 0 2.946136191894766e-06
within O 0 5.812391918880166e-07
this O 0 6.918353960827517e-07
family O 0 1.0942379049083684e-05
. O 0 1.335799606749788e-05

While O 0 5.4502670536749065e-05
the O 0 8.42843292048201e-06
proband O 0 0.0028166065458208323
( O 0 1.144861653301632e-05
patient O 0 6.165919330669567e-05
1 O 0 3.868791736749699e-06
) O 0 7.091210818543914e-07
was O 0 7.494155624954146e-07
classified O 0 1.0446468650116003e-06
as O 0 1.5628341998308315e-07
having O 0 4.68644202555879e-07
a O 0 1.1389952305762563e-06
rare O 0 2.3689165118412348e-06
intermediate O 0 2.1950834252493223e-06
type O 0 8.73700571446534e-07
of O 0 2.535307714879309e-07
adult O 0 1.9883209461113438e-05
cerebral O 0 0.013313566334545612
and O 0 6.926025434950134e-06
cerebello O 1 0.8273695707321167
- O 1 0.5283046960830688
brain O 0 0.0039933896623551846
stem O 0 3.0460252673947252e-05
forms O 0 6.392168643287732e-07
, O 0 2.125253217855061e-07
his O 0 8.823453185868857e-07
younger O 0 1.3218410458648577e-05
brother O 0 3.972929698647931e-05
( O 0 3.4424790555931395e-06
patient O 0 1.2041266927553806e-05
2 O 0 1.3931122566646081e-06
) O 0 3.027751631634601e-07
and O 0 3.007950795108627e-07
nephew O 0 0.0002512634382583201
( O 0 3.455820660747122e-06
patient O 0 1.72602722159354e-05
3 O 0 3.191741598129738e-06
) O 0 7.43037730899232e-07
had O 0 1.5617077906426857e-06
a O 0 3.094823841820471e-05
childhood O 0 0.15977142751216888
ALD B-Disease 1 0.9999998807907104
type O 0 0.00038299994776025414
. O 0 4.6130251575959846e-05

Another O 0 0.00035830234992317855
nephew O 0 0.04900754243135452
( O 0 5.7523258874425665e-05
patient O 0 9.086407226277515e-05
4 O 0 6.9432135205715895e-06
) O 0 8.02392264631635e-07
of O 0 5.363519903767155e-07
patient O 0 7.130319136194885e-05
1 O 0 5.121024969412247e-06
was O 0 2.3449356376659125e-06
classified O 0 2.050504690487287e-06
as O 0 2.2888001183218876e-07
having O 0 5.635229172185063e-07
an O 0 9.836487606662558e-07
adolescent O 0 0.0007972991443239152
form O 0 1.9905046428903006e-05
. O 0 2.2860935132484883e-05

The O 0 3.0375666028703563e-05
tau O 0 4.109665678697638e-05
level O 0 2.3685597625444643e-06
in O 0 7.420378551614704e-07
the O 0 1.873526912277157e-06
cerebrospinal O 0 0.011582033708691597
fluid O 0 0.004496628884226084
( O 0 3.196555553586222e-05
CSF O 0 0.17222996056079865
) O 0 1.0349526746722404e-06
in O 0 4.108465532226546e-07
patient O 0 1.7861753804027103e-05
1 O 0 1.995578259084141e-06
was O 0 5.086172905066633e-07
as O 0 1.0885459289511346e-07
high O 0 9.46730210671376e-07
as O 0 1.5333839087361412e-07
that O 0 1.1014803646958171e-07
of O 0 1.196422772409278e-06
patients O 0 0.0032807199750095606
with O 0 0.0026849256828427315
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.9130967259407043
( O 0 2.2003581761964597e-05
AD B-Disease 0 9.241205407306552e-05
) O 0 1.3843707165506203e-05
. O 0 1.7809470591600984e-05

His O 0 0.00048380318912677467
brain O 0 0.0032571712508797646
magnetic O 0 0.00012873813102487475
resonance O 0 0.00014121447748038918
image O 0 0.00022308151528704911
( O 0 2.2400481611839496e-05
MRI O 0 0.010466991923749447
) O 0 1.3451302038447466e-05
showed O 0 7.21876640454866e-05
abnormalities B-Disease 0 0.04001448675990105
in I-Disease 0 5.054722578279325e-07
the I-Disease 0 9.840250640991144e-07
bilateral I-Disease 0 1.1272155461483635e-05
cerebellar I-Disease 0 0.4190819561481476
hemispheres I-Disease 0 0.0001921622606460005
and O 0 1.0703978659876157e-05
brain O 0 0.008924280293285847
stem O 0 8.223858458222821e-05
, O 0 3.2479690048603516e-07
but O 0 9.290143054840883e-08
not O 0 3.810064796994084e-08
in O 0 1.3030350487497344e-07
the O 0 1.1527412198120146e-06
cerebral O 0 0.3172965943813324
white O 0 7.530512812081724e-05
matter O 0 2.8253478490114503e-07
, O 0 1.6347524933735258e-07
where O 0 1.3507334983842156e-07
marked O 0 1.1967958926106803e-06
reductions O 0 2.325345349163399e-06
of O 0 1.4856681218589074e-07
the O 0 1.6313961168634705e-06
cerebral O 0 0.12626256048679352
blood O 0 1.4893899788148701e-05
flow O 0 2.8297667995502707e-06
and O 0 6.484983714472037e-07
oxygen O 0 7.808496775396634e-06
metabolism O 0 3.16145042233984e-06
were O 0 2.6277635356564133e-07
clearly O 0 7.688016125939612e-07
demonstrated O 0 1.435759145351767e-06
by O 0 4.6455571123260597e-07
positron O 0 6.262539682211354e-05
emission O 0 2.2842586986371316e-05
tomography O 0 0.00026288870139978826
( O 0 1.0870342521229759e-05
PET O 0 3.062134419451468e-05
) O 0 8.63103832671186e-06
. O 0 1.1435859960329253e-05

In O 0 0.0005271356785669923
patients O 0 0.00289278500713408
2 O 0 1.4745602129551116e-05
and O 0 1.219443220179528e-06
3 O 0 2.922810608652071e-06
, O 0 3.3824690603978524e-07
the O 0 4.11455488347201e-07
autopsy O 0 0.00012188297841930762
findings O 0 1.0063417903438676e-05
showed O 0 1.2971588148502633e-05
massive O 0 6.556778680533171e-05
demyelination B-Disease 1 0.9976847171783447
of I-Disease 0 1.3232271385277272e-06
the I-Disease 0 9.45468491408974e-06
cerebral I-Disease 1 0.6690129041671753
white I-Disease 0 4.500831346376799e-05
matter I-Disease 0 3.9025468367981375e-07
with O 0 1.933410516130607e-07
sparing O 0 3.3383544177922886e-06
of O 0 2.1438509634208458e-07
the O 0 6.016775273565145e-07
U O 0 0.0006697492790408432
- O 0 0.00039044395089149475
fibers O 0 2.2477302991319448e-05
, O 0 1.8071726515245246e-07
compatible O 0 7.607417273902684e-07
with O 0 1.9487806923734752e-07
the O 0 4.836311973122065e-07
findings O 0 4.0301788430952e-06
of O 0 3.3488004191895016e-06
childhood O 0 0.18240441381931305
ALD B-Disease 1 1.0
. O 0 0.00014508439926430583

Oleic O 0 0.25056686997413635
and O 0 8.729605906410143e-05
erucic O 0 0.48085901141166687
acids O 0 0.000108054700831417
( O 0 3.6599381019186694e-06
Lorenzos O 0 5.8168046962236986e-05
Oil O 0 4.310932126827538e-06
) O 0 2.985775608976837e-07
were O 0 1.241506879523513e-07
administered O 0 8.804692015473847e-07
to O 0 3.4387804248581233e-07
patients O 0 9.115057764574885e-06
1 O 0 4.869718850386562e-07
and O 0 1.857543878713841e-07
4 O 0 1.2580611610246706e-06
, O 0 1.8922992239822634e-07
but O 0 1.1011966449814281e-07
sufficient O 0 6.15520207247755e-07
effectiveness O 0 2.9646282655448886e-06
was O 0 1.1698986099872855e-06
not O 0 5.642639848701947e-07
obtained O 0 5.489766408572905e-06
. O 0 9.769347343535628e-06

The O 0 4.76245695608668e-05
findings O 0 2.276922714372631e-05
in O 0 1.1838359341709292e-06
this O 0 4.005477194368723e-07
family O 0 1.6399287687818287e-06
suggest O 0 8.206945381061814e-07
that O 0 1.3823381550537306e-07
delGAG291 O 0 4.19149364461191e-05
is O 0 1.4266372261317883e-07
part O 0 1.891999659164867e-07
of O 0 1.1204854644120132e-07
the O 0 4.411515703850455e-07
cause O 0 5.6845542530936655e-06
of O 0 1.0947064765787218e-06
Japanese O 0 7.311435911105946e-05
ALD B-Disease 1 0.9999879598617554
with O 0 5.957059329375625e-06
phenotypic O 0 0.00016042368952184916
variations O 0 0.00010974126780638471
. O 0 2.902708001784049e-05

Moreover O 0 0.00028607845888473094
, O 0 4.480368261283729e-06
although O 0 8.422096016147407e-07
the O 0 1.9918503824101208e-07
scale O 0 1.795785351532686e-06
of O 0 8.813665886009403e-08
the O 0 1.9309985077597958e-07
study O 0 4.605143146818591e-07
is O 0 1.1962957557898335e-07
limited O 0 4.3421192685855203e-07
, O 0 1.3981285462705273e-07
there O 0 4.1901362379803686e-08
is O 0 5.102652167465749e-08
a O 0 4.085849525381491e-07
possibility O 0 6.186693326526438e-07
that O 0 1.4027683903350407e-07
PET O 0 7.046736755000893e-06
can O 0 6.53174595299788e-07
detect O 0 1.2040726687700953e-05
an O 0 1.1757034599213512e-06
insidious B-Disease 0 0.0038449284620583057
lesion I-Disease 0 0.35909193754196167
which O 0 6.617809162889898e-07
is O 0 3.589425148220471e-07
undetectable O 0 6.936773843335686e-06
by O 0 4.126567887396959e-07
computed O 0 7.767381248413585e-06
tomogram O 0 0.00024110723461490124
( O 0 3.343066509842174e-06
CT O 0 0.00032971048494800925
) O 0 4.722603819118376e-07
or O 0 3.6677192838396877e-07
MRI O 0 4.352019095676951e-05
analysis O 0 5.492010473062692e-07
, O 0 1.082107914385233e-07
and O 0 5.9366037419295026e-08
that O 0 2.662564391187061e-08
the O 0 6.803804808441782e-08
higher O 0 3.4332362019995344e-07
level O 0 1.0373910441785483e-07
of O 0 7.933407886184796e-08
tau O 0 1.775082068888878e-06
reflects O 0 4.991309197066585e-07
the O 0 1.0207741496515155e-07
process O 0 6.919535167071444e-07
of O 0 1.7860926391222165e-06
neuronal B-Disease 0 0.09321971237659454
degeneration I-Disease 1 0.9984958171844482
in O 0 0.0006868390482850373
ALD B-Disease 1 0.9999997615814209
. O 0 0.00018350928439758718

Lorenzos O 0 0.01974865049123764
Oil O 0 0.0002781747025437653
should O 0 3.984214345109649e-06
be O 0 3.10060528363465e-07
given O 0 2.851213594112778e-07
in O 0 2.7192359652872256e-07
the O 0 4.774892090608773e-07
early O 0 3.3243691177631263e-06
stage O 0 2.2681610062136315e-05
. O 0 4.629194791050395e-06
. O 0 1.155979680333985e-05

Nonsense O 0 0.004006067290902138
mutation O 0 0.0007320194272324443
in O 0 1.5340876416303217e-05
exon O 0 6.0877100622747093e-05
4 O 0 6.4925111473712604e-06
of O 0 6.154609195618832e-07
human O 0 1.399211896568886e-06
complement O 0 6.7431556090014055e-06
C9 O 0 0.0026464296970516443
gene O 0 3.436053702898789e-06
is O 0 2.509860337340797e-07
the O 0 2.492723467639735e-07
major O 0 1.556374627398327e-06
cause O 0 2.310519448656123e-06
of O 0 5.58971237296646e-07
Japanese O 0 3.3569631341379136e-05
complement B-Disease 0 0.0008639098377898335
C9 I-Disease 1 0.9998264908790588
deficiency I-Disease 1 0.8514823913574219
. O 0 3.6860401451122016e-05

Deficiency B-Disease 1 0.9984721541404724
of I-Disease 0 8.031156539800577e-06
the I-Disease 0 3.6778594676434295e-06
ninth I-Disease 0 5.8668643760029227e-05
component I-Disease 0 5.007007530366536e-06
of I-Disease 0 5.026600433666317e-07
human I-Disease 0 1.2036452972097322e-06
complement I-Disease 0 5.143858288647607e-06
( O 0 4.039498890051618e-06
C9 O 0 0.0005558496341109276
) O 0 3.610877001847257e-07
is O 0 8.344198221266197e-08
the O 0 1.0005839357063451e-07
most O 0 2.762157862434833e-07
common O 0 3.595714952098206e-05
complement B-Disease 1 0.9995877146720886
deficiency I-Disease 1 0.9999953508377075
in O 0 1.050971150107216e-06
Japan O 0 1.4260647276387317e-06
but O 0 1.8947370961086563e-07
is O 0 1.6441993011540035e-07
rare O 0 3.8779492683715944e-07
in O 0 2.454596881307225e-07
other O 0 2.992123597778118e-07
countries O 0 1.531000634713564e-06
. O 0 6.713517905154731e-06

We O 0 2.4538845536881126e-05
studied O 0 9.80813547357684e-06
the O 0 1.1335218914609868e-06
molecular O 0 5.429520115285413e-06
basis O 0 1.956051391971414e-06
of O 0 6.296636456681881e-06
C9 B-Disease 1 0.999985933303833
deficiency I-Disease 1 0.6698225736618042
in O 0 8.497904104842746e-07
four O 0 2.7361886623111786e-06
Japanese O 0 2.410881825198885e-05
C9 B-Disease 1 0.963878333568573
- I-Disease 1 0.9205536842346191
deficient I-Disease 1 0.7584185600280762
patients O 0 0.0005689589306712151
who O 0 2.263031456095632e-05
had O 0 0.0001807957305572927
suffered O 1 0.9940928816795349
from O 0 0.0005700687179341912
meningococcal B-Disease 1 0.9999997615814209
meningitis I-Disease 1 0.9999978542327881
. O 0 0.00013525715621653944

Direct O 0 0.00011578158591873944
sequencing O 0 8.798712951829657e-05
of O 0 5.532121122087119e-06
amplified O 0 5.775345198344439e-05
C9 O 0 0.0005585646140389144
cDNA O 0 4.252757571521215e-05
and O 0 2.0501606741163414e-06
DNA O 0 9.595553819963243e-06
revealed O 0 2.235776719317073e-06
a O 0 1.0029548320744652e-06
nonsense O 0 4.07782545153168e-06
substitution O 0 3.5321093037055107e-06
( O 0 1.6337813804057078e-06
CGA O 0 6.777011731173843e-05
- O 0 0.00013598641089629382
- O 0 0.0001715780672384426
> O 0 4.10662978538312e-05
TGA O 0 7.390837708953768e-05
) O 0 6.227371613931609e-07
at O 0 2.7015505565941567e-07
codon O 0 2.999734533659648e-06
95 O 0 7.243703521453426e-07
in O 0 2.2150030076772964e-07
exon O 0 6.568979188159574e-06
4 O 0 1.201400891659432e-06
in O 0 3.249134010729904e-07
the O 0 8.070983312791213e-07
four O 0 1.6469048205181025e-05
C9 B-Disease 1 0.9834154844284058
- I-Disease 1 0.7842865586280823
deficient I-Disease 0 0.11141977459192276
individuals O 0 2.4369537641177885e-05
. O 0 1.693537888058927e-05

An O 0 4.0472426917403936e-05
allele O 0 0.0002490301267243922
- O 0 5.835722549818456e-05
specific O 0 2.5448669020988746e-06
polymerase O 0 2.4952545572887175e-05
chain O 0 1.6510437490069307e-05
reaction O 0 2.8661911528615747e-06
system O 0 1.0030274779637693e-06
designed O 0 1.6059201470852713e-06
to O 0 1.6962302140655083e-07
detect O 0 3.0952805900597014e-06
exclusively O 0 1.8171911619901948e-07
only O 0 2.7384357892401567e-08
one O 0 2.8274817154283483e-08
of O 0 2.9044326055327474e-08
the O 0 9.065161776788955e-08
normal O 0 6.417358235921711e-07
and O 0 2.6195439772891405e-07
mutant O 0 4.4038883061148226e-05
alleles O 0 5.370867256715428e-06
indicated O 0 9.396359246238717e-07
that O 0 2.424495981756536e-08
all O 0 1.996105503110357e-08
the O 0 9.500062958522904e-08
four O 0 3.6150295272818767e-06
patients O 0 6.0605154430959374e-05
were O 0 4.4014092281940975e-07
homozygous O 0 1.6213769413297996e-05
for O 0 1.002597471710942e-07
the O 0 2.5981350404435943e-07
mutation O 0 1.7238193095181487e-06
in O 0 1.3720412539441895e-07
exon O 0 6.930670679139439e-06
4 O 0 1.7060385744116502e-06
and O 0 1.2718746233986167e-07
that O 0 4.716410373362123e-08
the O 0 1.207355921906128e-07
parents O 0 8.147910648403922e-07
of O 0 3.880968222347292e-07
patient O 0 4.919101775158197e-05
2 O 0 7.35454477762687e-06
were O 0 4.244660431140801e-06
heterozygous O 0 0.0001056813052855432
. O 0 1.0549866601650137e-05

The O 0 4.518855348578654e-05
common O 0 2.6955545763485134e-05
mutation O 0 1.531404268462211e-05
at O 0 1.0891010333580198e-06
codon O 0 6.095965545682702e-06
95 O 0 2.2056763100408716e-06
in O 0 4.2287067003599077e-07
exon O 0 1.709994103293866e-05
4 O 0 5.06751166540198e-06
might O 0 8.041963042160205e-07
be O 0 1.0998239474702132e-07
responsible O 0 5.463779189085471e-07
for O 0 4.368294241885451e-07
most O 0 1.7231981246368377e-06
Japanese O 0 0.0002449938328936696
C9 B-Disease 1 0.999966025352478
deficiency I-Disease 1 0.8633363842964172
. O 0 4.968781922798371e-06
. O 0 2.5698216632008553e-05

BRCA1 O 0 0.02073650248348713
required O 0 4.281604924472049e-05
for O 0 4.472146429179702e-06
transcription O 0 4.5147156924940646e-05
- O 0 0.0005295558949001133
coupled O 0 0.000669224071316421
repair O 0 0.003073303494602442
of O 0 1.0894035767705645e-05
oxidative O 0 0.1792861521244049
DNA O 0 0.0007154270424507558
damage O 0 0.00042646817746572196
. O 0 3.9557358832098544e-05

The O 0 0.0008238024893216789
breast B-Disease 1 0.9999771118164062
and I-Disease 1 0.9960249662399292
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 1 0.5904675722122192
gene O 0 0.0001340647868346423
BRCA1 O 0 0.0003764302236959338
encodes O 0 2.6846053515328094e-05
a O 0 2.1789213860756718e-05
zinc O 0 0.00034422086901031435
finger O 0 6.014541213517077e-05
protein O 0 5.666232937073801e-06
of O 0 1.2373408253552043e-06
unknown O 0 1.121866353059886e-05
function O 0 2.178950671805069e-05
. O 0 2.026314723480027e-05

Association O 0 0.00010381321772001684
of O 0 4.406311745697167e-06
the O 0 4.351190909801517e-06
BRCA1 O 0 0.00019818155851680785
protein O 0 2.518946303098346e-06
with O 0 3.849202130368212e-07
the O 0 9.34283548303938e-07
DNA O 0 2.2353320673573762e-05
repair O 0 0.00031107725226320326
protein O 0 5.937338755757082e-06
Rad51 O 0 8.897498628357425e-05
and O 0 3.2457984389111516e-07
changes O 0 3.694751455896039e-07
in O 0 8.814304663928851e-08
the O 0 8.377831051120666e-08
phosphorylation O 0 4.942482405567716e-07
and O 0 1.2834183849008696e-07
cellular O 0 1.5650415434720344e-06
localization O 0 1.122309299717017e-06
of O 0 7.530809398303973e-08
the O 0 1.7526699025438575e-07
protein O 0 8.207125574699603e-07
after O 0 7.113779929568409e-07
exposure O 0 1.8298946997674648e-06
to O 0 1.501939834724908e-07
DNA O 0 4.555718078336213e-06
- O 0 2.368180503253825e-05
damaging O 0 5.051868356531486e-06
agents O 0 6.856094501017651e-07
are O 0 3.876417764558937e-08
consistent O 0 2.2957672740631097e-07
with O 0 1.1714768533011011e-07
a O 0 6.886211281198484e-07
role O 0 1.947812279468053e-06
for O 0 2.225119942522724e-06
BRCA1 O 0 0.0004694855015259236
in O 0 8.061881999310572e-06
DNA O 0 0.00026435148902237415
repair O 0 0.016384609043598175
. O 0 6.103393388912082e-05

Here O 0 4.808223820873536e-05
, O 0 5.990077625028789e-06
it O 0 7.415907816721301e-07
is O 0 6.290007377174334e-07
shown O 0 1.4274485238274792e-06
that O 0 6.806646979384823e-07
mouse O 0 0.00010470960114616901
embryonic O 0 0.0015598046593368053
stem O 0 0.020871182903647423
cells O 0 0.0005907869781367481
deficient B-Disease 0 0.00032697711139917374
in I-Disease 0 2.3888378564151935e-06
BRCA1 I-Disease 0 0.0007056526374071836
are O 0 2.6259547780682624e-07
defective O 0 1.999707819777541e-05
in O 0 2.5882627596729435e-07
the O 0 1.6583628337230039e-07
ability O 0 4.408605605021876e-07
to O 0 6.539548991213451e-08
carry O 0 2.0745811468714237e-07
out O 0 1.7632889637297922e-07
transcription O 0 3.112846798103419e-06
- O 0 3.2250532967736945e-05
coupled O 0 9.29313973756507e-05
repair O 0 0.00015963328769430518
of O 0 1.493280478825909e-06
oxidative O 0 0.00922371819615364
DNA O 0 0.00012892902304884046
damage O 0 1.8596669178805314e-05
, O 0 3.3178622516061296e-07
and O 0 2.44348882461054e-07
are O 0 2.3079924460489565e-07
hypersensitive O 0 2.7220143238082528e-05
to O 0 2.2082037958170986e-06
ionizing O 0 0.000821149442344904
radiation O 0 0.00017878657672554255
and O 0 2.2351434836309636e-06
hydrogen O 0 4.9129375838674605e-05
peroxide O 0 0.0029421469662338495
. O 0 2.970482273667585e-05

These O 0 2.4178465537261218e-05
results O 0 2.5773171728360467e-05
suggest O 0 6.7726987253990956e-06
that O 0 6.901122446834052e-07
BRCA1 O 0 0.00012261247320566326
participates O 0 5.3702528930443805e-06
, O 0 3.738275324849383e-07
directly O 0 5.584618065768154e-07
or O 0 6.14110092556075e-07
indirectly O 0 1.8124054577128845e-06
, O 0 1.6990470896871557e-07
in O 0 2.505693998955394e-07
transcription O 0 5.217542366153793e-06
- O 0 7.325511978706345e-05
coupled O 0 0.00022627660655416548
repair O 0 0.0014840762596577406
of O 0 2.7564999527385226e-06
oxidative O 0 0.03252541646361351
DNA O 0 0.0002570140059106052
damage O 0 0.0001845431688707322
. O 0 4.468954102776479e-06
. O 0 1.989003794733435e-05

Truncation O 0 0.016482416540384293
mutations O 0 0.002256836509332061
in O 0 8.020870154723525e-06
the O 0 3.0087996947258944e-06
transactivation O 0 0.00015135767171159387
region O 0 1.0126454981218558e-05
of O 0 1.4813829238846665e-06
PAX6 O 0 0.0009401364368386567
result O 0 3.942117473343387e-06
in O 0 1.6491444512212183e-06
dominant O 0 3.043690958293155e-05
- O 0 0.00013825210044160485
negative O 0 3.9944359741639346e-05
mutants O 0 0.0002381474187131971
. O 0 1.6735286408220418e-05

PAX6 O 0 0.06709779053926468
is O 0 2.598041101009585e-05
a O 0 9.518892511550803e-06
transcription O 0 2.18821078306064e-05
factor O 0 2.888335075112991e-06
with O 0 3.8550729186681565e-07
two O 0 8.196229828172363e-07
DNA O 0 6.791721261834027e-06
- O 0 1.4158554222376551e-05
binding O 0 1.6266670854747645e-06
domains O 0 1.378619231218181e-06
( O 0 4.6991343083391257e-07
paired O 0 1.654338007028855e-06
box O 0 2.0413517631823197e-06
and O 0 8.910594146982476e-07
homeobox O 0 0.0001617585076019168
) O 0 5.465300887408375e-07
and O 0 2.1337503142149217e-07
a O 0 1.8585834595796769e-06
proline O 0 6.110433605499566e-05
- O 0 8.136569522321224e-05
serine O 0 4.992452886654064e-05
- O 0 7.799618470016867e-05
threonine O 0 0.00013124638644512743
( O 0 4.820849426323548e-06
PST O 0 0.00012492241512518376
) O 0 2.4791677333269035e-06
- O 0 2.007919283641968e-05
rich O 0 1.1639398508123122e-05
transactivation O 0 0.00020126324670854956
domain O 0 3.8293659599730745e-05
. O 0 2.510413105483167e-05

PAX6 O 0 0.3109172284603119
regulates O 0 0.0011283293133601546
eye O 0 0.0010546187404543161
development O 0 1.206856995850103e-05
in O 0 1.3896213886255282e-06
animals O 0 1.0626317816786468e-06
ranging O 0 2.036187652265653e-06
from O 0 5.174542252461833e-07
jellyfish O 0 3.1389188279717928e-06
to O 0 4.4285286548984004e-07
Drosophila O 0 7.670493687328417e-06
to O 0 1.577657826601353e-06
humans O 0 7.625710168213118e-06
. O 0 8.978263394965325e-06

Heterozygous O 0 0.4497259557247162
mutations O 0 0.0015677021583542228
in O 0 6.16462284597219e-06
the O 0 4.17541150454781e-06
human O 0 8.687638000992592e-06
PAX6 O 0 0.0013732034713029861
gene O 0 1.353911284240894e-05
result O 0 1.1235987358304556e-06
in O 0 3.7561073895631125e-07
various O 0 7.382657258858671e-07
phenotypes O 0 0.00018069198995362967
, O 0 6.412561788238236e-07
including O 0 4.35704578194418e-06
aniridia B-Disease 1 0.9999921321868896
, O 0 8.524588338332251e-05
Peters B-Disease 1 0.9993058443069458
anomaly I-Disease 1 0.9976229071617126
, O 0 5.258317833067849e-05
autosomal B-Disease 1 0.8433041572570801
dominant I-Disease 0 0.0022778604179620743
keratitis I-Disease 1 0.590614378452301
, O 0 5.3925464271742385e-06
and O 0 1.806196269171778e-05
familial B-Disease 1 0.9869394302368164
foveal I-Disease 1 0.999931812286377
dysplasia I-Disease 1 0.9999985694885254
. O 0 0.00027610419783741236

It O 0 2.667631270014681e-05
is O 0 4.847884156333748e-06
believed O 0 4.2692827264545485e-06
that O 0 2.49890007353315e-07
the O 0 6.755293497917592e-07
mutated O 0 1.3743235285801347e-05
allele O 0 6.988865152379731e-06
of O 0 4.941963993587706e-07
PAX6 O 0 0.00046560412738472223
produces O 0 2.3268871700565796e-06
an O 0 3.5125384556522476e-07
inactive O 0 4.911442374577746e-06
protein O 0 1.5651265812266502e-06
and O 0 6.908760497026378e-07
aniridia B-Disease 1 0.9595394730567932
is O 0 1.5942162008286687e-06
caused O 0 6.79234335621004e-06
due O 0 3.952477527491283e-06
to O 0 2.9167795219109394e-06
genetic O 0 0.00015229273412842304
haploinsufficiency O 0 0.004398088902235031
. O 0 4.07172083214391e-05

However O 0 5.862490797881037e-05
, O 0 4.909517883788794e-06
several O 0 1.9833405531244352e-06
truncation O 0 0.0005269258981570601
mutations O 0 0.00010678180842660367
have O 0 4.0770603959572327e-07
been O 0 3.3485406447653077e-07
found O 0 2.4881680360522296e-07
to O 0 1.8981950233865064e-07
occur O 0 4.907734592052293e-07
in O 0 1.295353371233432e-07
the O 0 3.099677030604653e-07
C O 0 3.730968091986142e-05
- O 0 3.728008960024454e-05
terminal O 0 1.6341540685971268e-05
half O 0 1.0175690476899035e-06
of O 0 3.873565788126143e-07
PAX6 O 0 0.0017672888934612274
in O 0 6.761578788427869e-06
patients O 0 4.33511049777735e-05
with O 0 1.4808716741754324e-06
Aniridia B-Disease 1 0.9992232322692871
resulting O 0 8.416038326686248e-06
in O 0 3.879007124396594e-07
mutant O 0 9.676679837866686e-06
proteins O 0 3.2374609304497426e-07
that O 0 6.356035697763218e-08
retain O 0 4.2002744748970144e-07
the O 0 1.8717770444709458e-07
DNA O 0 2.0469135506573366e-06
- O 0 3.483848786345334e-06
binding O 0 7.73830095113226e-07
domains O 0 5.250649337540381e-07
but O 0 9.813899737309839e-08
have O 0 1.3916540808622813e-07
lost O 0 7.418206564580032e-07
most O 0 7.234453391902207e-08
of O 0 1.1478339700943252e-07
the O 0 1.0249877959722653e-06
transactivation O 0 0.0001933932362589985
domain O 0 1.4506257684843149e-05
. O 0 9.356877853861079e-06

It O 0 1.7875641788123176e-05
is O 0 2.4975613541755592e-06
not O 0 4.907472543891345e-07
clear O 0 7.7633876571781e-07
whether O 0 3.231716902973858e-07
such O 0 2.003410344286749e-07
mutants O 0 9.548162779537961e-05
really O 0 1.019415549308178e-06
behave O 0 9.787445378606208e-07
as O 0 1.4781694801513368e-07
loss O 0 4.109842848265544e-06
- O 0 5.401831913331989e-06
of O 0 2.588109850876208e-07
- O 0 3.326662408653647e-05
function O 0 2.2918807189853396e-06
mutants O 0 9.648242667026352e-06
as O 0 6.21273102296982e-07
predicted O 0 1.00480920082191e-05
by O 0 2.3090544800652424e-06
haploinsufficiency O 0 0.0007405542419292033
. O 0 3.27928937622346e-05

Contrary O 0 0.00012665077520068735
to O 0 4.002073637821013e-06
this O 0 6.049941134733672e-07
theory O 0 6.516626740449283e-07
, O 0 1.3111800001297524e-07
our O 0 1.4511074653000833e-07
data O 0 5.028676923757303e-07
showed O 0 7.618402264597535e-07
that O 0 3.960080263709642e-08
these O 0 5.9213707714889097e-08
mutants O 0 3.4896079341706354e-06
are O 0 1.0878008538384165e-07
dominant O 0 2.320120074728038e-06
- O 0 9.829082046053372e-06
negative O 0 1.9013598375750007e-06
in O 0 6.719448037983966e-07
transient O 0 7.839257159503177e-05
transfection O 0 0.013288047164678574
assays O 0 2.0917505025863647e-05
when O 0 4.323261180161353e-07
they O 0 1.5594336844060308e-07
are O 0 1.3109124097354652e-07
coexpressed O 0 2.0418681742739864e-05
with O 0 8.05074932941352e-07
wild O 0 9.68750100582838e-06
- O 0 0.0005252843257039785
type O 0 8.139658893924206e-05
PAX6 O 0 0.004553827922791243
. O 0 6.683929677819833e-05

We O 0 2.6836660254048184e-05
found O 0 3.731724746103282e-06
that O 0 4.613416137999593e-07
the O 0 6.982943432376487e-07
dominant O 0 1.7607946574571542e-05
- O 0 0.00016796075215097517
negative O 0 6.183570803841576e-06
effects O 0 6.4583978200971615e-06
result O 0 5.753030904998013e-07
from O 0 1.3991423486459098e-07
the O 0 1.8729609507772693e-07
enhanced O 0 5.541318842006149e-06
DNA O 0 4.0994736991706304e-06
binding O 0 1.098456550607807e-06
ability O 0 4.887230602435011e-07
of O 0 2.6132536845580034e-07
these O 0 8.420626613769855e-07
mutants O 0 0.00010825799108715728
. O 0 1.732349664962385e-05

Kinetic O 0 0.0005237634759396315
studies O 0 2.8574562747962773e-05
of O 0 2.0754055185534526e-06
binding O 0 5.6649359976290725e-06
and O 0 1.4924603419785853e-06
dissociation O 0 0.00015338063531089574
revealed O 0 3.6796873246203177e-06
that O 0 1.083433858184435e-07
various O 0 2.2713307146204897e-07
truncation O 0 1.8756039935396984e-05
mutants O 0 2.1980682504363358e-05
have O 0 3.5535873621483915e-07
3 O 0 1.406228307132551e-06
- O 0 4.814187832380412e-06
5 O 0 9.527624342808849e-07
- O 0 3.093710574830766e-06
fold O 0 3.4073573260684498e-06
higher O 0 3.043878109565412e-07
affinity O 0 3.128830030618701e-07
to O 0 4.0318209215683964e-08
various O 0 8.831874254155991e-08
DNA O 0 9.348763114758185e-07
- O 0 1.2263227517905761e-06
binding O 0 4.3759163759204966e-07
sites O 0 1.637553310729345e-07
when O 0 1.3248430263956834e-07
compared O 0 4.442199497134425e-07
with O 0 1.2562635731683258e-07
the O 0 4.081153122115211e-07
wild O 0 6.240323727979558e-06
- O 0 0.0003754505596589297
type O 0 6.414057133952156e-05
PAX6 O 0 0.0025848103687167168
. O 0 2.5487346647423692e-05

These O 0 1.717493978503626e-05
results O 0 8.79785238794284e-06
provide O 0 1.4879186664984445e-06
a O 0 1.6960666471277364e-06
new O 0 1.237359697370266e-06
insight O 0 2.679882982192794e-06
into O 0 2.2611382632931054e-07
the O 0 1.635037847336207e-07
role O 0 6.157985694699164e-07
of O 0 5.920179546592408e-07
mutant O 0 8.085814624791965e-05
PAX6 O 0 0.000813598744571209
in O 0 7.604343863931717e-06
causing O 0 8.137121039908379e-05
aniridia B-Disease 1 0.9835259914398193
. O 0 8.972237992566079e-06
. O 0 2.0050700186402537e-05

Reversal O 0 0.019804736599326134
of O 0 0.000779021589551121
severe O 1 0.9999918937683105
hypertrophic B-Disease 1 0.9999996423721313
cardiomyopathy I-Disease 1 1.0
and O 0 0.00016083617811091244
excellent O 0 7.155023922678083e-05
neuropsychologic O 0 0.044456109404563904
outcome O 0 9.998997484217398e-06
in O 0 9.561448450767784e-07
very B-Disease 0 7.232672487589298e-07
- I-Disease 0 7.901603385107592e-05
long I-Disease 0 2.658488847373519e-05
- I-Disease 0 0.00011120023555122316
chain I-Disease 0 4.2828261939575896e-05
acyl I-Disease 0 5.484422217705287e-05
- I-Disease 0 5.517938916455023e-05
coenzyme I-Disease 0 0.00012204859376652166
A I-Disease 0 0.00038994927308522165
dehydrogenase I-Disease 1 0.9446696639060974
deficiency I-Disease 1 0.749750018119812
. O 0 5.059827890363522e-05

Very B-Disease 0 0.00015665160026401281
- I-Disease 0 0.001074881525710225
long I-Disease 0 8.056053047766909e-05
- I-Disease 0 0.00013833689445164055
chain I-Disease 0 5.488095121108927e-05
acyl I-Disease 0 4.9703299737302586e-05
- I-Disease 0 3.623808152042329e-05
coenzyme I-Disease 0 4.092988820048049e-05
A I-Disease 0 2.0447912902454846e-05
dehydrogenase I-Disease 0 0.0013069515116512775
( I-Disease 0 3.718057268997654e-05
VLCAD I-Disease 1 0.9732611775398254
) I-Disease 0 0.0003012903325725347
deficiency I-Disease 0 0.14871127903461456
is O 0 8.848143124851049e-07
a O 0 2.3771002815919928e-05
disorder O 0 0.4991074204444885
of O 0 1.4039904954188387e-06
fatty O 0 7.566179556306452e-05
acid O 0 2.3880451408331282e-05
beta O 0 3.5619852951640496e-06
oxidation O 0 1.7528515172671177e-06
that O 0 1.4996712138781731e-07
reportedly O 0 3.5212190141464816e-06
has O 0 3.808917483638652e-07
high O 0 1.941369646374369e-06
rates O 0 2.8336203286016826e-06
of O 0 7.897143063928524e-07
morbidity O 1 0.5423442125320435
and O 0 1.6389112715842202e-05
mortality O 0 0.007992489263415337
. O 0 2.24501418415457e-05

We O 0 3.2728439691709355e-05
describe O 0 1.8297872884431854e-05
the O 0 1.4155299368212582e-06
outcome O 0 2.3234833861351945e-06
of O 0 3.169687374793284e-07
a O 0 1.7358022432745202e-06
5 O 0 4.7990743041737005e-06
- O 0 3.0503857487929054e-05
year O 0 1.6686269646015717e-06
- O 0 1.680854256846942e-05
old O 0 1.6193109331652522e-05
girl O 0 0.00043687442666850984
with O 0 0.0004489930288400501
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
who O 0 4.074132903042482e-06
was O 0 7.276757969520986e-07
first O 0 3.6310507312009577e-07
seen O 0 3.382626800885191e-07
at O 0 1.7132681762177526e-07
5 O 0 8.074540005509334e-07
months O 0 5.983541200293985e-07
of O 0 1.709589270149081e-07
age O 0 2.722214503592113e-06
with O 0 1.0127942005055957e-05
severe O 1 0.9997060894966125
hypertrophic B-Disease 1 0.9999998807907104
cardiomyopathy I-Disease 1 1.0
, O 0 0.23881620168685913
hepatomegaly B-Disease 1 1.0
, O 0 0.00243820296600461
encephalopathy B-Disease 0 0.42077693343162537
, O 0 4.540575901046395e-06
and O 0 1.238068853126606e-05
hypotonia B-Disease 1 0.9870733022689819
. O 0 7.047927647363394e-05

Biochemical O 0 0.06607070565223694
studies O 0 0.012004466727375984
indicated O 1 0.9920418858528137
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 0.00028730405028909445
by O 0 2.1676032702089287e-06
a O 0 1.4097131497692317e-05
stable O 0 0.00020027779100928456
yet O 0 1.4065746654523537e-05
inactive O 0 0.0001186980662168935
enzyme O 0 7.353360706474632e-05
. O 0 1.6514704839210026e-05

Molecular O 0 0.0012673626188188791
genetic O 0 0.00014217011630535126
analysis O 0 7.555435331596527e-06
of O 0 1.2041159607178997e-06
her O 0 2.3722313926555216e-05
VLCAD O 0 0.303678035736084
gene O 0 2.0510329704848118e-05
revealed O 0 9.935530215443578e-06
a O 0 6.530875452881446e-06
T1372C O 0 0.0004294062964618206
( O 0 3.825477051577764e-06
F458L O 0 7.449731492670253e-05
) O 0 2.7914190923183924e-06
missense O 0 5.619375588139519e-05
mutation O 0 8.245651770266704e-06
and O 0 9.042753390531288e-07
a O 0 1.42609205795452e-05
1668 O 0 0.01679641380906105
ACAG O 0 0.007226456422358751
1669 O 0 0.001317109097726643
splice O 0 0.0009953166591003537
site O 0 0.00013530954311136156
mutation O 0 0.0002236721193185076
. O 0 3.293781992397271e-05

After O 0 0.0004015017475467175
initial O 0 0.0002944075968116522
treatment O 0 0.00019898285972885787
with O 0 4.422064648679225e-06
intravenous O 0 0.002493895823135972
glucose O 0 0.0003493871190585196
and O 0 1.829271809583588e-06
carnitine O 0 8.81944433785975e-05
, O 0 3.571185516193509e-07
the O 0 3.100226990682131e-07
patient O 0 1.3776670130027924e-05
has O 0 4.373605122509616e-07
thrived O 0 2.2654646727460204e-06
on O 0 2.317069771606839e-07
a O 0 9.489864396527992e-07
low O 0 4.647755758924177e-06
- O 0 1.986389725061599e-05
fat O 0 6.207429123605834e-06
diet O 0 2.7449129902379354e-06
supplemented O 0 1.5636943544450332e-06
with O 0 3.2346892453460896e-07
medium O 0 3.3152730338770198e-06
- O 0 1.8946529962704517e-05
chain O 0 1.349464127997635e-05
triglyceride O 0 1.0442043276270851e-05
oil O 0 2.506215423636604e-06
and O 0 5.94542484577687e-07
carnitine O 0 3.735553764272481e-05
and O 0 9.416849025001284e-07
avoidance O 0 3.717089202837087e-05
of O 0 8.055356374825351e-06
fasting O 0 0.001851789653301239
. O 0 5.3655170631827787e-05

Her O 0 0.0024735548067837954
ventricular O 1 0.999751627445221
hypertrophy O 1 0.9977930784225464
resolved O 0 0.0005818171193823218
significantly O 0 5.7204440963687375e-05
over O 0 1.8567551478554378e-06
1 O 0 4.32247543358244e-06
year O 0 1.0929653626590152e-06
, O 0 2.729816515056882e-07
and O 0 8.07706555860932e-07
cognitively O 0 0.0063680438324809074
, O 0 2.788700328437699e-07
she O 0 2.4083516336759203e-07
is O 0 5.530115032570393e-08
in O 0 9.069070472378371e-08
the O 0 3.338693943533144e-07
superior O 0 7.900766831880901e-06
range O 0 1.8325667952012736e-06
for O 0 7.950629310471413e-07
age O 0 9.563251296640374e-06
. O 0 9.407493053004146e-06

Clinical O 0 0.005003038793802261
recognition O 0 0.000207726945518516
of O 0 0.00234542996622622
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 1.7654473367656465e-06
important O 0 3.451841337209771e-07
because O 0 1.7092551729547267e-07
it O 0 4.8220908155371944e-08
is O 0 3.979069163051463e-08
one O 0 4.26276720588703e-08
of O 0 5.360165644674453e-08
the O 0 2.535167595851817e-07
few O 0 8.574703542763018e-07
directly O 0 4.459868250705767e-06
treatable O 0 0.02447761595249176
causes O 0 1.0860757356567774e-05
of O 0 4.60792898593354e-06
cardiomyopathy B-Disease 1 0.9999998807907104
in O 0 4.809828897123225e-05
children O 0 9.930166561389342e-05
. O 0 6.570332516275812e-06
. O 0 1.845272709033452e-05

Cloning O 0 0.0002738417242653668
of O 0 5.053222139395075e-06
a O 0 5.086525106889894e-06
novel O 0 3.710694727487862e-06
member O 0 6.85128441091365e-07
of O 0 1.565614837772955e-07
the O 0 6.784184733987786e-07
low O 0 2.379808393015992e-05
- O 0 0.0002207959332736209
density O 0 6.23800078756176e-05
lipoprotein O 0 0.0012885351898148656
receptor O 0 7.274784002220258e-05
family O 0 2.6443820388522e-05
. O 0 2.7647020033327863e-05

A O 0 0.00022869431995786726
gene O 0 9.753490303410217e-05
encoding O 0 2.834622500813566e-05
a O 0 8.401452760153916e-06
novel O 0 1.2952119504916482e-05
transmembrane O 0 2.789245809253771e-05
protein O 0 3.40220435646188e-06
was O 0 1.1410163551772712e-06
identified O 0 1.2987936770514352e-06
by O 0 2.3164159301813925e-07
DNA O 0 1.4918456372470246e-06
sequence O 0 6.71847431021888e-07
analysis O 0 3.891679227763234e-07
within O 0 3.462998847680865e-07
the O 0 6.711954370075546e-07
insulin B-Disease 0 0.0021222711075097322
- I-Disease 1 0.8647199869155884
dependent I-Disease 0 0.35298264026641846
diabetes I-Disease 1 1.0
mellitus I-Disease 1 0.9999997615814209
( O 0 7.666611054446548e-05
IDDM B-Disease 0 0.0022263475693762302
) O 0 6.473598205047892e-06
locus O 0 8.242905460065231e-05
IDDM4 O 0 0.0005827328423038125
on O 0 1.6562367818551138e-05
chromosome O 0 0.0007980752852745354
11q13 O 0 0.000913969473913312
. O 0 5.6115943152690306e-05

Based O 0 6.787548045394942e-05
on O 0 5.060808234702563e-06
its O 0 2.405460008958471e-06
chromosomal O 0 0.000394966802559793
position O 0 3.389771563888644e-06
, O 0 3.941430577469873e-07
this O 0 1.406774146062162e-07
gene O 0 8.861679816618562e-07
is O 0 1.246230567630846e-07
a O 0 5.651816650242836e-07
candidate O 0 2.4905473310354864e-06
for O 0 9.290113212045981e-07
conferring O 0 8.908177551347762e-05
susceptibility O 0 0.012702550739049911
to O 0 4.5670996769331396e-05
diabetes B-Disease 1 0.9996333122253418
. O 0 6.636479520238936e-05

The O 0 6.035386468283832e-05
gene O 0 7.478715997422114e-05
, O 0 6.779478098906111e-06
termed O 0 4.951973824063316e-05
low O 0 6.304406269919127e-05
- O 0 0.00011929037282243371
density O 0 2.461581607349217e-05
lipoprotein O 0 0.00042910166666842997
receptor O 0 1.8658682165551e-05
related O 0 2.4632552140246844e-06
protein O 0 1.545845293549064e-06
5 O 0 1.453028403375356e-06
( O 0 1.0243536507914541e-06
LRP5 O 0 6.097714867792092e-05
) O 0 3.0520109817189223e-07
, O 0 1.213314249071118e-07
encodes O 0 7.121110456864699e-07
a O 0 3.8581109151891724e-07
protein O 0 7.257034440044663e-07
of O 0 1.6788906975762075e-07
1615 O 0 4.007622555946e-05
amino O 0 1.6037099612731254e-06
acids O 0 4.0614060026200605e-07
that O 0 3.234053735923226e-08
contains O 0 1.0382164816746808e-07
conserved O 0 5.531243232326233e-07
modules O 0 1.4606629292757134e-06
which O 0 8.548692420617954e-08
are O 0 3.3873977400844524e-08
characteristic O 0 2.2690876733122423e-07
of O 0 7.366327281488338e-08
the O 0 3.4926802072732244e-07
low O 0 1.1208632713533007e-05
- O 0 9.395433153258637e-05
density O 0 5.421424430096522e-05
lipoprotein O 0 0.0021416773088276386
( O 0 7.237416866701096e-06
LDL O 0 6.526572542497888e-05
) O 0 3.931616447516717e-06
receptor O 0 1.5323124898714013e-05
family O 0 1.1560105122043751e-05
. O 0 1.527254789834842e-05

These O 0 2.0447307178983465e-05
modules O 0 4.808438825421035e-05
include O 0 4.720973720395705e-06
a O 0 6.169821972434875e-06
putative O 0 8.802037336863577e-05
signal O 0 1.0550076694926247e-05
peptide O 0 4.05995251639979e-06
for O 0 2.0145571966168063e-07
protein O 0 9.325263476966938e-07
export O 0 6.48400657610182e-07
, O 0 2.157638476774082e-07
four O 0 6.114627808528894e-07
epidermal O 0 6.932634278200567e-05
growth O 0 1.0766193554445636e-05
factor O 0 2.2106059986981563e-06
( O 0 1.2425047088981955e-06
EGF O 0 2.8917665986227803e-05
) O 0 6.017854161655123e-07
repeats O 0 2.1983389615343185e-06
with O 0 3.1333033234659524e-07
associated O 0 1.1715432037817664e-06
spacer O 0 3.554561044438742e-05
domains O 0 4.143870683037676e-06
, O 0 4.244889169058297e-07
three O 0 9.220164542966813e-07
LDL O 0 7.037382601993158e-05
- O 0 6.730685709044337e-05
receptor O 0 1.1319089935568627e-05
( O 0 2.0756431240442907e-06
LDLR O 0 7.246169116115198e-05
) O 0 9.001392982099787e-07
repeats O 0 2.6125460408366052e-06
, O 0 2.1149094209249597e-07
a O 0 5.725336222894839e-07
single O 0 1.737619186314987e-06
transmembrane O 0 6.909340754646109e-06
spanning O 0 2.1651137558365008e-06
domain O 0 1.4386537259269971e-06
, O 0 3.2265742788695206e-07
and O 0 4.4211355998413637e-07
a O 0 3.999158707301831e-06
cytoplasmic O 0 6.0801507061114535e-05
domain O 0 2.732044958975166e-05
. O 0 1.727524067973718e-05

The O 0 2.2997448468231596e-05
encoded O 0 2.0476400095503777e-05
protein O 0 6.7978644437971525e-06
has O 0 5.22703714977979e-07
a O 0 5.660760962200584e-07
unique O 0 5.133705940352229e-07
organization O 0 4.312328485411854e-07
of O 0 1.7904655180700502e-07
EGF O 0 4.102997263544239e-05
and O 0 8.878098469722318e-07
LDLR O 0 0.0029096812941133976
repeats O 0 2.1367457520682365e-05
; O 0 1.0895175819314318e-06
therefore O 0 2.4290417854899715e-07
, O 0 1.9522796890214522e-07
LRP5 O 0 0.0001462666259612888
likely O 0 1.0861562032005168e-06
represents O 0 3.0210085810722376e-07
a O 0 2.14088032635118e-07
new O 0 3.5564488598538446e-07
category O 0 7.028294248812017e-07
of O 0 2.170098554188371e-07
the O 0 1.4653691096100374e-06
LDLR O 0 0.007156616076827049
family O 0 3.416733306949027e-05
. O 0 1.9598493963712826e-05

Both O 0 3.3255968446610495e-05
human O 0 8.589259778091218e-06
and O 0 2.391000862189685e-06
mouse O 0 0.00012879385030828416
LRP5 O 0 0.008449478074908257
cDNAs O 0 0.00032859304337762296
have O 0 5.707390187126293e-07
been O 0 2.865158705844806e-07
isolated O 0 1.342490577371791e-06
and O 0 1.270875600312138e-07
the O 0 1.7730354784362135e-07
encoded O 0 7.061530595819931e-07
mature O 0 7.562792347926006e-07
proteins O 0 1.580701507464255e-07
are O 0 4.58916709078494e-08
95 O 0 1.301285692534293e-06
% O 0 9.97379743239435e-07
identical O 0 1.356717802991625e-06
, O 0 1.4686901295135613e-07
indicating O 0 5.80241760417266e-07
a O 0 4.545670151401282e-07
high O 0 2.1372788978624158e-06
degree O 0 2.29052147915354e-06
of O 0 3.488113407001947e-07
evolutionary O 0 1.2062517271260731e-05
conservation O 0 6.9043016992509365e-06
. O 0 3.1227718864101917e-06
. O 0 1.241135487362044e-05

The O 0 8.865923155099154e-05
APC B-Disease 0 0.0003767964371945709
variants O 0 6.347937596729025e-05
I1307K O 0 0.00016517186304554343
and O 0 3.3717710721248295e-06
E1317Q O 0 0.00015798574895597994
are O 0 1.3095009308017325e-06
associated O 0 2.4218528778874315e-05
with O 1 0.5261578559875488
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.3349350410862826e-05
but O 0 2.4733719783398556e-07
not O 0 9.339159134924557e-08
always O 0 1.9399912787321227e-07
with O 0 1.2143769367867208e-07
a O 0 2.514911102480255e-06
family O 0 8.436360985797364e-06
history O 0 7.2400953285978176e-06
. O 0 1.3213407328294124e-05

Classical O 0 0.09329870343208313
familial B-Disease 1 0.9999990463256836
adenomatous I-Disease 1 0.9999995231628418
polyposis I-Disease 1 0.9999998807907104
( O 0 0.00547378696501255
FAP B-Disease 0 0.025501541793346405
) O 0 8.95093944563996e-06
is O 0 9.04712635474425e-07
a O 0 3.2777963951957645e-06
high O 0 9.82690544333309e-05
- O 1 0.9840229749679565
penetrance O 1 0.9998006224632263
autosomal B-Disease 1 0.9999581575393677
dominant I-Disease 1 0.8855758309364319
disease I-Disease 0 0.028231671079993248
that O 0 3.7298710253708123e-07
predisposes O 0 2.753269836830441e-05
to O 0 3.95154756915872e-07
hundreds O 0 7.842062927920779e-07
or O 0 7.07775200226024e-07
thousands O 0 3.2295620258082636e-06
of O 0 5.68260220461525e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.4064754247665405
carcinoma I-Disease 1 1.0
and O 0 4.485476893023588e-06
that O 0 2.9822496117049013e-07
results O 0 2.079018713629921e-06
from O 0 1.2894535075247404e-06
truncating O 0 0.00035933955223299563
mutations O 0 1.838564276113175e-05
in O 0 9.10775895590632e-07
the O 0 3.2817340525070904e-06
APC B-Disease 0 0.0001687618059804663
gene O 0 5.6486675021005794e-05
. O 0 2.431115717627108e-05

A O 0 0.0006076078279875219
variant O 0 0.0010892805876210332
of O 0 6.0207567003089935e-05
FAP B-Disease 0 0.018945185467600822
is O 0 0.00018679322965908796
attenuated B-Disease 1 0.9969168901443481
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 0.9998270869255066
, O 0 6.0983957155258395e-06
which O 0 1.109515551434015e-06
results O 0 9.152968232228886e-07
from O 0 5.293748586154834e-07
germ O 0 0.0002205243508797139
- O 0 0.0001533712784294039
line O 0 6.250123988138512e-05
mutations O 0 3.497113766570692e-06
in O 0 1.1880664629870807e-07
the O 0 1.755175560447242e-07
5 O 0 6.697803769384336e-07
and O 0 1.671580065476519e-07
3 O 0 6.14460475389933e-07
regions O 0 4.666622146487498e-07
of O 0 1.8223853714971483e-07
the O 0 1.127960899793834e-06
APC B-Disease 0 0.0001752390671754256
gene O 0 4.474516390473582e-05
. O 0 1.5592713680234738e-05

Attenuated B-Disease 1 0.9998341798782349
adenomatous I-Disease 1 0.9999997615814209
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 0.9999995231628418
patients O 1 0.9902580976486206
have O 0 4.480284405872226e-05
" O 0 2.67733139480697e-05
multiple O 0 0.0003856747644022107
" O 0 0.19068196415901184
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 4.965374682797119e-05
typically O 0 2.5105737222475e-06
fewer O 0 4.551326640012121e-07
than O 0 1.232674975426562e-07
100 O 0 2.5096926492551574e-07
) O 0 2.3165395646174147e-07
without O 0 2.1844090269951266e-07
the O 0 5.547402679439983e-07
florid O 0 0.006223563104867935
phenotype O 0 0.0006739774835295975
of O 0 2.198420816057478e-06
classical O 0 3.703120819409378e-05
FAP B-Disease 0 0.0013478255132213235
. O 0 2.947310531453695e-05

Another O 0 0.0001035274108289741
group O 0 3.3666263334453106e-05
of O 0 3.3812896162999095e-06
patients O 0 6.72321257297881e-05
with O 0 2.4014029804675374e-06
multiple O 0 0.00017044479318428785
adenomas B-Disease 1 0.7638332843780518
has O 0 3.443129344304907e-06
no O 0 1.1259456869083806e-06
mutations O 0 3.222989789719577e-06
in O 0 1.6298335481224058e-07
the O 0 3.4598332376845065e-07
APC B-Disease 0 1.1993944099231157e-05
gene O 0 9.554211146678426e-07
, O 0 1.5987914991910657e-07
and O 0 1.8665612344648252e-07
their O 0 9.311427220382029e-07
phenotype O 0 0.03122183494269848
probably O 0 9.74916702034534e-07
results O 0 3.8265025636974315e-07
from O 0 1.0532112071359734e-07
variation O 0 1.1120579301859834e-06
at O 0 2.2662719345589721e-07
a O 0 6.63790899579908e-07
locus O 0 1.1275337783445138e-05
, O 0 3.886957529175561e-07
or O 0 5.915206884310464e-07
loci O 0 4.3325908336555585e-06
, O 0 2.1832865115811728e-07
elsewhere O 0 6.131725740488037e-07
in O 0 3.4723214525911317e-07
the O 0 1.783172137947986e-06
genome O 0 5.605721889878623e-05
. O 0 1.574611997057218e-05

Recently O 0 0.0005914951907470822
, O 0 7.129073310352396e-06
however O 0 1.5437901765835704e-06
, O 0 6.083840276005503e-07
a O 0 2.499865559002501e-06
missense O 0 0.00011330512643326074
variant O 0 1.6222586054936983e-05
of O 0 7.467344858014258e-07
APC B-Disease 0 8.790176798356697e-05
( O 0 2.3156878796726232e-06
I1307K O 0 3.1341416615759954e-05
) O 0 6.296332912825164e-07
was O 0 4.490526919198601e-07
described O 0 9.326242320639722e-07
that O 0 1.1869951066501017e-07
confers O 0 1.890705902951595e-06
an O 0 5.276701813272666e-07
increased O 0 3.981106783612631e-05
risk O 0 0.0002432514011161402
of O 0 0.005665012169629335
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.1047757652704604e-05
including O 0 2.7734870400308864e-06
multiple O 0 6.822271825512871e-05
adenomas B-Disease 0 0.14192892611026764
, O 0 2.267455329274526e-06
in O 0 4.686835836764658e-06
Ashkenazim O 0 0.0005504374275915325
. O 0 1.6049192709033377e-05

We O 0 2.6480995074962266e-05
have O 0 2.793427256619907e-06
studied O 0 1.4937875221221475e-06
a O 0 7.104518431333418e-07
set O 0 7.268338322319323e-07
of O 0 7.074931431816367e-07
164 O 0 0.0021854692604392767
patients O 0 0.0003206132387276739
with O 0 1.7291329641011544e-05
multiple O 1 0.9857553839683533
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.0022196127101778984
/ I-Disease 1 0.9270506501197815
or I-Disease 0 0.0004784661578014493
carcinoma I-Disease 1 1.0
and O 0 1.093611899705138e-05
analyzed O 0 2.588608731457498e-05
codons O 0 0.00010903187649091706
1263 O 0 0.0005873554036952555
- O 0 0.0001322589669143781
1377 O 0 0.00047118248767219484
( O 0 5.123990376887377e-06
exon O 0 4.2886542360065505e-05
15G O 0 6.404473970178515e-05
) O 0 8.376214850613906e-07
of O 0 1.920728038840025e-07
the O 0 5.69451515275432e-07
APC B-Disease 0 1.661156420595944e-05
gene O 0 3.723619556694757e-06
for O 0 1.182634150609374e-06
germ O 0 0.00033103013993240893
- O 0 0.00025726656895130873
line O 0 4.999222801416181e-05
variants O 0 4.998507574782707e-05
. O 0 2.2584092221222818e-05

Three O 0 0.0003704180126078427
patients O 0 0.0006868406780995429
with O 0 2.1710975488531403e-06
the O 0 2.252184231110732e-06
I1307K O 0 0.0003284906269982457
allele O 0 2.9926262868684717e-05
were O 0 1.2645107290154556e-06
detected O 0 2.7386713554733433e-06
, O 0 2.3366686718873098e-07
each O 0 2.569120169937378e-07
of O 0 8.456414661850431e-07
Ashkenazi O 0 0.0009154502768069506
descent O 0 0.0004982613609172404
. O 0 2.3665234039071947e-05

Four O 0 0.0012557368027046323
patients O 0 0.00627492880448699
had O 0 9.301716090703849e-06
a O 0 9.732401849760208e-06
germ O 0 0.0005957953399047256
- O 0 0.00014966590970288962
line O 0 5.006684295949526e-05
E1317Q O 0 0.00022620931849814951
missense O 0 0.00012288051948416978
variant O 0 1.3864688298781402e-05
of O 0 6.3801098804106e-07
APC O 0 4.4016880565322936e-05
that O 0 2.0773725850631308e-07
was O 0 7.110809292498743e-07
not O 0 7.700742088445622e-08
present O 0 1.3283208488701348e-07
in O 0 1.3127214515407104e-07
controls O 0 4.340237410360714e-06
; O 0 4.9086423814515e-07
one O 0 3.487759769882359e-08
of O 0 3.6152179916371097e-08
these O 0 4.2864520821694896e-08
individuals O 0 1.346219704601026e-07
had O 0 1.7597007229142037e-07
an O 0 1.4758087729660474e-07
unusually O 0 7.3768892434600275e-06
large O 0 2.205875233585175e-07
number O 0 1.0826983753986497e-07
of O 0 4.288251034267887e-07
metaplastic B-Disease 0 0.010409836657345295
polyps I-Disease 0 0.00037339210393838584
of I-Disease 0 7.441454386025725e-07
the I-Disease 0 3.3929929941223236e-06
colorectum I-Disease 0 0.001039296155795455
. O 0 2.8611186280613765e-05

There O 0 1.8459553757566027e-05
is O 0 2.611637000882183e-06
increasing O 0 2.949517920569633e-06
evidence O 0 6.689364795420261e-07
that O 0 1.1632774032932502e-07
there O 0 1.5237976924709074e-07
exist O 0 4.4313929947747965e-07
germ O 0 3.4519929613452405e-05
- O 0 1.903225711430423e-05
line O 0 3.837143594864756e-06
variants O 0 7.544078357568651e-07
of O 0 1.197244188233526e-07
the O 0 4.5212340182843036e-07
APC B-Disease 0 1.516808242740808e-05
gene O 0 1.2368853958832915e-06
that O 0 1.2426322371084098e-07
predispose O 0 2.3763336685078684e-06
to O 0 6.456880186078706e-08
the O 0 1.3843724389062118e-07
development O 0 8.931055504035612e-07
of O 0 2.0025920548505383e-06
multiple O 1 0.9956733584403992
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.6884192824363708
carcinoma I-Disease 1 1.0
, O 0 3.7253812479320914e-06
but O 0 1.9558783037609828e-07
without O 0 2.1701112018490676e-07
the O 0 5.298637688611052e-07
florid O 0 0.025800764560699463
phenotype O 0 0.0005959799746051431
of O 0 2.7059186891165155e-07
classical O 0 3.0217856874514837e-06
FAP B-Disease 0 0.00011290187103440985
, O 0 3.970419584220508e-07
and O 0 2.999780690515763e-07
possibly O 0 7.634643566234445e-07
with O 0 3.730255002665217e-07
importance O 0 9.17206853046082e-06
for O 0 0.4785587787628174
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 0.0005090472986921668
in O 0 7.447424650308676e-07
the O 0 7.8684928439543e-07
general O 0 2.4209346065617865e-06
population O 0 3.924697011825629e-06
. O 0 2.4399034828093136e-06
. O 0 1.2815197806048673e-05

Genomic O 0 0.00102120207156986
structure O 0 5.796361074317247e-05
of O 0 8.022101610549726e-06
the O 0 2.535751809773501e-05
human O 0 0.005983738694339991
congenital B-Disease 1 1.0
chloride I-Disease 1 0.999996542930603
diarrhea I-Disease 1 1.0
( O 0 0.004193694330751896
CLD B-Disease 1 0.9899789094924927
) O 0 2.3093136405805126e-05
gene O 0 6.212414882611483e-05
. O 0 3.184813613188453e-05

Congenital B-Disease 1 1.0
chloride I-Disease 1 0.9999982118606567
diarrhea I-Disease 1 1.0
( O 0 0.09641902893781662
CLD B-Disease 1 0.9998452663421631
) O 0 2.4557173674111255e-05
is O 0 1.7459312857681653e-06
caused O 0 4.730993168777786e-06
by O 0 6.269919481383113e-07
mutations O 0 8.480743417749181e-06
in O 0 3.521698772601667e-07
a O 0 2.282623427163344e-06
gene O 0 4.862149580731057e-06
which O 0 8.653452141516027e-07
encodes O 0 8.983025509223808e-06
an O 0 8.884730959834997e-06
intestinal O 1 0.9291694760322571
anion O 0 0.005358483176678419
transporter O 0 0.002263016765937209
. O 0 3.816463868133724e-05

We O 0 3.1111525458982214e-05
report O 0 6.862544978503138e-06
here O 0 4.7447514361920184e-07
the O 0 4.611427755207842e-07
complete O 0 2.090948783006752e-06
genomic O 0 8.814708053250797e-06
organization O 0 5.758997758675832e-07
of O 0 9.680417178969947e-08
the O 0 3.522686142787279e-07
human O 0 2.679729732335545e-06
CLD B-Disease 0 0.01958036608994007
gene O 0 3.3048463592422195e-06
which O 0 3.062045834667515e-07
spans O 0 1.7888560250867158e-06
approximately O 0 6.448295835070894e-07
39kb O 0 1.97381159523502e-05
, O 0 3.1088930541045556e-07
and O 0 3.440240163854469e-07
comprises O 0 3.7041784253233345e-06
21 O 0 2.1040925275883637e-05
exons O 0 0.00021305200061760843
. O 0 2.673035669431556e-05

All O 0 5.933747161179781e-05
exon O 0 0.0005217227735556662
/ O 0 0.00017585135356057435
intron O 0 0.0002387214481132105
boundaries O 0 9.854404197540134e-06
conform O 0 6.027600193192484e-06
to O 0 7.976854590197036e-07
the O 0 3.5037603538512485e-06
GT O 0 0.008788956329226494
/ O 0 0.047759491950273514
AG O 1 0.8518952131271362
rule O 0 6.985111394897103e-05
. O 0 3.2496307539986446e-05

An O 0 1.2759966921294108e-05
analysis O 0 5.683702966052806e-06
of O 0 7.591117991978535e-07
the O 0 9.678160495241173e-07
putative O 0 2.3899339794297703e-05
promoter O 0 1.5472625818802044e-05
region O 0 2.336339775865781e-06
sequence O 0 1.509894673290546e-06
shows O 0 7.041047069833439e-07
a O 0 1.3783155736746266e-06
putative O 0 0.00014055917563382536
TATA O 0 3.492975884000771e-05
box O 0 1.673611905061989e-06
and O 0 6.116849817772163e-07
predicts O 0 2.2395397536456585e-05
multiple O 0 6.220003342605196e-06
transcription O 0 1.3368995496421121e-05
factor O 0 7.824687600077596e-06
binding O 0 9.568570021656342e-06
sites O 0 1.0225567166344263e-05
. O 0 2.1532205209950916e-05

The O 0 4.885685120825656e-05
genomic O 0 0.00013795922859571874
structure O 0 9.519990271655843e-06
was O 0 1.920062686622259e-06
determined O 0 1.8912090808953508e-06
using O 0 7.41334758913581e-07
DNA O 0 1.4969863286751206e-06
from O 0 1.1599207994095195e-07
several O 0 1.2638594171221484e-07
sources O 0 1.4098631595516053e-07
including O 0 1.259558928268234e-07
multiple O 0 8.909005373425316e-07
large O 0 4.5141078430788184e-07
- O 0 7.3419869295321405e-06
insert O 0 1.9214849089621566e-05
libaries O 0 4.288494528736919e-05
and O 0 5.165460947864631e-07
genomic O 0 1.537066236778628e-05
DNA O 0 5.339509698387701e-06
from O 0 1.5529200254604802e-06
Finnish O 0 0.023925188928842545
CLD B-Disease 1 0.9994889497756958
patients O 0 0.0003930579696316272
and O 0 3.2177226785279345e-06
controls O 0 6.417115946533158e-05
. O 0 2.0164527086308226e-05

Exon O 0 0.0035065975971519947
- O 0 0.0008959535625763237
specific O 0 1.5485424228245392e-05
primers O 0 9.177212632494047e-05
developed O 0 8.103460459096823e-06
in O 0 6.130240990387392e-07
this O 0 2.3437858942543244e-07
study O 0 6.6765989004125e-07
will O 0 2.785122887871694e-07
facilitate O 0 1.8791043885357794e-06
mutation O 0 8.075401638052426e-06
screening O 0 3.3440198876633076e-06
studies O 0 1.146559839071415e-06
of O 0 7.69658470289869e-07
patients O 0 6.16701363469474e-05
with O 0 3.3823828289314406e-06
the O 0 8.438830991508439e-05
disease O 0 0.0734640434384346
. O 0 2.471998413966503e-05

Genomic O 0 0.001099528861232102
sequencing O 0 0.0001474579330533743
of O 0 5.8452392295293976e-06
a O 0 3.9239992474904284e-05
BAC O 0 0.0022820669692009687
clone O 0 0.03619387373328209
H O 1 0.9946604371070862
_ O 0 8.09658467915142e-06
RG364P16 O 0 7.627735612913966e-05
revealed O 0 2.866008117052843e-06
the O 0 1.9090896330453688e-07
presence O 0 3.1186627325041627e-07
of O 0 7.09118452846269e-08
another O 0 5.237475875219388e-07
, O 0 2.805995507060288e-07
highly O 0 5.577688284574833e-07
homologous O 0 3.173327741023968e-06
gene O 0 1.2464628298403113e-06
3 O 0 4.835878826270346e-07
of O 0 1.4097770417720312e-07
the O 0 1.3611746680908254e-06
CLD B-Disease 0 0.3722298741340637
gene O 0 2.8932806799275568e-06
, O 0 1.5543393772077252e-07
with O 0 1.1353487394671902e-07
a O 0 6.50725553441589e-07
similar O 0 8.9956091642307e-07
genomic O 0 1.0385298082837835e-05
structure O 0 9.480691574026423e-07
, O 0 3.398840817681048e-07
recently O 0 1.757186396389443e-06
identified O 0 1.2214007938382565e-06
as O 0 4.563313495964394e-07
the O 0 2.7089368813904002e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 0.0001393123675370589
( O 0 1.117095052904915e-05
PDS B-Disease 0 0.0006954955169931054
) O 0 3.5938410292146727e-06
. O 0 2.7633539048110833e-06
. O 0 8.312122190545779e-06

The O 0 7.277294935192913e-05
APCI1307K O 0 0.02309803105890751
allele O 0 0.0015334426425397396
and O 0 0.00012177227472420782
cancer B-Disease 1 0.8297496438026428
risk O 0 2.1473395463544875e-05
in O 0 5.034564765082905e-07
a O 0 1.960582039828296e-06
community O 0 2.1275823200994637e-06
- O 0 2.3358907128567807e-05
based O 0 2.1339833438105416e-06
study O 0 1.7706136077322299e-06
of O 0 1.4966237813496264e-06
Ashkenazi O 0 0.000983926933258772
Jews O 0 3.412500154809095e-05
. O 0 1.2680450709012803e-05

Mutations O 0 0.008684167638421059
in O 0 6.780451076338068e-05
APC O 0 0.00034729763865470886
are O 0 4.655181328416802e-06
classically O 0 0.009701832197606564
associated O 0 0.00010973980533890426
with O 0 0.0006265000556595623
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.0011111234780400991
FAP B-Disease 0 0.003084785770624876
) O 0 5.146444436832098e-06
, O 0 1.4171628208714537e-06
a O 0 1.407821400789544e-05
highly O 0 0.0003494117991067469
penetrant O 1 0.9999594688415527
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999508857727051
disorder I-Disease 1 1.0
characterized O 0 0.03857763111591339
by O 0 1.2950032214575913e-05
multiple O 0 0.48706701397895813
intestinal O 1 0.9999994039535522
polyps B-Disease 1 0.9759014844894409
and O 0 2.1775567802251317e-06
, O 0 7.095086971276032e-07
without O 0 7.271249842233374e-07
surgical O 0 0.004706230014562607
intervention O 0 1.4065518371353392e-05
, O 0 3.9419794006789743e-07
the O 0 4.432572211499064e-07
development O 0 1.4819544958299957e-05
of O 0 0.016078362241387367
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.00024378704256378114
CRC B-Disease 0 0.004462041892111301
) O 0 2.3014803446130827e-05
. O 0 2.9644286769325845e-05

APC B-Disease 0 0.004135324619710445
is O 0 3.7353256630012766e-05
a O 0 0.00010616704093990847
tumour O 1 0.999955415725708
- O 0 0.002157042035833001
suppressor O 0 0.0011636307463049889
gene O 0 8.259204150817823e-06
, O 0 8.112143632388324e-07
and O 0 1.1923756346732262e-06
somatic O 0 0.0009420044953003526
loss O 0 0.003380414331331849
occurs O 0 3.62318278348539e-05
in O 0 4.327089845901355e-05
tumours B-Disease 1 0.9999949932098389
. O 0 6.271678284974769e-05

The O 0 0.0001776678691385314
germline O 0 0.21606583893299103
T O 0 0.03013784810900688
- O 0 4.0543080103816465e-05
to O 0 1.0239931498290389e-06
- O 0 1.250781315320637e-05
A O 0 2.870195658033481e-06
transversion O 0 0.00012484940816648304
responsible O 0 1.1864376574521884e-06
for O 0 2.1730849653067708e-07
the O 0 6.615820780098147e-07
APC O 0 1.8174412616644986e-05
I1307K O 0 2.9040815206826665e-05
allele O 0 5.108337518322514e-06
converts O 0 1.4842112250335049e-06
the O 0 2.0111977505621326e-07
wild O 0 1.0176671594308573e-06
- O 0 6.129748271632707e-06
type O 0 1.2958749948666082e-06
sequence O 0 5.894877403989085e-07
to O 0 1.7789295725378906e-07
a O 0 5.126081759954104e-06
homopolymer O 1 0.7453954219818115
tract O 0 0.0957086905837059
( O 0 5.782233529316727e-06
A8 O 0 0.016618702560663223
) O 0 1.0320068213331979e-06
that O 0 1.455912013170746e-07
is O 0 4.687309171913512e-07
genetically O 0 6.4601476879033726e-06
unstable O 0 0.0002790060534607619
and O 0 7.022423687885748e-06
prone O 0 0.00019140337826684117
to O 0 4.125106443098048e-06
somatic O 0 0.0016901876078918576
mutation O 0 0.0002828661527018994
. O 0 2.4492321244906634e-05

The O 0 8.39810527395457e-05
I1307K O 0 0.001429739873856306
allele O 0 0.00020345587108749896
was O 0 6.592583304154687e-06
found O 0 2.0492359453783138e-06
in O 0 1.898612936201971e-06
6 O 0 4.53598695457913e-05
. O 0 1.997870276682079e-05

1 O 0 0.00014934130012989044
% O 0 2.356519689783454e-05
of O 0 1.6721697875254904e-06
unselected O 0 0.0005622193566523492
Ashkenazi O 0 0.002900098916143179
Jews O 0 8.928423085308168e-06
and O 0 9.91874344435928e-07
higher O 0 2.2802844341640593e-06
proportions O 0 4.287288447812898e-06
of O 0 2.492637918294349e-07
Ashkenazim O 0 2.7673895601765253e-05
with O 0 4.5074230570207874e-07
family O 0 1.5342719734690036e-06
or O 0 3.9390556594298687e-07
personal O 0 1.2835263305532862e-06
histories O 0 3.3409151001251303e-06
of O 0 9.011580459628021e-07
CRC B-Disease 0 0.0030812991317361593
( O 0 4.7251760406652465e-06
ref O 0 0.00021141213073860854
. O 0 9.45281271924614e-07
2 O 0 6.175290764076635e-06
) O 0 5.05214757140493e-06
. O 0 8.744535989535507e-06

To O 0 2.816520463966299e-05
evaluate O 0 2.8811222364311107e-05
the O 0 1.5655834886274533e-06
role O 0 2.374761606915854e-06
of O 0 9.783292398424237e-07
I1307K O 0 0.0014890182064846158
in O 0 1.9339233404025435e-05
cancer B-Disease 0 0.0034820702858269215
, O 0 5.613040343632747e-07
we O 0 2.32605884775694e-07
genotyped O 0 3.1456522265216336e-05
5 O 0 2.8589865905814804e-06
, O 0 9.378445611218922e-07
081 O 0 0.00014861115778330714
Ashkenazi O 0 0.00012986775254830718
volunteers O 0 3.589039124562987e-06
in O 0 7.15429507636145e-07
a O 0 3.079234602409997e-06
community O 0 9.487128409091383e-06
survey O 0 3.439945794525556e-05
. O 0 1.6770465663284995e-05

Risk O 0 0.0037308605387806892
of O 0 6.181478238431737e-05
developing O 0 0.0065802051685750484
colorectal B-Disease 1 1.0
, I-Disease 0 0.00048177162534557283
breast I-Disease 1 0.9875904321670532
and I-Disease 0 1.9339382561156526e-05
other I-Disease 0 5.0320195441599935e-06
cancers I-Disease 0 0.3181682229042053
were O 0 8.552808026252023e-07
compared O 0 2.8471536097640637e-06
between O 0 1.0071588576465729e-06
genotyped O 0 0.0002764097007457167
I1307K O 0 0.00020449969451874495
carriers O 0 2.634006250445964e-06
and O 0 1.708572199277114e-07
non O 0 9.299553767050384e-07
- O 0 7.806605935911648e-06
carriers O 0 9.101264595301473e-07
and O 0 6.922558526412104e-08
their O 0 8.373820747920036e-08
first O 0 7.615373078806442e-07
- O 0 6.263639079406857e-05
degree O 0 6.465685873990878e-05
relatives O 0 4.126612111576833e-05
. O 0 1.829708526202012e-05

Sperm O 0 0.002468878636136651
DNA O 0 0.00028078380273655057
analysis O 0 4.798887312063016e-05
in O 0 1.0561875569692347e-05
a O 0 8.470305328955874e-05
Friedreich B-Disease 1 0.9953448176383972
ataxia I-Disease 1 0.9998788833618164
premutation O 1 0.9515917897224426
carrier O 0 0.001269028289243579
suggests O 0 1.483532560087042e-05
both O 0 9.303456636189367e-07
meiotic O 0 0.000128722153021954
and O 0 1.209934907819843e-06
mitotic O 0 8.53479650686495e-05
expansion O 0 8.805515790299978e-06
in O 0 1.6701616232239758e-06
the O 0 3.0563617201551097e-06
FRDA B-Disease 0 0.0019091053400188684
gene O 0 8.27339754323475e-05
. O 0 2.735572161327582e-05

Friedreich B-Disease 1 0.999962568283081
ataxia I-Disease 1 0.9999912977218628
is O 0 0.00018891973013523966
usually O 0 3.568682950572111e-05
caused O 0 8.248687663581222e-06
by O 0 2.570012043179304e-07
an O 0 2.621125929636037e-07
expansion O 0 2.5872707283269847e-06
of O 0 4.1638301695456903e-07
a O 0 8.192962013708893e-06
GAA O 0 0.00022815748525317758
trinucleotide O 0 0.0014430205337703228
repeat O 0 2.360168036830146e-05
in O 0 1.4725457049280521e-06
intron O 0 6.87072315486148e-05
1 O 0 1.7748672007655841e-06
of O 0 5.868558901056531e-07
the O 0 3.17065359922708e-06
FRDA B-Disease 0 0.0021740607917308807
gene O 0 9.219825733453035e-05
. O 0 3.0552248063031584e-05

Occasionally O 0 0.00016888529353309423
, O 0 7.2649604589969385e-06
a O 0 4.738533334602835e-06
fully O 0 2.6557331693766173e-06
expanded O 0 2.18721811506839e-06
allele O 0 6.338255388982361e-06
has O 0 3.1469048167309666e-07
been O 0 1.6208031183850835e-07
found O 0 1.878174913372277e-07
to O 0 1.500116155739306e-07
arise O 0 7.806485768924176e-07
from O 0 1.4032232797944744e-07
a O 0 4.954856649419526e-07
premutation O 0 2.2162963432492688e-05
of O 0 2.987088691952522e-07
100 O 0 9.404849379279767e-07
or O 0 8.913493161344377e-07
less O 0 4.291350251151016e-06
triplet O 0 0.004564023111015558
repeats O 0 0.0004091066075488925
. O 0 3.935023778467439e-05

We O 0 3.990978802903555e-05
have O 0 5.2683371905004606e-06
examined O 0 8.169258762791287e-06
the O 0 1.0668203458408243e-06
sperm O 0 1.0112182280863635e-05
DNA O 0 2.88170417661604e-06
of O 0 4.467124483653606e-07
a O 0 8.853242434270214e-06
premutation O 0 0.004875234793871641
carrier O 0 0.0002540297282394022
. O 0 2.6200557840638794e-05

This O 0 3.8511079765157774e-05
mans O 0 0.00030660798074677587
leucocyte O 0 0.0030148187652230263
DNA O 0 7.2345559601672e-05
showed O 0 6.770238087483449e-06
one O 0 5.037177288613748e-07
normal O 0 2.9032698876108043e-06
allele O 0 3.583003262974671e-06
and O 0 1.3432560308501706e-07
one O 0 1.3841163593042438e-07
allele O 0 1.960987901838962e-06
of O 0 1.8818541036580427e-07
approximately O 0 1.808632646316255e-06
100 O 0 3.7426880226121284e-06
repeats O 0 6.517542351502925e-05
. O 0 1.6015297660487704e-05

His O 0 0.00012520875316113234
sperm O 0 0.00034043434425257146
showed O 0 2.436298382235691e-05
an O 0 1.1694525028360658e-06
expanded O 0 4.964949766872451e-06
allele O 0 1.0058342013508081e-05
in O 0 4.7117799795159954e-07
a O 0 1.2260923085705144e-06
tight O 0 1.9627334040706046e-05
range O 0 1.928765414049849e-06
centering O 0 3.3030380564014195e-06
on O 0 3.730956166236865e-07
a O 0 6.585800065295189e-07
size O 0 9.087942203223065e-07
of O 0 5.492250920724473e-07
approximately O 0 5.964130195934558e-06
320 O 0 4.475984678720124e-05
trinucleotide O 0 0.0013129470171406865
repeats O 0 0.00023155212693382055
. O 0 3.033294342458248e-05

His O 0 0.00025513142463751137
affected O 0 0.00017477900837548077
son O 0 0.00024619154282845557
has O 0 7.240005743369693e-06
repeat O 0 2.2557704141945578e-05
sizes O 0 9.780963409866672e-06
of O 0 1.7437814676668495e-06
1040 O 0 0.00020481405954342335
and O 0 6.4803184613992926e-06
540 O 0 0.0001611943735042587
. O 0 3.331373955006711e-05

These O 0 1.0165585990762338e-05
data O 0 4.869593340117717e-06
suggest O 0 2.9374305086093955e-06
that O 0 2.5235166845050117e-07
expansion O 0 3.8136315652081976e-06
occurs O 0 6.828115033385984e-07
in O 0 1.0605265288177179e-07
two O 0 2.1468380850819813e-07
stages O 0 4.784259999723872e-06
, O 0 9.989477689487103e-08
the O 0 7.212683783563989e-08
first O 0 2.911350236445287e-07
during O 0 1.0288385965395719e-06
meiosis O 0 4.673785042541567e-06
followed O 0 8.01663304628164e-07
by O 0 1.9325017319715698e-07
a O 0 1.4804338661633665e-06
second O 0 9.22408617043402e-06
mitotic O 0 0.0005232106195762753
expansion O 0 0.00010225031292065978
. O 0 3.529036257532425e-05

We O 0 2.5640250896685757e-05
also O 0 3.07269283439382e-06
show O 0 9.547926538289175e-07
that O 0 1.3246862806681747e-07
in O 0 1.1622395135191255e-07
all O 0 8.251406313775078e-08
informative O 0 1.1837072406706284e-06
carrier O 0 9.93992762232665e-06
father O 0 8.36143385640753e-07
to O 0 1.713791135671272e-07
affected O 0 8.215661182475742e-07
child O 0 7.798221304256003e-06
transmissions O 0 9.994859283324331e-06
, O 0 9.273129819575843e-08
with O 0 5.544838188598078e-08
the O 0 1.2992404663236812e-07
notable O 0 3.9891878600428754e-07
exception O 0 2.2947975253373443e-07
of O 0 5.9330378832100905e-08
the O 0 2.1868895316856651e-07
premutation O 0 0.0001481056970078498
carrier O 0 7.75711396272527e-06
, O 0 7.988481343090825e-08
the O 0 1.081340386122065e-07
expansion O 0 1.3802188050249242e-06
size O 0 2.7548967409529723e-06
decreases O 0 1.776546923792921e-05
. O 0 1.863464376583579e-06
. O 0 1.0974285942211282e-05

The O 0 8.01500427769497e-05
R496H O 0 0.0008089295588433743
mutation O 0 6.990083056734875e-05
of O 0 2.05795481633686e-06
arylsulfatase O 0 0.00040396052645519376
A O 0 2.4229664632002823e-05
does O 0 4.475815785554005e-06
not O 0 5.7286524679511786e-06
cause O 0 0.0003071196551900357
metachromatic B-Disease 1 0.9999903440475464
leukodystrophy I-Disease 1 0.9999986886978149
. O 0 0.00016403522749897093

Deficiency B-Disease 1 0.9993637204170227
of I-Disease 0 4.027791146654636e-05
arylsulfatase I-Disease 0 0.005139386747032404
A I-Disease 0 0.00015615260053891689
( O 0 4.932884985464625e-05
ARSA O 0 0.010262464173138142
) O 0 1.2535589121398516e-05
enzyme O 0 4.276137406122871e-05
activity O 0 2.7471902285469696e-05
causes O 0 0.0003276439674664289
metachromatic B-Disease 1 0.999995231628418
leukodystrophy I-Disease 1 0.9999998807907104
( O 0 0.0008675911813043058
MLD B-Disease 1 0.9999363422393799
) O 0 9.688840509625152e-05
. O 0 6.149734690552577e-05

A O 0 0.00010838349408004433
number O 0 1.1275747056060936e-05
of O 0 7.220086445158813e-06
ARSA O 0 0.21181359887123108
gene O 0 0.00013091028085909784
mutations O 0 6.574057624675333e-05
responsible O 0 6.58862973068608e-06
for O 0 4.50158586318139e-06
MLD B-Disease 1 0.9999943971633911
have O 0 6.933314580237493e-06
been O 0 4.504287517193006e-06
identified O 0 3.248933717259206e-05
. O 0 1.877515205706004e-05

Recently O 0 0.00023075036006048322
, O 0 6.189848591020564e-06
the O 0 1.8242805026602582e-06
R496H O 0 0.00013016084267292172
mutation O 0 1.816006624721922e-05
of O 0 9.892726211546687e-07
ARSA O 0 0.0205061212182045
was O 0 2.206294766438077e-06
proposed O 0 1.1584830872379825e-06
to O 0 1.740709620889902e-07
be O 0 9.884440288487895e-08
a O 0 1.276958869311784e-06
cause O 0 5.891443379368866e-06
of O 0 1.8328358919461607e-06
MLD B-Disease 1 0.9999964237213135
( O 0 1.6119984138640575e-05
Draghia O 0 0.0009691031300462782
et O 0 0.00011225014895899221
al O 0 1.894172419270035e-05
. O 0 7.153687988648016e-07
, O 0 8.293564519590291e-07
1997 O 0 7.496066245948896e-06
) O 0 5.341333235264756e-06
. O 0 1.2455582691472955e-05

We O 0 2.9561460905824788e-05
have O 0 3.678992470668163e-06
investigated O 0 6.335753823805135e-06
the O 0 1.091753802029416e-06
R496H O 0 0.0004616892256308347
mutation O 0 1.002190856524976e-05
and O 0 1.7531212392896123e-07
found O 0 2.5319297947135055e-07
this O 0 1.2139300054059277e-07
mutation O 0 1.9408846583246486e-06
at O 0 1.5659760776998155e-07
a O 0 6.145694442238891e-07
relatively O 0 8.85530141658819e-07
high O 0 8.416828904955764e-07
frequency O 0 7.153503247536719e-07
in O 0 6.48915303713693e-08
an O 0 8.021567765581494e-08
African O 0 4.228029126807087e-07
American O 0 3.727861894731177e-07
population O 0 4.3740431010519387e-07
( O 0 4.7254872015400906e-07
f O 0 9.12145696929656e-06
= O 0 9.862772458291147e-06
0 O 0 8.210883493120491e-07
. O 0 1.7155309706140542e-07
09 O 0 1.8518126125854906e-06
, O 0 5.067527695246099e-07
n O 0 1.398921540385345e-05
= O 0 4.8323334340238944e-05
61 O 0 1.6616872017038986e-05
subjects O 0 8.259795322373975e-06
) O 0 9.202382898365613e-06
. O 0 1.2458598575904034e-05

The O 0 0.0001298006682191044
ARSA O 0 0.01226297952234745
enzyme O 0 7.469792035408318e-05
activity O 0 7.747036761429626e-06
in O 0 5.722148443965125e-07
subjects O 0 9.223911661138118e-07
with O 0 2.3060188425461092e-07
and O 0 3.1817384638088697e-07
without O 0 2.557259506374976e-07
the O 0 3.3508982255625597e-07
R496H O 0 0.00018719027866609395
mutation O 0 6.796179150114767e-06
was O 0 4.7026219363033306e-07
determined O 0 5.731859005209117e-07
and O 0 2.263671206037543e-07
found O 0 3.7029067811999994e-07
to O 0 3.206824317203427e-07
be O 0 7.371119181698305e-07
normal O 0 1.8136788639822043e-05
. O 0 1.527938002254814e-05

It O 0 2.2984884708421305e-05
is O 0 3.605891379265813e-06
therefore O 0 2.1683042632503202e-06
concluded O 0 2.957765673272661e-06
that O 0 1.5110053652733768e-07
the O 0 6.300513746282377e-07
R496H O 0 0.00015673780580982566
mutation O 0 1.0185022802033927e-05
of O 0 5.464837045110471e-07
ARSA O 0 0.005152913276106119
does O 0 7.146963980630971e-07
not O 0 1.2081667932761775e-07
negatively O 0 3.9437620102944493e-07
influence O 0 2.083531143171058e-07
the O 0 1.2360889911633421e-07
activity O 0 4.6981486434560793e-07
of O 0 2.0955792479071533e-07
ARSA O 0 0.0028451273683458567
and O 0 5.311554218678793e-07
is O 0 2.659326980847254e-07
not O 0 3.0627700198238017e-07
a O 0 4.6523232413164806e-06
cause O 0 4.69424448965583e-05
of O 0 3.56775417458266e-05
MLD B-Disease 1 0.9999799728393555

Down O 0 0.00033097207779064775
- O 0 0.0003298399969935417
regulation O 0 2.746771315287333e-05
of O 0 3.890895641234238e-06
transmembrane O 0 8.664997585583478e-05
carbonic O 0 0.0004068939306307584
anhydrases O 0 0.0025783302262425423
in O 0 0.00012587349920067936
renal B-Disease 1 0.9999998807907104
cell I-Disease 1 0.9999985694885254
carcinoma I-Disease 1 1.0
cell O 0 0.04913266375660896
lines O 0 2.024765490205027e-05
by O 0 1.1372325161573826e-06
wild O 0 1.120613069360843e-05
- O 0 0.00042703383951447904
type O 0 0.00012176355812698603
von B-Disease 1 0.7924237251281738
Hippel I-Disease 1 0.9893222451210022
- I-Disease 0 0.04892976954579353
Lindau I-Disease 0 0.0926385372877121
transgenes O 0 0.004496674053370953
. O 0 9.638801566325128e-05

To O 0 4.273052036296576e-05
discover O 0 9.740421955939382e-05
genes O 0 3.017431663465686e-05
involved O 0 7.0394289650721475e-06
in O 0 6.75351020618109e-06
von B-Disease 1 0.993560791015625
Hippel I-Disease 1 0.9999561309814453
- I-Disease 1 0.8184683918952942
Lindau I-Disease 1 0.7786955237388611
( O 0 1.7879463484860025e-05
VHL B-Disease 0 0.000897615565918386
) O 0 3.976137122663204e-06
- O 0 5.120063724461943e-05
mediated O 0 0.0003148903779219836
carcinogenesis O 0 0.0020345544908195734
, O 0 1.760515942805796e-06
we O 0 9.65817093856458e-07
used O 0 3.421532892389223e-05
renal B-Disease 1 0.9999996423721313
cell I-Disease 1 0.9999769926071167
carcinoma I-Disease 1 1.0
cell O 0 0.03822707012295723
lines O 0 6.832350482000038e-05
stably O 0 0.00015523098409175873
transfected O 0 0.00024390144972130656
with O 0 1.5305540728149936e-06
wild O 0 1.2906497431686148e-05
- O 0 0.0004211292543914169
type O 0 8.150914072757587e-05
VHL O 0 0.059907570481300354
- O 0 0.002117030555382371
expressing O 0 0.0001506077533122152
transgenes O 0 0.0011493662605062127
. O 0 6.78976794006303e-05

Large O 0 9.529661474516615e-05
- O 0 0.00012651739234570414
scale O 0 4.145595448790118e-05
RNA O 0 1.6076046449597925e-05
differential O 0 1.1568597074074205e-05
display O 0 1.8498286635804106e-06
technology O 0 1.9364954368938925e-06
applied O 0 7.169451237132307e-07
to O 0 1.424793509841038e-07
these O 0 1.1053337800603913e-07
cell O 0 5.5806640375521965e-06
lines O 0 2.916862968049827e-06
identified O 0 1.4849076706013875e-06
several O 0 3.9088490666472353e-07
differentially O 0 1.099871860787971e-05
expressed O 0 1.0170753057536785e-06
genes O 0 1.1855056527565466e-06
, O 0 1.508701359398401e-07
including O 0 3.114296589501464e-07
an O 0 1.0717375289459596e-06
alpha O 0 2.7602520276559517e-05
carbonic O 0 0.00012991669063922018
anhydrase O 0 0.00014733296120539308
gene O 0 1.0445190127938986e-05
, O 0 3.785830358538078e-06
termed O 0 9.224160021403804e-05
CA12 O 0 0.0028938250616192818
. O 0 4.340993473306298e-05

The O 0 3.5573924833443016e-05
deduced O 0 6.519637099700049e-05
protein O 0 9.783734640222974e-06
sequence O 0 3.4672625588427763e-06
was O 0 1.088966996576346e-06
classified O 0 1.4479420542556909e-06
as O 0 1.8866951734253234e-07
a O 0 8.693603490428359e-07
one O 0 4.953888037562137e-07
- O 0 4.385766078485176e-05
pass O 0 6.813311756559415e-06
transmembrane O 0 1.4759207260794938e-05
CA O 0 3.680413783513359e-06
possessing O 0 8.857320494826126e-07
an O 0 2.3888986788733746e-07
apparently O 0 4.5128822421247605e-06
intact O 0 2.261755980725866e-06
catalytic O 0 2.2979386358201737e-06
domain O 0 1.016465375869302e-06
in O 0 2.5109039825110813e-07
the O 0 9.412467534275493e-07
extracellular O 0 2.605007466627285e-05
CA O 0 2.9681828891625628e-05
module O 0 0.00023380611673928797
. O 0 2.4290624423883855e-05

Reintroduced O 0 0.0022086326498538256
wild O 0 0.0003085883508902043
- O 0 0.0010946743423119187
type O 0 7.504483073716983e-05
VHL B-Disease 0 0.0017847534036263824
strongly O 0 2.2593785615754314e-05
inhibited O 0 2.4106864657369442e-05
the O 0 7.725050750195805e-07
overexpression O 0 1.2141945262555964e-05
of O 0 3.378932262876333e-07
the O 0 1.146701947618567e-06
CA12 O 0 0.00034237877116538584
gene O 0 4.3679256123141386e-06
in O 0 8.734873517823871e-07
the O 0 4.250935035088332e-06
parental O 1 0.7128397226333618
renal B-Disease 1 1.0
cell I-Disease 1 0.9999986886978149
carcinoma I-Disease 1 1.0
cell O 1 0.6911998391151428
lines O 0 0.0007616189541295171
. O 0 4.759969306178391e-05

Similar O 0 0.0001948018034454435
results O 0 3.1080566259333864e-05
were O 0 2.0042830328748096e-06
obtained O 0 2.120233830282814e-06
with O 0 1.5529288930338225e-06
CA9 O 0 0.15584176778793335
, O 0 8.14572672425129e-07
encoding O 0 2.9210466436779825e-06
another O 0 2.1783584998047445e-06
transmembrane O 0 1.5840660125832073e-05
CA O 0 2.2579156393476296e-06
with O 0 2.6086422622029204e-07
an O 0 1.1253166576352669e-06
intact O 0 2.3472344764741138e-05
catalytic O 0 3.5261364246252924e-05
domain O 0 2.8858108635176904e-05
. O 0 1.576944487169385e-05

Although O 0 2.7424681320553645e-05
both O 0 2.035108309428324e-06
domains O 0 2.8167085019958904e-06
of O 0 4.475793673464068e-07
the O 0 1.1555513310668175e-06
VHL B-Disease 0 0.0005069769686087966
protein O 0 2.397791831754148e-06
contribute O 0 5.359481178857095e-07
to O 0 1.1083758977292746e-07
regulation O 0 9.517027024230629e-07
of O 0 2.503520590835251e-07
CA12 O 0 0.00046064588241279125
expression O 0 8.556078796573274e-07
, O 0 1.3191733216899593e-07
the O 0 2.538014598485461e-07
elongin O 0 2.021489490289241e-05
binding O 0 1.4899690086167539e-06
domain O 0 1.4477072909357958e-06
alone O 0 1.992493707803078e-06
could O 0 1.026292693495634e-06
effectively O 0 9.101264367927797e-06
regulate O 0 4.215505032334477e-05
CA9 O 0 0.008645746856927872
expression O 0 4.468742190510966e-05
. O 0 2.6687917852541432e-05

We O 0 9.630074782762676e-05
mapped O 0 0.0002599008148536086
CA12 O 0 0.0024362122640013695
and O 0 2.849336487997789e-05
CA9 O 0 0.07034178823232651
loci O 0 8.192675159079954e-05
to O 0 4.6411564653681125e-06
chromosome O 0 0.00011389450810384005
bands O 0 2.5453022317378782e-05
15q22 O 0 0.00013831726391799748
and O 0 6.629850759054534e-06
17q21 O 0 0.0004916145699098706
. O 0 2.560345092206262e-05

2 O 0 0.00030207005329430103
respectively O 0 5.966418393654749e-05
, O 0 3.3804769827838754e-06
regions O 0 6.199743438628502e-06
prone O 0 2.2063530195737258e-05
to O 0 8.984172268355906e-07
amplification O 0 5.7599776482675225e-05
in O 0 1.1640181583061349e-06
some O 0 1.38420637085801e-06
human O 0 4.7272624215111136e-05
cancers B-Disease 0 0.3943319320678711
. O 0 4.549745790427551e-05

Additional O 0 9.93701396510005e-05
experiments O 0 3.2398253097198904e-05
are O 0 8.283660122287984e-07
needed O 0 1.6283713648590492e-06
to O 0 2.1891054302614066e-07
define O 0 1.2907908057968598e-06
the O 0 2.0509669695911725e-07
role O 0 4.964250024386274e-07
of O 0 4.3240609670647245e-07
CA O 0 1.7212687453138642e-05
IX O 0 0.00023142941063269973
and O 0 2.4295893581438577e-06
CA O 0 1.4028960322320927e-05
XII O 0 9.132689592661336e-05
enzymes O 0 1.9728311144717736e-06
in O 0 1.5175731959971017e-07
the O 0 1.544959502552956e-07
regulation O 0 1.1476822692202404e-06
of O 0 2.5711690909702156e-07
pH O 0 3.7067387893330306e-05
in O 0 1.5577154499624157e-07
the O 0 1.9970430287230556e-07
extracellular O 0 2.404959786872496e-06
microenvironment O 0 2.3296506697079167e-05
and O 0 2.2285932743670855e-07
its O 0 3.9326596379396506e-07
potential O 0 1.2127941317885416e-06
impact O 0 2.843126821971964e-06
on O 0 2.6521483960095793e-05
cancer B-Disease 0 0.15817612409591675
cell O 0 0.0006350880139507353
growth O 0 6.321213732007891e-05
. O 0 1.9458073438727297e-05

A O 0 0.00015816738596186042
gene O 0 7.122164242900908e-05
encoding O 0 3.06220754282549e-05
a O 0 1.1147943041578401e-05
transmembrane O 0 3.212970477761701e-05
protein O 0 4.9772470447351225e-06
is O 0 6.757497317266825e-07
mutated O 0 1.5255645848810673e-05
in O 0 1.3025897715124302e-05
patients O 0 0.007267420180141926
with O 0 0.020527269691228867
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9278344511985779
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999988079071045
( O 0 0.31414881348609924
Wolfram B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
) O 0 9.467788186157122e-05
. O 0 4.271792568033561e-05

Wolfram B-Disease 1 0.9999997615814209
syndrome I-Disease 1 1.0
( O 0 0.018726257607340813
WFS B-Disease 1 0.9990407824516296
; O 0 0.0008426134590990841
OMIM O 1 0.8748548030853271
222300 O 0 0.0012514638947322965
) O 0 7.560899575764779e-06
is O 0 3.71104511032172e-06
an O 0 8.735659503145143e-05
autosomal B-Disease 1 0.9999996423721313
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 0.9999984502792358
defined O 0 3.366324745002203e-05
by O 0 1.93992605090898e-06
young O 0 1.7645939806243405e-05
- O 0 0.006792112719267607
onset O 1 0.9147201776504517
non O 0 0.00014489512250293046
- O 0 0.1792718768119812
immune O 0 0.0072226556949317455
insulin B-Disease 0 0.021930145099759102
- I-Disease 1 0.671704113483429
dependent I-Disease 0 0.03022640198469162
diabetes I-Disease 1 1.0
mellitus I-Disease 1 0.9999995231628418
and O 0 0.0011613639071583748
progressive O 1 0.974346399307251
optic B-Disease 1 0.9999550580978394
atrophy I-Disease 1 0.9655665755271912
. O 0 9.639353811508045e-05

Linkage O 0 0.0008722964557819068
to O 0 1.607319609320257e-05
markers O 0 5.5787746532587335e-05
on O 0 7.907581675681286e-06
chromosome O 0 0.0008881907560862601
4p O 0 0.27330875396728516
was O 0 6.438804575736867e-06
confirmed O 0 2.473495214871946e-06
in O 0 7.168453066697111e-07
five O 0 3.4360964491497725e-06
families O 0 2.2643311240244657e-05
. O 0 1.7371357898809947e-05

On O 0 2.7658277758746408e-05
the O 0 2.6584370971249882e-06
basis O 0 3.2123389246407896e-06
of O 0 2.070601567538688e-06
meiotic O 0 0.230321004986763
recombinants O 1 0.7223014235496521
and O 0 0.0001616115914657712
disease O 0 0.0612594373524189
- O 0 0.0006105797947384417
associated O 0 1.3334818504517898e-05
haplotypes O 0 0.00010619843669701368
, O 0 5.672060297001735e-07
the O 0 9.167207508653519e-07
WFS B-Disease 0 0.014650975354015827
gene O 0 4.549870027403813e-06
was O 0 1.1172816130056162e-06
localized O 0 5.297048573993379e-06
to O 0 5.030437364439422e-07
a O 0 6.557668257300975e-06
BAC O 0 0.00045365249388851225
/ O 0 8.804755634628236e-05
P1 O 0 5.253245399217121e-05
contig O 0 3.276832649135031e-05
of O 0 6.082998424972175e-07
less O 0 1.1504985195642803e-06
than O 0 9.643721341490163e-07
250 O 0 1.1000502126989886e-05
kb O 0 0.002043936401605606
. O 0 2.8608046704903245e-05

Mutations O 0 0.003844095394015312
in O 0 9.219670573656913e-06
a O 0 8.431286005361471e-06
novel O 0 1.7048469089786522e-05
gene O 0 1.764979424478952e-05
( O 0 3.0681189855386037e-06
WFS1 O 0 0.00010504943202249706
) O 0 7.389841698568489e-07
encoding O 0 1.7985122440222767e-06
a O 0 1.4834130297458614e-06
putative O 0 2.6418087145430036e-05
transmembrane O 0 8.684556632942986e-06
protein O 0 1.2818102277378784e-06
were O 0 1.308994939108743e-07
found O 0 1.2952705219504423e-07
in O 0 1.2394390580539039e-07
all O 0 8.806994600263351e-08
affected O 0 7.930387369015079e-07
individuals O 0 2.147169766431034e-07
in O 0 2.6840930900107196e-07
six O 0 9.255084478354547e-06
WFS B-Disease 1 0.8417755365371704
families O 0 6.1492269196605776e-06
, O 0 2.1033797281688749e-07
and O 0 1.631348141017952e-07
these O 0 1.9067370260472671e-07
mutations O 0 4.557191459753085e-06
were O 0 2.3591337594552897e-07
associated O 0 9.312128668170772e-07
with O 0 2.131260089299758e-06
the O 0 0.00021240195201244205
disease O 1 0.9762566089630127
phenotype O 1 0.8128384947776794
. O 0 3.5362048947717994e-05

WFS1 O 0 0.06326840817928314
appears O 0 0.00013229454634711146
to O 0 4.336513939051656e-06
function O 0 5.292963123793015e-06
in O 0 9.785429710973403e-07
survival O 0 4.281233486835845e-05
of O 0 6.995387593633495e-07
islet O 0 0.00042218880844302475
beta O 0 5.431416866485961e-05
- O 0 0.0002784068346954882
cells O 0 1.898213849926833e-05
and O 0 2.2891065327712568e-06
neurons O 0 3.8246213080128655e-05
. O 0 2.9850118608010234e-06
. O 0 1.569778032717295e-05

Stable O 0 0.00046502574696205556
interaction O 0 1.5302479368983768e-05
between O 0 1.7468039459345164e-06
the O 0 5.051811626799463e-07
products O 0 7.59349291001854e-07
of O 0 2.435513692944369e-07
the O 0 1.0380456387792947e-06
BRCA1 O 0 0.0002784938842523843
and O 0 2.169756407965906e-05
BRCA2 O 0 0.05380959436297417
tumor B-Disease 0 0.0008180832373909652
suppressor O 0 0.0002071336202789098
genes O 0 1.0959183782688342e-05
in O 0 2.4728324206080288e-06
mitotic O 0 0.0004225781885907054
and O 0 2.276992381666787e-05
meiotic O 1 0.8369136452674866
cells O 0 0.0006710555171594024
. O 0 2.4569049855927005e-05

BRCA1 O 0 0.3240351378917694
and O 0 0.0001214961230289191
BRCA2 O 0 0.00825497042387724
account O 0 8.03744751465274e-06
for O 0 7.534306973866478e-07
most O 0 4.7075221232262265e-07
cases O 0 6.51714231025835e-07
of O 0 4.299061231449741e-07
familial O 0 0.0028300040867179632
, O 0 6.165234481159132e-06
early O 0 3.331037441967055e-05
onset O 1 0.9717905521392822
breast B-Disease 1 0.9543383121490479
and I-Disease 0 8.929422619985417e-05
/ I-Disease 1 0.9992111921310425
or I-Disease 1 0.9434900879859924
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
and O 0 1.4051665857550688e-06
encode O 0 3.3771548260119744e-06
products O 0 5.836265586367517e-07
that O 0 9.828416835944154e-08
each O 0 2.371730403183392e-07
interact O 0 1.46375577969593e-06
with O 0 2.3135710307542467e-06
hRAD51 O 0 0.00048807295388542116
. O 0 2.65889975707978e-05

Results O 0 0.00018915405962616205
presented O 0 2.1679319615941495e-05
here O 0 2.3567483822262147e-06
show O 0 2.508699708414497e-06
that O 0 5.89358478464419e-07
BRCA1 O 0 0.00011384869867470115
and O 0 9.97813549474813e-06
BRCA2 O 0 0.0341530479490757
coexist O 0 1.5828625691938214e-05
in O 0 5.249016794550698e-07
a O 0 1.6732657286411268e-06
biochemical O 0 2.7864727599080652e-05
complex O 0 2.1728540104959393e-06
and O 0 6.233883595996303e-07
colocalize O 0 9.012624650495127e-05
in O 0 1.2695978739429847e-06
subnuclear O 0 0.00013937801122665405
foci O 0 8.351148426299915e-05
in O 0 1.1517599887156393e-06
somatic O 0 7.389801612589508e-05
cells O 0 4.6707637011422776e-06
and O 0 1.207450281981437e-07
on O 0 1.5437959177688754e-07
the O 0 2.0391965449562122e-07
axial O 0 6.154507445899071e-06
elements O 0 1.0830666496985941e-06
of O 0 1.0162976877836627e-06
developing O 0 1.3924899576522876e-05
synaptonemal O 0 0.0008118721307255328
complexes O 0 7.534507312811911e-05
. O 0 1.6455593140562996e-05

Like O 0 0.0002776267356239259
BRCA1 O 0 0.0034333965741097927
and O 0 2.938444413302932e-05
RAD51 O 0 0.013028421439230442
, O 0 2.239398963865824e-05
BRCA2 O 0 0.0005645154160447419
relocates O 0 9.671478619566187e-05
to O 0 3.715581442520488e-06
PCNA O 0 0.0004606115981005132
+ O 0 2.3643016902497038e-05
replication O 0 6.199069957801839e-06
sites O 0 9.39398546506709e-07
following O 0 1.5075032706590719e-06
exposure O 0 6.144467079138849e-06
of O 0 9.426274232282594e-07
S O 0 0.0009845138993114233
phase O 0 4.6563738578697667e-05
cells O 0 1.2106298527214676e-05
to O 0 1.8786563487083185e-06
hydroxyurea O 0 0.0009122671908698976
or O 0 1.882808282971382e-05
UV O 0 0.0008119362755678594
irradiation O 0 0.00015537832223344594
. O 0 2.4778513761702925e-05

Thus O 0 0.00018850693595595658
, O 0 2.129200947820209e-05
BRCA1 O 0 0.0005855025956407189
and O 0 1.1583921150304377e-05
BRCA2 O 0 0.0013200155226513743
participate O 0 1.511799382569734e-06
, O 0 3.1654764143240754e-07
together O 0 3.7952906950522447e-07
, O 0 1.7621744063944789e-07
in O 0 2.270265326842491e-07
a O 0 2.6339055239077425e-06
pathway O 0 1.334418175247265e-05
( O 0 1.9070475900662132e-06
s O 0 4.923898814013228e-05
) O 0 3.0752738666706136e-07
associated O 0 1.5185780455340137e-07
with O 0 3.98180972638329e-08
the O 0 8.351219094038242e-08
activation O 0 9.147383934760001e-07
of O 0 9.601584594065571e-08
double O 0 7.869747605582234e-06
- O 0 9.26729990169406e-05
strand O 0 5.400469672167674e-05
break O 0 1.5154634638747666e-05
repair O 0 0.00013119183131493628
and O 0 1.6047137023633695e-06
/ O 0 6.514808046631515e-05
or O 0 4.945971340930555e-06
homologous O 0 7.521319639636204e-05
recombination O 0 0.00018416311650071293
. O 0 3.7513073039008304e-05

Dysfunction O 1 0.9605428576469421
of O 0 1.8883431039284915e-05
this O 0 3.7863358102185884e-06
pathway O 0 5.655221684719436e-05
may O 0 3.251730049669277e-06
be O 0 1.0641434045055576e-07
a O 0 3.974359685798845e-07
general O 0 4.6281340360110335e-07
phenomenon O 0 9.73290070760413e-07
in O 0 8.120242256381971e-08
the O 0 1.3513752605831542e-07
majority O 0 4.269321323135955e-07
of O 0 8.966952691480401e-08
cases O 0 8.746160347072873e-07
of O 0 7.741047056697425e-07
hereditary B-Disease 1 0.7960940003395081
breast I-Disease 1 0.9749976992607117
and I-Disease 0 0.00022041669581085443
/ I-Disease 1 0.9986357092857361
or I-Disease 1 0.9762584567070007
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 1.3781609595753253e-05
. O 0 2.240232061012648e-05

A O 0 0.0003802474238909781
novel O 0 0.00025454320712015033
Arg362Ser O 0 0.045658137649297714
mutation O 0 0.00011625663319136947
in O 0 1.6662560256008874e-06
the O 0 1.7044935702870134e-06
sterol O 0 0.00010715279495343566
27 O 0 3.1521743949269876e-05
- O 0 7.458637264790013e-05
hydroxylase O 0 0.0007946088444441557
gene O 0 9.524186680209823e-06
( O 0 2.359456175327068e-06
CYP27 O 0 0.0001197105084429495
) O 0 5.899174198020773e-07
: O 0 1.9368137316178036e-07
its O 0 2.3715878683105984e-07
effects O 0 1.6704116205801256e-06
on O 0 5.154595328349387e-07
pre O 0 8.907543815439567e-06
- O 0 7.271885351656238e-06
mRNA O 0 4.730469754576916e-06
splicing O 0 1.1160248504893389e-05
and O 0 2.0494019281613873e-06
enzyme O 0 1.522978436696576e-05
activity O 0 1.2381751730572432e-05
. O 0 9.790715921553783e-06

A O 0 0.00022749493655283004
novel O 0 7.926378020783886e-05
C O 0 7.635245856363326e-05
to O 0 1.1563130328795523e-06
A O 0 6.552599188580643e-06
mutation O 0 6.740679509675829e-06
in O 0 3.0652481086690386e-07
the O 0 6.411901267711073e-07
sterol O 0 5.469145253300667e-05
27 O 0 1.852441710070707e-05
- O 0 5.9688481997000054e-05
hydroxylase O 0 0.0005029339226894081
gene O 0 4.9505997594678774e-06
( O 0 1.958591838047141e-06
CYP27 O 0 0.00013396715803537518
) O 0 5.522683181879984e-07
was O 0 4.6843194922985276e-07
identified O 0 7.007733415775874e-07
by O 0 1.7282013686781283e-07
sequencing O 0 3.014026333403308e-06
amplified O 0 6.7275150286150165e-06
CYP27 O 0 8.953978976933286e-05
gene O 0 2.6538393740338506e-06
products O 0 8.878835160430754e-07
from O 0 4.2314016468480986e-07
a O 0 4.142839316045865e-06
patient O 0 0.00010777275019790977
with O 0 2.3285554561880417e-05
cerebrotendinous B-Disease 1 0.9999982118606567
xanthomatosis I-Disease 1 0.9999923706054688
( O 0 0.00011523691500769928
CTX B-Disease 0 0.06921347230672836
) O 0 3.50574373442214e-05
. O 0 2.998059062520042e-05

The O 0 9.453669190406799e-05
mutation O 0 0.000171221952768974
changed O 0 1.0321965419279877e-05
the O 0 2.0008567389595555e-06
adrenodoxin O 0 6.288517761277035e-05
cofactor O 0 1.8964748960570432e-05
binding O 0 3.913036380254198e-06
residue O 0 5.4828128668305e-06
362Arg O 0 2.038774618995376e-05
to O 0 6.524996933876537e-07
362Ser O 0 4.532104867394082e-05
( O 0 2.0970535388187272e-06
CGT O 0 6.456880510086194e-05
362Arg O 0 1.9666624211822636e-05
to O 0 5.798169127047004e-07
AGT O 0 0.00015167839592322707
362Ser O 0 4.720591095974669e-05
) O 0 5.808220180369972e-07
, O 0 9.63728865599478e-08
and O 0 1.511593410441492e-07
was O 0 1.653273329793592e-06
responsible O 0 3.756225623874343e-06
for O 0 7.980963346199133e-06
deficiency O 0 0.10232897102832794
in O 0 2.871105380108929e-07
the O 0 5.072212729828607e-07
sterol O 0 9.484712791163474e-05
27 O 0 1.600914401933551e-05
- O 0 3.4512097045080736e-05
hydroxylase O 0 0.00016911652346607298
activity O 0 1.034207912198326e-06
, O 0 1.0544473383333752e-07
as O 0 1.0081893009328269e-07
confirmed O 0 3.564366863884061e-07
by O 0 8.374954774126309e-08
expression O 0 3.6737401387654245e-07
of O 0 1.5687265886299429e-07
mutant O 0 4.6084210225671995e-06
cDNA O 0 7.88253964856267e-06
into O 0 2.019001385633601e-06
COS O 0 0.0005454201018437743
- O 0 7.110303704394028e-05
1 O 0 1.8866907339543104e-05
cells O 0 4.974085095454939e-05
. O 0 1.5383391655632295e-05

Quantitative O 0 0.0007277576369233429
analysis O 0 7.257046672748402e-05
showed O 0 2.6880692530539818e-05
that O 0 4.2211559048155323e-07
the O 0 3.0598971534345765e-07
expression O 0 1.0662791964932694e-06
of O 0 3.0339143108903954e-07
CYP27 O 0 7.19018789823167e-05
gene O 0 2.2180772702995455e-06
mRNA O 0 1.4709793276779237e-06
in O 0 3.83573876661103e-07
the O 0 1.3460954733091057e-06
patient O 0 2.9056353014311753e-05
represented O 0 7.271628874150338e-06
52 O 0 6.299280357779935e-05
. O 0 1.5080674529599492e-05

5 O 0 0.00039468982140533626
% O 0 3.0031409551156685e-05
of O 0 1.5423449895024532e-06
the O 0 2.1458647552208276e-06
normal O 0 1.4435477169172373e-05
level O 0 9.498352483205963e-06
. O 0 1.6509651686646976e-05

As O 0 2.7339841835782863e-05
the O 0 9.2034533736296e-06
mutation O 0 5.3630716138286516e-05
occurred O 0 6.086990197218256e-06
at O 0 7.338741738749377e-07
the O 0 5.431578529169201e-07
penultimate O 0 3.0906776373740286e-05
nucleotide O 0 6.104452950239647e-06
of O 0 3.937688575206266e-07
exon O 0 1.8501976228435524e-05
6 O 0 6.32813862466719e-06
( O 0 6.440263859985862e-07
- O 0 2.8814652068831492e-06
2 O 0 8.843317687023955e-07
position O 0 3.8455146977867116e-07
of O 0 1.564877294413236e-07
exon O 0 1.0723075320129283e-05
6 O 0 4.929348961013602e-06
- O 0 1.259563669009367e-05
intron O 0 8.448123116977513e-05
6 O 0 3.2834275316417916e-06
splice O 0 1.4493590242636856e-05
site O 0 1.08901269868511e-06
) O 0 1.32248501927279e-07
of O 0 4.417333698825132e-08
the O 0 1.4794866842748888e-07
gene O 0 9.788043371372623e-07
, O 0 1.857072646771485e-07
we O 0 8.964438080738546e-08
hypothesized O 0 1.359658085675619e-06
that O 0 9.243375131973153e-08
the O 0 5.37866071681492e-07
mutation O 0 3.871201624860987e-05
may O 0 3.873472905979725e-06
partially O 0 6.119433237472549e-06
affect O 0 4.838582299271366e-07
the O 0 1.5680025455822033e-07
normal O 0 1.4439181086345343e-06
splicing O 0 3.150014435959747e-06
efficiency O 0 1.528721895738272e-06
in O 0 3.0058947686484316e-07
exon O 0 1.3527202099794522e-05
6 O 0 3.610646672314033e-06
and O 0 5.397492941483506e-07
cause O 0 1.3867974075765233e-06
alternative O 0 9.495984159002546e-07
splicing O 0 6.2004710343899205e-06
elsewhere O 0 1.4106769867794355e-06
, O 0 1.7228532556146092e-07
which O 0 1.487499901031697e-07
resulted O 0 1.3243254670669558e-06
in O 0 6.861700398985704e-07
decreased O 0 2.4141600079019554e-05
transcript O 0 2.1787760488223284e-05
in O 0 1.5132389989958028e-06
the O 0 5.6014114306890406e-06
patient O 0 0.00034834793768823147
. O 0 2.6794181394507177e-05

Transfection O 0 0.02384304068982601
of O 0 3.4941222111228853e-05
constructed O 0 6.241600931389257e-05
minigenes O 0 0.00040296203223988414
, O 0 1.1458645303719095e-06
with O 0 4.379348297334218e-07
or O 0 1.0187643511017086e-06
without O 0 4.139653810852906e-07
the O 0 3.455968169419066e-07
mutation O 0 3.4426302590873092e-06
, O 0 1.9698502740084223e-07
into O 0 5.390810997596418e-07
COS O 0 0.001400114968419075
- O 0 4.431245179148391e-05
1 O 0 3.5604093682195526e-06
cells O 0 2.8989788916078396e-06
confirmed O 0 2.6103194272764085e-07
that O 0 3.0589983879281135e-08
the O 0 1.749583731225357e-07
mutant O 0 2.824705734383315e-05
minigene O 0 0.0001308352657360956
was O 0 1.0289935516993864e-06
responsible O 0 3.1169292924460024e-07
for O 0 9.888098162491588e-08
a O 0 6.730774089191982e-07
mRNA O 0 2.2838601125840796e-06
species O 0 2.476681402185932e-07
alternatively O 0 1.1686319112413912e-06
spliced O 0 1.0589872545097023e-05
at O 0 4.106593110009271e-07
an O 0 5.938630351920438e-07
activated O 0 5.485358269652352e-05
cryptic O 0 1.9052324205404148e-05
5 O 0 1.5615544270985993e-06
splice O 0 1.3378790754359215e-05
site O 0 1.99742703443917e-06
88 O 0 4.458405328477966e-06
bp O 0 8.067019734880887e-06
upstream O 0 1.0424712399981217e-06
from O 0 1.210468809631493e-07
the O 0 1.330521683939878e-07
3 O 0 7.632597771589644e-07
end O 0 9.03989018752327e-07
of O 0 5.062479999651259e-07
exon O 0 7.063010707497597e-05
6 O 0 5.840360245201737e-05
. O 0 2.1050116629339755e-05

Our O 0 4.076468394487165e-05
data O 0 9.345409125671722e-06
suggest O 0 2.6362904463894665e-06
that O 0 2.2884400152634043e-07
the O 0 2.382598580652484e-07
C O 0 5.980385594739346e-06
to O 0 1.769589346167777e-07
A O 0 2.3780521587468684e-06
mutation O 0 2.686658717721002e-06
at O 0 1.1393924381764009e-07
the O 0 1.4125359371064405e-07
penultimate O 0 1.1693582564475946e-05
nucleotide O 0 2.0928998765157303e-06
of O 0 1.1046635250977488e-07
exon O 0 4.845665444008773e-06
6 O 0 7.643217827535409e-07
of O 0 7.217982300744552e-08
the O 0 2.3076270849742286e-07
CYP27 O 0 0.0003018199058715254
gene O 0 1.258904717360565e-06
not O 0 1.2184092668121593e-07
only O 0 1.3608772064799268e-07
causes O 0 4.52493213742855e-06
the O 0 4.410735073179239e-06
deficiency B-Disease 0 0.003955108113586903
in I-Disease 0 1.9015433849745023e-07
the I-Disease 0 5.190694309931132e-07
sterol I-Disease 0 6.57832933939062e-05
27 I-Disease 0 1.198877453134628e-05
- I-Disease 0 3.572271816665307e-05
hydroxylase I-Disease 0 0.0001177080994239077
activity I-Disease 0 1.1519499594214722e-06
, O 0 2.3592170350639208e-07
but O 0 1.6423533111264987e-07
also O 0 3.6798695646211854e-07
partially O 0 5.569631866819691e-06
leads O 0 1.4440421409744886e-06
to O 0 2.165533885545301e-07
alternative O 0 1.5282305412256392e-06
pre O 0 7.30447663954692e-06
- O 0 4.283691851014737e-06
mRNA O 0 1.989550582948141e-06
splicing O 0 2.8829797429352766e-06
of O 0 3.125016121430235e-07
the O 0 2.097243623211398e-06
gene O 0 3.996085797552951e-05
. O 0 1.7764419681043364e-05

To O 0 2.0407098418218084e-05
our O 0 3.7676559259125497e-06
knowledge O 0 1.5919036968625733e-06
, O 0 4.286125090402493e-07
this O 0 9.395224509489708e-08
is O 0 9.917336996068116e-08
the O 0 8.954339136835188e-08
first O 0 3.323508792618668e-07
report O 0 5.885361815671786e-07
regarding O 0 3.261844483404275e-07
effects O 0 2.1893802113481797e-06
on O 0 4.7635577971050225e-07
pre O 0 1.5032000192150008e-05
- O 0 9.075540219782852e-06
mRNA O 0 1.463972239434952e-06
splicing O 0 1.767500862115412e-06
of O 0 1.249304233397197e-07
a O 0 7.502979997298098e-07
mutation O 0 1.9932044779125135e-06
at O 0 1.243491567493038e-07
the O 0 2.2121930953744595e-07
- O 0 7.649885446880944e-06
2 O 0 1.305439809584641e-06
position O 0 4.607603329986887e-07
of O 0 1.5301556288704887e-07
a O 0 1.480867354075599e-06
5 O 0 6.930108611413743e-06
splice O 0 0.00010433592979097739
site O 0 2.016329744947143e-05
. O 0 1.3555908481066581e-05

ATM O 0 0.18521706759929657
germline O 1 0.9510842561721802
mutations O 0 0.0023193308152258396
in O 0 3.5978278901893646e-05
classical O 0 0.0008562759030610323
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
patients O 1 0.8775194883346558
in O 0 4.272398655302823e-06
the O 0 4.065473603986902e-06
Dutch O 0 7.837433076929301e-05
population O 0 1.9267141396994703e-05
. O 0 1.7374952221871354e-05

Germline O 1 0.9952986836433411
mutations O 0 0.0027002603746950626
in O 0 6.1376276789815165e-06
the O 0 1.9602643988037016e-06
ATM O 0 6.711937749059871e-05
gene O 0 8.935603545978665e-06
are O 0 3.5019724009544007e-07
responsible O 0 2.5070999072340783e-06
for O 0 5.383287316362839e-06
the O 0 0.20870357751846313
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.006489320658147335
A B-Disease 1 0.997696578502655
- I-Disease 1 0.9999674558639526
T I-Disease 1 0.999997615814209
) O 0 3.338879832881503e-05
. O 0 2.331626274099108e-05

In O 0 3.60093436029274e-05
our O 0 8.93524702405557e-06
study O 0 3.161402219120646e-06
, O 0 4.947188472215203e-07
we O 0 1.2596395038144692e-07
have O 0 1.2921428549361735e-07
determined O 0 4.2216711904075055e-07
the O 0 2.6302456035409705e-07
ATM O 0 3.238308272557333e-05
mutation O 0 4.099184479855467e-06
spectrum O 0 2.11453516385518e-06
in O 0 1.9584091148772131e-07
19 O 0 1.8515071360525326e-06
classical O 0 2.337346813874319e-06
A B-Disease 1 0.987764298915863
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
patients O 0 0.00026322825578972697
, O 0 9.682891288775863e-08
including O 0 7.082073949504775e-08
some O 0 5.918040102415034e-08
immigrant O 0 2.920408769568894e-05
populations O 0 1.2603571803992963e-06
, O 0 6.476454927906161e-08
as O 0 4.417763221908899e-08
well O 0 6.43198987404503e-08
as O 0 8.208662194419958e-08
12 O 0 2.8679141905740835e-07
of O 0 1.5996241131688294e-07
Dutch O 0 9.045555998454802e-06
ethnic O 0 4.976601758244215e-06
origin O 0 7.199967967608245e-06
. O 0 1.1208247087779455e-05

Both O 0 2.3194399545900524e-05
the O 0 6.863755515951198e-06
protein O 0 1.1912780792044941e-05
truncation O 0 6.334187492029741e-05
test O 0 5.585647613770561e-06
( O 0 1.5763433793836157e-06
PTT O 0 3.605739948397968e-06
) O 0 2.5430324512853986e-07
and O 0 8.938759776810912e-08
the O 0 2.113824422167454e-07
restriction O 0 1.727352469060861e-06
endonuclease O 0 2.6216204787488095e-05
fingerprinting O 0 1.7221716916537844e-05
( O 0 1.9933756902901223e-06
REF O 0 8.578449342167005e-05
) O 0 3.2842561381585256e-07
method O 0 4.2212525386275956e-07
were O 0 7.913806143733382e-08
used O 0 9.206741680145569e-08
and O 0 8.666950179758715e-08
compared O 0 4.74889787938082e-07
for O 0 6.154338905162149e-08
their O 0 1.2962728135335055e-07
detection O 0 4.659387741412502e-06
efficiency O 0 3.6973244732507737e-06
, O 0 3.151776581944432e-07
identifying O 0 1.929361587826861e-06
76 O 0 1.0986998859152663e-05
% O 0 7.753880026939441e-07
and O 0 1.0717513276858881e-07
60 O 0 7.288453502951597e-07
% O 0 3.0581063015233667e-07
of O 0 5.186814888702429e-08
the O 0 5.039214556745719e-07
mutations O 0 1.653255822020583e-05
, O 0 1.2369090427455376e-06
respectively O 0 1.0785267477331217e-05
. O 0 1.0002773706219159e-05

Most O 0 0.0002309592382516712
patients O 0 0.0012480203295126557
were O 0 3.0996702662378084e-06
found O 0 1.5341050811912282e-06
to O 0 7.112612934179197e-07
be O 0 1.3088080095258192e-06
compound O 0 0.00015416627866216004
heterozygote O 0 0.0017916832584887743
. O 0 3.4331882488913834e-05

Seventeen O 0 0.0018175131408497691
mutations O 0 0.0013388493098318577
were O 0 3.675864263641415e-06
distinct O 0 2.461036274326034e-06
, O 0 2.4512846152902057e-07
of O 0 1.439439927253261e-07
which O 0 3.344825358908565e-07
10 O 0 7.678710289837909e-07
were O 0 4.462564220375498e-07
not O 0 8.578392112212896e-07
reported O 0 1.0620599823596422e-05
previously O 0 1.6795498595456593e-05
. O 0 1.0302995178790297e-05

Mutations O 0 0.00480251107364893
are O 0 5.315787348081358e-06
small O 0 6.430789653677493e-06
deletions O 0 4.1462004446657375e-05
or O 0 4.179806182946777e-06
point O 0 1.4046967407921329e-05
mutations O 0 6.265388947213069e-05
frequently O 0 7.566042313555954e-06
affecting O 0 1.8121399989468046e-05
splice O 0 0.0002085875312332064
sites O 0 3.5563305573305115e-05
. O 0 2.3624152163392864e-05

Moreover O 0 0.0005841898382641375
, O 0 2.5190996893798e-05
a O 0 2.9309161618584767e-05
16 O 0 6.641627260250971e-05
. O 0 3.755574289243668e-05

7 O 0 0.0009055986884050071
- O 0 0.0006693426985293627
kb O 0 0.0017415274633094668
genomic O 0 0.00010220761032542214
deletion O 0 5.7239154557464644e-05
of O 0 5.17641808528424e-07
the O 0 3.1428982083525625e-07
3 O 0 1.07200446564093e-06
end O 0 4.5703342266278923e-07
of O 0 7.554331205028575e-08
the O 0 2.0019130886339553e-07
gene O 0 8.799193551567441e-07
, O 0 1.6209359898766706e-07
most O 0 8.320977684661557e-08
likely O 0 3.9175557731141453e-07
a O 0 3.1547597245662473e-07
result O 0 2.2526795362409757e-07
of O 0 7.352164743679168e-08
recombination O 0 2.135428758265334e-06
between O 0 1.705843430954701e-07
two O 0 2.713816513733036e-07
LINE O 0 8.73552471603034e-06
elements O 0 1.5043839312056662e-06
, O 0 7.434615554302582e-07
was O 0 3.5938203382102074e-06
identified O 0 1.934720239660237e-05
. O 0 1.8292532331543043e-05

The O 0 2.5688737878226675e-05
most O 0 5.919551767874509e-06
frequently O 0 1.281706863665022e-05
found O 0 5.188068826100789e-06
mutation O 0 2.0799963749595918e-05
, O 0 3.6121926427767903e-07
identified O 0 1.0504732017579954e-06
in O 0 1.9299748998946598e-07
three O 0 8.779185236562626e-07
unrelated O 0 3.4933626011479646e-05
Turkish O 0 3.389712219359353e-05
A B-Disease 1 0.9090844988822937
- I-Disease 1 0.9997016787528992
T I-Disease 1 0.9999983310699463
individuals O 0 1.1720226211764384e-06
, O 0 2.106688157255121e-07
was O 0 6.216915267032164e-07
previously O 0 9.34825493459357e-07
described O 0 5.571127985604107e-07
to O 0 8.10347060564709e-08
be O 0 5.750256093506323e-08
a O 0 7.439197133862763e-07
Turkish O 0 1.1048674423363991e-05
A B-Disease 0 0.21305304765701294
- I-Disease 1 0.9960712194442749
T I-Disease 1 0.999987006187439
founder O 0 0.0004393559938762337
mutation O 0 0.0001254453818546608
. O 0 2.6966523364535533e-05

The O 0 2.5004566850839183e-05
presence O 0 1.1745171832444612e-05
of O 0 8.411950034314941e-07
a O 0 3.836375526589109e-06
founder O 0 5.415363557403907e-05
mutation O 0 1.053216419677483e-05
among O 0 2.3379034530535137e-07
relatively O 0 4.742426256143517e-07
small O 0 1.7847138167326193e-07
ethnic O 0 9.323671861238836e-07
population O 0 3.8121152101666667e-07
groups O 0 1.1182564207956602e-07
in O 0 5.9367732063719814e-08
Western O 0 2.662996791968908e-07
Europe O 0 4.426518671607482e-07
could O 0 2.0761545727054909e-07
indicate O 0 3.556822036898666e-07
a O 0 4.1199854194928776e-07
high O 0 2.11000292438257e-06
carrier O 0 1.7470507373218425e-05
frequency O 0 2.1698183445550967e-06
in O 0 4.197559633212222e-07
such O 0 1.0160244983126177e-06
communities O 0 2.0817979020648636e-05
. O 0 1.9620671082520857e-05

In O 0 0.00025543058291077614
patients O 0 0.0004563720431178808
of O 0 1.8391690446151188e-06
Dutch O 0 2.6036863346234895e-05
ethnic O 0 3.815406216745032e-06
origin O 0 2.2722824724041857e-06
, O 0 4.705946423655405e-07
however O 0 2.555499349909951e-07
, O 0 1.5111379525478696e-07
no O 0 2.076691316688084e-07
significant O 0 5.772034796791559e-07
founder O 0 5.024270649300888e-06
effect O 0 1.3085383443467435e-06
could O 0 6.170436677166435e-07
be O 0 8.146783443407912e-07
identified O 0 1.6469535694341175e-05
. O 0 1.3933747140981723e-05

The O 0 6.507705256808549e-05
observed O 0 7.379084854619578e-05
genetic O 0 4.227328099659644e-05
heterogeneity O 0 5.372403029468842e-05
including O 0 1.1893287137354491e-06
the O 0 5.625687435895088e-07
relative O 0 4.322760105424095e-06
high O 0 2.981293391712825e-06
percentage O 0 2.6818720471055713e-06
of O 0 1.7593433199181163e-07
splice O 0 5.5812812206568196e-05
- O 0 0.00016735310782678425
site O 0 4.182697011856362e-06
mutations O 0 6.344690063997405e-06
had O 0 5.646252247970551e-07
no O 0 2.7080508857579844e-07
reflection O 0 1.1670349522319157e-06
on O 0 1.0777037005027523e-06
the O 0 5.8670202633948065e-06
phenotype O 0 0.026609476655721664
. O 0 2.662091537786182e-05

All O 0 7.868511602282524e-05
patients O 0 0.0034289176110178232
manifested O 0 0.0001307058410020545
classical O 0 2.491404848115053e-05
A B-Disease 0 0.3589332699775696
- I-Disease 1 0.9123926162719727
T I-Disease 1 0.9983898401260376
and O 0 1.5569846709695412e-06
increased O 0 7.974634172569495e-06
cellular O 0 3.882573582814075e-05
radioresistant O 0 0.0002643469488248229
DNA O 0 5.882337791263126e-05
synthesis O 0 6.192918226588517e-05
. O 0 2.4339018636965193e-05

Determination O 0 0.00014083647693041712
of O 0 3.739170324479346e-06
the O 0 2.475156406944734e-06
genomic O 0 2.8001650207443163e-05
structure O 0 1.3886821079722722e-06
of O 0 2.3455991993159842e-07
the O 0 8.107704161375295e-07
COL4A4 O 0 0.0003057937719859183
gene O 0 2.79109985967807e-06
and O 0 5.12440237798728e-07
of O 0 1.4625725270889234e-06
novel O 0 0.0002713095163926482
mutations O 0 0.10096176713705063
causing O 0 0.03271688520908356
autosomal B-Disease 1 0.9999949932098389
recessive I-Disease 1 0.9999998807907104
Alport I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
. O 0 0.00021946507331449538

Autosomal B-Disease 1 0.9999998807907104
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 6.897986168041825e-05
a O 0 0.00016801583115011454
progressive O 0 0.189534530043602
hematuric B-Disease 1 0.9878237247467041
glomerulonephritis I-Disease 1 0.9999991655349731
characterized O 0 0.002216123044490814
by O 0 6.964952717680717e-06
glomerular B-Disease 1 0.8092933297157288
basement I-Disease 0 0.15152645111083984
membrane I-Disease 0 0.0007538601639680564
abnormalities I-Disease 1 0.9447296857833862
and O 0 2.555163291617646e-06
associated O 0 3.930105776817072e-06
with O 0 1.738350192681537e-06
mutations O 0 2.711231900320854e-05
in O 0 2.448854274916812e-07
either O 0 2.9099427933942934e-07
the O 0 4.690510877480847e-07
COL4A3 O 0 0.00030991414678283036
or O 0 6.76714535075007e-07
the O 0 4.3337462329873233e-07
COL4A4 O 0 0.0002607596106827259
gene O 0 1.7610180975680123e-06
, O 0 1.6864167662333784e-07
which O 0 1.200941284196233e-07
encode O 0 5.440879817797395e-07
the O 0 2.5611134901737387e-07
alpha3 O 0 6.967654189793393e-05
and O 0 1.8620786477185902e-06
alpha4 O 0 0.0003879799332935363
type O 0 1.4795411516388413e-05
IV O 0 0.0005885459249839187
collagen O 0 5.911409971304238e-05
chains O 0 3.290284439572133e-05
, O 0 3.3149410683108727e-06
respectively O 0 1.3952869267086498e-05
. O 0 1.2608532415470108e-05

To O 0 2.3289154341910034e-05
date O 0 1.7153039152617566e-05
, O 0 2.8729095902235713e-06
mutation O 0 8.038834494072944e-06
screening O 0 2.197225967393024e-06
in O 0 1.8997054951341852e-07
the O 0 1.5687983534462546e-07
two O 0 3.484190074232174e-07
genes O 0 1.3599004660136416e-06
has O 0 3.313030845220055e-07
been O 0 2.700123502563656e-07
hampered O 0 3.515774369589053e-05
by O 0 2.0768852948549466e-07
the O 0 2.461023882460722e-07
lack O 0 1.0437654509587446e-06
of O 0 4.2332581529080926e-07
genomic O 0 5.208014044910669e-05
structure O 0 8.936907761381008e-06
information O 0 3.893627763318364e-06
. O 0 1.3127559213899076e-05

We O 0 4.303883179090917e-05
report O 0 7.774110599712003e-06
here O 0 6.433651833503973e-07
the O 0 3.3077111538659665e-07
complete O 0 1.4767759921596735e-06
characterization O 0 2.242385562567506e-06
of O 0 1.321070612902986e-07
the O 0 3.3407704336241295e-07
48 O 0 2.7693267838913016e-06
exons O 0 3.268110958742909e-06
of O 0 1.0921083060111414e-07
the O 0 4.0157354419534386e-07
COL4A4 O 0 0.0004914486780762672
gene O 0 1.3812907582178013e-06
, O 0 1.1653683174017715e-07
a O 0 3.5795187613985036e-07
comprehensive O 0 2.242879645564244e-06
gene O 0 1.0583274843156687e-06
screen O 0 1.1074150734202703e-06
, O 0 7.932303702773424e-08
and O 0 6.24479596922356e-08
the O 0 1.065733883365283e-07
subsequent O 0 7.345365702349227e-07
detection O 0 1.7996566157307825e-06
of O 0 1.4406677451006544e-07
10 O 0 1.0278813533659559e-06
novel O 0 3.8035193483665353e-06
mutations O 0 6.831516202510102e-06
in O 0 1.256291511708696e-06
eight O 0 0.00021083962928969413
patients O 1 0.9675545692443848
diagnosed O 1 0.999996542930603
with O 0 0.4418375492095947
autosomal B-Disease 1 0.9999998807907104
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
. O 0 0.0002896114019677043

Furthermore O 0 0.00036590464878827333
, O 0 7.628372259205207e-06
we O 0 8.739089594200777e-07
identified O 0 1.4113794577497174e-06
a O 0 7.12089331500465e-07
glycine O 0 5.165246875549201e-06
to O 0 3.2067450206341164e-07
alanine O 0 6.641254458372714e-06
substitution O 0 1.2103457720513688e-06
in O 0 1.8610013796660496e-07
the O 0 2.626656225857005e-07
collagenous O 0 9.544338536215946e-05
domain O 0 7.809271096448356e-07
that O 0 9.230319619746297e-08
is O 0 1.548328327771742e-07
apparently O 0 1.944768200701219e-06
silent O 0 1.5767058130222722e-06
in O 0 2.1267334204821964e-07
the O 0 6.100904670347518e-07
heterozygous O 0 2.8946584279765375e-05
carriers O 0 4.018557319795946e-06
, O 0 6.648590442637214e-07
in O 0 1.840676304709632e-06
11 O 0 2.055123150057625e-05
. O 0 1.8877977709053084e-05

5 O 0 0.00024122819013427943
% O 0 1.327753943769494e-05
of O 0 3.2987017561936227e-07
all O 0 1.2258522019692464e-07
control O 0 3.304591245978372e-06
individuals O 0 2.611738807445363e-07
, O 0 6.534773433486407e-08
and O 0 7.378308453098725e-08
in O 0 1.1917352082946309e-07
one O 0 1.031652985261644e-07
control O 0 2.3468930976378033e-06
individual O 0 5.854394089510606e-07
homozygous O 0 7.856594493205193e-06
for O 0 1.8354650421770202e-07
this O 0 4.6831314648443367e-07
glycine O 0 3.0750750738661736e-05
substitution O 0 3.853371163131669e-05
. O 0 2.329117342014797e-05

There O 0 2.540115747251548e-05
has O 0 4.411323970998637e-06
been O 0 8.10019230357284e-07
no O 0 2.8820895181524975e-07
previous O 0 5.515967131941579e-07
finding O 0 3.205974508091458e-07
of O 0 7.920390032722935e-08
a O 0 4.5073971932652057e-07
glycine O 0 4.4999810597801115e-06
substitution O 0 1.0532588703426882e-06
that O 0 7.152924297315622e-08
is O 0 9.296097402966552e-08
not O 0 6.911331240644358e-08
associated O 0 2.1308932218744303e-07
with O 0 1.4682839832858008e-07
any O 0 6.950917850190308e-07
obvious O 0 1.897140646178741e-05
phenotype O 0 0.07334838807582855
in O 0 1.1264870408922434e-05
homozygous O 0 0.007883066311478615
individuals O 0 9.677860361989588e-06
. O 0 1.4727852430951316e-05

Founder O 0 0.006618162617087364
BRCA1 O 0 0.01946999691426754
and O 0 0.00018378946697339416
BRCA2 O 0 0.18101023137569427
mutations O 0 0.0001601470576133579
in O 0 3.4995696296391543e-06
French O 0 0.00014346996613312513
Canadian O 0 0.001153314602561295
breast B-Disease 1 0.9999184608459473
and I-Disease 1 0.9836400151252747
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 0.0005163945606909692
. O 0 4.691890353569761e-05

We O 0 3.207509143976495e-05
have O 0 4.076814093423309e-06
identified O 0 7.308831754926359e-06
four O 0 2.8145684609626187e-06
mutations O 0 7.854159775888547e-06
in O 0 2.114054353796746e-07
each O 0 1.736496528792486e-07
of O 0 3.899830858244968e-07
the O 0 2.7149522793479264e-05
breast B-Disease 1 0.9999790191650391
cancer I-Disease 1 0.9953538179397583
- O 0 0.1820271909236908
susceptibility O 0 0.0030553187243640423
genes O 0 8.646434253023472e-06
, O 0 1.468865434617328e-06
BRCA1 O 0 0.0001287289196625352
and O 0 2.647827841428807e-06
BRCA2 O 0 0.00023160911223385483
, O 0 5.379907292990538e-07
in O 0 7.17202283340157e-07
French O 0 5.401675298344344e-05
Canadian O 0 0.0004345219349488616
breast B-Disease 1 0.9994285702705383
cancer I-Disease 1 0.9920392036437988
and O 0 0.003853957634419203
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 9.668259735917673e-05
from O 0 7.992236533027608e-06
Quebec O 0 0.0002759297494776547
. O 0 2.8182212190586142e-05

To O 0 4.9273465265287086e-05
identify O 0 3.467109854682349e-05
founder O 0 5.718883767258376e-05
effects O 0 3.546721927705221e-05
, O 0 9.569823760102736e-07
we O 0 4.489259595175099e-07
examined O 0 3.1744657462695614e-06
independently O 0 1.4630579698859947e-06
ascertained O 0 5.933105057920329e-06
French O 0 3.2495470804860815e-05
Canadian O 0 0.00013190682511776686
cancer B-Disease 0 0.007638103328645229
families O 0 7.846589369364665e-07
for O 0 6.293115006883454e-08
the O 0 1.2327785725574358e-07
distribution O 0 5.86952694447973e-07
of O 0 1.5785924745159718e-07
these O 0 3.1365800623461837e-07
eight O 0 8.433232324023265e-06
mutations O 0 8.67156995809637e-05
. O 0 1.219700243382249e-05

Mutations O 0 0.005526491440832615
were O 0 1.1514071047713514e-05
found O 0 2.2171425371197984e-06
in O 0 9.332060812994314e-07
41 O 0 6.155211849545594e-06
of O 0 1.0026832342191483e-06
97 O 0 5.569202039623633e-05
families O 0 3.8839738408569247e-05
. O 0 2.0807379769394174e-05

Six O 0 6.028138523106463e-05
of O 0 4.933779109705938e-06
eight O 0 1.6886882804101333e-05
mutations O 0 4.114250259590335e-05
were O 0 1.0946354223051458e-06
observed O 0 2.4984021820273483e-06
at O 0 1.5453293826794834e-06
least O 0 3.0177279768395238e-06
twice O 0 1.7094120266847312e-05
. O 0 1.4211867892299779e-05

The O 0 0.00021425695740617812
BRCA1 O 0 0.01202714815735817
C4446T O 0 0.03363947570323944
mutation O 0 0.00035930974991060793
was O 0 2.747167854977306e-06
the O 0 5.230058377492242e-07
most O 0 3.67112420462945e-07
common O 0 3.30970988215995e-06
mutation O 0 1.0815620044013485e-05
found O 0 3.4074898280778143e-07
, O 0 1.8359797593348048e-07
followed O 0 1.0909253660429385e-06
by O 0 4.153177997068269e-07
the O 0 4.594825895765098e-06
BRCA2 O 0 0.008560175076127052
8765delAG O 0 0.003526739776134491
mutation O 0 0.00023323680215980858
. O 0 1.7205893527716398e-05

Together O 0 6.2249404436443e-05
, O 0 6.738301635778043e-06
these O 0 9.535751814837568e-07
mutations O 0 9.31753766053589e-06
were O 0 2.4918892904679524e-07
found O 0 2.1196788679844758e-07
in O 0 1.7801887963742047e-07
28 O 0 1.3087829984215205e-06
of O 0 1.1598323368389174e-07
41 O 0 9.3602229753742e-06
families O 0 1.3098418776280596e-06
identified O 0 8.5012595718581e-07
to O 0 1.3732351078488136e-07
have O 0 3.9500966408922977e-07
a O 0 1.0485581697139423e-05
mutation O 0 0.00010767352796392515
. O 0 1.229894860443892e-05

The O 0 4.8061468987725675e-05
odds O 0 7.770783122396097e-05
of O 0 2.1947464574623154e-06
detection O 0 1.2001541108475067e-05
of O 0 2.543924892961513e-07
any O 0 1.3479720450959576e-07
of O 0 1.4169964401844481e-07
the O 0 5.931362920819083e-07
four O 0 2.2527046894538216e-05
BRCA1 O 0 0.18382079899311066
mutations O 0 7.696548709645867e-05
was O 0 6.062010015739361e-06
18 O 0 2.3029977455735207e-05
. O 0 1.5862293366808444e-05

7x O 0 0.04083695635199547
greater O 0 0.0001175989382318221
if O 0 3.286854962425423e-06
one O 0 5.50926927189721e-07
or O 0 6.66119490233541e-07
more O 0 3.2769290214673674e-07
cases O 0 4.954902578901965e-06
of O 0 0.0006467075436376035
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 6.795738045184407e-06
also O 0 6.068200377740141e-07
present O 0 3.352432429437613e-07
in O 0 3.7045811041025445e-07
the O 0 1.3787296211376088e-06
family O 0 1.4339924746309407e-05
. O 0 1.3155657143215649e-05

The O 0 3.077019937336445e-05
odds O 0 6.0545473388629034e-05
of O 0 1.4690098169012344e-06
detection O 0 7.300472134375013e-06
of O 0 1.997014322796531e-07
any O 0 1.1556345924645939e-07
of O 0 1.5595183811001334e-07
the O 0 8.15118255559355e-07
four O 0 3.350247425260022e-05
BRCA2 O 1 0.6109962463378906
mutations O 0 7.230603659991175e-05
was O 0 4.907471975457156e-06
5 O 0 1.1836059456982184e-05
. O 0 1.1971513231401332e-05

3x O 0 0.002827561227604747
greater O 0 9.858949488261715e-05
if O 0 3.448840971032041e-06
there O 0 4.084782290192379e-07
were O 0 2.5118717417171865e-07
at O 0 3.457346053892252e-07
least O 0 3.0215386459531146e-07
five O 0 7.056265758365043e-07
cases O 0 1.9493659237923566e-06
of O 0 8.852769497025292e-06
breast B-Disease 1 0.9999936819076538
cancer I-Disease 1 0.9015740156173706
in O 0 1.9239487301092595e-06
the O 0 3.0904523100616643e-06
family O 0 3.656463377410546e-05
. O 0 1.8157954400521703e-05

Interestingly O 0 0.0005572497611865401
, O 0 7.602545792906312e-06
the O 0 9.416058901479119e-07
presence O 0 1.6143100083354511e-06
of O 0 7.713213108218042e-07
a O 0 0.00014829252904746681
breast B-Disease 1 0.9999829530715942
cancer I-Disease 1 0.8784638047218323
case O 0 1.2056008017680142e-05
< O 0 0.00014549237675964832
36 O 0 4.242057912051678e-06
years O 0 2.5375621248713287e-07
of O 0 6.83386147670717e-08
age O 0 4.428199247286102e-07
was O 0 2.580983959887817e-07
strongly O 0 3.9914752392178343e-07
predictive O 0 1.0253837672280497e-06
of O 0 4.502456718569192e-08
the O 0 4.7457465512934505e-08
presence O 0 1.2055954812240088e-07
of O 0 4.565751154927966e-08
any O 0 6.250468942425869e-08
of O 0 8.921131211536704e-08
the O 0 7.714824619142746e-07
eight O 0 1.5631216228939593e-05
mutations O 0 6.900407606735826e-05
screened O 0 6.078382284613326e-05
. O 0 1.7996215319726616e-05

Carriers O 0 0.0002488991303835064
of O 0 3.484769194983528e-06
the O 0 1.7644694025875651e-06
same O 0 1.863165834947722e-06
mutation O 0 5.246096407063305e-06
, O 0 1.2863469578405784e-07
from O 0 7.443569671750083e-08
different O 0 7.717253680539216e-08
families O 0 4.580780341711943e-07
, O 0 1.2911772273582756e-07
shared O 0 3.9094231851777295e-07
similar O 0 1.4343795555760153e-06
haplotypes O 0 5.5097523727454245e-05
, O 0 2.892955990319024e-07
indicating O 0 6.036754598426342e-07
that O 0 4.132679265467232e-08
the O 0 1.3988234570661007e-07
mutant O 0 3.302235927549191e-05
alleles O 0 3.7787101518915733e-06
were O 0 2.0513267884325614e-07
likely O 0 2.758819732662232e-07
to O 0 4.7784361356661975e-08
be O 0 3.2565846908028107e-08
identical O 0 5.065450068286736e-07
by O 0 8.252177252643378e-08
descent O 0 7.639788236701861e-06
for O 0 1.630312311817761e-07
a O 0 3.7073486964800395e-06
mutation O 0 6.090816441428615e-06
in O 0 2.418224767097854e-07
the O 0 7.482528872060357e-07
founder O 0 3.4377262636553496e-05
population O 0 7.602879122714512e-06
. O 0 8.50535070640035e-06

The O 0 2.4520433726138435e-05
identification O 0 1.4203385944711044e-05
of O 0 3.2982031825667946e-06
common O 0 3.588432082324289e-05
BRCA1 O 0 0.009273645468056202
and O 0 3.411061697988771e-05
BRCA2 O 1 0.5176712274551392
mutations O 0 3.429274511290714e-05
will O 0 4.1434853415012185e-07
facilitate O 0 1.6667740965203848e-06
carrier O 0 1.3348814718483482e-05
detection O 0 5.553799383051228e-06
in O 0 8.93613275820826e-07
French O 0 7.211831689346582e-05
Canadian O 0 0.0003124847135040909
breast B-Disease 1 0.9987607002258301
cancer I-Disease 1 0.9659805297851562
and O 0 0.007193914148956537
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 0.0007225333247333765
. O 0 5.351204163162038e-05

Are O 0 8.404554682783782e-05
Dp71 O 0 0.0014518738025799394
and O 0 3.1428604415850714e-05
Dp140 O 0 0.009865927509963512
brain O 0 0.003964399453252554
dystrophin O 0 0.0015184850199148059
isoforms O 0 8.223034819820896e-05
related O 0 2.482664967828896e-05
to O 0 1.6120444342959672e-05
cognitive B-Disease 1 0.6333844065666199
impairment I-Disease 1 0.9991886019706726
in O 0 0.0009138919413089752
Duchenne B-Disease 1 0.999998927116394
muscular I-Disease 1 0.9999992847442627
dystrophy I-Disease 1 0.9999972581863403
? O 0 0.0014408535789698362

Molecular O 0 0.0009044493781402707
study O 0 6.324004789348692e-05
and O 0 5.8422797337698285e-06
neuropsychological O 0 0.00032205466413870454
analysis O 0 3.697892452692031e-06
were O 0 5.521145567399799e-07
performed O 0 1.4911074686096981e-06
concurrently O 0 2.3555530788144097e-06
on O 0 2.9112104584783083e-06
49 O 0 0.00019518256885930896
patients O 0 0.00023320363834500313
with O 0 9.873363160295412e-05
Duchenne B-Disease 1 0.9999998807907104
muscular I-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
( O 0 0.024086052551865578
DMD B-Disease 1 0.9999998807907104
) O 0 2.7572677936404943e-06
in O 0 1.9779901094807428e-07
order O 0 1.9647490034913062e-07
to O 0 9.017428226343327e-08
find O 0 2.0624568719540548e-07
a O 0 4.0629205955156067e-07
molecular O 0 1.619807676433993e-06
explanation O 0 4.781713869306259e-07
for O 0 2.3606393995123653e-07
the O 0 2.3142838472267613e-06
cognitive B-Disease 0 0.12885387241840363
impairment I-Disease 0 0.44130128622055054
observed O 0 1.906659235828556e-05
in O 0 3.8890293581062e-06
most O 0 2.9853033993276767e-05
DMD B-Disease 1 1.0
patients O 1 0.9006736874580383
. O 0 5.416685598902404e-05

Complete O 0 9.5295712526422e-05
analysis O 0 1.0416005352453794e-05
of O 0 1.158121904154541e-06
the O 0 2.1657829165633302e-06
dystrophin O 0 0.00037879403680562973
gene O 0 7.343639481405262e-06
was O 0 1.6132080418174155e-06
performed O 0 9.978210755434702e-07
to O 0 1.4893650757130672e-07
define O 0 9.133906360148103e-07
the O 0 2.61235669540838e-07
localization O 0 2.335847284484771e-06
of O 0 2.0079858131794026e-07
deletions O 0 6.177805971674388e-06
and O 0 3.2832915053404577e-07
duplications O 0 4.937234280077973e-06
in O 0 3.314405603305204e-07
relation O 0 8.229933996517502e-07
to O 0 2.694618501664081e-07
the O 0 1.2636246538022533e-06
different O 0 7.105411441443721e-06
DMD B-Disease 1 0.9999674558639526
promoters O 0 0.000301778462016955
. O 0 3.950432801502757e-05

Qualitative O 0 0.00032706561614759266
analysis O 0 2.1476591427926905e-05
of O 0 1.4001997215018491e-06
the O 0 1.6984361081995303e-06
Dp71 O 0 0.00024099739675875753
transcript O 0 2.6833791707758792e-05
and O 0 7.449264103343012e-07
testing O 0 1.0709927664720453e-06
for O 0 7.199351870212922e-08
the O 0 7.712147720440043e-08
specific O 0 1.5433690236932307e-07
first O 0 2.581601847850834e-07
exon O 0 5.134017555974424e-06
of O 0 3.226303419978649e-07
Dp140 O 0 4.8080906708491966e-05
were O 0 4.440331906607753e-07
also O 0 8.869940302247414e-07
carried O 0 4.985931809642352e-06
out O 0 4.507621724769706e-06
. O 0 1.4139622180664446e-05

Neuropsychological O 0 0.014491206966340542
analysis O 0 0.0001220313788508065
assessed O 0 6.632279837504029e-05
verbal O 0 6.635796307818964e-05
and O 0 5.646048521157354e-06
visuospatial O 0 0.0007294404204003513
intelligence O 0 1.7139089322881773e-05
, O 0 1.810494836718135e-06
verbal O 0 1.74956312548602e-05
memory O 0 3.538023156579584e-05
, O 0 1.123108063438849e-06
and O 0 9.234086064680014e-07
reading O 0 7.588913376821438e-06
skills O 0 3.1901454349281266e-05
. O 0 1.8358994566369802e-05

Comparison O 0 5.972293365630321e-05
of O 0 3.4691909149842104e-06
molecular O 0 1.6205500287469476e-05
and O 0 2.3946474811964436e-06
psychometric O 0 0.0006944202468730509
findings O 0 1.5390891348943114e-05
demonstrated O 0 5.091398179501994e-06
that O 0 1.052618685548623e-07
deletions O 0 3.3654937396931928e-06
and O 0 3.525153147165838e-07
duplications O 0 4.816943146579433e-06
that O 0 1.2229074286551622e-07
were O 0 1.9573336373923667e-07
localized O 0 4.63669721284532e-06
in O 0 2.3429501538885233e-07
the O 0 3.0814445040050487e-07
distal O 0 9.917013085214421e-05
part O 0 2.8052704692527186e-07
of O 0 9.7789580877361e-08
the O 0 3.2631575663799595e-07
gene O 0 1.5360857332780142e-06
seemed O 0 1.2006186125290697e-06
to O 0 1.410613492680568e-07
be O 0 2.1891682422392478e-07
preferentially O 0 3.75273839381407e-06
associated O 0 3.032042059203377e-06
with O 0 6.871150162623962e-06
cognitive B-Disease 1 0.8347436189651489
impairment I-Disease 1 0.9090045690536499
. O 0 6.152140122139826e-05

Two O 0 4.723171514342539e-05
altered O 0 0.0001329559599980712
Dp71 O 0 0.0003457142738625407
transcripts O 0 9.410561688127927e-06
and O 0 3.606743632644793e-07
two O 0 3.136496218303364e-07
deleted O 0 6.678689715045039e-06
Dp140 O 0 4.476512913242914e-05
DNA O 0 3.4143445191148203e-06
sequences O 0 9.14508916594059e-07
were O 0 1.2553641681734007e-07
found O 0 2.3139959637319407e-07
in O 0 3.665691110654734e-07
four O 0 1.5866711692069657e-05
patients O 0 0.0028148444835096598
with O 0 0.00019670579058583826
severe O 1 0.9999887943267822
cerebral B-Disease 1 0.9999992847442627
dysfunction I-Disease 1 0.9999717473983765
. O 0 0.00017101800767704844

These O 0 3.1618837965652347e-05
findings O 0 3.0613315175287426e-05
suggest O 0 3.6216408716427395e-06
that O 0 2.063676873831355e-07
some O 0 8.414776431209248e-08
sequences O 0 4.915791578241624e-07
located O 0 3.374803441147378e-07
in O 0 1.4567521589015087e-07
the O 0 2.1612341072341223e-07
distal O 0 6.574491271749139e-05
part O 0 3.4602359733071353e-07
of O 0 6.978888933417693e-08
the O 0 1.5989438395536126e-07
gene O 0 8.707601750757021e-07
and O 0 1.3503625950761489e-07
, O 0 1.3057220371592848e-07
in O 0 1.5255919549872488e-07
particular O 0 2.8900109327878454e-07
, O 0 2.3969315066096897e-07
some O 0 2.837044519310439e-07
DMD B-Disease 1 0.9982922673225403
isoforms O 0 8.177115887519903e-06
expressed O 0 9.76007868302986e-07
in O 0 4.182670636510011e-07
the O 0 2.6660638923203805e-06
brain O 0 0.006813617888838053
may O 0 3.1621289053873625e-06
be O 0 1.0614230205874264e-07
related O 0 5.851782134413952e-07
to O 0 2.0214316975852853e-07
the O 0 3.692380914799287e-06
cognitive B-Disease 0 0.4750325083732605
impairment I-Disease 1 0.6755800843238831
associated O 0 2.8867851142422296e-05
with O 0 6.782863783882931e-05
DMD B-Disease 1 1.0
. O 0 3.310162355774082e-05
. O 0 3.518501398502849e-05

I1307K O 0 0.00972659233957529
APC O 0 0.0018252113368362188
and O 0 4.2532687075436115e-05
hMLH1 O 0 0.002352107083424926
mutations O 0 9.149460674962029e-05
in O 0 7.304653308892739e-07
a O 0 2.014736992350663e-06
non O 0 3.1491194931732025e-06
- O 0 2.62043049588101e-05
Jewish O 0 7.682163413846865e-06
family O 0 3.161676659146906e-06
with O 0 5.428453732747585e-06
hereditary B-Disease 1 0.5497543215751648
non I-Disease 0 0.09587495028972626
- I-Disease 1 0.9999963045120239
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00030112548847682774

We O 0 5.079392940388061e-05
describe O 0 5.012197289033793e-05
a O 0 1.930031976371538e-05
French O 0 0.00010391819523647428
Canadian O 0 0.0003325820725876838
hereditary B-Disease 1 0.5962086915969849
non I-Disease 0 0.15608112514019012
- I-Disease 1 0.999998927116394
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.006764894817024469
HNPCC B-Disease 1 0.9988424181938171
) O 0 1.0626435141602997e-05
kindred O 0 6.840095011284575e-05
which O 0 1.3097832152197952e-06
carries O 0 5.1421661737549584e-06
a O 0 4.205307050142437e-06
novel O 0 1.7162528820335865e-05
truncating O 0 0.00046401351573877037
mutation O 0 5.365655306377448e-05
in O 0 6.864796887384728e-06
hMLH1 O 0 0.0006821604911237955
. O 0 3.835344614344649e-05

Interestingly O 0 0.0006563978386111557
, O 0 9.72333782556234e-06
the O 0 4.3775708036264405e-06
I1307K O 0 0.0003803027211688459
APC O 0 0.00014446138811763376
polymorphism O 0 3.849015411105938e-05
, O 0 5.000542842026334e-07
associated O 0 3.964857171467884e-07
with O 0 1.5039550760320708e-07
an O 0 7.39841709673783e-07
increased O 0 6.908795330673456e-05
risk O 0 0.002495298394933343
of O 0 0.05302097648382187
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 4.487595106184017e-06
is O 0 2.9368325726863986e-07
also O 0 2.8517413852569007e-07
present O 0 2.8191411161060387e-07
in O 0 4.0149697611013835e-07
this O 0 8.954507961789204e-07
family O 0 1.61381049110787e-05
. O 0 1.6437570593552664e-05

The O 0 7.224248838610947e-05
I1307K O 0 0.0012137994635850191
polymorphism O 0 0.00033871986670419574
has O 0 3.1544336707156617e-06
previously O 0 1.8054704469250282e-06
only O 0 2.0672165135238174e-07
been O 0 2.553497040480579e-07
identified O 0 8.657679018142517e-07
in O 0 2.596109140995395e-07
individuals O 0 2.3309576135943644e-07
of O 0 2.322206569260743e-07
self O 0 2.6289757443009876e-05
- O 0 0.003233999712392688
reported O 0 7.678383553866297e-05
Ashkenazi O 0 0.0002678623131942004
Jewish O 0 3.7619862268911675e-05
origins O 0 4.6679509978275746e-05
. O 0 1.9806942873401567e-05

In O 0 2.4099828806356527e-05
addition O 0 5.5627360779908486e-06
, O 0 1.0866162938327761e-06
in O 0 3.9766720760781027e-07
this O 0 1.759051286853719e-07
family O 0 7.790295057930052e-07
, O 0 1.834715988024982e-07
there O 0 7.00275677445461e-08
appears O 0 4.770145096699707e-07
to O 0 5.418025139647398e-08
be O 0 6.717192491123569e-08
no O 0 1.0596369293125463e-07
relationship O 0 3.6881820619782957e-07
between O 0 1.82323205422108e-07
the O 0 2.1928080684574525e-07
I1307K O 0 6.265711999731138e-05
polymorphism O 0 4.4287585296842735e-06
and O 0 7.874658791706679e-08
the O 0 1.4646003876350733e-07
presence O 0 5.752361857958022e-07
or O 0 4.857816406911297e-07
absence O 0 7.31149475541315e-06
of O 0 5.141896963323234e-06
cancer B-Disease 0 0.29073479771614075
. O 0 5.034784408053383e-06
. O 0 1.691039688012097e-05

Identification O 0 0.00012582633644342422
of O 0 5.832443093822803e-06
a O 0 9.565723303239793e-06
novel O 0 1.8815337170963176e-05
mutation O 0 9.391671483172104e-06
of O 0 2.1686587103886268e-07
the O 0 5.432262355498096e-07
CPO O 0 3.5636534448713064e-05
gene O 0 2.189344513681135e-06
in O 0 5.566996037487115e-07
a O 0 3.6208950859872857e-06
Japanese O 0 1.9331415387568995e-05
hereditary B-Disease 0 0.001184037304483354
coproporphyria I-Disease 0 0.0025825875345617533
family O 0 6.215567555045709e-05
. O 0 2.927052992163226e-05

Hereditary B-Disease 1 0.9980257749557495
coproporphyria I-Disease 1 0.8452096581459045
( O 0 0.00044687025365419686
HCP B-Disease 0 0.18628151714801788
) O 0 8.451500434603076e-06
is O 0 1.8702938859860296e-06
an O 0 8.906099537853152e-06
autosomal B-Disease 1 0.9997708201408386
dominant I-Disease 1 0.9955124258995056
disease I-Disease 1 0.7748413681983948
characterized O 0 0.00017508890596218407
by O 0 3.8092475733719766e-06
a O 0 0.0012342400150373578
deficiency B-Disease 0 0.2701561152935028
of I-Disease 0 1.1600197922234656e-06
coproporphyrinogen I-Disease 0 0.09675410389900208
oxidase I-Disease 0 0.00010270763596054167
( O 0 2.1021896827733144e-06
CPO O 0 1.826356128731277e-05
) O 0 5.31476132437092e-07
caused O 0 8.124260375552694e-07
by O 0 1.2274385596811044e-07
a O 0 1.3207359188527334e-06
mutation O 0 5.858678377990145e-06
in O 0 4.5817503746548027e-07
the O 0 1.6450163684567087e-06
CPO O 0 0.0001511168375145644
gene O 0 3.976633524871431e-05
. O 0 1.4851943888061214e-05

Only O 0 3.769125760300085e-05
11 O 0 5.990351928630844e-05
mutations O 0 1.074282954505179e-05
of O 0 2.3327720555244014e-07
the O 0 3.191027815319103e-07
gene O 0 1.9022703554583131e-06
have O 0 3.9206838664540555e-07
been O 0 1.3846064348399523e-06
reported O 0 2.230417521786876e-05
in O 0 1.6549183783354238e-05
HCP B-Disease 1 0.9981763362884521
patients O 0 0.01404496654868126
. O 0 4.500363502302207e-05

We O 0 4.9948666855925694e-05
report O 0 1.9968378182966262e-05
another O 0 5.501884061231976e-06
mutation O 0 2.1324685803847387e-05
in O 0 1.0959620340145193e-06
a O 0 4.6296931941469666e-06
Japanese O 0 1.1488164091133513e-05
family O 0 2.13604471355211e-05
. O 0 1.7201413356815465e-05

Polymerase O 0 0.002208312973380089
chain O 0 0.0006386536988429725
reaction O 0 8.82746244315058e-05
- O 0 6.400162965292111e-05
single O 0 7.343429388129152e-06
strand O 0 4.85727287014015e-05
conformational O 0 2.604952715046238e-05
polymorphism O 0 1.0919726264546625e-05
and O 0 2.3456038888980402e-07
direct O 0 5.641186930915865e-07
sequence O 0 1.213231371366419e-06
analyses O 0 1.3396436315815663e-06
demonstrated O 0 1.7006681218845188e-06
a O 0 8.056956062318932e-07
C O 0 8.063750101428013e-06
to O 0 3.4828977391043736e-07
T O 0 1.7736791050992906e-05
substitution O 0 6.429290806408972e-07
in O 0 2.1981720976782526e-07
exon O 0 4.670866019296227e-06
1 O 0 3.2651374226588814e-07
of O 0 5.634703725831969e-08
the O 0 2.1095671343118738e-07
CPO O 0 6.217512691364391e-06
gene O 0 9.088132628676249e-07
at O 0 2.3206523280805413e-07
nucleotide O 0 2.1833227492606966e-06
position O 0 8.296507303384715e-07
85 O 0 1.2197361911603366e-06
, O 0 9.158016922583556e-08
which O 0 6.411253394844607e-08
lies O 0 2.2213576755802933e-07
in O 0 9.018666702331757e-08
the O 0 3.008800320003502e-07
putative O 0 1.0631878467393108e-05
presequence O 0 2.229392521257978e-05
for O 0 4.3344158484615036e-07
targeting O 0 4.730924956675153e-06
to O 0 2.846537199729937e-06
mitochondria O 0 8.349755080416799e-05
. O 0 1.8215239833807573e-05

This O 0 3.7873607652727515e-05
mutation O 0 8.333790174219757e-05
changes O 0 4.388840352476109e-06
the O 0 7.325687079173804e-07
codon O 0 5.419871740741655e-06
for O 0 3.8360133203241276e-07
glutamine O 0 6.18287504039472e-06
to O 0 3.6937646541446156e-07
a O 0 1.8388604985375423e-06
termination O 0 2.2051521227695048e-05
codon O 0 2.045688233920373e-05
at O 0 2.077655153698288e-06
amino O 0 7.1267891144088935e-06
acid O 0 1.5591762348776683e-05
position O 0 6.716360985592473e-06
29 O 0 3.6179175367578864e-05
. O 0 1.4695739992021117e-05

MaeI O 0 0.003427237970754504
restriction O 0 0.00013764727918896824
analysis O 0 2.533414590288885e-05
showed O 0 1.0435015610710252e-05
two O 0 5.142339318808808e-07
other O 0 2.3955055894475663e-07
carriers O 0 2.3247778244694928e-06
in O 0 2.831092729138618e-07
the O 0 1.4434266404350637e-06
family O 0 1.822317972255405e-05
. O 0 1.4710421055497136e-05

The O 0 0.00013522196968551725
C O 0 0.018152905628085136
- O 1 0.6430912017822266
T O 1 0.8819140791893005
mutation O 0 1.4685791938973125e-05
is O 0 2.814643949022866e-07
located O 0 4.5083859845362895e-07
within O 0 2.453796525969665e-07
a O 0 7.859253514652664e-07
recently O 0 2.590529447843437e-06
proposed O 0 2.1389039375208085e-06
putative O 0 8.419338882958982e-06
alternative O 0 1.288910084440431e-06
translation O 0 1.5679054286010796e-06
initiation O 0 4.442179942998337e-06
codon O 0 1.2435913959052414e-05
( O 0 1.8102807644027052e-06
TIC O 0 1.6046637028921396e-05
- O 0 3.920884864783147e-06
1 O 0 9.063275001608417e-07
) O 0 2.457592813698284e-07
, O 0 1.12443331090617e-07
supporting O 0 3.760910658456851e-07
that O 0 1.1954368517308467e-07
TIC O 0 2.650193709996529e-05
- O 0 1.585222162248101e-05
1 O 0 8.967043640950578e-07
is O 0 1.5741575509764516e-07
the O 0 1.924978647593889e-07
real O 0 1.6835836049722275e-06
TIC O 0 1.726420669001527e-05
rather O 0 5.787672989754356e-07
than O 0 6.033652084624919e-07
TIC O 0 3.828701301245019e-05
- O 0 2.091198075504508e-05
2 O 0 5.4762335821578745e-06
. O 0 2.5540232400089735e-06
. O 0 6.582085461559473e-06

Human B-Disease 0 0.0005245888605713844
complement I-Disease 0 0.0011707564117386937
factor I-Disease 0 0.012807340361177921
H I-Disease 1 0.9999996423721313
deficiency I-Disease 1 0.9999474287033081
associated O 0 0.00178947439417243
with O 1 0.5156795382499695
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.001088756718672812

This O 0 1.5736857676529326e-05
study O 0 9.142620001512114e-06
reports O 0 2.7333799152984284e-06
on O 0 1.2117385495002964e-06
six O 0 6.201831638463773e-06
cases O 0 5.2223363127268385e-06
of O 0 6.3500415308226366e-06
deficiency B-Disease 0 0.4828258454799652
in I-Disease 0 2.3606393995123653e-07
the I-Disease 0 2.588168968031823e-07
human I-Disease 0 6.313655944722996e-07
complement I-Disease 0 1.8523284097682335e-06
regulatory I-Disease 0 5.717730800824938e-06
protein I-Disease 0 3.250666622989229e-06
Factor I-Disease 0 4.2044048313982785e-06
H I-Disease 1 0.5491313934326172
( O 0 3.6561286833602935e-06
FH O 0 0.0001780041347956285
) O 0 3.6852989637736755e-07
in O 0 9.444417514714587e-08
the O 0 1.7584928002634115e-07
context O 0 1.0904676628342713e-06
of O 0 1.5813845948287053e-06
an O 0 0.0007968146237544715
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.0003111229161731899

Five O 0 2.6828061891137622e-05
of O 0 1.716262090667442e-06
the O 0 1.2603992445292533e-06
cases O 0 1.8354631947659072e-06
were O 0 8.91336526365194e-07
observed O 0 1.982984940696042e-06
in O 0 6.369555194396526e-07
children O 0 9.109652637562249e-06
presenting O 0 0.00011029341840185225
with O 0 0.12412519007921219
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.09937745332717896
HUS B-Disease 1 0.9999762773513794
) O 0 4.673359217122197e-05
. O 0 4.362428080639802e-05

Two O 0 1.0285491953254677e-05
of O 0 1.9903495740436483e-06
the O 0 1.8780921209327062e-06
children O 0 1.706670445855707e-05
exhibited O 0 9.139623580267653e-05
a O 0 0.016673684120178223
homozygous O 1 0.9999948740005493
deficiency O 1 0.9881036877632141
characterized O 0 3.4343640436418355e-05
by O 0 2.341388665172417e-07
the O 0 2.2196381621597538e-07
absence O 0 9.105536378228862e-07
of O 0 8.086038860710687e-08
the O 0 2.2053494319607125e-07
150 O 0 1.0268408914271276e-06
- O 0 1.1066285878769122e-05
kD O 0 2.0716144717880525e-05
form O 0 2.9774787435599137e-07
of O 0 1.5200268421722285e-07
Factor O 0 1.980522483790992e-06
H O 0 0.05399484559893608
and O 0 1.1201670702121191e-07
the O 0 9.474819506749554e-08
presence O 0 3.233042491501692e-07
, O 0 9.433652081725086e-08
upon O 0 1.7894822690323053e-07
immunoblotting O 0 1.0810886124090757e-05
, O 0 6.157720378041631e-08
of O 0 4.9634827803402004e-08
the O 0 1.6757778098508425e-07
42 O 0 4.926830115437042e-06
- O 0 1.668559889367316e-05
kD O 0 0.00010477131581865251
Factor O 0 4.207858637528261e-06
H O 0 0.000707580242305994
- O 0 3.1347249205282424e-06
like O 0 3.4791034408954147e-07
protein O 0 1.054794893207145e-06
1 O 0 7.535614940934465e-07
( O 0 9.144155797002895e-07
FHL O 0 4.6238066715886816e-05
- O 0 6.409800334949978e-06
1 O 0 1.0949037232421688e-06
) O 0 2.9381544663920067e-07
and O 0 2.1280925466271583e-07
other O 0 5.171108909962641e-07
FH O 0 0.005517075303941965
- O 0 0.00017091791960410774
related O 0 1.3323225175554398e-05
protein O 0 7.66948505770415e-06
( O 0 4.404547325975727e-06
FHR O 0 0.00016634985513519496
) O 0 5.525756478164112e-06
bands O 0 2.9329376047826372e-05
. O 0 2.3530123144155368e-05

Southern O 0 0.0004085590480826795
blot O 0 0.000764763040933758
and O 0 8.660951607453171e-06
PCR O 0 5.6249777117045596e-05
analysis O 0 1.4436097899306333e-06
of O 0 2.016894882217457e-07
DNA O 0 1.6209064597205725e-06
of O 0 1.5960736732267833e-07
one O 0 6.483796255452035e-07
patient O 0 9.339692041976377e-05
with O 0 9.127856174018234e-05
homozygous O 1 0.9999828338623047
deficiency O 1 0.978344202041626
ruled O 0 6.198426035552984e-06
out O 0 1.8585184591302095e-07
the O 0 1.1786938358682164e-07
presence O 0 1.6249043710558908e-07
of O 0 5.6054716424114304e-08
a O 0 3.3040385005733697e-07
large O 0 3.4182403396698646e-07
deletion O 0 4.669383088184986e-06
of O 0 9.879727969064334e-08
the O 0 4.1367772496414545e-07
FH O 0 0.0018465205794200301
gene O 0 1.6807697420517798e-06
as O 0 2.207817715316196e-07
the O 0 7.630428626725916e-07
underlying O 0 9.330060856882483e-05
defect O 0 0.0002687791711650789
for O 0 4.401994374347851e-06
the O 0 6.869537173770368e-05
deficiency O 1 0.8480753898620605
. O 0 3.418623600737192e-05

The O 0 2.0696594219771214e-05
other O 0 2.1873850073461654e-06
four O 0 1.8303188653590041e-06
children O 0 4.520209586189594e-06
presented O 0 3.725722308445256e-06
with O 0 2.336833131266758e-05
heterozygous O 1 0.994996190071106
deficiency O 0 0.4030570685863495
and O 0 1.2208395219204249e-06
exhibited O 0 5.3264589041646104e-06
a O 0 2.69485258286295e-06
normal O 0 7.2797124630596954e-06
immunoblotting O 0 0.00016733889060560614
pattern O 0 4.741964858112624e-06
of O 0 2.0871347317097388e-07
proteins O 0 5.314629447639163e-07
of O 0 2.55514862601558e-07
the O 0 2.2855770112073515e-06
FH O 0 0.017934419214725494
family O 0 5.1992410590173677e-05
. O 0 2.1910613213549368e-05

Factor B-Disease 1 0.9750798344612122
H I-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9990807771682739
is O 0 3.443556124693714e-06
the O 0 1.6627255945422803e-06
only O 0 5.068637619842775e-06
complement B-Disease 1 0.9974545836448669
deficiency I-Disease 1 0.9999990463256836
associated O 0 3.709886368596926e-05
with O 0 4.4599124521482736e-05
HUS B-Disease 1 0.999982476234436
. O 0 0.0001318431895924732

These O 0 1.334994794888189e-05
observations O 0 1.7931562979356386e-05
suggest O 0 4.117433945793891e-06
a O 0 1.4419669014387182e-06
role O 0 2.044786924670916e-06
for O 0 1.871317977020226e-06
FH O 0 0.018257539719343185
and O 0 4.939230620948365e-06
/ O 0 0.00023890244483482093
or O 0 4.524099495029077e-06
FH O 0 0.004648398142307997
receptors O 0 8.208948202081956e-06
in O 0 6.5262412363154e-07
the O 0 1.968512378880405e-06
pathogenesis O 0 0.00033984531182795763
of O 0 3.390555502846837e-05
idiopathic O 1 0.9999996423721313
HUS B-Disease 1 0.9999996423721313
. O 0 3.220265352865681e-05
. O 0 4.693205846706405e-05

Further O 0 4.0560018533142284e-05
evidence O 0 3.590621190596721e-06
for O 0 7.944027515804919e-07
a O 0 2.906932422774844e-06
major O 0 4.993393304175697e-06
ancient O 0 1.450566287530819e-05
mutation O 0 0.0010014089057222009
underlying O 0 0.26255273818969727
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
from O 0 1.706112379906699e-05
linkage O 0 0.0003746609145309776
disequilibrium O 0 0.02860540896654129
studies O 0 4.882432222075295e-06
in O 0 4.3457941956148716e-07
the O 0 7.9746558867555e-07
Japanese O 0 9.808462891669478e-06
population O 0 1.0066786671814043e-05
. O 0 1.1876095413754229e-05

The O 0 0.023905783891677856
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.7405632734298706
DM B-Disease 1 1.0
) O 0 0.0001338479050900787
mutation O 0 8.318696200149134e-05
is O 0 5.887517318114988e-07
an O 0 7.924256237856753e-07
unstable O 0 0.0004941844963468611
( O 0 8.292588972835802e-06
CTG O 0 0.00018713802273850888
) O 0 8.837121185933938e-07
n O 0 3.985848707088735e-06
repeat O 0 1.8216206854049233e-06
, O 0 9.069935202887791e-08
present O 0 8.855236188765048e-08
at O 0 8.747980473344796e-08
a O 0 2.4528512199140096e-07
copy O 0 4.823930339625804e-07
number O 0 1.0582594001107282e-07
of O 0 1.0607026013076393e-07
5 O 0 1.0638973435561638e-06
- O 0 6.676963494101074e-06
37 O 0 2.395044703007443e-06
repeats O 0 2.282901959915762e-06
on O 0 3.5090329220111016e-07
normal O 0 9.82843403107836e-07
chromosomes O 0 1.8363385834163637e-06
but O 0 1.0832375352265444e-07
amplified O 0 1.2725581655104179e-06
to O 0 1.429461775614982e-07
50 O 0 5.401735734267277e-07
- O 0 4.279808308638167e-06
3000 O 0 7.453332273144042e-06
copies O 0 2.875658992707031e-06
on O 0 8.113373951346148e-06
DM B-Disease 1 0.9997708201408386
chromosomes O 0 0.0003820548881776631
. O 0 3.029966501344461e-05

Previous O 0 0.00035122240660712123
findings O 0 7.938482303870842e-05
in O 0 6.540805316035403e-06
Caucasian O 0 0.00029897174681536853
populations O 0 1.0107910384249408e-05
of O 0 1.1186270967300516e-06
a O 0 5.421615787781775e-05
DM B-Disease 1 0.9999998807907104
founder O 0 0.00035220515565015376
chromosome O 0 0.00016156211495399475
raise O 0 1.93163350559189e-06
a O 0 7.478191719201277e-07
question O 0 3.3196758408848837e-07
about O 0 1.0102489511609747e-07
the O 0 2.023013081497993e-07
molecular O 0 1.621543333385489e-06
events O 0 3.807864175087161e-07
involved O 0 4.06042204303958e-07
in O 0 3.8677777070006414e-07
the O 0 1.582441996106354e-06
expansion O 0 6.412791117327288e-05
mutation O 0 9.701673843665048e-05
. O 0 1.6301290088449605e-05

To O 0 2.5666500732768327e-05
investigate O 0 1.7192804079968482e-05
whether O 0 2.472603682690533e-06
a O 0 3.4196725664514815e-06
founder O 0 2.5492643544566818e-05
chromosome O 0 5.8887526392936707e-05
for O 0 8.820366019790526e-07
the O 0 1.5319063095375896e-05
DM B-Disease 1 1.0
mutation O 0 0.00011239078594371676
exists O 0 3.4394332715237397e-07
in O 0 7.946538005398907e-08
the O 0 1.0610809653144315e-07
Japanese O 0 8.9143003378922e-07
population O 0 3.366937164628325e-07
, O 0 1.2773520552400441e-07
we O 0 9.641922105174672e-08
genotyped O 0 1.3848829439666588e-05
families O 0 5.659087491949322e-07
using O 0 5.504757609742228e-07
polymorphic O 0 1.8004524463322014e-05
markers O 0 3.006590986842639e-06
near O 0 1.3348421816772316e-06
the O 0 4.441140788458142e-07
( O 0 1.5328766949096462e-06
CTG O 0 7.274007657542825e-05
) O 0 8.874882269083173e-07
n O 0 4.620602339855395e-06
repeat O 0 4.38581946582417e-06
region O 0 3.755666512006428e-06
and O 0 1.6124142803164432e-06
constructed O 0 5.7243956689490005e-05
haplotypes O 0 0.0004428746469784528
. O 0 1.8094580809702165e-05

Six O 0 0.00010057137842522934
different O 0 8.955978046287782e-06
haplotypes O 0 0.00016577205678913742
were O 0 2.652710918482626e-06
found O 0 3.093008444920997e-06
and O 0 5.514270469575422e-06
DM B-Disease 1 0.9999998807907104
alleles O 0 0.0001739991275826469
were O 0 3.550115479811211e-06
always O 0 6.146043233457021e-06
haplotype O 0 0.0002927531022578478
A O 0 4.173194611212239e-05
. O 0 4.946026820107363e-05

To O 0 1.5610477930749767e-05
find O 0 3.479535735095851e-06
an O 0 6.138033086244832e-07
origin O 0 7.917291782177927e-07
of O 0 1.7039702981946903e-07
the O 0 4.2410329115227796e-07
( O 0 1.635489979889826e-06
CTG O 0 4.67996796942316e-05
) O 0 8.165911253854574e-07
n O 0 5.177739240025403e-06
repeat O 0 9.923266588884871e-06
mutation O 0 2.410654587947647e-06
and O 0 1.1769292029839562e-07
to O 0 1.0197427258162861e-07
investigate O 0 5.116901320434408e-07
the O 0 9.679992274413962e-08
mechanism O 0 3.6771893974218983e-07
of O 0 5.5035666690628204e-08
the O 0 1.4570800033197884e-07
expansion O 0 6.996074262133334e-06
mutation O 0 1.5812170204299036e-06
in O 0 7.602580609500365e-08
the O 0 1.3925675546033744e-07
Japanese O 0 5.282734036882175e-07
population O 0 2.110464691895686e-07
we O 0 5.38062145949425e-08
have O 0 6.161021559591973e-08
studied O 0 4.2716305870271754e-07
90 O 0 1.2710553392025759e-06
Japanese O 0 4.604317837220151e-06
DM B-Disease 1 0.9992932081222534
families O 0 2.136225248250412e-06
comprising O 0 1.1111876574432245e-06
190 O 0 2.8675719931925414e-06
affected O 0 1.2373501476758975e-06
and O 0 5.904971658310387e-07
130 O 0 1.1947230632358696e-05
unaffected O 0 4.651944982470013e-05
members O 0 4.413428086991189e-06
. O 0 1.2653632438741624e-05

The O 0 6.192293221829459e-05
results O 0 4.2451603803783655e-05
suggest O 0 5.47951458429452e-06
that O 0 3.162851101023989e-07
a O 0 1.0459866643941496e-06
few O 0 6.017849045747425e-07
common O 0 2.1052553620393155e-06
ancestral O 0 5.709969627787359e-05
mutations O 0 1.4091794582782313e-05
in O 0 1.7920268646776094e-07
both O 0 3.060288236156339e-07
Caucasian O 0 6.986250809859484e-05
and O 0 8.469077101835865e-07
Japanese O 0 1.9470805909804767e-06
populations O 0 1.2441493026926764e-06
have O 0 9.556693214562983e-08
originated O 0 3.080363342178316e-07
by O 0 5.449032514093233e-08
expansion O 0 3.922217217677826e-07
of O 0 6.261852547595481e-08
an O 0 1.8725607731084892e-07
ancestral O 0 4.289001935831038e-06
n O 0 2.278649844811298e-05
= O 0 1.9488456018734723e-05
5 O 0 8.534694870832027e-07
repeat O 0 1.867858941295708e-06
to O 0 3.3073391136895225e-07
n O 0 1.0150076377613004e-05
= O 0 2.2637221263721585e-05
19 O 0 4.072205683769425e-06
- O 0 9.692823368823156e-06
37 O 0 8.947124115366023e-06
copies O 0 7.021426426945254e-06
. O 0 1.0207765626546461e-05

These O 0 2.0623401724151336e-05
data O 0 7.26031339581823e-06
support O 0 2.8702093004540075e-06
multistep O 0 2.96475973300403e-05
models O 0 3.036223461094778e-06
of O 0 4.7599979779988644e-07
triplet O 0 0.0008323371293954551
repeat O 0 3.7967085518175736e-05
expansion O 0 5.023887297284091e-06
that O 0 1.3163834466922708e-07
have O 0 1.3912838880969502e-07
been O 0 1.6202189101477416e-07
proposed O 0 6.40078212654771e-07
for O 0 3.299425657132815e-07
both O 0 2.9376685688475845e-06
DM B-Disease 1 0.9999992847442627
and O 0 5.810457150801085e-05
Friedreichs B-Disease 1 0.7850351333618164
ataxia I-Disease 1 0.9860960841178894
. O 0 7.714604180364404e-06
. O 0 1.5502624592045322e-05

The O 0 3.650126382126473e-05
molecular O 0 7.051812281133607e-05
basis O 0 2.3573176804347895e-05
of O 0 0.00010375206329626963
C6 B-Disease 1 1.0
deficiency I-Disease 1 0.9999992847442627
in O 0 1.5024771755633992e-06
the O 0 7.247240887409134e-07
western O 0 3.8369130379578564e-06
Cape O 0 5.309674816089682e-05
, O 0 1.5764621821290348e-06
South O 0 5.294331458571833e-06
Africa O 0 1.8313405234948732e-05
. O 0 1.6327830962836742e-05

Deficiency B-Disease 1 0.9984754920005798
of I-Disease 0 8.22738184069749e-06
the I-Disease 0 2.463205873937113e-06
sixth I-Disease 0 1.4380239917954896e-05
component I-Disease 0 2.903455424529966e-06
of I-Disease 0 2.2093279028467805e-07
human I-Disease 0 8.943813440964732e-07
complement I-Disease 0 3.6096209896641085e-06
( O 0 4.053383236168884e-06
C6 O 0 0.0003073085390496999
) O 0 4.1822636376309674e-07
has O 0 1.797747444243214e-07
been O 0 2.0365766317809175e-07
reported O 0 6.959999154787511e-07
in O 0 5.225561849897531e-08
a O 0 2.1811906947277748e-07
number O 0 5.278251791196453e-08
of O 0 4.892509153364699e-08
families O 0 3.031719018053991e-07
from O 0 5.4780652902763904e-08
the O 0 1.0661831595371041e-07
western O 0 1.0236885827907827e-06
Cape O 0 1.754070763126947e-05
, O 0 4.44325905846199e-07
South O 0 2.1986179490340874e-06
Africa O 0 7.738817657809705e-06
. O 0 8.05438139650505e-06

Meningococcal B-Disease 1 0.999998927116394
disease I-Disease 1 0.9993368983268738
is O 0 2.4559985831729136e-05
endemic O 0 3.283069600001909e-05
in O 0 1.3783338772554998e-06
the O 0 7.303385700652143e-07
Cape O 0 3.388793993508443e-05
and O 0 3.036458622318605e-07
almost O 0 3.0109012527645973e-07
all O 0 9.420399749160424e-08
pedigrees O 0 5.200949090067297e-06
of O 0 1.5259121255439823e-06
total O 0 0.0017883273540064692
C6 B-Disease 1 1.0
deficiency I-Disease 1 0.9999996423721313
( O 0 6.847757958894363e-06
C6Q0 O 0 0.00041332928230986
) O 0 6.947187216610473e-07
have O 0 2.1043589981672994e-07
been O 0 6.693480827379972e-07
ascertained O 0 1.0650572221493348e-05
because O 0 1.3338584494704264e-06
of O 0 4.577410436468199e-06
recurrent O 1 0.9998966455459595
disease O 1 0.9541682004928589
. O 0 5.430210512713529e-05

We O 0 3.716507853823714e-05
have O 0 5.189974672248354e-06
sequenced O 0 1.3130764273228124e-05
the O 0 7.156280616982258e-07
expressed O 0 1.060354179571732e-06
exons O 0 4.353116764832521e-06
of O 0 2.511215200229344e-07
the O 0 7.803724315635918e-07
C6 O 0 0.0005470211035571992
gene O 0 2.066663910227362e-06
from O 0 2.695235536975815e-07
selected O 0 3.5012141097467975e-07
cases O 0 3.1817839385439584e-07
and O 0 1.9354897062839882e-07
have O 0 1.6491587473410618e-07
found O 0 3.1587214266437513e-07
three O 0 6.024946515026386e-07
molecular O 0 9.460927685722709e-05
defects O 0 0.4821990430355072
leading O 0 3.21872335007356e-06
to O 0 9.091826314033824e-07
total O 0 4.056261241203174e-05
deficiency O 0 0.3915821313858032
879delG O 0 0.00024400843540206552
, O 0 2.393395561739453e-07
which O 0 7.37716803200783e-08
is O 0 6.627978166307003e-08
the O 0 2.0329422056875046e-07
common O 0 5.045734269515378e-06
defect O 0 4.8970148782245815e-05
in O 0 3.4864967801695457e-07
the O 0 6.062404622753093e-07
Cape O 0 3.001829463755712e-05
and O 0 5.063436105956498e-07
hitherto O 0 6.669256890745601e-06
unreported O 0 3.0812966542725917e-06
, O 0 2.0165100522717694e-07
and O 0 1.7617963976590545e-07
1195delC O 0 2.4137620130204596e-05
and O 0 5.6821414773367e-07
1936delG O 0 5.4640058806398883e-05
, O 0 2.3683963945586584e-07
which O 0 8.275473106778009e-08
have O 0 7.794711365249896e-08
been O 0 1.799253510625931e-07
previously O 0 1.152745539911848e-06
reported O 0 1.2769954764735303e-06
in O 0 5.652388495036575e-07
African O 0 5.831536327605136e-06
- O 0 0.00023831732687540352
Americans O 0 2.8477936211857013e-05
. O 0 1.6075922758318484e-05

We O 0 2.6884123144554906e-05
also O 0 4.558469299809076e-06
show O 0 1.3841324744134909e-06
that O 0 1.607910888878905e-07
the O 0 3.987259731275117e-07
879delG O 0 0.00010115974146174267
and O 0 4.178769813734107e-06
1195delC O 0 0.46321946382522583
defects O 0 0.49561312794685364
are O 0 2.860577410501719e-07
associated O 0 1.1201558436368941e-06
with O 0 9.609551625544555e-07
characteristic O 0 0.00012116660218453035
C6 O 1 0.5388010740280151
/ O 0 0.000661493104416877
C7 O 0 0.000924585503526032
region O 0 1.612130472494755e-05
DNA O 0 1.1077446288254578e-05
marker O 0 1.6488331311848015e-05
haplotypes O 0 4.9559697799850255e-05
, O 0 5.78785488869471e-07
although O 0 3.9346852531707555e-07
small O 0 5.985493203297665e-07
variations O 0 9.089606464840472e-06
were O 0 2.895809302572161e-06
observed O 0 2.1613965145661496e-05
. O 0 1.2217562471050769e-05

The O 0 0.00010999649384757504
1936delG O 0 0.00815879087895155
defect O 0 0.002327020512893796
was O 0 9.590009540261235e-06
observed O 0 2.109648903569905e-06
only O 0 1.0805301542404777e-07
once O 0 2.2199895965968608e-07
in O 0 1.463528036538264e-07
the O 0 2.847344262590923e-07
Cape O 0 2.2787933630752377e-05
, O 0 1.7933022888882988e-07
but O 0 1.2491112499901647e-07
its O 0 4.683872987243376e-07
associated O 0 2.797116621877649e-06
haplotype O 0 7.753618410788476e-05
could O 0 1.2598392231666367e-06
be O 0 1.1739714409486623e-06
deduced O 0 3.1189119908958673e-05
. O 0 1.38834111567121e-05

The O 0 1.6077134205261245e-05
data O 0 7.1746890171198174e-06
from O 0 9.83985614766425e-07
the O 0 8.89373438894836e-07
haplotypes O 0 7.148885197238997e-05
indicate O 0 1.1592898090384551e-06
that O 0 6.094600024653118e-08
these O 0 4.821603027949095e-08
three O 0 5.987194526824169e-07
molecular O 0 0.0001066323384293355
defects O 0 0.0604330375790596
account O 0 6.833704446762567e-07
for O 0 1.7769151838820108e-07
the O 0 1.8604491742735263e-06
defects O 0 0.08696445822715759
in O 0 1.7877324864912225e-07
all O 0 5.0787566152621366e-08
the O 0 2.6022763677246985e-07
38 O 0 9.701766430225689e-06
unrelated O 0 2.0084058633074164e-05
C6Q0 O 0 0.002466116100549698
individuals O 0 3.5046653579229314e-07
we O 0 8.476327906237202e-08
have O 0 1.3436851986625697e-07
studied O 0 5.701236887034611e-07
from O 0 2.998424974975933e-07
the O 0 8.39507208638679e-07
Cape O 0 9.077737195184454e-05
. O 0 1.3212222256697714e-05

We O 0 3.451031807344407e-05
have O 0 3.813056764556677e-06
also O 0 1.3126580142852617e-06
observed O 0 2.5212509626726387e-06
the O 0 1.0761426665339968e-06
879delG O 0 0.0002473545609973371
defect O 0 2.8823729735449888e-05
in O 0 6.545526503032306e-07
two O 0 2.668513616299606e-06
Dutch O 0 0.05403084680438042
C6 B-Disease 1 0.9999990463256836
- I-Disease 1 0.9880852699279785
deficient I-Disease 1 0.9954065084457397
kindreds O 0 0.00026299749151803553
, O 0 5.934554110353929e-07
but O 0 1.474950295232702e-07
the O 0 4.1929746430469095e-07
879delG O 0 0.0002019822277361527
defect O 0 3.122352063655853e-05
in O 0 3.68166666930847e-07
the O 0 4.606162065101671e-07
Cape O 0 3.5925480915466323e-05
probably O 0 9.151388553618744e-07
did O 0 9.986125348859787e-08
not O 0 4.141003628888029e-08
come O 0 7.569229865111993e-08
from O 0 9.828379887721894e-08
The O 0 3.347212498283625e-07
Netherlands O 0 5.069706276117358e-06
. O 0 1.7283049373872927e-06
. O 0 6.1387454479699954e-06

Complement B-Disease 1 0.9984481334686279
C7 I-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
: O 0 1.802572478482034e-05
seven O 0 8.946843081503175e-06
further O 0 4.256334250385407e-06
molecular O 0 0.0001883118529804051
defects O 1 0.5501442551612854
and O 0 1.459498776057444e-06
their O 0 1.8806424577633152e-06
associated O 0 2.5912022465490736e-05
marker O 0 0.00018589061801321805
haplotypes O 0 0.000979396398179233
. O 0 3.416394247324206e-05

Seven O 0 0.00011251581599935889
further O 0 2.0858124116784893e-05
molecular O 0 5.078399772173725e-05
bases O 0 3.7916575820418075e-05
of O 0 0.00022132709273137152
C7 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
are O 0 6.2859448917151894e-06
described O 0 7.039099727990106e-05
. O 0 2.543744631111622e-05

All O 0 1.2507503015513066e-05
these O 0 2.0618288090190617e-06
new O 0 5.040713404014241e-06
molecular O 0 0.00013676912931259722
defects O 0 0.018053939566016197
involve O 0 1.3735838138018153e-06
single O 0 1.5632768963769195e-06
- O 0 1.4048628145246767e-05
nucleotide O 0 4.408392214827472e-06
events O 0 4.5685038685405743e-07
, O 0 2.1219480572653993e-07
deletions O 0 2.889235929615097e-06
and O 0 2.3327899612013425e-07
substitutions O 0 1.384574716212228e-06
, O 0 9.058128114247666e-08
some O 0 2.3147281424940047e-08
of O 0 5.8270785530112335e-08
which O 0 2.30086982355715e-07
alter O 0 6.517585461551789e-06
splice O 0 2.674284769454971e-05
sites O 0 9.61556452239165e-07
, O 0 4.4934057541468064e-07
and O 0 1.3084809324936941e-06
others O 0 8.626397175248712e-06
codons O 0 0.00013191009929869324
. O 0 1.8953900507767685e-05

They O 0 1.1675218956952449e-05
are O 0 1.1068491403420921e-06
distributed O 0 1.0106032277690247e-06
along O 0 5.297505936141533e-07
the O 0 5.090156491860398e-07
C7 O 0 0.00021180982002988458
gene O 0 1.8093038534061634e-06
, O 0 1.9257828398622223e-07
but O 0 1.1033495184165076e-07
predominantly O 0 4.255934982211329e-07
towards O 0 4.4978986579735647e-07
the O 0 4.505196784521104e-07
3 O 0 5.5440837058995385e-06
end O 0 1.3729846614296548e-05
. O 0 1.7707179722492583e-05

All O 0 1.5977922885213047e-05
were O 0 5.630842224491062e-06
found O 0 3.416337904127431e-06
in O 0 2.814039817167213e-06
compound O 0 0.0003183131921105087
heterozygous O 0 0.00044739068835042417
individuals O 0 1.6864159988472238e-05
. O 0 1.5141922631300986e-05

The O 0 0.00031301035778596997
C6 O 0 0.22291573882102966
/ O 0 0.0060860775411129
C7 O 0 0.007579335011541843
marker O 0 0.00024378103262279183
haplotypes O 0 0.0007417373126372695
associated O 0 1.148822957475204e-05
with O 0 3.536942813298083e-06
most O 0 1.0416501936560962e-05
C7 B-Disease 1 0.9993434548377991
defects I-Disease 1 0.9870872497558594
are O 0 1.7527378304293961e-06
tabulated O 0 6.729677988914773e-05
. O 0 5.2895975386491045e-06
. O 0 2.0299685274949297e-05

A O 0 0.00024570192908868194
genome O 0 0.00012088583025615662
- O 0 3.782628846238367e-05
wide O 0 7.007325166341616e-06
search O 0 5.480371783050941e-06
for O 0 1.5093346519279294e-06
chromosomal O 0 0.03217349201440811
loci O 0 0.00012489012442529202
linked O 0 8.310576959047467e-05
to O 0 3.499946615193039e-06
mental O 1 0.8917180895805359
health O 0 0.005370848346501589
wellness O 0 0.05029434338212013
in O 0 2.9611301215481944e-06
relatives O 0 8.109823284030426e-06
at O 0 1.4506621255350183e-06
high O 0 3.945112257497385e-05
risk O 0 0.00010543216922087595
for O 0 5.778540071332827e-05
bipolar B-Disease 1 1.0
affective I-Disease 1 0.9999998807907104
disorder I-Disease 1 0.9999241828918457
among O 0 1.2340317425696412e-06
the O 0 6.330615747174306e-07
Old O 0 1.1635826012934558e-05
Order O 0 7.853291208448354e-06
Amish O 0 0.00012694844917859882
. O 0 1.641883500269614e-05

Bipolar B-Disease 1 0.9999997615814209
affective I-Disease 1 0.9999995231628418
disorder I-Disease 1 0.9999998807907104
( O 0 0.02070513367652893
BPAD B-Disease 1 0.9999995231628418
; O 1 0.9313202500343323
manic B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999995231628418
depressive I-Disease 1 1.0
illness I-Disease 1 0.9980167150497437
) O 0 4.124921360926237e-06
is O 0 5.085803991278226e-07
characterized O 0 6.38254641671665e-06
by O 0 3.199230604877812e-07
episodes O 0 2.742722699622391e-06
of O 0 7.344875143644458e-07
mania B-Disease 0 0.0032460130751132965
and O 0 2.5262474991905037e-06
/ O 0 0.0002852675970643759
or O 0 4.795885615749285e-06
hypomania B-Disease 0 0.022792935371398926
interspersed O 0 1.916817927849479e-05
with O 0 1.4751094568055123e-06
periods O 0 3.2433865271741524e-05
of O 0 6.631014457525453e-06
depression B-Disease 0 0.08216023445129395
. O 0 3.5496042983140796e-05

Compelling O 0 0.0004112017631996423
evidence O 0 5.495872028404847e-05
supports O 0 3.2455369364470243e-05
a O 0 9.402945579495281e-06
significant O 0 5.7278275562566705e-06
genetic O 0 1.2965490896021947e-05
component O 0 3.5949515222455375e-06
in O 0 5.113271868140146e-07
the O 0 8.860167213242676e-07
susceptibility O 0 0.00013451244740281254
to O 0 4.395407813717611e-06
develop O 0 0.00012569323007483035
BPAD B-Disease 1 0.9998879432678223
. O 0 4.967700078850612e-05

To O 0 2.0710733224404976e-05
date O 0 1.1692412044794764e-05
, O 0 1.3813527175443596e-06
however O 0 4.842755174649938e-07
, O 0 2.643367054133705e-07
linkage O 0 5.720785338780843e-06
studies O 0 9.942258429873618e-07
have O 0 2.3618596856067597e-07
attempted O 0 4.383640771266073e-06
only O 0 1.1045793257835612e-07
to O 0 2.390389113315905e-07
identify O 0 3.0366315968421986e-06
chromosomal O 0 0.0010708051268011332
loci O 0 1.1344388440193143e-05
that O 0 1.8727160977505264e-07
cause O 0 1.6905403299460886e-06
or O 0 3.8072829511293094e-07
increase O 0 1.7673761476544314e-06
the O 0 5.806785452477925e-07
risk O 0 6.812973424530355e-06
of O 0 2.041998186541605e-06
developing O 0 9.263731044484302e-05
BPAD B-Disease 1 0.9997490048408508
. O 0 4.622554479283281e-05

To O 0 1.926839104271494e-05
determine O 0 7.849314897612203e-06
whether O 0 1.2187118727524648e-06
there O 0 2.1835322172591987e-07
could O 0 3.687127048124239e-07
be O 0 2.0240473475041654e-07
protective O 0 5.649771628668532e-05
alleles O 0 6.78215519656078e-06
that O 0 1.8577104299311031e-07
prevent O 0 2.28931594392634e-06
or O 0 9.936902642948553e-07
reduce O 0 6.247624241950689e-06
the O 0 5.250989261185168e-07
risk O 0 3.2289244700223207e-06
of O 0 2.708960096242663e-07
developing O 0 7.727166121185292e-06
BPAD B-Disease 1 0.9991469383239746
, O 0 3.2366980917686305e-07
similar O 0 2.4541989773751993e-07
to O 0 6.311530853508884e-08
what O 0 7.580412386687385e-08
is O 0 1.627935262149549e-07
observed O 0 8.004699907360191e-07
in O 0 5.463633101498999e-07
other O 0 3.301287051726831e-06
genetic B-Disease 1 0.9999793767929077
disorders I-Disease 1 1.0
, O 0 2.9302682378329337e-06
we O 0 6.000433359076851e-07
used O 0 1.7254000340471976e-05
mental O 1 0.963702917098999
health O 0 0.012127331458032131
wellness O 0 0.2056797742843628
( O 0 4.677155629906338e-06
absence O 0 2.35156221606303e-06
of O 0 1.2527322041933076e-06
any O 0 2.325470995856449e-05
psychiatric B-Disease 1 0.9999992847442627
disorder I-Disease 1 0.9999825954437256
) O 0 1.8356242890149588e-06
as O 0 2.788638937545329e-07
the O 0 7.779938187013613e-07
phenotype O 0 0.00044292659731581807
in O 0 2.784097716812539e-07
our O 0 3.5836859524351894e-07
genome O 0 3.12172960548196e-06
- O 0 6.701601250824751e-06
wide O 0 2.8614172151719686e-06
linkage O 0 1.1416038432798814e-05
scan O 0 1.3407810001808684e-05
of O 0 1.3417900390777504e-07
several O 0 1.9666255468564486e-07
large O 0 4.1076114598581626e-07
multigeneration O 0 2.71646749752108e-05
Old O 0 3.222012537662522e-06
Order O 0 6.974470352361095e-07
Amish O 0 1.2772386071446817e-05
pedigrees O 0 2.3251648599398322e-05
exhibiting O 0 3.104744109805324e-06
an O 0 5.75911315081612e-07
extremely O 0 8.611337761976756e-06
high O 0 3.199513957952149e-05
incidence O 0 0.001993955345824361
of O 0 7.628269941051258e-06
BPAD B-Disease 1 0.9999719858169556
. O 0 7.072831795085222e-05

We O 0 2.0900535673717968e-05
have O 0 2.4329838197445497e-06
found O 0 1.022710762299539e-06
strong O 0 9.404948286828585e-07
evidence O 0 2.760878032859182e-07
for O 0 1.667421258844115e-07
a O 0 1.652430000831373e-06
locus O 0 1.80745410034433e-05
on O 0 4.7991707106120884e-06
chromosome O 0 0.00018361622642260045
4p O 0 0.0018288776045665145
at O 0 1.8209744894193136e-06
D4S2949 O 0 2.8643125915550627e-05
( O 0 1.194663468595536e-06
maximum O 0 2.6245379558531567e-06
GENEHUNTER O 0 6.699710502289236e-05
- O 0 1.4988168004492763e-05
PLUS O 0 7.453239959431812e-06
nonparametric O 0 2.1047870177426375e-05
linkage O 0 1.2462970516935457e-05
score O 0 2.606655243653222e-06
= O 0 9.146919182967395e-06
4 O 0 9.335478807770414e-07
. O 0 1.3034676271672652e-07
05 O 0 4.792479103343794e-06
, O 0 7.36011941171455e-07
P O 0 5.6190325267380103e-05
= O 0 1.444508961867541e-05
5 O 0 6.746872713847551e-07
. O 0 1.2884930811196682e-07
22 O 0 7.065896170388442e-07
x O 0 4.428788088262081e-06
10 O 0 4.979841037311417e-07
( O 0 3.983109309046995e-07
- O 0 2.512916580599267e-06
4 O 0 1.3755736745224567e-06
) O 0 4.494815755151649e-07
; O 0 6.134135333013546e-07
SIBPAL O 0 3.192750955349766e-05
Pempirical O 0 1.647322642384097e-05
value O 0 2.9846026450286445e-07
< O 0 3.6293201901571592e-06
3 O 0 7.088627853590879e-07
x O 0 4.947886282025138e-06
10 O 0 5.562172304962587e-07
( O 0 3.597156137402635e-07
- O 0 2.9253676530061057e-06
5 O 0 5.597169661086809e-07
) O 0 1.4366148093358788e-07
) O 0 8.463904066502437e-08
and O 0 8.243068805313669e-08
suggestive O 0 2.669037939995178e-06
evidence O 0 1.1495231433400477e-07
for O 0 8.175552324019009e-08
a O 0 7.551074645562039e-07
locus O 0 1.456510290154256e-05
on O 0 3.175246774844709e-06
chromosome O 0 0.0012215105816721916
4q O 0 0.43709635734558105
at O 0 1.6713933064238518e-06
D4S397 O 0 3.118323002126999e-05
( O 0 1.3826455642629298e-06
maximum O 0 3.421864903430105e-06
GENEHUNTER O 0 8.113124931696802e-05
- O 0 1.590552528796252e-05
PLUS O 0 5.2111772674834356e-06
nonparametric O 0 1.929549762280658e-05
linkage O 0 1.2960595995537005e-05
score O 0 2.273706741107162e-06
= O 0 1.1391732186893933e-05
3 O 0 8.954780810199736e-07
. O 0 1.540372380759436e-07
29 O 0 1.678924149928207e-06
, O 0 3.2998599408529117e-07
P O 0 4.6735774958506227e-05
= O 0 5.709856850444339e-06
2 O 0 4.6700148459422053e-07
. O 0 1.1279303180344868e-07
57 O 0 1.4752148445040802e-06
x O 0 1.1221723070775624e-05
10 O 0 5.532583031708782e-07
( O 0 3.7269555264174414e-07
- O 0 2.9318809993128525e-06
3 O 0 8.761746244090318e-07
) O 0 3.574306504106062e-07
; O 0 7.084228172971052e-07
SIBPAL O 0 2.6006464395322837e-05
Pempirical O 0 1.4731687770108692e-05
value O 0 4.1153984398079047e-07
< O 0 3.350711040184251e-06
1 O 0 5.330014118953841e-07
x O 0 3.3142016491183313e-06
10 O 0 4.393637880184542e-07
( O 0 3.560259642654273e-07
- O 0 2.2001636352797505e-06
3 O 0 7.054496791170095e-07
) O 0 1.8782502309022675e-07
) O 0 1.19739368642513e-07
that O 0 4.665020369998274e-08
are O 0 1.0767857361315691e-07
linked O 0 1.2735336895275395e-05
to O 0 7.141729838622268e-06
mental O 1 0.967603325843811
health O 0 0.05758056789636612
wellness O 1 0.721259355545044
. O 0 6.6132124629803e-05

These O 0 2.1636729798046872e-05
findings O 0 1.538312790216878e-05
are O 0 5.960907287771988e-07
consistent O 0 8.81563153143361e-07
with O 0 2.5207748421962606e-07
the O 0 4.4139946453469747e-07
hypothesis O 0 1.6663498172420077e-06
that O 0 1.0111048709404713e-07
certain O 0 2.720501868225256e-07
alleles O 0 5.749856427428313e-06
could O 0 8.218717653107888e-07
prevent O 0 1.315113877353724e-06
or O 0 5.234269906395639e-07
modify O 0 7.928874765639193e-06
the O 0 1.0682956599339377e-06
clinical O 0 8.57943159644492e-05
manifestations O 0 1.3330889487406239e-05
of O 0 9.848944273471716e-07
BPAD B-Disease 1 0.9997621178627014
and O 0 2.213124616901041e-06
perhaps O 0 1.9010026335308794e-06
other O 0 1.9645201518869726e-06
related O 0 0.00037650359445251524
affective B-Disease 1 0.9999935626983643
disorders I-Disease 1 0.999993085861206
. O 0 6.174191366881132e-05

Segregation O 0 0.01756838709115982
distortion O 0 0.1037556380033493
in O 0 0.00574968196451664
myotonic B-Disease 1 0.9999995231628418
dystrophy I-Disease 1 0.9999998807907104
. O 0 0.0012480238219723105

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.8473459482192993
DM B-Disease 1 0.9999998807907104
) O 0 7.18041046638973e-05
is O 0 5.811821665702155e-06
an O 0 2.52211593760876e-05
autosomal B-Disease 1 0.9999133348464966
dominant I-Disease 1 0.9859806299209595
disease I-Disease 0 0.1675359457731247
which O 0 5.433956857814337e-07
, O 0 2.2888765727202554e-07
in O 0 1.499014956607425e-07
the O 0 3.3730722748259723e-07
typical O 0 4.258267381374026e-06
pedigree O 0 1.5026782421045937e-05
, O 0 2.8509364824458316e-07
shows O 0 3.622500628353009e-07
a O 0 9.406858225702308e-07
three O 0 1.6910532849578885e-06
generation O 0 2.7456399038783275e-05
anticipation O 0 4.68764228571672e-05
cascade O 0 0.0003486757050268352
. O 0 4.7683461161796004e-05

This O 0 6.458567804656923e-05
results O 0 0.00010006038792198524
in O 0 7.776069105602801e-05
infertility B-Disease 1 0.9999963045120239
and O 1 0.9981643557548523
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.006670033093541861
CDM B-Disease 0 0.0038613895885646343
) O 0 1.8422323364575277e-06
with O 0 2.919552173352713e-07
the O 0 6.397602305696637e-07
disappearance O 0 3.7296304071787745e-05
of O 0 2.5169651962642092e-06
DM B-Disease 1 0.9999996423721313
in O 0 5.759944087913027e-06
that O 0 2.0300490177760366e-06
pedigree O 0 0.000125385558931157
. O 0 1.6695625163265504e-05

The O 0 3.155931335641071e-05
concept O 0 1.3723850315727759e-05
of O 0 2.4445193957944866e-06
segregation O 0 0.00011139550770167261
distortion O 0 0.00021406137966550887
, O 0 6.114557891123695e-07
where O 0 2.0140788592470926e-07
there O 0 9.130268807666653e-08
is O 0 1.731817746986053e-07
preferential O 0 3.917902176908683e-06
transmission O 0 7.089363862178288e-06
of O 0 8.67012488470209e-08
the O 0 1.2682363603744307e-07
larger O 0 5.18632532475749e-07
allele O 0 1.7672244894129108e-06
at O 0 2.1938328131909657e-07
the O 0 5.971672294435848e-07
DM B-Disease 1 0.9999843835830688
locus O 0 7.323130557779223e-05
, O 0 3.937823862543155e-07
has O 0 2.3119136471905222e-07
been O 0 1.1466304528084947e-07
put O 0 2.323992163155708e-07
forward O 0 5.626583288176334e-07
to O 0 1.6427354410097905e-07
explain O 0 1.161702584795421e-06
partially O 0 3.2702653243177338e-06
the O 0 2.1630486912727065e-07
maintenance O 0 8.550184247724246e-06
of O 0 1.1234509429414175e-06
DM B-Disease 1 0.9999994039535522
in O 0 2.7040739496442256e-06
the O 0 1.5250581100190175e-06
population O 0 1.1768413969548419e-05
. O 0 1.176422847493086e-05

In O 0 3.573999856598675e-05
a O 0 2.0097792003070936e-05
survey O 0 1.979485750780441e-05
of O 0 2.0617305835912703e-06
DM B-Disease 1 0.9999860525131226
in O 0 1.9848885131068528e-06
Northern O 0 4.791405444848351e-06
Ireland O 0 3.33179923472926e-06
, O 0 1.0824893479366438e-06
59 O 0 2.0900575691484846e-05
pedigrees O 0 5.349959246814251e-05
were O 0 5.201083240535809e-06
ascertained O 0 0.00011363405792508274
. O 0 2.6736370273283683e-05

Sibships O 0 0.0032916259951889515
where O 0 1.0465430932526942e-05
the O 0 1.142542942034197e-06
status O 0 6.516303301395965e-07
of O 0 8.321612909867326e-08
all O 0 3.8434865956560316e-08
the O 0 7.827771497659342e-08
members O 0 2.0912150944241148e-07
had O 0 5.740540700571728e-07
been O 0 2.2193376025825273e-07
identified O 0 8.049827897593786e-07
were O 0 1.6412134584697924e-07
examined O 0 1.1142021776322508e-06
to O 0 1.271459950658027e-07
determine O 0 3.751539452423458e-07
the O 0 2.9233470399958605e-07
transmission O 0 4.238709607307101e-06
of O 0 1.4648308876985539e-07
the O 0 9.847385626926553e-07
DM B-Disease 1 0.9999902248382568
expansion O 0 2.4590006432845257e-05
from O 0 1.0591594445941155e-06
affected O 0 1.866961383711896e-06
parents O 0 8.844000944918662e-07
to O 0 4.0224583131021063e-07
their O 0 2.4117998691508546e-06
offspring O 0 7.957322668517008e-05
. O 0 1.5838742911000736e-05

Where O 0 5.257219891063869e-05
the O 0 1.383997096127132e-05
transmitting O 0 0.00022065873781684786
parent O 0 7.204738358268514e-05
was O 0 5.934111868555192e-06
male O 0 2.7630570912151597e-05
, O 0 4.0029972296906635e-06
58 O 0 6.266966374823824e-05
. O 0 2.383233186264988e-05

3 O 0 0.0002707312232814729
% O 0 1.7771602870197967e-05
of O 0 5.592148681898834e-07
the O 0 1.1759323115256848e-06
offspring O 0 2.9116854420863092e-05
were O 0 6.383602908499597e-07
affected O 0 9.825143933994696e-07
, O 0 1.1268357269500484e-07
and O 0 1.038901871197595e-07
in O 0 1.193374004060388e-07
the O 0 1.1518001485910645e-07
case O 0 3.2465135291204206e-07
of O 0 8.147267749336606e-08
a O 0 2.5681745228212094e-06
female O 0 4.3853015085915104e-05
transmitting O 0 0.0001258550037164241
parent O 0 1.3465639312926214e-05
, O 0 1.8347385548622697e-06
68 O 0 3.484120315988548e-05
. O 0 1.356243865302531e-05

7 O 0 0.002246157033368945
% O 0 0.00030292777228169143
were O 0 2.1331439711502753e-05
affected O 0 5.678323213942349e-05
. O 0 4.0928094676928595e-05

Studies O 0 0.00017708215455058962
on O 0 1.5915476978989318e-05
meiotic O 0 0.0010347358183935285
drive O 0 0.00013142595707904547
in O 0 1.2515103662735783e-05
DM B-Disease 1 0.9999992847442627
have O 0 5.167833933228394e-06
shown O 0 1.3805164371660794e-06
increased O 0 1.5937813486743835e-06
transmission O 0 3.1192864753393224e-06
of O 0 6.860425827426297e-08
the O 0 1.5662359942325565e-07
larger O 0 1.0320529781893129e-06
allele O 0 3.27125098920078e-06
at O 0 3.0418667051890225e-07
the O 0 9.020608331411495e-07
DM B-Disease 1 0.999622106552124
locus O 0 5.083613723400049e-05
in O 0 3.24651205119153e-06
non O 0 3.6446617741603404e-05
- O 0 0.05257789418101311
DM O 1 0.9999984502792358
heterozygotes O 0 0.0017606682376936078
for O 0 8.807498488749843e-06
CTGn O 0 0.0027493233792483807
. O 0 4.0133822039933875e-05

This O 0 2.9085798814776354e-05
study O 0 1.0193717571382876e-05
provides O 0 3.858493073494174e-06
further O 0 1.05490141777409e-06
evidence O 0 6.014348628013977e-07
that O 0 1.501765041211911e-07
the O 0 1.406176011187199e-06
DM B-Disease 1 0.9999892711639404
expansion O 0 3.215239121345803e-05
tends O 0 4.087450179213192e-06
to O 0 5.013243935536593e-07
be O 0 1.016660235109157e-06
transmitted O 0 2.3212211090140045e-05
preferentially O 0 5.0748029025271535e-05
. O 0 1.6554124158574268e-05

Diagnosis O 1 0.9994657635688782
of O 0 0.0022687215823680162
hemochromatosis B-Disease 1 0.9999973773956299
. O 0 0.0009571936097927392

If O 0 0.0007630191976204515
untreated O 1 0.6907748579978943
, O 0 0.00022428971715271473
hemochromatosis B-Disease 1 0.9999998807907104
can O 0 0.0002074666554108262
cause O 0 0.007732412777841091
serious O 0 0.05754699185490608
illness O 1 0.6825245022773743
and O 0 4.9237155508308206e-06
early B-Disease 0 2.47260213654954e-05
death I-Disease 0 3.6993584217270836e-05
, O 0 7.218477549031377e-07
but O 0 2.841240984707838e-07
the O 0 2.2964293293625815e-06
disease O 0 0.00021178254974074662
is O 0 4.6209632387217425e-07
still O 0 1.53119344759034e-06
substantially O 0 6.984059291426092e-05
under O 0 4.250442361808382e-05
- O 1 0.9777132868766785
diagnosed O 1 0.9995905756950378
. O 0 4.572581747197546e-05

The O 0 2.60749802691862e-05
cornerstone O 0 7.828895468264818e-05
of O 0 2.3997592961677583e-06
screening O 0 1.3767293239652645e-05
and O 0 1.7336037672066595e-06
case O 0 3.6258295494917547e-06
detection O 0 1.6118568964884616e-05
is O 0 3.0981286158748844e-07
the O 0 2.654264790180605e-07
measurement O 0 3.5542145724321017e-06
of O 0 6.556135190294299e-07
serum O 0 3.091219696216285e-05
transferrin O 0 3.1003008189145476e-05
saturation O 0 9.489046533417422e-06
and O 0 8.88559554823587e-07
the O 0 2.5867129807011224e-06
serum O 0 7.954114698804915e-05
ferritin O 0 0.00023218886053655297
level O 0 1.744563451211434e-05
. O 0 1.991100907616783e-05

Once O 0 0.00027383078122511506
the O 0 2.635055352584459e-05
diagnosis O 0 0.2128608375787735
is O 0 6.758458766853437e-06
suspected O 0 9.681822848506272e-05
, O 0 2.2820486265118234e-06
physicians O 0 1.679149499977939e-05
must O 0 9.383455221723125e-07
use O 0 1.2905460380352451e-06
serum O 0 2.976277937705163e-05
ferritin O 0 7.748983625788242e-05
levels O 0 1.4830367263130029e-06
and O 0 7.743764172118972e-07
hepatic O 0 0.0007136001368053257
iron O 0 4.631176125258207e-05
stores O 0 6.591571036551613e-06
on O 0 4.723603524325881e-06
liver O 0 0.0009266469860449433
biopsy O 0 0.0031370045617222786
specimens O 0 2.3981599497346906e-06
to O 0 7.679552709305426e-07
assess O 0 9.24900668906048e-05
patients O 0 4.45627338194754e-05
for O 0 2.2800378474130412e-07
the O 0 3.751782742256182e-07
presence O 0 1.982924459298374e-06
of O 0 1.944139739862294e-06
iron B-Disease 0 0.0016922290669754148
overload I-Disease 0 0.0029942479450255632
. O 0 3.2797899621073157e-05

Liver O 1 0.9999645948410034
biopsy O 1 0.9694907665252686
is O 0 8.350934876943938e-06
also O 0 1.1864772204717156e-06
used O 0 4.808928792954248e-07
to O 0 1.660562674032917e-07
establish O 0 5.88887644425995e-07
the O 0 1.5354750360074831e-07
presence O 0 5.53327424768213e-07
or O 0 4.1064129163714824e-07
absence O 0 2.1038824797869893e-06
of O 0 7.737835971965978e-07
cirrhosis B-Disease 0 0.0940946713089943
, O 0 8.564863378524024e-07
which O 0 5.858963163518638e-07
can O 0 1.4088175248616608e-06
affect O 0 2.461548865539953e-05
prognosis O 1 0.8694995045661926
and O 0 2.4007318643270992e-05
management O 0 0.00017678980657365173
. O 0 3.3089949283748865e-05

A O 0 0.0004363766056485474
DNA O 0 0.0001931210863403976
- O 0 0.00017267408838961273
based O 0 3.499228796499665e-06
test O 0 9.61921614361927e-07
for O 0 2.1000245453706157e-07
the O 0 5.918954002481769e-07
HFE O 0 0.002043790416792035
gene O 0 2.0569405023707077e-06
is O 0 1.1211738382144176e-07
commercially O 0 2.546405823977693e-07
available O 0 9.147159119038406e-08
, O 0 5.789014423385197e-08
but O 0 2.4480506510826672e-08
its O 0 4.5745466081825725e-08
place O 0 1.4997385733295232e-07
in O 0 1.9229199210712977e-07
the O 0 1.2774498827639036e-06
diagnosis O 0 0.050678204745054245
of O 0 7.213038770714775e-06
hemochromatosis B-Disease 1 0.9999998807907104
is O 0 2.8745732834067894e-06
still O 0 1.9192609670426464e-06
being O 0 4.755931968247751e-06
evaluated O 0 7.335403643082827e-05
. O 0 1.4410085896088276e-05

Currently O 0 5.197228165343404e-05
, O 0 2.353446916458779e-06
the O 0 3.826261831818556e-07
most O 0 1.8399165924165573e-07
useful O 0 1.8523817857385438e-07
role O 0 2.921908901498682e-07
for O 0 1.2294465534523624e-07
this O 0 1.2298886531425524e-07
test O 0 4.222101779305376e-07
is O 0 6.832844690052298e-08
in O 0 7.874597685031404e-08
the O 0 1.979224180104211e-07
detection O 0 7.531551545980619e-06
of O 0 9.811632253331481e-07
hemochromatosis B-Disease 1 0.9999932050704956
in O 0 6.5680308125593e-07
the O 0 3.541441913057497e-07
family O 0 7.197689910753979e-07
members O 0 2.6701326305555995e-07
of O 0 3.346861205955065e-07
patients O 0 1.4409481082111597e-05
with O 0 4.476463857372437e-07
a O 0 1.8575468857306987e-05
proven O 0 3.71222231478896e-05
case O 0 2.221621343778679e-06
of O 0 1.0542920563239022e-06
the O 0 3.215140895918012e-05
disease O 0 0.006602587644010782
. O 0 3.224463216611184e-05

It O 0 2.0591527572833e-05
is O 0 6.358682639984181e-06
crucial O 0 2.2468990209745243e-05
to O 0 4.864072616328485e-05
diagnose O 1 0.9999868869781494
hemochromatosis B-Disease 1 1.0
before O 0 0.021586861461400986
hepatic B-Disease 1 0.9999935626983643
cirrhosis I-Disease 1 0.999940037727356
develops O 0 0.004181382246315479
because O 0 1.7361237041768618e-05
phlebotomy O 1 0.6907538175582886
therapy O 0 0.17112573981285095
can O 0 3.1486055377172306e-05
avert O 1 0.99905925989151
serious O 1 0.9991098046302795
chronic O 1 1.0
disease O 1 0.9922256469726562
and O 0 3.902951448253589e-06
can O 0 6.005545287735004e-07
even O 0 4.018662593807676e-07
lead O 0 3.4049439818772953e-06
to O 0 7.53461677049927e-07
normal O 0 8.392819836444687e-06
life O 0 5.256387794361217e-06
expectancy O 0 6.179964839247987e-05
. O 0 2.9106995498295873e-06
. O 0 9.556613804306835e-06

Prevalence O 0 0.005584462080150843
of O 0 1.3749842764809728e-05
the O 0 8.202202479878906e-06
I1307K O 0 0.00047201005509123206
APC B-Disease 0 0.0001327598438365385
gene O 0 8.633623110654298e-06
variant O 0 1.0659697181836236e-05
in O 0 5.446289037536189e-07
Israeli O 0 7.639365321665537e-06
Jews O 0 8.435729910161172e-07
of O 0 9.586652538473572e-08
differing O 0 8.384574812225765e-07
ethnic O 0 1.667569108576572e-06
origin O 0 1.5013198435553932e-06
and O 0 5.861114914296195e-06
risk O 0 0.001572013832628727
for O 0 0.04822581261396408
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00014393751916941255

BACKGROUND O 0 0.0018196390010416508
& O 0 0.0010032443096861243
AIMS O 0 0.00013118832430336624
Israeli O 0 2.2055855879443698e-05
Jews O 0 3.5240543638792587e-06
of O 0 3.647285780061793e-07
European O 0 1.4431914223678177e-06
birth O 0 2.5501933123450726e-05
, O 0 3.221199733616231e-07
i O 0 2.3452996344985877e-07
. O 0 1.1083548656642961e-07
e O 0 8.569161309424089e-07
. O 0 6.632821225593943e-08
, O 0 1.316102355986004e-07
Ashkenazim O 0 5.451409833767684e-06
, O 0 1.2391080872475868e-07
have O 0 2.0607092210411793e-07
the O 0 4.51765799880377e-06
highest O 1 0.9637126922607422
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.1745109260082245
of O 0 6.772051506231946e-07
any O 0 6.90466379182908e-07
Israeli O 0 2.4778773877187632e-05
ethnic O 0 2.2645772332907654e-05
group O 0 3.8689795474056154e-05
. O 0 1.4946204828447662e-05

The O 0 0.00012793704809155315
I1307K O 0 0.001968035940080881
APC B-Disease 0 0.0006850818172097206
gene O 0 6.414583185687661e-05
variant O 0 8.076659287326038e-05
was O 0 6.810426839365391e-06
found O 0 2.1431776531244395e-06
in O 0 2.768518470475101e-06
6 O 0 4.011331111541949e-05
. O 0 1.8296248526894487e-05

1 O 0 0.00018072163220494986
% O 0 2.199320078943856e-05
of O 0 6.790437510062475e-07
American O 0 1.3343941418497707e-06
Jews O 0 2.473598897267948e-06
, O 0 3.0037827514206583e-07
28 O 0 1.3706056734008598e-06
% O 0 3.863663380343496e-07
of O 0 2.2472509897397686e-07
their O 0 2.6568593966658227e-05
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 4.899467603536323e-05
, O 0 6.951627256057691e-07
but O 0 1.9181726429451373e-07
not O 0 1.1333063554275213e-07
in O 0 5.43016994924983e-07
non O 0 9.458562999498099e-06
- O 0 0.00017155372188426554
Jews O 0 4.539440124062821e-05
. O 0 1.7347665561828762e-05

We O 0 3.85865532734897e-05
assessed O 0 2.753847547865007e-05
the O 0 3.6335279673949117e-06
I1307K O 0 0.00040151472785510123
prevalence O 0 0.00017174979439005256
in O 0 6.305887723101478e-07
Israeli O 0 3.885274054482579e-06
Jews O 0 9.06739046513394e-07
of O 0 1.538727900651793e-07
differing O 0 9.513823329143634e-07
ethnic O 0 1.5338124512709328e-06
origin O 0 1.8255232134833932e-06
and O 0 3.6974727208871627e-06
risk O 0 0.000357029348379001
for O 0 0.007313685026019812
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0002258838649140671

METHODS O 0 0.00019304669694975019
DNA O 0 9.398032125318423e-05
samples O 0 8.945836270868313e-06
from O 0 9.807159813135513e-07
500 O 0 1.8995764321516617e-06
unrelated O 0 3.6727558381244307e-06
Jews O 0 7.17853652076883e-07
of O 0 8.530953721219703e-08
European O 0 3.0068696332818945e-07
or O 0 2.6042823719762964e-07
non O 0 7.172446316872083e-07
- O 0 2.9832447125954786e-06
European O 0 3.118897780041152e-07
origin O 0 2.1282734508076828e-07
, O 0 6.510899197564868e-08
with O 0 7.308138094686001e-08
or O 0 2.569031778421049e-07
without O 0 8.354947311772776e-08
a O 0 2.3556422945603117e-07
personal O 0 7.196935030151508e-07
and O 0 8.578588790442154e-07
/ O 0 0.00010614516941132024
or O 0 6.304780981736258e-07
family O 0 5.058735155216709e-07
history O 0 2.795274269828951e-07
of O 0 3.5556755051402433e-07
neoplasia B-Disease 0 0.20330192148685455
, O 0 4.642793385301047e-07
were O 0 2.585551328593283e-07
examined O 0 1.7592604990568361e-06
for O 0 1.5861498070535163e-07
the O 0 3.5723505220630614e-07
I1307K O 0 6.325518916128203e-05
variant O 0 5.1491592785168905e-06
by O 0 1.593482039652372e-07
the O 0 3.4528650871834543e-07
allele O 0 5.464625701279147e-06
- O 0 9.641693395678885e-06
specific O 0 2.398560354777146e-06
oligonucleotide O 0 0.00021777499932795763
( O 0 7.821069630153943e-06
ASO O 0 0.0001380150206387043
) O 0 4.016362254333217e-06
method O 0 1.5060037185321562e-05
. O 0 1.4867601748846937e-05

RESULTS O 0 0.0003673891769722104
In O 0 9.641987162467558e-06
persons O 0 8.149292625603266e-06
at O 0 2.3243965188157745e-06
average O 0 3.93506525142584e-05
risk O 0 0.00019138475181534886
for O 0 0.007111328188329935
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.0658436622179579e-05
I1307K O 0 0.0003950419486500323
was O 0 2.6949012408294948e-06
found O 0 1.0064770776807563e-06
in O 0 1.5304196949728066e-06
5 O 0 1.4078671483730432e-05
. O 0 1.0642063898558263e-05

0 O 0 0.0003861101868096739
% O 0 2.8669111998169683e-05
of O 0 1.2074611959178583e-06
120 O 0 3.206749624951044e-06
European O 0 2.1003359051974257e-06
and O 0 1.96705809685227e-06
1 O 0 1.4045278476260137e-05
. O 0 1.9279732441646047e-05

6 O 0 0.0004303199239075184
% O 0 1.8595639630802907e-05
of O 0 9.225019539371715e-07
188 O 0 6.543281870108331e-06
non O 0 2.9821637781424215e-06
- O 0 9.745618626766372e-06
European O 0 1.7133087339971098e-06
Jews O 0 3.258391870986088e-06
( O 0 2.377428700128803e-06
P O 0 9.521904576104134e-05
= O 0 1.8228307453682646e-05
0 O 0 1.948391854966758e-06
. O 0 5.351569711820048e-07
08 O 0 1.1698580237862188e-05
) O 0 5.334079105523415e-06
. O 0 1.3058583135716617e-05

It O 0 7.6598662417382e-05
occurred O 0 9.999608300859109e-05
in O 0 1.2301740753173362e-05
15 O 0 4.285522300051525e-05
. O 0 2.3237238565343432e-05

4 O 0 0.0004913411685265601
% O 0 5.600394433713518e-05
of O 0 3.2076977731776424e-06
52 O 0 6.65690895402804e-05
Ashkenazi O 0 0.0005966557073406875
Israelis O 0 0.0001653338549658656
with O 0 1.7684938939055428e-05
familial O 1 0.9988158941268921
cancer B-Disease 1 0.9935732483863831
( O 0 2.585001857369207e-05
P O 0 0.003074329113587737
= O 0 3.5352877603145316e-05
0 O 0 1.4786362498853123e-06
. O 0 1.6172518257917545e-07
02 O 0 6.9028797042847145e-06
) O 0 3.0820734764347435e-07
and O 0 9.766376507513996e-08
was O 0 5.748353260059957e-07
not O 0 1.3585339786459372e-07
detected O 0 7.916128765828034e-07
in O 0 1.5496225103106553e-07
51 O 0 3.342770014569396e-06
non O 0 8.375591846743191e-07
- O 0 4.2440451579750516e-06
European O 0 9.245011369785061e-07
Jews O 0 2.965615067296312e-06
at O 0 2.0328523078205762e-06
increased O 0 0.00013518727791961282
cancer B-Disease 0 0.23609451949596405
risk O 0 0.00012859444541390985
. O 0 1.6914058505790308e-05

Colorectal B-Disease 1 0.9999973773956299
neoplasia I-Disease 1 0.9998739957809448
occurred O 0 0.012594586238265038
personally O 0 0.00014426730922423303
or O 0 3.243002993258415e-06
in O 0 5.64049855711346e-07
the O 0 2.8813087737944443e-07
families O 0 5.592377760876843e-07
of O 0 1.3702549495064886e-07
13 O 0 9.54201937020116e-07
of O 0 1.880956972399872e-07
20 O 0 1.805831971068983e-06
Ashkenazi O 0 6.838125409558415e-05
I1307K O 0 5.842237806064077e-05
carriers O 0 2.1859857497474877e-06
, O 0 1.6814867365155806e-07
8 O 0 3.8930343748688756e-07
of O 0 9.830179692471575e-08
whom O 0 1.0418223155284068e-06
also O 0 2.966920362723613e-07
had O 0 3.9149563235696405e-07
a O 0 7.318794246202742e-07
personal O 0 1.97875169760664e-06
or O 0 9.494065125181805e-07
family O 0 1.555386347718013e-06
history O 0 1.6889159724087222e-06
of O 0 4.837635970034171e-06
noncolonic O 0 0.2938685417175293
neoplasia B-Disease 1 0.9545907974243164
. O 0 4.2480074625927955e-05

CONCLUSIONS O 0 0.0003859686548821628
The O 0 3.0234026780817658e-05
I1307K O 0 0.0013515190221369267
APC O 0 0.0006922992179170251
variant O 0 0.00017272729019168764
may O 0 4.557652118819533e-06
represent O 0 6.244064252314274e-07
a O 0 4.075002834724728e-06
susceptibility O 0 0.00017902403487823904
gene O 0 1.000154315988766e-05
for O 0 1.5304405678762123e-05
colorectal B-Disease 1 1.0
, I-Disease 0 4.9225982365896925e-06
or I-Disease 0 7.929661478556227e-07
other I-Disease 0 3.001002539804176e-07
, I-Disease 0 4.53271923106513e-06
cancers I-Disease 0 0.02883313223719597
in O 0 1.955887228177744e-06
Ashkenazi O 0 0.0018751963507384062
Jews O 0 2.313017148480867e-06
, O 0 2.0693585156550398e-07
and O 0 2.2007732525253232e-07
partially O 0 6.512689196824795e-06
explains O 0 1.6072316384452279e-06
the O 0 4.116403431453364e-07
higher O 0 9.921544915414415e-06
incidence O 0 0.15882045030593872
of O 0 0.007738723885267973
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
in O 0 9.238672646461055e-06
European O 0 1.9725059246411547e-05
Israelis O 0 0.0002906436857301742
. O 0 3.321403346490115e-05

Systematic O 0 0.0004922213265672326
analysis O 0 7.425389776472002e-05
of O 0 1.4973638826631941e-05
coproporphyrinogen O 0 0.030715512111783028
oxidase O 0 0.0018200998893007636
gene O 0 0.00030430505285039544
defects O 1 0.5366889834403992
in O 0 1.2753009286825545e-05
hereditary B-Disease 0 0.023617595434188843
coproporphyria I-Disease 0 0.05557767674326897
and O 0 2.3842902010073885e-05
mutation O 0 0.00017624280008021742
update O 0 0.0002984528837259859
. O 0 3.054601256735623e-05

Hereditary B-Disease 1 0.9903242588043213
coproporphyria I-Disease 1 0.7082372307777405
( O 0 0.00011458495282568038
HC B-Disease 0 0.020136499777436256
) O 0 9.959900125977583e-06
is O 0 2.199616119469283e-06
an O 0 2.497356581443455e-05
acute O 1 0.9999884366989136
hepatic B-Disease 1 0.9999992847442627
porphyria I-Disease 1 0.9999979734420776
with O 0 0.0019061799393966794
autosomal O 1 0.9999456405639648
dominant O 0 0.18773722648620605
inheritance O 0 0.11034806072711945
caused O 0 0.0001269735221285373
by O 0 2.3447344119631452e-06
deficient B-Disease 0 0.0002780479262582958
activity I-Disease 0 1.9755705125135137e-06
of I-Disease 0 7.212697141767421e-07
coproporphyrinogen I-Disease 0 0.04118061065673828
III I-Disease 0 0.010764054954051971
oxidase I-Disease 0 9.363948629470542e-05
( O 0 4.321428605180699e-06
CPO O 0 4.512998566497117e-05
) O 0 6.255088464968139e-06
. O 0 1.1362643817847129e-05

Clinical O 0 0.4273616075515747
manifestations O 0 0.0006304678390733898
of O 0 9.979267815651838e-06
the O 0 7.712057413300499e-05
disease O 0 0.10661308467388153
are O 0 1.0793669389386196e-06
characterized O 0 0.00014209245273377746
by O 0 5.06742435391061e-06
acute O 1 0.9559457898139954
attacks O 0 0.01636544056236744
of O 0 0.00010932724399026483
neurological B-Disease 1 0.9999995231628418
dysfunction I-Disease 1 0.999860405921936
often O 0 1.9570832591853105e-05
precipitated O 0 0.0002026027359534055
by O 0 7.284332923518377e-07
drugs O 0 7.507936061301734e-06
, O 0 8.265296855825e-07
fasting O 0 4.5319146011024714e-05
, O 0 9.95250388768909e-07
cyclical O 0 8.00025081844069e-05
hormonal O 0 0.0003748824237845838
changes O 0 3.6889666716888314e-06
, O 0 2.0757142920047045e-06
or O 0 5.7384422689210624e-05
infectious B-Disease 1 0.8884910345077515
diseases I-Disease 0 0.18474489450454712
. O 0 3.185184323228896e-05

Skin O 1 0.999897837638855
photosensitivity O 1 0.9984148740768433
may O 0 0.0003335180808790028
also O 0 1.0343082067265641e-05
be O 0 2.133769612555625e-06
present O 0 8.86020188772818e-06
. O 0 2.445635254844092e-05

The O 0 4.546250784187578e-05
seven O 0 2.2795104086981155e-05
exons O 0 8.401246304856613e-05
, O 0 2.8462384307204047e-06
the O 0 1.363759110972751e-06
exon O 0 5.6899883929872885e-05
/ O 0 4.6315250074258074e-05
intron O 0 5.1124814490322024e-05
boundaries O 0 1.2114669516449794e-06
and O 0 1.808439833439479e-07
part O 0 2.6717628998085274e-07
of O 0 1.2909690383366978e-07
3 O 0 1.6904469930523192e-06
noncoding O 0 1.0711760296544526e-05
sequence O 0 3.1209629014483653e-07
of O 0 6.532842178330611e-08
the O 0 1.7496320481313887e-07
CPO O 0 7.806129360687919e-06
gene O 0 8.791946015662688e-07
were O 0 1.4536324499658804e-07
systematically O 0 2.392652277194429e-06
analyzed O 0 7.263058137141343e-07
by O 0 8.361132586287567e-08
an O 0 2.1047803500096052e-07
exon O 0 1.2081836757715791e-05
- O 0 1.4040685528016184e-05
by O 0 9.302019066126377e-07
- O 0 3.770355397136882e-05
exon O 0 0.00013178236258681864
denaturing O 0 0.005185804795473814
gradient O 0 0.001489422284066677
gel O 0 0.0036303354427218437
electrophoresis O 0 0.0028110055718570948
( O 0 7.322960300371051e-06
DGGE O 0 0.0001292482193093747
) O 0 5.505896751856199e-07
strategy O 0 1.5106119235497317e-06
followed O 0 5.242198426458344e-07
by O 0 9.185500005060021e-08
direct O 0 3.154091814394633e-07
sequencing O 0 1.4116378679318586e-06
in O 0 4.050366726460197e-07
seven O 0 2.998081527039176e-06
unrelated O 0 0.0001383175258524716
heterozygous O 0 0.0010395804420113564
HC B-Disease 1 0.8535835146903992
patients O 0 0.0010137163335457444
from O 0 1.1921219993382692e-06
France O 0 4.327986516727833e-06
, O 0 4.518570051459392e-07
Holland O 0 6.886664777994156e-06
, O 0 4.1700215547280095e-07
and O 0 6.178462399475393e-07
Czech O 0 1.1091506166849285e-05
Republic O 0 1.5749064914416522e-05
. O 0 1.3207851225160994e-05

Seven O 0 0.00019082553626503795
novel O 0 0.00014331766578834504
mutations O 0 0.00013179580855648965
and O 0 1.0702780173232895e-06
two O 0 1.546485236758599e-06
new O 0 1.6803285689093173e-05
polymorphisms O 0 0.000968777691014111
were O 0 8.82658514456125e-06
detected O 0 7.797112630214542e-05
. O 0 2.1573621779680252e-05

Among O 0 6.98063668096438e-05
these O 0 5.819181296828901e-06
mutations O 0 2.7296202461002395e-05
two O 0 7.031035806903674e-07
are O 0 7.584952754768892e-07
missense O 0 0.00012841886200476438
( O 0 2.256393827337888e-06
G197W O 0 2.849727934517432e-05
, O 0 6.61266710721975e-07
W427R O 0 4.485187673708424e-05
) O 0 3.1375913067677175e-07
, O 0 9.133211875678171e-08
two O 0 1.0102874625772529e-07
are O 0 1.1492951301761423e-07
nonsense O 0 5.4870761232450604e-06
( O 0 1.1540533932929975e-06
Q306X O 0 1.800109021132812e-05
, O 0 4.40197595708014e-07
Q385X O 0 1.941877417266369e-05
) O 0 2.8724144840452936e-07
, O 0 6.77641338597823e-08
two O 0 8.81955202203244e-08
are O 0 4.72525272243729e-08
small O 0 3.7316502243811556e-07
deletions O 0 1.0314506653230637e-05
( O 0 1.3782735095446697e-06
662de14bp O 0 2.0642273739213124e-05
; O 0 1.0324368986402988e-06
1168del3bp O 0 1.3695505913347006e-05
removing O 0 1.155216295956052e-06
a O 0 6.77506818647089e-07
glycine O 0 5.220951607043389e-06
at O 0 3.726201782683347e-07
position O 0 6.616022574235103e-07
390 O 0 4.480355528357904e-06
) O 0 2.680583293113159e-07
, O 0 6.921423789663095e-08
and O 0 7.082722675022524e-08
one O 0 8.100735016114413e-08
is O 0 9.007458601217877e-08
a O 0 7.135862460927456e-07
splicing O 0 2.178167414967902e-05
mutation O 0 1.413290920027066e-05
( O 0 9.462842740504129e-07
IVS1 O 0 5.5467713536927477e-05
- O 0 2.7557680368772708e-05
15c O 0 7.763376925140619e-05
- O 0 4.051958239870146e-05
- O 0 8.486313163302839e-05
> O 0 9.311838948633522e-05
g O 0 6.693108298350126e-05
) O 0 5.798086704089656e-07
which O 0 2.0543946277484793e-07
creates O 0 1.218046122630767e-06
a O 0 8.287065611511935e-07
new O 0 2.6669897579267854e-06
acceptor O 0 2.753364242380485e-05
splice O 0 0.0002382275997661054
site O 0 3.9418970118276775e-05
. O 0 2.2000727767590433e-05

The O 0 5.74177029193379e-05
pathological O 0 0.00021245298557914793
significance O 0 1.262041951122228e-05
of O 0 1.0245089470117819e-06
the O 0 1.3724616110266652e-06
point O 0 8.199855983548332e-06
mutations O 0 1.7075186406145804e-05
G197W O 0 2.304586087120697e-05
, O 0 4.3093314161524177e-07
W427R O 0 1.86087690963177e-05
, O 0 1.2122015391469176e-07
and O 0 7.363405529758893e-08
the O 0 9.237435705244934e-08
in O 0 2.4369725792894315e-07
- O 0 2.7604890419752337e-05
frame O 0 9.856542601482943e-05
deletion O 0 0.00012343304115347564
390delGly O 0 9.058781870407984e-05
were O 0 4.139914722145477e-07
assessed O 0 8.982270855995012e-07
by O 0 8.375226201451369e-08
their O 0 8.443667809387989e-08
respective O 0 6.023940954946738e-07
expression O 0 5.567526955019275e-07
in O 0 1.3021158906667551e-07
a O 0 6.723037131450837e-07
prokaryotic O 0 1.9258118300058413e-06
system O 0 9.297061183133337e-07
using O 0 7.872681067055964e-07
site O 0 3.256319814681774e-06
- O 0 2.542408401495777e-05
directed O 0 1.9317039914312772e-05
mutagenesis O 0 0.00031054861028678715
. O 0 2.4101162125589326e-05

These O 0 6.903639587108046e-05
mutations O 0 0.000328882597386837
resulted O 0 1.9480281480355188e-05
in O 0 8.21749551960238e-07
the O 0 6.012519975229225e-07
absence O 0 5.220050752541283e-06
or O 0 8.55913924624474e-07
a O 0 2.1420291886897758e-06
dramatic O 0 3.340498005854897e-05
decrease O 0 3.1412091630045325e-05
of O 0 1.3791557194053894e-06
CPO O 0 0.0001036604808177799
activity O 0 2.0193951058899984e-05
. O 0 9.372263775730971e-06

The O 0 3.13056334562134e-05
two O 0 1.1386355254217051e-05
polymorphisms O 0 0.00024133699480444193
were O 0 1.7206182292284211e-06
localized O 0 2.2325753889163025e-05
in O 0 9.420882065569458e-07
noncoding O 0 5.6436114391544834e-05
part O 0 3.59900212743014e-07
of O 0 1.0686159868100731e-07
the O 0 2.3699327300619188e-07
gene O 0 1.3133768561601755e-06
1 O 0 6.085331278882222e-07
) O 0 3.505233507894445e-07
a O 0 1.5630637335561914e-06
C O 0 5.8423658629180863e-05
/ O 0 9.335026697954163e-05
G O 0 0.00018478368292562664
polymorphism O 0 6.106484761403408e-06
in O 0 2.4030654799389595e-07
the O 0 4.288643538075121e-07
promotor O 0 0.00010216951341135427
region O 0 2.9844397886336083e-06
, O 0 4.360889533927548e-07
142 O 0 3.1126062367548e-06
bp O 0 5.323757250152994e-06
upstream O 0 8.643793876217387e-07
from O 0 6.480099301597875e-08
the O 0 9.596860905958238e-08
transcriptional O 0 2.1565451788774226e-06
initiation O 0 2.243414655822562e-06
site O 0 1.233027205671533e-06
( O 0 9.707945309855859e-07
- O 0 1.578385490574874e-05
142C O 0 0.00016044022049754858
/ O 0 0.0001386691874358803
G O 0 0.00016832903202157468
) O 0 4.971584530721884e-07
, O 0 1.0033148356569654e-07
and O 0 9.294555525229953e-08
2 O 0 4.0661959133103664e-07
) O 0 1.582194499860634e-07
a O 0 3.8664720136694086e-07
6 O 0 5.8666960285336245e-06
bp O 0 2.8526726964628324e-05
deletion O 0 4.2798215872608125e-05
polymorphism O 0 6.942101208551321e-06
in O 0 1.2097024182367022e-07
the O 0 2.0732795746880583e-07
3 O 0 1.400615133206884e-06
noncoding O 0 1.0454268704052083e-05
part O 0 2.0990034954593284e-07
of O 0 8.399014461701881e-08
the O 0 2.593179431187309e-07
CPO O 0 1.620478906261269e-05
gene O 0 1.648329885028943e-06
, O 0 3.002233484039607e-07
574 O 0 8.732526111998595e-06
bp O 0 5.447922376333736e-06
downstream O 0 7.089662403814145e-07
of O 0 6.754038395229145e-08
the O 0 1.076648175057926e-07
last O 0 3.4888614663941553e-07
base O 0 3.676824462672812e-07
of O 0 6.953007414267631e-08
the O 0 3.5181471957912436e-07
normal O 0 4.596456165018026e-06
termination O 0 3.8266676710918546e-05
codon O 0 3.06489564536605e-05
( O 0 7.287520020327065e-06
+ O 0 3.720699533005245e-05
574 O 0 6.427398329833522e-05
delATTCTT O 0 0.0001047260666382499
) O 0 1.1893222108483315e-05
. O 0 1.644407893763855e-05

Five O 0 0.00015433762746397406
intragenic O 0 0.0033847286831587553
dimorphisms O 0 0.0015246206894516945
are O 0 1.1365701766408165e-06
now O 0 6.514451911243668e-07
well O 0 2.6765371785586467e-07
characterized O 0 5.535857781069353e-06
and O 0 2.809254056046484e-07
the O 0 2.5227612354683515e-07
high O 0 2.760345978458645e-06
degree O 0 2.7794762900157366e-06
of O 0 4.489443483635114e-07
allelic O 0 0.0001336652785539627
heterogeneity O 0 9.182132635032758e-05
in O 0 1.519851480225043e-06
HC B-Disease 0 0.027356168255209923
is O 0 1.2766886356985196e-06
demonstrated O 0 1.7420544509150204e-06
with O 0 1.3559065337176435e-07
seven O 0 5.516198484656343e-07
new O 0 5.153061692908523e-07
different O 0 1.8291743231202418e-07
mutations O 0 1.1259693337706267e-06
making O 0 6.652624762182313e-08
a O 0 1.6396177215938224e-07
total O 0 1.817593329178635e-07
of O 0 1.3228911655005504e-07
nineteen O 0 6.061090971343219e-06
CPO O 0 0.00020083290291950107
gene B-Disease 0 2.6672143576433882e-05
defects I-Disease 0 0.0335237979888916
reported O 0 6.943828793737339e-06
so O 0 3.4742095067485934e-07
far O 0 1.0862681847356725e-06
. O 0 1.4442680367210414e-06
. O 0 8.714665455045179e-06

Coincidence O 0 0.00033694846206344664
of O 0 6.5236922637268435e-06
two O 0 4.3314094000379555e-06
novel O 0 9.037554264068604e-06
arylsulfatase O 0 0.00025128069682978094
A O 0 9.003127161122393e-06
alleles O 0 1.994246122194454e-05
and O 0 2.5448330234212335e-06
mutation O 0 2.8393382308422588e-05
459 O 0 6.050443698768504e-05
+ O 0 3.25117762258742e-05
1G O 0 0.00018936715787276626
> O 0 1.4919915884092916e-05
A O 0 1.2987936770514352e-06
within O 0 4.232604169374099e-07
a O 0 6.961757890167064e-07
family O 0 2.464698127369047e-06
with O 0 5.321447588357842e-06
metachromatic B-Disease 1 0.9999971389770508
leukodystrophy I-Disease 1 0.9999840259552002
: O 0 2.6848044853977626e-06
molecular O 0 5.913384484301787e-06
basis O 0 2.203716803705902e-06
of O 0 2.4295293314935407e-06
phenotypic O 0 0.00023517799854744226
heterogeneity O 0 0.0011136587709188461
. O 0 4.270839417586103e-05

In O 0 2.0391673388076015e-05
a O 0 7.910341992101166e-06
family O 0 4.055262252222747e-06
with O 0 6.540790309372824e-07
three O 0 1.8445405203237897e-06
siblings O 0 5.8785353758139536e-05
, O 0 3.37432084052125e-07
one O 0 1.8893058495450532e-07
developed O 0 1.9487488316372037e-06
classical O 0 4.602658464136766e-06
late O 0 9.582514030626044e-05
infantile O 1 0.9961349964141846
metachromatic B-Disease 1 0.9999997615814209
leukodystrophy I-Disease 1 0.9999998807907104
( O 0 0.00020580831915140152
MLD B-Disease 1 0.9999667406082153
) O 0 6.399978246918181e-06
, O 0 1.5547678913208074e-06
fatal O 0 5.5316217185463756e-05
at O 0 9.555332098898361e-07
age O 0 1.3473181752488017e-06
5 O 0 1.41667101161147e-06
years O 0 4.474517538710643e-07
, O 0 1.8694970549404388e-07
with O 0 7.143359539441008e-07
deficient O 0 0.001818812103010714
arylsulfatase O 0 0.00048615114064887166
A O 0 8.635985977889504e-06
( O 0 3.1800045690033585e-06
ARSA O 0 0.00022518607147503644
) O 0 7.088282814038394e-07
activity O 0 5.896046673115052e-07
and O 0 3.276657309925213e-07
increased O 0 6.7744495027000085e-06
galactosylsulfatide O 0 0.0033090724609792233
( O 0 2.1941223167232238e-05
GS O 1 0.9950610995292664
) O 0 1.453818185837008e-05
excretion O 0 9.823757864069194e-05
. O 0 1.611767766007688e-05

The O 0 1.3931766261521261e-05
two O 0 3.0511398563248804e-06
other O 0 8.856568456394598e-07
siblings O 0 5.904092176933773e-05
, O 0 1.645675411054981e-06
apparently O 0 1.3705958735954482e-05
healthy O 0 4.694611106970115e-06
at O 0 3.5328264402778586e-07
12 O 0 8.804280469121295e-07
( O 0 3.941453030620323e-07
1 O 0 5.083689984530793e-07
/ O 0 5.366080586099997e-06
2 O 0 3.912086015134264e-07
) O 0 1.0020621488138204e-07
and O 0 5.743351039200206e-08
15 O 0 3.8204862562452035e-07
years O 0 1.19606639259473e-07
, O 0 7.090670095522e-08
respectively O 0 4.272208968814084e-07
, O 0 6.743752578586282e-08
and O 0 5.028336147461232e-08
their O 0 1.0959958984813056e-07
father O 0 2.163759518225561e-06
, O 0 3.925510441149527e-07
apparently O 0 2.633056737977313e-06
healthy O 0 1.2562711617647437e-06
as O 0 8.458142275458158e-08
well O 0 1.4357739530623803e-07
, O 0 2.4925046204771206e-07
presented O 0 1.6090535837065545e-06
ARSA O 0 0.0010077615734189749
and O 0 1.7901001001519035e-06
GS O 1 0.9728267192840576
values O 0 7.825843795217224e-07
within O 0 2.7772506427936605e-07
the O 0 3.6926024904460064e-07
range O 0 3.7883871755184373e-06
of O 0 6.1654809542233124e-06
MLD B-Disease 1 0.9999990463256836
patients O 0 0.08741600066423416
. O 0 4.0733404603088275e-05

Mutation O 0 0.0015434905653819442
screening O 0 7.275214738911018e-05
and O 0 3.2416239719168516e-06
sequence O 0 5.3147632570471615e-06
analysis O 0 2.2961773993301904e-06
disclosed O 0 4.25796679337509e-06
the O 0 3.0138141937641194e-07
involvement O 0 1.3142613397576497e-06
of O 0 1.8297292569968704e-07
three O 0 6.477899887613603e-07
different O 0 1.488818497819011e-06
ARSA O 1 0.7943399548530579
mutations O 0 1.6776704796939157e-05
being O 0 2.133245828872532e-07
the O 0 1.564859388736295e-07
molecular O 0 1.6582505395490443e-06
basis O 0 9.843685120358714e-07
of O 0 1.424356355528289e-06
intrafamilial O 0 0.0007063934463076293
phenotypic O 0 0.00035692943492904305
heterogeneity O 0 0.001431301119737327
. O 0 6.308026058832183e-05

The O 0 0.00011785647075157613
late O 0 0.0012609040131792426
infantile O 1 0.999207079410553
patient O 1 0.9181159734725952
inherited O 0 0.012484513223171234
from O 0 1.8144339719583513e-06
his O 0 1.791428758224356e-06
mother O 0 2.5808465579757467e-05
the O 0 7.502915764234785e-07
frequent O 0 8.25656570668798e-06
0 O 0 1.1850912414956838e-05
- O 0 9.055862028617412e-05
type O 0 1.4165698303258978e-05
mutation O 0 1.819739190977998e-05
459 O 0 4.4723914470523596e-05
+ O 0 4.1316121496493e-05
1G O 0 0.00020660106383729726
> O 0 1.1429285223130137e-05
A O 0 8.880520567799977e-07
, O 0 1.5931826169435226e-07
and O 0 1.0239995162919513e-07
from O 0 9.965024361235919e-08
his O 0 2.60065860402392e-07
father O 0 1.3721763707508217e-06
a O 0 8.137682812048297e-07
novel O 0 1.2330024219409097e-06
, O 0 2.5127533831437177e-07
single O 0 1.0451699381519575e-06
basepair O 0 4.2070631025126204e-05
microdeletion O 0 9.903696081892122e-06
of O 0 1.414099415342207e-07
guanine O 0 2.3759077976137633e-06
at O 0 3.209063947906543e-07
nucleotide O 0 2.8159699922980508e-06
7 O 0 1.1096340131189208e-06
in O 0 3.7188320334280434e-07
exon O 0 1.2039383364026435e-05
1 O 0 4.669187092076754e-06
( O 0 4.302307388570625e-06
7delG O 0 9.492658136878163e-05
) O 0 7.777165592415258e-06
. O 0 1.2384986803226639e-05

The O 0 6.948690861463547e-05
two O 0 5.611904998659156e-05
clinically O 0 0.004101247992366552
unaffected O 0 0.0004159913514740765
siblings O 0 0.00011128806363558397
carried O 0 6.430250323319342e-06
the O 0 1.8581226868263911e-06
maternal O 0 0.00025723909493535757
mutation O 0 6.0337122704368085e-05
459 O 0 5.749742922489531e-05
+ O 0 3.805375672527589e-05
1G O 0 0.0002791459846775979
> O 0 1.4226161511032842e-05
A O 0 1.071376800609869e-06
and O 0 1.930324629029201e-07
, O 0 1.0745268497203142e-07
on O 0 1.5152650689742586e-07
their O 0 2.814724666677648e-07
paternal O 0 3.14251592499204e-05
allele O 0 6.308139745669905e-06
, O 0 2.136303578481602e-07
a O 0 4.6314013957271527e-07
novel O 0 1.7394662563674501e-06
cytosine O 0 5.221011633693706e-06
to O 0 2.900685842632811e-07
thymidine O 0 2.0605630197678693e-05
transition O 0 4.65611401523347e-06
at O 0 1.0711540880947723e-06
nucleotide O 0 9.965734534489457e-06
2435 O 0 5.33219390490558e-05
in O 0 6.410311357285536e-07
exon O 0 1.4037070286576636e-05
8 O 0 2.7381909148971317e-06
, O 0 2.097374647291872e-07
resulting O 0 7.656860816496192e-07
in O 0 1.1437821001436532e-07
substitution O 0 9.042571491590934e-07
of O 0 3.2513565884073614e-07
alanine O 0 7.26664366084151e-05
464 O 0 7.460344932042062e-05
by O 0 3.001875256813946e-06
valine O 0 0.0013379505835473537
( O 0 1.3099670468363911e-05
A464V O 0 0.0002026854344876483
) O 0 6.687178483844036e-06
. O 0 1.2785841136064846e-05

The O 0 0.000138533185236156
fathers O 0 0.0005254811840131879
genotype O 0 0.0009462625603191555
thus O 0 1.839748256315943e-05
was O 0 1.2545850040623918e-05
7delG O 0 0.0009791846387088299
/ O 0 0.0008574515813961625
A464V O 0 0.001346489996649325
. O 0 4.139109296374954e-05

Mutation O 0 0.006098799407482147
A464V O 0 0.0013688351027667522
was O 0 1.5421172065543942e-05
not O 0 8.596663292337325e-07
found O 0 9.200331305692089e-07
in O 0 1.1935519523831317e-06
18 O 0 4.855633233091794e-05
unrelated O 0 0.01776473969221115
MLD B-Disease 1 0.9999998807907104
patients O 0 0.01577126234769821
and O 0 2.768310196188395e-06
50 O 0 6.895687874930445e-06
controls O 0 3.759426545002498e-05
. O 0 2.064827822323423e-05

A464V O 0 0.005864738021045923
, O 0 2.4717979613342322e-05
although O 0 5.83871542403358e-06
clearly O 0 7.99915233073989e-06
modifying O 0 3.594048757804558e-05
ARSA O 0 0.05336739867925644
and O 0 3.388270488358103e-05
GS O 1 0.9999867677688599
levels O 0 8.759451702644583e-06
, O 0 1.346609110441932e-06
apparently O 0 6.682104412902845e-06
bears O 0 2.508281113478006e-06
little O 0 7.879426107137988e-07
significance O 0 1.584855567671184e-06
for O 0 1.5612565675837686e-06
clinical O 0 0.00020606278849299997
manifestation O 0 6.201121868798509e-05
of O 0 4.8705173867347185e-06
MLD B-Disease 1 0.9999827146530151
, O 0 6.784769084333675e-06
mimicking O 0 6.69212531647645e-05
the O 0 4.363640982774086e-06
frequent O 0 7.581744284834713e-05
ARSA O 0 0.14379945397377014
pseudodeficiency O 0 0.004356121178716421
allele O 0 0.0004944017273373902
. O 0 6.016279075993225e-05

Our O 0 0.00010428728273836896
results O 0 3.0038714612601325e-05
demonstrate O 0 7.2818511398509145e-06
that O 0 3.585682293305581e-07
in O 0 5.888455234526191e-07
certain O 0 1.2661132586799795e-06
genetic O 0 8.404699474340305e-05
conditions O 0 0.0018263532547280192
MLD B-Disease 1 0.9999984502792358
- O 0 0.005717562511563301
like O 0 4.000989974883851e-06
ARSA O 0 0.04890045151114464
and O 0 4.265111329004867e-06
GS O 1 0.9965658783912659
values O 0 1.566788796480978e-06
need O 0 3.3933474696823396e-07
not O 0 8.106716364864042e-08
be O 0 1.0939012184962849e-07
paralleled O 0 1.2562217307277024e-05
by O 0 5.047880222264212e-06
clinical O 1 0.5532827377319336
disease O 0 0.008372262120246887
, O 0 5.522683181879984e-07
a O 0 1.7315218201474636e-06
finding O 0 1.8461349782228353e-06
with O 0 1.6031564200602588e-06
serious O 0 0.00010395368735771626
diagnostic O 0 0.007502623833715916
and O 0 3.179760824423283e-05
prognostic O 0 0.1614324003458023
implications O 0 0.00024474330712109804
. O 0 4.2733696318464354e-05

Moreover O 0 0.0005275086150504649
, O 0 2.0134455553488806e-05
further O 0 1.887291728053242e-05
ARSA O 0 0.13784711062908173
alleles O 0 0.00017156059038825333
functionally O 0 7.434004510287195e-05
similar O 0 2.7041278372053057e-06
to O 0 8.896880672182306e-07
A464V O 0 0.0006356604862958193
might O 0 1.7177604831886129e-06
exist O 0 1.9896785374839965e-07
which O 0 5.9366605853483634e-08
, O 0 5.123639823523263e-08
together O 0 1.2349318012638832e-07
with O 0 2.0143458812071913e-07
0 O 0 9.094721463043243e-06
- O 0 0.00023530764156021178
type O 0 2.2975240426603705e-05
mutations O 0 1.6318927009706385e-05
, O 0 7.823933856343501e-07
may O 0 4.0596082726551685e-06
cause O 0 6.47088836558396e-06
pathological O 0 9.988191595766693e-05
ARSA O 1 0.8030481338500977
and O 0 2.030104042205494e-05
GS O 1 0.9999876022338867
levels O 0 2.93803304884932e-06
, O 0 2.1734869903866638e-07
but O 0 1.7734008395109413e-07
not O 0 2.7649252842820715e-07
clinical O 0 7.022071076789871e-05
outbreak O 0 2.641556602611672e-05
of O 0 1.226405743182113e-06
the O 0 2.691878216865007e-05
disease O 0 0.009859724901616573
. O 0 4.067672307428438e-06
. O 0 1.5928719221847132e-05

Human O 0 0.06436701118946075
MLH1 O 1 0.9998394250869751
deficiency O 1 0.999923825263977
predisposes O 0 0.09350874274969101
to O 0 0.00044357473962008953
hematological B-Disease 1 0.9999700784683228
malignancy I-Disease 1 0.9999842643737793
and O 0 0.0009023137972690165
neurofibromatosis B-Disease 1 0.9998630285263062
type I-Disease 0 0.0003230235306546092
1 I-Disease 0 0.0001641466369619593
. O 0 7.65141230658628e-05

Heterozygous O 0 0.019473224878311157
germ O 0 0.02341414988040924
- O 0 0.012640941888093948
line O 0 0.0005222691688686609
mutations O 0 4.117048956686631e-05
in O 0 6.025767902428925e-07
the O 0 1.1564233091121423e-06
DNA O 0 2.2548390916199423e-05
mismatch O 0 0.000633794057648629
repair O 0 0.005462957546114922
genes O 0 1.4830715372227132e-05
lead O 0 2.3907496142783202e-05
to O 0 2.603539905976504e-05
hereditary B-Disease 1 0.9997072815895081
nonpolyposis I-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00017251644749194384

The O 0 0.000638609635643661
disease O 0 0.4562293589115143
susceptibility O 0 0.0009000615100376308
of O 0 3.3173382689710706e-06
individuals O 0 7.149294106056914e-06
who O 0 4.956395969202276e-06
constitutionally O 0 7.203117274912074e-05
lack O 0 2.0314319044700824e-06
both O 0 3.145248683722457e-07
wild O 0 3.261127631049021e-06
- O 0 0.0001708276686258614
type O 0 1.0279921298206318e-05
alleles O 0 1.8414280930301175e-05
is O 0 1.5760653013785486e-06
unknown O 0 1.664518094912637e-05
. O 0 1.9641753169707954e-05

We O 0 2.49304484896129e-05
have O 0 5.830524514749413e-06
identified O 0 5.913621407671599e-06
three O 0 1.1048896340071224e-06
offspring O 0 9.827283065533265e-06
in O 0 2.2218205231183674e-06
a O 0 0.00015761516988277435
hereditary B-Disease 1 0.9999285936355591
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.00014889398880768567
who O 0 2.8216229111421853e-05
developed O 0 0.0001437688188161701
hematological B-Disease 1 0.9958114624023438
malignancy I-Disease 1 0.8744804263114929
at O 0 1.2798582247341983e-06
a O 0 1.6116825918288669e-06
very O 0 3.182888406172424e-07
early O 0 1.15338013984001e-06
age O 0 5.065919026492338e-07
, O 0 9.206829076902068e-08
and O 0 5.8465939645202525e-08
at O 0 8.999507628004721e-08
least O 0 5.5225996220542584e-08
two O 0 3.324484509903414e-08
of O 0 3.5222555538894085e-08
them O 0 7.498245224724087e-08
displayed O 0 1.7399307807863806e-06
signs O 0 2.98698250844609e-06
of O 0 1.0892224509007065e-06
neurofibromatosis B-Disease 1 0.9272475242614746
type I-Disease 0 2.676738949958235e-05
1 I-Disease 0 1.695231367193628e-05
( O 0 1.641614107938949e-05
NF1 B-Disease 0 0.0011038053780794144
) O 0 1.55137458932586e-05
. O 0 1.588833583809901e-05

DNA O 0 0.0002902200794778764
sequence O 0 3.1187093554763123e-05
analysis O 0 6.3786219470785e-06
and O 0 1.4159631973598152e-06
allele O 0 2.3425876861438155e-05
- O 0 9.437929293198977e-06
specific O 0 8.809378755358921e-07
amplification O 0 1.3964077879791148e-05
in O 0 3.5594550240602985e-07
two O 0 6.743309199919167e-07
siblings O 0 7.17065850039944e-05
revealed O 0 3.325403304188512e-05
a O 0 3.402705624466762e-05
homozygous O 0 0.0658591017127037
MLH1 O 0 0.41235247254371643
mutation O 0 8.583522867411375e-05
( O 0 4.314658781368053e-06
C676T O 0 6.93028123350814e-05
- O 0 0.00017615525575820357
- O 0 0.0004894823068752885
> O 0 0.00027893445803783834
Arg226Stop O 0 0.0005031650071032345
) O 0 1.1085509868280496e-05
. O 0 1.5423936929437332e-05

Thus O 0 0.00014040472160559148
, O 0 1.1420578630350064e-05
a O 0 1.7613539966987446e-05
homozygous O 0 0.0005817996570840478
germ O 0 0.0011497072409838438
- O 0 0.0006337855593301356
line O 0 0.0001648810866754502
MLH1 O 0 0.024139005690813065
mutation O 0 5.0358412408968434e-05
and O 0 3.9118576751207e-06
consequent O 1 0.7448122501373291
mismatch O 1 0.9999978542327881
repair O 1 1.0
deficiency O 1 0.999966025352478
results O 0 7.781921340210829e-06
in O 0 1.3178485005482798e-06
a O 0 5.953358777333051e-05
mutator O 1 0.9996997117996216
phenotype O 1 0.8937629461288452
characterized O 0 0.00035570672480389476
by O 0 1.3650740584125742e-05
leukemia B-Disease 1 0.9998897314071655
and O 0 6.99753945809789e-05
/ O 1 0.9943087697029114
or O 0 0.16031122207641602
lymphoma B-Disease 1 1.0
associated O 0 0.0001233962393598631
with O 0 1.6444846551166847e-05
neurofibromatosis B-Disease 1 0.9970124959945679
type I-Disease 0 1.9444883946562186e-05
1 I-Disease 0 1.1880468264280353e-05
. O 0 3.723896497831447e-06
. O 0 1.4904130694048945e-05

Missense O 1 0.9782031774520874
mutations O 0 0.003213502699509263
in O 0 5.76902539251023e-06
the O 0 1.0617221732900362e-06
most O 0 3.582971430660109e-07
ancient O 0 5.273985266285308e-07
residues O 0 9.301859336119378e-07
of O 0 1.431095881798683e-07
the O 0 7.955156888783677e-07
PAX6 O 0 0.00035533474874682724
paired O 0 1.7479040252510458e-05
domain O 0 4.09509766541305e-06
underlie O 0 1.4314701729745138e-05
a O 0 3.6041171824763296e-06
spectrum O 0 3.309323074063286e-05
of O 0 4.795107997779269e-06
human O 0 0.0006845899624750018
congenital B-Disease 1 1.0
eye I-Disease 1 0.999721348285675
malformations I-Disease 1 0.9999732971191406
. O 0 0.00011162647570017725

Mutations O 0 0.0026207780465483665
of O 0 1.2605574738699943e-05
the O 0 6.2053218243818264e-06
human O 0 2.1609635950881056e-05
PAX6 O 0 0.028535621240735054
gene O 0 0.00035045796539634466
underlie O 0 0.29528549313545227
aniridia B-Disease 1 1.0
( O 0 0.21861732006072998
congenital B-Disease 1 0.9999974966049194
absence I-Disease 0 4.4504806282930076e-05
of I-Disease 0 4.958912427355244e-07
the I-Disease 0 1.8854408381230314e-06
iris I-Disease 0 0.022502614185214043
) O 0 1.2611795909833745e-06
, O 0 2.518967505693581e-07
a O 0 1.7708280211081728e-06
rare O 0 2.4220007617259398e-05
dominant O 0 0.001655173022300005
malformation B-Disease 1 0.9725735187530518
of I-Disease 0 1.6195127727769432e-06
the I-Disease 0 8.066387636063155e-06
eye I-Disease 0 0.002352715702727437
. O 0 3.5651493817567825e-05

The O 0 6.139351899037138e-05
spectrum O 0 0.0001529099972685799
of O 0 6.063993168936577e-06
PAX6 O 0 0.2631682753562927
mutations O 0 0.0009345297003164887
in O 0 2.6035821065306664e-05
aniridia B-Disease 1 0.9999996423721313
patients O 0 0.011459539644420147
is O 0 3.867327791340358e-07
highly O 0 4.7693720262032e-07
biased O 0 1.6316420214934624e-06
, O 0 1.7740536861765577e-07
with O 0 2.7408037794884876e-07
92 O 0 1.2006395081698429e-05
% O 0 5.493686217050708e-07
of O 0 6.574041577778189e-08
all O 0 1.0511540438074007e-07
reported O 0 7.43509417588939e-06
mutations O 0 3.1491015306528425e-06
leading O 0 5.494326273947081e-07
to O 0 1.3421418998404988e-07
premature O 0 7.324140369746601e-06
truncation O 0 4.541771431831876e-06
of O 0 1.4919680779712508e-07
the O 0 4.149733285885304e-07
protein O 0 1.2194012697364087e-06
( O 0 3.483007446902775e-07
nonsense O 0 1.2540148190964828e-06
, O 0 1.6263462043752952e-07
splicing O 0 1.932130771820084e-06
, O 0 1.9966354614098236e-07
insertions O 0 3.898264822055353e-06
and O 0 4.2599307903401495e-07
deletions O 0 5.56752320335363e-06
) O 0 3.377881796495785e-07
and O 0 9.183170135429464e-08
just O 0 1.8190706896348274e-07
2 O 0 1.284174118154624e-06
% O 0 6.051937475604063e-07
leading O 0 1.118454875381758e-07
to O 0 3.282802651938255e-08
substitution O 0 2.412926392025838e-07
of O 0 6.052421497315663e-08
one O 0 2.5576937900950725e-07
amino O 0 2.3456311737390934e-06
acid O 0 1.972411610040581e-06
by O 0 2.853493299426191e-07
another O 0 1.8183367274104967e-06
( O 0 7.04857166056172e-06
missense O 0 0.00011518309474922717
) O 0 8.09936500445474e-06
. O 0 1.2538614100776613e-05

The O 0 1.9691640773089603e-05
extraordinary O 0 2.2128282580524683e-05
conservation O 0 4.180870746495202e-06
of O 0 4.031283253880247e-07
the O 0 1.04207663298439e-06
PAX6 O 0 0.0002635615528561175
protein O 0 1.9246863303123973e-06
at O 0 3.075602421631629e-07
the O 0 2.907653993133863e-07
amino O 0 1.998213974729879e-06
acid O 0 3.197435717083863e-06
level O 0 3.381285296200076e-07
amongst O 0 6.871503615002439e-07
vertebrates O 0 1.609446258044045e-06
predicts O 0 7.937424015835859e-06
that O 0 2.8739759727614e-07
pathological O 0 5.079092443338595e-05
missense O 0 0.03972518816590309
mutations O 0 2.658159428392537e-05
should O 0 2.5268255399168993e-07
in O 0 1.442760293457468e-07
fact O 0 2.0390390886859677e-07
be O 0 6.526179419097389e-08
common O 0 4.3230960500295623e-07
even O 0 1.896490573471965e-07
though O 0 1.6900104071737587e-07
they O 0 7.412980806975611e-08
are O 0 9.089470864864779e-08
hardly O 0 1.322907905887405e-06
ever O 0 8.273333378383541e-07
seen O 0 3.094867452091421e-06
in O 0 8.258401066996157e-06
aniridia B-Disease 1 0.9999963045120239
patients O 0 0.03207886219024658
. O 0 4.179367533652112e-05

This O 0 2.5194478439516388e-05
indicates O 0 2.4257176846731454e-05
that O 0 5.345127647160552e-07
there O 0 2.0691908275694004e-07
is O 0 1.8399445878003462e-07
a O 0 1.3709650374948978e-06
heavy O 0 0.00012929763761349022
ascertainment O 0 0.01010928861796856
bias O 0 4.8875393986236304e-05
in O 0 3.070180696340685e-07
the O 0 1.4884875554344035e-07
selection O 0 5.843867825205962e-07
of O 0 6.076377303543268e-07
patients O 0 3.758071397896856e-05
for O 0 1.2862393532486749e-06
PAX6 O 0 0.16648021340370178
mutation O 0 1.8441958673065528e-05
analysis O 0 8.878750463736651e-07
and O 0 1.6565925875511311e-07
that O 0 1.1699071222892599e-07
the O 0 8.254473868873902e-07
missing O 0 2.264346221636515e-05
PAX6 O 0 0.06939750909805298
missense O 0 0.0062760282307863235
mutations O 0 0.0001396142615703866
frequently O 0 1.8077918866765685e-05
may O 0 1.4973424185882322e-05
underlie O 0 0.00028611632296815515
phenotypes O 0 0.0007225680164992809
distinct O 0 1.2139791579102166e-05
from O 0 6.619685791520169e-06
textbook O 0 0.0003611741994973272
aniridia B-Disease 1 0.9996719360351562
. O 0 6.287343421718106e-05

Here O 0 3.2310963433701545e-05
we O 0 2.968770331790438e-06
present O 0 1.8974344584421488e-06
four O 0 2.0722116005345015e-06
novel O 0 2.3207076083053835e-05
PAX6 O 0 0.24890661239624023
missense O 0 0.04258580505847931
mutations O 0 4.179662573733367e-05
, O 0 2.97115036573814e-07
two O 0 1.9337849721523526e-07
in O 0 4.438659573224868e-07
association O 0 1.1025801995856455e-06
with O 0 1.96347491510096e-06
atypical O 0 0.056430134922266006
phenotypes O 0 0.21066369116306305
ectopia B-Disease 0 0.16219459474086761
pupillae I-Disease 0 0.09251926839351654
( O 0 6.972855317144422e-06
displaced B-Disease 0 3.475517951301299e-05
pupils I-Disease 0 2.2353107851813547e-05
) O 0 5.170170425117249e-06
and O 0 2.9633687518071383e-05
congenital B-Disease 1 0.9999992847442627
nystagmus I-Disease 1 0.9692351222038269
( O 0 4.126916337554576e-06
searching B-Disease 0 3.132101255687303e-06
gaze I-Disease 0 1.6803573089418933e-05
) O 0 3.0240465775932535e-07
, O 0 8.217685376621375e-08
and O 0 8.009857310753432e-08
two O 0 1.4074960574816942e-07
in O 0 3.0009309170964116e-07
association O 0 4.613741566572571e-07
with O 0 3.7389239082585846e-07
more O 0 1.345254872830992e-06
recognizable O 0 0.00011900644312845543
aniridia B-Disease 1 0.9997597336769104
phenotypes O 0 0.028117340058088303
. O 0 4.457318937056698e-05

Strikingly O 0 0.004500513430684805
, O 0 1.6696070815669373e-05
all O 0 1.5661150882806396e-06
four O 0 3.799723572228686e-06
mutations O 0 8.26569703349378e-06
are O 0 6.172242450475096e-08
located O 0 2.422180784833472e-07
within O 0 1.990843827570643e-07
the O 0 2.9138888635316107e-07
PAX6 O 0 9.522121399641037e-05
paired O 0 5.632620286633028e-06
domain O 0 1.0960656027236837e-06
and O 0 2.3354878919690236e-07
affect O 0 6.823427725066722e-07
amino O 0 1.4821997638136963e-06
acids O 0 6.104535827944346e-07
which O 0 9.153738744771545e-08
are O 0 4.004537146329312e-08
highly O 0 1.3095205986246583e-07
conserved O 0 3.546335562987224e-07
in O 0 1.0434973063411235e-07
all O 0 7.424583259307838e-08
known O 0 5.812569838781201e-07
paired O 0 5.5697537391097285e-06
domain O 0 5.587085979641415e-06
proteins O 0 6.778255738026928e-06
. O 0 8.93607284524478e-06

Our O 0 8.117172546917573e-05
results O 0 1.99058649741346e-05
support O 0 3.446687287578243e-06
the O 0 4.5455314534592617e-07
hypothesis O 0 1.584769393048191e-06
that O 0 5.4931945214775624e-08
the O 0 7.376056743169102e-08
under O 0 2.736525743785023e-07
- O 0 5.19575405633077e-06
representation O 0 7.926493594823114e-07
of O 0 6.662071427854244e-07
missense O 0 0.0011860996019095182
mutations O 0 2.4138127628248185e-05
is O 0 2.5940502723642567e-07
caused O 0 1.227536131409579e-06
by O 0 3.331766151859483e-07
ascertainment O 0 0.002611279720440507
bias O 0 9.323976701125503e-05
and O 0 5.852618869539583e-07
suggest O 0 1.0807440276039415e-06
that O 0 6.437831245875714e-08
a O 0 7.51844481783337e-07
substantial O 0 2.1854018541489495e-06
burden O 0 6.194289653649321e-06
of O 0 1.2810170346710947e-06
PAX6 B-Disease 1 0.8568872213363647
- I-Disease 1 0.8306429982185364
related I-Disease 0 0.0027056101243942976
disease I-Disease 0 0.0019222357077524066
remains O 0 2.4317637326021213e-06
to O 0 4.508618189902336e-07
be O 0 5.914214398217155e-07
uncovered O 0 3.5315679269842803e-05
. O 0 3.173566710756859e-06
. O 0 1.2905488802061882e-05

The O 0 4.796101347892545e-05
chromosomal O 0 0.00324047589674592
order O 0 7.443324648193084e-06
of O 0 1.1381624744899455e-06
genes O 0 5.188979685044615e-06
controlling O 0 5.693304956366774e-06
the O 0 8.673430329508847e-07
major O 0 2.7804437650047475e-06
histocompatibility O 0 0.00025029960670508444
complex O 0 2.6429540866956813e-06
, O 0 6.713369202770991e-07
properdin O 0 8.523580618202686e-05
factor O 0 3.0385840545932297e-06
B O 0 6.970707545406185e-06
, O 0 5.763167791883461e-07
and O 0 3.974874289269792e-06
deficiency B-Disease 0 0.0007892735302448273
of I-Disease 0 6.37208330545036e-08
the I-Disease 0 1.1849705572331004e-07
second I-Disease 0 1.5885916582192294e-06
component I-Disease 0 2.9963721317471936e-06
of I-Disease 0 6.337212425933103e-07
complement I-Disease 0 2.0140945707680658e-05
. O 0 1.5744182746857405e-05

The O 0 2.5741042918525636e-05
relationship O 0 1.866126331151463e-05
of O 0 1.2320432460910524e-06
the O 0 8.220151812565746e-07
genes O 0 3.0460055313596968e-06
coding O 0 1.2969448107469361e-05
for O 0 1.057326812770043e-06
HLA O 0 0.0003145216032862663
to O 0 2.1493249846571416e-07
those O 0 1.522246435570196e-07
coding O 0 4.748182163893944e-06
for O 0 3.478048427041358e-07
properdin O 0 0.00010420637408969924
Factor O 0 2.283391950186342e-06
B O 0 3.8498883441207e-06
allotypes O 0 2.7198113457416184e-05
and O 0 7.110816113709006e-07
for O 0 3.598182502173586e-06
deficiency B-Disease 0 0.0007749057840555906
of I-Disease 0 7.625904885344426e-08
the I-Disease 0 1.1267282928884015e-07
second I-Disease 0 1.1631802863121266e-06
component I-Disease 0 7.093516956047097e-07
of I-Disease 0 1.28958475897889e-07
complement I-Disease 0 2.328680693608476e-06
( O 0 1.9605784018494887e-06
C2 O 0 5.957969551673159e-05
) O 0 3.384537308193103e-07
was O 0 2.514270818210207e-07
studied O 0 4.5005589299762505e-07
in O 0 2.9890318842262786e-07
families O 0 1.3664644029631745e-06
of O 0 8.341220336660626e-07
patients O 0 0.00021186878439038992
with O 0 6.930822564754635e-05
connective O 1 0.9999948740005493
tissue O 1 0.9999936819076538
disorders O 1 0.9999984502792358
. O 0 9.575060539646074e-05

Patients O 1 0.8398259878158569
were O 0 1.3269816918182187e-05
selected O 0 2.7199828309676377e-06
because O 0 7.69640905673441e-07
they O 0 2.5127150138359866e-07
were O 0 8.807286917544843e-07
heterozygous O 0 3.406783434911631e-05
or O 0 1.0176914656767622e-05
homozygous O 0 0.015176543965935707
for O 0 0.00044171983608976007
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999995231628418
. O 0 8.776372851571068e-05

12 O 0 0.0002162325254175812
families O 0 2.6485944545129314e-05
with O 0 2.9628588436025893e-06
15 O 0 1.0862269846256822e-05
matings O 0 0.00011939915566472337
informative O 0 6.965045031392947e-05
for O 0 0.0005387193523347378
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
were O 0 9.644084457249846e-06
found O 0 1.1513917343108915e-05
. O 0 2.3220203729579225e-05

Of O 0 5.15997271577362e-05
57 O 0 9.703940304461867e-05
informative O 0 1.9883760614902712e-05
meioses O 0 0.00018278004426974803
, O 0 1.2913905038658413e-06
two O 0 3.2172945907404937e-07
crossovers O 0 4.6964019020379055e-06
were O 0 4.1467112055215694e-07
noted O 0 5.669286338161328e-07
between O 0 8.163341362887877e-07
the O 0 5.391690865508281e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999940395355225
gene O 0 2.7614939881459577e-06
and O 0 2.4893071781662e-07
the O 0 6.844726954113867e-07
HLA O 0 0.0027571420650929213
- O 0 0.0001504858664702624
B O 0 9.650515494286083e-06
gene O 0 9.830570206759148e-07
, O 0 1.338418655905116e-07
with O 0 1.2496198564804217e-07
a O 0 1.0584213896436268e-06
recombinant O 0 7.525219189119525e-06
fraction O 0 2.9528334835049463e-06
of O 0 8.126251600515388e-07
0 O 0 1.5715277186245658e-05
. O 0 8.531865205441136e-06

035 O 1 0.7337912321090698
. O 0 0.002697436837479472

A O 0 0.00020641183073166758
lod O 0 0.001597944414243102
score O 0 1.0020246008934919e-05
of O 0 1.1527764627317083e-06
13 O 0 3.624578084782115e-06
was O 0 7.67691687997285e-07
calculated O 0 9.464611707699078e-07
for O 0 3.737961264960177e-07
linkage O 0 0.00011883612023666501
between O 0 0.0009199563646689057
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999990463256836
and O 0 7.610794000356691e-06
HLA O 0 0.013722507283091545
- O 0 0.00010193556954618543
B O 0 5.759251962444978e-06
at O 0 2.718338976137602e-07
a O 0 5.588358362729196e-07
maximum O 0 1.2260537687325268e-06
likelihood O 0 8.736431595934846e-07
value O 0 8.04177417990104e-08
of O 0 6.856684109379785e-08
the O 0 2.9600894890791096e-07
recombinant O 0 6.717501037201146e-06
fraction O 0 2.728457502598758e-06
of O 0 1.1273737072770018e-06
0 O 0 1.959264227480162e-05
. O 0 1.0729047971835826e-05

04 O 0 0.033710774034261703
. O 0 0.0021339883096516132

18 O 0 0.0003931259852834046
families O 0 3.791375638684258e-05
with O 0 3.3179585443576798e-06
21 O 0 6.8309882408357225e-06
informative O 0 2.944307425423176e-06
matings O 0 1.6335650798282586e-05
for O 0 5.619365879283578e-07
both O 0 8.824193855616613e-07
properdin O 0 0.00018198323959950358
Factor O 0 5.360858267522417e-06
B O 0 9.315351235272828e-06
allotype O 0 3.5504475818015635e-05
and O 0 1.934841293405043e-06
HLA O 0 0.0009703148389235139
- O 0 0.00011227359937038273
B O 0 2.0415274775587022e-05
were O 0 1.553305196466681e-06
found O 0 6.038059837010223e-06
. O 0 1.4873913642077241e-05

Of O 0 3.7984900700394064e-05
72 O 0 8.473973866784945e-05
informative O 0 1.625389813852962e-05
meioses O 0 0.0002041961415670812
, O 0 1.6154928061951068e-06
three O 0 1.1181791705894284e-06
recombinants O 0 0.00025120354257524014
were O 0 6.302436759142438e-07
found O 0 3.8912489230824576e-07
, O 0 2.6666054964152863e-07
giving O 0 5.857046403434651e-07
a O 0 1.4600723261537496e-06
recombinant O 0 9.807808055484202e-06
fraction O 0 3.7231616261124145e-06
of O 0 1.446374199076672e-06
0 O 0 3.100436879321933e-05
. O 0 1.4288527381722815e-05

042 O 0 0.06463148444890976
. O 0 0.0014775220770388842

A O 0 0.0002978706907015294
lod O 0 0.001048339414410293
score O 0 1.1890817404491827e-05
of O 0 1.6657858168400708e-06
16 O 0 4.171376076556044e-06
between O 0 1.8497704559194972e-06
HLA O 0 0.0004909825511276722
- O 0 6.724591366946697e-05
B O 0 4.9470986596134026e-06
and O 0 3.355602302690386e-07
Factor O 0 1.437516857549781e-06
B O 0 2.4305743409058778e-06
allotypes O 0 1.527500899101142e-05
was O 0 6.888825510031893e-07
calculated O 0 4.973756517756556e-07
at O 0 1.7299936416748096e-07
a O 0 4.77387231967441e-07
maximum O 0 1.4424592791328905e-06
likelihood O 0 8.382672262996493e-07
value O 0 7.663231826882111e-08
of O 0 6.163396193414883e-08
the O 0 2.073204541375162e-07
recombinant O 0 5.347832029656274e-06
fraction O 0 1.8795882397171226e-06
of O 0 7.812085982550343e-07
0 O 0 2.521940587030258e-05
. O 0 1.4361329704115633e-05

04 O 0 0.034272272139787674
. O 0 0.0014824464451521635

A O 0 0.00012017474364256486
crossover O 0 0.00015421742864418775
was O 0 1.4098167412157636e-05
shown O 0 1.4330751127999974e-06
to O 0 2.2083125372773793e-07
have O 0 2.2090499385285511e-07
occurred O 0 1.0753342394309584e-06
between O 0 2.0128614153236413e-07
genes O 0 5.566975005422137e-07
for O 0 1.6417081383224286e-07
Factor O 0 1.4807585557718994e-06
B O 0 4.193792847217992e-06
and O 0 8.214110494009219e-07
HLA O 0 0.008601173758506775
- O 0 0.0013325916370376945
D O 0 0.0051964325830340385
, O 0 1.8377753008280706e-07
in O 0 2.091637725243345e-07
which O 0 6.715360427733685e-07
HLA O 0 0.00022411039390135556
- O 0 0.00012097034777980298
D O 0 0.0021225125528872013
segregared O 0 5.1337141485419124e-05
with O 0 1.1482384252303746e-06
HLA O 0 0.0008626480121165514
- O 0 2.9436865588650107e-05
A O 0 6.191265583765926e-06
and O 0 4.1059061004489195e-06
B O 0 5.9377831348683685e-05
. O 0 2.016112375713419e-05

These O 0 1.7627991837798618e-05
studies O 0 1.4185749023454264e-05
suggest O 0 3.6552919482346624e-06
that O 0 1.6026230298393784e-07
the O 0 3.05040487091901e-07
genes O 0 1.2379097142911633e-06
for O 0 2.896478576985828e-07
Factor O 0 4.435275968717178e-06
B O 0 9.141706686932594e-05
and O 0 0.0008453070768155158
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.999996542930603
are O 0 1.3173064417060232e-07
located O 0 2.047503926405625e-07
outside O 0 1.3136407517322368e-07
those O 0 6.727565704522931e-08
for O 0 2.8484524250416143e-07
HLA O 0 0.001805413980036974
, O 0 1.1840351277214722e-07
that O 0 2.6840920597237528e-08
the O 0 5.651504864090384e-08
order O 0 1.1920671028065044e-07
of O 0 1.307556232177376e-07
genese O 0 7.672409992665052e-05
is O 0 6.417798772417882e-07
HLA O 0 0.00010620775719871745
- O 0 9.875139767245855e-06
A O 0 1.6149582506841398e-06
, O 0 6.492700208582391e-07
- O 0 3.2074294722406194e-05
B O 0 5.613845132756978e-06
, O 0 3.871475655614631e-07
- O 0 2.9888695280533284e-05
D O 0 0.00018393552454654127
, O 0 6.286366556196299e-07
Factor O 0 2.6254590466123773e-06
B O 0 1.703879752312787e-05
allotype O 0 0.016396094113588333
, O 0 0.0010948401177302003
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999983310699463
, O 0 4.57295897149379e-07
that O 0 1.3133475817994622e-07
the O 0 2.9262338330227067e-07
genes O 0 4.137434189033229e-06
coding O 0 0.0002160118310712278
for O 0 0.0006005515460856259
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999983310699463
and O 0 2.514628477001679e-06
Factor O 0 3.3278899991273647e-06
B O 0 4.913995780952973e-06
allotypes O 0 1.3169654266675934e-05
are O 0 8.332126810728369e-08
approximately O 0 2.504915244117001e-07
3 O 0 5.901121085116756e-07
- O 0 4.449982043297496e-06
- O 0 5.870031145605026e-06
5 O 0 9.293586344938376e-07
centimorgans O 0 5.170476015337044e-06
from O 0 1.9629865732895269e-07
the O 0 2.7944986413785955e-07
HLA O 0 7.70404003560543e-05
- O 0 9.427547411178239e-06
A O 0 2.5071594791370444e-06
and O 0 1.626839207347075e-06
HLA O 0 0.0018395757069811225
- O 0 0.00016187700384762138
B O 0 1.1227922186662909e-05
loci O 0 1.9714768768608337e-06
, O 0 1.0833532115839262e-07
and O 0 1.0777103653936138e-07
that O 0 5.3965521829013596e-08
the O 0 1.9825301933451556e-07
apparent O 0 8.181358680303674e-06
lack O 0 6.481088234977506e-07
of O 0 1.393635642443769e-07
recombinants O 0 7.11279790266417e-05
between O 0 3.0834465292173263e-07
the O 0 2.7786603595814086e-07
Factor O 0 2.3515060547651956e-06
B O 0 1.2017552762699779e-05
gene O 0 8.712903763807844e-06
and O 0 4.1518233047099784e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.999998927116394
gene O 0 9.807910828385502e-06
suggests O 0 1.1895964462382835e-06
that O 0 5.334240071874774e-08
these O 0 3.840057516413253e-08
two O 0 1.6854167483870697e-07
genes O 0 1.2780310498783365e-06
lie O 0 8.01245960246888e-07
in O 0 1.2403613425249205e-07
close O 0 5.699220082533429e-07
proximity O 0 1.1908995247722487e-06
to O 0 3.064120051021746e-07
one O 0 8.137760687532136e-07
another O 0 7.9484234447591e-06
. O 0 1.7544807633385062e-05

Distribution O 0 0.00010347284114686772
of O 0 1.0596045285637956e-05
emerin O 0 0.0004983330145478249
and O 0 4.9019708967534825e-06
lamins O 0 0.0004980896483175457
in O 0 1.4766042113478761e-06
the O 0 1.156315192929469e-06
heart O 0 8.511583291692659e-05
and O 0 1.765945739862218e-06
implications O 0 1.3463956747727934e-05
for O 0 5.3495250540436246e-06
Emery B-Disease 0 0.3199230134487152
- I-Disease 1 0.9731900095939636
Dreifuss I-Disease 1 0.9999606609344482
muscular I-Disease 1 0.9999943971633911
dystrophy I-Disease 1 0.9999774694442749
. O 0 0.00022081741190049797

Emerin O 0 0.007593991234898567
is O 0 1.7343581930617802e-05
a O 0 1.0922871297225356e-05
nuclear O 0 1.3206818948674481e-05
membrane O 0 3.3914302548510022e-06
protein O 0 1.70452767633833e-06
which O 0 2.5035586759258877e-07
is O 0 1.499824264783456e-07
missing O 0 1.40665747494495e-06
or O 0 1.026196741804597e-06
defective O 0 8.610199438408017e-05
in O 0 8.820114089758135e-06
Emery B-Disease 0 0.1006360575556755
- I-Disease 1 0.935807466506958
Dreifuss I-Disease 1 0.9999878406524658
muscular I-Disease 1 0.9999984502792358
dystrophy I-Disease 1 0.9999986886978149
( O 0 0.000718782190233469
EDMD B-Disease 1 0.9999181032180786
) O 0 2.77563067356823e-05
. O 0 2.1578149244305678e-05

It O 0 1.1628015272435732e-05
is O 0 1.7323476413366734e-06
one O 0 4.7070639652702084e-07
member O 0 3.675169750749774e-07
of O 0 1.2283307171401248e-07
a O 0 1.1723826673915028e-06
family O 0 1.15573084258358e-06
of O 0 4.293153210710443e-07
lamina O 0 0.0014794876333326101
- O 0 9.054248221218586e-05
associated O 0 1.5570395817121607e-06
proteins O 0 3.8363461385415576e-07
which O 0 1.4925045377367496e-07
includes O 0 7.818175618012901e-07
LAP1 O 0 0.00010261619900120422
, O 0 1.2304252550165984e-06
LAP2 O 0 0.00011938618263229728
and O 0 3.5838538678945042e-06
lamin O 0 0.006943088490515947
B O 0 0.00014476102660410106
receptor O 0 5.381694791140035e-05
( O 0 1.1888436347362585e-05
LBR O 0 0.00046776121598668396
) O 0 1.4420121260627639e-05
. O 0 1.3905737432651222e-05

A O 0 0.00023416729527525604
panel O 0 4.6803339500911534e-05
of O 0 3.6777962577616563e-06
16 O 0 4.176364018348977e-05
monoclonal O 0 0.00046918686712160707
antibodies O 0 2.077044700854458e-05
( O 0 3.0337689622683683e-06
mAbs O 0 4.753378016175702e-05
) O 0 5.313504516379908e-07
has O 0 1.6574173855588015e-07
been O 0 1.0409826245449949e-07
mapped O 0 1.1952913610002724e-06
to O 0 7.914395183661327e-08
six O 0 2.0982108139833144e-07
specific O 0 1.2632315815608308e-07
sites O 0 1.4187030217271968e-07
throughout O 0 1.537135148055313e-07
the O 0 2.4088751615636284e-07
emerin O 0 1.7104002836276777e-05
molecule O 0 1.832220732467249e-06
using O 0 8.243759452852828e-07
phage O 0 9.585520274413284e-06
- O 0 4.241257101966767e-06
displayed O 0 1.2301002243475523e-06
peptide O 0 1.6645931282255333e-06
libraries O 0 2.6357346882832644e-07
and O 0 1.0245934589647732e-07
has O 0 1.4767942957405467e-07
been O 0 9.423077784731504e-08
used O 0 1.471642860906286e-07
to O 0 2.043391731376687e-07
localize O 0 1.4124934750725515e-05
emerin O 0 8.712649287190288e-05
in O 0 6.686341293971054e-07
human O 0 1.3733558716921834e-06
and O 0 2.879995463445084e-06
rabbit O 0 0.000811943260487169
heart O 0 0.002318265149369836
. O 0 4.366298526292667e-05

Several O 0 0.00011222488683415577
mAbs O 0 0.000893584277946502
against O 0 1.2866766155639198e-05
different O 0 3.4509532724769088e-06
emerin O 0 0.0006168877589516342
epitopes O 0 0.0003248796856496483
did O 0 1.4081904282647884e-06
not O 0 2.2422929646381817e-07
recognize O 0 1.1660291647785925e-06
intercalated O 0 1.347284432995366e-05
discs O 0 8.238923328462988e-06
in O 0 3.550145777353464e-07
the O 0 8.464644452033099e-07
heart O 0 6.752042099833488e-05
, O 0 3.9306499388658267e-07
though O 0 2.5908803991114837e-07
they O 0 1.2569394414185808e-07
recognized O 0 5.634874469251372e-07
cardiomyocyte O 0 4.2658204620238394e-05
nuclei O 0 7.0537362262257375e-06
strongly O 0 1.2098622619305388e-06
, O 0 9.69477369494598e-08
both O 0 5.680391979012711e-08
at O 0 1.1050407522361638e-07
the O 0 2.0187459881526593e-07
rim O 0 2.167617822124157e-06
and O 0 2.921479733686283e-07
in O 0 6.093154070185847e-07
intranuclear O 0 9.272320312447846e-05
spots O 0 7.662612006242853e-06
or O 0 3.1748593301017536e-06
channels O 0 1.784227970347274e-05
. O 0 1.0683877007977571e-05

A O 0 0.00085165083874017
polyclonal O 0 0.005399381276220083
rabbit O 0 0.0011705461656674743
antiserum O 0 0.001461509265936911
against O 0 4.437156894709915e-05
emerin O 0 0.0020654466934502125
did O 0 7.6140681812830735e-06
recognize O 0 2.4699922960280674e-06
both O 0 4.5791205138812074e-07
nuclear O 0 2.2888684725330677e-06
membrane O 0 1.6586047877353849e-06
and O 0 2.831621941368212e-07
intercalated O 0 1.460725070501212e-05
discs O 0 6.269032382988371e-06
but O 0 1.8409433266697306e-07
, O 0 1.56405377538249e-07
after O 0 3.42847215506481e-07
affinity O 0 9.929882480719243e-07
purification O 0 3.3827279821707634e-06
against O 0 3.4501132972764026e-07
a O 0 7.016353151811927e-07
pure O 0 1.8584702274893061e-06
- O 0 2.164368561352603e-05
emerin O 0 2.754771958279889e-05
band O 0 1.28171484448103e-06
on O 0 1.992387979043997e-07
a O 0 5.003008709536516e-07
western O 0 8.773226909397636e-07
blot O 0 2.524303454265464e-05
, O 0 4.02905413920962e-07
it O 0 1.1803282973232854e-07
stained O 0 1.0173402188229375e-05
only O 0 2.0473203221627045e-07
the O 0 8.002348863556108e-07
nuclear O 0 1.5302959582186304e-05
membrane O 0 2.8890877729281783e-05
. O 0 1.3656287592311855e-05

These O 0 1.9748435079236515e-05
results O 0 1.5798914319020696e-05
would O 0 1.140934728027787e-06
not O 0 2.179103404387206e-07
be O 0 1.5349904458616948e-07
expected O 0 6.990039196352882e-07
if O 0 2.462665236180328e-07
immunostaining O 0 3.423328234930523e-05
at O 0 4.150248003043089e-07
intercalated O 0 7.962990821397398e-06
discs O 0 5.1242100198578555e-06
were O 0 3.2156688689610746e-07
due O 0 2.8302127930146526e-07
to O 0 4.1688593910294e-08
a O 0 1.6205588337925292e-07
product O 0 1.7642915395299497e-07
of O 0 4.794732788582223e-08
the O 0 1.7774237903722678e-07
emerin O 0 6.320635293377563e-05
gene O 0 1.1863743338835775e-06
and O 0 1.9186592226105859e-07
, O 0 2.9087857456033817e-07
therefore O 0 2.1124944282746583e-07
, O 0 8.026664488625102e-08
cast O 0 3.3018557132891146e-07
some O 0 7.012126701511079e-08
doubt O 0 2.693591056868172e-07
upon O 0 1.0137311079461142e-07
the O 0 2.573524113813619e-07
hypothesis O 0 6.636765192524763e-06
that O 0 2.6917753075395012e-06
cardiac B-Disease 1 0.9999949932098389
defects I-Disease 1 0.9998100399971008
in O 0 4.752521635964513e-05
EDMD B-Disease 1 0.999998927116394
are O 0 8.676491347614501e-07
caused O 0 2.730841970333131e-06
by O 0 3.1051862947606423e-07
absence O 0 2.7233336368226446e-06
of O 0 6.543598374264548e-07
emerin O 0 0.0005653239204548299
from O 0 2.857771050912561e-06
intercalated O 0 0.00022843173064757138
discs O 0 0.00018830789485946298
. O 0 2.668081651790999e-05

Although O 0 0.0001654336811043322
emerin O 0 0.0019745295867323875
was O 0 7.363232725765556e-06
abundant O 0 1.6430158211733215e-06
in O 0 3.435692690345604e-07
the O 0 3.44911995853181e-07
membranes O 0 2.4537125682400074e-06
of O 0 2.75603753152609e-07
cardiomyocyte O 0 0.0007736270199529827
nuclei O 0 2.1746038328274153e-05
, O 0 2.641552612203668e-07
it O 0 7.090129372500087e-08
was O 0 3.9357098557957215e-07
absent O 0 1.1013569292117609e-06
from O 0 1.1355783158251143e-07
many O 0 9.068862993899529e-08
non O 0 2.761878477031132e-06
- O 0 0.00016382732428610325
myocyte O 1 0.5204528570175171
cells O 0 1.519101260782918e-05
in O 0 4.695075688232464e-07
the O 0 1.8934449599328218e-06
heart O 0 0.00023947762383613735
. O 0 2.3607486582477577e-05

This O 0 1.5531748431385495e-05
distribution O 0 8.403536412515678e-06
of O 0 1.3579137885244563e-06
emerin O 0 0.0003689216682687402
was O 0 1.653500362408522e-06
similar O 0 5.260302486931323e-07
to O 0 1.0970018848865948e-07
that O 0 7.418270087100609e-08
of O 0 1.6886151854578202e-07
lamin O 0 0.00029669387731701136
A O 0 4.091966729902197e-06
, O 0 2.2476002925486682e-07
a O 0 7.268698709594901e-07
candidate O 0 3.146465587633429e-06
gene O 0 1.4326433301903307e-06
for O 0 2.3304463070417114e-07
an O 0 2.8213671612320468e-06
autosomal O 0 0.024478012695908546
form O 0 7.073966116877273e-06
of O 0 9.20519232749939e-06
EDMD B-Disease 1 0.9999939203262329
. O 0 6.152169225970283e-05

In O 0 6.426136678783223e-05
contrast O 0 0.00013947852130513638
, O 0 1.384024835715536e-05
lamin O 0 0.01951146125793457
B1 O 0 0.02408512867987156
was O 0 7.5810285125044174e-06
absent O 0 8.069835530477576e-06
from O 0 8.099914907688799e-07
cardiomyocyte O 0 0.00010022358037531376
nuclei O 0 1.2373606296023354e-05
, O 0 5.423275979410391e-07
showing O 0 2.0191264411550947e-06
that O 0 3.782153328302229e-07
lamin O 0 0.027325158938765526
B1 O 0 0.0402652807533741
is O 0 2.457234131725272e-07
not O 0 6.261745255642381e-08
essential O 0 1.583088078405126e-07
for O 0 1.009593972867151e-07
localization O 0 2.3787574718880933e-06
of O 0 2.5009549631249683e-07
emerin O 0 0.00010116079647559673
to O 0 7.303490292542847e-07
the O 0 2.5967751753341872e-06
nuclear O 0 6.184037192724645e-05
lamina O 0 0.002369218971580267
. O 0 5.183681059861556e-05

Lamin O 1 0.9054625630378723
B1 O 1 0.6094189286231995
is O 0 1.6830033928272314e-05
also O 0 4.448738764040172e-06
almost O 0 3.2241980534308823e-06
completely O 0 8.673068805364892e-06
absent O 0 2.5422774342587218e-05
from O 0 6.455626589740859e-06
skeletal O 0 0.042882177978754044
muscle O 0 0.0026544728316366673
nuclei O 0 0.0006066096248105168
. O 0 4.237423127051443e-05

In O 0 0.0003329360915813595
EDMD B-Disease 1 0.9987700581550598
, O 0 5.690612852049526e-06
the O 0 1.3519672847905895e-06
additional O 0 2.129165523001575e-06
absence O 0 3.8162361306604e-06
of O 0 1.769472532942018e-06
lamin O 0 0.3389946520328522
B1 O 0 0.22139066457748413
from O 0 3.39964208251331e-06
heart O 0 0.00010819265298778191
and O 0 2.8302310965955257e-06
skeletal O 0 0.025550775229930878
muscle O 0 0.001023065415211022
nuclei O 0 6.624144589295611e-05
which O 0 1.0622447916830424e-06
already O 0 1.9804335806838935e-06
lack O 0 3.3892608826135984e-06
emerin O 0 0.023239552974700928
may O 0 3.800789045271813e-06
offer O 0 2.8424173592611623e-07
an O 0 1.6497942567639257e-07
alternative O 0 7.363158829321037e-07
explanation O 0 3.169258206980885e-07
of O 0 1.0481869594514137e-07
why O 0 2.554763511852798e-07
these O 0 1.5312694756630663e-07
tissues O 0 5.335325568012195e-06
are O 0 2.1913153602781676e-07
particularly O 0 1.7535837741888827e-06
affected O 0 4.583757345244521e-06
. O 0 2.1840496629010886e-06
. O 0 9.204928574035875e-06

Genetic O 0 0.0007191192707978189
mapping O 0 0.00010286643373547122
of O 0 3.9330002437054645e-06
the O 0 5.507385594683001e-06
copper B-Disease 0 0.0002983936865348369
toxicosis I-Disease 0 0.015407354570925236
locus O 0 4.8479156248504296e-05
in O 0 2.8418583042366663e-06
Bedlington O 0 0.00014695667778141797
terriers O 0 6.796427624067292e-05
to O 0 1.1367131946826703e-06
dog O 0 2.3567063180962577e-05
chromosome O 0 6.631444557569921e-05
10 O 0 6.117007274042408e-07
, O 0 1.230875454893976e-07
in O 0 1.7721445999541174e-07
a O 0 9.841245400821208e-07
region O 0 5.8301516219216865e-06
syntenic O 0 9.879088611342013e-05
to O 0 7.756594300190045e-07
human O 0 4.424895450938493e-06
chromosome O 0 8.158916898537427e-05
region O 0 1.6202626284211874e-05
2p13 O 0 0.0004143542319070548
- O 0 0.0004244305891916156
p16 O 0 0.0005598787683993578
. O 0 3.6816694773733616e-05

Abnormal O 1 0.9973896145820618
hepatic B-Disease 1 0.9999098777770996
copper I-Disease 0 0.004659844562411308
accumulation I-Disease 0 0.0003037230053450912
is O 0 2.5667227419035044e-06
recognized O 0 2.329056314920308e-06
as O 0 1.223893718815816e-06
an O 0 0.00015720179362688214
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 6.947909696464194e-06
man O 0 2.7134950869367458e-05
, O 0 1.2186573030703585e-06
mouse O 0 4.102965976926498e-05
, O 0 1.3379940355662256e-06
rat O 0 0.00012512423563748598
and O 0 5.005513230571523e-06
dog O 0 0.00015393183275591582
. O 0 2.6950841856887564e-05

The O 0 6.874378595966846e-05
major O 0 3.2372183341067284e-05
cause O 0 3.622481381171383e-05
of O 0 3.926486897398718e-06
hepatic B-Disease 1 0.9694012403488159
copper I-Disease 0 0.000870641553774476
accumulation I-Disease 0 2.86136673821602e-05
in O 0 7.560600465694733e-07
man O 0 4.327330316300504e-06
is O 0 3.376564450263686e-07
a O 0 2.302036136825336e-06
dysfunctional O 0 0.000345201842719689
ATP7B O 0 0.03747791051864624
gene O 0 2.419848897261545e-05
, O 0 5.568755113927182e-06
causing O 0 0.0002269829565193504
Wilson B-Disease 0 0.08999913930892944
disease I-Disease 0 0.15390995144844055
( O 0 0.00010132685565622523
WD B-Disease 1 0.8003811240196228
) O 0 3.044756522285752e-05
. O 0 2.119442433468066e-05

Mutations O 0 0.0025599501095712185
in O 0 8.17666295915842e-06
the O 0 3.6797891880269162e-06
ATP7B O 0 0.0034118208568543196
genes O 0 8.86360794538632e-06
have O 0 5.72299995837966e-07
also O 0 5.137506491337263e-07
been O 0 6.183472578413785e-07
demonstrated O 0 2.1582486624538433e-06
in O 0 7.753658337605884e-07
mouse O 0 3.153088255203329e-05
and O 0 7.128107881726464e-06
rat O 0 0.001594659755937755
. O 0 4.1681912989588454e-05

The O 0 0.00011810937576228753
ATP7B O 0 0.0032009233254939318
gene O 0 7.972347520990297e-05
has O 0 5.2617447181546595e-06
been O 0 1.2685316050919937e-06
excluded O 0 2.649110911079333e-06
in O 0 2.671008871857339e-07
the O 0 2.865300814391958e-07
much O 0 7.220343150038389e-07
rarer O 0 2.615766970848199e-05
human O 0 7.762538189126644e-06
copper B-Disease 0 0.003416986670345068
overload I-Disease 0 0.1905851513147354
disease O 0 0.00033706013346090913
non B-Disease 0 7.387132882286096e-06
- I-Disease 0 9.80055338004604e-05
Indian I-Disease 0 1.8011118299909867e-05
childhood I-Disease 0 0.0005283164791762829
cirrhosis I-Disease 1 0.8160984516143799
, O 0 1.2554612112580799e-05
indicating O 0 0.0001074853862519376
genetic O 0 0.00016884323849808425
heterogeneity O 0 0.001353142666630447
. O 0 4.450777851161547e-05

By O 0 6.7245724494569e-05
investigating O 0 0.00011111469939351082
the O 0 2.2504844309878536e-05
common O 0 0.0005798247293569148
autosomal O 1 0.9997723698616028
recessive O 1 0.9999798536300659
copper B-Disease 1 0.9039928317070007
toxicosis I-Disease 1 0.9976668357849121
( O 0 2.893283817684278e-05
CT B-Disease 0 0.0015585855580866337
) O 0 1.861677333181433e-06
in O 0 1.0703903399189585e-06
Bedlington O 0 0.00019731141219381243
terriers O 0 0.00010398482118034735
, O 0 5.34728883394564e-07
we O 0 1.0736439293168587e-07
have O 0 1.2116538528061938e-07
identified O 0 5.235917797108414e-07
a O 0 4.4187581238475104e-07
new O 0 1.605397983439616e-06
locus O 0 4.292087032808922e-05
involved O 0 6.095453954912955e-06
in O 0 5.506190791493282e-05
progressive O 1 0.9995266199111938
liver B-Disease 1 1.0
disease I-Disease 1 0.9999985694885254
. O 0 7.704972813371569e-05

We O 0 6.449293141486123e-05
examined O 0 4.5658063754672185e-05
whether O 0 5.384509222494671e-06
the O 0 3.983188435086049e-06
WD B-Disease 0 0.059956468641757965
gene O 0 4.367318979348056e-05
ATP7B O 0 0.0008077129605226219
was O 0 3.0653902740596095e-06
also O 0 7.73551164456876e-07
causative O 0 8.033638550841715e-06
for O 0 6.127855840531993e-07
CT B-Disease 0 0.0009262837702408433
by O 0 3.828371575309575e-07
investigating O 0 1.7169955981444218e-06
the O 0 6.822757541158353e-07
chromosomal O 0 0.002170527121052146
co O 0 2.8761622161255218e-05
- O 0 3.0299463105620816e-05
localization O 0 8.031064680835698e-06
of O 0 4.958104113939044e-07
ATP7B O 0 0.00048158635036088526
and O 0 8.431081255366735e-07
C04107 O 0 4.336297570262104e-05
, O 0 3.6092518485020264e-07
using O 0 7.471782623724721e-07
fluorescence O 0 6.282300546445185e-06
in O 0 9.774554428076954e-07
situ O 0 1.8743701730272733e-05
hybridization O 0 1.3617028344015125e-05
( O 0 2.4665180262672948e-06
FISH O 0 3.6526921576296445e-06
) O 0 5.754552148573566e-06
. O 0 1.1551630450412631e-05

C04107 O 0 0.0033210287801921368
is O 0 2.2013300622347742e-05
an O 0 6.384781045198906e-06
anonymous O 0 2.5351255317218602e-05
microsatellite O 0 0.0006731305620633066
marker O 0 7.917208858998492e-05
closely O 0 2.7396004952606745e-05
linked O 0 7.926181569928303e-05
to O 0 1.2515712114691269e-05
CT B-Disease 0 0.16165660321712494
. O 0 4.379505480756052e-05

However O 0 0.00014847431157249957
, O 0 2.1706153347622603e-05
BAC O 0 0.0002925196022260934
clones O 0 4.108215944143012e-05
containing O 0 4.62457001049188e-06
ATP7B O 0 0.00016878015594556928
and O 0 1.0377447097198456e-06
C04107 O 0 4.17473929701373e-05
mapped O 0 4.830269517697161e-06
to O 0 2.180903777571075e-07
the O 0 4.2969546143467596e-07
canine O 0 8.544339652871713e-05
chromosome O 0 8.794586028670892e-05
regions O 0 2.344557742617326e-06
CFA22q11 O 0 3.736327198566869e-05
and O 0 7.16635440767277e-07
CFA10q26 O 0 0.00010727383778430521
, O 0 4.218266269617743e-07
respectively O 0 1.1957382639593561e-06
, O 0 1.854584326110853e-07
demonstrating O 0 1.6332672885255306e-06
that O 0 3.582202907637111e-07
WD B-Disease 0 0.01689792424440384
cannot O 0 1.2959998230144265e-06
be O 0 3.0067405987210805e-07
homologous O 0 8.338106454175431e-06
to O 0 6.308549018285703e-06
CT B-Disease 0 0.010265514254570007
. O 0 2.456804213579744e-05

The O 0 4.518217610893771e-05
copper O 0 0.0001532562164356932
transport O 0 3.1250423489836976e-05
genes O 0 1.561379940540064e-05
CTR1 O 0 0.00013179391680750996
and O 0 1.4426987036131322e-06
CTR2 O 0 0.001197422156110406
were O 0 7.718194865447003e-07
also O 0 3.999392959030956e-07
excluded O 0 1.0978743603118346e-06
as O 0 1.4866375863675785e-07
candidate O 0 1.3827406064592651e-06
genes O 0 9.680265975475777e-07
for O 0 3.1255555654752243e-07
CT B-Disease 0 0.003677296219393611
since O 0 9.85287101684662e-07
they O 0 1.28497617879475e-07
both O 0 1.4813474535912974e-07
mapped O 0 5.361062903830316e-06
to O 0 8.512000704286038e-07
canine O 0 0.0002987019543070346
chromosome O 0 0.00038138244417496026
region O 0 3.692048630909994e-05
CFA11q22 O 0 0.0010794906411319971
. O 0 2.8025049687130377e-05

2 O 0 0.0013009654358029366
- O 0 0.003766111098229885
22 O 0 0.00027569226222112775
. O 0 6.533815758302808e-05

5 O 0 0.003120363224297762
. O 0 0.000500351598020643

A O 0 0.0001418964093318209
transcribed O 0 0.00010346258204663172
sequence O 0 2.139435127901379e-05
identified O 0 5.0759422265400644e-06
from O 0 3.947020275063551e-07
the O 0 2.8674384111582185e-07
C04107 O 0 3.506352368276566e-05
- O 0 1.1758317668864038e-05
containing O 0 1.3840281098964624e-06
BAC O 0 3.307177757960744e-05
was O 0 5.175579076421855e-07
found O 0 8.497257653061752e-08
to O 0 5.873284791846345e-08
be O 0 5.995376284317899e-08
homologous O 0 6.283208335844392e-07
to O 0 8.538507501043568e-08
a O 0 5.956588324806944e-07
gene O 0 1.2824876876038616e-06
expressed O 0 2.555097466938605e-07
from O 0 2.3977500518412853e-07
human O 0 1.096371761377668e-06
chromosome O 0 4.4173095375299454e-05
2p13 O 0 6.910759111633524e-05
- O 0 6.801199924666435e-05
p16 O 0 1.6350239093299024e-05
, O 0 2.1420851226139348e-07
a O 0 6.307198532340408e-07
region O 0 1.984551545319846e-06
devoid O 0 2.619606675580144e-06
of O 0 3.029392416920018e-07
any O 0 5.255588462205196e-07
positional O 0 5.381869414122775e-05
candidate O 0 6.1005877796560526e-05
genes O 0 4.477140828385018e-05
. O 0 1.8229646229883656e-05

Molecular O 0 0.0003289720043540001
analysis O 0 1.667587821430061e-05
of O 0 1.5259921610777383e-06
the O 0 1.3720637070946395e-06
APC B-Disease 0 2.9283988624229096e-05
gene O 0 2.3508089270762866e-06
in O 0 3.9510123883701453e-07
205 O 0 4.713973794423509e-06
families O 0 1.7774791558622383e-06
: O 0 5.738089043916261e-07
extended O 0 9.631840839574579e-06
genotype O 0 0.0003955816209781915
- O 0 0.0005150717333890498
phenotype O 0 0.0016349792713299394
correlations O 0 9.227780537912622e-06
in O 0 6.521513569168746e-07
FAP B-Disease 0 5.786828478449024e-05
and O 0 2.24532286097201e-07
evidence O 0 1.7587846912192617e-07
for O 0 6.736926394523834e-08
the O 0 1.3681658117548068e-07
role O 0 5.827889140164189e-07
of O 0 5.915512133469747e-07
APC B-Disease 0 4.276088293408975e-05
amino O 0 8.326109309564345e-06
acid O 0 1.6031663108151406e-05
changes O 0 1.199251437355997e-05
in O 0 0.0007103757816366851
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9280384182929993
. O 0 8.771009015617892e-05

BACKGROUND O 0 0.0012502059107646346
/ O 0 0.0008657309226691723
AIMS O 0 4.873930447502062e-05
The O 0 2.3872528345236788e-06
development O 0 1.4808921150688548e-05
of O 0 0.0010879287729039788
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.5573087896191282e-06
a O 0 3.908963662979659e-06
variable O 0 9.01581734069623e-06
range O 0 2.349744136154186e-06
of O 0 1.2900943602289772e-06
extracolonic O 0 0.0014201832236722112
manifestations O 0 0.0002219318994320929
in O 0 0.00014543633733410388
familial B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
( O 0 0.0006042614113539457
FAP B-Disease 0 0.0038306033238768578
) O 0 1.6074907307483954e-06
is O 0 1.7912442729084432e-07
the O 0 1.528906921066664e-07
result O 0 2.507054261968733e-07
of O 0 1.5866565661326604e-07
the O 0 1.219910814143077e-06
dominant O 0 6.25456013949588e-05
inheritance O 0 0.0003601743374019861
of O 0 0.00017449572624173015
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 0.9996656179428101
( O 0 6.887483323225752e-05
APC B-Disease 0 0.00029605196323245764
) O 0 1.9039591279579327e-05
gene O 0 0.00012230701395310462
mutations O 0 0.00014365260722115636
. O 0 3.546677908161655e-05

In O 0 2.541913818276953e-05
this O 0 2.1953369468974415e-06
study O 0 1.725962761156552e-06
, O 0 3.5541231113711547e-07
direct O 0 9.990523039959953e-07
mutation O 0 3.050977056773263e-06
analysis O 0 2.379485550818572e-07
of O 0 6.769992211275166e-08
the O 0 3.152113094984088e-07
APC B-Disease 0 1.7417421986465342e-05
gene O 0 1.6064623196143657e-06
was O 0 5.510656251317414e-07
performed O 0 6.107692342993687e-07
to O 0 3.325728243908088e-07
determine O 0 3.406064251976204e-06
genotype O 0 0.000380026176571846
- O 0 0.0012410087510943413
phenotype O 0 0.0006104381172917783
correlations O 0 5.259085810394026e-06
for O 0 3.8097238075351925e-07
nine O 0 3.3015924145729514e-06
extracolonic O 0 0.0004777490976266563
manifestations O 0 8.57634313433664e-06
and O 0 2.6208257963844517e-07
to O 0 2.4061270664788026e-07
investigate O 0 1.4056168993192841e-06
the O 0 6.380766421898443e-07
incidence O 0 6.285916606429964e-05
of O 0 9.75523107626941e-07
APC B-Disease 0 0.00020027912978548557
mutations O 0 1.877722934295889e-05
in O 0 3.042315711354604e-06
non O 0 0.0003348127647768706
- O 1 0.999373733997345
FAP O 1 0.9999912977218628
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0001523788960184902

METHODS O 0 0.00019370234804227948
The O 0 1.981680361495819e-05
APC B-Disease 0 0.00017792894504964352
gene O 0 1.7606604160391726e-05
was O 0 2.438582214381313e-06
analysed O 0 4.74569242214784e-06
in O 0 1.0931415772574837e-06
190 O 0 1.0935358659480698e-05
unrelated O 0 2.6328927560825832e-05
FAP B-Disease 0 0.00013124974793754518
and O 0 2.3837151275074575e-06
15 O 0 1.9908540707547218e-05
non O 0 0.00015814612561371177
- O 1 0.9994083642959595
FAP O 1 0.9999969005584717
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.02276219241321087
using O 0 1.5586083463858813e-05
denaturing O 0 0.02492588758468628
gradient O 0 0.0036379287485033274
gel O 0 0.0011017475044354796
electrophoresis O 0 0.00033376875217072666
, O 0 1.2935943232150748e-06
the O 0 3.9766757709003286e-07
protein O 0 1.685482402535854e-06
truncation O 0 1.1531531526998151e-05
test O 0 1.5086280882314895e-06
, O 0 4.4226200657249137e-07
and O 0 8.603996661804558e-07
direct O 0 5.7057304729823954e-06
sequencing O 0 5.0297403504373506e-05
. O 0 1.9081162463407964e-05

RESULTS O 0 0.0004542972892522812
Chain O 0 0.00018213773728348315
terminating O 0 0.00011565181921469048
signals O 0 2.1402860511443578e-05
were O 0 1.032342424878152e-06
only O 0 2.8048691547155613e-07
identified O 0 3.784029104281217e-06
in O 0 3.058647735088016e-06
patients O 0 4.484251621761359e-05
belonging O 0 1.5098255516932113e-06
to O 0 2.732295740770496e-07
the O 0 1.5393517287520808e-06
FAP B-Disease 0 0.0003907008795067668
group O 0 1.102844180422835e-05
( O 0 4.0594763959234115e-06
105 O 0 4.412173802847974e-05
patients O 0 0.00012510883971117437
) O 0 6.643794222327415e-06
. O 0 1.0593762453936506e-05

Amino O 0 0.0009101444156840444
acid O 0 0.0001999371888814494
changes O 0 9.036580195243005e-06
were O 0 1.427452730240475e-06
identified O 0 2.36603113989986e-06
in O 0 7.759613254165743e-07
four O 0 1.539081677037757e-05
patients O 0 0.00014145289605949074
, O 0 1.8410364077681152e-07
three O 0 1.1596830518101342e-07
of O 0 1.2150766792728973e-07
whom O 0 2.0945092273905175e-06
belonged O 0 1.4147537967801327e-06
to O 0 1.0365781122345652e-07
the O 0 3.352509168053075e-07
non O 0 5.586947736446746e-06
- O 0 0.0002597851271275431
FAP O 0 0.0009054995607584715
group O 0 0.00013151750317774713
of O 0 0.0005281850462779403
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9844046235084534
. O 0 0.00010309818753739819

Genotype O 1 0.9909232258796692
- O 1 0.9432415962219238
phenotype O 1 0.908279538154602
correlations O 0 0.0004417358723003417
identified O 0 3.811669739661738e-05
significant O 0 3.031828100574785e-06
differences O 0 2.9134600936231436e-06
in O 0 4.781193752023682e-07
the O 0 2.5899416300489975e-07
nature O 0 4.959924808645155e-07
of O 0 2.1635192126723268e-07
certain O 0 7.18948513167561e-07
extracolonic O 0 0.0011501702247187495
manifestations O 0 5.208694710745476e-05
in O 0 7.71446411818033e-06
FAP B-Disease 0 0.07049739360809326
patients O 0 0.00011185171752003953
belonging O 0 3.5630860111268703e-06
to O 0 7.90734645761404e-07
three O 0 6.142885013105115e-06
mutation O 0 0.00011818070197477937
subgroups O 0 0.00019034507567994297
. O 0 2.6492614779272117e-05

CONCLUSIONS O 0 0.0006134002469480038
Extended O 0 0.0006429890636354685
genotype O 0 0.029632026329636574
- O 0 0.06261498481035233
phenotype O 0 0.04615660011768341
correlations O 0 2.551786928961519e-05
made O 0 6.710840807500063e-07
in O 0 3.9660105244365695e-07
this O 0 1.8641381416273362e-07
study O 0 1.1089622375948238e-06
may O 0 9.116501473727112e-07
have O 0 6.095785920479102e-08
the O 0 8.941129436834672e-08
potential O 0 2.2124737597550848e-07
to O 0 5.811494929730543e-08
determine O 0 2.161127099498117e-07
the O 0 7.555930636726771e-08
most O 0 7.865126860906457e-08
appropriate O 0 2.863230292859953e-07
surveillance O 0 2.5864417239063187e-06
and O 0 1.0280206197421649e-06
prophylactic O 0 0.0031195797491818666
treatment O 0 0.005058152135461569
regimens O 0 0.0018999740714207292
for O 0 1.2955314332430135e-06
those O 0 1.7210121541211265e-06
patients O 0 3.678111170302145e-05
with O 0 1.974896122192149e-06
mutations O 0 6.433181260945275e-05
associated O 0 1.570512381476874e-06
with O 0 1.2519332130978e-06
life O 0 5.4303291108226404e-05
threatening O 0 0.00510729243978858
conditions O 0 0.0005140826106071472
. O 0 2.4855287847458385e-05

This O 0 2.2089912818046287e-05
study O 0 8.443588740192354e-06
also O 0 9.515911187918391e-07
provided O 0 7.821545864317159e-07
evidence O 0 2.636006399825419e-07
for O 0 1.1735802729617717e-07
the O 0 3.0772451964367065e-07
pathological O 0 1.2936762686877046e-05
nature O 0 5.235697813077422e-07
of O 0 2.36213011817199e-07
amino O 0 3.504883125060587e-06
acid O 0 2.370957417952013e-06
changes O 0 4.721549942132697e-07
in O 0 3.191198061358591e-07
APC O 0 7.716642357991077e-06
associated O 0 5.978898229841434e-07
with O 0 2.338101836585338e-07
both O 0 9.14476629532146e-07
FAP B-Disease 0 0.00016803762991912663
and O 0 1.0471570931258611e-05
non O 0 0.0003394632076378912
- O 1 0.9999243021011353
FAP O 1 0.9999991655349731
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9160003066062927
. O 0 1.3538531675294507e-05
. O 0 2.884891910071019e-05

Inherited B-Disease 1 0.9999955892562866
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999997615814209
and O 1 0.888858437538147
cancer B-Disease 1 0.9999525547027588
risk O 0 0.00011775301391026005
of O 0 2.531802238081582e-06
the O 0 8.801737749308813e-06
APC O 0 0.0009161665802821517
I1307K O 0 0.0024178766179829836
polymorphism O 0 0.0006090477691031992
. O 0 3.6332032323116437e-05

Germ O 0 0.016344329342246056
- O 0 0.0011004714760929346
line O 0 7.75236840127036e-05
and O 0 6.715054041706026e-06
somatic O 0 0.00020599365234375
truncating O 0 0.0005242991610430181
mutations O 0 2.0618857888621278e-05
of O 0 4.2757511664603953e-07
the O 0 8.539823852515838e-07
APC B-Disease 0 2.8501330234576017e-05
gene O 0 2.788274287013337e-06
are O 0 2.640862533098698e-07
thought O 0 9.143921033683e-07
to O 0 1.4898708968758e-06
initiate O 0 0.0008146052714437246
colorectal B-Disease 1 1.0
tumor I-Disease 1 0.9908260703086853
formation O 0 0.0005153818055987358
in O 0 0.0003226246917620301
familial B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.0008771326392889023
sporadic O 1 0.9974207878112793
colorectal O 1 1.0
carcinogenesis O 1 0.9993728995323181
, O 0 5.777140177087858e-05
respectively O 0 0.0001172089105239138
. O 0 4.8768917622510344e-05

Recently O 0 0.0003301269025541842
, O 0 1.0907009709626436e-05
an O 0 4.3525774344743695e-06
isoleucine O 0 0.018569819629192352
- O 0 0.002673265291377902
- O 0 0.004428476560860872
> O 0 0.00023261249589268118
lysine O 0 3.737780571100302e-05
polymorphism O 0 1.3887662134948187e-05
at O 0 9.108384801947977e-07
codon O 0 1.3708310689253267e-05
1307 O 0 4.641620034817606e-05
( O 0 1.5348163060480147e-06
I1307K O 0 7.3980531851702835e-06
) O 0 1.9574083864881686e-07
of O 0 5.909625500066795e-08
the O 0 2.2721148695836746e-07
APC B-Disease 0 1.0617642146826256e-05
gene O 0 1.2052292959197075e-06
has O 0 1.875590243116676e-07
been O 0 1.4612268728342315e-07
identified O 0 4.989300919078232e-07
in O 0 1.8199278883912484e-07
6 O 0 5.992203114146832e-06
% O 0 2.9341381377889775e-06
- O 0 1.3758264685748145e-05
7 O 0 6.0691886574204545e-06
% O 0 5.85525413043797e-07
of O 0 1.0767713831683068e-07
the O 0 8.509841791237704e-07
Ashkenazi O 0 0.0005066016456112266
Jewish O 0 2.9024840841884725e-05
population O 0 9.066923666978255e-06
. O 0 9.487833267485257e-06

To O 0 4.8953763325698674e-05
assess O 0 6.78149881423451e-05
the O 0 3.8143298297654837e-06
risk O 0 1.0730122994573321e-05
of O 0 2.939970897841704e-07
this O 0 4.0868474115995923e-07
common O 0 5.258654255158035e-06
APC B-Disease 0 8.608704956714064e-05
allelic O 0 0.00021479719725903124
variant O 0 0.00032446120167151093
in O 0 8.76771446201019e-05
colorectal O 1 1.0
carcinogenesis O 1 0.9468912482261658
, O 0 3.630022774814279e-06
we O 0 2.44413200789495e-07
have O 0 1.8049730954317056e-07
analyzed O 0 8.529471529072907e-07
a O 0 5.705506396225246e-07
large O 0 6.906784051352588e-07
cohort O 0 2.3592543584527448e-05
of O 0 7.005909310464631e-07
unselected O 0 0.00015414098743349314
Ashkenazi O 0 0.00019254851213190705
Jewish O 0 6.097883670008741e-06
subjects O 0 3.09631104755681e-06
with O 0 3.5567441045714077e-06
adenomatous B-Disease 1 0.9893775582313538
polyps I-Disease 1 0.6620062589645386
and O 0 5.562354090216104e-06
. O 0 7.052040928101633e-06
or O 0 0.253802090883255
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 1.6315159427904291e-06
for O 0 6.088773716328433e-07
the O 0 4.458728653844446e-06
APC O 0 0.0003046818310394883
I1307K O 0 0.0009649813873693347
polymorphism O 0 0.0003523390041664243
. O 0 2.916387347795535e-05

The O 0 5.5346288718283176e-05
APC O 0 0.0003665116091724485
I1307K O 0 0.0005368548445403576
allele O 0 0.00010918513726210222
was O 0 4.635162895283429e-06
identified O 0 2.8398617359925993e-06
in O 0 4.6571437906095525e-07
48 O 0 3.2069422104541445e-06
( O 0 3.5964976063951326e-07
10 O 0 2.2873686589264253e-07
. O 0 7.376999633379455e-08
1 O 0 9.04452122085786e-07
% O 0 1.1139536582049914e-06
) O 0 5.833272211930307e-07
of O 0 1.1711690603988245e-06
476 O 0 0.0009224350797012448
patients O 0 0.0008952206117101014
. O 0 3.0192941267159767e-05

Compared O 0 0.00019612802134361118
with O 0 2.8378067327139433e-06
the O 0 1.0013530982178054e-06
frequency O 0 3.3000155781337526e-06
in O 0 2.479408465205779e-07
two O 0 2.1403290872967773e-07
separate O 0 9.768701829671045e-07
population O 0 6.150959848127968e-07
control O 0 1.0976607427437557e-06
groups O 0 2.1879033340610476e-07
, O 0 1.1899964391659523e-07
the O 0 2.6881610892814933e-07
APC O 0 1.9203069314244203e-05
I1307K O 0 6.608459807466716e-05
allele O 0 4.681051450461382e-06
is O 0 1.213232110330864e-07
associated O 0 1.9027768871637818e-07
with O 0 9.69727054211944e-08
an O 0 4.892061724603991e-07
estimated O 0 4.345477009337628e-06
relative O 0 7.631602784385905e-06
risk O 0 5.519400019693421e-06
of O 0 8.007135079424188e-07
1 O 0 1.3942572877567727e-05
. O 0 1.1788397387135774e-05

5 O 0 0.0011129078920930624
- O 0 0.001264600083231926
1 O 0 0.00018070974329020828
. O 0 8.682376210344955e-05

7 O 0 0.0039891889318823814
for O 0 0.0004867592651862651
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9998369216918945
( O 0 3.23097592627164e-05
both O 0 6.540387403219938e-06
P O 0 0.03285270929336548
= O 0 0.00036077454569749534
. O 0 2.25529447561712e-06
01 O 0 8.993145456770435e-05
) O 0 7.632737833773717e-06
. O 0 1.6490013877046295e-05

Furthermore O 0 0.00022207836445886642
, O 0 6.962163297430379e-06
compared O 0 5.62112018087646e-06
with O 0 1.1263086889812257e-06
noncarriers O 0 0.0004946438129991293
, O 0 2.3226107259688433e-06
APC O 0 3.6864516005152836e-05
I1307K O 0 7.716877007624134e-05
carriers O 0 4.006579729320947e-06
had O 0 5.467198320729949e-07
increased O 0 8.600026148997131e-07
numbers O 0 4.662040851144411e-07
of O 0 7.052754540382011e-07
adenomas B-Disease 1 0.5304650664329529
and O 0 0.014281516894698143
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.999884843826294
per O 0 7.475264283129945e-05
patient O 0 0.000259185180766508
( O 0 9.525749192107469e-06
P O 0 0.001309239654801786
= O 0 3.975829167757183e-05
. O 0 2.8725949619001767e-07
03 O 0 4.61987110611517e-06
) O 0 2.950886823782639e-07
, O 0 7.525855494350253e-08
as O 0 5.777112832561215e-08
well O 0 9.956265500932204e-08
as O 0 1.0974580533229528e-07
a O 0 1.3887880641050288e-06
younger O 0 7.799508239259012e-06
age O 0 4.646603429137031e-06
at O 0 6.677938017674023e-06
diagnosis O 0 0.006151693873107433
. O 0 3.204439417459071e-05

We O 0 1.8752194591797888e-05
conclude O 0 1.6102378140203655e-05
that O 0 5.640369522552646e-07
the O 0 1.0072030818264466e-06
APC O 0 3.3752803574316204e-05
I1307K O 0 7.257807737914845e-05
variant O 0 1.7327578461845405e-05
leads O 0 7.534633823524928e-06
to O 0 1.1243137123528868e-06
increased O 0 6.730756285833195e-05
adenoma B-Disease 1 0.9999783039093018
formation O 0 1.0323205060558394e-05
and O 0 3.973249249611399e-07
directly O 0 3.824580119271559e-07
contributes O 0 6.894181865391147e-07
to O 0 1.823781587972917e-07
3 O 0 1.708488980511902e-06
% O 0 1.4172765077091753e-06
- O 0 4.420533969096141e-06
4 O 0 1.9744989003811497e-06
% O 0 7.47693661651283e-07
of O 0 2.1976418906888284e-07
all O 0 1.058810084941797e-06
Ashkenazi O 0 0.2939038872718811
Jewish O 1 0.9632049798965454
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 0.00012278764916118234

The O 0 5.112252620165236e-05
estimated O 0 4.484648889047094e-05
relative O 0 4.7652276407461613e-05
risk O 0 3.4578970371512696e-05
for O 0 1.1976294445048552e-06
carriers O 0 2.4108172510750592e-05
may O 0 2.3353838969342178e-06
justify O 0 2.9214061214588583e-06
specific O 0 7.813897013875248e-07
clinical O 0 1.2430212336767e-05
screening O 0 2.2020990400051232e-06
for O 0 1.007754732995636e-07
the O 0 1.517956746965865e-07
360 O 0 2.8252661650185473e-06
, O 0 1.9455718813787826e-07
000 O 0 7.400407184832147e-07
Americans O 0 3.7232535987641313e-07
expected O 0 3.06717510056842e-07
to O 0 8.064045431410705e-08
harbor O 0 4.4135626922070514e-06
this O 0 9.663389732850192e-08
allele O 0 1.1970755622314755e-06
, O 0 6.616029679662461e-08
and O 0 1.3845308899362863e-07
genetic O 0 1.687628014224174e-06
testing O 0 2.8161477416688285e-07
in O 0 3.702878004219201e-08
the O 0 5.369497912965926e-08
setting O 0 3.4248219549226633e-07
of O 0 1.3808347887334094e-07
long O 0 1.1211817763978615e-05
- O 0 9.265400149160996e-05
term O 0 1.1529355106176808e-05
- O 0 3.3522159355925396e-05
outcome O 0 3.593251676647924e-06
studies O 0 1.1901273637704435e-06
may O 0 1.1791732958954526e-06
impact O 0 4.1370512917637825e-06
significantly O 0 0.00014825207472313195
on O 1 0.5225933194160461
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 0.06809154152870178
in O 0 3.0941710065235384e-06
this O 0 2.128412461388507e-06
population O 0 1.8293963876203634e-05
. O 0 2.2090924176154658e-05

Localization O 0 0.0010307038901373744
of O 0 2.0130997654632665e-05
human O 0 1.7416443370166235e-05
BRCA1 O 0 0.000381806050427258
and O 0 1.965826413652394e-06
its O 0 1.572102178215573e-06
loss O 0 2.0144787413300946e-05
in O 0 1.152130153059261e-06
high O 0 2.5639492378104478e-05
- O 0 0.0005572104710154235
grade O 0 2.530116580601316e-05
, O 0 2.203456233473844e-06
non B-Disease 0 4.7218924009939656e-05
- I-Disease 0 0.495817095041275
inherited I-Disease 1 0.9822851419448853
breast I-Disease 1 0.9999790191650391
carcinomas I-Disease 1 0.9999994039535522
. O 0 0.00016343616880476475

Although O 0 5.136573963682167e-05
the O 0 5.266785137791885e-06
link O 0 1.0656444828782696e-05
between O 0 3.2377743082179222e-06
the O 0 7.403184554277686e-06
BRCA1 O 0 0.36308830976486206
tumour B-Disease 1 0.9999874830245972
- O 0 0.003313028486445546
suppressor O 0 0.0026131845079362392
gene O 0 3.135523002129048e-05
and O 0 1.7540054614073597e-05
hereditary B-Disease 1 0.9966087341308594
breast I-Disease 1 0.9999990463256836
and I-Disease 1 0.9998995065689087
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 1.4060915418667719e-06
established O 0 5.958883662060543e-07
, O 0 8.186334099491432e-08
the O 0 6.541096553291936e-08
role O 0 6.356490303005558e-07
, O 0 2.164575789720402e-07
if O 0 7.780065658380408e-08
any O 0 4.936838848834668e-08
, O 0 1.2507884150636528e-07
of O 0 2.094396478469207e-07
BRCA1 O 0 8.379219798371196e-05
in O 0 2.675516043382231e-06
non B-Disease 0 6.754276546416804e-05
- I-Disease 1 0.8769576549530029
familial I-Disease 1 0.9997777342796326
cancers I-Disease 1 0.9997441172599792
is O 0 8.251378858403768e-06
unclear O 0 4.695605821325444e-05
. O 0 3.018686402356252e-05

BRCA1 O 1 0.999213695526123
mutations O 0 0.0489967055618763
are O 0 7.091717179719126e-06
rare O 0 1.0332897545595188e-05
in O 0 6.680613296339288e-06
sporadic B-Disease 0 0.22731557488441467
cancers I-Disease 1 0.998123824596405
, O 0 3.5466841836750973e-06
but O 0 8.795979624665051e-07
loss O 0 2.3475346097256988e-05
of O 0 1.2914102853756049e-06
BRCA1 O 0 0.0025488820392638445
resulting O 0 1.2752425391227007e-05
from O 0 4.576178298520972e-07
reduced O 0 6.2235098994278815e-06
expression O 0 8.933695312407508e-07
or O 0 3.216116795101698e-07
incorrect O 0 2.456259835525998e-06
subcellular O 0 2.6469835574971512e-05
localization O 0 8.125468411890324e-06
is O 0 3.739530143320735e-07
postulated O 0 2.186684014304774e-06
to O 0 1.2914530600482976e-07
be O 0 9.914121079646065e-08
important O 0 1.554705590933736e-07
in O 0 6.714054165968264e-07
non B-Disease 0 1.8152224583900534e-05
- I-Disease 0 0.05245514214038849
familial I-Disease 1 0.9972147345542908
breast I-Disease 1 0.9999982118606567
and I-Disease 1 0.9904159307479858
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 0.00024400121765211225

Epigenetic O 0 0.0869494304060936
loss O 0 0.05911722406744957
, O 0 8.352265467692632e-06
however O 0 1.1852863508465816e-06
, O 0 3.866567794830189e-07
has O 0 2.418639724055538e-07
not O 0 9.039677451028183e-08
received O 0 4.092526069143787e-07
general O 0 4.862590685661417e-07
acceptance O 0 2.554841785240569e-06
due O 0 4.6002182330084906e-07
to O 0 1.0501060643264282e-07
controversy O 0 4.99970326472976e-07
regarding O 0 2.8309202093623753e-07
the O 0 2.894280726195575e-07
subcellular O 0 9.930064152285922e-06
localization O 0 5.3597591431753244e-06
of O 0 5.375819682740257e-07
BRCA1 O 0 6.545208452735096e-05
proteins O 0 5.371770726014802e-07
, O 0 1.5324542346206727e-07
reports O 0 1.6613070386028994e-07
of O 0 5.642694134166959e-08
which O 0 1.128003361827723e-07
have O 0 1.2911414160043932e-07
ranged O 0 3.1508559459325625e-06
from O 0 1.5349230864103447e-07
exclusively O 0 3.8416624192905147e-07
nuclear O 0 9.127184057433624e-07
, O 0 7.58288507540783e-08
to O 0 6.513519679174351e-08
conditionally O 0 6.169780590425944e-06
nuclear O 0 1.1054261221943307e-06
, O 0 7.862831807869952e-08
to O 0 8.319391042732605e-08
the O 0 5.297222855915606e-07
ER O 0 0.00022943670046515763
/ O 0 3.8647576729999855e-05
golgi O 0 5.523904474102892e-05
, O 0 3.9051229805409093e-07
to O 0 2.776387475478259e-07
cytoplasmic O 0 6.323740763036767e-06
invaginations O 0 1.7815636965679005e-05
into O 0 1.1852614534291206e-06
the O 0 1.9862668523273896e-06
nucleus O 0 3.869898500852287e-05
. O 0 1.534004150016699e-05

In O 0 1.4559492228727322e-05
an O 0 1.981669129236252e-06
attempt O 0 1.0808257684402633e-05
to O 0 8.210539022002195e-07
resolve O 0 1.0189491149503738e-05
this O 0 2.558896596838167e-07
issue O 0 6.767809850316553e-07
, O 0 2.6799492047757667e-07
we O 0 1.2371775426345266e-07
have O 0 4.1287958651992085e-07
comprehensively O 0 2.7245489036431536e-05
characterized O 0 3.991093035438098e-05
19 O 0 2.5195944544975646e-05
anti O 0 8.396401244681329e-05
- O 0 0.0031710092443972826
BRCA1 O 0 0.007291934918612242
antibodies O 0 0.00019902117492165416
. O 0 3.422185545787215e-05

These O 0 6.54984251013957e-05
reagents O 0 0.00017425348050892353
detect O 0 4.665210144594312e-05
a O 0 7.056817594275344e-06
220 O 0 1.4917355656507425e-05
- O 0 3.804707739618607e-05
kD O 0 0.00011018713848898187
protein O 0 3.3875480767164845e-06
localized O 0 4.3599552554951515e-06
in O 0 4.980420271749608e-07
discrete O 0 6.097499863244593e-06
nuclear O 0 6.210549145180266e-06
foci O 0 3.5075529012829065e-05
in O 0 3.4363611689514073e-07
all O 0 1.9840091169953666e-07
epithelial O 0 7.781490421621129e-05
cell O 0 4.858277316088788e-05
lines O 0 3.552832140485407e-06
, O 0 1.9904868509001972e-07
including O 0 2.4932609221650637e-07
those O 0 4.3093314161524177e-07
derived O 0 3.7915933717158623e-06
from O 0 7.086504865583265e-06
breast B-Disease 1 0.7103753089904785
malignancies I-Disease 0 0.4844137132167816
. O 0 4.7734694817336276e-05

Immunohistochemical O 0 0.019328925758600235
staining O 0 0.0032609780319035053
of O 0 4.437991083250381e-05
human O 0 9.64975479291752e-05
breast O 1 0.6147429943084717
specimens O 0 1.3483011571224779e-05
also O 0 6.875882718304638e-06
revealed O 0 4.3260086385998875e-05
BRCA1 O 0 0.0005551541107706726
nuclear O 0 4.8663878260413185e-05
foci O 0 0.0007972776074893773
in O 0 2.3081356630427763e-05
benign O 1 0.9298051595687866
breast O 1 0.9979876279830933
, O 0 0.00010981706873280928
invasive B-Disease 1 0.9683939218521118
lobular I-Disease 1 0.9999996423721313
cancers I-Disease 1 0.9996988773345947
and O 0 2.0733221390401013e-05
low B-Disease 0 0.0035801425110548735
- I-Disease 1 0.7157945036888123
grade I-Disease 0 0.04330795258283615
ductal I-Disease 1 0.9999758005142212
carcinomas I-Disease 1 0.9999996423721313
. O 0 0.0001410858239978552

Conversely O 0 0.0016060828929767013
, O 0 3.408200791454874e-05
BRCA1 O 0 0.0008786997641436756
expression O 0 1.842545134422835e-05
was O 0 2.8916917926835595e-06
reduced O 0 7.044176982162753e-06
or O 0 1.1489897815408767e-06
undetectable O 0 1.2112453077861574e-05
in O 0 1.7327064938399417e-07
the O 0 1.4007096638124494e-07
majority O 0 4.2377095610390825e-07
of O 0 1.392534301203341e-07
high O 0 6.917232894920744e-06
- O 0 0.0007779637235216796
grade O 0 3.01298605336342e-05
, O 0 5.4346432989405e-06
ductal B-Disease 1 0.9965347051620483
carcinomas I-Disease 1 0.9999995231628418
, O 0 2.2390456706489203e-06
suggesting O 0 2.6082343538291752e-06
that O 0 1.0096036362483574e-07
absence O 0 1.3309854693943635e-06
of O 0 1.0802050383063033e-06
BRCA1 O 0 0.020702844485640526
may O 0 2.9551210900535807e-06
contribute O 0 3.0244100912568683e-07
to O 0 1.051942319918453e-07
the O 0 3.196778664005251e-07
pathogenesis O 0 8.154812348948326e-06
of O 0 2.3139739369071322e-07
a O 0 3.197219257344841e-06
significant O 0 2.6102027277374873e-06
percentage O 0 1.368476114294026e-05
of O 0 2.0224392756063025e-06
sporadic B-Disease 1 0.6443684697151184
breast I-Disease 1 0.9999990463256836
cancers I-Disease 1 0.9997827410697937
. O 0 8.393716598220635e-06
. O 0 1.765443812473677e-05

